<SEC-DOCUMENT>0001711279-23-000008.txt : 20230227
<SEC-HEADER>0001711279-23-000008.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227071424
ACCESSION NUMBER:		0001711279-23-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Krystal Biotech, Inc.
		CENTRAL INDEX KEY:			0001711279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				821080209
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38210
		FILM NUMBER:		23670033

	BUSINESS ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		(412) 586-5830

	MAIL ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>krys-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:3bf7ccaf-2752-4fdb-93c0-341f465affc3,g:6dace288-7a26-4def-b28c-90440b1ff335,d:f50fdf1a469a4104bbe6f4c216cff277--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:krys="http://www.krystalbio.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>krys-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV80LTEtMS0xLTQ2NTM4_14a34afb-07eb-4984-a68a-7990978e720f">false</ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV82LTEtMS0xLTQ2NTM4_72239979-87d1-40dc-89df-7aa566d88a58">2021</ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV83LTEtMS0xLTQ2NTM4_babdd637-ddda-4c89-97b1-f4c9257181ec">FY</ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV85LTEtMS0xLTQ2NTM4_6c999033-0f44-4d42-b54a-a7040e6d22ab">0001711279</ix:nonNumeric><ix:nonNumeric contextRef="i73cbc13ff387448bbd68fa1f41555112_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE5NQ_581f1165-b5dd-4145-a11c-77520dcce020">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="id569cee70e244c0a91e103af3fdc3981_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxODQxNQ_e82f6b9b-070f-474c-9202-f9ee87935c71">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xNjM1L2ZyYWc6MDMzZDY3NzhiYTc0NGY5NGIyMDkwYzhjZGNiNGM0YzYvdGV4dHJlZ2lvbjowMzNkNjc3OGJhNzQ0Zjk0YjIwOTBjOGNkY2I0YzRjNl8yMTk5MDIzMjU1NTkx_1a15ccd3-d20c-49a0-97c3-e0da84de53c2">4</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="krys-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e1c55a604642dc8a755cffeb2fc42b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9cdc37180ee546aab3866b3edea133cc_I20230220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c0637d46d649d4bacab028175efbaa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d56c1a54244984a5f923ac922fdede_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36267cfc53644c10b377545a419cdc2b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1791ab32bfb844bdb1549f6e0fa6ebf2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i496ec5ae5f474b68a6e6e266a5883626_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i804bccd139d04bf3b19b95e33e6df55e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c619239c03440b5b8db4727db939247_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62eddb7037c4f82b6f2687e0a52e6ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fd0edbd57ff47fb919fb61349c64819_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208aa8cb27e54c60b096966b6240e133_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91001397acca4edbb0a19b9c79aa5b7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9c855a0e3a4e13a53433cc5c0364b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24f42b2bb4c47b89466941d0f5831db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922596331dd24a1dbd0e0b79d3ef475b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf8e1134b7c94d26a0c3d22afc73d215_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2f2c779195497fb1144f46db638bfb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie413a0f15f0d4717be8217ec39b221df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica5904f7fef443a68940ec9e9da0ce98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2465df77d804826b661dda93a47a9e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8ca4dafce8c49c38953d0c3cc1e563b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a31534ac7ce4d699f4394d4b19576c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ebe6bcc927412c83fb26d401bcacaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996e18257f394eff9914fcba8ed4e078_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4b03d778584b14ad55239cd91fef14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie289a738c54a427ea3a8922f170941dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d5acffc6e34806bcad27370483078d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915fb9f46db84704ab0d72c2ada7e20e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f61bb3407246f1923b173d13ac2592_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eafaed6c8534eb88f2e16210025076a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb62cd25fa1545ddb2adf0d82820735f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>krys:segment</xbrli:measure></xbrli:unit><xbrli:context id="iee87fb1c670d4a8fabfd071c375435ee_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e616f277cb401d95b1e1572f6cf8c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73935a9788274be9a2a5a77ba030b6f2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2bd6fcadcdd473ea0f07dc041889bed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e119a9d7434b2583f9e8b3f823f74b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cdf55bd7cb34dc7b7afcf71ada77513_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd3eeb0d882a48b0b15625e5774f3daf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib15d39f02c324677aeac9f5d4a570fa7_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69af799c800a4519a24465b3e66df634_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85ab137db9d24527ad70578422157edc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb022f76121f4e10b847528fc749dceb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e196aef98d946ef9ba6a9d94c73d645_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96d3206ab1847cd9a05a879d0efe67c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a6fa4bf942a419fbec493f4bf7f4b31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d46f0e247a640828b2290ff03d295cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e649be5847e4c318f3b5b62ca8bd797_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4613ad1330074364a3d902cd8b6f8599_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc145339ddd143598976c49d98e634a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75f7cf345d4447f6a47ad9669b43afd0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib381b024b3f44b17b2017dc67c13aab4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie820ccd74fbb44e0b053b5527111f83d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474abeb633a744ebbe6c051fccc138d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e9a31bc727469d97f0ab1f1c104519_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15667ce7b0c40e5b2f6147b95913a03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c142c1f1d9844f38df3bcfa1684428a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36361a0fa8ca486fbe97852c6f806b2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8132445eec974341992bfe7b7684bafc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i457106579689420ea580675819005893_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae3f849bf20446db2cc1146dcd478d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e3d585465c4e46b41b696bc03baddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5bf368359a4d94adb4f27bedbb43b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic622f20a96d14ab59d16de8af2ade381_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c9585ccfdd4de685f78c97d566a741_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32b08f8717549848438881335ea2b84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719c13df2acf4bbc80d5a66f47c2c5f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56384752fd2647389a6264b9b7752b99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69f790be83c94488822a264523f7aa15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da056f4632343f5ade54138b94c15a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995af0deed0b466cb43a86929a821007_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7449a1b73c48eba712df83a6750173_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id297898530e345fdb9c39bf76182c6cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf57f87b5d64c0285b86a7324814667_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2664a396fda544d5b299ff5ebffde6f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eedc946a09f4463a2514f7732506d68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb31ec5446de4fe8ac13a013fc88446a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a01a2413bfa418289c898f2b33b80ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba9efc2fefc4fef9a71d9e9ad291bf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64f00a32bc643ec9155226e65fdce96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09a4d167ef143e0bd15f47ab94c5ad3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38459e6001414efe8cfeb8e4f948bc27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fe90f1305345ceb8f4eec74b095c49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629b96ba6adf4d8aa35b23c9ad34341a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01e245d2c6b4ecbb264de581059c082_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a1d6851402493eb7158bcdc4c40c4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd317320604f464d92352b55af94077e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85a7c903384425b9eb947f6782aa70b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256fac5f703848e2b8ab04acc69e5f3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea876abef962460799265e18643c6fb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc859be73b64ed295ad31b068c1c6b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic202baf205634534bffe9efeed3c7c9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8bb7ba5bc104672859794003515136c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie84cd465b49e427c810883f086042263_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02fbe5b2532b456baed4ef03a2689550_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6be49196b1a40cebb048dcca6eb9e34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e748ec3ff764d03a108335cdb1f671c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61ac7a1eeb045dcacea633ccb659966_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i832fb48c719242fba8c5af845c762e6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3bab3e2c074cf09d136a1988e3d2e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i495e2c1097804e028fc462ff30675a6f_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb54fd3a1a9429dbd4579a4ca4375c3_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>krys:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i4284a105f3d94405949b41403e9a7675_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93b6151f6f9401a9cf2ece6f8285911_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66aa90c0684b46ac8099d45d53db5a8d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc45f2a4236a42068da733f353b95494_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f6d31d7c164477b1d0048e8a3d3c31_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945482856edd461ca395d4030b16ab54_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a82f78a44f492d8069e2d68d1056a8_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6729dd8891e24732929f1da30607e91a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="id3550b062fe645a5b0ed51ef12d694db_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ShortTermAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-31</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4370047cb1b348508f41d2e789bc71c0_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if35ae989164e43cdb1a778a5e6515540_I20211215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonMassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia171e05bea12459f9ba3be58aa9b540f_I20220316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30156baee55b420397418386f0108370_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20353f3c4a5844c1812426b1fb75b765_I20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22d7707724741a49fc8f50872fbdfdb_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9b5e8d6ec94209880102cc2bc8b200_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30752247a0714b92a9d3f37982cfdcaa_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9957e8c329c246278995d54d846e0a2b_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-31</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18c855dfb0d4abf9b71ece6213ab70d_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95615b0260094824b79b22c82e8d1a1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb780c5cb8b14431832716c15e1dac80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7ad365543f4254838ab4c58a691a10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cef0fcaddce44cfa4ae5cd35b69a9db_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d7eb26698e4662a210b4e03cb7f40e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0436d21be92494794b2f1a66dba88ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd3104f8c0ce402b88a79fb05859ba61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:A2017IPOStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73cbc13ff387448bbd68fa1f41555112_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id569cee70e244c0a91e103af3fdc3981_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9274bc3d5034d649742d7cf95cad4c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44284afec0974ca383f35189fcf5836c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib074476f73164a7380886e3036b586df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2d691354374a8292be807107fe9093_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae3c74e3eaa49338980a2180ec9032f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0073addc8943b48ff41400a0b94650_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ce9bbd561d4f208adfe62e207934e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f3a841eea6448987a04b6c2d676f22_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0747f5930bf4422fab3034a04de464a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec828eaae79146849fd3782a3949449d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcdeed31d4564d29a353803d0d00dc6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e51c635ee14313b6fb1c0daa7415bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic416c201f5284d9f943605c62536d8be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64502038e5f64b25854ef8736435d9a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d98e41008f24785ad933f9a46c178e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06852b1b5d247e4803f084678fb20d7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc8ab265e2b84543a478bdf30eed184f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib231c197185e448c8293b564b7342929_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb9664479bc48ffb663071fe28743f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc6d3fd9adf476d8c19b91e06ad9df9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57562bb09e14b62821f7c7ee59bc9d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i880d88ff54e545f6b66cbd9fa91d7c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e042df24d94919831c05275e22f61c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">krys:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4cd79ab6b4405a9b60c9b5803d3e47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">krys:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba614e370fda465e9bd79ec170d9f9b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299015c71eda4062b0883fb132997c3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326eceb3ac84481fb3a1888cdd980f89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf96a3872b434ff2ba6fae61cdb19b56_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTExLTEtMS00Njk1NA_73410a37-24a9-4291-95c4-de61f9230b56 id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtMTEtMS0xLTQ2NTM4_92072b1d-a959-4fb6-8610-776ba755c68f id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2NTM4_d176a3eb-bacc-4ff4-ab00-5834e3bec456 id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY1Mzg_66d153e5-c44b-4b13-957b-71394af8d915 id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTctMS0xLTQ2OTU0_eb74d109-be99-4c24-bab6-7e03aa46ecd8 id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtNy0xLTEtNDY1Mzg_a9cf32ce-a28e-49ee-980b-703d4bd72274" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4" order="1"></ix:relationship></ix:resources></ix:header></div><div id="if50fdf1a469a4104bbe6f4c216cff277_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_______________________________________________________________________________</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTgy_f6e15c5d-25b8-4b5d-8edb-2e812ee233bf">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_______________________________________________________________________________</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark&#160;One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6MTRlMzI2ZTVhMmU3NDZkZThjYzlhYTRlNjg2YjBiMjgvdGFibGVyYW5nZToxNGUzMjZlNWEyZTc0NmRlOGNjOWFhNGU2ODZiMGIyOF8wLTAtMS0xLTQ2NTM4_041abf61-17c9-4046-898f-bfa9548dbd26">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N18yODg_7aceddbb-faac-4719-8839-a6d2268d45cf"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N18yODg_1abaf1bf-12fd-4268-92ae-ca67055762dd">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6YzlhYWE5NDM2OTdjNGUxODkyY2IzOWM0ZDkxYzMxM2IvdGFibGVyYW5nZTpjOWFhYTk0MzY5N2M0ZTE4OTJjYjM5YzRkOTFjMzEzYl8wLTAtMS0xLTQ2NTM4_a8a4959a-2032-46bb-a773-1dae36db1997">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTg3_89d95551-07e3-428d-9fec-1410aa37e4d9">001-38210</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTkw_7689f0a4-805d-4d3c-a4fc-29f83915dee4">Krystal Biotech, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_______________________________________________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18wLTAtMS0xLTQ2NTM4_7199c703-5892-4650-9105-c4adef9c4ea8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18wLTEtMS0xLTQ2NTM4_ea82e976-8158-43fc-b865-cbd2302c3fe6">82-1080209</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18yLTAtMS0xLTQ2NTM4_5366df9a-a7f5-42f3-9843-010d384e0d01">2100 Wharton Street</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18zLTAtMS0xLTQ2NTM4_a845e90e-1ef1-4a45-8167-4f722af1a0c3">Suite 701</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY180LTAtMS0xLTQ2NTM4_3cfeaf3b-8345-47c5-a7c9-abb4d39796d8">Pittsburgh</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY181LTAtMS0xLTQ2NTM4_58de99db-d14d-478b-a896-dc98a3bbc9df">Pennsylvania</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY181LTEtMS0xLTQ2NTM4_978aacdb-e2d3-4cca-9dbe-63427e6c800d">15203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTkx_58372ffe-0e91-438e-91cb-c21e1fb53f65">412</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTkz_a0dc090c-f422-4a05-936e-34342beb4c28">586-5830</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_______________________________________________________________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZjYzNTRiMjEyNDUzNDhmZDk5MmZmNjFlOTRjZDVhYWYvdGFibGVyYW5nZTpmNjM1NGIyMTI0NTM0OGZkOTkyZmY2MWU5NGNkNWFhZl8xLTAtMS0xLTQ2NTM4_b62bdbe4-5caf-4de1-b9e6-3efa3c0d3419">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZjYzNTRiMjEyNDUzNDhmZDk5MmZmNjFlOTRjZDVhYWYvdGFibGVyYW5nZTpmNjM1NGIyMTI0NTM0OGZkOTkyZmY2MWU5NGNkNWFhZl8xLTEtMS0xLTQ2NTM4_9a766c79-2c8f-43a1-b1a2-54e68863f2a7">KRYS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZjYzNTRiMjEyNDUzNDhmZDk5MmZmNjFlOTRjZDVhYWYvdGFibGVyYW5nZTpmNjM1NGIyMTI0NTM0OGZkOTkyZmY2MWU5NGNkNWFhZl8xLTItMS0xLTQ2NTM4L3RleHRyZWdpb246YmI3ODUzYmNjM2ExNDgyOWE4NTNlODQ5NGMyOTUwZjdfNA_fc42c02e-b3c4-414e-ac99-e323d9a1cd42">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N181NDk3NTU4MjQ4MDU_c961f6e1-924f-4c30-83a2-3f73870c8742">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTk0_b90ffd06-0438-4f18-814c-7234cde8e514">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTk1_098b0b6a-a629-4eb7-947f-4e5f44da2098">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTky_894a4965-b348-42c1-b02a-e2eb8e9f20b6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZWY5MjZmYWEyYjhmNDMwN2JmMjUwNGVlMmEzODI5YjEvdGFibGVyYW5nZTplZjkyNmZhYTJiOGY0MzA3YmYyNTA0ZWUyYTM4MjliMV8wLTAtMS0xLTQ2NTM4_cbd69242-a0ff-4232-aab6-9abfc3b4d8a3">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZWY5MjZmYWEyYjhmNDMwN2JmMjUwNGVlMmEzODI5YjEvdGFibGVyYW5nZTplZjkyNmZhYTJiOGY0MzA3YmYyNTA0ZWUyYTM4MjliMV8yLTMtMS0xLTQ2NTM4_d75177c5-7892-41a2-b53b-1b65f9f4bb67">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZWY5MjZmYWEyYjhmNDMwN2JmMjUwNGVlMmEzODI5YjEvdGFibGVyYW5nZTplZjkyNmZhYTJiOGY0MzA3YmYyNTA0ZWUyYTM4MjliMV80LTEtMS0xLTQ2NTM4_06749d7b-cbd6-477c-bbec-7092e43b6634">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.    Yes&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTg5_efdba7d5-e719-4275-9348-c60061770890">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTg1_5b19236c-6619-44f2-a083-9521b39989df">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the Registrant, based on the closing sales price for such stock on June 30, 2022 as reported by The Nasdaq Stock Market, was $<ix:nonFraction unitRef="usd" contextRef="i52e1c55a604642dc8a755cffeb2fc42b_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N18zMDk2_8ab134bc-6eab-4232-b07a-ad4ec28ec497">1.4</ix:nonFraction>&#160;billion. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s common stock outstanding as of February&#160;20, 2023 was <ix:nonFraction unitRef="shares" contextRef="i9cdc37180ee546aab3866b3edea133cc_I20230220" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N181NDk3NTU4MjMyMjg_cee48360-bbb3-4c86-acc3-36488b0df707">25,763,743</ix:nonFraction>.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTk3_f9c267a2-96e8-4995-922b-91e6676abece" escape="true">Portions of the Registrant&#8217;s definitive proxy statement relating to its 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Report where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_13">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_19">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_43">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_43">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_43">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_46">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_46">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_46">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_49">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_49">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_49">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_52">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_52">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_52">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_55">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_58">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_58">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_58">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_61">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_61">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_61">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_64">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_64">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_88">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_88">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_91">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_91">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_91">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_145">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_145">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_145">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_148">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_148">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_148">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_151">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_151">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_151">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_154">Item&#160;9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_154">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_154">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_157">PART&#160;III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_160">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_160">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_160">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_163">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_163">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_163">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_166">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_166">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_166">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_169">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_169">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_169">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_172">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_172">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_172">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_175">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_178">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_178">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_178">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_181">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_181">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_181">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_184">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_184">92</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as&#160;amended, or&#160;the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict&#8221;, &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements appearing in a number of places throughout this Annual Report on Form 10-K include, but are not limited to, statements about the following, among other things:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, timing, progress and results of preclinical and clinical trials for Beremagene Geperpavec ("B-VEC", previously &#8220;KB103&#8221; and now known as Vyjuvek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), KB105, KB104, KB301, KB407, KB408 and any other product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of public health crises including  the COVID-19 pandemic and measures to contain or prevent these outbreaks may have on our business operations, access to capital, research and development activities, and preclinical and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing, scope or results of regulatory filings and approvals, including timing of final U.S. Food and Drug Administration (&#8220;FDA&#8221;), marketing and other regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve certain accelerated or orphan drug designations from the FDA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates regarding the potential market opportunity for any of our  product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our research and development programs for our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans and ability to successfully develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to identify, recruit and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the implementation of our business model, strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scalability and commercial viability of our proprietary manufacturing methods and processes;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitive position;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intellectual property position and our ability to protect and enforce our intellectual property;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain collaborations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for or ability to obtain additional financing;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully resolve any intellectual property or other claims that may be brought against us;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any statements regarding economic conditions, including statements related to the economic fallout from the COVID-19 pandemic and the impact on our business, or performance and any statement of assumptions underlying any of the foregoing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report.&#160;We undertake no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. You should read this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report, unless the context requires otherwise, all references to &#8220;Krystal,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries.</span></div><div style="text-align:justify;text-indent:29.25pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These summary risks provide an overview of many of the risks we are exposed to in the normal course of our business and are discussed more fully in &#8220;Risk Factors&#8221; herein. These risks include, but are not limited to, the following: </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We have incurred net losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">We may need to raise additional funding in order to receive approval for our product candidates. Such funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitations.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We are substantially dependent on the commercial success of B-VEC.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The effect of the COVID-19 pandemic or similar public health crises on our operations and the operations of our third-party partners could cause a disruption of the development efforts for our product candidates and adversely impact our business.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to advance our product candidates through clinical trials, obtain regulatory approval and ultimately commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our lead candidate, B-VEC, has not received regulatory approval, and if we obtain regulatory approval to commercialize B-VEC the approval may be for a narrower indication than we seek.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">B-VEC is based on a novel technology, which makes it difficult to predict the time and cost of obtaining regulatory approval.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our products may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight. We will continue to incur costs related to regulatory compliance and are subject to risks related to non-compliance with or changes to applicable laws and regulations, which could cause our product candidates to lose approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our product candidates.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Delays in obtaining regulatory approvals of the process and facilities needed to manufacture our product candidates or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Although we have established our own manufacturing facility for our product candidates, we may need to continue to utilize third parties for the manufacturing of sterile gel that is mixed with our in-house produced vector for the near future. Therefore, we are subject to the risk that these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to expand our market development capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any product revenue.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to obtain and maintain adequate U.S. and foreign patent protection for our product candidates, and/or our vector platform, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technologies similar or identical to ours, and our ability to successfully commercialize our current product candidates, any future product candidates we may develop, and our platform technologies may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our Chief Executive Officer and Chairman of the Board of Directors and our founder, President of R&amp;D and director will have the ability to substantially influence all matters submitted to stockholders for approval.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_13"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practice ("CGMP") manufacturing capabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Redosable Gene Therapy Platform</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that certain inherent features of the HSV-1 virus, combined with the modifications we have made to the viral backbone provides our proprietary gene therapy platform with specific advantages over other viral and non-viral vector platforms including the following: </span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Repeat Administration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: One of the major challenges with many viral vector platforms is that the host immune system may recognize them as foreign agents and launch a robust immune response, resulting in toxicity and rapid removal of the virus. Wild-type HSV-1 is known to persist in the body by becoming latent and hiding from the immune system. We have harnessed the natural ability of HSV-1 to evade host-mediated immunogenicity, while removing specific viral elements that exacerbate the host immunity, thus making our viral vector safer for repeat administration as needed to achieve durability of effect. The immune evasive properties of our vector also enable us to treat patients who may have baseline antibodies to HSV-1, ensuring that prior exposure to the wild-type virus will not limit the number of patients who may be amenable to treatment with our product candidates.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Non-Integrating Nature</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Upon entry into cells, the HSV-1 vector persists as an episomal unit in the nucleus, meaning it remains physically separate from the host cell chromosome. Certain other viral vectors currently being used in the development of gene therapy treatments, such as the lentiviral and retroviral vectors, integrate into the host cell DNA to achieve gene expression. Integration into the host cell DNA carries the risk of disrupting host genes. In contrast, a non-integrating vector such as our HSV-1 vector does not carry the same risk of disrupting the expression of host cell genes.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Payload Capacity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: HSV-1 is a large virus, approximately 150 kilobases, or Kb, of DNA in size. We have made strategic deletions within this genome to remove critical &#8220;immediate early&#8221;, or IE, genes. These IE genes are required for expression of most of the downstream genes that allow the HSV-1 virus to replicate and destroy host cells. Deletion of these IE genes inhibits expression of most of the viral proteins, making the resulting viral vector replication-deficient and non-toxic. These deletions also enable the vector to easily accommodate a payload of 35Kb or greater without any significant impact on yield or titer. In our lead product candidate, B-VEC, we have successfully inserted two functional copies of the complete ~9Kb human </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. In contrast, packaging capacity for most other vectors being used is at or under ~10Kb, which limits their ability to deliver large transgenes. In addition, we believe the high payload capacity of our viral vector will allow us to insert multiple and/or combinations of genes or effectors that could enable the treatment of non-monogenic conditions.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">High Transduction Efficiency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Poor transduction efficiency has remained a major hurdle for direct delivery of most vectors particularly in the epithelia of the skin and lung. HSV-1 has a natural affinity, or tropism, for epithelial cells. Consequently, our vector penetrates and delivers its payload much more efficiently than other vectors, resulting in transduction efficiencies or cell penetration as high as 95% in cell-based studies. The greater payload capacity of our vector and the high transduction efficiencies achieved allow us to deliver a full gene (or genes) directly to any patient&#8217;s tissues for off-the-shelf, in vivo gene expression without additional manipulation.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Direct Delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our engineered HSV-1 vector allows for noninvasive or minimally invasive local gene delivery. The advantages of direct delivery are that our products can be administered in a doctor&#8217;s office or potentially the patient&#8217;s home, requiring no hospitalization or expensive, invasive, and time-consuming procedures or sophisticated medical teams. Taking gene therapy to the patient minimizes patient travel and circumvents upfront logistical burdens typical of other gene therapy approaches.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Stability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: HSV-1 is extremely stable and resistant to degradation by physical shearing, solvents, and enzymes, facilitating purification and flexibility with final formulation of our product candidates. Our vectors are stable frozen for long-term storage, under refrigerated conditions for short-term storage and shipment, in addition to being stable over several freeze-thaw cycles. This should facilitate our ability to ship our products globally from our manufacturing facilities in Pennsylvania.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Reproducible and Scalable Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Successful production of viral vectors involves two steps: (i) the &#8216;upstream&#8217; process, which yields a bulk virus harvest; and (ii) the &#8216;downstream&#8217; process, which involves purification and concentration of the clinical product. Successful and reproducible execution of both processes is critical for clinical manufacturing and scale-up. Our scientific team collectively has decades of experience and expertise in HSV engineering and purification that has allowed us to successfully optimize our HSV-1 vector production process and develop in-house Chemistry, Manufacturing and Control (&#8220;CMC&#8221;) capabilities.</span></div><div style="margin-top:6pt;padding-left:85.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.5pt">Existing Regulatory Precedent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The first FDA- and European Medicines Agency&#160;(&#8220;EMA&#8221;)-approved oncolytic virus product, Imlygic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Amgen, for treatment of melanoma, a skin cancer, is based on a genetically engineered HSV-1 virus. Because this product also employs an HSV-1 backbone, it has created a regulatory precedent for approval of an HSV-1-based therapy. In addition, Imlygic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a chronic therapy, given bi-weekly, which provides support for the use of an HSV-1 backbone in chronic gene therapy of the type we are developing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above listed benefits of our innovative platform make it the ideal choice for topical and intradermal applications to treat skin diseases, skin conditions and inhaled formulations to treat respiratory diseases. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development as of the date of this Annual Report:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><img src="krys-20221231_g1.jpg" alt="krys-20221231_g1.jpg" style="height:840px;margin-bottom:5pt;vertical-align:text-bottom;width:667px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dermatology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigational Beremagene Geperpavec (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B-VEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">) for dystrophic epidermolysis bullosa (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DEB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Background</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DEB is a rare and severe monogenic skin disease. DEB affects the skin and mucosal tissues and is caused by one or more mutations in a gene called </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is responsible for the formation of the protein type VII collagen ("COL7") that forms anchoring fibrils that bind the dermis (inner layer of the skin) to the epidermis (outer layer of the skin). In DEB patients, the genetic defect in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> results in loss or malfunctioning of these anchoring fibrils, leading to extremely fragile skin that blisters and tears from minor friction or trauma. Those who are born with DEB are sometimes called &#8220;butterfly children,&#8221; because their skin is likened to be as fragile as the wings of a butterfly. DEB patients may suffer from open wounds, skin infections, fusion of fingers and toes and gastrointestinal tract problems throughout their lifetime, and may eventually develop squamous cell carcinoma, a potentially fatal condition. We believe that there are, at present, approximately 3,000 diagnosed DEB patients in the United States and approximately 9,000 worldwide. The current standard of care for DEB patients is limited to palliative measures that seek to provide relief from some of the symptoms of DEB but do not meaningfully impact disease outcomes. While not disease-modifying, current treatment is estimated to cost between $200,000 and $400,000 annually per patient in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">B-VEC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-VEC is a redosable, off-the-shelf gene therapy designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene when applied topically, directly onto an open wound. Unlike the current standard of care, B-VEC seeks to treat DEB at the molecular level by providing the patient&#8217;s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. B-VEC was specifically designed to be easily administered by a healthcare professional in a doctor&#8217;s office or potentially at the patient&#8217;s home. The FDA and the European Medicines Agency (&#8220;EMA&#8221;) have each granted B-VEC orphan drug designation for the treatment of DEB, and the FDA has granted B-VEC fast track designation and rare pediatric designation for the treatment of DEB. In addition, the FDA granted Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) to B-VEC for the treatment of DEB and the EMA granted PRIority MEdicines (&#8220;PRIME&#8221;), eligibility for B-VEC to treat DEB. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our approach to treating DEB is positively differentiated relative to other known efforts to develop corrective treatments that employ autologous approaches. Autologous treatments use a patient&#8217;s own tissues and cells to manufacture an individualized therapy. Such therapies tend to be expensive, invasive and time consuming to use, and require extensive patient travel, extended hospital stays, highly sophisticated medical teams and procedures. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development of B-VEC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated Phase 1 testing of B-VEC in May 2018 at Stanford University, and we announced positive interim results from this clinical study on two patients in October 2018. The Phase 2 portion of the trial commenced in December 2018 at Stanford University, and we announced positive interim results from this clinical study on June 24, 2019. In March 2022, results from the complete Phase 1/2 study of topical B-VEC for the treatment of DEB were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Medicine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a pivotal Phase 3 trial (&#8220;GEM-3 trial&#8221;) in July 2020. The GEM-3 trial of B-VEC for the treatment of DEB was a randomized, double-blind, intra-patient placebo-controlled multicenter study designed to evaluate the efficacy and safety of B-VEC for patients suffering from both recessive and dominant forms of DEB. The trial enrolled 31 participants with DEB, aged 6 months or older at time of consent. In each patient, a primary wound pair was identified by the investigator; one wound was randomized to receive a weekly topical application of B-VEC and the other to receive placebo. These primary wounds were treated once weekly for six months until wound closure. If a wound re-opened at any point during the study, weekly dosage resumed until closure. The dose administered to each wound was dependent on the size of the wound. A maximum vector dose per patient per week was defined on the basis of preclinical and clinical safety data. In the event that the maximum dose per patient had not been reached based on dosing of the primary wounds, the study investigators and patients had the opportunity to select additional &#8220;secondary&#8221; wounds across which the remaining weekly dose was applied. We announced positive results from the GEM-3 trial in November 2021 and in December 2022 full results from the GEM-3 trial were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, following feedback from the FDA, we announced that we planned to offer patients with DEB, who were enrolled in the GEM-3 open label extension study (&#8220;OLE&#8221;), the opportunity to be dosed in their homes by a health care professional. Further study details are available at www.clinicaltrials.gov under NCT identifier NCT04917887. Nothing included on this website shall be deemed incorporated by reference into this Annual Report on Form 10-K. We are pleased with the on-going progress of the OLE in terms of both patient and physician experiences and plan to provide an update on the OLE study in 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted a Biologics License Application (&#8220;BLA&#8221;) to the FDA for B-VEC for the treatment of DEB in June 2022. The FDA accepted the BLA in August 2022 granting B-VEC a Priority Review Designation with a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) action date of February 17, 2023. In January 2023, the FDA notified us, that based on manufacturing information submitted to the agency on December 20, 2022 in response to an information request from the FDA, the PDUFA date has been revised to May 19, 2023. In this notification, we were also informed that there will be no Advisory Committee meeting for B-VEC, and that a Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) program was not needed for the B-VEC application.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted a request for Marketing Authorization Application (&#8220;MAA&#8221;) with the European Medicines Agency (&#8220;EMA&#8221;) in November 2022 for B-VEC for the treatment of DEB in patients 6 months and older. The Company was informed by the EMA in January 2023 to modify the PIP waiver request to include patients between birth and 6 months. The Company is modifying the application so that the MAA procedure can officially start in the second half of 2023 with an approval expected in early 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial readiness efforts have been underway for the past two years as we prepare for the potential approval of B-VEC by the FDA and the EMA. In the United States, our Medical Science Liaisons have been interacting with and educating health care professionals (&#8220;HCPs&#8221;) on DEB and the importance of genetic testing in ensuring an accurate diagnosis. We have completed the build of Krystal Connect, our US in-house patient services call center staffed with Krystal employees, and are ready, pending FDA approval of B-VEC, to assist patients, care givers and HCPs interested in accessing B-VEC. Additionally, we have hired, trained and deployed commercial field teams who are interacting with physicians, patients, and commercial payers across the U.S. to educate on DEB and to prepare for a U.S. launch of B-VEC. We are interacting frequently with the leading physicians in the major markets across Europe and in Japan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">KB105 for TGM1-deficient autosomal recessive congenital ichthyosis (&#8220;ARCI&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Background</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARCI is a life-long, severe monogenic skin disease. While a number of genetic mutations have been associated with the development of ARCI, the most common cause of ARCI is an inactivating mutation in the human transglutaminase-1 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) gene encoding the enzyme transglutaminase-1, a protein that is essential for the proper formation of the skin barrier. Mutations in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene, and the subsequent disruption to the epidermal barrier, leads to pronounced dehydration, trans-epidermal exposure to unwanted toxins and surface microorganisms, and a greatly increased risk of infection. Transglutaminase-1 deficiency is associated with increased mortality in the neonatal period and has a dramatic impact on quality of life.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients suffering from ARCI often exhibit life-long pronounced plate-like scaling of the skin, which is often of a dark color and can cover the whole body. Such patients frequently suffer from exposure of the inner eyelid surface due to turning away of the eyelids from the eye (ectropion), the turning outwards of the lips (eclabium), deformities of joint and nasal cartilage (hypoplasia), scarring alopecia (especially at the edge of the scalp) and a thickening of the skin on the palms of the hands and soles of the feet (palmoplantar keratoderma). Additional complications experienced by ARCI patients include episodes of sepsis, fluid and electrolyte imbalances due to impaired skin barrier function, and failure to thrive, especially during the neonatal period and infancy. Severe heat intolerance and nail dystrophy are also frequently observed. There are currently no treatments targeting molecular correction of this disease. There are approximately 20,000 cases of TGM1-deficient ARCI worldwide and about 400 new cases per year globally. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KB105 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB105 is a redosable, off the-shelf gene therapy designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene when applied topically, directly to a patient&#8217;s exfoliated skin. The goal of direct supplementation of TGM1 protein at the site of administration is local correction and phenotypic improvement. Like B-VEC, KB105 was designed to be easily administered by a healthcare professional in the doctor&#8217;s office or, potentially, at the patient&#8217;s home.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the EMA have each granted KB105 orphan drug designation for the treatment of TGM1-ARCI, and the FDA has granted KB105 fast track designation and rare pediatric designation for the treatment of TGM1-ARCI. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development of KB105</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019 we initiated a Phase 1/2 trial in TGM1-ARCI patients. In May 2020, initial clinical data from the Phase 1 portion of the study which enrolled adult patients were presented at the Society for Investigative Dermatology (&#8220;SID&#8221;) meeting. In August 2020, we initiated the second phase of our Phase 2 portion of the clinical trial of KB105 to treat ARCI. We enrolled one patient in whom four rectangular 100cm2 (4-inch x 4-inch) areas of skin were selected as Target Areas (TAs). Each treatment area was assigned to receive repeat doses of 4.0x109 PFU (n=2 treatment areas) or 1.0x1010 PFU (n=2 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment areas). Each area was dosed on Day 1 and 3, after which dosing continued either every 3 days (n=2 treatment areas) or every 6 days (n=2 treatment areas) up to day 30. Treatment areas were clinically evaluated at pre- and post-KB105 application timepoints, using a 5-point IGA scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = very severe). In July 2021, we announced initial Phase 2 data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repeated topical doses of KB105 were well tolerated, and no drug-related adverse effects were reported. No vector shedding or systemic viral exposure was detected at any time point. Improvement on the IGA scale was observed in each treatment area, with the maximum effect observed in TA3 and TA4 that received the highest dose; at day 27, the investigator assigned an IGA score of 2, which was improved as compared to baseline score of 4 in each area. Variable 1-point improvements were observed at other time points and in the treatment areas that received the lowest dose. As in the Phase 1 portion of the trial, TGM1 turnover was observed to be variable but relatively rapid, and the observed IGA improvements were not sustained through day 60.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to resume enrollment in the Phase 2 portion of this trial in the first half of 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KB104 for Netherton Syndrome </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Background</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Netherton Syndrome is a debilitating monogenic autosomal recessive skin disorder. The disease arises due to mutations in the Serine Protease Inhibitor Kazal-type 5 (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) gene, resulting in loss of activity of its encoded serine protease inhibitor protein SPINK5 (also known as Lympho-Epithelial Kazal type-related Inhibitor (&#8220;LEKTI&#8221;)). In healthy individuals, SPINK5 is one of the serine protease inhibitors expressed in the outermost layers of the skin, and it plays a critical role in the regulation of serine proteases which hydrolyze extracellular proteins that hold corneocytes together. In patients suffering from Netherton Syndrome, the suppressive effects of SPINK5 on these serine proteases is abolished due to underlying genetic mutations in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Consequently, hyperactivated serine proteases in the skin cause uncontrolled desquamation, leading to a defective skin barrier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In infants, severe Netherton Syndrome can be associated with failure to thrive, hypernatremic dehydration secondary to excess fluid loss, delayed growth, short stature, and recurrent infections. Clinically, Netherton Syndrome is characterized by congenital ichthyosiform erythroderma, hair shaft defects, recurrent infections, and a defective skin barrier. A predisposition to allergies, asthma, and eczema is also characteristic of Netherton Syndrome. Ultimately, those afflicted by Netherton Syndrome often experience chronic skin inflammation, severe dehydration, and stunted growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are approximately 38,000 cases of patients worldwide and about 700 new cases per year globally. There are no current approved treatments for Netherton Syndrome. Existing approaches are limited to palliative treatments, including topical moisturizers, repair formulas and steroids.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KB104</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB104 is a redoseable off-the-shelf gene therapy designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene to relevant skin cells when applied topically. By directly supplementing the skin with functional SPINK5, the goal of therapy is to locally correct the desquamation and improve the barrier function of the skin.  In preclinical testing a properly localized human </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene was detected 48 hours after topical KB104 application in mice without toxicity. KB104-mediated human SPINK5 was expressed in the correct layer of skin at the transcript and protein levels. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has granted KB104 rare pediatric designation for the treatment of Netherton Syndrome.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to file an investigational new drug (&#8220;IND&#8221;) application with the FDA and initiate a clinical trial of KB104 in Netherton Syndrome in 2023.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Respiratory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KB407 for Cystic Fibrosis (&#8220;CF&#8221;) </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Background</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CF is the most common inherited genetic disorder in the United States and is caused by mutations in the cystic fibrosis transmembrane conductance regulator (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CFTR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) gene. Lack of functional CFTR protein in secretory airway epithelia results in defective Cl-, bicarbonate, and thiocyanate secretion, coupled with enhanced Na+ absorption and mucus production, leading to dehydration and acidification of the airway surface liquid. CF is characterized by recurrent chest infections, increased airway secretions, and eventually, respiratory failure. While CF comprises a multiorgan pathology affecting the upper and lower </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">airways, gastrointestinal and reproductive tracts, and the endocrine system, the primary cause of morbidity and mortality in CF is due to progressive lung destruction. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the U.S. Cystic Fibrosis Foundation (&#8220;CFF&#8221;), the median age at death for patients with CF in the United States was 30.8 years in 2018. Currently approved CFTR modulating therapies are limited to patients with specific genetic mutations and there is a significant unmet medical need for the approximately 10% of patients with CF who have genetic mutations non-amenable to currently approved CFTR small molecule &#8220;modulators&#8221;. According to the CFF, approximately 30,000 patients in the United States and more than 70,000 patients worldwide are living with CF, and approximately 850 new cases of CF were diagnosed in 2018.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KB407 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB407 is a redosable off the-shelf gene therapy designed to deliver two copies of the full-length </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CFTR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene directly to the airway epithelia via inhaled (nebulized) administration. By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation. Preclinical efforts to date have shown that KB407 successfully transduces patient-derived epithelial cells and delivers functional CFTR in vitro in 2D and 3D organotypic systems, and is amendable to non-invasive inhaled administration in vivo, as indicated by successful delivery to the lungs through the use of a clinically relevant nebulizer in small animal models. Successful delivery and distribution throughout the lung also was observed in a nonhuman primate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the EMA have each granted KB407 orphan drug designation for the treatment of cystic fibrosis, and the FDA has granted KB407 rare pediatric designation for the treatment of cystic fibrosis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development of KB407</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced that we were granted approval by the Bellberry Human Research Ethics Committee (&#8220;HREC&#8221;) in Australia to conduct a Phase 1 clinical study of inhaled KB407 in patients with CF. We previously received license to evaluate KB407 from Australia's Office of the Gene Technology Regulator (&#8220;OGTR&#8221;). We plan to dose our first patient in the Phase 1 clinical trial in Australia in the first half of 2023.  </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced, in August 2022, that the FDA had accepted our IND application to evaluate KB407 in a clinical trial to treat patients with CF. We are closely working with the Therapeutics Development Network (&#8220;TDN&#8221;) of the CFF to validate our clinical protocol and plan on initiating a Phase 1 clinical trial in the U.S. in the first half of 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KB408 for Alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Background</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AATD is a genetic condition caused by mutations that lead to decreased levels and/or decreased functionality of the alpha-1- antitrypsin (&#8220;AAT&#8221;) protein. AATD lung disease is a consequence of diminished or absent functional protein in the lungs due to impaired transport into, and low concentrations in, patient plasma. Low AAT serum levels can result in life threatening, progressive pulmonary impairment and severe respiratory insufficiency, manifesting as chronic obstructive pulmonary disease (&#8220;COPD&#8221;) and panacinar emphysema. The lung degeneration observed in AATD patients derives from an unopposed, and therefore enhanced, neutrophil elastase (&#8220;NE&#8221;) activity, leading to an excessive degradation of elastin, collagen, and fibronectin. The absence of proper NE inactivation by functional AAT ultimately results in lung tissue destruction, airway obstruction, and an increased inflammation state that compromises the integrity of the organ and contributes to an inadequate response to insults, including inefficient pulmonary bacterial clearance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are an estimated 90,000 to 100,000 people in the U.S. with severe AAT deficiency. Currently, many AATD patients undergo &#8220;augmentation therapy&#8221; consisting of weekly intravenous (&#8220;IV&#8221;) infusions of either plasma-purified AAT or recombinant AAT. This therapy requires burdensome weekly IV infusions and often includes the risk of exposure to bloodborne pathogens connected with the use of blood-derived products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KB408</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB408 is an inhaled (nebulized) formulation of our proprietary vector, designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SERPINA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene that encodes functional, full-length human protein, for the treatment of AATD. Preclinical studies to date have shown that KB408 successfully transduces patient-derived lung epithelial cells in vitro, leading to production and secretion of full-length human AAT protein capable of irreversibly binding its cognate target NE. In small animal models, analysis of lung tissue biopsies, serum, and bronchoalveolar lavage fluid harvested 24 and 48 hours after inhalation of KB408 shows secretion of full-length AAT protein, with no evidence of significant or systemic toxicity. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are planning to file an IND for KB408 to treat AATD patients in 2023.  </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aesthetics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our focus is on the development of gene therapies to treat serious rare diseases, we are also evaluating the potential of our platform to address more prevalent and/or non-genetic conditions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To that end, in April 2019, we incorporated Jeune Aesthetics, Inc. (&#8220;Jeune Aesthetics&#8221;), a wholly-owned subsidiary, for the purposes of undertaking preclinical and clinical studies for aesthetic skin conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KB301 for aesthetic skin conditions</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Background</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skin is largely composed of collagen-rich connective tissue, with dermal collagen, composed primarily of types 1 and 3 collagen fibrils, representing &gt;90% (dry weight) of human skin. The characteristics of skin aging are largely due to aberrant collagen homeostasis, including reduced collagen biosynthesis, increased collagen fibril fragmentation, and progressive loss of dermal collagen culminating in a net collagen deficiency, resulting from both intrinsic (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, passage of time, genetics) and extrinsic (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, chronic light exposure, pollution) pressures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facial injectables, including hyaluronic acid, botulinum toxin type A, collagen, polymer fillers, and calcium hydroxyapatite microparticles, are intended to correct perceived facial defects (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, fine lines, shallow wrinkles, and deeper furrows), and are administered for both cosmetic and therapeutic indications. In 2017, the global facial injectables market generated more than $7.2 billion in revenue from approximately 8.5 million procedures performed, with a majority (~70%) of revenue being generated in the aesthetic setting. While the United States and Europe represent the largest markets for facial injectables to-date, significant expansion in market share is projected for Asia and Latin America in the coming years. Due to the rising awareness of cosmetic procedures, the growing geriatric population, and a shift from invasive to minimally/non-invasive treatment options, the aesthetics facial injectables market is projected to grow to more than a $12 billion industry by 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KB301</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB301 leverages our clinical experience in delivering genes of interest to the skin, and is designed to stimulate biorejuvenation of the skin via delivery of the gene that encodes for type III collagen (&#8220;COL3&#8221;) when administered via intradermal injection. We believe that our approach of directed expression of full-length human type III collagen via intradermal application of KB301 provides a unique and straightforward approach to restoring collagen homeostasis, and by extension, reconstructing an optimal physiologic environment in the skin to treat wrinkles or other presentations of aged or damaged skin.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical development of KB301</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase 1 clinical trial, the PEARL-1 trial, for the treatment of aesthetic skin conditions in August 2020. The Phase 1 dose-ranging trial evaluated the safety, tolerability, and initial efficacy of intradermal injections of KB301 in adult subjects aged 18-75 (NCT04540900). KB301 was well tolerated, and we were able to biopsy and demonstrate proof-of-mechanism. Complete results from Cohort 1 focused on safety were presented at the 2021 SID Annual Meeting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced positive proof-of-concept efficacy and safety data from Cohort 2 of the PEARL-1 study of KB301 for the treatment of aesthetic skin indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cohort 2 was a randomized, double-blind, placebo-controlled clinical trial that evaluated the safety and efficacy of KB301 for the improvement of fine lines and skin texture in the lower and upper cheek and for improvement in skin thickness in the knee. Cohort 2 enrolled 27 subjects across two trial sites. Bilateral treatment areas included the neck behind the ear to assess initial safety and on the cheek below and above the zygomatic arch (lower and upper cheek), and around the knee. Subjects were randomized 2:1 to receive low dose KB301 or placebo in the upper cheek and knee as multiple micro depot injections over the selected treatment area with a 33 G needle. Subjects receiving KB301 in the lower check were randomized 2:1 to receive either low dose KB301, high dose KB301 or placebo. Four patients dropped out of the Cohort 2 study &#8211; one subject following the initial safety assessment behind the ear, two subjects for unspecified reasons, and one subject due to unevenness in face between active and placebo during the study. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subset of subjects from the PEARL-1 Cohort 2 trial (Cohort 3) were enrolled into a durability trial to look for duration of effect, reduction of the unevenness in placebo treated sites, and for long term safety monitoring. Ten subjects from the PEARL-1 Cohort 2 study were enrolled in the durability trial, an open-label study to assess duration of effect below the zygomatic arch (the lower cheek area). The extension cohort enrolled subjects who had received the high dose regimen of KB301 during the efficacy cohort in one or both of their lower cheeks. Subject Satisfaction Scores and Investigator Assessments were measured monthly for three consecutive visits that correspond to timepoints up to nine-months following </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administration of the last dose of KB301. In addition, subjects with placebo-treated lower cheeks were dosed with KB301 during the open-label extension cohort to normalize their appearance. In November 2022, we announced nine-month durability of effect in Cohort 3 of the PEARL-1 study of KB301.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are planning to initiate a Phase 2 study in fine lines in 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Opportunities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the ability to redose, as well as the large payload capacity of our proprietary vectors, will allow us to deliver multiple genes and other effectors, which could enable development of therapies to treat non-monogenic skin diseases like psoriasis and atopic dermatitis, as well as conditions that are not necessarily the result of an inherited genetic defect, such as chronic wounds. For example, as proof-of concept we have generated a library of vectors designed to deliver anti-inflammatory antibodies. Further, we evaluated one of these vectors in an animal model of atopic dermatitis where expression of the vector-encoded-antibody was confirmed and efficacy was observed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are able to successfully generate product candidates to treat these non-orphan diseases, we intend to seek collaborative alliances towards the development and potential commercialization of these therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-House CGMP Facilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built in-house CGMP facilities to enable better quality control, shorten lead times, lower costs and strengthen command over our intellectual property. Our first facility, ANCORIS, a commercial scale CGMP-compliant manufacturing facility, is producing the long-term extension study material for B-VEC at commercial scale, and we expect to produce initial commercial launch material of B-VEC at the facility following FDA approval. In December 2022, the FDA completed a successful audit of our ANCORIS facility as part of the B-VEC BLA review process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second commercial scale CGMP facility, ASTRA, is expected to be completed and validated in 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is a state-of-the-art CGMP manufacturing facility that, in addition to adding significant capacity to support the growing pipeline, will also allow the in-house incorporation of raw material preparation, excipient manufacturing, testing, packaging, labeling and distribution, thereby fully integrating all components of the supply chain from starting materials to patient experience. We announced the ground breaking of ASTRA in January 2020. We are planning to initiate our first GMP run in ASTRA in 1H 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary manufacturing process which was initially developed for B-VEC and is now being used across our platform, was developed and optimized internally and involves both an upstream production process and downstream purification process. Recombinant viral vectors are rendered incapable of, or attenuated for, replacing in human cells by removal of specific viral machinery, including packaging proteins. However, to produce the recombinant virus, these viral proteins have to be re-introduced into the virus production process so that the viral vector can be packaged. In most other viral vector production systems, the missing viral proteins are supplied in one or more individual helper plasmids, along with the base viral vector plasmid. All the plasmids are then co-transfected into a production cell line in the presence of a transfection agent to facilitate viral vector production and packaging. The difficulty of this approach is that it requires c-scale manufacturing and qualification of each of the packaging plasmids and optimization of the transfection method. Even with optimized reagents and methods, significant batch-to-batch variability is seen in viral vector yield and titer that, we believe, drives up the cost of viral vector manufacturing and scale-up and increases the risk of failure during manufacturing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary upstream process for HSV-1 production avoids the aforementioned issues. Our process requires three critical components:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">Production of a master virus seed stock (&#8220;MVSS&#8221;);</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">Production of complementing master cell bank (&#8220;MCB&#8221;); and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Optimized transduction parameters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of our product candidates, we generate a MVSS which is scaled up from a single purified clone of the modified HSV-1 vector expressing the therapeutic effector. The MCB is a complementing cell line that stably expresses the HSV-1 viral proteins that are required for HSV-1 growth but have been deleted from the recombinant HSV-1 backbone. By introducing the deleted proteins into the MCB, as opposed to including them in the viral replication process via co-transfection of individual plasmids, we eliminate the need for multiple qualifications of the plasmids or variability in transfection efficiency from batch to batch, that other production processes face. Infection of the MCB with the MVSS at the optimal concentration results in production of the viral particle. Once the MCB, the MVSS, and the conditions of infection are established, virus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production and resultant yield and titer are highly reproducible and scalable over multiple runs, and the risk of failure is minimal.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Optimization of MCB, MVSS and production methods requires extensive knowledge and technical experience with the HSV-1 genome and significant upfront effort to design and select the best virus seed stock and complementing cell line. To date we have screened hundreds of cell line clones to find the best complementing cell lines, and similarly designed and generated the optimal virus seed stocks for each of our product candidates. The viral seed stock expresses the therapeutic proteins under the control of strong constitutive or tissue-specific promoters and additional non-coding regulatory sequences have been included to optimize gene expression. We also have optimized the transduction conditions to reproducibly obtain high yields of the virus.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike the upstream process, steps used to purify and concentrate the viral vector product are often common across different viral vector platforms and usually involve multiple stages of purification, clarification, concentration, and diafiltration, with the ultimate goal to remove contaminants and concentrate the product. We have developed a robust and reproducible process for purifying our viral vector to required concentrations for clinical use, while successfully removing contaminants to meet FDA guidelines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the MVSS and MCB are a vital part of the production of our product candidates, as they ensure the reproducible production of multiple clinical and potentially commercial batches in a short six-week cycle time frame and in a cost-effective manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made significant investments in developing the most comprehensive and optimized manufacturing process for our vector product candidates including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A proprietary vector manufacturing technique and a series of high-efficiency purification processes that produce &#160;&#160;&#160;&#160;highly purified therapeutic vectors and can be adapted for each product candidate; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">A critical list of CGMP assays to accurately characterize our process and the HSV-1 vectors we produce. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive. In particular, the field of gene therapy is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Some of our competitors have substantially greater financial resources and larger research and development organizations. In addition, our experience in clinical trials, obtaining FDA and other regulatory approvals, and manufacturing and commercialization of products may be more limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epidermolysis Bullosa</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies are developing drug candidates for EB. There is no approved treatment for DEB at this time. We believe our competitors fall into two broad categories:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.8pt">Corrective approaches:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are aware of two companies, Abeona and Castle Creek Pharmaceuticals, which are developing autologous or grafting gene therapy approaches to treating DEB. We are also aware of a recombinant-protein based approach being developed by Phoenix Tissue Repair. </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:31.8pt">Palliative Treatments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are aware of companies, such as Amryt Pharmaceuticals and Castle Creek Pharmaceuticals, which are developing product candidates taking a palliative approach to treating the disease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Autosomal Recessive Congenital Ichthyosis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of companies such as Novartis Inc. and Patagonia Pharmaceuticals, LLC who have conducted clinical trials for ARCI in the past. We are unaware of any companies conducting active clinical trials in ARCI presently.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Netherton Syndrome</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware that Novartis Inc. has conducted clinical trials for Netherton Syndrome. We are unaware of any companies currently conducting active clinical trials in Netherton Syndrome presently.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several preclinical or early clinical stage nucleic-acid-based programs for the treatment of CF including TranslateBio, ReCode Therapeutics, Spirovant, and 4D Molecular Therapeutics. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to maintain proprietary protection surrounding our product candidates, platform technology, and know-how, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. We have a portfolio of patents, patent applications and other intellectual property owned entirely by the Company that protect our core platform technology and products based thereupon, and affords us freedom to use this platform for the development of novel therapeutics for multiple applications. We continue to advance our intellectual property portfolio actively through the filing of new patent applications, divisionals, and continuations relating to our technologies as we deem appropriate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our patents, we rely on trade secrets and know-how to develop and maintain our competitive position. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, through confidentiality agreements and intellectual property assignment agreements with our employees, consultants and commercial partners. We also seek to preserve the integrity and confidentiality of our data, trade secrets, and know-how, including by implementing measures intended to maintain the physical and electronic security of our research and manufacturing facilities, as well as our information technology systems.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Platform</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country / Region*</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Type</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date**</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owner / Licensor</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. 10,441,614</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Composition of Matter &amp; Methods of Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#8211; The Skin TARgeted Delivery platform, or STAR-D, for skin-targeted therapeutics, as well as methods of its use for delivering any effector of interest to the skin</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/28/2036</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. 11,185,564</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Methods of Use</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211; Methods of their using replication-defective HSV vectors for delivering any effector as skin-target therapeutics interest to the skin.</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/28/2036</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B-VEC (Beremagene Geperpavec)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country / Region*</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Type</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date**</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owner / Licensor</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. 9,877,990</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Composition of Matter &amp; Methods of Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Compositions comprising HSV vectors encoding certain effectors, including the effector encoded in B-VEC, and methods of using the same for providing prophylactic, palliative or therapeutic relief of a wound, disorder or disease of the skin</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/28/2036</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. 10,155,016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Composition of Matter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211; Covers compositions containing B-VEC, formulated for alternate routes of administration</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/28/2036</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EP 3 377 637 B1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Composition of Matter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211; Pharmaceutical compositions comprising B-VEC, as well as uses thereof, including for providing prophylactic, palliative or therapeutic relief of a wound, disorder or disease of the skin.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/28/2036</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">KB105</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country / Region*</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Type</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date**</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owner / Licensor</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. 10,525,090</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Composition of Matter &amp; Methods of Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; KB105, as well as medical applications of this product for treating TGM1-deficient ARC</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4/11/2039</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">KB301</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country / Region*</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Type</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date**</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owner / Licensor</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. 10,786,438</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Composition of Matter &amp; Methods of Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8211; Pharmaceutical compositions comprising HSV vectors encoding one or more cosmetic proteins, as well as methods of their use for improving skin condition, quality, and/or appearance.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4/26/2039</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">KB407</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country / Region*</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Type</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date**</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owner / Licensor</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. 10,829,529</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Methods of Use &#8211;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Methods of using KB407 for the treatment of cystic fibrosis and other diseases causing progressive lung destruction</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/07/2040</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Krystal</span></div></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">Granted patents in the U.S. and Europe ("EP") are shown. Additional patent protection in the U.S. and Europe or other countries or regions through pending or granted counterparts may be available.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">Stated expiration dates do not account for any patent term extension, supplemental protection certificate, or pediatric extensions that may be available.</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologic products including gene therapy products under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;), and regulations and guidance implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, importation, advertising and other promotional practices involving biologic products. IND applications to the FDA are required before conducting human clinical testing of biologic products. Additionally, each clinical trial protocol for a gene therapy product candidate is reviewed by the FDA, and in limited instances the National Institutes of Health (&#8220;NIH&#8221;), through its Recombinant DNA Advisory Committee, or RAC. The FDA&#8217;s authorization also must be obtained before marketing of biologic products. The process of obtaining regulatory approvals or licenses and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the FDA, the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) regulates gene therapy products. Within CBER, the review of gene therapy and related products is in the Office of Therapeutic Products (&#8220;OTP&#8221;) and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee (&#8220;CTGTAC&#8221;) to advise CBER on its reviews. CBER works closely with the NIH and the RAC, which makes recommendations to the NIH on gene therapy issues and engages in a public discussion of scientific, safety, ethical and societal issues related to proposed and ongoing gene therapy protocols. The FDA has provided guidance for the development of gene therapy products generally, including a growing body of guidance documents on CMC clinical investigations and other areas of gene therapy development, all of which are intended to facilitate the industry&#8217;s development of gene therapy products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive regulations or claims that our products are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Biologic Products Development Process</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA must authorize the marketing of a product candidate for marketing in the United States. The process required by the FDA before a biologic product candidate may be marketed in the United States generally involves the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">completion of preclinical laboratory tests and in vivo studies in accordance with the FDA&#8217;s current Good Laboratory Practice (&#8220;GLP&#8221;), regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">submission to the FDA of an IND application, which allows human clinical trials to begin unless FDA objects within 30 days;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">approval by each clinical trial site&#8217;s Institutional Review Board (&#8220;IRB&#8221;) and Institutional Biosafety Committee (&#8220;IBC&#8221;), before the clinical trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s Good Clinical Practice (&#8220;GCP&#8221;) regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biologic product candidate for its intended use;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preparation and submission to the FDA of an application for marketing approval that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">review of the product by an FDA advisory committee, if applicable;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biologic product candidate is produced to assess compliance with CGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the biologic product candidate&#8217;s identity, safety, strength, quality, potency and purity;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the application; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">payment of user fees and FDA review and marketing authorization..</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any new biologic product candidate in humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vivo studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually must complete some long-term preclinical testing, such as animal studies of reproductive adverse events and carcinogenicity and must also develop additional information about the chemistry and physical characteristics of the biological product and finalize a process for manufacturing the biological product in commercial quantities in accordance with CGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the biological product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final biological  product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted, to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. With gene therapy protocols, if the FDA allows the IND to proceed, but the RAC decides that full public review of the protocol is warranted, the FDA will request at the completion of its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND review that sponsors delay initiation of the protocol until after completion of the RAC review process. The FDA also may impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND for our future product candidates will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such studies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Clinical Trials Under an IND</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the biologic product candidate to healthy volunteers or patients under the supervision of qualified investigators who generally are physicians not employed by or under the control of the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. An IND becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an IRB and IBC at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed. Clinical trials involving recombinant DNA also must be reviewed by an IBC, a local institutional committee that reviews and oversees basic and clinical research that utilizes recombinant DNA at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 1. The biologic product candidate initially is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early understanding of its effectiveness. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Phase 1 clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 2. The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Phase 3. Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes studies that present the data the FDA or other relevant regulatory agencies will use to determine whether or not to approve a biologic product. In Phase 3 studies, the biologic product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the potency and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Regulation for Gene Therapy Clinical Trials</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire. The NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information on gene therapy trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Review and Approval Processes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical tests and clinical trials, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things, are submitted to the FDA as part of a BLA or other submission requesting authorization to market the product for one or more indications. For gene therapies, selecting patients with applicable genetic defects is a necessary condition to effective treatment. For the therapy we are currently developing, we believe that diagnoses based on existing genetic tests developed and administered by laboratories certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) are sufficient to select appropriate patients and will be permitted by the FDA. Under the PDUFA, each BLA (or New Drug Application (&#8220;NDA&#8221;) for some biologics) must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual product fee for biologics and an annual establishment license fee on facilities used to manufacture prescription biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs or NDAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews a BLA within 60 days of submission to determine if it is substantially complete before it accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and potent, or effective, for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with CGMP to assure and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a REMS program is necessary to assure the safe use of the product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate unless it determines that the manufacturing processes and facilities are in compliance with CGMP requirements and adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a BLA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter or license authorizes commercial marketing of the biologic product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biologic product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review standard BLAs in 10 months after the FDA accepts the BLA for filing, and priority BLAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track Designation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast Track designation is granted to drugs being developed for the treatment of serious or life-threatening diseases or conditions where there is an unmet medical need. The purpose of the Fast Track designation provision is to help facilitate development and expedite the review and potential approval of drugs to treat serious and life-threatening conditions. Sponsors of drugs that receive Fast Track designation have the opportunity for more frequent interactions with the FDA review team throughout the development program. These can include meetings to discuss study design, data required to support approval, or other aspects of the clinical program. Additionally, products that have been granted Fast Track designation may be eligible for priority review of a BLA application and the FDA may consider reviewing portions of the submission before the sponsor submits the complete application, also known as a rolling review.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a biologic product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment of the disease or condition will be recovered from sales of the product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Other benefits include reduced regulatory fees, protocol assistance and tax credits for certain clinical research costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan medicinal product status in the European Union (&#8220;EU&#8221;) has similar, but not identical benefits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regenerative Medicine Advanced Therapy Designation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Established under the 21st Century Cures Act, RMAT designation is a program designed to expedite the development and approval of regenerative medicine products, including gene therapy products. An investigational therapy is eligible for the RMAT designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates a potential to address unmet medical needs for that disease or condition. The designation includes all the benefits of the FDA&#8217;s Fast Track and Breakthrough Therapy designations and enables the ability to work more closely and frequently with the FDA to discuss surrogate or intermediate endpoints to support the potential acceleration of approval and satisfy post-approval requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prime Designation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PRIME designation is awarded by the EMA to promising medicines that target an unmet medical need. These medicines are considered priority medicines by the EMA. To be eligible and accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on early clinical data coupled with non-clinical data. Through PRIME, the EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accelerated evaluation by the agency. The program is intended to optimize development plans and expedite the review and approval process so that these medicines may reach patients as early as possible.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rare Pediatric Disease Priority Review Voucher</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also offers a rare pediatric disease drug designation. If a drug receives the designation of a &#8220;rare pediatric disease&#8221; drug, it is eligible during the FDA marketing process to apply for a Rare Pediatric Disease Priority Review Voucher. According to the FDA website, under the Rare Pediatric Priority Review Voucher Program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Patent Term Restoration and Marketing Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA approval of product candidates, some of a sponsor&#8217;s U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period generally is one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biologic product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. Moreover, a given patent may only be extended once based on a single product. The United States Patent and Trademark Office (&#8220;USPTO&#8221;), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigorous and extensive FDA regulation of biologic products continues after approval, particularly with respect to CGMP requirements. Manufacturers are required to comply with applicable requirements in the CGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biologic products include reporting of CGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product; recordkeeping requirements; reporting of adverse effects; reporting updated safety and efficacy information; and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA, together with a release protocol, showing a summary of the history of manufacture of the lot and the results of all tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologic products. A sponsor also must comply with the FDA&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in- patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label promotion&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation Outside of the United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, sponsors are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of biologic products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not a sponsor obtains FDA approval for a product, a sponsor must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application, much like the IND, prior to the commencement of human clinical trials. In the EU, for example, a request for a Clinical Trial Authorization (&#8220;CTA&#8221;) must be submitted to the competent regulatory authorities and the competent Ethics Committees in the EU Member States in which the clinical trial takes place, much like FDA and the IRB, respectively. Once the CTA request is approved in accordance with the EU and the EU Member State&#8217;s requirements, clinical trial development may proceed. The requirements and processes governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCPs and the applicable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements of the country or countries in which the clinical trial is performed, as well as the ethical principles that have their origin in the Declaration of Helsinki (whichever provides the greater protection to the clinical trial participants).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable foreign regulatory requirements may result in, among other things, fines; suspension, variation or withdrawal of regulatory approvals; product recalls; seizure of products; operating restrictions; and criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and use of pharmaceutical products that are granted marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources are subject to broadly applicable fraud and abuse and other healthcare laws and regulations, and these laws and regulations may constrain the business or financial arrangements and relationships through which manufacturers market, sell and distribute the products for which they obtain marketing approval. Such restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers on the other. The Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;) amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to commit a violation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal false claims and civil monetary penalties laws, including the civil False Claims Act (&#8220;FCA&#8221;), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. Certain marketing practices, including off-label promotion, also may implicate the FCA. In addition, the PPACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments and other transfers of value to physicians, certain other healthcare providers and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Care Fraud statute imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which imposes obligations, including mandatory contractual terms, with respect to safeguarding the transmission, security and privacy of protected health information;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for federally sponsored healthcare benefits, items or services; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violation of the laws described above or any other governmental laws and regulations may result in penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and imprisonment. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to incurring the costs required to obtain FDA approvals. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all FDA-approved drugs for a particular indication. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. EU member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing arrangements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Reform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, for example, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected and continues to face major uncertainty due to the status of major legislative initiatives surrounding healthcare reform. On August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. The IRA includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including allowing Medicare to negotiate prices for certain prescription drugs, requiring drug manufacturers to pay a rebate to the federal government if prices for single-source drugs and biologicals covered under Medicare Part B and nearly all covered drugs under Part D increase faster than the rate of inflation (CPI-U), and limiting out of pocket spending for Medicare Part D enrollees. Additionally, On October 14, 2022, President Biden signed Executive Order 14087 on &#8220;Lowering Prescription Drug Costs for Americans.&#8221; The Executive Order specifically requests that the Center for Medicare and Medicaid Innovation consider &#8220;models that may lead to lower cost sharing for commonly used drugs and support value-based payment that supports high-quality care.&#8221;  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Foreign Corrupt Practices Act</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that impose similar obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;20, 2023, we had 210 full-time employees, primarily engaged in research and development, manufacturing, administrative activities, and activities in preparation of commercialization of B-VEC. None of our employees are represented by a labor union and we consider our employee relations to be good.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our employees are among the most important assets to our company and are key to achieving our goals and expectations. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our existing and new employees. We offer robust compensation packages, including competitive base pay, incentive compensation and stock compensation programs, and provide a broad range of benefits. The principal purpose of our stock compensation program is to attract, retain and reward personnel through the granting of stock-based awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. In addition, we are committed to the professional advancement of our employees and offer various training programs and career development opportunities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in April 2016. In March 2017, we converted from a California limited liability company to a Delaware&#160;C-corporation,&#160;and changed our name from Krystal Biotech, LLC to Krystal Biotech, Inc. Our principal offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, and our telephone number is 412-586-5830. In June 2018, the Company incorporated an Australian subsidiary, for the purpose of undertaking&#160;preclinical and clinical studies in Australia.&#160;In April 2019, the Company incorporated Jeune Aesthetics, Inc. in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical studies for aesthetic skin conditions. In January 2022, August 2022 and December 2022, we incorporated subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal&#8217;s pipeline. Our website address is&#160;www.krystalbio.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K. You should not rely on any such information in making your decision whether to purchase our common stock. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available free of charge on the investor relations section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to the Securities and Exchange Commission, or the SEC. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding the Company that we file electronically with the SEC. The address of the website is http://www.sec.gov.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_22"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred recurring losses and negative cash flows from operations and, at December&#160;31, 2022, we had an accumulated deficit of $280.8 million. Our ability to achieve profitability depends on our ability to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize our product candidates. We have devoted substantially all our efforts to date to research and development of our gene therapy product candidates as well as to building out our infrastructure. We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our research and the clinical development of our product candidates, including our current clinical trials and planned future trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">initiate clinical trials for certain of our product candidates and preclinical studies for any additional product candidates that we may pursue in the future;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prepare for regulatory approvals for our product candidates in the United States, EU and in other key geographies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to operate our in-house commercial-scale CGMP manufacturing facility, ANCORIS, and complete build out and startup of operations at our second CGMP manufacturing facility, ASTRA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacture material for clinical trials or potential commercial sales;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">further develop our gene therapy product candidate portfolio;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">further establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop, maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire or in-license other product candidates and technologies,</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing the clinical trials for our product candidates, developing and validating commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing and selling any product candidates for which we may obtain marketing approval and satisfying any post-marketing requirements. If we were required to discontinue development of any of our product candidates, if any of our product candidates do not receive regulatory approval, if we do not obtain our targeted indications for our product candidates or if any of our product candidates fails to achieve sufficient market acceptance for any indication, we could be delayed by many years in our ability to achieve profitability, if ever, and would materially adversely affect our business prospects and financial condition. Moreover, if we decide to leverage any success with any of our current product candidates to develop other product opportunities, we may not be successful in such efforts. In any such event, our business will be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have several product candidates in the clinical trials stages, but we may never develop, acquire or in-license additional product candidates. We may never succeed in any or all these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product and biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the EMA, or other regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of our product candidates, our expenses could increase and revenue from product candidates in development and profitability from commercially available products could be further delayed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional funding in order to receive approval for our product candidates. Such funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complete the process of obtaining regulatory approval for our product candidates and to continue building the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding. In addition, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. We anticipate that we may need additional funding to complete the development of our product candidates and to commercialize any such approved products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the length of our open label study for B-VEC;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing results and costs of our Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, results and costs of our Phase 2 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, results and costs of our Phase 1 clinical trials for KB407;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the continued development and the filing of IND applications for KB104 and other product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of building and maintaining our own commercial-scale CGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers, if necessary;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, in the event we receive marketing approval for any of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements, if any;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our current license agreements, if any, remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for our product candidates in development. Furthermore, even if we obtain approval for a product candidate, we may not be able to successfully generate significant revenue from the sale of such product candidate. Accordingly, we may need to continue to rely on additional financing to achieve our business objectives. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all our stockholders. Existing stockholders may not agree with our financing plans or the terms of such financings. Adequate additional financing may not be available to us on acceptable terms, or at all. The terms of additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing may be impacted by, among other things, general market conditions, the market&#8217;s perception of our product candidates and growth potential and the market price per share of our common stock. See &#8220;Raising additional capital could cause the price of our common stock to decline and cause dilution to our stockholders, restrict our operations or require us to relinquish rights.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have U.S. federal and state net operating loss carryforwards, which are available to reduce future taxable income. Federal net operating loss carryforwards generated 2018 through 2021 will be limited to offset 80% of taxable income for an indefinite period of time, until fully utilized. These federal and state net operating loss carryforwards expire beginning in 2037. We also have federal and state research and development tax credits which may be used to offset future tax liabilities and expire beginning in 2039 and 2032, respectively. We also have federal orphan drug tax credits which may be used to offset future tax liabilities which expire beginning in 2038.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. Private placements and other transactions that have occurred since our inception, as well as our initial public offering, may trigger such an ownership change pursuant to Sections 382 and 383. Any such limitation, whether as the result of the initial public offering, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. Generally, under current law, federal net operating losses generated after December 31, 2017 are not subject to expiration and may not be carried back to prior taxable years. However, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, suspended the 80% taxable income limitation for net operating losses generated in 2018, 2019, and 2020 to the extent these losses are exhausted during the special five-year carryback period or during the 2018, 2019 or 2020 tax years. Additionally, as noted above, for taxable years beginning after December 31, 2020, the CARES Act provisions no longer apply and the deductibility of such federal net operating losses is limited to 80% of our taxable income in any future taxable year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in 2016. Our efforts to date, with respect to the development of our product candidates have been limited to organizing and staffing our company, business planning, raising capital, developing our vector platform and related technologies, identifying potential gene therapy product candidates, and undertaking preclinical studies and clinical trials. We have not yet demonstrated an ability to obtain marketing approvals for any of our products, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success, performance or viability may not be as accurate as they could be if we had more experience developing gene therapy products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We will need to transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_25"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the commercial success of B-VEC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have invested substantial efforts and financial resources in the research and development of our product candidates. Our near-term prospects, including our ability to develop our product candidates and generate revenue, and our future growth is substantially dependent on the commercial success of B-VEC. We initiated Phase 3 testing of B-VEC in July of 2020 and announced positive topline results in November 2021. We submitted the BLA for B-VEC in June 2022, which was accepted by the FDA in August 2022 and granted priority review. The PDUFA target date is May 19, 2023, but we cannot be certain of how long it will take to successfully complete the regulatory approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining FDA approval of the BLA for B-VEC would further delay commercialization and would adversely impact our ability to generate revenue and further develop our other product candidates. If the BLA for B-VEC is not approved on a timely basis or at all, our business, financial condition, results of operations and prospects would be adversely impacted. The successful development, regulatory approval and commercialization of B-VEC will depend on a number of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors, including the risks identified in these &#8220;Risk Factors.&#8221; One or more of these factors, many of which are beyond our control, could cause significant delays or an inability to successfully commercialize B-VEC. Accordingly, we cannot assure you that we will be able to generate revenue through the sale of B-VEC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The effect of the COVID-19 pandemic or similar public health crises on our operations and the operations of our third-party partners could cause a disruption of the development efforts for our product candidates and adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has previously adversely affected our international business and could have a material adverse effect on our financial condition and results of operations. Authorities have previously imposed, and businesses and individuals have implemented, numerous measures to try to contain the virus or treat its impact, such as travel bans and restrictions, quarantines, shelter-in-place/stay-at-home and social distancing orders, shutdowns, and vaccine requirements. These measures have impacted and may further impact our workforce and operations, the operations of our customers, and those of our third-party partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 or similar public health crises impacts our operations or those of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19, including new strains, and the actions to contain COVID-19 or address its impact in the short and long term, among others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Timely initiation and completion of planned clinical trials is dependent upon the availability of, for example, clinical trial sites, researchers and investigators, regulatory agency personnel, and materials, which may be adversely affected by global health matters, such as pandemics. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that governmental authorities were to further modify or implement new restrictions, our employees conducting research and development or manufacturing activities may not be able to access our laboratory or manufacturing spaces, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to advance our product candidates through clinical trials, obtain regulatory approval and ultimately commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The development and commercialization of our product candidates are subject to many uncertainties, including the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful enrollment and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">positive results from our current and planned future clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">receipt of regulatory approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successful development of our internal manufacturing processes on an ongoing basis and maintenance of our existing arrangements with third-party manufacturers for clinical supply;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercial launch of our product candidates, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our lead candidate, B-VEC, has not received regulatory approval, and if we obtain regulatory approval to commercialize B-VEC the approval may be for a narrower indication than we seek.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. In June 2022, we filed a BLA with the FDA seeking approval of B-VEC for the treatment of patients with DEB with a request for six-month priority review. In August 2022, the FDA accepted the BLA and granted priority review with a PDUFA target date of February 17, 2023. In January 2023, the FDA notified us that based on manufacturing information submitted to the agency on December 20, 2022, in response to an information request, the PDUFA date had been revised to May 19, 2023. Even though B-VEC met its safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we submitted a request for MAA with the EMA in November 2022 for B-VEC for the treatment of DEB in patients 6 months and older. The Company was informed by the EMA in January 2023 to modify the PIP waiver request to include patients between birth and 6 months. The Company is modifying the application so that the MAA procedure can officially start in the second half of 2023 with an approval expected in early 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a post-approval safety monitoring program. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of B-VEC. Any of the foregoing scenarios could materially harm the commercial prospects for B-VEC and materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B-VEC is based on a novel technology, which makes it difficult to predict the time and cost of obtaining regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial requirements of the FDA, EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied product candidates. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or the European Union or how long it will take to commercialize our product candidates. Approvals by the European Commission may not be indicative of what FDA may require for approval and approval by the FDA may not be indicative of what the European Commission would require for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements and policy governing gene and cell therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within its CBER to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. If we were to engage a National Institutes of Health funded institution to conduct a clinical trial, that institution&#8217;s IBC as well as its IRB, would need to review the proposed clinical trial to assess the safety of the trial. Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of B-VEC or future product candidates or lead to significant post-approval limitations or restrictions. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several significant adverse side effects in gene therapy trials using other vectors in the past. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If in the future we are unable to demonstrate that such adverse events were caused by the administration process or related procedures, the FDA, the European Commission, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our products for any or all targeted indications. Even if we can demonstrate that any serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our products, the commercial prospects of such product candidate may be harmed and our ability to generate product revenues from the product candidate may be delayed or eliminated. Any of these occurrences may harm our ability to develop product candidates, and may harm our business, financial condition and prospects significantly.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one of our product candidates receives marketing approval, the FDA could require us to adopt a post-approval safety monitoring program to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate for its intended indications. Clinical trials are expensive, time consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in opening sites and recruiting a sufficient number and diversity of suitable patients to participate in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or concerns with a class of product candidates, or after an inspection of our clinical trial operations or trial sites;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we make manufacturing or formulation changes to our products, we may need to conduct additional studies to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our products or allow our competitors to bring products to market before we do, which could limit our potential revenue or impair our ability to successfully commercialize our products and may harm our business, financial condition, results of operations and prospects. Any delays, setbacks or failures in our clinical trials could materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be delayed in obtaining marketing approval, if at all, or be required to conduct additional confirmatory safety and/or efficacy studies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be required to perform additional clinical trials to support approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be subject to the addition of labeling statements, such as warnings or contraindications;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be sued; or</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">experience damage to our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we, the FDA or an IRB, may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current GCP regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our IND applications or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight. We will continue to incur costs related to regulatory compliance and are subject to risks related to non-compliance with or changes to applicable law and regulations, which would cause our product candidates to lose approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain any regulatory approval for B-VEC, our lead product candidate, or other future product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our product candidates may also be subject to a post-approval safety monitoring program, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with CGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or a regulatory authority disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements, a regulatory authority may:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issue a warning letter asserting that we are in violation of the law;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners, if any;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrict the marketing or manufacturing of the product;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seize or detain the product or otherwise require the withdrawal of the product from the market;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refuse to permit the import or export of product candidates; or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">While we have obtained orphan drug designation for B-VEC, KB105, and KB407, it may not effectively protect us from competition, and we may be unable to obtain orphan drug designation for our future product candidates. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates before us, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2017, the FDA granted orphan drug designation to our lead product candidate, B-VEC, for the treatment of  DEB. On April 16, 2018, the European Commission granted the Orphan Medicinal Product Designation (&#8220;OMPD&#8221;), for B-VEC. On August 7, 2018, the FDA granted orphan drug designation to our product candidate, KB105, currently in clinical development for treatment of patients with TGM1-ARCI, and on October 10, 2019, the European Commission granted the OMPD for KB105. On August 17, 2020, the FDA granted orphan drug designation to our product candidate, KB407, currently in clinical development, for the treatment of cystic fibrosis, and on January 13, 2023, the European Commission granted the OMPD for KB407. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the European Commission, upon a recommendation from the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 5 in 10,000 persons in the EU. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biologic product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the EU. The exclusivity period in the EU can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we have obtained orphan drug exclusivity for B-VEC, KB105 and KB407, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EU, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the second applicant can establish in its application that its medicinal product, although like the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the holder of the marketing authorization for the original orphan medicinal product cannot supply enough quantities of orphan medicinal product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough therapy designation, Regenerative Medicine Advanced Therapy designation, Fast Track designation or Rare Pediatric Disease designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that any of our product candidates will receive marketing approval in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted Fast Track designation in the United States for B-VEC and for KB105. In addition, B-VEC was granted RMAT by the FDA and PRIME by the EMA. The receipt of any of these designations for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA and EMA procedures and does not assure ultimate approval by either the FDA or EMA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A RMAT/PRIME therapy product candidate is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease. Drugs designated as RMAT therapies by the FDA are eligible for accelerated approval and increased interaction and communication with the FDA designed to expedite the development and review process. If a drug, or biologic in our case, is intended for the treatment of a serious or life-threatening condition and the biologic demonstrates the potential to address unmet medical needs for this condition, the biologic sponsor may apply for FDA Fast Track designation. Even after having received Fast Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many biologics that have received Fast Track designation have failed to obtain approval. A sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. We received the designation of &#8220;rare pediatric disease&#8221; for B-VEC, KB105, KB104, and for KB407, which could qualify us to receive a Rare Pediatric Priority Review Voucher.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance we will receive RMAT, PRIME or breakthrough therapy or Fast Track designations for any of our other product candidates and the receipt of any of these designations for a product candidate may not result in a faster development process, review or approval and does not assure ultimate approval by the FDA. Further, even though we have received rare pediatric disease designation for B-VEC, KB105, KB104, and KB407, we may not experience a faster review or approval for a subsequent marketing application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a product candidate or indication to the exclusion of other product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited financial and managerial resources. As a result, we may forego or delay pursuit of opportunities with product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts focuses on the potential approval of B-VEC, KB105, KB301, KB104 and KB407, a key component our strategy is to discover, develop and potentially commercialize a portfolio of product candidates to treat orphan diseases and ultimately, non-orphan diseases. Identifying new product candidates requires substantial technical, financial and human resources, whether any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we may fail to successfully develop and commercialize such product candidates for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the research methodology used may not be successful in identifying potential product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competitors may develop alternatives that render our product candidates obsolete;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth may be impaired.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize and market our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several companies and institutions that are currently developing alternative autologous or palliative gene therapy approaches for DEB and cystic fibrosis. Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunities could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidate that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly or earlier than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render B-VEC or any future product candidate uneconomical or obsolete, and we may not be successful in marketing B-VEC or any future product candidate against competitors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, even if we commercialize a product candidate faster than our competitors, we could also face competition from lower cost biosimilars in the United States or in Europe.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the expiration or successful challenge of our patent rights, we could face litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any product candidate that we may develop and commercialize.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and testing of our product candidates. Product liability claims may be brought against us by participants enrolled in our clinical trials, patients, health care providers or others using, or administering any of our approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for our approved products; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">termination of clinical trial sites or entire trial programs; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increased regulatory scrutiny; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant litigation costs; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to or costly settlement with patients or other claimants; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product recalls for approved products or a change in the indications for which they may be used; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue; </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diversion of management and scientific resources from our business operations; and </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize our product candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any of our product candidates that are approved for commercial sale, we are, and will be, highly dependent upon physician and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity could have a material adverse impact on our financial condition or results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product liability insurance coverage may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operations. </span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in obtaining regulatory approvals of the process and facilities needed to manufacture our product candidates or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can begin to commercially manufacture our product candidates, we must pass a pre-approval inspection of our manufacturing facilities by the FDA. A manufacturing authorization must also be obtained from the appropriate EU regulatory authorities. The timeframe required for us to obtain such approvals is uncertain. To obtain approval, we will need to ensure that all our processes, methods and equipment are compliant with CGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with CGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The CGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with CGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing process used to produce our product candidates is complex, novel and has not been validated for commercial use. In order to produce enough quantities of our product candidates for future clinical trials and initial U.S. commercial demand, we will need to increase the scale of our manufacturing process. The production of our product candidates requires processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our manufacturing process to assure that the process works and that our product candidates are made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have established our own manufacturing facilities for our product candidates, we may also utilize third parties to conduct our product manufacturing. Therefore, we are subject to the risk that these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain the validation from the FDA of our CGMP manufacturing facilities, we may maintain third-party manufacturing capabilities in order to provide multiple sources of supply. We utilize a third-party for manufacturing of the sterile gel that is mixed with our in-house produced vector. In the event that these third-party manufacturers do not successfully carry out their contractual duties, meet expected deadlines or manufacture in accordance with regulatory requirements or if there are disagreements between us and these third-party manufacturers, we may not be able to manufacture our products for commercial or regulatory purposes. In such instances, we may need to locate an appropriate replacement third-party relationship, which may not be readily available or on acceptable terms, which would cause additional delay or increased expense and would thereby have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a third-party manufacturer fails to comply with applicable CGMP regulations, the FDA and foreign regulatory authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects to be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce our product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development timelines and our business, financial condition, results of operations and prospects.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to expand our market development capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any product revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To successfully commercialize B-VEC, and any other approved product candidates, we have expanded our capabilities to promote market access and build awareness. To successfully commercialize any products that may result from our development programs, we will need to further expand our market development organization, either on our own or with a third-party. The development of our own market development team is expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may enter into collaboration agreements regarding any of our product candidates with third parties to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize our products, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded medical affairs, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our products. If any of our product candidates is approved but fails to achieve market acceptance among physicians, patients or third-party payors, we will not be able to generate significant revenues from such product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our gene therapy product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy remains a novel technology. Ethical, social and legal concerns about gene therapy could result in additional regulations restricting or prohibiting our product candidates. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well- publicized adverse events, including cases of leukemia and death seen in trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product candidates are smaller than we believe they are, our product revenues may be adversely impacted, and our business may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have mainly focused our research and product development efforts to date on B-VEC for DEB. Our understanding of both the number of people who have this disease, as well as the subset of people with this disease who have the potential to benefit from treatment with B-VEC, are based on estimates in published literature. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of this disease. The number of patients in the United States, the EU and elsewhere may turn out to be lower than expected or these patients may not be otherwise amenable to treatment with B-VEC or may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there are several factors that could contribute to making the actual number of patients who receive B-VEC less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. Further, the severity of the progression of a disease up to the time of treatment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will likely diminish the therapeutic benefit conferred by a gene therapy due to irreversible cell damage. Lastly, certain patients&#8217; immune systems might prohibit the successful delivery of certain gene therapy products to the target tissue, thereby limiting the treatment outcomes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our product candidates will depend upon their degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the requisite approvals from the FDA in the United States, the EMA in the EU and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on the acceptance of physicians, patients and health care payors of gene therapy products in general, and our product candidates, in particular, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and our product candidates, if approved for commercial sale, will depend on several factors, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and safety of our product candidates as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy, potential and perceived advantages of our product candidates over alternative treatments, if available;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of our product candidates relative to alternative treatments, if any are available;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical indications for which our product candidates are approved by the FDA or the EMA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of physicians to prescribe new therapies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of the target patient population to try new therapies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relative convenience and ease of administration;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of market introduction of competitive products;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the availability of products and their ability to meet market demand;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">publicity concerning our product candidates or competing products and treatments;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any restrictions on the use of our products together with other medications; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">favorable third-party payor coverage and adequate reimbursement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates, if approved, which would adversely affect our revenue and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that coverage and reimbursement of pharmaceuticals may be increasingly restricted both in the U.S. and internationally. The escalating cost of health care has led to increased pressure on the health care industry to reduce costs. Drug pricing by pharmaceutical companies recently has come under increased scrutiny and continues to be subject to intense political and public debate in the U.S. and abroad. Government and private third-party payors have proposed health care reforms and cost reductions. A number of federal and state proposals to control the cost of health care, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding health care may affect coverage and reimbursement for medical treatment by third-party payors, which may render our product candidates, if approved, not commercially viable or may adversely affect our anticipated future revenues and gross margins.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our future products, which would adversely affect our anticipated revenue and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford our products. Accordingly, sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">appropriate for the specific patient;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cost-effective; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. In the United States, third-party payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare and Medicaid programs increasingly are used as models for how private payors and government payors develop their coverage and reimbursement policies. It is difficult to predict what CMS will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these types of products. Moreover, reimbursement agencies in the European Union may be more conservative than CMS. For example, several cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European Union Member States. It is difficult to predict what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations generally are subject to extensive government price controls and other market regulations and increasing emphasis on cost-containment initiatives in the EU, Canada and other countries may put pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. It also can take a significant amount of time after approval of a product to secure pricing and reimbursement for such product in many counties outside the United States. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by government and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Payors increasingly are considering new metrics as the basis for reimbursement rates, such as Average Sales Price, Average Manufacturer Price, and Actual Acquisition Cost. The existing data for reimbursement based on some of these metrics is relatively limited, although certain states have begun to survey acquisition cost data for the purpose of setting Medicaid reimbursement rates, and CMS has begun making pharmacy National Average Drug Acquisition Cost and National Average Retail Price data publicly available on at least a monthly basis. Therefore, it may be difficult to project the impact of these evolving reimbursement metrics on the willingness of payors to cover candidate products that we are able to commercialize. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional potential legislative and administrative changes. The downward </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products such as ours.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal and social issues related to genetic testing may reduce demand for our product candidates, if approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that prior to receiving certain gene therapies, patients may be required to undergo genetic testing. Genetic testing has raised concerns regarding the appropriate utilization and the confidentiality of information provided by genetic testing. Genetic tests for assessing a person&#8217;s likelihood of developing a chronic disease have focused public attention on the need to protect the privacy of genetic information. For example, concerns have been expressed that insurance carriers and employers may use these tests to discriminate based on genetic information, resulting in barriers to the acceptance of genetic tests by consumers. Concerns have also been raised about the accuracy of genetic testing. This could lead to governmental authorities restricting genetic testing or calling for additional regulation of genetic testing, particularly for diseases for which there is no known cure. Any of these scenarios could decrease demand for our product candidates, if approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for them outside of the United States, which would limit our market opportunities and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of B-VEC or other future product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for our product candidates, if approved, is also subject to approval. Obtaining a Marketing Authorization Application from the European Commission following the opinion of the EMA is a lengthy and expensive process. We submitted a request for MAA with the EMA in November 2022 for B-VEC for the treatment of DEB in patients 6 months and older. The Company was informed by the EMA in January 2023 to modify the PIP waiver request to include patients between birth and 6 months. The Company is modifying the application so that the MAA procedure can officially start in the second half of 2023 with an approval expected in early 2024. Even if a product candidate is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and the EU also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for any of our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing demand for compassionate use or expanded access of our unapproved therapies could negatively affect our reputation and harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our product candidates for illnesses for which there are currently limited to no available therapeutic options. At least one other company has been the target of disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide our product candidates under an expanded access corporate policy, our reputation may be negatively affected and our business may be harmed. Recent media attention to individual patients&#8217; expanded access requests has resulted in the introduction of legislation at the local and national level referred to as &#8220;Right to Try&#8221; laws, such as the Right to Try Act, which are intended to give patients access to unapproved therapies. New and emerging legislation regarding expanded access to unapproved drugs for life-threatening illnesses could negatively impact our business in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A possible consequence of both activism and legislation in this area is the need for us to initiate an unanticipated expanded access program or to make our product candidates more widely available sooner than anticipated. We are a small company with limited resources and unanticipated trials or access programs could result in diversion of resources from our primary goals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is high which could have a negative impact on the safety profile of our product candidates if we were to provide them to these patients in accordance with our expanded access corporate policy, which could cause significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. If we were to provide patients with our product candidates under our expanded access corporate policy, we may in the future need to restructure or pause ongoing compassionate use and/or expanded access programs in order to perform the controlled clinical trials required for regulatory approval and successful commercialization of our product candidates, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends upon our ability to identify, develop and commercialize product candidates based on our gene therapy platform. Research programs to identify new product candidates require substantial technical, financial and human resources. Although certain of our product candidates are currently in clinical or preclinical development, we may fail to identify other potential product candidates for clinical development for several reasons. For example, our research may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects, may be commercially impracticable to manufacture or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have commercial potential. Our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced significant growth in the number of employees and infrastructure and may experience difficulties in managing this growth. If we are unable to manage expected growth in the scale and complexity of our operations, our performance may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a period of significant expansion in personnel and of our facilities, infrastructure and overhead as we develop our own manufacturing facilities, build our sales, marketing and distribution infrastructure that we believe will be necessary to commercialize B-VEC, and increase our research and development efforts. The anticipated commercialization of B-VEC and our ongoing development of other product candidates, will continue to impose significant added capital requirements, as well as added responsibilities on members of management, including the need to identify, recruit, maintain and integrate new personnel. Our future financial performance and our ability to compete effectively will depend, in part, on our ability to manage our growth effectively. If we are successful in executing our business strategy, we will need to expand our managerial, operational, financial and other systems and resources to manage our operations, continue our research and development activities and build a commercial infrastructure to support commercialization of any of our product candidates that are approved for sale. Future growth would impose significant added responsibilities on members of management. It is likely that our management, finance, development personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and product candidates requires that we continue to develop more robust business processes and improve our systems and procedures in each of these areas and to attract and retain enough numbers of talented employees. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development and growth goals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees and scientific advisors and to attract, retain and motivate qualified personnel.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on members of our management team, the loss of whose services may adversely impact the achievement of our objectives. Our employees and scientific advisors are at-will employees and consultants, and the loss of one or more of them might impede the achievement of our research, development and commercialization objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining other qualified employees and scientific advisors for our business, including scientific and technical personnel, also will be critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators and advisors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and advisors. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions, provide accurate information to the FDA, the EMA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. Sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in criminal and civil penalties or sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines, criminal penalties, or other sanctions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future drug candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., there have been and continue to be a number of legislative efforts to contain healthcare costs. For example, in March 2010, PPACA, as amended by the Health Care and Education Reconciliation Act, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things: (i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expands the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v) establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the PPACA, and we expect there will be additional challenges in the future. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the PPACA. Most recently, under President Biden, the Department of Justice dropped support of two Supreme Court cases challenging the PPACA in addition to a case before the U.S. Court of Appeals for the Fifth Circuit, and in June 2021, the Supreme Court upheld the PPACA in a 7-2 opinion that the states and individuals that challenged the individual mandate did not have standing to challenge the law. Further, on January 28, 2021, President Biden signed an executive order to expand access to PPACA coverage, stating that it is the &#8220;policy&#8221; of the Biden administration to protect and strengthen the PPACA and directing agencies to consider suspending, revising, or rescinding actions related to President Trump&#8217;s executive orders that are inconsistent with this policy position. However, other legislators continue efforts to repeal and replace other elements of the PPACA. While the ultimate outcome of PPACA result of these efforts is not yet known, any changes that result in price controls reduce access to and reimbursement for care or add additional regulations may have an adverse effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the impact that such actions against the PPACA or other health care reform under the Biden administration will have on our business, and there is uncertainty as to what healthcare programs and regulations may be implemented or changed at the federal and/or state level in the United States, or the effect of any future legislation or regulation. However, it is possible that such initiatives could have an adverse effect on our ability to obtain approval and/or successfully commercialize products in the United States in the future. For example, any changes that reduce, or impede the ability to obtain, reimbursement for the type of products we intend to commercialize in the United States (or our products more specifically, if approved) could adversely affect our business plan to introduce our products in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Congress has not passed repeal legislation, the Tax Reform Act includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Further, the Bipartisan Budget Act of 2018, among other things, amended the PPACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; Congress may consider other legislation to repeal and replace elements of the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the time for Medicare contractors to recoup Medicare overpayments to providers from three to five years. On August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. The IRA includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government. In relevant part, the IRA allows Medicare to negotiate prices for certain prescription drugs, requires drug manufacturers to pay a rebate to the federal government if prices for single-source drugs and biologicals covered under Medicare Part B and nearly all covered drugs under Part D increase faster than the rate of inflation (&#8220;CPI-U&#8221;) and caps out of pocket spending for Medicare Part D enrollees and makes other benefit design changes to Medicare Part D intended to lower drug costs for enrollees and Medicare. These requirements, which begin to go into effect in 2023, will affect the amounts available through reimbursement for Medicare programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These significant changes made under the IRA, which will affect pricing for both brand and generic drugs, may affect reimbursement for our products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products and the cost of prescription drugs to consumers and government healthcare programs, which have resulted in several recent Congressional inquiries and proposed and enacted bills designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, the United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs to limit the growth of government paid health care costs. For example, the United States government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Individual states in the United States have also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been increasingly passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes may affect our business, including those governing enrollment in federal healthcare programs, reimbursement changes, fraud and abuse enforcement, and expansion of new programs, such as Medicare payment for performance initiatives. On October 14, 2022, President Biden signed Executive Order 14087 on &#8220;Lowering Prescription Drug Costs for Americans.&#8221; The Executive Order specifically requests that the Center for Medicare and Medicaid Innovation consider &#8220;models that may lead to lower cost sharing for commonly used drugs and support value-based payment that supports high-quality care.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcomes of the findings made under the Executive Order could lead to further drug pricing initiatives that could affect reimbursement for our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These initiatives, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms could result in reduced demand for our product candidates or additional pricing pressures and may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain FDA approval for our product candidates and begin commercializing them in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Anti-Kickback Statute, federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business as well as other jurisdictions. The laws that will affect our operations include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti-Kickback Statute to clarify that a person or entity does not have to have actual knowledge of this statute or specific intent to violate it;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent. The PPACA provides that a claim for items or services resulting from an Anti-Kickback Statute violation is a false claim under the federal FCA. Cases against pharmaceutical manufacturers support the view that certain marketing practices, including off-label promotion, may implicate the FCA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Care Fraud statute imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Notification Rules under HITECH and the Genetic Information Nondiscrimination Act; Other modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the CMS </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances, such as specific disease states; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Often, to avoid the threat of treble damages and penalties under the FCA, health care providers will resolve allegations in a settlement without admitting liability. Any such settlement could materially affect our business, financial operations, and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Moreover, certain environmental laws may impose liability without regard to fault or legality of the action at the time of its occurrence. We also could incur significant costs associated with civil or criminal fines and penalties. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may incur substantial costs to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including conditions that are outside of our control. Inflation and rising interest rates have caused volatility in the capital and credit markets, and it is unclear how long such volatility will continue. A severe or prolonged economic downturn could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber-security incidents, including data security breaches or computer viruses, could harm our business by disrupting our operations, damaging our reputation or exposing us to liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, process, store, and transmit, often electronically, confidential data of others, including the participants in our clinical trials. Unauthorized access to our computer systems or stored data could result in the theft or improper disclosure of confidential information, the deletion or modification of records, or could cause interruptions in our operations. These cyber-security risks increase when we transmit information from one location to another, including transmissions over the Internet or other electronic networks. Despite implemented security measures, our facilities, systems, and procedures, and those of our third-party service providers, may be vulnerable to security breaches, acts of vandalism, software viruses, misplaced or lost data, programming and/or human errors, or other similar events which may disrupt our operations or expose confidential information of the patients who participate in our clinical trials. Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information of others, whether by us or a third-party, could: (i) subject us to civil and criminal penalties; (ii) have a negative impact on our reputation; or (iii) expose us to liability to third parties or government authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters could severely disrupt our operations or the operations of third-party suppliers or service providers and have a material adverse effect on our business, financial condition, results of operations and prospects. The severity and frequency of weather-related natural disasters have been amplified, and are expected to continue to be amplified by, global climate change. Such natural disasters may cause, damage to and/or disrupt our operations, which may result in a material adverse effect on our product sales, if approved, business and results of operations. Moreover, climate change may also result in various chronic physical changes, such as changes in temperature or precipitation patterns or sea-level rise, that may also have an adverse impact on our operations. Our suppliers, vendors and business partners also face similar risks, and any disruption to their operations could have an adverse effect on our supply and manufacturing chain. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facilities, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans that we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. Substantially all our current supply of our product candidates is located at our manufacturing facility in Pittsburgh, Pennsylvania. We are constructing an additional manufacturing facility for the commercial supply of our products. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased attention to, and evolving expectations for, environmental, social, and governance (&#8220;ESG&#8221;) initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies across industries are facing increasing scrutiny from a variety of stakeholders related to their ESG and sustainability practices. Expectations regarding voluntary ESG initiatives and disclosures may result in increased costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) to improve the ESG profile of our company and/or products, such initiatives may be costly and may not have the desired effect. Moreover, we may not be able to successfully complete such initiatives due to factors that are within or outside of our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently voluntary.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain market participants, including major institutional investors and capital providers, use third-party benchmarks and scores to assess companies&#8217; ESG profiles in making investment or voting decisions. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us or our industry, which could negatively impact our share price as well as our access to and cost of capital. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees or customers, which may adversely impact our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect there will likely be increasing levels of regulation, disclosure-related and otherwise, with respect to ESG matters. For example, the SEC has published proposed rules that would require companies to provide significantly expanded climate-related disclosures in their periodic reporting, which may require us to incur significant additional costs to comply, including the implementation of significant additional internal controls processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors. These and other changes in stakeholder expectations will likely lead to increased costs as well as scrutiny that could heighten all of the risks identified in this risk factor. Additionally, many of our customers and suppliers may be subject to similar expectations, which may augment or create additional risks, including risks that may not be known to us.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate U.S. and foreign patent protection for our product candidates, including our current product candidates, and any future product candidates we may develop, and/or our vector platform, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technologies similar or identical to ours, and our ability to successfully commercialize our current product candidates, any future product candidates we may develop, and our platform technologies may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current product candidates, and additional product candidates in our pipeline, and current and future innovations related to our vector platform. The patent prosecution process is expensive, time-consuming and complex; we may not be able to file, prosecute, maintain, and/or enforce all necessary or desirable patent applications and issued patents at a reasonable cost or in a timely manner. We currently have seven issued patents in the United States: (1) U.S. Patent No. 9,877,990, covering, in part, pharmaceutical formulations comprising our lead clinical product B-VEC, as well as methods of its use for treating wounds, disorders, and diseases of the skin, which we refer to as the &#8217;990 patent; (2) U.S. Patent No. 10,155,016 covering pharmaceutical compositions containing B-VEC formulated for myriad routes of administration; (3) U.S. Patent No. 10,441,614 covering aspects of our vector platform technology, and its uses in delivering any gene of interest to the skin; (4) U.S. Patent No. 10,525,090, covering pharmaceutical compositions comprising our clinical product candidate, KB105, and methods of its use for treating TGM1-deficient autosomal recessive congenital ichthyosis; (5) U.S. Patent No. 10,786,438 covering pharmaceutical compositions comprising vectors encoding cosmetic proteins, including our product candidate, KB301, and methods of its use for improving skin condition, quality, and/or appearance; (6) U.S. Patent No. 10,829,529 covering methods of using KB407 for the treatment of cystic fibrosis and other diseases causing progressive lung destruction; and (7) U.S. Patent No. 11,185,564 covering aspects of our vector platform technology, and its uses in delivering any gene of interest to the skin. Furthermore, we have nine international patent applications filed in accordance with the Paris Cooperation treaty directed to multiple discovery, preclinical, and clinical programs, including B-VEC, KB105, KB301, KB104, and KB407, as well as multiple patent applications filed in foreign jurisdictions stemming from these international applications. B-VEC is also the subject of patents granted in Australia, Europe, Japan, Mexico, New Zealand, and Singapore including European Patent No. 3 377 637 B1, covering pharmaceutical compositions containing B-VEC as well as uses thereof.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are granted the patents we are currently pursuing, they may not issue in a form that will provide us with the full scope of protection we desire, they may not prevent competitors or other third parties from competing with us, and/or they may not otherwise provide us with a competitive advantage. Our competitors, or other third parties, may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. For example, there is no assurance that the '990 patent or any other patent we are granted will prevent third parties from developing competing technologies. Moreover, our patent estate does not preclude third parties from having intellectual property rights that could interfere with our freedom to use our platform, including for dermatological or pulmonary indications. Even assuming patents issue from our pending and future patent applications, changes in either the patent laws or interpretation of the patent laws in the United States and foreign jurisdictions may diminish the value of our patents or narrow their scope of protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may not be aware of all third-party intellectual property rights potentially relating to technologies similar to our own. Publications of discoveries in the scientific literature often lag their actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after earliest priority date or, in some cases, not at all until patents are issued. Therefore, it is impossible to be certain that we were the first to develop the specific technologies as claimed in any owned patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on each and every one of our product candidates, and current and future innovations related to our vector platform, in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States may differ in scope from those eventually granted in the United States. Thus, in some cases, we may not have the opportunity to obtain patent protection for certain technologies in some jurisdictions outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products. Such challenges in enforcing rights in these countries could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our current and future patent rights in foreign jurisdictions could result in substantial costs and may divert our efforts and attention from other aspects of our business; could put our patents at risk of being invalidated or interpreted narrowly; could put any future patent applications, including continuation and divisional applications, at risk of not issuing; and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce any intellectual property rights around the world stemming from intellectual property that we develop may be inadequate to obtain a significant commercial advantage in these foreign jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability (and the ability of any potential future collaborators) to develop, manufacture, market and sell our product candidates, and to freely use our proprietary technologies (e.g., without infringing the rights and intellectual property of others). Many companies and institutions have filed, and continue to file, patent applications related to various aspects of gene therapy. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing, and can be revised before issuance, there may be applications now pending which may later result in issued patents that a third-party asserts are infringed by the manufacture, use, sale, or importation of our products. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates or related technologies, including, for example, interference proceedings, post grant review challenges, and inter partes review before the USPTO. Our competitors or other third parties may assert infringement claims against us, alleging that our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue, and against whom our patent portfolio may therefore have no deterrent effect.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patents or other intellectual property rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize our products. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. In such a hypothetical situation, there is no assurance that a court of competent jurisdiction would find that our product candidates or technologies do not infringe a third-party patent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcomes are uncertain. If we are found, or believe there is a risk that we may be found, to infringe a third-party&#8217;s valid and enforceable intellectual property rights, we could be required (or may choose) to obtain a license from such a third-party to continue developing, manufacturing and marketing our technologies. However, we may not be able to obtain any required license on commercially reasonable terms, if at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and further, it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technologies. We also could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our technologies or force us to cease some or all our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming. Competitors may infringe our current or future patents, should such patents issue, or we may be required to defend against claims of infringement or other unauthorized use of intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our scientific and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating, or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been subject to claims asserting that we, our employees or our advisors have wrongfully used or disclosed alleged trade secrets of other parties or claims asserting ownership of what we regard as our own intellectual property and we may face other such claims in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our employees or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including potential competitors, and we have and may in the future enter into agreements providing us with rights to intellectual property of third parties for limited purposes. Although we try to observe the terms of agreements under which we obtain access to third-party intellectual property and to ensure that our employees and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of third parties or the current or former employers of employees or advisors. If we fail in defending any such claims, in addition to paying monetary damages, we may be subject to an injunction and may lose valuable intellectual property rights or personnel. Moreover, any such litigation, or the threat thereof, may adversely affect our ability to hire new employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which would have an adverse effect on our business, results of operations, and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is our policy to require our employees and contractors who may be involved in the conception of intellectual property to execute agreements assigning such intellectual property rights to us, unforeseen complications may arise when fully and adequately executing such an agreement with each party who, in fact, conceives of intellectual property that we regard as our own. Examples of such complications may include, for example, when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. Such complications may lead to us being forced to bring claims against third parties or current and former employees, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Moreover, individuals executing agreements with us may have preexisting or competing obligations to a third-party, such as an academic institution, and thus an agreement with us may be insufficient in fully perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we may own may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act included several significant changes to U.S. patent law, including provisions that affected the way patent applications are prosecuted, and altered strategies regarding patent litigation. These provisions also switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allowed third-party submissions of prior art to the USPTO during patent prosecution, and set forth additional procedures to attack the validity of a patent through various post grant proceedings administered by the USPTO. As patent reform legislation can inject serious uncertainty into the patent prosecution and litigation processes, it is not clear what impact future patent reform legislation will have on the operation of our business. However, such future legislation, and its implementation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain given the ever evolving and constantly shifting nature of precedential patent cases decided by both the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. We cannot assure you that our efforts to seek patent protection for our technology and product candidates will not be negatively impacted by the future court decisions or changes in guidance or procedures issued by the USPTO. These decisions, and any guidance issued by the USPTO (or changes thereto), could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property rights in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of registering our trademarks and trade names. Once trademarks or trade names have been registered, they may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which are important for building name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. There also could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trade names that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to patents, trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of current and future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may be able to make gene therapy products that are similar to our product candidates but that are not covered by the claims of our current patents, or of patents that we may own or license in the future;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we, or any future license partners or collaborators, might not have been the first to file patent applications covering certain aspects of the concerned technologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may independently develop similar or alternative technologies, or duplicate any of our technologies, potentially without falling within the scope of our current or future issued claims, thus not infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">it is possible that our filed or future patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issued patents to which we currently hold rights or to which we may hold rights in the future may be held invalid or unenforceable, including as a result of legal challenges by third parties or our competitors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may have access to any future intellectual property rights licensed to us on a non-exclusive basis;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors might conduct research and development activities in countries where we do not have or pursue patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents or other intellectual property rights of others may have an adverse effect on our business; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may choose not to file a patent application covering certain of our trade secrets or know-how, and a third-party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_40"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Chief Executive Officer and Chairman of the Board of Directors and our founder, President, Research &amp; Development  and director will have the ability to substantially influence all matters submitted to stockholders for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, Krish S. Krishnan and Suma M. Krishnan, our Chief Executive Officer and Chairman of the Board and our founder, President, Research &amp; Development and director, respectively, in the aggregate, beneficially owned shares representing approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly 15% of our capital stock. As a result, they will be able to substantially influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons would substantially influence the election of directors and approval of any merger, consolidation or sale of all or substantially all our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in management of our company that our public stockholders disagree with.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts publish negative evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If securities analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital could cause the price of our common stock to decline and cause dilution to our stockholders, restrict our operations or require us to relinquish rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We may issue additional common stock or restricted securities as part of such financing activities and any such issuances may have a dilutive effect on our then-existing stockholders. Sales of substantial amounts of our common stock in the open market, or the availability of such shares for sale, could adversely affect the price of our common stock. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incurrence of indebtedness would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity or debt financings when needed, and instead raise additional capital through marketing and distribution agreements or other collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our current and future product candidates, technologies, future revenue streams or discovery programs or grant licenses on terms that may not be favorable to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our common stock has been and is likely to continue to be volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies specifically has experienced extreme volatility that has often been unrelated to the operating performance of such companies. As a result of this volatility, you may not be able to sell your common stock at or above the price that you paid for it. The market price of our common stock may be influenced by many factors, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully proceed to and conduct clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain regulatory approval for our product candidates and our ability to successfully commercialize any of our approved product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commencement or termination of collaborations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of our efforts to discover, develop, acquire or in-license additional product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to manufacture adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain effective internal control over financial reporting, we may not be able to accurately report our financial results, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and is required to have an independent auditor assess the effectiveness of our internal control over financial reporting, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;). We cannot give any assurances that material weaknesses will not be identified in the future in connection with our compliance with the provisions of Section 404 of the Sarbanes-Oxley Act. The existence of any material weakness would preclude a conclusion by management and our independent auditors that we maintained effective internal control over financial reporting. Our management may be required to devote significant time and expense to remediate any material weaknesses that may be discovered and may not be able to remediate any material weakness in a timely manner. The existence of any material weakness in our internal control over financial reporting could also result in errors in our financial statements that could require us to restate our financial statements, cause us to fail to meet our reporting obligations and cause investors to lose confidence in our reported financial information, all of which could lead to a decline in the per-share trading price of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require the approval of the holders of at least 80% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our bylaws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash, cash equivalents and marketable securities and may not use them effectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents and marketable securities and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuing additional shares of our common stock could cause the price of our common stock to decline and cause dilution to our stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 25.8 million shares of common stock issued and outstanding, and 80.0 million shares authorized for issuance. As of December&#160;31, 2022, we also had outstanding options to purchase 3.6 million shares of common stock with a weighted-average exercise price of $61.50 per share. Outstanding vested options are likely to be exercised if the market price of our common stock exceeds the applicable exercise price. As of December&#160;31, 2022, we had 66,600 non-vested restricted stock awards (&#8220;RSAs&#8221;) at a weighted-average price of $78.89. We expect to issue additional equity awards to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors and employees. The issuance of restricted common stock or common stock upon exercise of any outstanding options would be dilutive, and may cause the market price for a share of our common stock to decline.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we lease approximately 54,000 square feet of combined laboratory and office space in Pittsburgh, Pennsylvania that we use for our research, development and manufacturing efforts. The lease for approximately 7,000 square feet of office space expires in September 2023, and the lease covering the remaining combined laboratory and office space expires in October 2031. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we also lease additional U.S. office space in Boston, Massachusetts and European office space in Zug, Switzerland, and Amsterdam, Netherlands.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area, which contained an option to purchase the building. In January 2021, we entered into a Purchase and Sale Agreement (&#8220;PSA&#8221;) with Northfield I, LLC, an Ohio limited liability company to acquire ASTRA, and the related purchase closed in March 2021. In June 2021, we entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. The facility is under construction and expected to be completed and validated in 2023. Refer to Note 7 of the Notes to the Consolidated Financial Statements included in Part II of Item 8 of this Annual Report on Form 10-K for more information regarding this transaction. </span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth in Note 6 of the Notes to the Consolidated Financial Statements included in Part II Item 8 of this Annual Report on Form 10-K is incorporated by reference into this Item 3.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been listed on the Nasdaq Capital Market under the symbol &#8220;KRYS&#8221; since September 2017. Prior to that, there was no public market for our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;20, 2023, there were two stockholders of record of our common stock. We are unable to estimate the total number of stockholders represented by these record holders, as many of our shares are held by brokers and other institutions on behalf of our stockholders. The closing price of our common stock was $78.25 per share as of February&#160;20, 2023 as reported on the Nasdaq Capital Market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation and growth of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no repurchases of shares of common stock made during the three months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of unregistered securities by us during the last three calendar years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a graph comparing the cumulative total return on an indexed basis of a $100 investment in the Company&#8217;s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index commencing on December 31, 2017 and continuing through December&#160;31, 2022. The graph assumes our closing sale price on December 31, 2017 of $10.52 per share as the initial value of our common stock for indexing purposes.&#160;Points on the graph represent the performance as of the last business day of each of the months indicated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section&#160;18 of the Exchange Act or incorporated by reference into any filing of Krystal Biotech, Inc. under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such filing.&#160;The past performance of our common stock is no indication of future performance.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="krys-20221231_g2.jpg" alt="krys-20221231_g2.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span><br/></span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with the consolidated financial statements and related notes thereto included in this Annual Report on Form 10-K. In addition to historical information, this report contains forward-looking statements that involve risks and uncertainties which may cause our actual results to differ materially from plans and results discussed in forward-looking statements. We encourage you to review the risks and uncertainties discussed in the sections entitled Item 1A. &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements&#8221; included at the beginning of this Annual Report on Form 10-K. The risks and uncertainties can cause actual results to differ significantly from those forecast in forward-looking statements or implied in historical results and trends. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This section of this Form 10-K generally discusses 2022, 2021 and 2020 items and year-to-year comparisons between 2022 and 2021, and 2021 and 2020 of the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s results of operations and cash flows. </span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions. Our innovative technology platform is supported by in-house, commercial scale CGMP manufacturing capabilities. Refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part I, Item 1 - Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information about our clinical development pipeline and research programs and the status of our product candidates.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Highlights and Recent Developments:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">B-VEC is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of DEB, a serious rare skin disease caused by missing or mutated COL7 protein. We submitted a BLA to the FDA for B-VEC for the treatment of DEB in June 2022. The FDA accepted the BLA in August 2022 granting B-VEC a Priority Review Designation with a PDUFA action date of February 17, 2023. In January 2023, the FDA notified us, that based on manufacturing information submitted to the Agency on December 20, 2022 in response to an information request from the FDA, the PDUFA date has been revised to May 19, 2023. In this notification, we were also informed that there will be no Advisory Committee meeting for B-VEC and a REMS program is not needed for the B-VEC application. Commercial readiness efforts have been underway for the past two years as we prepare for the potential approval of B-VEC by the FDA and the EMA. In the United States our Medical Science Liaisons have been interacting with and educating HCPs on DEB and the importance of genetic testing in ensuring an accurate diagnosis. We have completed the build of Krystal Connect, our US in-house patient services call center staffed with Krystal employees, and are ready, pending FDA approval of B-VEC, to assist patients, care givers and HCPs interested in accessing B-VEC. Additionally, we have hired, trained and deployed commercial field teams who are interacting with physicians, patients, commercial payers across the U.S. to educate on DEB and to prepare for a U.S. launch of B-VEC. We are interacting frequently with the leading physicians in the major markets across Europe and in Japan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We submitted a request for MAA with the EMA in November 2022 for B-VEC for the treatment of DEB in patients 6 months and older. The Company was informed by the EMA in January 2023 to modify the PIP waiver request to include patients between birth and 6 months. The Company is modifying the application so that the MAA procedure can officially start in the second half of 2023 with an approval expected in early 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KB105 is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of TGM1-ARCI, a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. On July 1, 2021, we announced complete data from the Phase 1 trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response. Details of the Phase 1/2 study can be found at www.clinicaltrials.gov under NCT identifier NCT04047732. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing included on this website shall be deemed incorporated by reference into this Annual Report on Form 10-K.  We plan to initiate a Phase 2 study in 1H 2023.   </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. The FDA has granted KB104 rare pediatric designation for the treatment of Netherton Syndrome.  We plan to file an IND and initiate a clinical trial of KB104 to treat patients with Netherton Syndrome in 2023. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length CFTR transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated CFTR protein. On September 29, 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study of inhaled KB407 in patients with cystic fibrosis, and trial initiation is anticipated in first half of 2023. In August 2022, we announced that the FDA had accepted our IND application to evaluate KB407 in a clinical trial to treat patients with cystic fibrosis. We are closely working with Therapeutics Development Network (&#8220;TDN&#8221;) of the Cystic Fibrosis Foundation (&#8220;CFF&#8221;) to validate our Phase 1 clinical protocol and plan on initiating a Phase 1 clinical trial in the US in first half of 2023.   </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KB408 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SERPINA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene, that encodes for normal human alpha-1 antitrypsin protein, for the treatment of alpha-1 antitrypsin deficiency ("AATD"). We presented preclinical pharmacology data for KB408 at the European Society of Gene &amp; Cell Therapy Virtual Congress that was held October 19-22, 2021. We are planning to file an IND for KB408 to treat AATD patients in 2023.   </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KB301 is a solution formulation of our novel vector for intradermal injection designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen. We initiated a Phase 1 clinical trial, the PEARL-1 trial, for the treatment of aesthetic skin conditions on August 25, 2020. The Phase 1 dose-ranging trial evaluated the safety, tolerability, and initial efficacy of intradermal injections of KB301 in adult subjects aged 18-75. Details of the Phase 1 study can be found at www.clinicaltrials.gov under NCT identifier (NCT04540900). Nothing included on this website shall be deemed incorporated by reference into this Annual Report on Form 10-K. Complete results from Cohort 1 focused on safety were presented at the 2021 SID Annual Meeting. In March 2022, we announced positive proof-of-concept efficacy and safety data from Cohort 2 of the PEARL-1 study of KB301 for the treatment of aesthetic skin indications. Cohort 2 is a randomized, double-blind, placebo-controlled clinical trial that evaluated the safety and efficacy of KB301 for the improvement of fine lines and skin texture in the lower and upper cheek and for improvement in skin thickness in the knee. Cohort 2 enrolled 27 subjects across two trial sites. Bilateral treatment areas included the neck behind the ear to assess initial safety and on the cheek below and above the zygomatic arch (lower and upper cheek), and around the knee. Subjects were randomized 2:1 to receive low dose KB301 or placebo in the upper cheek and knee as multiple micro depot injections over the selected treatment area with a 33 G needle. Subjects receiving KB301 in the lower check were randomized 2:1 to receive either low dose KB301, high dose KB301 or placebo. Four patients dropped out of the Cohort 2 study &#8211; one subject following the initial safety assessment behind the ear, two subjects for unspecified reasons, and one subject due to unevenness in face between active and placebo during the study. A subset of subjects from the PEARL-1 Cohort 2 trial (Cohort 3) were enrolled into a durability trial to look for duration of effect, reduction of the unevenness in placebo treated sites, and for long term safety monitoring. Ten subjects from the PEARL-1 Cohort 2 study were enrolled in durability trial, an open-label study to assess duration of effect below the zygomatic arch (the lower cheek area). The extension cohort enrolled subjects who had received the high dose regimen of KB301 during the efficacy cohort in one or both of their lower cheeks. Subject Satisfaction Scores and Investigator Assessments were measured monthly for three consecutive visits that correspond to timepoints up to nine-months following administration of the last dose of KB301. In addition, subjects with placebo-treated lower cheeks were dosed with KB301 during the open-label extension cohort to normalize their appearance. In November 2022, we announced nine-month durability of effect in Cohort 3 of the PEARL-1 study of KB301. We are planning to initiate a Phase 2 study in fine lines in 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeune Aesthetics has several other aesthetic medicine product candidates in various stages of preclinical development reflected in the chart above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1- Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, we presented additional results from our Phase 3 study of the clinical efficacy and safety of B-VEC for the treatment of DEB at the 2022 American Academy of Dermatology Annual Meeting.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, results from the complete Phase 1/2 study of topical B-VEC for the treatment of DEB were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Medicine.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 5, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1 million after deducting selling commissions of approximately $900 thousand.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 28, 2022, the Company entered into a final settlement agreement with PeriphaGen, Inc. (&#8220;PeriphaGen&#8221;) to resolve all claims in the trade secret litigation filed by PeriphaGen in May 2020. We paid PeriphaGen an upfront payment of $25.0 million for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of the Company's first product by the FDA, the Company will pay PeriphaGen an additional $12.5 million, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, following feedback from the FDA, we announced that we planned to offer patients with DEB, who were enrolled in the GEM-3 OLE, the opportunity to be dosed in their homes by a health care professional.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, Jeune Aesthetics announced the formation and members of its Scientific Advisory Board, comprised of industry leaders to serve as strategic advisors assisting with program strategy and clinical development.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, we presented new data entitled &#8220;GEM-3: phase 3 safety and immunogenicity results of Beremagene Geperpavec (&#8220;B-VEC&#8221;), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)&#8221; at the SID 2022 Annual Meeting.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2022 full results from the GEM-3 trial of B-VEC for DEB were published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date the impact of the COVID-19 pandemic on our business and clinical trials in the U.S. has been minimal. We will continue to assess the potential impact of the pandemic on our business and operations, including our supply chain and preclinical and clinical trial activities. Outside of the U.S., we have experienced pandemic-related delays in clinical trial initiation in Australia, and we will continue to closely monitor the impact that future pandemic developments have on this and our other clinical trials, going forward. For additional information regarding the impact of the coronavirus pandemic, please see &#8220;Risk Factors - Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development efforts of our product candidates and adversely impact our business.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">expenses incurred under agreements with contract manufacturing organizations (&#8220;CMOs&#8221;), consultants and other vendors that conduct our preclinical activities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">payroll related expenses, including stock-based compensation expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense internal research and development costs to operations as incurred. We expense third-party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided to us by our vendors. We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue our open label extension study for B-VEC, resume dosing with KB105 Phase 1/2 clinical trial, initiate a Phase 2 trial for KB301, initiate Phase 1 trials for KB407, initiate a Phase 1 trial for KB104, and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of clinical trials, and, as a result, the actual costs to complete clinical trials may exceed the expected costs.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and other related costs, including stock-based compensation, for personnel in our executive, commercial, business development and other administrative functions. General and administrative expenses also include professional fees associated with corporate and intellectual property related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include travel expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates. These increases will likely include increased costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate that we will continue to increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASTRA Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we closed on the purchase of the building that was constructed to house our second CGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who manages the construction of ASTRA. Further, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. We expect to continue to incur significant capital expenditures related to ASTRA as we construct and validate the facility, which is expected to be completed in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of non-cash interest expense recognized to accrete the build to suit financial obligation to a balance that equaled the cash consideration that was paid upon the close of the purchase of ASTRA.  </span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_70"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial position and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, we evaluate estimates which include, but are not limited to, estimates related to clinical trial and contract manufacturing prepayments and accruals, stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation during the period. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from those estimates or assumptions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses, prepaid assets and other current liabilities. This process involves reviewing open contracts and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments, communicating with our personnel to identify services that have been performed for us and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued research and development expenses, prepaid assets and other current liabilities as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of accrued research and development expenses, prepaid assets and other current liabilities include fees paid to contract manufacturers made in connection with the manufacturing of preclinical and clinical trials materials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to clinical manufacturing on our estimates of the services performed pursuant to contracts with the entities producing clinical materials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under these types of contracts depend heavily upon the successful completion of many separate tasks involved in the manufacturing of drug product. In accruing service fees, we estimate the time period over which services will be performed, and the actual services performed in each period. If our estimates of the status and timing of services performed differs from the actual status and timing of services performed we may report amounts that are too high or too low in any particular period. To date, there have been no material differences from our estimates to the amount actually incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have applied the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 718&#8221;), to account for stock-based compensation. We recognize compensation costs related to stock options granted based on the estimated fair value of the awards on the date of grant. Described below is the methodology we have utilized in measuring stock-based compensation expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the amount of stock-based compensation to be recorded requires us to develop estimates of the fair value of stock-based awards as of their measurement date. We recognize stock-based compensation expense over the requisite service period, which is the vesting period of the award. Calculating the fair value of stock-based awards requires that we make  assumptions. We use the Black-Scholes option pricing model to value our stock option awards. Use of this valuation methodology requires that we make assumptions as to the volatility of our common stock, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. Once our own sufficient historical volatility data was obtained, we eliminated the use of a representative peer group and as of Q4 2021 we use only our own historical volatility data in its estimate of expected volatility given that there is now sufficient amount of historical information regarding the volatility of our own stock price. We use the simplified method to calculate the expected term as prescribed by the SEC Staff Accounting Bulletin No.&#160;107,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we do not have sufficient historical stock option activity data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention of paying cash dividends. The risk-free interest rate used for each grant is based on the U.S. Treasury yield curve in effect at the time of grant for instruments with a similar expected life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our lease agreements in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;). As our lease agreements do not provide an implicit rate and as we do not have external borrowings, we use an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that we would expect to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that we have control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, we record a construction-in-progress asset (&#8220;CIP&#8221;) and corresponding financial obligation on the consolidated balance sheet. Once the construction is complete, an assessment will be performed to determine whether the lease meets certain &#8220;sale-leaseback&#8221; criteria.  If the sale-leaseback criteria are determined to be met, we will remove the asset and related financial obligation from the balance sheet and treat the building lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the &#8220;sale-leaseback&#8221; criteria, the lease will be treated as a financing obligation and we will depreciate the asset over its estimated useful life for financial reporting purposes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Years Ended December 31, 2022, 2021 and 2020</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 vs.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,196)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,275)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,999)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,921)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,276)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,975)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,570)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,167)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,405)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,403)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $14.6 million for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021. Higher research and development expenses were due to increases in payroll related expenses of $8.9 million which is primarily driven by an increase in personnel to support overall growth and includes a $4.5 million increase in stock-based compensation, an increase in outsourced research and development activities of $2.3 million, an increase in preclinical, clinical and pre-commercial manufacturing activities of $1.0 million, and an increase in other research and development expenses of $2.4 million, primarily due to increases in depreciation and licensing fees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $9.9 million for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. Higher research and development expenses were due to increases in preclinical, clinical and pre-commercial manufacturing activities of $3.3 million, payroll related expenses of approximately $3.1 million which is primarily driven by an increase in personnel to support overall growth and includes a $2.4 million increase in stock-based compensation,  an increase in outsourced research and development activities of $2.0 million, travel related expenses associated with our clinical trial sites of $187 thousand, and other research and development expenses of $1.3&#160;million, primarily due to depreciation and rent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $37.3 million for the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021. Higher general and administrative spending was due largely to increased payroll related expenses of approximately $28.8 million which is primarily driven by an increase in personnel to support overall growth and includes an approximate $13.4 million increase in stock-based compensation, increased commercial preparedness expenses of approximately $5.7 million, increased medical affairs costs of $581 thousand, increased travel costs of $536 thousand, and an increase in other administrative expenses of $2.9 million, primarily due to increases in utilities, information technology costs, and conference fees.  These increases were partially offset by a decrease in net legal costs of $1.2 million, which consists of a decrease in legal and professional fees of $2.8 million offset by a decrease in litigation proceeds of approximately $1.6 million, due primarily to the settlement of the PeriphaGen litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $25.3 million for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020. Higher general and administrative spending was due largely to increased payroll related expenses of approximately $14.7 million which is primarily driven by an increase in personnel to support overall growth and includes an approximate $9.6 million increase in stock-based compensation, commercial preparedness expenses of approximately $3.8 million, legal and professional fees of approximately $3.7&#160;million which is net of $2.1 million of insurance proceeds, software related costs of $1.0 million, medical affairs costs of $508 thousand, insurance costs of $427 thousand and other administrative expenses of $1.2 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation settlement</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred litigation settlement expenses for the year ended December&#160;31, 2022 of $25.0 million, which consisted of the settlement of litigation with PeriphaGen. See &#8220;Legal Proceedings&#8221; in Note 6 of the notes to consolidated financial statements included in this Form 10-K for more information. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the year ended December&#160;31, 2022, 2021, and 2020 was $5.2 million, $197 thousand and $832 thousand, respectively, and consisted of realized gains from maturities of our investments, interest, and dividend income earned from our cash, cash equivalents and investments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the year ended December&#160;31, 2022, 2021 and 2020 was zero, $1.5 million, and zero, respectively. The 2021 interest expense related to accretion of the financial obligation for the build to suit lease liability during the year ended December&#160;31, 2021 to a balance that equaled the purchase consideration for ASTRA.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, our cash, cash equivalents and short-term investments balance was approximately $379.2 million. Since operations began, we have incurred operating losses. Our net losses were $140.0 million, $69.6 million, and $32.2 million for the years ended December&#160;31, 2022, 2021, and 2020 respectively. At December&#160;31, 2022, we had an accumulated deficit of $280.8 million. With the net proceeds raised from our previous public offerings, we believe that our cash, cash equivalents and short-term investments will be sufficient to allow us to fund our operations for at least 12 months from the filing date of this Form 10-K. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support our cost structure. Furthermore, we expect to incur increasing costs associated with satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates.  We may never achieve profitability, and until we do, the Company will continue to need to raise additional capital or obtain financing from other sources. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB301 or our planned clinical and preclinical studies for our other product candidates, or our operations.  Further, we do not expect to generate any product revenues in the first quarter of 2023, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party Contract Research Organizations (&#8220;CROs&#8221;) to carry out some of our clinical development activities. As we seek to obtain regulatory approval for any of our product candidates, we expect to continue to incur significant manufacturing and commercialization expenses as we prepare for product sales, marketing, commercial manufacturing, packaging, labeling and distribution. Furthermore, pursuant to our settlement agreement with PeriphaGen, we will be required to pay $12.5 million upon the approval of our first product by the FDA, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales. Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third-party clinical trial research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, payments of settlement amounts to PeriphaGen and general overhead costs. In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timeline and cost of our OLE study for B-VEC;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing and costs of our ongoing Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, results and costs of our Phase 2 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, results and costs of our Phase 1 clinical trials for KB407;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the progress, timing, and costs of manufacturing of B-VEC;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the continued development and the filing of an IND application for future product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of maintaining our own commercial-scale CGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs associated with manufacturing process development and evaluation of third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our current license agreements remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we&#160;acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease payments represent our commitments for future minimum rent made under non-cancelable leases for our corporate headquarters in Pittsburgh, Pennsylvania, office location in Boston, Massachusetts, office locations in Switzerland and Netherlands, and for the ground lease associated with our second CGMP manufacturing facility, ASTRA. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total future payments for our operating lease obligations at December&#160;31, 2022 are $17.8 million, of which $1.6 million is due in the next twelve months and the remaining payments are due over the terms of the respective leases. For additional details regarding our leases, see Note 7 to our consolidated financial statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply and Product Manufacturing Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into various agreements in the normal course of business with CROs, CMOs and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. We are obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of December&#160;31, 2022 under these agreements is approximately $2.1 million, all of which is expected to be due in the next twelve months. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of December&#160;31, 2022 is $8.4&#160;million, all of which is expected to be due in the next twelve months.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracted with various third parties to construct our second CGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of December&#160;31, 2022 is $16.3&#160;million, all of which is expected to be due in the next twelve months.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,346)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year December&#160;31, 2022 was $100.6 million and consisted primarily of a net loss of $140.0 million adjusted for non-cash items of $36.6 million primarily made up of stock-based compensation expense of $33.2 million and depreciation and amortization of $4.1 million, and cash provided by decreases in net working capital of approximately $2.8 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year December&#160;31, 2021 was $47.9 million and consisted primarily of a net loss of $69.6 million adjusted for non-cash items of $19.1 million primarily made up of stock-based compensation expense of $15.3 million, depreciation and amortization of $2.8 million and build to suit interest expense of $1.5 million, and cash provided by decreases in net working capital of approximately $2.5 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2020 was $26.1 million and consisted primarily of a net loss of $32.2 million adjusted for non-cash items of $5.2 million primarily made up of depreciation and amortization of $1.9 million and stock-based compensation expense of $3.3 million, and cash provided by decreases in net working capital of approximately $918 thousand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2022 was approximately $114.1 million and consisted primarily of purchases of $318.8 million of available-for-sale investment securities, and expenditures of $53.0 million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, partially offset by proceeds of $257.7 million from maturities of investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2021 was approximately $226.8 million and consisted primarily of purchases of $190.5 million of available-for-sale investment securities, and expenditures of $68.3 million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, partially offset by proceeds of $32.0 million from maturities of investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2020 was $11.2 million and consisted primarily of purchases of $3.2 million of short-term available-for-sale investment securities, and expenditures of $14.8 million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, partially offset by proceeds of $6.9 million from maturities of short-term investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2022 was $35.3 million and was primarily from proceeds from public offerings of 434,782 shares of our common stock at a weighted average price of $69.00 per share through our at-the-market equity offering program (&#8220;ATM&#8221;) Program. Our net proceeds from the offerings were $29.1&#160;million after deducting underwriting discounts and commissions of approximately $900&#160;thousand. Additionally, we received $7.0 million of proceeds related to the exercise and settlement of employee stock options and restricted stock awards, offset by $649&#160;thousand of taxes paid for the settlement of restricted stock awards.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2021 was $347.7 million and was primarily from proceeds from follow-on public offerings of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters, at $65.00 per share and 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters, at $75.00 per share. Our net proceeds from the offerings were $336.8&#160;million after deducting underwriting discounts and commissions of approximately $21.5&#160;million, and other offering expenses payable of $425&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2020 was $118.0 million and was primarily from proceeds from our public offering in May 2020 of 2,275,000 shares of our common stock to the public at $55 per share. Our net proceeds from the offering were $117.2 million after deducting underwriting and commissions of approximately $7.5 million and other offering expenses of approximately $463 thousand.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See note 2 to our consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Qualitative and Quantitative Disclosures About Market Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of approximately $379.2 million as of December&#160;31, 2022, which consist primarily of money market funds, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have established operations in Europe and Australia and hold cash in Australian Dollars (&#8220;AUD&#8221;), Swiss Francs (&#8220;CHF&#8221;), and Euros (&#8220;EUR&#8221;). We are subject to foreign exchange rate risk arising from transactions conducted in the aforementioned foreign currencies, however our foreign operations are not currently material to our business. We do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments have significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that any investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short-term investments are recorded at fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">Report</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94"> of Independent Registered Public Accounting F</a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">irm</a><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">s</a><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94"> (</a></span><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDAwOQ_1c1af066-dc02-42bd-9de0-6c3b3a5dd534">KPMG, LLP</ix:nonNumeric></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">, </a></span><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDAyNg_b3e958a8-2eee-4af0-9a4c-b9f070a3bebb">Pittsburgh, PA</ix:nonNumeric> (US Firm)</span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">, </a><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">PCAOB ID No. </a><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5Xzc0_8dfe7932-6316-4e01-aa37-568ef863f25d">185</ix:nonNumeric><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_94">)</a> (<ix:nonNumeric contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDIwNg_27bbf98a-a079-4881-94b5-30075d9096de">Mayer Hoffman McCann P.C.</ix:nonNumeric>, <ix:nonNumeric contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDIzMg_2a6dacf8-e7a0-402c-842f-222ef167c2cf">San Diego, CA</ix:nonNumeric>, PCAOB ID No. <ix:nonNumeric contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDI0OA_5c1df667-0732-4131-a2d4-09be128d7c91">199</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_94">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_97">Consolidated Balance Sheets as of </a>December&#160;31, 2022<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_97"> and </a>December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_97">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_100">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December&#160;31, 2022,</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_100"> </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December&#160;31, 2021, and December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_100">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_103">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December&#160;31, 2022, December&#160;31, 2021,</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_103"> and </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_103">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_106">Consolidated Statements of Cash Flows for the Years Ended </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December&#160;31, 2022, December&#160;31, 2021,</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_106"> and </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_106">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if50fdf1a469a4104bbe6f4c216cff277_109">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if50fdf1a469a4104bbe6f4c216cff277_109">8</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Krystal Biotech, Inc. and subsidiaries (the Company) as of December 31, 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 27, 2023 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pittsburgh, Pennsylvania</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 27, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_549755815532"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Board of Directors and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stockholders of Krystal Biotech, Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheet of Krystal Biotech, Inc. (the &#8220;Company&#8221;) as of December 31, 2021, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the years ended December 31, 2021 and 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of their operations and their cash flows for the years ended December 31, 2021 and 2020, in conformity with accounting principles generally accepted in the United States of America. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Mayer Hoffman McCann P.C.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have served as the Company's auditor since 2017, which ended in 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 28, 2022</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares and par value data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNC0xLTEtMS00NjUzOA_2d08cab8-2a6e-48b7-937a-6a7d35c79166">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNC0zLTEtMS00NjUzOA_6eb08f49-1700-4f9a-9112-bc749d10dccf">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNS0xLTEtMS00NjUzOA_af62614f-b676-4faa-8fcd-acd29168e3ee">217,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNS0zLTEtMS00NjUzOA_d13b2494-81f9-4b84-8052-d9bd1a0642b3">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNi0xLTEtMS00NjUzOA_d56552ca-385a-40d2-bd81-afeda0ed4d28">4,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNi0zLTEtMS00NjUzOA_e326135a-4767-458e-90e7-8fc6448cbecb">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNy0xLTEtMS00NjUzOA_06305982-d0fc-4594-ab74-a1fb39db52c6">383,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNy0zLTEtMS00NjUzOA_268b92e9-fa50-460c-ba9a-c692dc93738f">442,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOC0xLTEtMS00NjUzOA_477781af-bf78-4c65-a296-84525a4d940a">161,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOC0zLTEtMS00NjUzOA_256cfad3-3f8d-4b7f-a862-6ad207c3dc3d">112,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOS0xLTEtMS00NjUzOA_e69e91ab-99f1-4299-b394-0513dbf1c9ab">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOS0zLTEtMS00NjUzOA_f4777800-18a2-40e2-be0b-81146280bc59">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTAtMS0xLTEtNDY1Mzg_b33ff9ac-f566-4f59-b09b-94c69ba2a924">8,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTAtMy0xLTEtNDY1Mzg_ae1ce9fb-5c83-4976-9677-2ead579064a8">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTEtMS0xLTEtNDY1Mzg_8baaaf84-24ec-4ed8-8973-ccc4f0befea1">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTEtMy0xLTEtNDY1Mzg_b7c063f4-adcb-4758-8b21-de01b9d8e07f">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTItMS0xLTEtNDY1Mzg_672a8a04-9343-4c74-a3da-053f060bf219">558,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTItMy0xLTEtNDY1Mzg_8a89570f-6e56-42c2-940d-5eb77e0d45be">626,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTUtMS0xLTEtNDY1Mzg_9c8dafa9-7c66-4e30-9db8-b227647bab19">3,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTUtMy0xLTEtNDY1Mzg_d8bfc24a-2c61-4bdb-a014-d5682bbb9ca8">8,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTYtMS0xLTEtNDY1Mzg_1197d4a9-029c-4bce-b057-51ecbb1cdbce">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTYtMy0xLTEtNDY1Mzg_2afb0798-569e-41e0-8bce-dc0cddd1cb09">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTctMS0xLTEtNDY1Mzg_720c4262-1a23-42f5-8bdf-9914e4a83f66">23,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTctMy0xLTEtNDY1Mzg_edb0a61b-0754-4362-8b61-03ec4247eecf">16,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTktMS0xLTEtNDY1Mzg_13daea04-e8ab-47fb-9e8c-6bbab178529a">28,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTktMy0xLTEtNDY1Mzg_cf1c9eea-af4c-405c-b801-229d8ec82e24">25,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjAtMS0xLTEtNDY1Mzg_b363fad2-ce4f-4b66-ac2c-ab9d7260ac35">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjAtMy0xLTEtNDY1Mzg_2d82cd5e-9d20-44fd-a6fc-0c913a49d91d">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjItMS0xLTEtNDY1Mzg_ad8c85d6-481e-4781-92f7-a67b18ec5fe1">36,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjItMy0xLTEtNDY1Mzg_35abde2b-d0bd-42c8-8d41-714f4000c7f8">32,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjMtMS0xLTEtNDY1Mzg_9e4aaecd-b43b-4c9e-9749-6690b4750301"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjMtMy0xLTEtNDY1Mzg_8713ea94-724c-4efb-984a-19cada738931"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18xOA_98fd48de-b9a9-4cf3-b516-6ebc52b39108"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18xOA_a8864ab6-e3ca-4bcc-b42d-766d0b71cccb">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18zMg_298e9849-afa5-40f1-a30a-9ae50b85c407"><ix:nonFraction unitRef="shares" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18zMg_2ae8cd86-1bd4-40ca-8666-54343040ebdf">80,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,<br/>2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M184Nw_2844dae5-0a3e-4177-930f-704b670cc11c"><ix:nonFraction unitRef="shares" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M184Nw_4d141888-b5da-4657-94e8-e01d65df223a">25,763,743</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M185NA_54821823-0350-441d-ae14-92c9d91153eb"><ix:nonFraction unitRef="shares" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M185NA_78b7dad3-82d9-4620-841d-5c6d115c3edc">25,207,985</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMS0xLTEtNDY1Mzg_ce639684-238d-4a21-9e41-4fc551b226fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMy0xLTEtNDY1Mzg_6c90d342-ea3b-4e13-b098-0b1f6f12f137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjctMS0xLTEtNDY1Mzg_354f4b69-e0b1-4447-9d96-da92b150a35c">803,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjctMy0xLTEtNDY1Mzg_74b582c8-dca9-4ab7-8073-bce93855b116">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjgtMS0xLTEtNDY1Mzg_f43aa299-c274-426c-a31c-f0c0befd1d4b">728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjgtMy0xLTEtNDY1Mzg_6ea69b30-4868-4dd4-8905-685665e31051">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjktMS0xLTEtNDY1Mzg_b1fdbcfd-32f8-423a-a5da-b09a1b18066c">280,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjktMy0xLTEtNDY1Mzg_e2064146-146f-4757-b604-ac4d30c9b6f2">140,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzAtMS0xLTEtNDY1Mzg_1365d6cb-a583-4182-a8d6-1c6a52e8e980">522,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzAtMy0xLTEtNDY1Mzg_2563565b-e7ed-4016-8382-93ca32309ccd">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzEtMS0xLTEtNDY1Mzg_d3cae2b6-a240-4dfd-8aa6-6b9934484758">558,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzEtMy0xLTEtNDY1Mzg_6bd808d4-47cc-4ca5-9531-0ab1e77ab30e">626,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzMtMS0xLTEtNDY1Mzg_f1d02abf-004a-4eed-b8aa-29b26c25afa6">42,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzMtMy0xLTEtNDY1Mzg_cd3efb01-e26b-4d6f-840c-c5d6e0e3657f">27,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzMtNS0xLTEtNDY4NDk_da371a8f-2622-461a-a528-5355a83abb5a">17,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzQtMS0xLTEtNDY1Mzg_4c7adc16-8e7c-4c81-824b-9dc9e1dd9db5">77,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzQtMy0xLTEtNDY1Mzg_09410bb4-927d-4f7a-ada8-559d77478064">40,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzQtNS0xLTEtNDY4NDk_8cc561e9-1586-4009-beb0-680c4ac172fb">15,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMS0xLTEtNTIzNDc_d052ed8a-9285-4cd0-aedb-676b996016ea">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMy0xLTEtNTIzNDc_ec2ddac4-7c95-4acc-84a3-24063ad7bda0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtNS0xLTEtNTIzNDc_6349336b-6bd1-4267-9b1b-f9c2a30a4003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMS0xLTEtNDY1Mzg_8287d040-fb5d-418b-bcab-63714f8616d2">145,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMy0xLTEtNDY1Mzg_c32a4b7c-2f46-475d-8dcf-897e515d8295">68,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtNS0xLTEtNDY4NDk_f37e74ff-c920-411b-a584-f2119f5c6774">32,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzYtMS0xLTEtNDY1Mzg_a40f604f-a7a6-4f58-8a1a-b739b900314a">145,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzYtMy0xLTEtNDY1Mzg_7abf5e67-f246-4e08-a36b-2d92d93eb513">68,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzYtNS0xLTEtNDY4NDk_500f7da0-5105-4968-ab80-b6a61532e795">32,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzgtMS0xLTEtNDY1Mzg_c8328507-71f0-430b-bc99-dd9c4d400356">5,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzgtMy0xLTEtNDY1Mzg_d68df78b-bdab-4bbe-ad33-18c805320b0b">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzgtNS0xLTEtNDY4NDk_c5de0b61-b61b-495d-8bf4-51cc6c6b2b94">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzktMS0xLTEtNDY1Mzg_51d05587-afba-4b74-837b-444cd5b53def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzktMy0xLTEtNDY1Mzg_05ba315f-5a36-4123-a5a9-a87faa4a3c92">1,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzktNS0xLTEtNDY4NDk_28e6b829-4740-40d5-8b80-22cdaaee3432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36267cfc53644c10b377545a419cdc2b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEwLTEtMS0xLTQ2NTM4_56fffb5c-ce93-4b86-b892-d0ffe887e8e1">139,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEwLTMtMS0xLTQ2NTM4_a3b2089f-8f8d-4c98-a7bc-8f5f96b56735">69,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEwLTUtMS0xLTQ2ODQ5_932e4373-cc26-438d-aab2-49d803a7d8f5">32,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1791ab32bfb844bdb1549f6e0fa6ebf2_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzExLTEtMS0xLTQ2NTM4_d121801a-8f56-4716-ab01-d038c3c5a0e4">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzExLTMtMS0xLTQ2NTM4_a78c2f25-a53b-4cd7-9ec5-5677e4de9277">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzExLTUtMS0xLTQ2ODQ5_6c76bc7c-60c8-4583-bb1d-8b2a59c610f1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEyLTEtMS0xLTQ2NTM4_6179d27c-af49-4cc1-823b-a9c8fabe9215">140,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEyLTMtMS0xLTQ2NTM4_e65cbdda-7956-4083-b6ae-44890cc18215">69,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEyLTUtMS0xLTQ2ODQ5_2ccc9aec-4589-42b1-935a-13314bb187e3">32,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share:<br/>&#160;&#160; Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTEtMS0xLTQ2NTM4_33418728-4a61-48a4-a002-5e08d1a25ba5"><ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTEtMS0xLTQ2NTM4_b3c541fd-54d3-49c0-9585-a834d1781a40">5.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTMtMS0xLTQ2NTM4_24cbc321-144d-41db-88e4-53dc885e41b1"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTMtMS0xLTQ2NTM4_500cfc1f-cc9b-436a-9645-06b5c8e4904e">3.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTUtMS0xLTQ2ODQ5_86e082ae-c63a-48c7-9199-7d349e1ab0da"><ix:nonFraction unitRef="usdPerShare" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTUtMS0xLTQ2ODQ5_8f75da8d-049c-4b0b-9b48-1fccc094db9d">1.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:<br/>&#160;&#160; Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTEtMS0xLTQ2NTM4_37048d14-5cae-44ed-bd7c-2fb4d715415d"><ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTEtMS0xLTQ2NTM4_7c03543e-f185-4d4f-8f43-e8db58c1950e">25,491,721</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTMtMS0xLTQ2NTM4_2b117dfd-5759-4364-b33b-841a2dd49372"><ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTMtMS0xLTQ2NTM4_6a124b09-2940-42c0-9d17-176f4fe3872e">22,196,846</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTUtMS0xLTQ2ODQ5_2c99d4d3-d049-4419-be65-0fc034016bd1"><ix:nonFraction unitRef="shares" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTUtMS0xLTQ2ODQ5_ec49537b-a2ee-4235-a107-2d3d5778d035">18,787,161</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders' Equity</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItMS0xLTEtNDY1Mzg_3c4d3a3a-8f1c-429e-87ec-f7066c9b4042">17,354,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItMy0xLTEtNDY1Mzg_7be714c5-61b7-4f6f-aaa5-42f3d2795211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496ec5ae5f474b68a6e6e266a5883626_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItNS0xLTEtNDY1Mzg_ab18504b-04f2-4b93-bcc3-a1d508eb852d">241,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804bccd139d04bf3b19b95e33e6df55e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItNy0xLTEtNDY1Mzg_3883b3f0-17a7-4526-8077-9ed1dd3df2f1">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c619239c03440b5b8db4727db939247_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItOS0xLTEtNDY1Mzg_24875321-3768-4c43-8f1d-0a1e76f653d7">39,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eddb7037c4f82b6f2687e0a52e6ff_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItMTEtMS0xLTQ2NTM4_024b0ccd-8c60-4bf8-9cff-8add17e61b25">202,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fd0edbd57ff47fb919fb61349c64819_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzMtMS0xLTEtNDY1Mzg_ec2e66c8-b84b-4868-ae91-d2f57ec8859e">2,359,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208aa8cb27e54c60b096966b6240e133_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzMtNS0xLTEtNDY1Mzg_4ae552b7-d2ab-4c76-96d7-f6de33fb77e2">118,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzMtMTEtMS0xLTQ2NTM4_6de85fde-56b6-43de-84cd-ab01d036510a">118,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208aa8cb27e54c60b096966b6240e133_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzQtNS0xLTEtNDY1Mzg_fb90f839-c5b9-463b-9c0a-707c3bb93f5d">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzQtMTEtMS0xLTQ2NTM4_5a910ab8-24cc-469b-a634-015db13a04d4">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91001397acca4edbb0a19b9c79aa5b7d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtNy0xLTEtNDY1Mzg_a9cf32ce-a28e-49ee-980b-703d4bd72274">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtMTEtMS0xLTQ2NTM4_92072b1d-a959-4fb6-8610-776ba755c68f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f9c855a0e3a4e13a53433cc5c0364b4_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzYtOS0xLTEtNDY1Mzg_8e0f90c5-a32a-4cbf-a7f8-e55a674937c7">32,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzYtMTEtMS0xLTQ2NTM4_96e57d43-71cd-4cc4-a985-871b140a813d">32,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia24f42b2bb4c47b89466941d0f5831db_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMS0xLTEtNDY5NTQ_45567069-fe4a-4ac6-b8e0-d377e372a06b">19,714,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24f42b2bb4c47b89466941d0f5831db_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMy0xLTEtNDY5NTQ_b93636d0-cb8e-414f-8616-6f358fbae7b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922596331dd24a1dbd0e0b79d3ef475b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNS0xLTEtNDY5NTQ_0f53c029-c115-4323-b857-3c4eb6658012">363,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8e1134b7c94d26a0c3d22afc73d215_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY5NTQ_aba97445-2766-4803-8cd1-9cdde296ada3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2f2c779195497fb1144f46db638bfb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctOS0xLTEtNDY5NTQ_efa93697-4d74-42f8-afba-c96749db66f1">71,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2OTU0_3d077d4f-6440-4108-9ce9-d7c08c6cd235">292,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica5904f7fef443a68940ec9e9da0ce98_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtMS0xLTEtNDY5NTQ_aa176841-daff-486f-aa1e-3f2e0a145396">5,493,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2465df77d804826b661dda93a47a9e0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtNS0xLTEtNDY5NTQ_99d60330-d162-4319-aefd-3cb76c1c377c">355,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtMTEtMS0xLTQ2OTU0_8b9dbc43-b47f-4768-9316-2021abf789d6">355,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2465df77d804826b661dda93a47a9e0_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktNS0xLTEtNDY5NTQ_2efc6226-7cdb-447f-8586-89c0ed7405e1">15,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMTEtMS0xLTQ2OTU0_33c670de-9320-4003-aafb-7d640a09a2fb">15,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8ca4dafce8c49c38953d0c3cc1e563b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTctMS0xLTQ2OTU0_eb74d109-be99-4c24-bab6-7e03aa46ecd8">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTExLTEtMS00Njk1NA_73410a37-24a9-4291-95c4-de61f9230b56">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a31534ac7ce4d699f4394d4b19576c9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzExLTktMS0xLTQ2OTU0_d2fc2560-7340-42a2-852f-127ef28218fc">69,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzExLTExLTEtMS00Njk1NA_a2151339-4899-4aae-b12c-6d33823a90d8">69,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66ebe6bcc927412c83fb26d401bcacaa_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTEtMS0xLTQ2OTcy_e26f0162-b071-4466-948c-891a28de0ba0">25,207,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ebe6bcc927412c83fb26d401bcacaa_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTMtMS0xLTQ2OTcy_64b0539a-b582-4f6d-b18d-6423b506ebdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996e18257f394eff9914fcba8ed4e078_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTUtMS0xLTQ2OTcy_8a9f8375-1b5d-452d-aca3-128af779c268">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc4b03d778584b14ad55239cd91fef14_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTctMS0xLTQ2OTcy_1da81279-95b4-4090-b820-45a83338bbc7">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie289a738c54a427ea3a8922f170941dd_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTktMS0xLTQ2OTcy_01752a30-1250-408d-8dbc-5252f321535b">140,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTExLTEtMS00Njk3Mg_1a43d60f-fff9-4624-812a-ac8ba5527aa9">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57d5acffc6e34806bcad27370483078d_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEzLTEtMS0xLTQ2OTcy_9678ff83-532f-4130-968b-58aec047f4aa">573,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEzLTUtMS0xLTQ2OTcy_6324b3b8-6901-47ec-b086-83a62b54c0f4">36,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEzLTExLTEtMS00Njk3Mg_df7ddb6a-bae9-46dc-9e1b-bdd25014000e">36,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes and forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i57d5acffc6e34806bcad27370483078d_D20220101-20221231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTEtMS0xLTUwNzE2_cfa685c4-b24b-43f3-a195-327ab06c7744">17,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTUtMS0xLTUwNzE2_d8294376-3c7f-4cc9-8acd-6d632a1c9dc2">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTExLTEtMS01MDcyNA_bd07d8a6-bbbc-465f-bede-ed67a5ed79c7">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTUtMS0xLTQ2OTcy_92c60fde-2cbe-4c1b-8dfc-621d8d7246d9">33,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTExLTEtMS00Njk3Mg_342603d6-a3c4-4937-9719-751bbdea64f7">33,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1791ab32bfb844bdb1549f6e0fa6ebf2_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY1Mzg_66d153e5-c44b-4b13-957b-71394af8d915">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2NTM4_d176a3eb-bacc-4ff4-ab00-5834e3bec456">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36267cfc53644c10b377545a419cdc2b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtOS0xLTEtNDY1Mzg_6fbbd09c-5af5-4c63-bb0b-b3329f8761e2">139,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtMTEtMS0xLTQ2NTM4_99695553-d89e-4b2e-85bb-8b186e2bc227">139,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i915fb9f46db84704ab0d72c2ada7e20e_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMS0xLTEtNDY1Mzg_119e90d5-d1ca-47ae-95c7-8aa09612bb56">25,763,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915fb9f46db84704ab0d72c2ada7e20e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMy0xLTEtNDY1Mzg_067fd721-bbb5-4e6b-bfd6-ce1df9a1a1fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f61bb3407246f1923b173d13ac2592_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktNS0xLTEtNDY1Mzg_64b49fdc-107f-430c-a316-6f36ab193471">803,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3eafaed6c8534eb88f2e16210025076a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktNy0xLTEtNDY1Mzg_58b1e7cc-b060-4d84-91c9-7ab739ce27c4">728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb62cd25fa1545ddb2adf0d82820735f_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktOS0xLTEtNDY1Mzg_4f60c08a-7f0f-4eb3-aa9a-4e03f528ea8c">280,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMTEtMS0xLTQ2NTM4_7af04ada-bf09-4b04-8258-6bc44fbe3644">522,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes foreign currency translation loss of $<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzEwOTk1MTE2MjgwNzM_d4730874-95f2-435c-9170-cc0a316b3c06">78</ix:nonFraction> thousand, gain of $<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzEwOTk1MTE2MjgwODA_5206472d-0e69-4267-a88e-2d5e5176ce95">7</ix:nonFraction> thousand, and loss of $<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzEwOTk1MTE2MjgxMzc_682bec3e-11ca-4962-9fd2-e1ec2dc0dfea">1</ix:nonFraction> thousand for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</ix:footnote></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMtMS0xLTEtNDY1Mzg_e900da02-bd79-4d40-b6e2-8702dfdab390">139,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMtMy0xLTEtNDY1Mzg_072d0e7a-dab7-4341-abd1-3159e83882ea">69,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMtNS0xLTEtNDcxMjQ_b3a1c958-bdb6-45e3-a914-243ad892852a">32,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzUtMS0xLTEtNDY1Mzg_3673f9b0-22c2-4998-bbb9-122694d3ecb2">4,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzUtMy0xLTEtNDY1Mzg_3326ff16-06d5-4843-ad28-1e8608614b4e">2,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzUtNS0xLTEtNDcxMjQ_000e2953-70f2-4f37-bede-90d6386e3d62">1,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzYtMS0xLTEtNDY1Mzg_834be741-e2ad-4b6d-a74d-bedcc88b8114">33,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzYtMy0xLTEtNDY1Mzg_5b53ad0a-4603-451d-a26a-9a2db1feb3aa">15,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzYtNS0xLTEtNDcxMjQ_d5ba786c-a5b6-4601-98b1-51e2e69f606c">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnSalesOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzctMS0xLTEtNDY1Mzg_8aa29233-ac78-4706-8bf9-743cf30adbdf">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnSalesOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzctMy0xLTEtNDY1Mzg_00a0c022-b731-4049-90c5-40a3145a5fda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnSalesOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzctNS0xLTEtNDcxMjQ_e3a54c2b-83a2-4029-bff2-c04c9110c467">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzgtMS0xLTEtNDY1Mzg_0b500b1c-0a80-4fca-9d7f-3ab75a8eb045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzgtMy0xLTEtNDY1Mzg_5366dc33-bad5-42ef-b957-519baa5140c6">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzgtNS0xLTEtNDcxOTM_06c4d517-16da-400a-bcb1-5658e35a3664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzktMS0xLTEtNTUzMTM_22c3affe-44b9-49cd-82d1-2451e0065fee">762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzktMy0xLTEtNTUzMTM_ef49cfe3-bea7-4672-86db-8242a33fed50">454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzktNS0xLTEtNTU5MzE_35b4c2a1-7e54-45a1-9034-b95a7a6406b5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEwLTEtMS0xLTQ2NTM4_11b5cb03-2ca2-4e68-8503-8923d66d300d">311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEwLTMtMS0xLTQ2NTM4_6511ae3c-ea22-44f4-ba5f-a1f9f9ad33e4">691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEwLTUtMS0xLTQ3MTI0_f26a2a3f-5cff-4953-aeb9-f844a1f228cb">1,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzExLTEtMS0xLTQ2NTM4_85a18622-76e8-4a3f-bec9-bd892d73b06d">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzExLTMtMS0xLTQ2NTM4_423a1978-b55f-4018-b7de-7632f289d47d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzExLTUtMS0xLTQ3MTI0_e3114a30-20aa-4559-8950-3b328451c8d8">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEyLTEtMS0xLTQ2NTM4_2157e8a2-c5d3-4eb9-8b57-735fa4bfe7b9">647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEyLTMtMS0xLTQ2NTM4_046966a8-2bb1-4e01-a7a7-4b8f4cb74e62">285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEyLTUtMS0xLTQ3MTI0_823ecf25-ac93-4280-8554-3d18badd2a78">685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEzLTEtMS0xLTQ2NTM4_e089c88e-48e0-48cc-80e4-8b93c22d1f56">1,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEzLTMtMS0xLTQ2NTM4_5c3ca248-799f-43d9-a792-f4bc2b8cb9fa">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEzLTUtMS0xLTQ3MTI0_e2d434b8-f345-424e-a097-88f4e421be8b">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE0LTEtMS0xLTQ2NTM4_a2ac8f03-ad75-49be-b660-7a11e9692a78">5,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE0LTMtMS0xLTQ2NTM4_24c1dc25-9fa2-4902-a4a7-8f72484f01b0">2,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE0LTUtMS0xLTQ3MTI0_6b772161-54b7-4b93-8b72-f5f704cc9515">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE1LTEtMS0xLTQ2NTM4_2821392e-eb50-481d-9f56-f2f4fae7693e">100,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE1LTMtMS0xLTQ2NTM4_cdf4c121-cdaa-492d-976e-08dfbabfe850">47,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE1LTUtMS0xLTUwMjQ5_fb700f41-ab8a-4d79-861a-817972feb4c9">26,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE4LTEtMS0xLTQ2NTM4_7db38885-2849-48f2-bce9-03cebef5f3cf">52,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE4LTMtMS0xLTQ2NTM4_a0341836-20d8-4605-a0d2-5b5412ad9966">68,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE4LTUtMS0xLTQ3MTM5_e6d18d86-c64c-48a0-9527-91fa1b3fa42f">14,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE5LTEtMS0xLTQ2NTM4_23da337d-1637-4a39-bffd-b0eb9a02f33d">318,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE5LTMtMS0xLTQ2NTM4_7a224b6d-b6ba-4eea-96f5-dba235e30599">190,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE5LTUtMS0xLTQ3MTM5_709a1a8c-0589-4341-93a6-af8dd67cb13a">3,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIwLTEtMS0xLTQ2NTM4_9c5b4ebb-e8da-4c39-ae49-603195a5e001">257,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIwLTMtMS0xLTQ2NTM4_c185f400-2e35-4b6b-81a7-a9cd5b0c426b">32,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIwLTUtMS0xLTQ3MTM5_9da1f554-d22d-458e-9ebe-76884a928814">6,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIxLTEtMS0xLTQ2NTM4_3ad6ae9b-5ddb-4d4f-8618-3f3144438a6c">114,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIxLTMtMS0xLTQ2NTM4_c87b8494-a291-4400-b25f-7142076e95e7">226,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIxLTUtMS0xLTUwMjU1_62d569c9-38a1-4f5a-8fb6-54b33fdc6379">11,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI0LTEtMS0xLTQ2NTM4_d4bff4f3-4eb4-4719-b55b-d9f7570da69a">35,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI0LTMtMS0xLTQ2NTM4_158e2160-d337-4315-9361-23e25c7a121b">355,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI0LTUtMS0xLTQ3MTUw_09440d53-73fb-4a93-8dd9-4441fa5e5fb7">118,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to settlement of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTEtMS0xLTU1NDU3_25f415fd-2bca-47d6-92b8-1fa190392a06">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTMtMS0xLTU1NDY1_72914d36-8b41-4ca7-92a5-79a994f844ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTUtMS0xLTU1NDY1_f38ba818-eb02-4798-b7c0-8246b104d18f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of ASTRA build to suit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI1LTEtMS0xLTQ2NTM4_01070b4e-ed34-4338-994d-455f02ef60bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI1LTMtMS0xLTQ2NTM4_ef8360b4-596b-4a87-aa00-36485724a076">7,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI1LTUtMS0xLTQ3MTUw_d78cdc01-85c8-46f0-9b84-bc432973da08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTEtMS0xLTQ2NTM4_855d9065-d4af-44be-b27d-76509003382b">35,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTMtMS0xLTQ2NTM4_b1447741-9bfd-4333-954b-41863659fbbb">347,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTUtMS0xLTUwMjYx_b1ceabd1-5e51-40c6-91c6-3cc4d9ea50c2">118,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTEtMS0xLTU4MTkw_da788347-6fa1-4bed-8526-1e8c22d533bd">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTMtMS0xLTU4MTkw_c8c1c2ca-f111-4f9a-ba33-8014eec0986d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTUtMS0xLTU4MTkw_04cef379-aa03-4e63-934c-a3790523ff81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI3LTEtMS0xLTQ2NTM4_6f522234-d0e5-45ab-bbe5-ae9dfcfe849d">179,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI3LTMtMS0xLTQ2NTM4_7bbb5277-b3d0-42bf-ba65-3adbec93699a">72,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI3LTUtMS0xLTUyMzY4_acece8c8-5501-4755-be9f-72a2c16cf546">80,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI5LTEtMS0xLTQ2NTM4_81a323dc-d55c-4436-9375-908fc98c7eff">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI5LTMtMS0xLTQ2NTM4_62b49187-aff2-44b0-9215-3e32375c7327">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62eddb7037c4f82b6f2687e0a52e6ff_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI5LTUtMS0xLTQ3MTYx_c2d2bdce-6134-42c2-9e78-6385796ea011">187,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTEtMS0xLTQ2NTM4_4e09f7e9-bdcc-4123-9770-edceac6a9edf">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTMtMS0xLTQ2NTM4_c58b0e7d-a987-47e2-9172-606d8b1ad661">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTUtMS0xLTUyMzY4_1297b274-1bf8-4d82-b35e-7527d34c4c97">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Investing and Financing Activities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMzLTEtMS0xLTQ2NTM4_ebf85e3f-8581-42f2-80e7-ceddf522ef90">14,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMzLTMtMS0xLTQ2NTM4_0edff0b7-d938-496c-a139-21fd647c72f0">15,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMzLTUtMS0xLTQ3MjIx_a1c7835d-2016-4e27-ba99-0e2e9ca4ca02">9,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzM0LTEtMS0xLTQ2NTM4_2c1bb753-a37f-4df3-b358-148cde1ec7e4">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzM0LTMtMS0xLTQ2NTM4_204b7f9f-8e55-4cf8-8951-c0c8819eb75e">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzM0LTUtMS0xLTQ3MjIx_dafa6caa-0e6c-4952-bb7a-37c82f444e48">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;padding-left:157.5pt;text-indent:36pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTIvZnJhZzphZWIyNWI5MjRlOGE0ZWRiYWMwNmJiYmIwNTg1MjdjYy90ZXh0cmVnaW9uOmFlYjI1YjkyNGU4YTRlZGJhYzA2YmJiYjA1ODUyN2NjXzMyNTY_3a427e27-1378-4e53-8c00-a1c1c2c2a691" continuedAt="i66ceedbe16b44e58a2e082b9f16cf315" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i66ceedbe16b44e58a2e082b9f16cf315" continuedAt="i5b889c15cce54e49b8eeb072ad5e42a3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics, Inc (&#8220;Jeune Aesthetics&#8221;), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, and December 2022, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's product pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practice ("CGMP") manufacturing capabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTIvZnJhZzphZWIyNWI5MjRlOGE0ZWRiYWMwNmJiYmIwNTg1MjdjYy90ZXh0cmVnaW9uOmFlYjI1YjkyNGU4YTRlZGJhYzA2YmJiYjA1ODUyN2NjXzE2NTk_23f0c114-30ec-4226-b089-ef02c9d95180">280.8</ix:nonFraction> million. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability, and unless and until it does the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, the sale of equity, and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b889c15cce54e49b8eeb072ad5e42a3">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to expand it's commercialization capabilities in advance of the potential global regulatory approvals of it's lead product, B-VEC. The Company believes that its cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTIvZnJhZzphZWIyNWI5MjRlOGE0ZWRiYWMwNmJiYmIwNTg1MjdjYy90ZXh0cmVnaW9uOmFlYjI1YjkyNGU4YTRlZGJhYzA2YmJiYjA1ODUyN2NjXzE5MDE_e4da97ae-7120-4099-bfb6-b77818fca03c">379.2</ix:nonFraction> million as of December&#160;31, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Annual Report on Form 10-K.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE5_87af4898-e356-495b-a268-51ed068958f6" continuedAt="i394495800df1434e928d1fcbc577d61d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i394495800df1434e928d1fcbc577d61d" continuedAt="i784f7697fbfe4ae0aaee110e3833d74a"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIw_8f660e02-1fc9-424d-b6dd-e3c7a41e335d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE2_ce91fb3d-2bca-4c87-a4d9-a66e0320e9d0" continuedAt="i052a16d01e8348ccbe2baab520b95184" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i784f7697fbfe4ae0aaee110e3833d74a" continuedAt="iaf131cf8ebdf4a1f910b961535b460b0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i052a16d01e8348ccbe2baab520b95184">representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</ix:continuation></span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTA4_820bd631-c5c6-49f7-9e0e-552cd82807ed" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in <ix:nonFraction unitRef="segment" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzM4MDU_b382bbb1-c6ad-443f-a019-8a581519b52f">one</ix:nonFraction> operating segment, which is the business of developing and commercializing pharmaceutical products.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE3_903f81d6-5fc0-4288-a037-980cab9ea828" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIx_ead2daf1-28a9-4e9a-bfa6-f782a82da39e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash,&#160;Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, or general and administrative expenses in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE4_e12ec33d-f79a-4334-bf2e-b8ddc87f3478" continuedAt="iefb57ee76ee545088f07b8682c49f165" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in inactive markets, or other inputs that are observable, or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="iaf131cf8ebdf4a1f910b961535b460b0" continuedAt="i375bfbe560aa4e759d0088f738e749e1"><ix:continuation id="iefb57ee76ee545088f07b8682c49f165"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div></ix:continuation><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzIxOTkwMjMyODAzMjE_9c8cc0c3-814a-4787-a7f7-2c2d8cad8e2d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="krys:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEy_f2d9154c-51ff-45d4-b941-8bbb55742fe9" continuedAt="i32d34b5b2a544d9e87a6b776e8fe61b7" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-top:14pt;text-align:justify"><ix:continuation id="i32d34b5b2a544d9e87a6b776e8fe61b7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.111%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee87fb1c670d4a8fabfd071c375435ee_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzAtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpmMDhiM2ExYzJhZDc0YWRhYTY5ZDkzMTRmMDkxOTZjMl80_5d593198-a05d-4d82-afcf-9a10781d9f45">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i61e616f277cb401d95b1e1572f6cf8c4_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzAtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpmMDhiM2ExYzJhZDc0YWRhYTY5ZDkzMTRmMDkxOTZjMl85_a1b3ce0e-0744-4f5f-bae5-9fb4becc3c4d">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73935a9788274be9a2a5a77ba030b6f2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzEtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjplOTc3OThhYjEyNWU0OThhODY4MTNiMjk4YzczYTA0NF80_702a240d-b332-4c79-ac47-18f70c1600f5">3</ix:nonNumeric> - <ix:nonNumeric contextRef="ia2bd6fcadcdd473ea0f07dc041889bed_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzEtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjplOTc3OThhYjEyNWU0OThhODY4MTNiMjk4YzczYTA0NF85_f098520c-ab2e-4cd0-a91b-bd0f861cba66">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71e119a9d7434b2583f9e8b3f823f74b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzItMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOTZjZDc3ZjEzNTk0Y2E1OGU5ZGRkZDlhMzUxZGNiMl80_047c920e-38a0-49b0-9c88-66129d7c361b">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i8cdf55bd7cb34dc7b7afcf71ada77513_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzItMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOTZjZDc3ZjEzNTk0Y2E1OGU5ZGRkZDlhMzUxZGNiMl85_a50aa6ef-980b-4a44-814f-71e2bc709b1c">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining life of lease</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from <ix:nonNumeric contextRef="icd3eeb0d882a48b0b15625e5774f3daf_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzQzOTgwNDY1MzU4NTk_b2fdf40a-3aaf-4402-a4d7-04c313f993e2">7</ix:nonNumeric> to <ix:nonNumeric contextRef="ib15d39f02c324677aeac9f5d4a570fa7_D20220701-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzQzOTgwNDY1MzU4NjI_7aacf46a-1cbd-44a7-909e-cc363a972c9d">15</ix:nonNumeric> years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress (&#8220;CIP&#8221;) is not depreciated until the asset is placed in service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEz_6a1bac82-f325-4bfb-a278-6f70f005f4f6" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company <ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzEwMTgy_13e0f2c4-1d7c-457d-8b75-1387f226ca8c"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzEwMTgy_90438cd4-afe7-492c-b7bb-4237ca9265d5"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzEwMTgy_eacfade9-17b2-4724-8aaf-01315e7a5144">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t experienced any triggering events or recognized any impairment losses for the years ended December&#160;31, 2022, 2021, and 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIy_1b1ed3d7-36fb-40a8-9a04-cc6c4c8af4fc" continuedAt="i7b47bf7232be4bbfa6897f6226aadb05" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i375bfbe560aa4e759d0088f738e749e1" continuedAt="i8e19c61ba2d94eee92e8905cc859c216"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b47bf7232be4bbfa6897f6226aadb05">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain &#8220;sale-leaseback&#8221; criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the  consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the &#8220;sale-leaseback&#8221; criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</ix:continuation></span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIz_8fca8e1b-9c69-411d-9aa6-34734e13bdc4" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organization and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE0_d99d4800-aa33-4c78-9a4d-4da53b556a1e" continuedAt="ibeb4cc9cdd414e5483639232cbc7b471" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;)  Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained in 2021, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibeb4cc9cdd414e5483639232cbc7b471">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEw_70629728-b945-4ef4-bf4b-e81bbd243ef1" continuedAt="i67e72c89b89f4b828b543eeac52f5630" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, income taxes were recorded in accordance with FASB ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, we record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December&#160;31, 2022 and 2021.&#160;We intend to maintain a valuation allowance until sufficient evidence exists to support its reversal.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i8e19c61ba2d94eee92e8905cc859c216"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i67e72c89b89f4b828b543eeac52f5630" continuedAt="i6828747ee9bd4868815034591596c2fb">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December&#160;31, 2022 and 2021, the Company did not have any significant uncertain tax positions.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6828747ee9bd4868815034591596c2fb">The Company may recognize interest and penalties related to uncertain tax positions in income tax expense.</ix:continuation> As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3NjI3_5fd3be95-cf71-4040-b288-04f2c9177e69"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3NjI3_9f9ab752-a3a6-4a42-b677-2e8188d5c685">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3Njk5_2a2ea254-f233-4244-a978-a25e39253d9c"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3Njk5_6dd14899-e778-488e-8faf-634d9e989490">no</ix:nonFraction></ix:nonFraction> amounts have been recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTI0_047774a6-c514-4f82-8a79-080a1bca51b6" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the consolidated statements of operations related to realized gains on sales of available-for-sale securities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the years ended December&#160;31, 2022, 2021, and 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEx_71a88df6-7df3-4885-a384-43caa005f663" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="if50fdf1a469a4104bbe6f4c216cff277_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzkyNw_57090242-7d75-4949-a2b1-e7cc7568e217" continuedAt="i88a4f52f1fd64f219418fb1faa6aa0d1" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i88a4f52f1fd64f219418fb1faa6aa0d1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were <ix:nonFraction unitRef="shares" contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU3OA_71211a2d-8478-4feb-bcd8-fb9e4d2c3298">3,582,181</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU4NQ_4d053cdd-ba5e-48d8-8ef6-618e78794c8c">2,043,179</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU0OTc1NTgxNTEwNA_dcd033a9-153c-476e-baaa-2fa88c456ec5">853,614</ix:nonFraction> common share equivalents outstanding in the form of stock options and <ix:nonFraction unitRef="shares" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="-2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU0OTc1NTgxNTA1Ng_2c4d146b-55b8-460f-a63b-81b39c587670">66,600</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231" decimals="-2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzY2NQ_d7737f0c-cf3f-45a7-9cc7-85baf4d96395">98,800</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i85ab137db9d24527ad70578422157edc_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzEwOTk1MTE2MjkwNTE_8bda7aba-4046-497d-a13e-1da6720a1976">zero</ix:nonFraction> unvested restricted stock awards as of December&#160;31, 2022, 2021 and 2020, respectively, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="text-align:center"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzkyOA_4af47766-cda4-4a08-999c-0e7092d827e1" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzMtMS0xLTEtNDY1Mzg_51845e2f-e78f-46f9-baac-0ca9c7a1eaf3">139,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzMtMy0xLTEtNDY1Mzg_36350f34-73f3-4e25-bc78-c7c7ecb8b472">69,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzMtNS0xLTEtNDc0MzM_034dc218-5aec-42bb-807a-a749cf140f07">32,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common<br/>&#160;&#160; shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMS0xLTEtNDY1Mzg_08439eeb-7567-4a5e-8cc0-80028632a664"><ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMS0xLTEtNDY1Mzg_3d918934-fcf5-4c93-ae43-8499962bf52e">25,491,721</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMy0xLTEtNDY1Mzg_5d8334b7-55e6-4f66-ab75-b24efc5544d8"><ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMy0xLTEtNDY1Mzg_8536af16-2e75-43db-ba5a-671366cb5f43">22,196,846</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtNS0xLTEtNDc0MzM_a91e1d4a-6419-44c3-8a12-544b30a1d25f"><ix:nonFraction unitRef="shares" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtNS0xLTEtNDc0MzM_d5992968-338a-4aa1-9f01-5a6a3ab5930c">18,787,161</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMS0xLTEtNDY1Mzg_ba77e3d1-1e41-4fdc-8064-56745f1c7a00"><ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMS0xLTEtNDY1Mzg_bf5a109a-ae89-4d7b-b00d-4261c85dcebc">5.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMy0xLTEtNDY1Mzg_4333b454-17d6-444e-9342-4260095ee060"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMy0xLTEtNDY1Mzg_583338df-04ee-4512-8481-67a6d2d2d1d1">3.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtNS0xLTEtNDc0NDU_884ac310-c93b-4271-9ee8-2944f97733f0"><ix:nonFraction unitRef="usdPerShare" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtNS0xLTEtNDc0NDU_aafda770-bd85-400b-8fc1-f584857b26c7">1.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzQ4Mw_5bb52e55-7381-42ee-8bc5-4904291bc53c" continuedAt="id8e5a982700f44248ccc916c6b51cd01" escape="true">Fair Value Instruments</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8e5a982700f44248ccc916c6b51cd01" continuedAt="i060ec764b7df48e3854e8e47f17d6bc6"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzQ4NA_2adede45-2ea9-43a8-b090-d7ddbddc3384" continuedAt="ic34a30e682f04b2baed7994d013c3173" escape="true">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i060ec764b7df48e3854e8e47f17d6bc6"><ix:continuation id="ic34a30e682f04b2baed7994d013c3173"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb022f76121f4e10b847528fc749dceb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzMtMS0xLTEtNDY1Mzg_43a501a6-0545-409f-9878-ef80e336fd30">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb022f76121f4e10b847528fc749dceb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzMtNy0xLTEtNDY1Mzg_4a192392-f502-4d0c-9ef5-f7331af2b589">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e196aef98d946ef9ba6a9d94c73d645_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzMtOS0xLTEtNDY1Mzg_0c9cbd7b-a503-4c30-9f1b-4bf3c5895e90">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96d3206ab1847cd9a05a879d0efe67c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzQtMS0xLTEtNDY1Mzg_14ce845c-7a4b-425e-abd4-adba57126e0d">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96d3206ab1847cd9a05a879d0efe67c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzQtNy0xLTEtNDY1Mzg_0df70bfe-8f94-4532-8bbc-2eac6a0f774d">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a6fa4bf942a419fbec493f4bf7f4b31_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzQtOS0xLTEtNDY1Mzg_ab969990-d257-48c3-8f65-32c3e0c59970">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMS0xLTEtNDY1Mzg_a2a6eeeb-a832-4adf-a0b4-87f1830c6082">63,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMy0xLTEtNDY1Mzg_7e3c8ca6-e751-45c4-8e59-199cee8f9ad4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtNS0xLTEtNDY1Mzg_7e2277fb-0a21-42d8-b622-fa2dc912305f">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtNy0xLTEtNDY1Mzg_ed5ef5b0-c27d-4198-b414-9802f89da314">63,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e649be5847e4c318f3b5b62ca8bd797_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMTEtMS0xLTQ2NTM4_a5deff8b-3bee-4a39-8b20-2b5794a16d89">63,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4613ad1330074364a3d902cd8b6f8599_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMTMtMS0xLTQ2NTM4_ffce909c-802a-4588-9455-bc00aca49061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc145339ddd143598976c49d98e634a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMS0xLTEtNDY1Mzg_0b1600ee-262f-44b6-ad34-fd77fe6c2090">82,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc145339ddd143598976c49d98e634a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMy0xLTEtNDY1Mzg_98b61186-351a-43f6-a66b-dcc13e6db2bc">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc145339ddd143598976c49d98e634a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctNS0xLTEtNDY1Mzg_71e642f9-9544-4fba-98cf-39d3aa4a965f">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc145339ddd143598976c49d98e634a4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctNy0xLTEtNDY1Mzg_f2abe9e1-d6b2-41cb-8ecb-df755d11d6d8">81,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f7cf345d4447f6a47ad9669b43afd0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMTEtMS0xLTQ2NTM4_516f2918-0bc2-47c3-8547-67ee6f094c84">77,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib381b024b3f44b17b2017dc67c13aab4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMTMtMS0xLTQ2NTM4_dd6c7b96-4686-49a8-ba60-aa8a1a9128e7">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMS0xLTEtNDY1Mzg_2d159ec2-3358-41a4-a676-1f626a2f488b">76,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMy0xLTEtNDY1Mzg_550e6e5e-1724-4913-ab26-f315f60c3249">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtNS0xLTEtNDY1Mzg_71c2019a-f948-4824-96e8-302608f07354">393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtNy0xLTEtNDY1Mzg_8adfbf69-b49e-410a-97de-96049d245b13">76,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie820ccd74fbb44e0b053b5527111f83d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMTEtMS0xLTQ2NTM4_5cdd1747-8e0c-4a75-9398-16d59519833c">76,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474abeb633a744ebbe6c051fccc138d3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMTMtMS0xLTQ2NTM4_12b70a35-a940-4d4f-9915-3d3b46cd8cc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMS0xLTEtNDY1Mzg_441ec2b4-e25f-496f-bf12-19edf06a5599">222,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMy0xLTEtNDY1Mzg_0fd3d9bc-a8ea-47f0-92fe-b2c65d260bb0">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktNS0xLTEtNDY1Mzg_5e5a977a-fa63-4441-bcc6-cd679746ee23">835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktNy0xLTEtNDY1Mzg_1b2b3d91-69ec-4bc4-9e1b-f53a1cabbd17">221,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15667ce7b0c40e5b2f6147b95913a03_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMTEtMS0xLTQ2NTM4_bc96df5b-180e-4968-98b1-53f61994f98e">217,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c142c1f1d9844f38df3bcfa1684428a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMTMtMS0xLTQ2NTM4_3638f834-cff8-4758-b6b9-50603394a4c0">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTEtMS0xLTQ2NTM4_ef3647e9-5f23-47e2-9acd-7a6b4b291d60">384,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTMtMS0xLTQ2NTM4_96bcddac-e336-4daf-9bb4-242342403473">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTUtMS0xLTQ2NTM4_96efc850-d363-4727-bafb-a88b65d0e7b9">835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTctMS0xLTQ2NTM4_08d1a9d2-2644-4e66-8412-87eb5f8325ba">383,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36361a0fa8ca486fbe97852c6f806b2e_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTktMS0xLTQ2NTM4_d77fadfa-6184-4eac-be76-02922b63006b">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8132445eec974341992bfe7b7684bafc_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTExLTEtMS00NjUzOA_d5f9f482-7f28-4223-9bdb-785d61816972">217,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457106579689420ea580675819005893_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTEzLTEtMS00NjUzOA_0348de0e-bdb8-444b-8ba7-ec694cf6e708">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae3f849bf20446db2cc1146dcd478d8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzMtMS0xLTEtNDY1Mzg_1086bca8-556d-432d-8d19-a46daeb68dcd">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae3f849bf20446db2cc1146dcd478d8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzMtNy0xLTEtNDY1Mzg_0dbdcd5e-82f5-4ee1-8da0-5f85a79a8508">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e3d585465c4e46b41b696bc03baddf_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzMtOS0xLTEtNDY1Mzg_0115666b-5427-4bb6-ab92-80960ce3fadb">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5bf368359a4d94adb4f27bedbb43b6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzQtMS0xLTEtNDY1Mzg_db330f53-954d-44a4-bba4-451c1439ee35">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5bf368359a4d94adb4f27bedbb43b6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzQtNy0xLTEtNDY1Mzg_a3c4973e-4ba4-490d-99cc-b9d3a9910681">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic622f20a96d14ab59d16de8af2ade381_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzQtOS0xLTEtNDY1Mzg_54a9d73a-19a9-45cf-8c54-147b10125c96">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMS0xLTEtNDc2MjQ_535d5c13-ff05-471d-93f2-bb6b9d93dfa2">40,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMy0xLTEtNDc2MjQ_45f62dfc-d30d-446d-991a-4b3c5c0480b1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNS0xLTEtNDc2MjQ_2632afd8-17be-4609-b423-20e1b92bc8ae">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNy0xLTEtNDc2MjQ_912bbd1a-fd7e-44fb-a789-0d0384089b7d">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32b08f8717549848438881335ea2b84_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTEtMS0xLTQ3NjI0_70bc190b-ecc3-4bd0-a8c3-6adcd69b60e8">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719c13df2acf4bbc80d5a66f47c2c5f8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTMtMS0xLTQ3NjI0_679691ae-ad8f-4ec9-a013-4b7337ea2a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56384752fd2647389a6264b9b7752b99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMS0xLTEtNDc2MjQ_b890d6eb-0ed1-4741-a804-070f10a614e0">83,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56384752fd2647389a6264b9b7752b99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMy0xLTEtNDc2MjQ_f449381b-bd72-4eda-ab91-af94da092599">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56384752fd2647389a6264b9b7752b99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNS0xLTEtNDc2MjQ_60fdbaa4-d57f-423b-8185-3040e61e1312">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56384752fd2647389a6264b9b7752b99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNy0xLTEtNDc2MjQ_ea9e9b9a-e6dc-48f5-8371-6993fd5e09a0">83,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f790be83c94488822a264523f7aa15_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTEtMS0xLTQ3NjI0_f738d021-be3f-4afc-99ca-717087cb4c3b">35,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da056f4632343f5ade54138b94c15a3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTMtMS0xLTQ3NjI0_fb1a7e5f-fdac-4ca5-9336-af0fbd042614">47,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995af0deed0b466cb43a86929a821007_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMS0xLTEtNDY1Mzg_a5a4a350-74a5-4f88-922e-0f44496180d1">37,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995af0deed0b466cb43a86929a821007_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMy0xLTEtNDY1Mzg_c1b0a6e8-dbc0-4095-accb-5c7b94aa619d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i995af0deed0b466cb43a86929a821007_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNS0xLTEtNDY1Mzg_5b564e39-f0e0-4dcc-8f6b-8f9d5fadb188">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995af0deed0b466cb43a86929a821007_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNy0xLTEtNDY1Mzg_53a01047-b223-4937-8211-de104e32e158">37,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7449a1b73c48eba712df83a6750173_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTEtMS0xLTQ2NTM4_7eb0af04-4091-4d3d-ad90-1028f7a431d2">20,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id297898530e345fdb9c39bf76182c6cc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTMtMS0xLTQ2NTM4_2cd3135b-abbb-47a6-becf-d3ab3bc4b873">16,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMS0xLTEtNDY1Mzg_14a1f9c8-b4c4-4569-bd57-f6caf5921d34">161,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMy0xLTEtNDY1Mzg_af1a4807-39f3-447d-bd15-67bc64b9b3c3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNS0xLTEtNDY1Mzg_a400b5ab-5d32-49cd-a7c5-089d02cf1783">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNy0xLTEtNDY1Mzg_47fddb83-3047-46bb-8fe1-d11e4e1209b7">161,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2664a396fda544d5b299ff5ebffde6f7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTEtMS0xLTQ2NTM4_8a6ce455-e357-4f2f-8d19-3408e7c963c7">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eedc946a09f4463a2514f7732506d68_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTMtMS0xLTQ2NTM4_d53e0aa1-e136-453b-8f90-2b3326a16038">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMS0xLTEtNDY1Mzg_41af07f0-65af-4af8-8259-5fbbfa5f136a">502,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMy0xLTEtNDY1Mzg_4c832540-a168-4f4a-bfc0-1f0c3e0974c6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtNS0xLTEtNDY1Mzg_ab82059d-d87e-470d-a57b-4b011470a8bc">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtNy0xLTEtNDY1Mzg_eda886cb-ca59-42f8-89c8-a91b41a18ed9">502,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb31ec5446de4fe8ac13a013fc88446a_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtOS0xLTEtNDY1Mzg_bdeb1d9d-8eef-4a1a-bb3c-39a11c42ea48">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a01a2413bfa418289c898f2b33b80ef_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMTEtMS0xLTQ2NTM4_db26da48-afc3-4119-afbf-31fc10e96bbf">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba9efc2fefc4fef9a71d9e9ad291bf5_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMTMtMS0xLTQ2NTM4_fba23ab7-904e-470d-8405-3ceb5d1a6764">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="id15667ce7b0c40e5b2f6147b95913a03_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzI3Mg_2eaecf9c-7b8a-4542-b13d-a6220d89274d">one year</ix:nonNumeric> or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s long-term marketable securities mature between <ix:nonNumeric contextRef="ib64f00a32bc643ec9155226e65fdce96_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzM0NQ_08f521ca-ae33-4da3-9ccb-cfc10befe978">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="id09a4d167ef143e0bd15f47ab94c5ad3_I20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzM1Mg_b436baf6-5e05-4c72-8952-43da7ad80343">two years</ix:nonNumeric>.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="krys:BalanceSheetComponentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzQxMQ_d3217920-87e2-47de-b662-7c8069d25fe6" continuedAt="iabf548d163f94a648544da6ba1897880" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="iabf548d163f94a648544da6ba1897880"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzQxMg_c12aafa7-b33d-466e-a0eb-6c36263fdf5a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:69.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38459e6001414efe8cfeb8e4f948bc27_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzEtMS0xLTEtNDY1Mzg_77822047-44a4-4cc7-b7bf-37d3638a4752">131,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36fe90f1305345ceb8f4eec74b095c49_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzEtMy0xLTEtNDY1Mzg_34531b36-13d1-4d0c-94c9-b1fa3231cfae">104,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629b96ba6adf4d8aa35b23c9ad34341a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzItMS0xLTEtNDY1Mzg_d7ee31c4-9e92-44e9-9f49-8265f1a54a93">24,217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01e245d2c6b4ecbb264de581059c082_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzItMy0xLTEtNDY1Mzg_81ec8b69-6d12-460e-911f-569a775d41f0">5,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a1d6851402493eb7158bcdc4c40c4b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzMtMS0xLTEtNDY1Mzg_4b801d83-67d2-42a9-a329-6e45a646e197">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd317320604f464d92352b55af94077e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzMtMy0xLTEtNDY1Mzg_a89c1774-a76b-410b-8fcf-19e1f21e35d1">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib85a7c903384425b9eb947f6782aa70b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzQtMS0xLTEtNDY1Mzg_ec385178-d4c0-498e-a364-ae0bc40d2bc9">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i256fac5f703848e2b8ab04acc69e5f3c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzQtMy0xLTEtNDY1Mzg_fefac8ff-1a12-4054-a4c9-0655f147caae">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea876abef962460799265e18643c6fb9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzUtMS0xLTEtNDY1Mzg_2d6862ec-a038-47c4-a635-09fb3ec7707c">11,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc859be73b64ed295ad31b068c1c6b5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzUtMy0xLTEtNDY1Mzg_6b9527df-a664-407c-b514-29a18d3d7586">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzYtMS0xLTEtNDY1Mzg_31af1a41-2dbb-46b3-ad85-afa3e86dfc73">168,477</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzYtMy0xLTEtNDY1Mzg_e8e5e347-e473-4bc6-b2ab-a56e078f8fc7">116,569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzctMS0xLTEtNDY1Mzg_4ea43a10-5fb6-4884-9c38-998b22075def">6,793</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzctMy0xLTEtNDY1Mzg_27df393e-3a81-4765-8072-7c26174a8ce9">4,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzgtMS0xLTEtNDY1Mzg_9b883451-c54f-46cc-956e-753071f9977d">161,684</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzgtMy0xLTEtNDY1Mzg_dcc1ff90-4900-4821-b3d0-abda65116579">112,355</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzU0OTc1NTgxNDQ2Mw_7fb25e26-6078-4432-aed4-cb3bd59bc3c0">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzU0OTc1NTgxNDMyMA_eb831d9b-1ad6-41bf-8e08-70fe1eeecbff">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzU0OTc1NTgxNDMzMA_4ccf555a-fd56-4f6e-a2d5-d680038b4edf">1.5</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzQxMw_7893b61f-c86f-4919-ba29-91a5efc2acb8" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzEtMS0xLTEtNDY1Mzg_ed0356a3-7ba3-4175-80d5-48f0548a13f3">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzEtMy0xLTEtNDY1Mzg_083d6945-1c74-4caf-9cdb-0e7a0dd9acbb">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzItMS0xLTEtNDY1Mzg_0efa9838-2772-4fdd-baff-128f6899ebca">3,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzItMy0xLTEtNDY1Mzg_0f7a41b8-9177-4db7-90a8-586416f817d0">2,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzMtMS0xLTEtNDY1Mzg_5829c54c-f682-4574-8f22-6c26eeb1f758">6,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzMtMy0xLTEtNDY1Mzg_fd2fbe3c-3b67-4c48-a071-0b2fd5ac7211">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:AccruedConstructionInProgressAndLaboratoryEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzUtMS0xLTEtNDY1Mzg_674c7828-8ef0-4f45-be76-83f855ee229a">11,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:AccruedConstructionInProgressAndLaboratoryEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzUtMy0xLTEtNDY1Mzg_e83f7fd8-f476-44e7-88ad-ff13e74d87a4">9,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:AccruedFinancingFeesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzYtMS0xLTEtNDY1Mzg_594f366d-9984-4a00-a957-0d22fc46b7d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzYtMy0xLTEtNDY1Mzg_984b2d5c-814b-4b9c-829a-f66bfa253c98">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMS0xLTEtNTkzMTQ_8d9a8705-99a1-46d3-98c7-4db36f0e7a64">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMy0xLTEtNTkzMTQ_e4e634f7-10a1-4c45-aeec-eb6657bf0e63">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMS0xLTEtNDY1Mzg_0a5c1679-2533-4c88-838c-9de1ba2ac274">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMy0xLTEtNDY1Mzg_1cb45a5a-e054-475a-868c-860e687973dc">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzgtMS0xLTEtNDY1Mzg_e44a89f1-e66b-4500-ba65-912d4acb1723">23,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzgtMy0xLTEtNDY1Mzg_ed8413d5-b6b9-4931-8919-84f01f8cccd1">16,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzIxOTkwMjMyNzY4ODk_db7358d9-07e4-4542-afcf-68dfb5076da6" continuedAt="i2b90b43759e146688f030d7e7ad13f36" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i2b90b43759e146688f030d7e7ad13f36" continuedAt="i59f94fdef09d41b2b589b987e13a5e16"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations (&#8220;CROs&#8221;), Contract Manufacturing Organizations (&#8220;CMOs&#8221;) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of December&#160;31, 2022 under these agreements is approximately $<ix:nonFraction unitRef="usd" contextRef="ic202baf205634534bffe9efeed3c7c9c_I20221231" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzYxMDk_491f0f1a-26a2-4d12-bdd5-8b479fc44021">2.1</ix:nonFraction> million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred research and development expenses under these agreements of $<ix:nonFraction unitRef="usd" contextRef="ie8bb7ba5bc104672859794003515136c_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzg4Nw_04c50fd8-9bb7-442e-a10e-fa7a5d5252fd">6.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie84cd465b49e427c810883f086042263_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzg2Nw_97725f86-ea11-42b4-9f4b-80e71452c6f9">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i02fbe5b2532b456baed4ef03a2689550_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzg3MQ_76201d00-cd8e-48c7-8410-142f08bdd8d4">4.6</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones or as services are rendered. The estimated remaining commitment as of December&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="ie6be49196b1a40cebb048dcca6eb9e34_I20221231" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzY2MjE_8a2c730c-d92e-42e8-8cf7-df7910ce7b7f">8.4</ix:nonFraction> million. The Company has incurred expenses under these activities of $<ix:nonFraction unitRef="usd" contextRef="i9e748ec3ff764d03a108335cdb1f671c_D20220101-20221231" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzkwOQ_e31685b6-390b-4367-ba04-109f81715be2">14.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia61ac7a1eeb045dcacea633ccb659966_D20210101-20211231" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzkwMg_aa2c54af-31c3-4f11-b401-100627faac15">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i832fb48c719242fba8c5af845c762e6d_D20200101-20201231" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzkwNg_d33b0dfa-3c07-4e90-93fc-43b82f30bdfe">1.9</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to complete the interior build-out of our second CGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of December&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTg0MTAxOA_8212a5fe-bcaa-4a47-ab74-fde8a96b6087">16.3</ix:nonFraction>&#160;million. The Company has included costs incurred to-date associated with ASTRA within construction-in-progress as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to <ix:nonFraction unitRef="number" contextRef="ifc3bab3e2c074cf09d136a1988e3d2e6_I20221231" decimals="INF" name="krys:CostOfWorkPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1Xzc3NzY_4dc9c43b-724a-4aae-955b-d62fd2588ceb">1.75</ix:nonFraction>% of the cost of work.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company, which has been amended from time to time for change orders additional work is awarded to Whiting-Turner, is currently $<ix:nonFraction unitRef="usd" contextRef="i495e2c1097804e028fc462ff30675a6f_I20210913" decimals="-5" name="krys:LossContingencyGuaranteedMaximumPriceToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzgyNjg_08e3c042-ffeb-45d5-b86a-fa05c4a72d87">85.5</ix:nonFraction>&#160;million. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement may not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement with Whiting-Turner constitutes only a portion of the total estimated cost of building and equipping ASTRA as there are various other third parties engaged in the project for which contracts are not individually material. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. (&#8220;PeriphaGen&#8221;), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint in June 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions. On March </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i59f94fdef09d41b2b589b987e13a5e16"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12, 2022, the Company entered into a binding term sheet to settle the dispute. In April 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i3fb54fd3a1a9429dbd4579a4ca4375c3_D20220428-20220428" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMDU_9d5aa0cf-3e21-4662-87b0-bd84e54ca575">25.0</ix:nonFraction>&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $<ix:nonFraction unitRef="usd" contextRef="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMjA_0b73274f-a4a5-4dda-9324-36dc13dda4ee">12.5</ix:nonFraction>&#160;million, followed by <ix:nonFraction unitRef="milestone" contextRef="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231" decimals="INF" name="krys:NumberOfMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzI0MzE_95f2189a-4f4d-4a7b-8e32-716a3275618e">three</ix:nonFraction> additional $<ix:nonFraction unitRef="usd" contextRef="i4284a105f3d94405949b41403e9a7675_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMzc_2b557880-5350-4387-a8dc-7e360a80ba1c"><ix:nonFraction unitRef="usd" contextRef="ie93b6151f6f9401a9cf2ece6f8285911_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMzc_69fba005-6c2c-46ad-beea-6f5e838e8567"><ix:nonFraction unitRef="usd" contextRef="i66aa90c0684b46ac8099d45d53db5a8d_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMzc_e106258d-3443-448f-b08e-4213da552ff3">12.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million contingent milestone payments upon reaching $<ix:nonFraction unitRef="usd" contextRef="idc45f2a4236a42068da733f353b95494_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzNTI_7c916303-d9f5-4f5c-b409-008ef7bf38ad">100.0</ix:nonFraction>&#160;million in total cumulative sales, $<ix:nonFraction unitRef="usd" contextRef="id2f6d31d7c164477b1d0048e8a3d3c31_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzNjg_4450af0a-2245-4b5c-bce5-f7629d495b92">200.0</ix:nonFraction>&#160;million in total cumulative sales and $<ix:nonFraction unitRef="usd" contextRef="i945482856edd461ca395d4030b16ab54_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzODQ_cd45f4c7-3873-4007-973a-ca893ae0a4b0">300.0</ix:nonFraction>&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $<ix:nonFraction unitRef="usd" contextRef="ie8a82f78a44f492d8069e2d68d1056a8_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementTotalConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzI0MDA_928f6cbb-0982-4aae-bee8-e8407de8d760">75.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $<ix:nonFraction unitRef="usd" contextRef="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzI0MTU_1b2dffed-8ee6-46d0-84af-6113587bfadc">25.0</ix:nonFraction>&#160;million within litigation settlement expense on the consolidated statements of operations for the year ended December 31, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of December 31, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTg0MDYxOQ_6df20bc4-3caf-4f82-874f-aefe69264bfc">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgzMzgzMg_b7eb3991-eaa4-4b4e-a84e-a75bfc90e87d">1.6</ix:nonFraction>&#160;million of insurance proceeds during fiscal years ending December&#160;31, 2022 and 2021, respectively. Additionally, the Company had outstanding receivables of <ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTg0MDQ2OQ_85a4e7d0-98a0-4d7a-bcfb-74be6304c7d1">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgzNDk3Mg_2a89fda1-67c5-45e3-8202-c7a98ef15304">560</ix:nonFraction>&#160;thousand as of December&#160;31, 2022 and 2021, respectively, recorded within prepaid expenses and other current assets on the consolidated balance sheets, as management determined that the amounts were probable of collection. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the consolidated statements of operations and within operating activities on the consolidated statements of cash flows.</span></div></ix:continuation><div id="if50fdf1a469a4104bbe6f4c216cff277_549755815462"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDM_8ea97014-3fc0-4c0f-b584-9c74fee9ee24" continuedAt="i8286a358ab9c492184dcd87f5ea8f015" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i8286a358ab9c492184dcd87f5ea8f015" continuedAt="i15a9448f92f04205be01dece83016fd5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company signed an operating lease for laboratory and office space in Pittsburgh, Pennsylvania that commenced in June 2016 and was scheduled to expire in October 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately <ix:nonFraction unitRef="sqft" contextRef="i6729dd8891e24732929f1da30607e91a_I20220930" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzEwOTk1MTE2NDc1NjI_6c561065-9e8a-44ee-85b2-52e0e9c7f211">54,000</ix:nonFraction> square feet and includes the commercial scale CGMP-compliant manufacturing facility, (&#8220;ANCORIS&#8221;). As a result of the lease amendments, the 2016 Lease expiration date was extended to October 2031. In September 2022, the Company amended the 2016 Lease (&#8220;Short-Term Amendment&#8221;) to add a short-term lease for additional office space that commenced in October 2022 and expires on September 2023. The Short-Term Amendment increased the area leased by approximately <ix:nonFraction unitRef="sqft" contextRef="id3550b062fe645a5b0ed51ef12d694db_I20220930" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzg0Mw_2a9dcaac-2220-4a06-8ce6-b8fcfac8fbbc">7,000</ix:nonFraction> square feet through September 2023. Due to the short-term nature of this amendment and the Company's lease accounting policy, the Company did not record a right-of-use asset or corresponding lease liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a lease agreement for a second commercial gene therapy facility, (&#8220;ASTRA&#8221;), in the Pittsburgh, Pennsylvania area (&#8220;ASTRA lease&#8221;) with Northfield I, LLC (the &#8220;Landlord&#8221;, &#8220;Northfield&#8221;, or &#8220;Lessor&#8221;) with an initial lease term that expired on October 2035. The ASTRA lease contained an option (&#8220;Purchase Option&#8221;) to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the &#8220;Ground Lease&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $<ix:nonFraction unitRef="usd" contextRef="i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzE5Nzk3_1f76f470-6258-4680-8df2-8f4f96103383">9.4</ix:nonFraction>&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA. The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i4370047cb1b348508f41d2e789bc71c0_I20201031" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzE5ODA1_3cbe941c-66c7-4e04-bb05-93ad007a5ba2">10</ix:nonFraction>&#160;million CIP asset and a corresponding build-to-suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contributions of $<ix:nonFraction unitRef="usd" contextRef="i4370047cb1b348508f41d2e789bc71c0_I20201031" decimals="-5" name="krys:PaymentToEscrowForReducingLeaseRentals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzE5ODAx_4aed6625-b1d0-4657-bddf-3d4f75174ebd">2.4</ix:nonFraction>&#160;million.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i15a9448f92f04205be01dece83016fd5" continuedAt="ifd3fc6734e904edb999a302323ef3f7a"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Purchase and Sale Agreement (&#8220;PSA&#8221;) for ASTRA with Northfield related to the purchase option exercised by the Company in October 2020, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzI1ODM_ed6904f4-b1e4-4c0c-8233-4fca4200625a">9.4</ix:nonFraction>&#160;million. The Company held approximately $<ix:nonFraction unitRef="usd" contextRef="i4370047cb1b348508f41d2e789bc71c0_I20201031" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzI2MTg_7b770694-f06a-4835-aaae-38055ee975ce">1.5</ix:nonFraction>&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. In February 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement. As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale. As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. In March 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. The building continues to be held under construction-in-progress as of December&#160;31, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2023. For more information about the expected construction costs associated with ASTRA, see &#8220;ASTRA Contractual Obligations&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability in October 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="krys:LessorOperatingLeaseLiabilityAnnualLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ0NzQ_c9e6ae07-333f-470f-a3c1-04803f45de75">82</ix:nonFraction>&#160;thousand, and are subject to a cumulative <ix:nonFraction unitRef="number" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="krys:CumulativeEscalationClausePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ1MTA_3ab9e177-6992-47da-842b-cfc9bd335c46">10</ix:nonFraction>% escalation clause every <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="krys:CumulativeEscalationClauseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ1Mzc_27835c95-9d63-4b68-864c-0e585b37403a">5</ix:nonNumeric> years through 2071.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a <ix:nonNumeric contextRef="if35ae989164e43cdb1a778a5e6515540_I20211215" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ2MDM_df5df25f-f9e0-4de6-a215-3e220ba7db22">3</ix:nonNumeric> year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into a <ix:nonNumeric contextRef="ia171e05bea12459f9ba3be58aa9b540f_I20220316" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ3Njg_ad6a24c8-e8a9-4b4d-89dc-5d7c6c90bb74">16</ix:nonNumeric> month lease agreement for the Zug, Switzerland office that commenced in September 2022 and expires December 2023.</span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDI_d827ab14-8155-443a-bf87-a620eb01923c" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:84.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating&#160;Leases</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzEtMS0xLTEtNTM3NTI_033101e3-dbb0-4da5-a316-ab18cf165d50">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzItMS0xLTEtNTM3NTI_c73b5cd5-cfa5-4add-a773-a3d4dc284aac">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzMtMS0xLTEtNTM3NTI_4b12abf9-dd69-4825-b441-1ec1a4d91475">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzQtMS0xLTEtNTM3NTI_8e7243b7-156e-4949-aae9-9eab0e444e06">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzUtMS0xLTEtNTM3NTI_d70faba6-9719-4ab5-b3ab-7e9bc5a7af2b">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzYtMS0xLTEtNTM3NTI_654db54f-0a03-4e4f-889f-4703d7b2354d">10,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzctMS0xLTEtNTM3NTI_0e64958e-3e07-404f-b540-b0de4faa4cf6">17,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzgtMS0xLTEtNTM3NTI_51e0cc31-4940-4118-b667-476baae40158">8,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzktMS0xLTEtNTM3NTI_56ab659e-7102-4a18-92de-41b0e387e164">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDQ_4088322f-65a8-450f-a1fe-783035615919" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzItMS0xLTEtNTM3NTI_1a11eb55-6812-4629-abf9-bdb8c4386f00">8,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzItMy0xLTEtNTM3NTI_0ca5e246-26db-4ee9-8229-d5d608ce8e28">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzMtMS0xLTEtNTM3NTI_6e80a332-db54-4273-a83a-0e838d1c7c03">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzMtMy0xLTEtNTM3NTI_49e799f7-90ba-4f98-a03f-fdd5364c79b9">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzQtMS0xLTEtNTM3NTI_e17b5c4f-1644-4099-a093-370b9ddff856">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzQtMy0xLTEtNTM3NTI_3c56e76a-1dc9-426b-b476-9793cef36af3">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzUtMS0xLTEtNTM3NTI_88c2dd1c-7cda-488c-93a6-0050c7f5896b">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzUtMy0xLTEtNTY3MTQ_5f6a8d0b-8c60-4968-ae5b-bd815998cc65">8,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzYtMS0xLTEtNTM3NTI_82e44fa8-4571-4dff-b8e2-29e3748fbaf3">12.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzYtMy0xLTEtNTM3NTI_6dea0813-034a-4312-97c9-56050d3ab13c">14.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzctMS0xLTEtNTM3NTI_c70b770b-e212-4263-bb06-c8fed549cc68">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzctMy0xLTEtNTM3NTI_9f51ac12-075a-4d3a-85cb-56bab7f48711">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:2pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="ifd3fc6734e904edb999a302323ef3f7a"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDU_ffcc67c1-ecdd-4ad2-aa50-6da484648a70" escape="true"><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzQtMS0xLTEtNTM3NTI_a0cf0206-9cbe-46a8-93f8-0172bb073a7b">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzQtMy0xLTEtNTM3NTI_6fd5b2a2-47f0-4aea-b2ee-3d588e3c2c22">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzQtNS0xLTEtNTM3NTI_c055a392-b026-474b-bc9f-2f76f410deab">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzUtMS0xLTEtNTM3NTI_24e2bf7c-f4fe-4443-a668-2062a80e4968">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzUtMy0xLTEtNTM3NTI_c66ca83d-e931-466d-aad4-9f29639d0643">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzUtNS0xLTEtNTM3NTI_a8ba57da-d3f8-4013-9122-db36e9e7bef0">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzYtMS0xLTEtNTY3MTc_9a42ef36-dcbb-40b8-84ef-5416670d845c">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzYtMy0xLTEtNTY3MTc_9bbad3a6-e933-48e6-b130-0efcf00c218d">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzYtNS0xLTEtNTY3MTc_58d66aff-a904-4fc2-bf30-dc7f9dd7994b">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if50fdf1a469a4104bbe6f4c216cff277_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzE5OTE_bc60303e-afef-41db-b6af-953dc318151d" continuedAt="i12b4deb3bda347afbb9835dadb728580" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="i12b4deb3bda347afbb9835dadb728580"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzEwOA_695aa5e3-16e9-40ed-935a-f49fb60ec28e">2,866,667</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i30156baee55b420397418386f0108370_D20211203-20211203" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzE0OQ_d742af12-8d70-4e36-86ed-a0984ec2d60d">200,000</ix:nonFraction> shares purchased by the underwriters pursuant to their option to purchase additional shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i20353f3c4a5844c1812426b1fb75b765_I20211203" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzE5Mw_128dc125-cd9e-4ca1-87fa-9b2df5fabef3">75.00</ix:nonFraction> per share. Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzI1OQ_d024c7a5-0e7e-4813-b304-217c03d0b132">201.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzMzNA_72b42431-7fbd-41be-980a-9ed427dc07e8">12.9</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="id22d7707724741a49fc8f50872fbdfdb_D20211203-20211203" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzM5Mg_56229491-6eca-4c56-9ce6-0fad6a7d53d1">227</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzQ2MA_8e641da4-a43d-4f5a-8303-afbaf8a0278b">2,211,538</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="ieb9b5e8d6ec94209880102cc2bc8b200_D20210201-20210201" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzUwMQ_b0aa6df1-5366-4603-9e4e-437ac32c91bd">288,461</ix:nonFraction> shares purchased by the underwriters pursuant to their option to purchase additional shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i30752247a0714b92a9d3f37982cfdcaa_I20210201" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0NQ_00ee61ea-6a1b-4612-9395-336f94c0e864">65.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzYxMQ_0d316add-9fb3-4a47-b718-ce38a83f1382">134.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzY4Ng_380dd778-8c87-477c-bd5a-fad3d3836403">8.6</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i9957e8c329c246278995d54d846e0a2b_D20210201-20210201" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2Xzc0NA_30bb8bea-654e-44d9-b723-bd1ae6c5e51f">198</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDIyMg_c8128a5b-b157-4941-b661-85683c751292">2,275,000</ix:nonFraction> shares of its common stock to the public at $<ix:nonFraction unitRef="usdPerShare" contextRef="ic18c855dfb0d4abf9b71ece6213ab70d_I20200531" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDI3MA_92cb4457-1c7e-4d36-b422-304b3b640fef">55.00</ix:nonFraction> per share. Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDMzNg_825fb016-122f-45c0-9913-d2ec526dc745">117.2</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDQxMg_a382ed6e-1ec2-4183-8839-f35a6eb28bf0">7.5</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDQ4NQ_fc9792ab-99b8-4bd4-ae27-027d035309de">463</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC (&#8220;Cowen&#8221;) with respect to an at-the-market equity offering program (&#8220;ATM&#8221;) finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="i95615b0260094824b79b22c82e8d1a1a_I20201231" decimals="-5" name="krys:SaleOfStockAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODIyOA_3e03970b-b166-48d3-87ea-5f5a54e8213b">150.0</ix:nonFraction>&#160;million (&#8220;Placement Shares&#8221;). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective &#8220;shelf&#8221; registration statement on Form S-3. During 2021, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="icb780c5cb8b14431832716c15e1dac80_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODQ3Mg_7b56cac6-7858-40c1-b8c5-7d39a80f9171">262,500</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f7ad365543f4254838ab4c58a691a10_I20211231" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODUzMA_b234b436-4dad-480c-98bb-568c5eb2f40b">66.50</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7cef0fcaddce44cfa4ae5cd35b69a9db_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODU2NA_b72ffd95-c449-4ff0-8a82-e1fe92f468e5">16.9</ix:nonFraction>&#160;million after deducting selling commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i7cef0fcaddce44cfa4ae5cd35b69a9db_D20210101-20211231" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODYyMQ_d7a0b98a-baa2-442a-bc41-a8c86dda6044">524</ix:nonFraction>&#160;thousand. During the year ended December&#160;31, 2022, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i94d7eb26698e4662a210b4e03cb7f40e_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODcwMw_4e341ea5-418c-4f8b-8f8f-2ce04e453a8d">434,782</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id0436d21be92494794b2f1a66dba88ec_I20221231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODc2MQ_e5d6621d-ffbd-4788-999a-b6621892ed49">69.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i94d7eb26698e4662a210b4e03cb7f40e_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODc5NQ_96740def-5e0b-4679-b148-a86f2c5c296e">29.1</ix:nonFraction>&#160;million after deducting selling commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="idd3104f8c0ce402b88a79fb05859ba61_D20220101-20221231" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODg1Mg_2ae9303f-6e41-4bfc-9bed-d10fc5636042">900</ix:nonFraction>&#160;thousand, resulting in a remaining $<ix:nonFraction unitRef="usd" contextRef="idd3104f8c0ce402b88a79fb05859ba61_D20220101-20221231" decimals="-5" name="krys:SaleOfStockRemainingAvailableIssuanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODg4Mg_84ea66ee-e337-413c-b3ea-84b7101efe8a">102.5</ix:nonFraction>&#160;million available for issuance under the ATM Program.</span></div></ix:continuation><div id="if50fdf1a469a4104bbe6f4c216cff277_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NTk_ce2937b1-987d-4f88-924f-4d1127121c39" continuedAt="i9100b8f8981b4ad0b7c69db06d52ae71" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i9100b8f8981b4ad0b7c69db06d52ae71" continuedAt="i70be99d9c9bd40a9b567f5f3b9f680b9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company adopted the 2017 IPO Stock Plan (the &#8220;Plan&#8221;), which governs the issuance of stock options to employees, certain non-employee consultants, and directors. Initially, the Company reserved <ix:nonFraction unitRef="shares" contextRef="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzEwOTk1MTE2MzE2NTQ_35ec1637-2945-40d1-ae35-239c62a51312">900</ix:nonFraction> thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzEwOTk1MTE2MzE3NTc_d65e7afa-da93-493f-8b75-2169d3786e2a">900</ix:nonFraction>&#160;thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over a <ix:nonNumeric contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjI_f6e358da-4a03-474e-85ad-3f79045b19d9">four-year</ix:nonNumeric> period and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE5NQ_581f1165-b5dd-4145-a11c-77520dcce020">one</span>-year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxODQxNQ_e82f6b9b-070f-474c-9202-f9ee87935c71">three</span>-year periods. Stock options have a life of <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI0Nw_a6ef1e8d-c60e-474e-8706-81c90c01e169">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="ic9274bc3d5034d649742d7cf95cad4c7_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxNjk2MQ_85815005-846b-40a1-b78d-836d4e78bc61">2,130,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i44284afec0974ca383f35189fcf5836c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3OQ_f92f63c1-ceb9-4319-8022-872ea87663ca">1,422,450</ix:nonFraction> stock options to employees, non-employees, and directors during the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="i70be99d9c9bd40a9b567f5f3b9f680b9" continuedAt="ie8fa3a4c3f904c87a4116b964eadf34f"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjA_3dc716b1-6a6d-4886-9257-95f0bc0e7a33" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:41.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtMS0xLTEtNDY1Mzg_7256a6da-ae9f-4fee-bc26-1b9caaa71237">853,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtMy0xLTEtNDY1Mzg_87b8f2a6-6217-49f7-b947-b97d26a6a632">40.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtNS0xLTEtNDY1Mzg_6e4760de-6207-43aa-809e-6cfe02d21aa9">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtNy0xLTEtNDY1Mzg_fe536cb6-006f-4261-85cc-89f9848b5ba4">16,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzctMS0xLTEtNDY1Mzg_f3391b90-6f75-4e34-9fa1-be1f1ba2c5a1">1,422,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzctMy0xLTEtNDY1Mzg_ba541387-8afe-46fd-a421-dbfaf0fa3577">66.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzgtMS0xLTEtNDY1Mzg_4dadccba-2f80-42ea-a757-263a15a3ba84">54,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzgtMy0xLTEtNDY1Mzg_73b41705-2282-4758-ac5a-b27dadf7c5ef">38.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzktMS0xLTEtNDY1Mzg_7a27b0b9-a9b7-41c2-8af1-bbb965264fbd">175,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzktMy0xLTEtNDY1Mzg_a7607f59-96b2-4611-ac01-26c28d973a17">61.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEwLTEtMS0xLTQ2NTM4_9e7101a5-15bb-4521-a4c5-1b712e11eea4">2,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEwLTMtMS0xLTQ2NTM4_a8348acc-e932-484d-97a6-39407eab76e3">75.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTEtMS0xLTQ2NTM4_ee42d460-1ab6-4bec-854f-0eba8f6baffd">2,043,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTMtMS0xLTQ2NTM4_bd041708-e3d2-49d7-a307-66fae780e0ea">57.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTUtMS0xLTQ2NTM4_1d1e7104-f742-439d-b849-527fe9598283">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTctMS0xLTQ2NTM4_2b7b8964-79b0-46bd-8ff8-29c81b8be5f0">31,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTEtMS0xLTQ4NTkw_c20c3544-e6da-4ae6-8929-e2b7b2a9ed92">2,130,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTMtMS0xLTQ4NTkw_fab4bc7b-aa3f-4dbd-aafc-2fc8b527e170">64.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEzLTEtMS0xLTQ4NTkw_86c17198-59ba-4439-b14d-72628225f5db">138,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEzLTMtMS0xLTQ4NTkw_ba773311-fe45-42cf-bad5-01975d249905">50.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE0LTEtMS0xLTQ4NTkw_aa9bc26e-8036-41d7-ac08-289c3b440e91">438,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE0LTMtMS0xLTQ4NTkw_7595db2c-b665-43fd-8f15-ac4e9e87270c">59.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE1LTEtMS0xLTQ4NTkw_34a7704f-728e-4b1c-97ce-49932aa9bfda">13,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE1LTMtMS0xLTQ4NTkw_fbc72762-aede-4bd1-bcd0-af1a0dbed4a6">78.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE2LTEtMS0xLTQ4NTkw_13b836f7-bcd4-4fc9-9ece-37d816a93085">3,582,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE2LTMtMS0xLTQ4NTkw_a525d2a8-3322-4b5a-91fd-b9287224f34b">61.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTUtMS0xLTUyNTg3_b77a0e5e-ddd5-43be-a0ca-09995f9a0039">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTctMS0xLTUyNTg3_7b203544-c53d-4205-89b0-2e73efefb395">64,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTEtMS0xLTQ2NTM4_127ccc56-e383-45c0-aeab-cec903da1900">666,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTMtMS0xLTQ2NTM4_97af4dc3-82fc-40db-aad0-5bbe9465d927">49.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTUtMS0xLTQ2NTM4_a625ac6f-e641-4048-aab3-05927b23a984">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTctMS0xLTQ2NTM4_8bf0b906-d977-4fe4-9606-70748382c4f7">20,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December&#160;31, 2022 and the exercise price of outstanding in-the-money options.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ic9274bc3d5034d649742d7cf95cad4c7_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzc4OA_7d797b5e-8897-46c0-9b9f-5dc2e31216c1">2.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i44284afec0974ca383f35189fcf5836c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzc5NQ_d2015589-22fb-49cf-93d9-cdc9d07ff402">1.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzk1Ng_6a6d20dc-30ae-41b8-a3f5-d22b290d375c">44.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzk2Mw_75cb81fb-c83c-4235-a5f7-b3f41b6a4294">43.05</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="ib074476f73164a7380886e3036b586df_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzk5MQ_bcbfc5c1-4063-4240-9e3b-04805c73ab4c">104.4</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to employees&#8217;, non-employees&#8217;, and directors&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="iae2d691354374a8292be807107fe9093_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxNzE4Mw_393821d1-a9fd-4983-8441-a4905c0451b4">2.9</ix:nonNumeric> years as of December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjE_f0b34634-a2f9-4e2a-bcab-a50caf87bec0" continuedAt="i2e0bf99190c64fd6a85f5460adf94b6b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the&#160;consolidated&#160;statements&#160;of operations for the years ended December&#160;31, 2022, 2021, and 2020&#160;as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:55.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae3c74e3eaa49338980a2180ec9032f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzItMS0xLTEtNDY1Mzg_72cc15d4-499f-4574-83d8-19d783f45462">7,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0073addc8943b48ff41400a0b94650_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzItMy0xLTEtNDY1Mzg_ba481c43-ed06-48a8-8a5d-e050146f84a3">3,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ce9bbd561d4f208adfe62e207934e6_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzItNS0xLTEtNDg3MDA_11a54d3f-dc6d-43c8-8094-c859f93335cf">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f3a841eea6448987a04b6c2d676f22_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzMtMS0xLTEtNDY1Mzg_9f1d2fc2-0f9d-48ee-8d62-a7408a691f3a">23,551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0747f5930bf4422fab3034a04de464a1_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzMtMy0xLTEtNDY1Mzg_1de7b2d5-5148-41c0-ad2f-6a8f6a7f6024">10,235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec828eaae79146849fd3782a3949449d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzMtNS0xLTEtNDg3MDA_e8ac3ebc-5f52-49ad-869c-03ddf6aaf729">2,278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzQtMS0xLTEtNDY1Mzg_05ece547-5a53-4074-9cca-010f9765a353">31,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzQtMy0xLTEtNDY1Mzg_4f252415-f9f9-4d93-a0b5-6310af75a7f8">13,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzQtNS0xLTEtNDg3MDA_2979da9b-b921-4f84-9009-137e8a336ffb">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of manufacturing facilities. There was $<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE1Mjg_2dce690e-01f7-4716-8c63-354909ece340">551</ix:nonFraction>&#160;thousand, $<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE1MzU_3fcd19ce-c625-4432-88f0-23d504a64760">284</ix:nonFraction>&#160;thousand, and $<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxNzAzMQ_7d23414f-f99d-4c59-bb9f-79986f2296b9">34</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the years ended December&#160;31, 2022, 2021, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjQ_210aec09-5f87-42f1-b194-219855530513" continuedAt="ic272d256f5d2491fb4ca260185f71081" escape="true">The fair value of options granted was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the years ended December&#160;31, 2022, 2021, and 2020:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ic272d256f5d2491fb4ca260185f71081"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzItMS0xLTEtNDY1Mzg_8997c2c5-0b08-453e-b271-86097dd8b2cc">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzItMy0xLTEtNDY1Mzg_6aef4eef-1cc2-4645-a223-dbf8cd45e7d5">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzItNS0xLTEtNDg3OTM_1ac516e6-d8ec-4b82-9a4f-f43997aa365e">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzMtMS0xLTEtNDY1Mzg_378c63ef-d918-4991-a581-8a653c32673a">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzMtMy0xLTEtNDY1Mzg_adc11827-48d1-402f-8b3a-881bafdafadc">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzMtNS0xLTEtNDg3OTM_732e4adf-d294-4000-b329-170f1b6247ff">6.2</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzQtMS0xLTEtNDY1Mzg_0ac0c0a4-456c-4b12-8351-6121be8b8cb6">2.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzQtMy0xLTEtNDY1Mzg_a10ee80e-44a9-4a39-97b6-2d8873f872e9">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzQtNS0xLTEtNDg3OTM_72822ef1-c1c7-4bf4-af27-3512ed650c03">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idcdeed31d4564d29a353803d0d00dc6b_I20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzUtMS0xLTEtNDY1Mzg_5ee25126-493c-4073-9d5b-9d61a75309d6">64.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34e51c635ee14313b6fb1c0daa7415bb_I20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzUtMy0xLTEtNDY1Mzg_5fc63db0-c9b9-48a6-87e5-48766dc6ab2a">66.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic416c201f5284d9f943605c62536d8be_I20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzUtNS0xLTEtNDg3OTM_4076991c-b089-474b-b108-f6c49a8d1e79">47.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture Rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzYtMS0xLTEtNDY1Mzg_8782fb94-5e69-45b9-8dd6-05f99be6fe99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzYtMy0xLTEtNDY1Mzg_45ac8675-085b-441c-bc59-035528d45d60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzYtNS0xLTEtNDg3OTM_711b7cc6-c890-4c8f-992d-2bde28eb30ea">14.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzctMS0xLTEtNTk0MzA_886b7398-eb37-480f-9434-8316587c1528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzctMy0xLTEtNTk0MzA_7dac2f9b-fbe1-44aa-8f21-b5b94c5a1c48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzctNS0xLTEtNTk0MzA_a30bb3db-8647-4623-84d1-84a4adefd7b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="ie8fa3a4c3f904c87a4116b964eadf34f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards (&#8220;RSAs&#8221;) granted to employees vest ratably over a <ix:nonNumeric contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjU_e70dfd47-6a24-4e14-9c5d-5166a9c44b3d">four-year</ix:nonNumeric> period. The Company granted <ix:nonFraction unitRef="shares" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIwNDk_789c9425-76fe-413f-9011-b60b2f551755">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIwNTY_8f84b127-adf7-4839-8f40-055f7e3cf133">98,800</ix:nonFraction> RSAs to employees of the Company during the year ended December&#160;31, 2022 and 2021 respectively.</span></div><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjY_036012df-cc7d-4a79-8d37-8570001ad25b" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSA activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:70.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64502038e5f64b25854ef8736435d9a6_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzEtMS0xLTEtNDY1Mzg_c68a1aba-1db8-4ac1-bc24-1b93fa43ea0d">98,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64502038e5f64b25854ef8736435d9a6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzEtMy0xLTEtNDY1Mzg_5a429553-3e92-4066-908b-b75f20d37cdb">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzItMS0xLTEtNDY1Mzg_dd34d431-c26b-4187-ac88-eaaed7cfb7e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzItMy0xLTEtNDY1Mzg_26805550-5505-4bf4-8b60-870ce0d0534e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzMtMS0xLTEtNDY1Mzg_7450f91a-2d5e-4b06-a14a-93c7b054c04b">14,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzMtMy0xLTEtNDY1Mzg_e82933ff-93b0-4a23-a993-73493905b826">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzQtMS0xLTEtNDY1Mzg_ef594c44-4c80-478a-af89-7c5cc91ce6be">17,879</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzQtMy0xLTEtNDY1Mzg_9713ac0f-05bc-4864-9146-943ba6987b46">78.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d98e41008f24785ad933f9a46c178e8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzUtMS0xLTEtNDY1Mzg_eae25a7c-1295-41c9-a8d2-9aed74f36c54">66,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d98e41008f24785ad933f9a46c178e8_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzUtMy0xLTEtNDY1Mzg_44cc30e2-d6fa-4e2c-b4f3-b5dd92435916">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i0d98e41008f24785ad933f9a46c178e8_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIyMDg_ab0fbb0f-5737-4af2-9c67-fe92ae927316">3.8</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIzNTc_0e371199-6e5e-4c37-92a3-378a9adb648d">2.2</ix:nonNumeric> years as of December&#160;31, 2022.</span></div><ix:continuation id="i2e0bf99190c64fd6a85f5460adf94b6b"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following stock-based compensation expense related to RSAs within general and administrative expenses in the accompanying consolidated statements of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:56.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06852b1b5d247e4803f084678fb20d7_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzItMS0xLTEtNDY1Mzg_6b410142-73af-4e7d-97c2-60c27d01b217">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc8ab265e2b84543a478bdf30eed184f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzItMy0xLTEtNDg5MzI_c23d2ab1-7146-4dc2-a1a5-0e87f138c29e">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib231c197185e448c8293b564b7342929_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzItNS0xLTEtNDg5MzI_3ccd2fe6-4188-40ae-a510-3abfa9c194f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzMtMS0xLTEtNDY1Mzg_ec0399b5-ef0e-428f-8f3f-eea44b672268">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzMtMy0xLTEtNTI1OTQ_0d6ce3e9-5cee-4249-af5c-23dc443f7d54">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85ab137db9d24527ad70578422157edc_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzMtNS0xLTEtNTI1OTE_1408fde6-9c45-4e95-8994-0913789ed8bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company's stock incentive plan were <ix:nonFraction unitRef="shares" contextRef="i1eb9664479bc48ffb663071fe28743f9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI2OTk_951ab5bf-83e8-45c6-bd9c-b7135498c101">469,616</ix:nonFraction>, with a remaining sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="i6cc6d3fd9adf476d8c19b91e06ad9df9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NTA_97d623c7-a888-453c-9c05-490c672e2941">5,581</ix:nonFraction>, at December&#160;31, 2022.</span></div></ix:continuation><div id="if50fdf1a469a4104bbe6f4c216cff277_136"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODI_c0d8d3e5-eee7-414e-910a-1f04466f2900" continuedAt="i25126dd10489434db4311c91f804d7df" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i25126dd10489434db4311c91f804d7df" continuedAt="if985aba8eaaf4988a398eb2d5d71bbc2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_186e7fbe-cd00-4f8b-a314-a89ed46d2e2f"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_27063663-157a-475e-91f4-58a3ebae7577"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_9ca9824a-74e2-4141-bcfa-f493d96737c7"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_b9c106af-11ef-417d-854d-ba3efda01a52">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record a current or deferred income tax expense or benefit for the years ended December&#160;31, 2022 and 2021 due to the valuation allowance position. <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODM_fed6dd5c-038a-4625-ad7a-bf643a3b25a3" continuedAt="id4c51ad3233045a98397c7ddf54384cd" escape="true">A reconciliation of income tax (benefit) expense computed at the statutory federal and state income tax rate for the year to income tax (benefit) expense as reflected in our financial statements for years ended December&#160;31, 2022, 2021 and 2020 are as follows (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="id4c51ad3233045a98397c7ddf54384cd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax (benefit) at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzItMS0xLTEtNDY1Mzg_542e5ad6-26c1-40ee-afe2-ba409394e0d8">29,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzItMy0xLTEtNDY1Mzg_062fe08f-2fb1-45f1-abfa-1b6776287511">14,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzMtNS0xLTEtNDkxMzY_621292a9-5a55-4727-9bb9-f1765d1fb9a2">6,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzMtMS0xLTEtNDY1Mzg_57cd0311-b0da-4bda-b948-dc8c71229265">39,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzMtMy0xLTEtNDY1Mzg_b089aba8-2351-4df7-a853-5922e7aa12e9">20,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzQtNS0xLTEtNDkxMzY_9aea6f77-9f60-4b69-9575-a831b376c024">11,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzQtMS0xLTEtNDY1Mzg_3afbfc64-bd52-484e-89b4-9cb49e6b698a">10,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzQtMy0xLTEtNDY1Mzg_1c1e2bc0-234a-4b36-867c-da2b773096b0">5,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzUtNS0xLTEtNDkxMzY_158dfe2b-8d35-45a4-9dca-1dc984c4e560">2,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzUtMS0xLTEtNDY1Mzg_4900087d-4c02-4f17-997b-751187e73294">1,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzUtMy0xLTEtNDY1Mzg_a9c93050-aac4-491c-af8d-81f18c11bf77">1,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzYtNS0xLTEtNDkxMzY_15cf2a64-8cfd-4b09-9b6c-fbe9d93f8877">887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzYtMS0xLTEtNDY1Mzg_fa52d01a-3d03-445e-9879-8950b565f15b">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzYtMy0xLTEtNDY1Mzg_59f2a855-6dc0-4772-a9cc-4d1f79c23700">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzctNS0xLTEtNDkxMzY_ac931041-836b-4882-aeb5-14dc0cd76395">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzctMS0xLTEtNDY1Mzg_ba74a07c-f517-4050-86b3-c71d771310bf">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzctMy0xLTEtNDY1Mzg_f7df4f1e-ee77-49a8-a397-6dc4e24c7413">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzgtNS0xLTEtNDkxMzY_132aa770-b92c-4a8f-aece-cab9050043b7">625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzgtMS0xLTEtNDY1Mzg_7abaab61-e36a-43b1-ac89-98d88c692af5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzgtMy0xLTEtNDY1Mzg_c2acf143-309a-48da-8033-4ffca8494a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzktNS0xLTEtNDkxMzY_94babbe6-0033-494d-854a-63d2e81b3a2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><ix:continuation id="if985aba8eaaf4988a398eb2d5d71bbc2" continuedAt="i2fdc0c281ccf44c98bccc21b8c8d04cd"><ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODQ_db262569-509e-499a-8194-fd2c2905924e" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzMtMS0xLTEtNDY1Mzg_ed986e65-a30e-4362-ae8d-ca162fc10e21">52,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzMtMy0xLTEtNDY1Mzg_23791cc4-342c-47f3-9039-86dc86bbd028">33,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzQtMS0xLTEtNDY1Mzg_c94f9c79-da3b-4015-863b-dfee177f36b5">7,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzQtMy0xLTEtNDY1Mzg_bc214c57-82b9-45a8-8472-9212499a7fce">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzYtMS0xLTEtNDY1Mzg_cc038048-3258-46de-bed8-bad919ee4236">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzYtMy0xLTEtNDY1Mzg_0a74ea3c-64cb-4adf-93fc-48191b2b0325">2,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzctMS0xLTEtNDY1Mzg_28cecf0c-9ec9-4608-8b05-a214a36fb3c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzctMy0xLTEtNDY1Mzg_78ec0bac-76fb-4a11-894e-e5db67211c50">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzgtMS0xLTEtNDY1Mzg_87704a9d-ce5b-4dfc-bc73-f434a351768e">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzgtMy0xLTEtNDY1Mzg_c078ec1b-8e6c-4dc3-b310-5a3d6e4eb439">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzktMS0xLTEtNDY1Mzg_9c8b9dfe-2e7d-4b62-ad4a-4108af886e8e">14,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzktMy0xLTEtNDY1Mzg_38f1d301-718c-4cc7-8a7c-92018f6e6f4f">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEwLTEtMS0xLTQ2NTM4_38ab9950-2ebb-46d4-be28-875ce2442db0">6,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEwLTMtMS0xLTQ2NTM4_f1901f88-3e28-47c2-97e0-3d503d9b086d">3,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTEtMS0xLTY0NTU2_cb38ddf2-5058-49ba-9402-385c7b49d9f5">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTMtMS0xLTY0NTU2_87f48cbb-4d60-4116-acff-92761fd9793c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTEtMS0xLTQ2NTM4_2a230c9c-b5b5-4845-9fc7-d7a6c00dc60d">85,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTMtMS0xLTQ2NTM4_5206ea5f-5f86-4807-b3c5-ec9fe9b489ab">45,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEyLTEtMS0xLTQ2NTM4_7de31dd7-aa99-41f5-9b3a-2da02aad6f8d">82,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEyLTMtMS0xLTQ2NTM4_99c1ecd3-0ab1-45c2-a4a2-81a8a5d7016a">42,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEzLTEtMS0xLTQ2NTM4_6f41b305-ceb3-4aed-8c74-5fcdc6c2614b">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEzLTMtMS0xLTQ2NTM4_936f935e-526f-4a1d-8646-548c2fd23fb3">2,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE1LTEtMS0xLTQ2NTM4_506469f8-1c4e-4f65-9071-c64b43f449fe">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE1LTMtMS0xLTQ2NTM4_ad63eaf7-28c4-4cf5-aca6-944d919c5130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="krys:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE2LTEtMS0xLTQ2NTM4_b7592759-93fb-4c67-b4cf-719f7cb64115">2,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="krys:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE2LTMtMS0xLTQ2NTM4_3a5a83de-7cf1-4c0a-9aee-7f3836aea54e">2,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE3LTEtMS0xLTQ2NTM4_ee9efafd-7ef0-4810-b330-31d0c4ea0f9c">854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE3LTMtMS0xLTQ2NTM4_b0be5418-2089-4b99-941a-c52ada6dd6cd">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE5LTEtMS0xLTQ2NTM4_53ac5cff-ea0c-4da8-b16c-f075dfc8dd3d">3,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE5LTMtMS0xLTQ2NTM4_861b1ac3-eb50-4543-91d1-edfcb9a23f71">2,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzIwLTEtMS0xLTQ2NTM4_3a98241c-da86-4629-aa80-032bc417aa13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzIwLTMtMS0xLTQ2NTM4_ae7ba598-054b-4ad7-94bd-6bc7a21cc226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had federal research and development credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="id57562bb09e14b62821f7c7ee59bc9d1_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTMyNA_3410859e-278f-4ebc-b7d0-733d6525f74c">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i880d88ff54e545f6b66cbd9fa91d7c0f_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTMzMw_f94d5c83-ae50-4e96-b4a3-0ccdae85bb89">2.4</ix:nonFraction> million, respectively. The federal tax credit carryforwards will begin to expire in 2039 if not utilized. As of December&#160;31, 2022 and 2021, the Company also had orphan drug tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ic1e042df24d94919831c05275e22f61c_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM0MA_984598a4-136a-44de-9b42-6d3189580b95">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4c4cd79ab6b4405a9b60c9b5803d3e47_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM0OQ_edce8db2-bf7e-4af2-89d5-fd5a1f208f3d">910</ix:nonFraction> thousand, respectively. The orphan drug tax credit carryforwards will begin to expire in 2038 if not utilized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had state research and development credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="iba614e370fda465e9bd79ec170d9f9b6_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM1Ng_b3b10aa2-ed72-4b64-b79f-bb28e5c3b55b">457</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i299015c71eda4062b0883fb132997c3e_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM2NQ_32a0472c-75fa-419f-98a1-7b0b29e78a10">321</ix:nonFraction> thousand, respectively. The state tax credit carryforwards will begin to expire in 2032 if not utilized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cumulative U.S. federal NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzE4NjU_69d38031-b9eb-41f2-9cd3-250acf0ecf20">177.7</ix:nonFraction> million. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzE4ODU_eed992d8-bb1e-4b1c-b632-3fd20bd73bb8">5.0</ix:nonFraction> million is available to offset future income tax liabilities and will expire in 2037, the remaining $<ix:nonFraction unitRef="usd" contextRef="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzE5Nzg_4d73d86f-a25d-4e5f-b9b4-3f9759c00cd6">172.7</ix:nonFraction> million is available indefinitely to offset future income tax liabilities with no expiration period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cumulative U.S. state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i326eceb3ac84481fb3a1888cdd980f89_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzIxNTc_df857c58-1a66-4bca-84fc-9f3f67d6f357">186.0</ix:nonFraction> million. The state NOLs are available to offset future state income tax liabilities and will begin to expire in 2037.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a <ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="krys:OwnershipInterestRateChangeOverPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODU_6a472a34-5228-4993-a3f5-b3774f84cc8b">three-year</ix:nonNumeric> period in excess of <ix:nonFraction unitRef="number" contextRef="idf96a3872b434ff2ba6fae61cdb19b56_D20220101-20221231" decimals="INF" name="krys:CumulativeChangesInOwnershipInterestOfShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI2Mzk_b6afba04-2dbf-4ba6-8677-d57d673218ec">50</ix:nonFraction>%, as defined under Internal Revenue Code Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred tax assets have been recognized on our consolidated balance sheets related to these NOLs, as they are fully offset by a valuation allowance. If we have previously had, or have in the future, one or more Section 382 &#8220;ownership changes,&#8221; including in connection with our initial public offering or another offering, or if we do not generate sufficient taxable income, we may not be able to utilize a material portion of our NOLs, even if we achieve profitability.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2fdc0c281ccf44c98bccc21b8c8d04cd">The Company files income tax returns in the United States at the federal and state level and in foreign jurisdictions in which the Company conducts business activities. The federal and state income tax returns are subject to tax examinations for the tax year ended December 31, 2019, 2020 and 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. Additionally, the Company is subject to tax examinations by taxing authorities in foreign jurisdictions where it has business operations. At this time, the Company is not undergoing examination by the Internal Revenue Service or any foreign taxing authorities.</ix:continuation></span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xNDIvZnJhZzoxMjVjZGRiMmEwN2M0MjI0YjVjMWM4NzdjNjc5OTgxMy90ZXh0cmVnaW9uOjEyNWNkZGIyYTA3YzQyMjRiNWMxYzg3N2M2Nzk5ODEzXzQxNw_b0b3932f-e369-4c23-aa8c-f7a8cb77d8c8" continuedAt="id88e77c475884be29a47f637aab68373" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id88e77c475884be29a47f637aab68373">The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the consolidated financial statements.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported in the Company&#8217;s Current Report on Form 8-K filed on May 26, 2022, effective May 24, 2022, the Audit Committee of the Company's Board of Directors dismissed Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm effective immediately and approved the engagement of KPMG LLP as the Company's new independent registered public accounting firm, commencing for its quarter ending June 30, 2022 and the Company's fiscal year ending December 31, 2022. For more information, please refer to the Company&#8217;s Current Report on Form 8-K filed on May 26, 2022.  </span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our Chief Executive Officer and Chief Accounting Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of December&#160;31, 2022.&#160;&#160;Based on that evaluation,&#160;our Chief Executive Officer and Chief Accounting Officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2022 to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated&#160;to our management, including our Chief Executive Officer and Chief Accounting Officer, as appropriate to allow timely discussion regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that&#160;any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate&#160;internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2022 based on the criteria established in&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of its evaluation, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2022. The effectiveness of our internal control over financial reporting as of December&#160;31, 2022 has been audited by KPMG, an independent registered public accounting firm, as stated in their report which is included herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the Chief Executive Officer and Chief Accounting Officer, do not expect that our disclosure controls and procedures and our internal controls will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. As these inherent limitations are known features of the financial reporting process, it is possible to design into the process safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. While our Chief Executive Officer and Chief Accounting Officer have concluded that, as of December&#160;31, 2022, the design of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act, was effective, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we implemented the first phase of our enterprise resource planning software, Microsoft Dynamics D365 (&#8220;Dynamics&#8221;), as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years as the Company grows and as we move towards commercialization of our initial product candidate, B-VEC. As the phased implementation of this system occurs, we expect certain changes to our processes and procedures which, in turn, will result in changes to our internal control over financial reporting. We expect Dynamics to continue to strengthen our internal financial controls. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve. As we are still in the process of implementing these additional phases, no change in our internal control over financial reporting occurred during the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as discussed above, there was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules&#160;13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Krystal Biotech, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 31, 2022 the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year ended December 31, 2022, and the related notes (collectively, the consolidated financial statements), and our report dated February 27, 2023 expressed an unqualified opinion on those consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pittsburgh, Pennsylvania </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 27, 2023</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_157"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information required by this Item is hereby incorporated by reference to our 2023 Definitive Proxy Statement, which will be filed prior to April 30, 2023..</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information required by this Item is hereby incorporated by reference to our 2023 Definitive Proxy Statement, which will be filed prior to April 30, 2023..</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information required by this Item is hereby incorporated by reference to our 2023 Definitive Proxy Statement, which will be filed prior to April 30, 2023..</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information required by this Item is hereby incorporated by reference to our 2023 Definitive Proxy Statement, which will be filed prior to April 30, 2023..</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_172"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information required by this Item is hereby incorporated by reference to our 2023 Definitive Proxy Statement, which will be filed prior to April 30, 2023..</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-88</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_178"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">List the following documents filed as a part of the report:</span></div><div style="padding-left:94.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Financial statements</span></div><div style="margin-top:6pt;padding-left:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this portion of Item 15 is set forth under Item 8 above.</span></div><div style="padding-left:94.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Financial statement schedule.</span></div><div style="margin-top:6pt;padding-left:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because they are not required or because the required information is given in the financial statements or notes thereto set forth under Item 8 above.</span></div><div style="padding-left:94.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Exhibits.</span></div><div style="margin-top:6pt;padding-left:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of exhibits filed with this report or incorporated herein by reference can be found in the Exhibit Index of this Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517291618/d460068dex31.htm">Second Amended and Restated Certificate of Incorporation of Krystal Biotech, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on September 25, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517291618/d460068dex32.htm">Amended and Restated Bylaws of Krystal Biotech, Inc. (incorporate by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on September 25, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517285053/d403532dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 14, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312518289059/d631164dex45.htm">Form of Indenture (including form of Debt Securities) (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Registration Statement on Form S-3 (Reg. No. 333-227632), as filed with the SEC on October 1, 2018)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex43xdescript.htm">Description of Common Stock</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517285053/d403532dex101.htm">Indemnification Agreement by and between Krystal Biotech, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 14, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517278107/d403532dex102.htm">Executive Employment Agreement, effective July 1, 2017, by and between Krystal Biotech, Inc. and Krish S. Krishnan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 7, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517278107/d403532dex103.htm">Executive Employment Agreement, effective May 1, 2017, by and between Krystal Biotech, Inc. and Suma M. Krishnan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 7, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127921000006/krys-20201231ex104_emplo.htm">Executive Employment Agreement, effective January 20, 2020, by and between Krystal Biotech, Inc. and Kathryn A. Romano (incorporated by reference to Exhibit 10.4 to the Company's Annual Report on Form 10-K, as filed with the SEC on March 1, 2021)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127922000004/krys-20211231ex105_emplo.htm">Executive Employment Agreement, effective May 3, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127922000004/krys-20211231ex105_emplo.htm">1 by and between Krystal Biotech, Inc. and Andy Orth</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517285053/d403532dex106.htm">Krystal Biotech, Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 14, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517285053/d403532dex107.htm">Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 14, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517285053/d403532dex108.htm">Form of Krystal Biotech, Inc. 2017 Stock Incentive Plan Notice of Stock Option Award (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 14, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517285053/d403532dex109.htm">Form of Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan Notice of Stock Option Award (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 14, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517278107/d403532dex1010.htm">Lease Agreement, dated as of May 26, 2016, by and between Wharton Lender Associates, L.P. and Krystal Biotech, LLC (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 7, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517278107/d403532dex1011.htm">Second Amendment to Lease Agreement, dated as of February 27, 2017, by and between Wharton Lender Associates, L.P. and Krystal Biotech, LLC (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-220085), as filed with the SEC on September 7, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000119312517263771/d403532dex109.htm">Investors&#8217; Rights Agreement, dated as of August 7, 2017, by and among Krystal Biotech, Inc. and the investors listed on Schedule A thereto (incorporated by reference to Exhibit 10.9 to Form S-1 (Reg. No. 333-220085), as filed with the SEC on August 21, 2017)</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127921000006/krys-20201231ex1013_thir.htm">Third amendment to Lease Agreement, dated as of May 31, 2018, by and between Wharton Lender Associate, L.P. and Krystal Biotech, Inc. (incorporated by reference to Exhibit 10.13 to the Company's Annual Report on Form 10-K, as filed with the SEC on March 1, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127921000006/krys-20201231ex1014_four.htm">Fourth amendment to Lease Agreement, dated as of October 22, 2018, by and between Wharton Lender Associate, L.P. and Krystal Biotech, Inc. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K, as filed with the SEC on March 1, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127921000006/krys-20201231ex1015_fift.htm">Fifth amendment to Lease Agreement, dated as of December 10, 2018, by and between Wharton Lender Associate, L.P. and Krystal Biotech, Inc. (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K, as filed with the SEC on March 1, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000171127922000004/krys-20211231ex1017_sixt.htm">Sixth amendment to Lease Agreement and first amendment to storage space agreement, dated as of January 13, 2021, by and between Wharton Lender Associates, L.P. and Krystal Biotech, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000171127922000004/krys-20211231ex1018_seve.htm">Seventh amendment to Lease Agreement, dated as of May 11, 2021, by and between Wharton Lender Associates, L.P. and Krystal Biotech, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000171127922000004/krys-20211231ex1019_eigh.htm">Eighth amendment to Lease Agreement, dated as of July 21, 2021, by and between Wharton Lender Associates, L.P. and Krystal Biotech, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000171127922000004/krys-20211231ex1020_nine.htm">Ninth amendment to Lease Agreement, dated as of January 4, 2022, by and between Wharton Lender Associates, L.P. and Krystal Biotech, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000119312521025839/d90144dex101.htm">Purchase and Sale Agreement, dated January 29, 2021, by and between Krystal Biotech, Inc. and Northfield I, LLC. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on February 2, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000171127921000027/exhibit101_krystal-wtcon.htm">Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction with The Whiting-Turner Contracting Company, dated June 30, 2021 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q, as filed with the SEC on August 9, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001711279/000119312521275175/d227179dex101.htm">Guaranteed Maximum Price Amendment to Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction with The Whiting-Turner Contracting Company dated September 13, 2021 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on September 16, 2021)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex1023xformof.htm">Form of Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan Notice of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex1023xformof.htm">Restricted Stock</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex1023xformof.htm"> Award</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex1023xformof.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex1023xformof.htm">and Restricted Stock Award Agreement</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1711279/000171127922000028/sec-krystalletterexhibit161.htm">Letter to Securities and Exchange Commission from Mayer Hoffman McCann P.C. dated May 26, 2022 (incorporated by reference to Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K, as filed with the SEC on May 26, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex211xlistofs.htm">Subsidiaries of Krystal Biotech, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex231xkpmgcon.htm">Consent of KPMG</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex231xkpmgcon.htm"> LLP</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex232xmhmcons.htm">Consent of Mayer Hoffman McCann P.C.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex311.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex312.htm">Certification of Periodic Report by Chief Accounting Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex321.htm">Certification of Chief Executive Officer </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex321.htm">and C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex321.htm">h</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex321.htm">ief Accounting Officer </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20221231ex321.htm">Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i) XBRL Instance Document, (ii) XBRL Taxonomy Extension Schema Document, (iii) XBRL Taxonomy Extension Calculation Linkbase Document, (iv) XBRL Taxonomy Extension Definition Linkbase Document, (v) XBRL Taxonomy Extension Label Linkbase Document, (vi) XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.339%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan or arrangement.</span></div><div id="if50fdf1a469a4104bbe6f4c216cff277_181"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-top:6pt;text-indent:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not include a summary.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="if50fdf1a469a4104bbe6f4c216cff277_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Pittsburgh, State of Pennsylvania, on February&#160;27, 2023.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Krish S. Krishnan and/or Kathryn A. Romano as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Suma M. Krishnan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, R&amp;D and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suma M. Krishnan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel S. Janney</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel S. Janney</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dino A. Rossi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dino A. Rossi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Kirti Ganorkar</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirti Ganorkar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Julian Gangolli</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Julian Gangolli</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Chris Mason</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris Mason</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ E. Rand Sutherland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E. Rand Sutherland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>krys-20221231ex43xdescript.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7a8ff2151bcc4a57aeaceb35e5e06ebe_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.3</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Our authorized capital stock consists of 80,000,000 shares of common stock, $0.00001 par value per share, and 20,000,000 shares of preferred stock, $0.00001 par value per share. Our common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We have no other securities registered under Section 12 of the Exchange Act. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">The following description summarizes the most important terms of our common stock. Because it is only a summary, it does not contain all the information that may be important to you. The description is intended as a summary, and is qualified in its entirety by reference to our second amended and restated certificate of incorporation (our &#8220;Certificate of Incorporation&#8221;) and our amended and restated bylaws (our &#8220;Bylaws&#8221;). For a complete description, you should refer to our Certificate of Incorporation and Bylaws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">Common Stock</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:95%">Dividend Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">The holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:95%">Voting Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, holders of a majority of the shares of our common stock will be able to elect all of our directors. Our Certificate of Incorporation has established a classified board of directors, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:95%">No Preemptive or Similar Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:95%">Right to Receive Liquidation Distributions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock at that time, subject to prior satisfaction of all outstanding debt and liabilities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">Anti-Takeover Provisions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:95%">Delaware Law</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">We are subject to the provisions of Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), regulating corporate takeovers. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder&#58; (i) shares owned by persons who are directors and also officers&#59; and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation&#8217;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 of the DGCL may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:95%">Second Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws Provisions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:14.5pt">Board of Directors Vacancies.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%"> Our Certificate of Incorporation and Bylaws authorizes only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors may only be set by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management. </font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:13.8pt">Classified Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Our Certificate of Incorporation and Bylaws provide that our board of directors will be classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:14.5pt">Stockholder Action&#59; Special Meetings of Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Our Certificate of Incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock may not amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our Certificate of Incorporation and Bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, or our Chief Executive Officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:14.5pt">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Our Bylaws provides advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specifies certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:13.8pt">No Cumulative Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation does not provide for cumulative voting. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:13.8pt">Directors Removed Only for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Our Certificate of Incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding common stock. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:13.8pt">Amendment of Charter Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Any amendment of the above expected provisions in our Certificate of Incorporation requires approval by holders of at least two-thirds of our outstanding common stock. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:13.8pt">Issuance of Undesignated Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Our board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock will enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means. </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:95%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%;padding-left:13.8pt">Choice of Forum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">. Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for&#58; any derivative action or proceeding brought on our behalf&#59; any action asserting a breach of fiduciary duty&#59; any action asserting a claim against us arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws&#59; any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or our Bylaws&#59; or any action asserting a claim against us that is governed by the internal affairs doctrine. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer Agent and Registrar</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150 Royall Street, Canton, MA 02021, and its telephone number is 1-800-962-4284. Our shares of common stock were issued in uncertificated form only, subject to limited circumstances.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NASDAQ Capital Market Listing</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our common stock is listed on The NASDAQ Capital Market under the symbol &#8220;KRYS.&#8221;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>krys-20221231ex1023xformof.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7ea801d99150469fbc89d64d6821d64e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.23</font></div></div><div style="padding-left:24.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.743%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC. 2017 IPO STOCK INCENTIVE PLAN<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICE OF RESTRICTED STOCK BONUS AWARD</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grantee&#8217;s Name and Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (the &#8220;Grantee&#8221;) have been granted shares of Common Stock of the Company (the &#8220;Award&#8221;), subject to the terms and conditions of this Notice of Restricted Stock Bonus Award (the &#8220;Notice&#8221;), the Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;), and the Restricted Stock Bonus Award Agreement (the &#8220;Agreement&#8221;) attached hereto, as follows.  Unless otherwise provided herein, the terms in this Notice shall have the same meaning as those defined in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Award Number&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of Award&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting Commencement Date&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Shares of Common <br>Stock Awarded (the &#8220;Shares&#8221;)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the Grantee&#8217;s Continuous Service and other limitations set forth in this Notice, the Agreement and the Plan, the Shares will &#8220;vest&#8221; in accordance with the following schedule (the &#8220;Vesting Schedule&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The unvested Award shall vest ratably over a four year period with one-fourth of the Award vesting on the Vesting Commencement Date and one-fourth vesting on each anniversary thereafter until all Shares have vested.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During any authorized leave of absence, the vesting of the Shares as provided in this schedule shall be suspended after the leave of absence exceeds a period of three (3) months.  Vesting of the Shares shall resume upon the Grantee&#8217;s termination of the leave of absence and return to service to the Company or a Related Entity.  The Vesting Schedule of the Shares shall be extended by the length of the suspension.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of the Grantee&#8217;s change in status from Employee, Director or Consultant to any other status of Employee, Director or Consultant, the Shares shall continue to vest in accordance with the Vesting Schedule set forth above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of this Notice and the Agreement, the term &#8220;vest&#8221; shall mean, with respect to any Shares, that such Shares are no longer subject to forfeiture to the Company.  Shares that have not vested are deemed &#8220;Restricted Shares.&#8221; If the Grantee would become vested in a fraction of a Restricted Share, such Restricted Share shall not vest until the Grantee becomes vested in the entire Share.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting shall cease upon the date of termination of the Grantee&#8217;s Continuous Service for any reason, including death or Disability.  In the event the Grantee&#8217;s Continuous Service is terminated for any reason, including death or Disability, any Restricted Shares held by the Grantee immediately following such termination of Continuous Service shall be deemed reconveyed to the Company and the Company shall thereafter be the legal and beneficial owner of the Restricted Shares and shall have all rights and interest in or related thereto without further action by the Grantee.  The foregoing forfeiture provisions set forth in this Notice as to Restricted Shares shall apply to the new capital stock or other property (including cash paid other than as a regular cash dividend) received in exchange for the Shares in consummation of any transaction described in Section 11 of the Plan and such stock or property shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">deemed Additional Securities (as defined in the Agreement) for purposes of the Agreement, but only to the extent the Shares are at the time covered by such forfeiture provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Award shall be subject to the provisions of Section 11 of the Plan in the event of a Corporate Transaction or Change in Control.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company and the Grantee have executed this Notice and agree that the Award is to be governed by the terms and conditions of this Notice, the Plan and the Agreement.</font></div><div style="margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krystal Biotech, Inc.,<br>a Delaware corporation</font></div><div style="margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THE GRANTEE ACKNOWLEDGES AND AGREES THAT THE SHARES SHALL VEST, IF AT ALL, ONLY DURING THE PERIOD OF THE GRANTEE&#8217;S CONTINUOUS SERVICE OR AS OTHERWISE SPECIFICALLY PROVIDED HEREIN (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER).  The GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS NOTICE, THE AGREEMENT, OR THE PLAN SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE GRANTEE&#8217;S CONTINUOUS SERVICE, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE&#8217;S RIGHT OR THE RIGHT OF THE COMPANY OR RELATED ENTITY TO WHICH THE GRANTEE PROVIDES SERVICES TO TERMINATE THE GRANTEE&#8217;S CONTINUOUS SERVICE AT ANY TIME, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT NOTICE.  THE GRANTEE ACKNOWLEDGES THAT UNLESS THE GRANTEE HAS A WRITTEN EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE GRANTEE&#8217;S STATUS IS AT WILL.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee acknowledges receipt of a copy of the Plan and the Agreement and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the Award subject to all of the terms and provisions hereof and thereof.  The Grantee has reviewed this Notice, the Agreement and the Plan in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice and fully understands all provisions of this Notice, the Agreement and the Plan.  The Grantee hereby agrees that all questions of interpretation and administration relating to this Notice, the Plan and the Agreement shall be resolved by the Administrator in accordance with Section 12 of the Agreement.  The Grantee further agrees to the venue selection and waiver of a jury trial in accordance with Section 13 of the Agreement.  The Grantee further agrees to notify the Company upon any change in the residence address indicated in this Notice.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee further acknowledges that, from time to time, the Company may be in a &#8220;blackout period&#8221; and&#47;or subject to applicable federal securities laws that could subject the Grantee to liability for engaging in any transaction involving the sale of the Shares.  The Grantee further acknowledges and agrees that, prior to the sale of any Shares acquired under the Award, it is the Grantee&#8217;s responsibility to determine whether or not the sale of the Shares will subject the Grantee to liability under insider trading rules or other applicable federal securities laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver this Notice, the Agreement, the Plan and the Plan prospectus (collectively, the &#8220;Plan Documents&#8221;) to the Grantee by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  The Grantee hereby agrees to Company&#8217;s provision to the Grantee of these documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee acknowledges that the Grantee has access to the Company&#8217;s intranet and has either received electronic or paper copies of the Plan Documents.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC. 2017 IPO STOCK INCENTIVE PLAN<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK BONUS AWARD AGREEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Krystal Biotech, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby issues to the Grantee (the &#8220;Grantee&#8221;) named in the Notice of Restricted Stock Bonus Award (the &#8220;Notice&#8221;), the Total Number of Shares of Common Stock Awarded set forth in the Notice (the &#8220;Shares&#8221;), subject to the Notice, this Restricted Stock Bonus Award Agreement (the &#8220;Agreement&#8221;) and the terms and provisions of the Company&#8217;s 2017 IPO Stock Incentive Plan (the &#8220;Plan&#8221;), as amended from time to time, which are incorporated herein by reference.  Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.  All Shares issued hereunder will be deemed issued to the Grantee as fully paid and nonassessable shares, and the Grantee will have the right to vote the Shares at meetings of the Company&#8217;s stockholders.  The Company shall pay any applicable stock transfer taxes imposed upon the issuance of the Shares to the Grantee hereunder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Shares issued to the Grantee hereunder may not be sold, transferred by gift, pledged, hypothecated, or otherwise transferred or disposed of by the Grantee prior to the date when the Shares become vested pursuant to the Vesting Schedule set forth in the Notice.  Any attempt to transfer Restricted Shares in violation of this Section 2 will be null and void and will be disregarded.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Escrow of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For purposes of facilitating the enforcement of the provisions of this Agreement, the Grantee agrees, immediately upon receipt of the certificate(s) for the Restricted Shares, to deliver such certificate(s), together with a Stock Assignment in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, executed in blank by the Grantee with respect to each such stock certificate, to the Secretary or Assistant Secretary of the Company, or their designee, to hold in escrow for so long as such Restricted Shares have not vested pursuant to the Vesting Schedule set forth in the Notice, with the authority to take all such actions and to effectuate all such transfers and&#47;or releases as may be necessary or appropriate to accomplish the objectives of this Agreement in accordance with the terms hereof.  The Grantee hereby acknowledges that the appointment of the Secretary or Assistant Secretary of the Company (or their designee) as the escrow holder hereunder with the stated authorities is a material inducement to the Company to make this Agreement and that such appointment is coupled with an interest and is accordingly irrevocable.  The Grantee agrees that the Restricted Shares may be held electronically in a book entry system maintained by the Company&#8217;s transfer agent or other third party and that all the terms and conditions of this Section 3 applicable to certificated Restricted Shares will apply with the same force and effect to such electronic method for holding the Restricted Shares.  The Grantee agrees that such escrow holder shall not be liable to any party hereto (or to any other party) for any actions or omissions unless such escrow holder is grossly negligent relative thereto.  The escrow holder may rely upon any letter, notice or other document executed by any signature purported to be genuine and may resign at any time.  Upon the vesting of Restricted Shares, the escrow holder will, without further order or instruction, transmit to the Grantee the certificate evidencing such Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that no transmittal of certificates evidencing the Shares will occur unless and until the Grantee has satisfied all Tax Withholding Obligations (as defined in Section 5(c) below).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Additional Securities and Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Any securities or cash received (other than a regular cash dividend) as the result of ownership of the Restricted Shares (the &#8220;Additional Securities&#8221;), including, but not by way of limitation, warrants, options and securities received as a stock dividend or stock split, or as a result of a recapitalization or reorganization or other similar change in the Company&#8217;s capital structure, shall be retained in escrow in the same manner and subject to the same conditions and restrictions as the Restricted Shares with respect to which they were issued, including, without limitation, the Vesting Schedule set forth in the Notice.  The Grantee shall be entitled to direct the Company to exercise any warrant or option received as Additional Securities upon supplying the funds necessary to do so, in which event the securities so purchased shall constitute Additional Securities, but the Grantee may not direct the Company to sell any such warrant or option.  If Additional Securities consist of a convertible security, the Grantee may exercise any conversion right, and any securities so acquired shall constitute Additional Securities.  In the event of any change in certificates evidencing the Shares or the Additional Securities by reason of any recapitalization, reorganization or other transaction that results in the creation of Additional Securities, the escrow holder is authorized to deliver to the issuer the certificates evidencing the Shares or the Additional Securities in exchange for the certificates of the replacement securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Company shall disburse to the Grantee all regular cash dividends with respect to the Shares and Additional Securities (whether vested or not), less any applicable withholding obligations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Section 83(b) Election and Withholding of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Grantee shall provide the Administrator with a copy of any timely election made pursuant to Section&#160;83(b) of the Internal Revenue Code or similar provision of state law (collectively, an &#8220;83(b) Election&#8221;), a form of which is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Grantee makes a timely 83(b) Election, the Grantee shall immediately pay the Company the amount necessary to satisfy any applicable foreign, federal, state, and local income and employment tax withholding obligations.  If the Grantee does not make a timely 83(b) Election, the Grantee shall, as Shares shall vest or at the time withholding is otherwise required by any Applicable Law, pay the Company the amount necessary to satisfy any applicable foreign, federal, state, and local income and employment tax withholding obligations.  The manners in which the Grantee may pay the Company the amount necessary to satisfy any applicable foreign, federal, state, and local income and employment tax withholding obligations are set forth in subsection (c) below.  The Grantee hereby represents that he or she understands (a)&#160;the contents and requirements of the 83(b) Election, (b)&#160;the application of Section&#160;83(b) to the receipt of the Shares by the Grantee pursuant to this Agreement, (c)&#160;the nature of the election to be made by the Grantee under Section&#160;83(b), and (d)&#160;the effect and requirements of the 83(b) Election under relevant state and local tax laws.  The Grantee further represents that he or she intends to file an election pursuant to Section&#160;83(b) with the Internal Revenue Service within thirty (30)&#160;days following the date of this Agreement, and submit a copy of such election to the Company and with his or her federal tax return for the calendar year in which the date of this Agreement falls.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Tax Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Grantee is ultimately liable and responsible for all taxes owed by the Grantee in connection with the Award, regardless of any action the Company or any Related Entity takes with respect to any tax withholding obligations that arise in connection with the Award.  Neither the Company nor any Related Entity makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or vesting of the Award or the subsequent sale of Shares subject to the Award.  The Company and its Related Entities do not commit and are under no obligation to structure the Award to reduce or eliminate the Grantee&#8217;s tax liability.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Prior to any event in connection with the Award (e.g., upon the filing of an  83(b) Election or vesting) that the Company determines may result in any tax withholding obligation, whether United States federal, state, local or non-U.S., including any social insurance, employment tax, payment on account or other tax-related obligation (the &#8220;Tax Withholding Obligation&#8221;), the Grantee must arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.57pt">By Share Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding Section 7(c) of the Plan, if permissible under Applicable Law, the Administrator may permit the Grantee to elect to authorize the Company to withhold from those Shares otherwise issuable to the Grantee the whole number of Shares sufficient to satisfy up to the maximum applicable Tax Withholding Obligation.  The maximum applicable Tax Withholding Obligation is based on the applicable rates of the relevant tax authorities (for example, federal, state and local), including the Grantee&#8217;s share of payroll or similar taxes, as provided in the tax law, regulations or the authority&#8217;s administrative practices, not to exceed the highest statutory rate in that jurisdiction.  Any elections to have Shares withheld or sold for this purpose will be made in accordance with the requirements established by the Administrator for such elections and be in writing in a form acceptable to the Administrator.  Further, if permissible under Applicable Law, the Grantee hereby authorizes the Company to, upon the exercise of its sole discretion, withhold from those Shares otherwise issuable to the Grantee the whole number of Shares sufficient to satisfy the minimum applicable Tax Withholding Obligation.  The Grantee acknowledges that the withheld Shares may still not be sufficient to satisfy the Grantee&#8217;s minimum Tax Withholding Obligation.  Accordingly, the Grantee agrees to pay to the Company or any Related Entity as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the withholding of Shares described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:23.8pt">By Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless the Grantee determines to satisfy the Tax Withholding Obligation by some other means in accordance with clause (iii) below, the Grantee&#8217;s acceptance of this Award constitutes the Grantee&#8217;s instruction and authorization to the Company and any brokerage firm determined acceptable to the Company for such purpose to, upon the exercise of Company&#8217;s sole discretion, sell on the Grantee&#8217;s behalf a whole number of Shares from those Shares issuable to the Grantee as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the minimum applicable Tax Withholding Obligation.  Such Shares will be sold on the day such Tax Withholding Obligation arises (e.g., a vesting date) or as soon thereafter as practicable.  The Grantee will be responsible for all broker&#8217;s fees and other costs of sale, and the Grantee agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale.  To the extent the proceeds of such sale exceed the Grantee&#8217;s minimum Tax Withholding Obligation, the Company agrees to pay such excess in cash to the Grantee.  The Grantee acknowledges that the Company or its designee is under no obligation to arrange for such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy the Grantee&#8217;s minimum Tax Withholding Obligation.  Accordingly, the Grantee agrees to pay to the Company or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any Related Entity as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the sale of Shares described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:21.03pt">By Check, Wire Transfer or Other Means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At any time not less than five (5) business days (or such fewer number of business days as determined by the Administrator) before any Tax Withholding Obligation arises (e.g., a vesting date), the Grantee may elect to satisfy the Grantee&#8217;s Tax Withholding Obligation by delivering to the Company an amount that the Company determines is sufficient to satisfy the Tax Withholding Obligation by (x) wire transfer to such account as the Company may direct, (y) delivery of a certified check payable to the Company, or (z) such other means as specified from time to time by the Administrator.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Company or a Related Entity also may satisfy any Tax Withholding Obligation by offsetting any amounts (including, but not limited to, salary, bonus and severance payments) payable to the Grantee by the Company and&#47;or a Related Entity.  Furthermore, in the event of any determination that the Company and&#47;or a Related Entity has failed to withhold a sum sufficient to pay all withholding taxes due in connection with the Award, the Grantee agrees to pay the Company and&#47;or the Related Entity the amount of such deficiency in cash within five (5) days after receiving a written demand from the Company and&#47;or the Related Entity to do so, whether or not the Grantee is an employee of the Company and&#47;or the Related Entity at that time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Stop-Transfer Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In order to ensure compliance with the restrictions on transfer set forth in this Agreement, the Notice or the Plan, the Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, and, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.  The Company may issue a &#8220;stop transfer&#8221; instruction if the Grantee fails to satisfy any Tax Withholding Obligations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Refusal to Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restrictive Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Grantee understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE RESTRICTED BY THE TERMS OF THAT CERTAIN RESTRICTED STOCK BONUS AWARD AGREEMENT BETWEEN THE COMPANY AND THE NAMED STOCKHOLDER.  The SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH SUCH AGREEMENT, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Lock-Up Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Grantee, if requested by the Company and the lead underwriter of any public offering of the Common Stock (the &#8220;Lead Underwriter&#8221;), hereby irrevocably agrees not to sell, contract to sell, grant any option to purchase, transfer the economic risk of ownership in, make any short sale of, pledge or otherwise transfer or dispose of any interest in any Common Stock or any securities convertible into or exchangeable or exercisable for or any other rights to purchase or acquire Common Stock (except Common Stock included in the public offering or acquired on the public market after the offering) during the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, or any shorter or longer period of time as the Lead Underwriter will specify.  The Grantee further agrees to sign all documents as may be requested by the Lead Underwriter to effect the foregoing and agrees that the Company may impose stop-transfer instructions with respect to the Common Stock subject to the lock-up period until the end of the period.  The Company and the Grantee acknowledge that each Lead Underwriter of a public offering of the Company&#8217;s stock, during the period of the offering and for the lock-up period thereafter, is an intended beneficiary of this Section 9.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">No Amendment Without Consent of Underwriter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During the period from identification of a Lead Underwriter in connection with any public offering of the Company&#8217;s Common Stock until the earlier of (i) the expiration of the lock-up period specified in Section 9(a) in connection with the offering or (ii) the abandonment of the offering by the Company and the Lead Underwriter, the provisions of this Section 9 may not be amended or waived except with the consent of the Lead Underwriter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Entire Agreement&#58; Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Notice, the Plan and this Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.  These agreements are to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.  Should any provision of the Notice or this Agreement be determined to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The captions used in the Notice and this Agreement are inserted for convenience and shall not be deemed a part of the Award for construction or interpretation.  Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.  Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Administration and Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any question or dispute regarding the administration or interpretation of the Notice, the Plan or this Agreement shall be submitted by the Grantee or by the Company to the Administrator.  The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Venue and Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The parties agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or this Agreement shall be brought in the United States District Court for Delaware (or should such court lack jurisdiction to hear such action, suit or proceeding, in a Delaware state court) and that the parties shall submit to the jurisdiction of such court.  The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THE PARTIES ALSO EXPRESSLY WAIVE ANY RIGHT THEY HAVE OR MAY HAVE TO A JURY TRIAL OF ANY SUCH SUIT, ACTION OR PROCEEDING.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any one or more provisions of this Section 13 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown in these instruments, or to such other address as such party may designate in writing from time to time to the other party.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Grantee has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version is different than the English version, the English version will control, unless otherwise prescribed by Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Nature of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In accepting the Award, the Grantee acknowledges and agrees that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Award is voluntary and occasional and does not create any contractual or other right to receive future awards, or benefits in lieu of awards, even if awards have been awarded repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">the Grantee&#8217;s participation in the Plan shall not create a right to any employment with the Grantee&#8217;s employer and shall not interfere with the ability of the Company or the employer to terminate the Grantee&#8217;s employment relationship, if any, at any time&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">the Award is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or any Related Entity&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in the event that the Grantee is not an Employee of the Company or any Related Entity, the Award and the Grantee&#8217;s participation in the Plan will not be interpreted to form an employment or service contract or relationship with the Company or any Related Entity&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the future value of the underlying Shares is unknown and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">in consideration of the Award, no claim or entitlement to compensation or damages shall arise from termination of the Award or diminution in value of the Award or Shares acquired upon vesting of the Award, resulting from termination of the Grantee&#8217;s Continuous Service by the Company or any Related Entity (for any reason whatsoever and whether or not in breach of local labor laws) and in consideration of the grant of the Award, the Grantee irrevocably releases the Company and any Related Entity from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing the Notice, the Grantee shall be deemed irrevocably to have waived his or her right to pursue or seek remedy for any such claim or entitlement&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">in the event of termination of the Grantee&#8217;s Continuous Service (whether or not in breach of local labor laws), the Grantee&#8217;s right to receive Awards under the Plan and to vest in such Awards, if any, will (except as otherwise provided in the Notice or herein) terminate effective as of the date that the Grantee is no longer providing services and will not be extended by any notice period mandated under local law (e.g., providing services would not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law)&#59; furthermore, in the event of termination of the Grantee&#8217;s Continuous Service (whether or not in breach of local labor laws), the Administrator shall have the exclusive discretion to determine when the Grantee is no longer providing services for purposes of this Award&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of the underlying Shares&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">the Grantee is hereby advised to consult with the Grantee&#8217;s own personal tax, legal and financial advisers regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.91pt">The Grantee hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Grantee&#8217;s personal data as described in the Notice and this Agreement by and among, as applicable, the Grantee&#8217;s employer, the Company and any Related Entity for the exclusive purpose of implementing, administering and managing the Grantee&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.34pt">The Grantee understands that the Company and the Grantee&#8217;s employer may hold certain personal information about the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, vested, unvested or outstanding in the Grantee&#8217;s favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Grantee understands that Data will be transferred to any third party assisting the Company with the implementation, administration and management of the Plan.  The Grantee understands that the recipients of the Data may be located in the Grantee&#8217;s country, or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Grantee&#8217;s country.  The Grantee understands that the Grantee may request a list with the names and addresses of any potential recipients of the Data by contacting the Grantee&#8217;s local human resources representative.  The Grantee authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Grantee&#8217;s participation in the Plan.  The Grantee understands that Data will be held only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan.  The Grantee understands that the Grantee may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Grantee&#8217;s local human resources representative.  The Grantee understands, however, that refusal or withdrawal of consent may affect the Grantee&#8217;s ability to participate in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan.  For more information on the consequences of the Grantee&#8217;s refusal to consent or withdrawal of consent, the Grantee understands that the Grantee may contact the Grantee&#8217;s local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">END OF AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCK ASSIGNMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FOR VALUE RECEIVED, hereby sells, assigns and transfers unto &#91;&#9679;&#93;, ( ) shares of the Common Stock of Krystal Biotech, Inc., a Delaware corporation (the &#8220;Company&#8221;), standing in his&#47;her name on the books of the Company &#91;represented by Certificate No. herewith&#93; and does hereby irrevocably constitute and appoint the Secretary of the Company attorney to transfer the said stock in the books of the Company with full power of substitution.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DATED&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Please sign this document but do not date it.  The date and information of the transferee will be completed if and when the shares are assigned.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ELECTION UNDER SECTION 83(b)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OF THE INTERNAL REVENUE CODE OF 1986</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned taxpayer hereby elects, pursuant to the Internal Revenue Code, to include in gross income for _____ the amount of any compensation taxable in connection with the taxpayer&#8217;s receipt of the property described below&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The name, address, taxpayer identification number and taxable year of the undersigned are&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAXPAYER&#8217;S NAME&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAXPAYER&#8217;S SOCIAL SECURITY NO.&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAXABLE YEAR&#58;  Calendar Year _______</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADDRESS&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The property which is the subject of this election is __________ shares of the Common Stock of Krystal Biotech, Inc.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The property was transferred to the undersigned on ____________, ____.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The property is subject to the following restrictions&#58;  The property is subject to a repurchase right pursuant to which the issuer has the right to acquire the property at the original purchase price if for any reason taxpayer&#8217;s employment or service with the issuer is terminated.  The issuer&#8217;s repurchase right lapses in a series of periodic installments.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The fair market value of the property at the time of transfer (determined without regard to any restriction other than a restriction which by its terms will never lapse) is&#58;  $_______ per share x&#160;________ shares&#160;&#61; $___________.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The undersigned paid $0 per share x&#160;_________ shares for the property transferred for a total of $______________. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned has submitted a copy of this statement to the person for whom the services were performed in connection with the undersigned&#8217;s receipt of the above-described property.  The undersigned taxpayer is the person performing the services in connection with the transfer of said property.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned will file this election with the Internal Revenue Service office to which he files his annual income tax return not later than 30 days after the date of transfer of the property.  A copy of the election also will be furnished to the person for whom the services were performed.  The undersigned understands that this election will also be effective as an election under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">_____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> law.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxpayer</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>krys-20221231ex211xlistofs.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icfa5cb4839684b65a1b7c23e93688d4c_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subsidiaries of Krystal Biotech, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have omitted the subsidiaries which, considered in the aggregate, would not constitute a &#8220;significant subsidiary,&#8221; as defined in Rule 1-02(w) of Regulation S-X.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>krys-20221231ex231xkpmgcon.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ieb2a9521956b499195bfc1f99d7e6a49_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consent to the incorporation by reference in the registration statements (No. 333-237983) on Form S-3ASR and (Nos. 333-269539, 333-220589, 333-252351, 333-262825) on Form S-8 of our reports dated February&#160;27,&#160;2023, with respect to the consolidated financial statements of Krystal Biotech, Inc. and the effectiveness of internal control over financial reporting.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; KPMG LLP</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pittsburgh, Pennsylvania<br>February&#160;27,&#160;2023</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>krys-20221231ex232xmhmcons.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i38037961b4e64890ac8552fed332f083_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 23.2</font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:127.07pt;padding-right:127.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:13.35pt;padding-right:8.35pt"><font><br></font></div><div style="padding-left:13.35pt;padding-right:8.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in Registration Statement on Form S-3-ASR (No. 333-237983) and Form S-8 (Nos. 333-269539, 333-220589, 333-252351, 333-262825) of our report dated February 28, 2022, with respect to the consolidated financial statements of Krystal Biotech, Inc. as of December 31, 2021 and for the years ended December 31, 2021 and 2020, included in this annual report on Form 10-K of Krystal Biotech, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as of and for the year ended December 31, 2022.</font></div><div style="padding-left:13.35pt;padding-right:8.35pt"><font><br></font></div><div style="margin-top:1.95pt;padding-left:13.35pt;padding-right:282pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Mayer Hoffman McCann P.C. </font></div><div style="margin-top:1.95pt;padding-left:13.35pt;padding-right:282pt"><font><br></font></div><div style="margin-top:1.95pt;padding-left:13.35pt;padding-right:282pt"><font><br></font></div><div style="margin-top:1.95pt;padding-left:13.35pt;padding-right:282pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, California</font></div><div style="padding-left:13.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">February 27, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.75pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>krys-20221231ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1ef8fdac81694cac9cf180004c899162_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its&#160;&#160;subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;27, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>krys-20221231ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i73f4ca385b364463bed2a6ca919147ec_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its&#160;&#160;subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;27, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>krys-20221231ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3f779b4b190b4b6abaf4506125a89c57_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Krystal Biotech, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;27, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;27, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>krys-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bf7ccaf-2752-4fdb-93c0-341f465affc3,g:6dace288-7a26-4def-b28c-90440b1ff335-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:krys="http://www.krystalbio.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.krystalbio.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.krystalbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.krystalbio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.krystalbio.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.krystalbio.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>0000010 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstruments" roleURI="http://www.krystalbio.com/role/FairValueInstruments">
        <link:definition>0000011 - Disclosure - Fair Value Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.krystalbio.com/role/BalanceSheetComponents">
        <link:definition>0000012 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.krystalbio.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.krystalbio.com/role/Capitalization">
        <link:definition>0000015 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.krystalbio.com/role/StockBasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.krystalbio.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.krystalbio.com/role/SubsequentEvents">
        <link:definition>0000018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>0000021 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsTables" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables">
        <link:definition>0000022 - Disclosure - Fair Value Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables">
        <link:definition>0000023 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.krystalbio.com/role/LeasesTables">
        <link:definition>0000024 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables">
        <link:definition>0000025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.krystalbio.com/role/IncomeTaxesTables">
        <link:definition>0000026 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>0000027 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
        <link:definition>0000030 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail">
        <link:definition>0000031 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>0000032 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1">
        <link:definition>0000032 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>0000033 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>0000034 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>0000035 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000036 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.krystalbio.com/role/LeasesAdditionalinformationDetails">
        <link:definition>0000037 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumcommitmentsDetails" roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails">
        <link:definition>0000038 - Disclosure - Leases - Minimum commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumcommitmentsDetails_1" roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1">
        <link:definition>0000038 - Disclosure - Leases - Minimum commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails" roleURI="http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails">
        <link:definition>0000039 - Disclosure - Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseexpenseDetails" roleURI="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails">
        <link:definition>0000040 - Disclosure - Leases - Lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail">
        <link:definition>0000041 - Disclosure - Capitalization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>0000042 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail">
        <link:definition>0000043 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail">
        <link:definition>0000044 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
        <link:definition>0000045 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
        <link:definition>0000046 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>0000047 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail" roleURI="http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail">
        <link:definition>0000048 - Disclosure - Income Taxes - Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" roleURI="http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails">
        <link:definition>0000049 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="krys_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ClinicalSupplyAgreementMember" abstract="true" name="ClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_ASTRAFacilityMember" abstract="true" name="ASTRAFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PlacementSharesMember" abstract="true" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_MilestonesDomain" abstract="true" name="MilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PeriphaGenMember" abstract="true" name="PeriphaGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_OrphanDrugTaxCreditCarryforwardMember" abstract="true" name="OrphanDrugTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_OwnershipInterestRateChangeOverPeriod" abstract="false" name="OwnershipInterestRateChangeOverPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="krys_BalanceSheetComponentsDisclosureTextBlock" abstract="false" name="BalanceSheetComponentsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_TwoThousandSixteenLeaseAgreementMember" abstract="true" name="TwoThousandSixteenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_A2017IPOStockPlanMember" abstract="true" name="A2017IPOStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CumulativeChangesInOwnershipInterestOfShareholders" abstract="false" name="CumulativeChangesInOwnershipInterestOfShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_CumulativeEscalationClausePercent" abstract="false" name="CumulativeEscalationClausePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_RemainingCommitmentAmount" abstract="false" name="RemainingCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_NumberOfMilestones" abstract="false" name="NumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="krys_PaymentToEscrowForReducingLeaseRentals" abstract="false" name="PaymentToEscrowForReducingLeaseRentals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_AccruedPreclinicalAndClinicalExpenses" abstract="false" name="AccruedPreclinicalAndClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestonesAxis" abstract="true" name="MilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_LossContingencyGuaranteedMaximumPriceToBePaid" abstract="false" name="LossContingencyGuaranteedMaximumPriceToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LitigationSettlementTotalConsideration" abstract="false" name="LitigationSettlementTotalConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SwitzerlandLeaseMember" abstract="true" name="SwitzerlandLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" abstract="false" name="LessorOperatingLeaseLiabilityAnnualLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_AdditionalAreaOfRealEstatePropertyLeased" abstract="false" name="AdditionalAreaOfRealEstatePropertyLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="krys_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PurchasePriceOfPotentialBuildingPurchase" abstract="false" name="PurchasePriceOfPotentialBuildingPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShortTermAmendmentMember" abstract="true" name="ShortTermAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedPayrollAndBenefits" abstract="false" name="AccruedPayrollAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClauseTerm" abstract="false" name="CumulativeEscalationClauseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="krys_CostOfWorkPercentage" abstract="false" name="CostOfWorkPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_LitigationSettlementMilestonePaymentsSalesThreshold" abstract="false" name="LitigationSettlementMilestonePaymentsSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedFinancingFeesCurrent" abstract="false" name="AccruedFinancingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_BostonMassachusettsLeaseMember" abstract="true" name="BostonMassachusettsLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PaymentsForSuitLiability" abstract="false" name="PaymentsForSuitLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_InterestIncomeExpenseAndOtherNonoperatingNet" abstract="false" name="InterestIncomeExpenseAndOtherNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_OtherContractualObligationsMember" abstract="true" name="OtherContractualObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_BalanceSheetComponentsAbstract" abstract="true" name="BalanceSheetComponentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_SaleOfStockRemainingAvailableIssuanceAmount" abstract="false" name="SaleOfStockRemainingAvailableIssuanceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="krys_AccruedConstructionInProgressAndLaboratoryEquipment" abstract="false" name="AccruedConstructionInProgressAndLaboratoryEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>krys-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bf7ccaf-2752-4fdb-93c0-341f465affc3,g:6dace288-7a26-4def-b28c-90440b1ff335-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0138b0b7-d937-4666-b75e-91fb4548ee8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b24d4525-81b9-43b0-a870-e7a1edea01be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0138b0b7-d937-4666-b75e-91fb4548ee8e" xlink:to="loc_us-gaap_AssetsCurrent_b24d4525-81b9-43b0-a870-e7a1edea01be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc74169b-62cc-41c3-8129-fe99c8695711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0138b0b7-d937-4666-b75e-91fb4548ee8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cc74169b-62cc-41c3-8129-fe99c8695711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7c14d06c-2090-4a91-8039-55a035338577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0138b0b7-d937-4666-b75e-91fb4548ee8e" xlink:to="loc_us-gaap_LongTermInvestments_7c14d06c-2090-4a91-8039-55a035338577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_49da493d-f9fe-450f-ab52-9b478ad49a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0138b0b7-d937-4666-b75e-91fb4548ee8e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_49da493d-f9fe-450f-ab52-9b478ad49a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_54475ba0-92c0-42aa-99cc-b23a7a769949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0138b0b7-d937-4666-b75e-91fb4548ee8e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_54475ba0-92c0-42aa-99cc-b23a7a769949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd5c1ebe-f16f-46d1-89c4-cee403cc6876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3562a65a-159a-45ba-a16c-3756cb4e924d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd5c1ebe-f16f-46d1-89c4-cee403cc6876" xlink:to="loc_us-gaap_CommonStockValue_3562a65a-159a-45ba-a16c-3756cb4e924d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_63efd358-cda7-4058-8e86-6a6677df2ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd5c1ebe-f16f-46d1-89c4-cee403cc6876" xlink:to="loc_us-gaap_AdditionalPaidInCapital_63efd358-cda7-4058-8e86-6a6677df2ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8d58c406-e2aa-4796-b655-7cb30b499729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd5c1ebe-f16f-46d1-89c4-cee403cc6876" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8d58c406-e2aa-4796-b655-7cb30b499729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c544228d-07a0-4840-8436-551b0c79392d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd5c1ebe-f16f-46d1-89c4-cee403cc6876" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c544228d-07a0-4840-8436-551b0c79392d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_65dbd145-22c5-4be8-9f0c-cb771d0a89c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a3f5edb5-9e7d-459f-b358-c2e2e6d79d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_65dbd145-22c5-4be8-9f0c-cb771d0a89c9" xlink:to="loc_us-gaap_LiabilitiesCurrent_a3f5edb5-9e7d-459f-b358-c2e2e6d79d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_acfed545-09e4-46b8-a6d9-4f067b492909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_65dbd145-22c5-4be8-9f0c-cb771d0a89c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_acfed545-09e4-46b8-a6d9-4f067b492909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_efdd3b71-7359-4349-a3b2-ea9dbaf74054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3a0a97c5-15da-45b1-8fa6-a9a3fab1e3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_efdd3b71-7359-4349-a3b2-ea9dbaf74054" xlink:to="loc_us-gaap_Liabilities_3a0a97c5-15da-45b1-8fa6-a9a3fab1e3fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_09dd950f-6365-45bd-807c-788d426b33d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_efdd3b71-7359-4349-a3b2-ea9dbaf74054" xlink:to="loc_us-gaap_CommitmentsAndContingencies_09dd950f-6365-45bd-807c-788d426b33d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a0ce4ca-4dc8-4eaf-a505-6a9017046edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_efdd3b71-7359-4349-a3b2-ea9dbaf74054" xlink:to="loc_us-gaap_StockholdersEquity_1a0ce4ca-4dc8-4eaf-a505-6a9017046edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d9c263d9-bd33-4504-ac7e-68168499b0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_befd0def-1c4c-49fd-9de7-731c8fe78cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d9c263d9-bd33-4504-ac7e-68168499b0e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_befd0def-1c4c-49fd-9de7-731c8fe78cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b09db4d7-5206-4a02-9113-e0ebd593cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d9c263d9-bd33-4504-ac7e-68168499b0e0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b09db4d7-5206-4a02-9113-e0ebd593cd4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70005eaa-d567-4100-8102-e0db9b771f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d9c263d9-bd33-4504-ac7e-68168499b0e0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_70005eaa-d567-4100-8102-e0db9b771f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_032d8b1f-f77e-4d9c-81a3-5608455d7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9f34b709-003d-4a4e-abcd-fca8c3c731c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_032d8b1f-f77e-4d9c-81a3-5608455d7a3f" xlink:to="loc_us-gaap_AccountsPayableCurrent_9f34b709-003d-4a4e-abcd-fca8c3c731c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b00b7187-2a32-4762-b88c-b1ee5e96e929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_032d8b1f-f77e-4d9c-81a3-5608455d7a3f" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b00b7187-2a32-4762-b88c-b1ee5e96e929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f60af8db-10db-44a3-a345-9860173ae1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_032d8b1f-f77e-4d9c-81a3-5608455d7a3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f60af8db-10db-44a3-a345-9860173ae1dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a87e402-7c59-4bc7-b841-887500a71e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ebdef20d-178b-4405-962d-88109cc181fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a87e402-7c59-4bc7-b841-887500a71e99" xlink:to="loc_us-gaap_OperatingIncomeLoss_ebdef20d-178b-4405-962d-88109cc181fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_ed389b2d-b73c-483d-bc5d-11535d6151c0" xlink:href="krys-20221231.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a87e402-7c59-4bc7-b841-887500a71e99" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_ed389b2d-b73c-483d-bc5d-11535d6151c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_70f8a1a8-0246-432c-afa3-f96944a8e224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a87e402-7c59-4bc7-b841-887500a71e99" xlink:to="loc_us-gaap_InterestExpense_70f8a1a8-0246-432c-afa3-f96944a8e224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_100bb2b2-8722-4fca-ad14-624455d7a4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42919370-f3f8-4b8b-a86c-4b22490f421b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_100bb2b2-8722-4fca-ad14-624455d7a4ab" xlink:to="loc_us-gaap_NetIncomeLoss_42919370-f3f8-4b8b-a86c-4b22490f421b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_03397800-bc30-4164-953f-7fd4686da8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_100bb2b2-8722-4fca-ad14-624455d7a4ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_03397800-bc30-4164-953f-7fd4686da8f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6b5307d8-d313-40c8-bf15-f255140ca062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8d8714bc-0668-4a54-8ad5-3d86c493d19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6b5307d8-d313-40c8-bf15-f255140ca062" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8d8714bc-0668-4a54-8ad5-3d86c493d19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bbd61d99-b6c7-4e2d-9f1d-ccaf0a175f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6b5307d8-d313-40c8-bf15-f255140ca062" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bbd61d99-b6c7-4e2d-9f1d-ccaf0a175f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_565725b4-8563-495f-b951-89cbe7339fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6b5307d8-d313-40c8-bf15-f255140ca062" xlink:to="loc_us-gaap_LitigationSettlementExpense_565725b4-8563-495f-b951-89cbe7339fc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42419025-5cd4-4ca3-b6af-a1f05fcaf018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fde041fa-5c13-495c-a965-cb528baace9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42419025-5cd4-4ca3-b6af-a1f05fcaf018" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fde041fa-5c13-495c-a965-cb528baace9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91c65be7-4443-406c-9f0e-e3cf9ba0334d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42419025-5cd4-4ca3-b6af-a1f05fcaf018" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_91c65be7-4443-406c-9f0e-e3cf9ba0334d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9df55ec7-c3f1-4aba-bfa0-26f5a0282e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42419025-5cd4-4ca3-b6af-a1f05fcaf018" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9df55ec7-c3f1-4aba-bfa0-26f5a0282e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35469c1d-ce9d-4f7f-9789-b6735307c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42419025-5cd4-4ca3-b6af-a1f05fcaf018" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35469c1d-ce9d-4f7f-9789-b6735307c3bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_805d7196-5b30-48b2-ba6f-8b94bcacf73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f6bc5b8d-a8ee-48a3-96e2-7fba0cfdacad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_805d7196-5b30-48b2-ba6f-8b94bcacf73d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f6bc5b8d-a8ee-48a3-96e2-7fba0cfdacad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cc6009d0-f4f1-4645-a55e-beaa449c9d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_805d7196-5b30-48b2-ba6f-8b94bcacf73d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cc6009d0-f4f1-4645-a55e-beaa449c9d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_919e2b92-9150-41a5-a4f0-be9a33e620bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_805d7196-5b30-48b2-ba6f-8b94bcacf73d" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_919e2b92-9150-41a5-a4f0-be9a33e620bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f977489-d2a4-41da-ae12-3cd7a5fb6b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_f06a0c43-3359-40b8-8c96-e61e7fc70c39" xlink:href="krys-20221231.xsd#krys_PaymentsForSuitLiability"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f977489-d2a4-41da-ae12-3cd7a5fb6b1b" xlink:to="loc_krys_PaymentsForSuitLiability_f06a0c43-3359-40b8-8c96-e61e7fc70c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0720f3c1-718b-46a6-b75a-1efc9d9d11e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f977489-d2a4-41da-ae12-3cd7a5fb6b1b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0720f3c1-718b-46a6-b75a-1efc9d9d11e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1e6a344c-a0ef-446d-9436-da1d1ed3160d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f977489-d2a4-41da-ae12-3cd7a5fb6b1b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1e6a344c-a0ef-446d-9436-da1d1ed3160d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b96c7a43-12c3-4587-9ebd-248bd8018ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_NetIncomeLoss_b96c7a43-12c3-4587-9ebd-248bd8018ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1df18c31-8f7a-46e9-b7c7-682dec58255a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1df18c31-8f7a-46e9-b7c7-682dec58255a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7c71d92f-7da7-4231-b22d-5930055c3b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_ShareBasedCompensation_7c71d92f-7da7-4231-b22d-5930055c3b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_1e08f106-9bf9-42de-84dc-f5029379f530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_1e08f106-9bf9-42de-84dc-f5029379f530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c937dbcb-f7f7-4133-a3ef-fa60256c8b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c937dbcb-f7f7-4133-a3ef-fa60256c8b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b69bc42f-b2aa-43e9-b778-3a9f8e7a7063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b69bc42f-b2aa-43e9-b778-3a9f8e7a7063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_cee1a736-a990-4b77-892c-4415c9babeec" xlink:href="krys-20221231.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_cee1a736-a990-4b77-892c-4415c9babeec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7ad2aba4-4428-4248-bb44-95502ca58595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7ad2aba4-4428-4248-bb44-95502ca58595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1c7551cd-b5d6-4fc1-9a06-64ef3ac269c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1c7551cd-b5d6-4fc1-9a06-64ef3ac269c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_ef958fcb-613d-439f-ba3e-349d4dc4fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_OtherNoncashExpense_ef958fcb-613d-439f-ba3e-349d4dc4fc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d8098979-fdeb-4592-9565-cbacdd20c005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1cc8f94-4673-4fa8-a4ba-fb06868e9a7a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d8098979-fdeb-4592-9565-cbacdd20c005" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_66ce180f-a21e-4528-9e92-c13da9493a41" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_491923aa-b4bc-451e-9eb7-af89d72b97a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_66ce180f-a21e-4528-9e92-c13da9493a41" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_491923aa-b4bc-451e-9eb7-af89d72b97a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cd1fbb7c-2202-48af-ac5d-187dd6c9879f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_66ce180f-a21e-4528-9e92-c13da9493a41" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cd1fbb7c-2202-48af-ac5d-187dd6c9879f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2746f285-fc69-4597-8a72-634dd1e792f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d4d994eb-140b-492f-a67a-b0f0df70ae01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2746f285-fc69-4597-8a72-634dd1e792f1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d4d994eb-140b-492f-a67a-b0f0df70ae01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ab5b2a8-e9f0-41e3-951a-470c614f3438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2746f285-fc69-4597-8a72-634dd1e792f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ab5b2a8-e9f0-41e3-951a-470c614f3438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1f2ea91e-e37b-45a4-852c-4783078fe6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2746f285-fc69-4597-8a72-634dd1e792f1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1f2ea91e-e37b-45a4-852c-4783078fe6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_19e932f4-d99a-4826-8269-5c252a4e715f" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2d753492-42f4-4aa9-8813-07df976c3ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_19e932f4-d99a-4826-8269-5c252a4e715f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2d753492-42f4-4aa9-8813-07df976c3ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_882375b6-1021-41f5-8ba2-14ffe784c704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_19e932f4-d99a-4826-8269-5c252a4e715f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_882375b6-1021-41f5-8ba2-14ffe784c704" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_e85e4be2-ae3b-4fbc-955b-51a225bfee1a" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_be7f6cbc-49db-4c7d-8008-1056bd525a6b" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_e85e4be2-ae3b-4fbc-955b-51a225bfee1a" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_be7f6cbc-49db-4c7d-8008-1056bd525a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3aec8bab-cc7e-46a6-ae93-3678d453befb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_e85e4be2-ae3b-4fbc-955b-51a225bfee1a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3aec8bab-cc7e-46a6-ae93-3678d453befb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_59b96423-0bcd-4143-a479-45818955585f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_e85e4be2-ae3b-4fbc-955b-51a225bfee1a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_59b96423-0bcd-4143-a479-45818955585f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a35188c-06bd-47e4-a824-6758dede40ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_33faf4c2-536b-404a-b5f1-2645153c8d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4a35188c-06bd-47e4-a824-6758dede40ce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_33faf4c2-536b-404a-b5f1-2645153c8d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eae69d96-e0b5-42a0-93bf-260be0012f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4a35188c-06bd-47e4-a824-6758dede40ce" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eae69d96-e0b5-42a0-93bf-260be0012f10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:href="krys-20221231.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_44c90875-ed76-42b4-b7cf-9354c20b501f" xlink:href="krys-20221231.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_44c90875-ed76-42b4-b7cf-9354c20b501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_046b7053-968e-454b-a7f9-0dcde9b8c862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_046b7053-968e-454b-a7f9-0dcde9b8c862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_84b7f719-334e-438c-b60e-f2a4024e4c29" xlink:href="krys-20221231.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_krys_AccruedPayrollAndBenefits_84b7f719-334e-438c-b60e-f2a4024e4c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_d173a105-5124-4909-8c40-808c6e485da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_us-gaap_AccruedIncomeTaxes_d173a105-5124-4909-8c40-808c6e485da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressAndLaboratoryEquipment_9e5d7344-2b61-41e5-94b5-bcd1e8161dbb" xlink:href="krys-20221231.xsd#krys_AccruedConstructionInProgressAndLaboratoryEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_krys_AccruedConstructionInProgressAndLaboratoryEquipment_9e5d7344-2b61-41e5-94b5-bcd1e8161dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_699b6068-7f05-4ee1-8bef-efd6a66a4e4a" xlink:href="krys-20221231.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_krys_AccruedFinancingFeesCurrent_699b6068-7f05-4ee1-8bef-efd6a66a4e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c9c966ef-f890-48c1-bc3b-2781ef87ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_611331ee-750d-4d2f-bb50-43ff7095939d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c9c966ef-f890-48c1-bc3b-2781ef87ef66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesMinimumcommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97593653-7741-4256-b2d7-c93ff6989e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33ba596a-d945-439c-9af4-7ac2fd74ed05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97593653-7741-4256-b2d7-c93ff6989e0a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33ba596a-d945-439c-9af4-7ac2fd74ed05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3c9a0375-e3aa-44c2-bc61-5c75d11c502a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97593653-7741-4256-b2d7-c93ff6989e0a" xlink:to="loc_us-gaap_OperatingLeaseLiability_3c9a0375-e3aa-44c2-bc61-5c75d11c502a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesMinimumcommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4f5b7fc8-73c5-49b6-b8f8-7f9bca4e538a" xlink:href="krys-20221231.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4f5b7fc8-73c5-49b6-b8f8-7f9bca4e538a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_19644e2a-37a0-400d-98ed-f3a133d2dcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_19644e2a-37a0-400d-98ed-f3a133d2dcd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06bb4378-91bf-4ba0-b123-30f053349d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06bb4378-91bf-4ba0-b123-30f053349d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_27ada33f-977d-42f8-b85b-27b145bb46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_27ada33f-977d-42f8-b85b-27b145bb46dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3b8d0ee7-99fd-49de-971d-83ebb7e495d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3b8d0ee7-99fd-49de-971d-83ebb7e495d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_415d4a80-7465-4365-b7ca-c7bd6d3470ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_730b4145-1715-43f4-83dd-2ada8a784924" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_415d4a80-7465-4365-b7ca-c7bd6d3470ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fdc13128-19dc-4ad5-a052-9bbd9ca9ec02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fdc13128-19dc-4ad5-a052-9bbd9ca9ec02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0c64a8c3-cebf-4032-a3ce-fa8e77d2e264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0c64a8c3-cebf-4032-a3ce-fa8e77d2e264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0700f041-7ab7-406e-8fdf-1ffda414f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0700f041-7ab7-406e-8fdf-1ffda414f2e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5b9a7616-fee1-45ca-b8d6-2d70cf7df3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5b9a7616-fee1-45ca-b8d6-2d70cf7df3aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_6aea932a-15e9-4aa4-8773-edd906fda29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_6aea932a-15e9-4aa4-8773-edd906fda29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_9ad340ca-b159-4560-bc8b-d19d3682ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_53ffe84f-5a27-49fb-b7a7-4b5c6cf1602c" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_9ad340ca-b159-4560-bc8b-d19d3682ec9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0679e8e0-c323-4a64-9437-87ef054fed55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1975e1c7-de67-401e-b87b-15ccb277189f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_0679e8e0-c323-4a64-9437-87ef054fed55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1975e1c7-de67-401e-b87b-15ccb277189f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1f51bf36-1922-44d9-90ce-603ba0a9e522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_0679e8e0-c323-4a64-9437-87ef054fed55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1f51bf36-1922-44d9-90ce-603ba0a9e522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_DeferredTaxLiabilitiesRightOfUseAsset_a2d0707c-8d93-4b34-b158-2a8933d48c73" xlink:href="krys-20221231.xsd#krys_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_0679e8e0-c323-4a64-9437-87ef054fed55" xlink:to="loc_krys_DeferredTaxLiabilitiesRightOfUseAsset_a2d0707c-8d93-4b34-b158-2a8933d48c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_97f999c6-de75-4ea6-98c7-57ad10c720a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_abca9f67-b27b-4ecf-8d3e-6499d3bea97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_97f999c6-de75-4ea6-98c7-57ad10c720a4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_abca9f67-b27b-4ecf-8d3e-6499d3bea97f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_22e11543-6e6b-453a-a12c-b0e1fe2e1e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_97f999c6-de75-4ea6-98c7-57ad10c720a4" xlink:to="loc_us-gaap_DeferredTaxLiabilities_22e11543-6e6b-453a-a12c-b0e1fe2e1e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_968cfc2c-3640-4f5e-b692-e70ace156ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ceff22c8-c579-4601-83e9-2bd414c8222e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_968cfc2c-3640-4f5e-b692-e70ace156ec3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ceff22c8-c579-4601-83e9-2bd414c8222e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_657e3d19-9825-44ee-9362-45c49d428f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_968cfc2c-3640-4f5e-b692-e70ace156ec3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_657e3d19-9825-44ee-9362-45c49d428f65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1b0cc0bd-a868-4ffc-af48-623fbac94341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1b0cc0bd-a868-4ffc-af48-623fbac94341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6dbaceef-190a-4abf-8e69-7d8cf5a3067f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6dbaceef-190a-4abf-8e69-7d8cf5a3067f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_DeferredTaxAssetsLeaseLiability_9de44aae-1963-4056-9316-2e9c7b5b5c34" xlink:href="krys-20221231.xsd#krys_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_krys_DeferredTaxAssetsLeaseLiability_9de44aae-1963-4056-9316-2e9c7b5b5c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b49a5ce2-3d79-4d9f-be67-bfc48518ce5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b49a5ce2-3d79-4d9f-be67-bfc48518ce5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_c46c60e4-169d-49a1-be8e-5fee58431113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_c46c60e4-169d-49a1-be8e-5fee58431113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a8fe7f46-e287-48f0-93ae-5a84271ddd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a8fe7f46-e287-48f0-93ae-5a84271ddd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_61965207-6bff-4fa7-b508-1ea7f5b27cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_61965207-6bff-4fa7-b508-1ea7f5b27cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_73bc40bb-1a6e-44d2-8af7-eec30ebb97ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_7299f3b2-d16f-4c5a-b201-6929d9997d04" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_73bc40bb-1a6e-44d2-8af7-eec30ebb97ab" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>krys-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bf7ccaf-2752-4fdb-93c0-341f465affc3,g:6dace288-7a26-4def-b28c-90440b1ff335-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2753d14708ec47dabb7581b6c0d95bec_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ec83ff00-b063-4616-9d35-c44d297ce3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_SharesOutstanding_ec83ff00-b063-4616-9d35-c44d297ce3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08c52c7f-5818-4c0d-9297-c1be16fc6f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockholdersEquity_08c52c7f-5818-4c0d-9297-c1be16fc6f7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49d2bf8d-1d18-4851-bdcd-a94341c601e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49d2bf8d-1d18-4851-bdcd-a94341c601e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9a3a83ec-1818-4aa6-be62-9d3866fdc9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9a3a83ec-1818-4aa6-be62-9d3866fdc9ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_61af4b8f-9232-4d1c-b1d2-1054b2bf1e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_61af4b8f-9232-4d1c-b1d2-1054b2bf1e4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ccdf6faa-0fe6-49f1-89ee-13ee5a4872f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ccdf6faa-0fe6-49f1-89ee-13ee5a4872f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_41adca69-e681-4328-b1f0-21199e88ef28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_41adca69-e681-4328-b1f0-21199e88ef28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22c7fa78-2d1f-4df3-a3e3-408c7c28a7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22c7fa78-2d1f-4df3-a3e3-408c7c28a7d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3dcef420-4511-4388-a7c1-439e933b5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_NetIncomeLoss_3dcef420-4511-4388-a7c1-439e933b5e95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f2c2dbc7-62fe-43c3-a62b-bb11f1dc0f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b191e28b-9c45-49cc-8c01-9a3deb2d6fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax_132a89ac-eb6a-4944-a625-8f1022e7dc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax_132a89ac-eb6a-4944-a625-8f1022e7dc57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:to="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79929a49-bb1a-492e-8ae7-bca1b0001ebe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:to="loc_us-gaap_EquityComponentDomain_79929a49-bb1a-492e-8ae7-bca1b0001ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:to="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b43a3edc-9e6a-4629-9d2b-cfdbb696df80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_CommonStockMember_b43a3edc-9e6a-4629-9d2b-cfdbb696df80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0cd8ca07-e1c7-4ea8-91ab-2903ad0bd876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0cd8ca07-e1c7-4ea8-91ab-2903ad0bd876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83b2c025-d369-4389-97b8-eb4891f2640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83b2c025-d369-4389-97b8-eb4891f2640b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0cfb4e31-38b9-48b6-be4c-40fa6cf78455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_RetainedEarningsMember_0cfb4e31-38b9-48b6-be4c-40fa6cf78455" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i68dc66d771bd401d876e2d65754e60f6_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7fd8943-8f72-43bc-b1c2-f640a131f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ad1d13bb-6aea-4eff-9a58-394907dadee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7fd8943-8f72-43bc-b1c2-f640a131f9e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ad1d13bb-6aea-4eff-9a58-394907dadee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7fd8943-8f72-43bc-b1c2-f640a131f9e1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f2ac38f-50d7-4f13-a024-2c728e434dec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8f2ac38f-50d7-4f13-a024-2c728e434dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6dcb24a4-0bf9-45b4-8cd6-080460a9ac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6dcb24a4-0bf9-45b4-8cd6-080460a9ac5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ad72b447-65b7-49d4-82c1-535d9e1d65e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6dcb24a4-0bf9-45b4-8cd6-080460a9ac5e" xlink:to="loc_us-gaap_EquipmentMember_ad72b447-65b7-49d4-82c1-535d9e1d65e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended" id="iec8ae2ee86af473ab2a04a7b4fbda0f8_SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0e45e0c1-f297-420b-b4ae-ad47f8b39283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e66f38a1-acd8-4d86-8d76-7a0bd222a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0e45e0c1-f297-420b-b4ae-ad47f8b39283" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e66f38a1-acd8-4d86-8d76-7a0bd222a1bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0e45e0c1-f297-420b-b4ae-ad47f8b39283" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a23381d5-c942-4b2f-8a72-3599ac1c3a66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a23381d5-c942-4b2f-8a72-3599ac1c3a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_1214d083-d92e-4dfb-836b-fd3d08475003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:to="loc_us-gaap_ComputerEquipmentMember_1214d083-d92e-4dfb-836b-fd3d08475003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_c79efd9f-e98d-44cb-96a4-99a4f4ae4441" xlink:href="krys-20221231.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:to="loc_krys_LabEquipmentMember_c79efd9f-e98d-44cb-96a4-99a4f4ae4441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a155b565-4cfb-4a0e-bead-96d33a1d18e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a155b565-4cfb-4a0e-bead-96d33a1d18e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:to="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ba77b73-acf2-48bb-a2ba-c61fbf546603_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:to="loc_srt_RangeMember_4ba77b73-acf2-48bb-a2ba-c61fbf546603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:to="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_13356ef7-d77d-476a-9d8c-6cd9ad662652" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:to="loc_srt_MinimumMember_13356ef7-d77d-476a-9d8c-6cd9ad662652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ba3ad2c-fc25-411e-9d62-818d6bb9e657" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:to="loc_srt_MaximumMember_6ba3ad2c-fc25-411e-9d62-818d6bb9e657" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended" id="ibe98da9c396749f8a8fbb852c08f7911_NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6cc4584-b07f-4526-b5af-d6190dd5197b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b4d74199-7996-4402-94a9-c637be709e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6cc4584-b07f-4526-b5af-d6190dd5197b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b4d74199-7996-4402-94a9-c637be709e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6cc4584-b07f-4526-b5af-d6190dd5197b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:to="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8347f808-d3f5-4905-9b3c-c29018a8dc5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8347f808-d3f5-4905-9b3c-c29018a8dc5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dfc6e7b7-a0f9-4079-8246-2f78300e572a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dfc6e7b7-a0f9-4079-8246-2f78300e572a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ace29a62-13be-4864-a41f-63ac9364a240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:to="loc_us-gaap_RestrictedStockMember_ace29a62-13be-4864-a41f-63ac9364a240" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="ic311e6bbf0294c01a180dfec5eaafda0_FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c19b18cf-d290-4594-b9da-958bee65fdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c19b18cf-d290-4594-b9da-958bee65fdb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca2ad02d-3ba4-4348-8b57-c4b21aa0ae0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca2ad02d-3ba4-4348-8b57-c4b21aa0ae0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07c47395-88ee-4fd2-aa95-8d554a182706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07c47395-88ee-4fd2-aa95-8d554a182706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1e50a3bd-772d-49de-8826-4e3183e4f112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1e50a3bd-772d-49de-8826-4e3183e4f112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2edb46-19ac-4aa0-a53d-c68fba92bca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2edb46-19ac-4aa0-a53d-c68fba92bca7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56fcf371-1826-46dd-98ff-46e7f12c5d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56fcf371-1826-46dd-98ff-46e7f12c5d02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_71d31169-3b2b-4685-a0bf-f02738d6da01" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_71d31169-3b2b-4685-a0bf-f02738d6da01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_9f2687f4-3237-4e41-9f55-f29692102b31" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_9f2687f4-3237-4e41-9f55-f29692102b31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_4081cc3e-bf16-41b8-b8b3-3a15dc152e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_4081cc3e-bf16-41b8-b8b3-3a15dc152e8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fd0335e9-3029-458e-94f2-41fdf015c17b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fd0335e9-3029-458e-94f2-41fdf015c17b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_fa5f0947-79c4-4cb1-b19f-6a3144c76a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_fa5f0947-79c4-4cb1-b19f-6a3144c76a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_11a7f850-cff3-4e8d-b6ec-5fffe6df8523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_11a7f850-cff3-4e8d-b6ec-5fffe6df8523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_8dbdc77e-ef11-415d-9ac2-6cd5cd1f9cce" xlink:href="krys-20221231.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_8dbdc77e-ef11-415d-9ac2-6cd5cd1f9cce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efee13ee-5893-47ef-a1a8-822f1eb73a26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_efee13ee-5893-47ef-a1a8-822f1eb73a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_383f8171-b8fc-4e8f-84ab-d10e3aea56e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:to="loc_us-gaap_CommercialPaperMember_383f8171-b8fc-4e8f-84ab-d10e3aea56e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2f4ef529-7a1d-419c-9c85-2ed00dcd2434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2f4ef529-7a1d-419c-9c85-2ed00dcd2434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_01d3a6ba-d37c-4119-bc39-b06542a9619d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_01d3a6ba-d37c-4119-bc39-b06542a9619d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_90067a72-c89b-4212-8490-6066d417b318_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_90067a72-c89b-4212-8490-6066d417b318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f692de08-0352-445d-ab8b-cb26edfbca90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f692de08-0352-445d-ab8b-cb26edfbca90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_87845c69-7f6b-465c-9bc0-383cfbc3138a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f692de08-0352-445d-ab8b-cb26edfbca90" xlink:to="loc_us-gaap_CashMember_87845c69-7f6b-465c-9bc0-383cfbc3138a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a5776f29-4831-4da3-91f9-8cf55e5420f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a5776f29-4831-4da3-91f9-8cf55e5420f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5787642-693a-4cca-9546-05dceff87b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5787642-693a-4cca-9546-05dceff87b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a0f6084-1e9f-439f-982f-52d3a49cb484_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:to="loc_srt_RangeMember_9a0f6084-1e9f-439f-982f-52d3a49cb484_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:to="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a705eff-e75e-421d-b85f-3112a0b1b5c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:to="loc_srt_MinimumMember_6a705eff-e75e-421d-b85f-3112a0b1b5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5bef1cc-6a04-4ced-b978-3f1839535f42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:to="loc_srt_MaximumMember_e5bef1cc-6a04-4ced-b978-3f1839535f42" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="ie005a02d6f5d4471898fafd75a23a984_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_71e2d9ca-c4b6-424b-9656-3155ef5db5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_71e2d9ca-c4b6-424b-9656-3155ef5db5a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27134ada-c406-4340-b161-06e18a6ba9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27134ada-c406-4340-b161-06e18a6ba9af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_176daf33-bcae-445b-8402-03e51367f6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_176daf33-bcae-445b-8402-03e51367f6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_16bc56c2-a25d-4c59-ad89-1c033e4cca59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_ConstructionInProgressMember_16bc56c2-a25d-4c59-ad89-1c033e4cca59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_30b7160f-2750-45d2-8e28-0d8fd515398b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_30b7160f-2750-45d2-8e28-0d8fd515398b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d90a82e0-e87e-48a8-8626-fa5055e7f563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d90a82e0-e87e-48a8-8626-fa5055e7f563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d7b1ee43-a3ec-4834-b4ad-9f0492758500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_ComputerEquipmentMember_d7b1ee43-a3ec-4834-b4ad-9f0492758500" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_2155d58f-5e86-4cc7-9160-19df0e33e4fe" xlink:href="krys-20221231.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_krys_LabEquipmentMember_2155d58f-5e86-4cc7-9160-19df0e33e4fe" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i2d4ab09c50d24962b2f82bb614bccd82_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_e00c6502-3a88-4c19-ab82-0ba8226c29ae" xlink:href="krys-20221231.xsd#krys_RemainingCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_RemainingCommitmentAmount_e00c6502-3a88-4c19-ab82-0ba8226c29ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_781ecdd1-d776-4cc1-9411-f3dbb13f2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_781ecdd1-d776-4cc1-9411-f3dbb13f2d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_453d4c11-d36b-403d-8b8d-6157b0200145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ProfessionalFees_453d4c11-d36b-403d-8b8d-6157b0200145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_353a8e27-ddee-4307-aeef-0e8c26dd193e" xlink:href="krys-20221231.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_353a8e27-ddee-4307-aeef-0e8c26dd193e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_30977e73-9a47-4745-b118-a77c0d90b4de" xlink:href="krys-20221231.xsd#krys_CostOfWorkPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_CostOfWorkPercentage_30977e73-9a47-4745-b118-a77c0d90b4de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_8bd05859-12d8-4855-8283-8b314e54f000" xlink:href="krys-20221231.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_8bd05859-12d8-4855-8283-8b314e54f000" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_587640be-db19-4156-9591-bdb9f9469a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_LitigationSettlementExpense_587640be-db19-4156-9591-bdb9f9469a12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_68e910a4-fb32-4962-a8cf-a3a309185924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_68e910a4-fb32-4962-a8cf-a3a309185924" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_a9e95661-889c-4cd5-a2ed-23bd89c06305" xlink:href="krys-20221231.xsd#krys_NumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_NumberOfMilestones_a9e95661-889c-4cd5-a2ed-23bd89c06305" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_963988ee-d98a-4168-9739-1575f8e6c378" xlink:href="krys-20221231.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_963988ee-d98a-4168-9739-1575f8e6c378" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_cd3d6368-5f73-4cf1-bd3b-d0dca60a5d4a" xlink:href="krys-20221231.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_LitigationSettlementTotalConsideration_cd3d6368-5f73-4cf1-bd3b-d0dca60a5d4a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_2a72fca5-4243-44ba-ac9e-60e2aac315c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_2a72fca5-4243-44ba-ac9e-60e2aac315c5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5eb150b4-d1be-4cd0-ba73-3cb51ccf4086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5eb150b4-d1be-4cd0-ba73-3cb51ccf4086" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_4d38a83a-4994-436b-b8c5-9bec3be8b445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_4d38a83a-4994-436b-b8c5-9bec3be8b445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_891fb0ed-71d1-46ec-924c-0b522b4a8142" xlink:href="krys-20221231.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:to="loc_krys_ClinicalSupplyAgreementMember_891fb0ed-71d1-46ec-924c-0b522b4a8142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_91d4b4b8-e31a-4ecc-93e7-346d7ebfa67a" xlink:href="krys-20221231.xsd#krys_OtherContractualObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:to="loc_krys_OtherContractualObligationsMember_91d4b4b8-e31a-4ecc-93e7-346d7ebfa67a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_7ce4002a-87a6-456a-886c-684ff5725f2b" xlink:href="krys-20221231.xsd#krys_ASTRAFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:to="loc_krys_ASTRAFacilityMember_7ce4002a-87a6-456a-886c-684ff5725f2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b0886faa-4df0-471e-b303-1d86f47ae844_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:to="loc_srt_LitigationCaseTypeDomain_b0886faa-4df0-471e-b303-1d86f47ae844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_60a00640-b85d-4135-aff4-95a7e8c7f6ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:to="loc_srt_LitigationCaseTypeDomain_60a00640-b85d-4135-aff4-95a7e8c7f6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_3518048b-587a-4764-8444-c5db30714163" xlink:href="krys-20221231.xsd#krys_PeriphaGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_60a00640-b85d-4135-aff4-95a7e8c7f6ed" xlink:to="loc_krys_PeriphaGenMember_3518048b-587a-4764-8444-c5db30714163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:href="krys-20221231.xsd#krys_MilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_a0028a2f-3e06-40d0-a92c-4edd70c5536d_default" xlink:href="krys-20221231.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:to="loc_krys_MilestonesDomain_a0028a2f-3e06-40d0-a92c-4edd70c5536d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:href="krys-20221231.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:to="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_db4d80e6-7962-4a1b-a18c-a608a20ed3af" xlink:href="krys-20221231.xsd#krys_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:to="loc_krys_MilestoneThreeMember_db4d80e6-7962-4a1b-a18c-a608a20ed3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_a6dd0bcb-f24c-4041-992f-c6aafcf52784" xlink:href="krys-20221231.xsd#krys_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:to="loc_krys_MilestoneTwoMember_a6dd0bcb-f24c-4041-992f-c6aafcf52784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_a59db918-4e8d-42a9-9905-42cc5f4b6710" xlink:href="krys-20221231.xsd#krys_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:to="loc_krys_MilestoneOneMember_a59db918-4e8d-42a9-9905-42cc5f4b6710" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="if9b178324fbd48c6bc434d9013c14967_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_553223f2-05d8-457f-8818-4e915fda6cc8" xlink:href="krys-20221231.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_553223f2-05d8-457f-8818-4e915fda6cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_c3070f05-0303-4f59-ad32-ee66717a924f" xlink:href="krys-20221231.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_c3070f05-0303-4f59-ad32-ee66717a924f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_40d7edc4-0d14-4593-94be-fc98fb2dfde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_ConstructionInProgressGross_40d7edc4-0d14-4593-94be-fc98fb2dfde5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_19d74851-20af-4aca-96b4-3f3f8e8b7292" xlink:href="krys-20221231.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_19d74851-20af-4aca-96b4-3f3f8e8b7292" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_c65eb526-359c-4e6b-90e5-d43b841b622b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_EscrowDeposit_c65eb526-359c-4e6b-90e5-d43b841b622b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbb37179-d4fe-4a3a-84ea-1c85bdd904a1" xlink:href="krys-20221231.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbb37179-d4fe-4a3a-84ea-1c85bdd904a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_65b31db6-b5ad-4b11-b440-425f63218eac" xlink:href="krys-20221231.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_CumulativeEscalationClausePercent_65b31db6-b5ad-4b11-b440-425f63218eac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_ed90fb7c-ff57-4171-9aa2-278866e7f5c0" xlink:href="krys-20221231.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_CumulativeEscalationClauseTerm_ed90fb7c-ff57-4171-9aa2-278866e7f5c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c7f64376-0034-4e40-bf04-190d6bbd576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c7f64376-0034-4e40-bf04-190d6bbd576b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27dc3834-332d-423e-8977-8f2505771c5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27dc3834-332d-423e-8977-8f2505771c5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_db74a133-7a85-4d39-9cb1-30a5837b8965" xlink:href="krys-20221231.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_db74a133-7a85-4d39-9cb1-30a5837b8965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShortTermAmendmentMember_68b33e5b-40fc-4129-bb49-ca9449e9eaaf" xlink:href="krys-20221231.xsd#krys_ShortTermAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_ShortTermAmendmentMember_68b33e5b-40fc-4129-bb49-ca9449e9eaaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember_7f49ba10-24ea-4e70-b551-d8cf6fe5ad26" xlink:href="krys-20221231.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_BostonMassachusettsLeaseMember_7f49ba10-24ea-4e70-b551-d8cf6fe5ad26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember_3cc757be-a864-4a13-af19-4e58b94a985c" xlink:href="krys-20221231.xsd#krys_SwitzerlandLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_SwitzerlandLeaseMember_3cc757be-a864-4a13-af19-4e58b94a985c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended" id="i863ef8d966394a20a9581813599d3147_CapitalizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f4c9e69c-4167-4345-ad73-1611632df36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f4c9e69c-4167-4345-ad73-1611632df36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cf36536c-d25a-40ba-b9e7-1ef1e818d832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cf36536c-d25a-40ba-b9e7-1ef1e818d832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0881f865-2663-4587-b805-2a564d80c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0881f865-2663-4587-b805-2a564d80c12c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_8327ea72-8c31-4948-9ab6-962276f4f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_8327ea72-8c31-4948-9ab6-962276f4f27a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ecf57ecf-a667-4033-bab9-68b72b409f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ecf57ecf-a667-4033-bab9-68b72b409f41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_277a6e76-4f9c-4ad0-85f1-089b28c2e648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_277a6e76-4f9c-4ad0-85f1-089b28c2e648" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0bab58a0-2726-4680-bfcc-edfae4ad5a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0bab58a0-2726-4680-bfcc-edfae4ad5a7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_99fd6158-794b-407c-8820-a2396662c0a2" xlink:href="krys-20221231.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_99fd6158-794b-407c-8820-a2396662c0a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_22d6928e-b101-4e82-8357-f7e1cdd177d1" xlink:href="krys-20221231.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_22d6928e-b101-4e82-8357-f7e1cdd177d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4df35edc-374c-4f29-a729-03918e066885_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4df35edc-374c-4f29-a729-03918e066885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_552853b6-6c09-4235-835c-16e9561cd008" xlink:href="krys-20221231.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_krys_PublicOfferingMember_552853b6-6c09-4235-835c-16e9561cd008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3d9dd383-cf31-47c1-8a0f-271132a300e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3d9dd383-cf31-47c1-8a0f-271132a300e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_2c2d8bc9-06bc-40a5-8171-19766ebf7953" xlink:href="krys-20221231.xsd#krys_PlacementSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_krys_PlacementSharesMember_2c2d8bc9-06bc-40a5-8171-19766ebf7953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_fdbfd09b-c7d3-4025-adfb-2b608ea4ecde" xlink:href="krys-20221231.xsd#krys_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_krys_ATMProgramMember_fdbfd09b-c7d3-4025-adfb-2b608ea4ecde" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i4d08fce540134f29a0f2eb2ad4b4a45f_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94901cb0-682f-427f-97ff-1c4976a9e029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94901cb0-682f-427f-97ff-1c4976a9e029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_0a47b4a9-d9bf-499b-ac35-69d0ddfce4a2" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_0a47b4a9-d9bf-499b-ac35-69d0ddfce4a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7b6a0bb-0390-4d98-af6f-8980d2665afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7b6a0bb-0390-4d98-af6f-8980d2665afe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8328d81a-3c7a-420e-8c06-d3726eaea5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8328d81a-3c7a-420e-8c06-d3726eaea5b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4b33960d-79a3-4456-afb7-b90316f637a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4b33960d-79a3-4456-afb7-b90316f637a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b2381774-4778-4392-8ca2-00bec4f61059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b2381774-4778-4392-8ca2-00bec4f61059" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d88ae257-d586-4900-bd28-2feac77ee086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d88ae257-d586-4900-bd28-2feac77ee086" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63263538-546c-4398-bc3d-f9293a5f8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63263538-546c-4398-bc3d-f9293a5f8f98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99707a6e-5333-4c7f-990d-09478c956719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99707a6e-5333-4c7f-990d-09478c956719" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b8598999-1eab-496f-b3a9-c486d8b0f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b8598999-1eab-496f-b3a9-c486d8b0f5e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de5196b6-fe3d-4751-aae8-c7853d561af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de5196b6-fe3d-4751-aae8-c7853d561af4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_668b3ba0-81ef-418d-b9bf-b2f550a2cce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_668b3ba0-81ef-418d-b9bf-b2f550a2cce7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138841c8-1607-4cf7-8a70-09f804e4b7b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138841c8-1607-4cf7-8a70-09f804e4b7b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_075c63d8-d2ce-478f-a566-1fd5001b5b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_us-gaap_EmployeeStockOptionMember_075c63d8-d2ce-478f-a566-1fd5001b5b27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_7c8a9049-f7f8-40d8-a2f4-31119a9e39f9" xlink:href="krys-20221231.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_krys_NonEmployeeStockOptionMember_7c8a9049-f7f8-40d8-a2f4-31119a9e39f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_97f046cc-e9db-4ac8-94a9-54e35d99c3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_us-gaap_RestrictedStockMember_97f046cc-e9db-4ac8-94a9-54e35d99c3a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_8175d388-0d69-4414-b5df-f38e37244c63" xlink:href="krys-20221231.xsd#krys_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_krys_IncentiveStockOptionsMember_8175d388-0d69-4414-b5df-f38e37244c63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:to="loc_srt_RangeMember_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:to="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fe32c56e-ce15-4bb8-a3ad-39d77f1b3ed6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:to="loc_srt_MinimumMember_fe32c56e-ce15-4bb8-a3ad-39d77f1b3ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aeaca4a8-a385-45ee-96b8-2f4a11b81977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:to="loc_srt_MaximumMember_aeaca4a8-a385-45ee-96b8-2f4a11b81977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cfb89424-f30f-42b6-801a-3cdb51a7705c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cfb89424-f30f-42b6-801a-3cdb51a7705c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96023f8f-ad1a-4376-9d79-7f2d656032f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96023f8f-ad1a-4376-9d79-7f2d656032f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_074092a0-b775-41b2-8358-015912c7a168" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96023f8f-ad1a-4376-9d79-7f2d656032f3" xlink:to="loc_srt_DirectorMember_074092a0-b775-41b2-8358-015912c7a168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e39c630b-fc93-433c-adb3-713093d4c248_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:to="loc_us-gaap_PlanNameDomain_e39c630b-fc93-433c-adb3-713093d4c248_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:to="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_6e3eef14-80e1-42f1-9683-5191d99f564f" xlink:href="krys-20221231.xsd#krys_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:to="loc_krys_StockIncentivePlanMember_6e3eef14-80e1-42f1-9683-5191d99f564f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_A2017IPOStockPlanMember_311cc259-5705-4f14-b3ec-1f82f89b0120" xlink:href="krys-20221231.xsd#krys_A2017IPOStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:to="loc_krys_A2017IPOStockPlanMember_311cc259-5705-4f14-b3ec-1f82f89b0120" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail" xlink:type="extended" id="i1334ff03596f4ef7a0433b7385766822_StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6214e61-3b04-4e5e-96a1-724fcfdda99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_af0f3d8e-e097-4861-805d-81a2f6279fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6214e61-3b04-4e5e-96a1-724fcfdda99f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_af0f3d8e-e097-4861-805d-81a2f6279fd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6214e61-3b04-4e5e-96a1-724fcfdda99f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923825d6-52f3-4fea-96dd-84adcf454207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923825d6-52f3-4fea-96dd-84adcf454207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_070042fc-a6bc-46cf-89f0-7d6b786de03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_070042fc-a6bc-46cf-89f0-7d6b786de03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:to="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72b08b3-c539-436a-9f02-4edcf7ba6780_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72b08b3-c539-436a-9f02-4edcf7ba6780_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_353bd532-5efc-46d9-9b17-d0475f04cfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_353bd532-5efc-46d9-9b17-d0475f04cfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f68273db-70cd-480e-821b-18ee85c230e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_353bd532-5efc-46d9-9b17-d0475f04cfd9" xlink:to="loc_us-gaap_RestrictedStockMember_f68273db-70cd-480e-821b-18ee85c230e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended" id="ib5a7cb8b3ece4c21a865e888a7022702_StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82ec5ccd-a397-4f00-b375-8af69be431b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82ec5ccd-a397-4f00-b375-8af69be431b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f0690d-dc7d-405b-a0c2-2be12f11ed14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f0690d-dc7d-405b-a0c2-2be12f11ed14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8fa27e38-f5a7-4e9d-aacb-58bcbcd1c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8fa27e38-f5a7-4e9d-aacb-58bcbcd1c4e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_ae1872d5-a406-4d44-88e0-9ef649c2908f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_ae1872d5-a406-4d44-88e0-9ef649c2908f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_62b042ec-435a-4af5-94b3-1cc1468af18d" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_62b042ec-435a-4af5-94b3-1cc1468af18d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef6e9d5-8c53-4ae9-93d3-9841f488e153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef6e9d5-8c53-4ae9-93d3-9841f488e153" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:to="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e71f2a0d-de45-49cb-acfc-83bb8cc8984b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e71f2a0d-de45-49cb-acfc-83bb8cc8984b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8563e98-be97-4be8-b2b8-b52b2f3cf40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8563e98-be97-4be8-b2b8-b52b2f3cf40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0a3defd3-06bc-4f2e-bcda-8fdfe62b94ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8563e98-be97-4be8-b2b8-b52b2f3cf40c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0a3defd3-06bc-4f2e-bcda-8fdfe62b94ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended" id="i1542be926c5f4ff696bd8a5971e52e87_StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c4cb791-b888-4b5b-8362-e24188d4a903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c4cb791-b888-4b5b-8362-e24188d4a903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ea564d34-b452-44d7-8f90-d421b4c4d52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ea564d34-b452-44d7-8f90-d421b4c4d52e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_282d1fcc-ae33-466c-8a94-532fcd33162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_282d1fcc-ae33-466c-8a94-532fcd33162d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_4e13b33f-6784-4bb6-bc30-8ece564d2de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_4e13b33f-6784-4bb6-bc30-8ece564d2de1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1355cbaa-d03d-476f-9fb9-72291bd3f62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da18c1e7-f34d-4455-84a6-f61d68d62d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da18c1e7-f34d-4455-84a6-f61d68d62d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995f94d2-a91d-4de0-b18b-11399588a9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995f94d2-a91d-4de0-b18b-11399588a9da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_153a1249-f502-4b7c-bb6e-d8f53ce02ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_153a1249-f502-4b7c-bb6e-d8f53ce02ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_43acb950-bf39-40d7-851e-40f38e116c28" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_43acb950-bf39-40d7-851e-40f38e116c28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4765623-1a0d-44a5-94e9-5b3779bb006b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:to="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_851a35b8-2d2a-4812-bb5f-34e4986c472b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_851a35b8-2d2a-4812-bb5f-34e4986c472b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ff876b1-bb01-4c8d-8bd2-6a2239d4fee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ff876b1-bb01-4c8d-8bd2-6a2239d4fee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_294d9ddf-0662-4e41-92b6-c7b2d49829e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ff876b1-bb01-4c8d-8bd2-6a2239d4fee7" xlink:to="loc_us-gaap_RestrictedStockMember_294d9ddf-0662-4e41-92b6-c7b2d49829e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="icb96c68d6f5c4fe08db3a022e95dd366_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:href="krys-20221231.xsd#krys_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a5298a2-eb6b-4004-92ca-e16d7e660d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a5298a2-eb6b-4004-92ca-e16d7e660d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_296fe2c2-1171-44b8-8c37-1b603d418fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_296fe2c2-1171-44b8-8c37-1b603d418fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a30e9f35-6c5c-469b-9fe1-1d629d9a4c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a30e9f35-6c5c-469b-9fe1-1d629d9a4c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c76a553-28d6-4465-a11f-edce1660b74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c76a553-28d6-4465-a11f-edce1660b74d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_062b7e2b-795f-4eb4-9fb9-f168b34d7a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_062b7e2b-795f-4eb4-9fb9-f168b34d7a1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9636ba10-73f3-445a-b5bc-9f0bec6e784e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9636ba10-73f3-445a-b5bc-9f0bec6e784e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OwnershipInterestRateChangeOverPeriod_e750dca4-2597-458e-884d-d4da4365fd90" xlink:href="krys-20221231.xsd#krys_OwnershipInterestRateChangeOverPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_krys_OwnershipInterestRateChangeOverPeriod_e750dca4-2597-458e-884d-d4da4365fd90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeChangesInOwnershipInterestOfShareholders_eef93d55-f517-4b70-9db3-c128014f88c9" xlink:href="krys-20221231.xsd#krys_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_krys_CumulativeChangesInOwnershipInterestOfShareholders_eef93d55-f517-4b70-9db3-c128014f88c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:href="krys-20221231.xsd#krys_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_798d6526-3f9a-4bcf-b67d-7e4470e516ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:to="loc_us-gaap_DomesticCountryMember_798d6526-3f9a-4bcf-b67d-7e4470e516ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3b8893ac-a692-4386-828f-d1630ecf0a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3b8893ac-a692-4386-828f-d1630ecf0a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:to="loc_srt_RangeMember_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_59d64385-5a3b-40c2-8251-bb812239d131" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:to="loc_srt_RangeMember_59d64385-5a3b-40c2-8251-bb812239d131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3fb538c0-0ad8-48b6-aa0f-f88dd70ccc33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_59d64385-5a3b-40c2-8251-bb812239d131" xlink:to="loc_srt_MinimumMember_3fb538c0-0ad8-48b6-aa0f-f88dd70ccc33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3bae0d58-a34e-4037-b948-3ccb6f31a83a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3bae0d58-a34e-4037-b948-3ccb6f31a83a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_f82825d1-cccf-4629-9692-1bbba30119b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:to="loc_us-gaap_ResearchMember_f82825d1-cccf-4629-9692-1bbba30119b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OrphanDrugTaxCreditCarryforwardMember_60f31ae4-fc16-43ec-8502-858bd76ef061" xlink:href="krys-20221231.xsd#krys_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:to="loc_krys_OrphanDrugTaxCreditCarryforwardMember_60f31ae4-fc16-43ec-8502-858bd76ef061" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>krys-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bf7ccaf-2752-4fdb-93c0-341f465affc3,g:6dace288-7a26-4def-b28c-90440b1ff335-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4165a7c-cc96-41bf-8c71-e001c7f725a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ATMProgramMember_ed293600-841a-4227-b97f-061096c792b4_terseLabel_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_krys_ATMProgramMember_label_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_krys_ATMProgramMember_documentation_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember" xlink:href="krys-20221231.xsd#krys_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ATMProgramMember" xlink:to="lab_krys_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d4decedf-fec5-4779-9c43-5f540d7cc058_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2bfdfef3-efb5-43fd-b6a7-c41c583c20d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8f0d9bd8-8a29-4b38-bf4f-861b57dd86f7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_b91d8c2c-48d2-4908-a50f-c645f3d04068_terseLabel_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreements</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember" xlink:href="krys-20221231.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ClinicalSupplyAgreementMember" xlink:to="lab_krys_ClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_cc4e4dc6-058c-4663-8b8e-436c52fa697a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c0eb344e-1a5c-4ac6-ac98-6582190bedb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_72287f12-a6d2-43f5-8a48-48e9b2ea7465_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f81987f3-59fb-4e1a-868d-0e12b4e20557_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_e95125ca-1274-43c8-a2d5-b0e0510c7dfb_terseLabel_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="krys-20221231.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SwitzerlandLeaseMember_87ffbcd3-48e3-4fcc-b2a1-ac515c430afb_terseLabel_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease</link:label>
    <link:label id="lab_krys_SwitzerlandLeaseMember_label_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease [Member]</link:label>
    <link:label id="lab_krys_SwitzerlandLeaseMember_documentation_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember" xlink:href="krys-20221231.xsd#krys_SwitzerlandLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SwitzerlandLeaseMember" xlink:to="lab_krys_SwitzerlandLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c606ac84-dd10-4876-af85-5b8512a46396_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_58b3492d-85b2-49e1-b336-a542b04b57ad_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a456483a-5cf2-4541-86c2-d751a7e8a4d3_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb868437-e5b3-42a2-8666-2ab817c61561_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b467ece9-0ab8-4f0f-87f6-100e2a33d9c7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e3b0c04-3d5c-4217-9ac0-cecca2365757_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_e89eb530-d89f-4790-a910-c039b8568055_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_5a1085eb-1165-4626-b255-d28e1b0c8e4b_terseLabel_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_label_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll And Benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_documentation_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits" xlink:href="krys-20221231.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPayrollAndBenefits" xlink:to="lab_krys_AccruedPayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_052798fe-bdca-4b60-87a8-0a5ca6d96f53_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5c32c912-2b8d-4daf-83d1-066a6ff79aa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_4ca90665-152a-4722-a6c2-804bf60cf9cf_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_05ab4810-281a-4765-b14f-8e884f936fbc_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:href="krys-20221231.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:to="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncomeTaxesLineItems_f5d55098-27c7-41f3-9d7c-d38ba4cc038a_terseLabel_en-US" xlink:label="lab_krys_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_krys_IncomeTaxesLineItems_label_en-US" xlink:label="lab_krys_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_krys_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_krys_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncomeTaxesLineItems" xlink:href="krys-20221231.xsd#krys_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncomeTaxesLineItems" xlink:to="lab_krys_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b190383f-7e56-400d-bf33-75b9facdc5ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_deea306a-6e80-4c9b-9bd5-8d38cfff6d4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c8c2bf09-219c-48f0-8faa-75a04d93825b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_52dfb0de-357a-4ff6-82e8-f4e769b3396c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6260431b-7145-4676-a7e1-ab0ba50685c8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_de1492a3-473c-4714-9302-1ebe3c7eed08_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common stockholders</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_720cb6cb-a4ce-48bb-bc24-f93f453d1d91_terseLabel_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease</link:label>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_label_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease [Member]</link:label>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_documentation_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember" xlink:href="krys-20221231.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BostonMassachusettsLeaseMember" xlink:to="lab_krys_BostonMassachusettsLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_535e48fc-a8bd-4bc9-8fc5-0389bae5539d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_16dd3d61-d418-4031-9bf5-101ffb549cf2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_70ec2cfc-eeba-46e3-ba50-13b8a1842bcd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_99521936-ef03-4b8e-820e-9430f469070a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_24374458-66e5-4463-b273-6f0114a1a025_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0535f6-18c2-4b3a-8e5d-0e2f5406a9ff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_b7749c59-1b60-4a2a-87a4-21d0e234fd6a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_c48f8cd4-bcc3-422e-beb6-e889b3490018_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders_5dfd6895-60c1-44a0-8857-5dd0aec2be32_terseLabel_en-US" xlink:label="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative changes in ownership interest of shareholders</link:label>
    <link:label id="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders_label_en-US" xlink:label="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Changes In Ownership Interest Of Shareholders</link:label>
    <link:label id="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders_documentation_en-US" xlink:label="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative changes in ownership interest of shareholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeChangesInOwnershipInterestOfShareholders" xlink:href="krys-20221231.xsd#krys_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeChangesInOwnershipInterestOfShareholders" xlink:to="lab_krys_CumulativeChangesInOwnershipInterestOfShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e3707fcf-14c8-4fee-ba40-46297adaafa8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_447c20d5-ec53-4056-84ae-61248f35e03f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_903e13e3-50b3-4a7b-9db7-c9fb18b253f6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a9f3f4bd-1edb-4907-8a92-f3faa6adb6fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_9f8e85da-2e8f-4456-992b-d90cfd9e78eb_terseLabel_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash contribution</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_label_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Escrow For Reducing Lease Rentals</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_documentation_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to escrow for reducing lease rentals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:href="krys-20221231.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:to="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OrphanDrugTaxCreditCarryforwardMember_ca0d0fca-0e75-4ab2-a908-a4ceaa2ac044_terseLabel_en-US" xlink:label="lab_krys_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Tax Credit Carryforward</link:label>
    <link:label id="lab_krys_OrphanDrugTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_krys_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_krys_OrphanDrugTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_krys_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Tax Credit Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OrphanDrugTaxCreditCarryforwardMember" xlink:href="krys-20221231.xsd#krys_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OrphanDrugTaxCreditCarryforwardMember" xlink:to="lab_krys_OrphanDrugTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7e835e1f-40c0-4dc7-8fee-3eaf5a2e78eb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_904e2605-8d20-44fa-aa2b-55ff93bca655_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f23c992b-f722-47a5-9bef-84aa87fd542b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9690306c-674a-4601-97ba-ecd14acb122f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_3e1e389f-858d-480a-bb09-11ea5924637a_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:href="krys-20221231.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:to="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_48d85ef5-d098-4821-b497-766cd852b524_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b7dffd2e-cbbe-407b-89bf-ba425c428f9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_378e66a1-02a2-47e2-b3ee-433be2c250c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8389014f-850f-449e-88b5-5bdaad10a845_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_45bd7065-f06f-4415-b4ca-379642fec6f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aed6043f-bc77-463b-96f7-2228c4562831_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_StockIncentivePlanMember_fdecb402-e229-4513-9c10-d1da459abe6a_terseLabel_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_label_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember" xlink:href="krys-20221231.xsd#krys_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockIncentivePlanMember" xlink:to="lab_krys_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_999a1096-cfab-4df5-8c61-bee4b2cf4454_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4811e7a-1be2-44e4-8d3f-48a7b83323b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AuditorInformationAbstract_label_en-US" xlink:label="lab_krys_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_krys_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_krys_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AuditorInformationAbstract" xlink:href="krys-20221231.xsd#krys_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AuditorInformationAbstract" xlink:to="lab_krys_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d3ffc53f-670f-4763-b75a-235278d699f2_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_d5729d11-7d93-4006-b7d8-da1e1c4168d8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9129c0a9-e96d-470d-a75b-9046cee2779b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e8ddb547-c811-4092-95bd-14f36b3e3614_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f72a5995-c12b-4399-962e-e2a233882a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ac2bb619-b0c9-4307-9b46-b78b7d861206_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c2f6877e-df4f-4327-ab7b-755f4f5555a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f2681be0-7ffe-4bc9-8644-88b56480dcd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_c217e724-9557-4dba-91f8-fc9d28ce8fd6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6f260b12-d3a7-4c69-a6f1-e5c4c7474eda_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0c3cebe-423f-4c88-8903-6237a3872e46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OwnershipInterestRateChangeOverPeriod_6d3ea86e-d868-451d-b038-5908a6e6be46_terseLabel_en-US" xlink:label="lab_krys_OwnershipInterestRateChangeOverPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative changes in ownership interest rate period</link:label>
    <link:label id="lab_krys_OwnershipInterestRateChangeOverPeriod_label_en-US" xlink:label="lab_krys_OwnershipInterestRateChangeOverPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Interest Rate Change Over Period</link:label>
    <link:label id="lab_krys_OwnershipInterestRateChangeOverPeriod_documentation_en-US" xlink:label="lab_krys_OwnershipInterestRateChangeOverPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest rate change over period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OwnershipInterestRateChangeOverPeriod" xlink:href="krys-20221231.xsd#krys_OwnershipInterestRateChangeOverPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OwnershipInterestRateChangeOverPeriod" xlink:to="lab_krys_OwnershipInterestRateChangeOverPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_027262f3-34d3-4da2-b3d8-aa38f01b8259_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_42e6066b-c1ab-49e1-afca-bfd73054dcba_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_75cc3920-ba77-4ec1-9836-b66d42ec06a0_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5847156c-1998-44a4-9ade-b78f5ba5ea03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c08914e9-b67c-4325-83cb-501531bb4c9e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fd26d42c-5c95-43db-80f3-5e11a2f36296_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c303b276-f238-467d-a1bb-2aa4fca9323d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2220a6f2-896a-43b4-b931-4808f90eeaf0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e2b69d77-da99-47d4-8530-e03f63af1b4c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d021715d-6b9c-4911-a3b5-b34d673baa1f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1b5b15dc-2e79-497e-848c-e21030823fc1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_21916c5d-ba14-4b92-84e1-a200d7c074fe_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_60631b20-1f7a-47b8-a536-fd9e1cbff583_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6539bc7f-7ce2-417e-b7fc-4a704eb2cb51_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f101fc01-f5b7-491b-84e7-78cdfc1d2b47_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_7e950530-4007-47ae-aa4b-dd3a3c910dee_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause, percent</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_label_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent" xlink:href="krys-20221231.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClausePercent" xlink:to="lab_krys_CumulativeEscalationClausePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3eb6b3d2-23ce-4309-925e-7332762a47f6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_39aebadf-8156-4419-9e17-5d248ffdb0ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital, stock issued, issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_589e25c8-e2d6-495f-9e92-8cacae68d56b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_2ced7b2f-c84c-4cb3-9972-cd540c4e7c6a_terseLabel_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, guaranteed maximum price to be paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_label_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_documentation_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:href="krys-20221231.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:to="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ebab5da2-91ac-493b-8241-c1c783ac9fb0_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_11b2ed47-7cad-4129-85a4-dcf996957b6b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ccd6ccd8-c38e-48c8-9ebf-7bae456af4c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f92dc03b-55db-475a-a5ab-9849baa52687_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_e758e951-12af-4436-b101-e8370f80b736_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9105bf8-20af-40a7-9591-0d130783506c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0f22a5b7-e1bb-4291-8289-fbb087053d02_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b259037-7b20-4dad-b0da-e195498e152d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6e4b3887-222b-40f7-831e-e36b64111374_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_5737d805-e704-4079-859f-f59e0e7b33b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShortTermAmendmentMember_b591844a-007f-48a4-a26c-a336d7243880_terseLabel_en-US" xlink:label="lab_krys_ShortTermAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Amendment</link:label>
    <link:label id="lab_krys_ShortTermAmendmentMember_label_en-US" xlink:label="lab_krys_ShortTermAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Amendment [Member]</link:label>
    <link:label id="lab_krys_ShortTermAmendmentMember_documentation_en-US" xlink:label="lab_krys_ShortTermAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShortTermAmendmentMember" xlink:href="krys-20221231.xsd#krys_ShortTermAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShortTermAmendmentMember" xlink:to="lab_krys_ShortTermAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_6343abdc-1994-4af9-9d1b-4df3af1dc29a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_654c84ce-5abf-4235-af83-d8669162bc83_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c62e597-d1f2-4e01-aa67-3fe39bfa66f6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8f6eb7a4-2518-4f58-ad1c-6f755ad36238_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b0c0970c-a1ff-491a-9964-fe55fb1d294a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_2db29262-c69c-417d-87fd-29f81a6ff566_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a9d5c09-a378-42c7-a3c4-5537e84dfa03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a7ea6aa0-98ca-4411-9ae4-6f74dd53c9e7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7d3968d3-faae-4097-a12e-4adf7405221f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual Life (years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_0353b812-1122-4748-a08f-363505699e64_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e3f6a3cc-d11f-487f-82c4-ad0a1b8f1fd6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02eb2408-8a93-41cd-afcc-a57706d95df6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3cff29ae-cc93-46f7-9455-ea14b1979466_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_41428695-4291-4533-8fd8-82d7630eed29_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3217ef28-9302-4b06-88b8-780f607ca223_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_492ea399-30d4-47aa-85c7-7a6e10822413_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in number of shares authorized</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_9477a286-5e84-433e-8ddf-25e8b125194f_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cf40051c-9df0-4b79-8f3a-48792d3c6121_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9a4c54a7-f9ef-4498-a686-2e651ce85650_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7d08721e-c026-4250-b61c-8f6d1e20d075_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative NOL carry forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1766b3e3-c69c-4887-8ab5-218ad9e47887_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4ad9add0-14ea-437a-8fd2-f854a10e4007_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_df603cbf-f786-4a5a-9e6a-c04b3e537806_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_46c1e79e-b807-4b4d-b40b-722e2a9e73b0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6e7c0b5e-a1af-4336-987d-5d408c823c93_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_66c42950-3b49-469b-95ae-56c5627eaafc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b16cd51-817f-47d2-aadc-7eda0cecf9b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_9f0d1fe9-3b8b-4800-92cb-9c7a7f104456_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_736be2fd-6db0-4be2-9a49-7a6dd6141537_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e9a79e2c-9ce4-4971-961b-6106de336dce_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ace8bf0a-9a1f-402a-b001-2abfdb0025b6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_b25abb0f-d8a0-445d-9726-6b04f0c5d92a_totalLabel_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="krys-20221231.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3c19fbc2-85df-48c3-a4b4-a673b9169d96_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesAxis_34df718b-f6ee-4724-b99d-4e922ba69da7_terseLabel_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_label_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_documentation_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis" xlink:href="krys-20221231.xsd#krys_MilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesAxis" xlink:to="lab_krys_MilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_390e2915-1d8a-414d-a395-d11e02488aa1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_40b8326e-29a1-48c6-82eb-f0ce8ec52ed0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_8676e861-5282-43eb-b214-e33e9ae2c33e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29bb1a0a-c074-41c4-9615-79c6bc09924f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bfc7f7dc-b50d-4b85-a199-41f18f485509_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CostOfWorkPercentage_9875d69c-2847-48e6-af3d-9d90ca1469a8_terseLabel_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of work, percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_label_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_documentation_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage" xlink:href="krys-20221231.xsd#krys_CostOfWorkPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CostOfWorkPercentage" xlink:to="lab_krys_CostOfWorkPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b7b0b8a8-837c-4625-8a27-88a5b8c1153a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_78c3262c-c7b2-4981-8754-11d3edc9a5cc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_10cf9638-68ef-4509-b68f-bc47f23a3cc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d3696152-714c-4b0e-90d8-667451dbebcf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_eea49b2a-6585-425b-816b-c6de128edfd1_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, milestone payments, sales threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_label_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_documentation_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:href="krys-20221231.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:to="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneOneMember_5d891a80-9754-4cca-8753-77cfc07a56d2_terseLabel_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_krys_MilestoneOneMember_label_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_krys_MilestoneOneMember_documentation_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember" xlink:href="krys-20221231.xsd#krys_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneOneMember" xlink:to="lab_krys_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2395339d-bb9d-4619-a660-cceb37bb3276_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7a1a1c9a-7060-4d60-94df-53e8d6263bc2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_508010b2-d436-4aa0-8508-99003fa55c0d_terseLabel_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_label_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense And Other Nonoperating Net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_documentation_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense) and other nonoperating, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:href="krys-20221231.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:to="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_5310cc93-4d13-4fa4-bbff-8fb99f9d3623_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c007c1c9-7243-41a6-94df-5050f693f7e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_558d3087-fde6-4b7e-a3a0-0fed966cc4a2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress, gross</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f62a784d-950b-49a5-917c-996050a48f24_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d99b6fc1-7860-4c8c-a4c9-392b6f63bba5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2eebe1fb-d616-4301-841b-c3466dee97ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_bdd07227-b841-40ba-a166-74f9e5f30677_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_009d55e5-410e-40e1-936c-7453476123a1_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_7555f206-18d6-4028-b723-a2f9f897dce6_terseLabel_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_label_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_documentation_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:href="krys-20221231.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:to="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_00805cd8-d08c-4315-a328-dedb160bba88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d7cce378-e121-4b15-820b-af3167f80147_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_895b2625-5ad7-4f18-9c94-9cc64db5bcfb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_58e1f7f4-f5db-4c3f-920a-4f722ca4f17f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_567f5983-0e2f-497b-b553-e7966f78d756_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PlacementSharesMember_d643e66c-6a8a-4ec1-b4aa-e1ba18c1228e_terseLabel_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:label id="lab_krys_PlacementSharesMember_label_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:label id="lab_krys_PlacementSharesMember_documentation_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember" xlink:href="krys-20221231.xsd#krys_PlacementSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PlacementSharesMember" xlink:to="lab_krys_PlacementSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d8e65e31-c2da-4483-ada6-8a5e5b795ddf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_969291ca-977f-464e-8c92-e6cc7c2c381a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_ecdce43a-4aed-4a2a-ba95-7ab13a1a9864_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d5052ab0-0547-47b7-a179-c3244a6f663a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_2e0c40fd-9ac8-4262-a1e0-976d43149293_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e6d7cc0d-3b5e-4247-8a74-40e5215a6a39_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3564f234-88be-4490-9c9f-c4720fbd36c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_ca6876be-900e-4c43-90e6-40d9654c2ab7_terseLabel_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_label_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area Of Real Estate Property Leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_documentation_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:href="krys-20221231.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:to="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_67988213-224f-4539-80bd-419d90ddb5d9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4bcd538d-f3bf-4e19-a0d5-70dfca12d72e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_8775dd75-c24e-4743-bedf-40f1df961911_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b2b46e43-9440-4074-b7ea-a5f47f0b111b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_33e2a1f7-0e6b-49ea-93f5-52501a298b6b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_10397777-46fc-4c08-9ef8-138e0d39c3e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7e401f30-045f-40bd-8270-ba9265bd4a5f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7cec542e-ffd8-4941-a335-b373603d4fc9_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f451b921-7fcc-4e36-8d4d-f2443007c92d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_faaf47ac-06b4-4988-9b1d-841820b4bc45_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties amounts recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ee9741d8-e629-451e-b4e1-ba6d38cc8590_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_A2017IPOStockPlanMember_f394b7ff-739d-4d52-a4e3-e9399c698ac4_terseLabel_en-US" xlink:label="lab_krys_A2017IPOStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 IPO Stock Plan</link:label>
    <link:label id="lab_krys_A2017IPOStockPlanMember_label_en-US" xlink:label="lab_krys_A2017IPOStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 IPO Stock Plan [Member]</link:label>
    <link:label id="lab_krys_A2017IPOStockPlanMember_documentation_en-US" xlink:label="lab_krys_A2017IPOStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 IPO Stock Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_A2017IPOStockPlanMember" xlink:href="krys-20221231.xsd#krys_A2017IPOStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_A2017IPOStockPlanMember" xlink:to="lab_krys_A2017IPOStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7cca3ab9-9e47-4b0e-8f93-da65d25c7379_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2922ab20-c367-4e36-bb4f-eb8d35d9c05e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_137002d1-f3ec-4056-b894-fe909a58d0fd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_f0b70359-f3d4-407f-bc32-dd35faab1a9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cdd78897-cf56-4a17-97cb-eeb1d03e379c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_212c64cf-bded-451e-9d54-e6605d796568_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9e9a86fb-aa17-42b6-ae68-209c2e7829e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OtherContractualObligationsMember_252b8d97-85df-4462-9cd2-5651f076b0f6_terseLabel_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_label_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations [Member]</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_documentation_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember" xlink:href="krys-20221231.xsd#krys_OtherContractualObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OtherContractualObligationsMember" xlink:to="lab_krys_OtherContractualObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b161b1d0-ffc9-4a63-b889-cb5540615dd5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_46526584-2458-4527-8b63-3af97d317acf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_849043f9-6470-4d01-8fe4-e7b88194d901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5743511b-1b70-4946-9813-6f5c9e6abdd5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2ce721d8-aa84-4aa0-af83-8d2058b1ad3f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneTwoMember_2c8423e7-4ae6-43cf-a1a8-d0a820dce1d1_terseLabel_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_label_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_documentation_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember" xlink:href="krys-20221231.xsd#krys_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneTwoMember" xlink:to="lab_krys_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_185228dc-a2fc-4c6c-a787-5d45a73f224b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f45179c6-e8ac-49d0-aec2-b3536dd7d5dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_232a5992-3e89-4c02-a3a8-311b75b1d88d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f2ad7015-7d95-4878-8360-3c3cfc587c5c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce3ffee6-a330-4261-92ca-c2d0d2f7a9c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_39178b73-b79a-421b-b63c-c6ab08d4e6d9_terseLabel_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated useful lives of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="krys-20221231.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_37171d23-5860-41c7-8fc8-84e5a9167861_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_df10bc40-a5fe-415c-a3a9-60dc1093e1ed_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b4bb9470-0b4b-41c1-b125-4f8da350e932_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bd9e0215-9456-4d12-9290-81dc93f053f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bf88c14b-3135-4e56-8d43-4532500e575a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_121826cf-802a-4f8a-b440-553e416720a4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_bbe94b22-3e78-4ab2-9664-67c32f811393_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax_eddc6ff2-8ccb-4fff-96bd-2360b7067dc6_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain/(loss)</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_23f448ae-cf87-436e-be99-7e7f271fb356_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0233b557-1db5-4609-8706-6b4199eb4d1c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_44e7b97d-5234-4d34-96a1-774b3c801547_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_16cd2380-47a4-4ab0-8c30-64419523fba9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2272e3d4-c641-43dc-b9dc-398a541c8b6b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_75fa38f7-ab87-4478-9f22-92eecf9956a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f17a0fcc-beb9-41b1-8915-4bb8cb54c546_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ac93cd84-d971-48ce-81bb-fe7ede5b4238_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_bd114493-85c4-4018-8b7b-2cd5a91c7798_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d730928e-bbfd-4a45-9a2f-41066393a753_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ed13254-9bdc-43ab-81e4-365aeef004ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2501599f-f8a3-4c25-95fb-4333ab885d77_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_60c465c3-0a55-4f50-81aa-a0b5ae512b72_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c382c240-d789-4028-8461-6a6a022cc9bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6dee0f76-a8d6-452e-918a-4c859ce73ee9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d4f15cf2-27da-4a55-b60d-3e07b6b4ba9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d5e21f13-bcc5-41c4-8b0a-31556be29621_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7bca0e18-d547-4666-bf1b-ec6de3a9bab9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized impairment losses for long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_317c190e-9dcf-45ad-9816-01ef5e95f25c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_dbe58367-6f3b-406c-a324-a562c67a10a6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8b0f550b-cbb3-447a-a43c-67399c7ffb2b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a8ceeb1a-21d4-434b-bf55-3902221f1dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e748a309-98bc-429c-956d-26df13999d78_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BalanceSheetComponentsAbstract_34b3f45f-7adb-4ec1-a354-bbac0045fc91_terseLabel_en-US" xlink:label="lab_krys_BalanceSheetComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_krys_BalanceSheetComponentsAbstract_label_en-US" xlink:label="lab_krys_BalanceSheetComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_krys_BalanceSheetComponentsAbstract_documentation_en-US" xlink:label="lab_krys_BalanceSheetComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet components.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsAbstract" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BalanceSheetComponentsAbstract" xlink:to="lab_krys_BalanceSheetComponentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f3247ca-bc01-41e3-aa98-dff2210d6dc4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33a25d7c-12ad-4097-a9cd-32f50c40e3ab_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_fa77c9c4-36fd-4394-972d-f2af8cc6dec8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1892f3a3-883c-4649-ac24-7baeab62eb0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_f79fddfc-c00d-41fd-a052-b4f3d6b36e38_terseLabel_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual lease payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_label_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_documentation_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:href="krys-20221231.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:to="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a5deb088-ae14-4000-a873-3ede6435c3c7_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7a47e915-4b61-4b1d-a9de-27d2fa1be7a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.00001 par value; 80,000,000 shares authorized at December&#160;31, 2022 and 2021; 25,763,743 and 25,207,985 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c7aab68d-6611-423c-9494-261e071aaefd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesDomain_95ede25a-992a-4bdc-8cc8-48c21c975119_terseLabel_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_label_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_documentation_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain" xlink:href="krys-20221231.xsd#krys_MilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesDomain" xlink:to="lab_krys_MilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2cbb1fa4-2cb1-4bc4-9820-e06aeda541f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be993dfb-7de0-42b0-aa80-a45acf122312_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c209497b-6ac1-4780-8b04-59f012a3a297_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_38d8a819-76be-470d-b19d-41565674a0ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cb5977c3-3b62-49d6-829f-056ef1c90548_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_17a33b27-3a55-4dfd-a3d0-165801172f42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncomeTaxesTable_f97313e3-8fe7-40b0-80d4-90ce1f288b73_terseLabel_en-US" xlink:label="lab_krys_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_krys_IncomeTaxesTable_label_en-US" xlink:label="lab_krys_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_krys_IncomeTaxesTable_documentation_en-US" xlink:label="lab_krys_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncomeTaxesTable" xlink:href="krys-20221231.xsd#krys_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncomeTaxesTable" xlink:to="lab_krys_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4dbef639-8bdf-4c78-bf5f-b1b9e9539b06_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d3bb5171-6fcd-4dad-a3d5-fe5bcd2aeb55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_63bafa9a-0a08-489d-8ad5-7cfa5c668daf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_646bef7d-1d4f-4339-ab7e-37f2d43418cd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e694ada1-451d-4292-b055-1ca52990e21f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_88617faf-7706-4421-ac32-e83277b2ea26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_7f383651-1f24-4212-b532-8200ccad26d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project management service fee</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b574b4d1-1a47-42a6-bd3b-751e03aeb19a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_96ce650c-bc2f-4f6b-9d44-648f79cbc815_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneThreeMember_0815ff0b-a2aa-4da8-95a4-f8b4dd9baa16_terseLabel_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_label_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_documentation_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember" xlink:href="krys-20221231.xsd#krys_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneThreeMember" xlink:to="lab_krys_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c9d2033f-1c1e-45fc-be3d-48ebe2a16eea_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a7289d60-8b28-4f18-93ce-06d401565440_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a42c0b89-c8e3-447f-a42a-2a66ec7096c3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3741c242-3ba1-47b0-8f7e-7d3a50706b66_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_cf6dbb2a-2e4d-4ca8-a8a4-2d4cccd069be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_30c88087-34e1-4136-b4f2-c766cec07ade_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_c114773f-c891-4c39-8ed7-219d54c04cfc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative NOL carry forwards with no expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NumberOfMilestones_8cd2e09d-7727-4853-8df4-f1792313f825_terseLabel_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_label_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_documentation_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones" xlink:href="krys-20221231.xsd#krys_NumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NumberOfMilestones" xlink:to="lab_krys_NumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_db896e72-0706-4f6e-b0aa-8af815f4e025_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a58b8605-a152-4445-b4b5-ad794b4f6b79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b8d006bd-2560-4480-89b7-5d3ce555b965_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4c77925a-3ddc-49f8-883b-c5660be458f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3e4ff401-a6ec-44f3-8238-73598660444e_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered or forfeited (in dollars per share)</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_253cb649-f24a-4abb-8995-0dd8543313c6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6021a5b8-5043-4fe0-a9d5-be53a7be1518_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ASTRAFacilityMember_0b55dbdc-f0ce-4ca1-948e-b0d082c0428c_terseLabel_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_label_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility [Member]</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_documentation_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember" xlink:href="krys-20221231.xsd#krys_ASTRAFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ASTRAFacilityMember" xlink:to="lab_krys_ASTRAFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_40dbc97f-39b6-4635-badd-50f1c3e9f6f9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_02d1b788-e2fc-4b62-be27-b1cf30fe2b74_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4dccc1d6-38c2-4233-b928-85deb33cc154_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c005ad73-f2f4-429d-abd5-720b1346e3a6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_61329942-2d15-4b25-a2cc-273973496604_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_63cbac1c-44b0-45db-9a56-f1bddd6d78f7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2a1bf680-66f9-4b8b-bad8-d2878033dcef_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_607896bd-6d3c-4e7e-9cdc-0433458680bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_dd1ef15e-31ef-44c7-9c4e-4ffd10afc2e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_89fb31f9-84e9-486f-9582-bde03e2d9b4e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_629e35f1-4fed-47c9-abc5-7f1732ea0779_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_bced8094-231b-45a1-be4b-d0ba8081ade8_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining available issuance amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_label_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_documentation_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:href="krys-20221231.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:to="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6ae01647-28d7-4474-a3f6-0c06b9f95a94_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_e80c824b-5d89-473c-a763-cab6536be0ac_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0c01a8c2-94d2-4b44-8f14-61acce10cfd9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_217ccb39-bcbe-4a46-8489-7c570f0c0bdf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_dfacd221-c675-4ff8-845f-489b85a69bf7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7e256b3e-9ac0-4a90-ae42-a7ce2afa6feb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BalanceSheetComponentsDisclosureTextBlock_6209c6a5-3c22-4edc-b05c-985e69980cc0_terseLabel_en-US" xlink:label="lab_krys_BalanceSheetComponentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_krys_BalanceSheetComponentsDisclosureTextBlock_label_en-US" xlink:label="lab_krys_BalanceSheetComponentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components Disclosure [Text Block]</link:label>
    <link:label id="lab_krys_BalanceSheetComponentsDisclosureTextBlock_documentation_en-US" xlink:label="lab_krys_BalanceSheetComponentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet components disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsDisclosureTextBlock" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BalanceSheetComponentsDisclosureTextBlock" xlink:to="lab_krys_BalanceSheetComponentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_adaff2c8-c414-4895-b4f9-fc08bd23954e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_22bc32b8-9db4-4c1c-9578-aa06d3dd2ef7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd495537-2f12-4fea-ad9f-9125fc405881_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7c7d311a-282c-4f92-ab41-92fca394257b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_dc96ab2e-1d19-40e6-b66e-5c92ab35cbaa_terseLabel_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued financing fees</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_label_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_documentation_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent" xlink:href="krys-20221231.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedFinancingFeesCurrent" xlink:to="lab_krys_AccruedFinancingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b02baf21-b0a1-4104-9758-cc3c23f4cab2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_664934d5-65d0-41d9-9371-b5eca785f897_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_73b928f6-86a4-43f0-bc4e-cb53cc34321c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a4757dd3-aaee-465a-85ba-02ba344b0552_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_f2c8c5a2-eb4d-4383-a13a-8793dd780d91_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_202ab0d7-2845-4cbc-be5c-ef7499316d45_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2dbc33be-769c-4cf8-af19-83b5ab44212f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PeriphaGenMember_20e65c68-76c7-49f5-a977-b6098b07e36c_terseLabel_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:label id="lab_krys_PeriphaGenMember_label_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen [Member]</link:label>
    <link:label id="lab_krys_PeriphaGenMember_documentation_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember" xlink:href="krys-20221231.xsd#krys_PeriphaGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PeriphaGenMember" xlink:to="lab_krys_PeriphaGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eeeae344-e8fe-4a84-8d16-1de210357b31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e04fe064-ad76-4219-9a93-a9b09c8dbc69_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="krys-20221231.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_3a7c7e47-1c56-4be7-a0a8-bd35f3a5664d_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, total consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_label_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_documentation_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration" xlink:href="krys-20221231.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementTotalConsideration" xlink:to="lab_krys_LitigationSettlementTotalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PublicOfferingMember_ca3bac96-5afb-4bc2-9281-c19cf1f36053_terseLabel_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_krys_PublicOfferingMember_label_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_krys_PublicOfferingMember_documentation_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember" xlink:href="krys-20221231.xsd#krys_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PublicOfferingMember" xlink:to="lab_krys_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6498dbf5-c9aa-427a-a4c2-05a867c5a439_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bf00c2ef-aca9-4006-aae3-2906ad9863dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6e2c593b-e1e4-4184-a236-64c2295b078b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_c83e0588-9931-40fc-90f2-5f2bd07e3247_terseLabel_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of potential building purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_label_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_documentation_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:href="krys-20221231.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:to="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2f05152f-0d85-44a7-8ec9-5b6c34633abd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentsForSuitLiability_6b476f62-8f5f-4bb7-979c-b989e7c8875e_negatedTerseLabel_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of ASTRA build to suit liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_label_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_documentation_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability" xlink:href="krys-20221231.xsd#krys_PaymentsForSuitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentsForSuitLiability" xlink:to="lab_krys_PaymentsForSuitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2b9e1d09-d1fd-411c-8b9d-d051d671a1e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_0885dd44-ed52-43ab-bfa6-1e7fef9c6186_terseLabel_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Lease Agreement</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_label_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Lease Agreement [Member]</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_documentation_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand sixteen lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:href="krys-20221231.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:to="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_24685e50-aed8-4622-a04a-9e577e471989_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_81d4b0a2-3b3f-47d7-9afc-b97b297c3246_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause, term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_label_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm" xlink:href="krys-20221231.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClauseTerm" xlink:to="lab_krys_CumulativeEscalationClauseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d000a25-745d-48c5-a610-2d620b1c156b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_f75d4a32-e2dc-4f18-98c9-de2e184eb5db_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_df9719bd-9624-40fc-bd39-1e6067b3146a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2c707567-7e18-49bd-9bed-6684dca2205b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce8f2c97-48d6-49c4-a822-d6e10ad55296_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_7a508e8f-14cd-4ea8-b71b-0ca7130b64ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a5896f6d-cc6b-4429-bfbe-4bcf9fc51d86_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_a940d882-1c81-4014-b56a-6e4a34e9a0b2_terseLabel_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Stock Option</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember" xlink:href="krys-20221231.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NonEmployeeStockOptionMember" xlink:to="lab_krys_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6c4a3bf3-de57-4985-b049-5e64d4574a73_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1d2e407d-3089-497a-b458-5c89ac3aa48b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_DeferredTaxAssetsLeaseLiability_84a621ff-f53d-4a15-a6e8-7864584dddfa_terseLabel_en-US" xlink:label="lab_krys_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_krys_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Liability</link:label>
    <link:label id="lab_krys_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_krys_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_DeferredTaxAssetsLeaseLiability" xlink:href="krys-20221231.xsd#krys_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_DeferredTaxAssetsLeaseLiability" xlink:to="lab_krys_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_da3c902e-95dc-4acb-928e-409e4136db54_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from insurance settlement, operating activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_3a57a98b-cf60-4dee-bf04-f97e1b224ebf_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_98683b45-a32d-4cb0-94cd-552122c03fef_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_df8e0836-c47f-4bc8-882c-da2e32e1efc4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d47e1eff-2a5a-4874-8b18-ee9000ea1d48_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bed39e60-6473-4749-a491-5c017dcaa9a0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bfd49412-2bb0-426c-880d-d7e4948b3a8f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c5379874-128f-4395-98ac-eb430cc1d036_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_915986cb-50c7-455c-b9e7-fb25596a6b28_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a4701a12-a13a-43a2-9d92-5a46109b5939_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b92186a-a4b2-4dad-ba56-4fd797d6d8eb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b437156d-fd44-4e61-96bd-ab7d40b31a30_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnSalesOfAssets_b30156dc-6f7a-4c71-94b4-5692a679b188_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnSalesOfAssets_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets for Financial Service Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:to="lab_us-gaap_GainsLossesOnSalesOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RemainingCommitmentAmount_9a5d5720-aced-4054-9280-50584d13f379_terseLabel_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining commitment</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_label_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Commitment Amount</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_documentation_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount" xlink:href="krys-20221231.xsd#krys_RemainingCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RemainingCommitmentAmount" xlink:to="lab_krys_RemainingCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_742182b0-d62c-4516-bef3-93d0beb71f28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d5a153d9-3a8f-44be-b89e-7e0beb2597db_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_3ebbcb8e-895b-4256-80c4-1ba17300ff64_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a7072c08-ad59-46de-a76b-182f83764a81_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_21cc558d-1213-4ffc-866e-fb195e7bff6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_92717a8a-a628-4eb3-826b-cdb93985c1ed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c4f0407c-b880-428b-b8ff-4f4bb5888abe_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a4b2075e-7098-4e12-a281-a6e26f98d08f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d2ef39fc-d6d0-4897-b6ae-f8b3a739416e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fd22581b-3a96-487c-9915-f44b0950ceef_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_41573e12-fb10-4a20-b41c-069a1e7513ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5c44f41c-4048-4435-852b-1c8a8d65ab2d_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9b2377bf-cc87-4358-a4c2-76ae2d36cf7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to settlement of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_025ec3c0-349a-4f82-9ad6-12065c9be6db_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d66a7dc2-96c6-4222-8937-02eb437eebb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Components of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_bb63e406-0daa-432e-8848-4c4ebdd94cf3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_955873e8-868a-4214-8751-84c7b15564fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0512e02f-17b5-4f80-a3f2-ee1d1b5c3ff6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_d486c379-6287-4220-80d8-01ca013db7e3_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_68375a02-4a83-4ecb-b00e-9abce4921daf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d26a5323-22bc-4065-ac16-198537b6630d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1b184a77-725f-4c2a-a67c-fb2ff82ccb30_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a940e37d-f2a1-4aeb-8fae-9cec3e9a9ac5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_866707e5-3f44-415b-a069-e9453e9fc30a_terseLabel_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember" xlink:href="krys-20221231.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LongTermMarketableSecuritiesMember" xlink:to="lab_krys_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4ec9b2a0-2910-4bc6-9178-99d74b3cce98_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset_142ae6d7-a8e1-45c7-94dc-6fc67b66aecf_negatedLabel_en-US" xlink:label="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:label id="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities right-of-use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="krys-20221231.xsd#krys_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_krys_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0b5df441-dd1b-4b32-8176-e45556e7c35a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a49aa30a-3ce2-406c-923e-c8e70d398b68_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d67bca4d-adb6-44a1-aa10-552b2b235284_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d82fecfb-328f-4f9a-893d-5c3a684f95db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_42310d6b-4000-487f-8726-03948f194948_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0f8a2634-9945-4c04-a2e9-10bf4f2bb361_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_624dbeb0-1881-454e-b1a5-57b5c82fa142_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ff57f00c-f004-4285-84b8-d34eb4d57a15_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_d851b8fe-0769-4407-86b2-03a0522c1cf7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative NOL carry forwards with expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f51e57f9-ac69-41bf-810d-d00b065a2a5f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_dde14f1a-40f0-4eff-820f-a6b3e00441d7_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e093b614-c819-455d-b0dd-b0e492e6f246_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_562e145a-b0f0-485c-8571-393f71127cab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_cbea53ad-c9c8-47c5-a1e0-98da79cb7869_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_360b9863-8b37-4991-a1fd-9f913448f3d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_ad01fe5a-daf8-4584-a01f-1469e1c09881_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4b65c374-b058-4ce0-863e-62ebad51adbe_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, amount capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_1d427a18-a233-46ab-af9d-f741d8a7b983_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_583483d2-ce77-4ba4-b1a6-412598175eee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_87e77820-d5e8-4f43-92a4-c8f7a2a0660e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_1f49de41-7fe2-476e-bb97-f17ac9d6f68c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fb1a0063-09c5-452c-982c-a9463700d802_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b2bde3bc-22da-45ef-a182-ec18d23904da_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_66b48ff2-a1fd-4c21-bc06-873a4b4aa920_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_6128f678-2ea7-493a-9b3c-b71dd2f9a5e6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_dd53d3b5-a8c3-4116-9ac5-36feb9019fce_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e3a0d8f4-7477-41a7-9817-288b85b5a17c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a69c28d6-c303-48ea-b864-4eb4ed8e5f18_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_24d5898a-f767-4967-b65d-bef701567bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncentiveStockOptionsMember_06c94458-3eb7-4fad-845f-7f6f677a8925_terseLabel_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember" xlink:href="krys-20221231.xsd#krys_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncentiveStockOptionsMember" xlink:to="lab_krys_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_044c2972-a53c-4238-8df3-bf3f3178680a_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_ced8d0e1-db7b-424c-a52d-9d70add5969a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9dd2d044-d081-4dd5-a6fb-10bd9e0858d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_5d8ae1f5-5a56-4d9f-9dca-25b187db5706_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment_a2b54166-2c98-4067-96df-770093b5cbe3_terseLabel_en-US" xlink:label="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment_label_en-US" xlink:label="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction In Progress And Laboratory Equipment</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment_documentation_en-US" xlink:label="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress and laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressAndLaboratoryEquipment" xlink:href="krys-20221231.xsd#krys_AccruedConstructionInProgressAndLaboratoryEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedConstructionInProgressAndLaboratoryEquipment" xlink:to="lab_krys_AccruedConstructionInProgressAndLaboratoryEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_53eefbaf-a721-40fc-8a5b-b36c234ef080_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6883c934-7faf-4425-84c6-6968a47bdaa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_00f28fad-ba0a-4c79-bcc7-19e62d62fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_fa67a458-07d9-4899-b798-e9814e43a9e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c77d6617-51ff-4d97-b29d-cd1abeb836fa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9b2a8517-772a-4527-909c-bacc145be914_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a8b6f293-90e8-4408-a816-aafc8efb7d4d_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a3dbc65e-05ca-40b1-95af-75d4137c39c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5653cd43-f0ce-46f6-8df2-f80457bc243e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7abd8a05-4727-4d76-aa41-571ba7912ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_262b0712-ff30-4693-bc78-f1bf25c710b4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_622001b7-c8fc-419f-a9c0-4aa95aafb4e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a01ed1a9-2dfd-4d93-a835-ced3675b4bca_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bc45122a-fdef-49c9-84a6-767db28218d3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4c6d0344-f522-41bc-af1b-5ee8dea02c94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a3097a6f-57a3-409f-88cc-709dcafcdb45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b8550811-b933-4ea0-b5f9-73e030621469_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax (benefit) at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2fe2b188-2584-481b-9844-97e29e38c153_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_22965f0f-d841-4b45-ac23-7f423c79469e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial offering of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b7571122-a8b5-464b-8767-407d2be2aab0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LabEquipmentMember_3324d07b-a0a2-4787-bbdc-851ee48886e8_terseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_5b3b3699-42b2-4671-93d4-49461bab6d4c_verboseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_label_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_krys_LabEquipmentMember_documentation_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember" xlink:href="krys-20221231.xsd#krys_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LabEquipmentMember" xlink:to="lab_krys_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d78c826-af59-4cc4-b92c-4d9c2cc05a40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24abb6af-0997-4fc8-b1e4-1ad40cc8c437_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8153dd33-b28d-4f18-aaf2-94dad3d62428_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_3ffc6547-8fd2-48dd-a619-9c5ecd15fa02_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_091f3dd0-e457-4488-a3f1-76f532efdd5a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1cb5df6a-1b41-4451-993e-9168840d82be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3a51f8f8-cc0b-4604-bfb1-35f8a3db8d19_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_ee6eed2f-be2c-4881-a045-c6fee792225e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>krys-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3bf7ccaf-2752-4fdb-93c0-341f465affc3,g:6dace288-7a26-4def-b28c-90440b1ff335-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/Cover" xlink:type="simple" xlink:href="krys-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_07f887e6-e95b-446d-a174-1013bc843ae0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentType_07f887e6-e95b-446d-a174-1013bc843ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3893bf4b-1b73-47d9-b9a2-ec1026d588a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentAnnualReport_3893bf4b-1b73-47d9-b9a2-ec1026d588a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ca33ec53-956b-4de9-b884-45761f412f60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentPeriodEndDate_ca33ec53-956b-4de9-b884-45761f412f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_25bd17ef-1e14-4db4-9efa-a6ce7d603897" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_CurrentFiscalYearEndDate_25bd17ef-1e14-4db4-9efa-a6ce7d603897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e6a13419-bb2c-4a76-acf7-3727c517cddc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentTransitionReport_e6a13419-bb2c-4a76-acf7-3727c517cddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_64451ead-8c2d-442d-85b7-6d00d12e2a0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityFileNumber_64451ead-8c2d-442d-85b7-6d00d12e2a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_06675017-5afa-48d2-b26e-1801ce2f79b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityRegistrantName_06675017-5afa-48d2-b26e-1801ce2f79b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2e7b9eda-2283-466a-9b04-f4245a96b49b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2e7b9eda-2283-466a-9b04-f4245a96b49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_88d6f88d-2957-4417-ab98-9caac4470812" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityTaxIdentificationNumber_88d6f88d-2957-4417-ab98-9caac4470812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3f4d2636-9de7-4b0a-bc13-d9dea4acd212" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityAddressAddressLine1_3f4d2636-9de7-4b0a-bc13-d9dea4acd212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_90f557f1-0bd9-4c06-a24d-79f589d8e008" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityAddressAddressLine2_90f557f1-0bd9-4c06-a24d-79f589d8e008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_68dcc077-50b1-49ef-a8fc-2d3ede545fa7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityAddressCityOrTown_68dcc077-50b1-49ef-a8fc-2d3ede545fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5b9be147-e6d8-4763-a9e4-1b2328e267ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityAddressStateOrProvince_5b9be147-e6d8-4763-a9e4-1b2328e267ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7da2865d-df77-45d0-a11f-a143ab670f1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityAddressPostalZipCode_7da2865d-df77-45d0-a11f-a143ab670f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0ce1f01f-d244-4c29-bbed-d28099467c28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_CityAreaCode_0ce1f01f-d244-4c29-bbed-d28099467c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_908ec8d8-8921-4995-90c7-0d35c581dc70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_LocalPhoneNumber_908ec8d8-8921-4995-90c7-0d35c581dc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_83a0545e-68b6-4f73-a3e1-cf35bc20bf1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_Security12bTitle_83a0545e-68b6-4f73-a3e1-cf35bc20bf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_13095a3f-d5e1-4a91-9a69-84e434595ff3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_TradingSymbol_13095a3f-d5e1-4a91-9a69-84e434595ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4cade7f5-3eb4-4158-a18e-54dd7bb10f7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_SecurityExchangeName_4cade7f5-3eb4-4158-a18e-54dd7bb10f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_11bbb80e-8106-454b-84c9-1063f602fb61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_11bbb80e-8106-454b-84c9-1063f602fb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_45829891-fc4c-4d69-b29f-dd5adcae7c57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityVoluntaryFilers_45829891-fc4c-4d69-b29f-dd5adcae7c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c0bc98d9-a12a-4ed7-a765-e1809ef75723" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityCurrentReportingStatus_c0bc98d9-a12a-4ed7-a765-e1809ef75723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3e585654-2303-4b29-9889-151411f05b15" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityInteractiveDataCurrent_3e585654-2303-4b29-9889-151411f05b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bbb3c2f9-82b4-449d-9071-09a29ebf2f2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityFilerCategory_bbb3c2f9-82b4-449d-9071-09a29ebf2f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c85a85b4-d491-4787-9935-8c18d90e8b98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntitySmallBusiness_c85a85b4-d491-4787-9935-8c18d90e8b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f7ee1b86-2846-4009-bbd3-99a23a9df5b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityEmergingGrowthCompany_f7ee1b86-2846-4009-bbd3-99a23a9df5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_65e5a1f1-0968-4b60-b6b7-5d43e610317b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_65e5a1f1-0968-4b60-b6b7-5d43e610317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6eac24d4-9a31-4a5e-8d05-bf87c9a1b43a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityShellCompany_6eac24d4-9a31-4a5e-8d05-bf87c9a1b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_03a3d10c-9ee6-475d-91a3-4f16e793c08e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityPublicFloat_03a3d10c-9ee6-475d-91a3-4f16e793c08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_40dd0be5-73a6-4143-84ac-94ba14adcd31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_40dd0be5-73a6-4143-84ac-94ba14adcd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a56cedfb-b25c-4c4d-94f8-1195f7ac7e2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_a56cedfb-b25c-4c4d-94f8-1195f7ac7e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5a4dc724-c615-4de2-9ab0-f0823fbd96e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_AmendmentFlag_5a4dc724-c615-4de2-9ab0-f0823fbd96e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d89c1629-48ef-49e7-86dc-38735b678a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentFiscalYearFocus_d89c1629-48ef-49e7-86dc-38735b678a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8dfdac1f-cbac-41dc-aa22-471f827e78c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8dfdac1f-cbac-41dc-aa22-471f827e78c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fb7ebf80-51aa-4938-ae1b-c3ffa7726171" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7ba2cef7-01ce-46b7-9d79-df592e65a44a" xlink:to="loc_dei_EntityCentralIndexKey_fb7ebf80-51aa-4938-ae1b-c3ffa7726171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/AuditInformation" xlink:type="simple" xlink:href="krys-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AuditorInformationAbstract_a3602c6f-8617-49ac-a924-4da6ba244d5e" xlink:href="krys-20221231.xsd#krys_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6222d3e2-62e0-4547-8b7d-4782a4ddc7d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_AuditorInformationAbstract_a3602c6f-8617-49ac-a924-4da6ba244d5e" xlink:to="loc_dei_AuditorName_6222d3e2-62e0-4547-8b7d-4782a4ddc7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_09b08d82-c2f2-4f43-9001-3a00caa9aa77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_AuditorInformationAbstract_a3602c6f-8617-49ac-a924-4da6ba244d5e" xlink:to="loc_dei_AuditorLocation_09b08d82-c2f2-4f43-9001-3a00caa9aa77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_fa34a629-33da-417a-ad55-eabdd781d1af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_AuditorInformationAbstract_a3602c6f-8617-49ac-a924-4da6ba244d5e" xlink:to="loc_dei_AuditorFirmId_fa34a629-33da-417a-ad55-eabdd781d1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3d561fa9-d928-4d13-9b97-95eebc759c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d561fa9-d928-4d13-9b97-95eebc759c3f" xlink:to="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_00c54775-e3d8-4543-a3fd-e427948d9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_00c54775-e3d8-4543-a3fd-e427948d9c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ed1fdc5-3a1f-4b2d-9c66-c0e5407d2f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00c54775-e3d8-4543-a3fd-e427948d9c13" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ed1fdc5-3a1f-4b2d-9c66-c0e5407d2f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d4aa32fc-51d4-4a4b-82c8-521d296bb079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00c54775-e3d8-4543-a3fd-e427948d9c13" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d4aa32fc-51d4-4a4b-82c8-521d296bb079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e4f86ba3-d4ec-4865-9c35-45ae3bbc0da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00c54775-e3d8-4543-a3fd-e427948d9c13" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e4f86ba3-d4ec-4865-9c35-45ae3bbc0da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_da94c74d-a319-4f66-ac26-3ed716ce790e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00c54775-e3d8-4543-a3fd-e427948d9c13" xlink:to="loc_us-gaap_AssetsCurrent_da94c74d-a319-4f66-ac26-3ed716ce790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8d0a3b04-110e-4e51-82d7-1ef00d0829fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8d0a3b04-110e-4e51-82d7-1ef00d0829fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_218cf1c8-0b91-4fc4-8ec6-69a5158737d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:to="loc_us-gaap_LongTermInvestments_218cf1c8-0b91-4fc4-8ec6-69a5158737d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e18c2db-43a9-4d2c-95e0-ce5a2017f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e18c2db-43a9-4d2c-95e0-ce5a2017f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d6e0e722-0d51-45ab-8880-3b9cd217d5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d6e0e722-0d51-45ab-8880-3b9cd217d5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6b9e6daf-0c67-44f7-86d1-5df8e0addb90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2fcb1ea1-dcb4-412a-9f78-416fdcbf4fe8" xlink:to="loc_us-gaap_Assets_6b9e6daf-0c67-44f7-86d1-5df8e0addb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d561fa9-d928-4d13-9b97-95eebc759c3f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c8db5a4e-ecbf-48aa-8b63-316a65809085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c8db5a4e-ecbf-48aa-8b63-316a65809085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3713a81e-4ada-456b-8796-0b534c631dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c8db5a4e-ecbf-48aa-8b63-316a65809085" xlink:to="loc_us-gaap_AccountsPayableCurrent_3713a81e-4ada-456b-8796-0b534c631dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_11b4c410-fbce-45d8-8e17-5376275fb2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c8db5a4e-ecbf-48aa-8b63-316a65809085" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_11b4c410-fbce-45d8-8e17-5376275fb2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9c8beb2c-15cf-4957-9680-ca4cbf1d8bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c8db5a4e-ecbf-48aa-8b63-316a65809085" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9c8beb2c-15cf-4957-9680-ca4cbf1d8bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1336d42a-90b6-4df2-8403-f041e5478099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c8db5a4e-ecbf-48aa-8b63-316a65809085" xlink:to="loc_us-gaap_LiabilitiesCurrent_1336d42a-90b6-4df2-8403-f041e5478099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff33ace3-47bd-4f43-a2bc-df1c8e38dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ff33ace3-47bd-4f43-a2bc-df1c8e38dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9f94fee5-1b7e-474f-9649-6ff6ffb37885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:to="loc_us-gaap_Liabilities_9f94fee5-1b7e-474f-9649-6ff6ffb37885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26ea7806-fd1b-4feb-976d-12e14cab49f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26ea7806-fd1b-4feb-976d-12e14cab49f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fc4ffaa6-9ce5-487e-b474-cba72a040cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:to="loc_us-gaap_CommonStockValue_fc4ffaa6-9ce5-487e-b474-cba72a040cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_57311ae9-5372-4e8c-ad6d-1a00cc159097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:to="loc_us-gaap_AdditionalPaidInCapital_57311ae9-5372-4e8c-ad6d-1a00cc159097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d9e914c4-698b-43fb-bea6-8e998093eefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d9e914c4-698b-43fb-bea6-8e998093eefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ba591b67-59da-48e6-a581-6cece413dce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ba591b67-59da-48e6-a581-6cece413dce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c393eab-d3aa-40e0-a29f-f42029f94c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2335339-e875-4b31-b1aa-f252ee2d2dcf" xlink:to="loc_us-gaap_StockholdersEquity_6c393eab-d3aa-40e0-a29f-f42029f94c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5aed6e8-22ce-4563-afc9-dd1932520a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad5bdaf6-f2ea-4bb8-bf94-0e35c1e8711b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5aed6e8-22ce-4563-afc9-dd1932520a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f57a64e3-552f-495b-9893-38e38904c53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2908360a-300f-4c94-ae74-9c8f879f35a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f57a64e3-552f-495b-9893-38e38904c53c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2908360a-300f-4c94-ae74-9c8f879f35a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c19989d0-4916-4289-98b0-e7a66145f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f57a64e3-552f-495b-9893-38e38904c53c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c19989d0-4916-4289-98b0-e7a66145f03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8c705e6f-ced1-4ebb-9dec-a208f58d4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f57a64e3-552f-495b-9893-38e38904c53c" xlink:to="loc_us-gaap_CommonStockSharesIssued_8c705e6f-ced1-4ebb-9dec-a208f58d4f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_447f04fb-afa9-4fa1-a8b1-f4bcfdf494db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f57a64e3-552f-495b-9893-38e38904c53c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_447f04fb-afa9-4fa1-a8b1-f4bcfdf494db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_96e02d6c-8d7a-4aff-bda6-60016fa0338d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_OperatingExpensesAbstract_96e02d6c-8d7a-4aff-bda6-60016fa0338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_886df3bd-f662-450d-b0ac-6483b3d80bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96e02d6c-8d7a-4aff-bda6-60016fa0338d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_886df3bd-f662-450d-b0ac-6483b3d80bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_00270075-1aa1-4aa2-84ac-342c65ff1937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96e02d6c-8d7a-4aff-bda6-60016fa0338d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_00270075-1aa1-4aa2-84ac-342c65ff1937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_3ba8460d-4cf1-46fa-ba33-308bc970274f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96e02d6c-8d7a-4aff-bda6-60016fa0338d" xlink:to="loc_us-gaap_LitigationSettlementExpense_3ba8460d-4cf1-46fa-ba33-308bc970274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6a354c5d-8d05-49f4-941e-8b8ef26f0f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_96e02d6c-8d7a-4aff-bda6-60016fa0338d" xlink:to="loc_us-gaap_OperatingExpenses_6a354c5d-8d05-49f4-941e-8b8ef26f0f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9d371b5a-d8ca-48d1-bc72-ccc13abd5700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_OperatingIncomeLoss_9d371b5a-d8ca-48d1-bc72-ccc13abd5700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_82f8f7f7-d4b1-480f-afde-27b7131fc31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_82f8f7f7-d4b1-480f-afde-27b7131fc31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_c861f71c-8278-44bd-8fce-ab123d6d20db" xlink:href="krys-20221231.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_82f8f7f7-d4b1-480f-afde-27b7131fc31c" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_c861f71c-8278-44bd-8fce-ab123d6d20db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_058a94ac-c97c-452e-a8ed-0f30e77736de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_82f8f7f7-d4b1-480f-afde-27b7131fc31c" xlink:to="loc_us-gaap_InterestExpense_058a94ac-c97c-452e-a8ed-0f30e77736de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01e833b6-36c1-4b61-bffd-5aa4eb8c7eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_NetIncomeLoss_01e833b6-36c1-4b61-bffd-5aa4eb8c7eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7faf1c57-32db-49f0-a492-2cba3fe5fcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7faf1c57-32db-49f0-a492-2cba3fe5fcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_45f4288e-a74c-4b6a-a5af-2d5c36e89fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_45f4288e-a74c-4b6a-a5af-2d5c36e89fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6fa4c029-8319-405c-b5cd-ca301d2d75f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_EarningsPerShareBasic_6fa4c029-8319-405c-b5cd-ca301d2d75f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3c88690a-bcf5-486b-8e2b-d8c0cba1ea38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3c88690a-bcf5-486b-8e2b-d8c0cba1ea38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32a3d429-2fba-48ba-80ed-16fe1e442fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32a3d429-2fba-48ba-80ed-16fe1e442fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62677e64-11e6-4570-94ec-0487680d12fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a51b637d-0c32-4454-bb5d-6290aa1b5e72" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_62677e64-11e6-4570-94ec-0487680d12fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0da69a73-36d0-4e73-83ba-0a375f52bfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0da69a73-36d0-4e73-83ba-0a375f52bfc6" xlink:to="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_79929a49-bb1a-492e-8ae7-bca1b0001ebe" xlink:to="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b43a3edc-9e6a-4629-9d2b-cfdbb696df80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_CommonStockMember_b43a3edc-9e6a-4629-9d2b-cfdbb696df80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0cd8ca07-e1c7-4ea8-91ab-2903ad0bd876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0cd8ca07-e1c7-4ea8-91ab-2903ad0bd876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83b2c025-d369-4389-97b8-eb4891f2640b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83b2c025-d369-4389-97b8-eb4891f2640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0cfb4e31-38b9-48b6-be4c-40fa6cf78455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa6ff46d-c23a-428b-9aa6-e7529394c0f0" xlink:to="loc_us-gaap_RetainedEarningsMember_0cfb4e31-38b9-48b6-be4c-40fa6cf78455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7a528bdb-79e6-4db7-b764-5e01240ff456" xlink:to="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ec83ff00-b063-4616-9d35-c44d297ce3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_SharesOutstanding_ec83ff00-b063-4616-9d35-c44d297ce3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08c52c7f-5818-4c0d-9297-c1be16fc6f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockholdersEquity_08c52c7f-5818-4c0d-9297-c1be16fc6f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49d2bf8d-1d18-4851-bdcd-a94341c601e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49d2bf8d-1d18-4851-bdcd-a94341c601e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9a3a83ec-1818-4aa6-be62-9d3866fdc9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9a3a83ec-1818-4aa6-be62-9d3866fdc9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_61af4b8f-9232-4d1c-b1d2-1054b2bf1e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_61af4b8f-9232-4d1c-b1d2-1054b2bf1e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ccdf6faa-0fe6-49f1-89ee-13ee5a4872f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ccdf6faa-0fe6-49f1-89ee-13ee5a4872f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_41adca69-e681-4328-b1f0-21199e88ef28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_41adca69-e681-4328-b1f0-21199e88ef28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22c7fa78-2d1f-4df3-a3e3-408c7c28a7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22c7fa78-2d1f-4df3-a3e3-408c7c28a7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3dcef420-4511-4388-a7c1-439e933b5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_NetIncomeLoss_3dcef420-4511-4388-a7c1-439e933b5e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f2c2dbc7-62fe-43c3-a62b-bb11f1dc0f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_SharesOutstanding_f2c2dbc7-62fe-43c3-a62b-bb11f1dc0f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b191e28b-9c45-49cc-8c01-9a3deb2d6fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c61ef0d-4459-4b3c-bc22-27bb533213af" xlink:to="loc_us-gaap_StockholdersEquity_b191e28b-9c45-49cc-8c01-9a3deb2d6fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax_132a89ac-eb6a-4944-a625-8f1022e7dc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1967e6bb-d2b4-4731-ad8b-a816c024075c" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax_132a89ac-eb6a-4944-a625-8f1022e7dc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="krys-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be45e09e-c347-411f-8318-f24ea00281c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be45e09e-c347-411f-8318-f24ea00281c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d33cfab-f4fe-4984-8c3e-f457693cb909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be45e09e-c347-411f-8318-f24ea00281c0" xlink:to="loc_us-gaap_NetIncomeLoss_8d33cfab-f4fe-4984-8c3e-f457693cb909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be45e09e-c347-411f-8318-f24ea00281c0" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8fadf9f1-d084-4c50-8013-cb5b73fc38f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8fadf9f1-d084-4c50-8013-cb5b73fc38f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d8572ce9-1a8d-4fb7-84f3-c2a069f61136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:to="loc_us-gaap_ShareBasedCompensation_d8572ce9-1a8d-4fb7-84f3-c2a069f61136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_dd9cf09c-af43-4449-93b5-d0ec0235fdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnSalesOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_dd9cf09c-af43-4449-93b5-d0ec0235fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_a33f41d3-e63c-4247-9c1e-a37da4cb3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:to="loc_us-gaap_OtherNoncashExpense_a33f41d3-e63c-4247-9c1e-a37da4cb3a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9476caed-293a-46e5-a481-d01c1bc64972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_030843ae-12ed-4335-b89f-2c13e28f37bf" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9476caed-293a-46e5-a481-d01c1bc64972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be45e09e-c347-411f-8318-f24ea00281c0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_81940584-a870-41ee-a76f-aa9cc1aa0451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_81940584-a870-41ee-a76f-aa9cc1aa0451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_236be233-ea47-41be-a3e8-9654d591a8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_236be233-ea47-41be-a3e8-9654d591a8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_91fb03d0-ca24-4b89-af23-26e7cb6a045f" xlink:href="krys-20221231.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_91fb03d0-ca24-4b89-af23-26e7cb6a045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14efcf17-1055-4f4c-ad55-5d3cdd2c22c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14efcf17-1055-4f4c-ad55-5d3cdd2c22c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cce35097-e330-4700-8a8e-e0d4d79160ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_706bd2a0-1260-415a-ab57-734529b67c35" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cce35097-e330-4700-8a8e-e0d4d79160ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c44f1e05-3b8a-4495-a3fa-370c8ee2326a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be45e09e-c347-411f-8318-f24ea00281c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c44f1e05-3b8a-4495-a3fa-370c8ee2326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dae52685-7a29-4fe5-98bd-67f484ed3cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dae52685-7a29-4fe5-98bd-67f484ed3cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db15e31a-3fbb-4da6-98f4-87879d1bfe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dae52685-7a29-4fe5-98bd-67f484ed3cbc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db15e31a-3fbb-4da6-98f4-87879d1bfe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b615ea77-cd87-401f-9844-2afb6ff438d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dae52685-7a29-4fe5-98bd-67f484ed3cbc" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b615ea77-cd87-401f-9844-2afb6ff438d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_acfe5186-9981-4b20-8d5c-9845627c7270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dae52685-7a29-4fe5-98bd-67f484ed3cbc" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_acfe5186-9981-4b20-8d5c-9845627c7270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02984fd3-28a9-4841-9444-9cd517829d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dae52685-7a29-4fe5-98bd-67f484ed3cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_02984fd3-28a9-4841-9444-9cd517829d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4babbdb8-defa-434c-ad49-39f589510930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4babbdb8-defa-434c-ad49-39f589510930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_369aed77-c626-463d-bc0d-91ca4f8cf13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4babbdb8-defa-434c-ad49-39f589510930" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_369aed77-c626-463d-bc0d-91ca4f8cf13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bf1cc422-6d9d-4f1b-a213-7d710d930b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4babbdb8-defa-434c-ad49-39f589510930" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bf1cc422-6d9d-4f1b-a213-7d710d930b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_54af9b39-bfc5-484f-b477-696653d4f187" xlink:href="krys-20221231.xsd#krys_PaymentsForSuitLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4babbdb8-defa-434c-ad49-39f589510930" xlink:to="loc_krys_PaymentsForSuitLiability_54af9b39-bfc5-484f-b477-696653d4f187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4584fe0d-0439-434c-b974-82929a7de640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4584fe0d-0439-434c-b974-82929a7de640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6fc4f88-bf12-45db-9fa9-8728def78637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6fc4f88-bf12-45db-9fa9-8728def78637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6ee33ef-ad20-496e-89ae-12c98e902333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6ee33ef-ad20-496e-89ae-12c98e902333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8dd3423-6970-452d-9fbf-7baaeb1f2fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8dd3423-6970-452d-9fbf-7baaeb1f2fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4efa85b-1416-463e-84dc-659fc7051034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4efa85b-1416-463e-84dc-659fc7051034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_80e9169b-244c-48c9-80dd-fbe5cfc98322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_336ee854-f52c-4437-87e6-8fe29f91ca93" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_80e9169b-244c-48c9-80dd-fbe5cfc98322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_56b964e8-f47b-47bd-a845-96dfb79dbc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_80e9169b-244c-48c9-80dd-fbe5cfc98322" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_56b964e8-f47b-47bd-a845-96dfb79dbc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c65d6b8d-6dac-41fb-a3c0-8b6c8eba806f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_80e9169b-244c-48c9-80dd-fbe5cfc98322" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c65d6b8d-6dac-41fb-a3c0-8b6c8eba806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Organization" xlink:type="simple" xlink:href="krys-20221231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2a4cbcbe-eb07-46b0-9db9-82ffce1116f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0df2e9b1-a5da-4331-9087-9a2cfbcbc2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2a4cbcbe-eb07-46b0-9db9-82ffce1116f8" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_0df2e9b1-a5da-4331-9087-9a2cfbcbc2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd741883-66d3-4b10-beb8-0edc35bb7149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_662a745f-e231-4a9e-8f57-2c545964cb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd741883-66d3-4b10-beb8-0edc35bb7149" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_662a745f-e231-4a9e-8f57-2c545964cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="krys-20221231.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c0730356-922e-400e-b0ff-05c75a949d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0e7a0bb8-ede1-47a8-ac4e-bbaac60fe55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c0730356-922e-400e-b0ff-05c75a949d7d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0e7a0bb8-ede1-47a8-ac4e-bbaac60fe55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstruments"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bf6bbed5-906e-44d3-ac6a-5e0a878b89e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3405ba26-56a3-44bf-8d03-674dc34a845c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bf6bbed5-906e-44d3-ac6a-5e0a878b89e6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3405ba26-56a3-44bf-8d03-674dc34a845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsAbstract_387221ed-e496-41a7-8da7-d10032b1338d" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsDisclosureTextBlock_0380bb44-7e86-44ba-8fd1-3520465966e2" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_387221ed-e496-41a7-8da7-d10032b1338d" xlink:to="loc_krys_BalanceSheetComponentsDisclosureTextBlock_0380bb44-7e86-44ba-8fd1-3520465966e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="krys-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_edd41850-9de6-402b-ae38-6378b9ef91cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_35e608d0-387e-4be1-9bcc-6136717e3504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_edd41850-9de6-402b-ae38-6378b9ef91cd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_35e608d0-387e-4be1-9bcc-6136717e3504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Leases" xlink:type="simple" xlink:href="krys-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f67718e7-6ada-4bc8-ab7b-85b8a49137db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4d44e2dc-1c68-4543-a5da-7e8a22dae33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f67718e7-6ada-4bc8-ab7b-85b8a49137db" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4d44e2dc-1c68-4543-a5da-7e8a22dae33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Capitalization" xlink:type="simple" xlink:href="krys-20221231.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f5fae1d4-f37e-405a-ac06-6a76464f3a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d6a92c94-b2d9-4f03-8754-d757037691d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f5fae1d4-f37e-405a-ac06-6a76464f3a1f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d6a92c94-b2d9-4f03-8754-d757037691d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58cad36f-77b3-41a5-9305-9ab919c14476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c3a9702e-b17a-48fa-8c89-99840b0f1621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58cad36f-77b3-41a5-9305-9ab919c14476" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c3a9702e-b17a-48fa-8c89-99840b0f1621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eb54265a-d38f-4c9b-a117-743c99cbcfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_da87fa97-1471-40f7-904a-fd786818c436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb54265a-d38f-4c9b-a117-743c99cbcfbd" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_da87fa97-1471-40f7-904a-fd786818c436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="krys-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_517a4ba3-7919-468e-8496-ee9708429091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_0dc68fa2-2e24-4837-bf0a-4275fea2a614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_517a4ba3-7919-468e-8496-ee9708429091" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_0dc68fa2-2e24-4837-bf0a-4275fea2a614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d03133b1-c389-48bf-a508-055d518927fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d03133b1-c389-48bf-a508-055d518927fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a3618c07-945d-467e-9e78-6dd8592de571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_UseOfEstimates_a3618c07-945d-467e-9e78-6dd8592de571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5c6a2418-4c1b-4535-a36f-00aa14370355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5c6a2418-4c1b-4535-a36f-00aa14370355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4fbe3bd6-e713-4635-b8c3-305828dc13d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4fbe3bd6-e713-4635-b8c3-305828dc13d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2ad8e3bb-469f-4b0e-bc88-292e3428a146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2ad8e3bb-469f-4b0e-bc88-292e3428a146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_afa98c34-c889-4605-9e2d-678348510764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_afa98c34-c889-4605-9e2d-678348510764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d54eb2d1-a3d0-43ff-b314-a7329c50cf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d54eb2d1-a3d0-43ff-b314-a7329c50cf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d5cc33c-6025-4904-8960-8cf6673f6952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d5cc33c-6025-4904-8960-8cf6673f6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6a36f534-b82c-48f0-b8b5-c8be338734fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6a36f534-b82c-48f0-b8b5-c8be338734fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_bd896914-823b-4fa2-ab05-9137244f7551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_bd896914-823b-4fa2-ab05-9137244f7551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0595442d-2100-4487-bbb2-d98ba9bb7628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0595442d-2100-4487-bbb2-d98ba9bb7628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_d627b8ff-f3fc-4a64-9800-e514a039a5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_d627b8ff-f3fc-4a64-9800-e514a039a5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_166bf6da-f18b-451c-b61b-611eb0496178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_166bf6da-f18b-451c-b61b-611eb0496178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8fd26bbb-bc59-4866-891e-cf0bc0c7b592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e4c61f3b-05b1-4747-862a-1f46bba810dd" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8fd26bbb-bc59-4866-891e-cf0bc0c7b592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ccd7f16c-1e58-4561-a7a1-e519dada37c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_d6159b2f-7113-4a17-8085-4251120f8603" xlink:href="krys-20221231.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ccd7f16c-1e58-4561-a7a1-e519dada37c6" xlink:to="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_d6159b2f-7113-4a17-8085-4251120f8603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="krys-20221231.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_be76dd3f-81a4-4345-ae8f-601b9eba2050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6dc491d6-23b7-4bf1-86f9-026532e8e6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_be76dd3f-81a4-4345-ae8f-601b9eba2050" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6dc491d6-23b7-4bf1-86f9-026532e8e6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6e868fc5-a575-4987-aa27-b9680468e200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_adf80293-2386-4a0e-bfe1-e7ab570de016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e868fc5-a575-4987-aa27-b9680468e200" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_adf80293-2386-4a0e-bfe1-e7ab570de016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsAbstract_e2b06c19-8419-4415-86e9-278f8d31beac" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d260a3f4-3648-4f29-af47-65bd99713662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e2b06c19-8419-4415-86e9-278f8d31beac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d260a3f4-3648-4f29-af47-65bd99713662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d7fd9717-0f91-44d7-af52-0d3f9348f33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e2b06c19-8419-4415-86e9-278f8d31beac" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d7fd9717-0f91-44d7-af52-0d3f9348f33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesTables" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8114d583-bef3-4f6e-953d-428c7df9786d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ffc5c452-8e66-4064-bcf0-ea39a8d30cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8114d583-bef3-4f6e-953d-428c7df9786d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ffc5c452-8e66-4064-bcf0-ea39a8d30cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_fd040ec8-2a20-4307-947c-5ef1595af84f" xlink:href="krys-20221231.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8114d583-bef3-4f6e-953d-428c7df9786d" xlink:to="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_fd040ec8-2a20-4307-947c-5ef1595af84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9b7796e9-37bd-4f49-9263-f8432b895202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8114d583-bef3-4f6e-953d-428c7df9786d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9b7796e9-37bd-4f49-9263-f8432b895202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_208758bf-28de-4854-86fb-93498d95c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f4d22895-b78b-4718-a5d3-8cb1becc3af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_208758bf-28de-4854-86fb-93498d95c12c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f4d22895-b78b-4718-a5d3-8cb1becc3af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f88393ec-cd30-4a5f-ac63-7dc35bb22fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_208758bf-28de-4854-86fb-93498d95c12c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f88393ec-cd30-4a5f-ac63-7dc35bb22fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3f857afd-e9b7-4717-b8f8-b81fc6a4892e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_208758bf-28de-4854-86fb-93498d95c12c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3f857afd-e9b7-4717-b8f8-b81fc6a4892e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_20533374-b6fc-4ddf-a73e-829c9f4501bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_208758bf-28de-4854-86fb-93498d95c12c" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_20533374-b6fc-4ddf-a73e-829c9f4501bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b528d5f3-422b-4834-998a-9d9dfdca85eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_df4b4ee3-b170-4b53-88c4-a4fde3e25731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b528d5f3-422b-4834-998a-9d9dfdca85eb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_df4b4ee3-b170-4b53-88c4-a4fde3e25731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_003ac4c8-77d7-4ccb-ace6-0de1b2048aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b528d5f3-422b-4834-998a-9d9dfdca85eb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_003ac4c8-77d7-4ccb-ace6-0de1b2048aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a25170b-d9e5-402a-aa31-6adc23caf8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0a5f17a-d915-4ef8-ac0e-6321d4afca69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a25170b-d9e5-402a-aa31-6adc23caf8ce" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0a5f17a-d915-4ef8-ac0e-6321d4afca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b1b973da-abba-4bd4-b991-f551c0798ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a25170b-d9e5-402a-aa31-6adc23caf8ce" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b1b973da-abba-4bd4-b991-f551c0798ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8a288398-dd45-4866-9ab7-4ab5f2e68bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9a665208-1f2d-4dd2-9b88-c2876aa37c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a288398-dd45-4866-9ab7-4ab5f2e68bd1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9a665208-1f2d-4dd2-9b88-c2876aa37c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a288398-dd45-4866-9ab7-4ab5f2e68bd1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6dcb24a4-0bf9-45b4-8cd6-080460a9ac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8f2ac38f-50d7-4f13-a024-2c728e434dec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6dcb24a4-0bf9-45b4-8cd6-080460a9ac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ad72b447-65b7-49d4-82c1-535d9e1d65e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6dcb24a4-0bf9-45b4-8cd6-080460a9ac5e" xlink:to="loc_us-gaap_EquipmentMember_ad72b447-65b7-49d4-82c1-535d9e1d65e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7fd8943-8f72-43bc-b1c2-f640a131f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bddf6b9f-1677-4086-97f7-c1729c3b13a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7fd8943-8f72-43bc-b1c2-f640a131f9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ad1d13bb-6aea-4eff-9a58-394907dadee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b7fd8943-8f72-43bc-b1c2-f640a131f9e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ad1d13bb-6aea-4eff-9a58-394907dadee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_24455af4-52d1-4e91-b38a-88cdf8b0f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a288398-dd45-4866-9ab7-4ab5f2e68bd1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_24455af4-52d1-4e91-b38a-88cdf8b0f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0cf58569-29bd-4da8-9977-ab75a6a2b6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a288398-dd45-4866-9ab7-4ab5f2e68bd1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0cf58569-29bd-4da8-9977-ab75a6a2b6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_62672af0-bed0-40fa-9a35-84ee502121ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a288398-dd45-4866-9ab7-4ab5f2e68bd1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_62672af0-bed0-40fa-9a35-84ee502121ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4cf125d3-b299-41ef-b8ee-617b0617315e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cf125d3-b299-41ef-b8ee-617b0617315e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a23381d5-c942-4b2f-8a72-3599ac1c3a66" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_1214d083-d92e-4dfb-836b-fd3d08475003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:to="loc_us-gaap_ComputerEquipmentMember_1214d083-d92e-4dfb-836b-fd3d08475003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_c79efd9f-e98d-44cb-96a4-99a4f4ae4441" xlink:href="krys-20221231.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:to="loc_krys_LabEquipmentMember_c79efd9f-e98d-44cb-96a4-99a4f4ae4441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a155b565-4cfb-4a0e-bead-96d33a1d18e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dfd0c09-34d2-4d32-a809-a68024cfc40e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a155b565-4cfb-4a0e-bead-96d33a1d18e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:to="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4ba77b73-acf2-48bb-a2ba-c61fbf546603" xlink:to="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_13356ef7-d77d-476a-9d8c-6cd9ad662652" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:to="loc_srt_MinimumMember_13356ef7-d77d-476a-9d8c-6cd9ad662652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ba3ad2c-fc25-411e-9d62-818d6bb9e657" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6b6e5546-6f7b-49a1-9a18-9fb14f90818d" xlink:to="loc_srt_MaximumMember_6ba3ad2c-fc25-411e-9d62-818d6bb9e657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0e45e0c1-f297-420b-b4ae-ad47f8b39283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5cf046e4-ab07-4b80-a00f-70687f97081c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0e45e0c1-f297-420b-b4ae-ad47f8b39283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e66f38a1-acd8-4d86-8d76-7a0bd222a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0e45e0c1-f297-420b-b4ae-ad47f8b39283" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e66f38a1-acd8-4d86-8d76-7a0bd222a1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b4a809ad-f4d8-41bd-becb-3876be3df9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b4a809ad-f4d8-41bd-becb-3876be3df9dc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:to="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8347f808-d3f5-4905-9b3c-c29018a8dc5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dfc6e7b7-a0f9-4079-8246-2f78300e572a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dfc6e7b7-a0f9-4079-8246-2f78300e572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ace29a62-13be-4864-a41f-63ac9364a240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35a601f9-b4f1-4dc7-83d4-abe175102a4b" xlink:to="loc_us-gaap_RestrictedStockMember_ace29a62-13be-4864-a41f-63ac9364a240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6cc4584-b07f-4526-b5af-d6190dd5197b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_24ee6238-997e-4594-bf6c-250294eef875" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6cc4584-b07f-4526-b5af-d6190dd5197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b4d74199-7996-4402-94a9-c637be709e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6cc4584-b07f-4526-b5af-d6190dd5197b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b4d74199-7996-4402-94a9-c637be709e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f73f39e3-b241-46e1-946b-26a2f54d0ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45a90bec-5dfc-4b31-9dd7-71491684b0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f73f39e3-b241-46e1-946b-26a2f54d0ee7" xlink:to="loc_us-gaap_NetIncomeLoss_45a90bec-5dfc-4b31-9dd7-71491684b0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_be95fe6d-0960-4efc-b850-6fa14d8ef256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f73f39e3-b241-46e1-946b-26a2f54d0ee7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_be95fe6d-0960-4efc-b850-6fa14d8ef256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afb14439-8602-4f35-b32a-b31fd5ac564a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f73f39e3-b241-46e1-946b-26a2f54d0ee7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afb14439-8602-4f35-b32a-b31fd5ac564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c49b58f4-a4d4-4c9d-8ab4-b609ab48fdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f73f39e3-b241-46e1-946b-26a2f54d0ee7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c49b58f4-a4d4-4c9d-8ab4-b609ab48fdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_749dbc3d-0dd6-45bf-9083-d9a949c999a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f73f39e3-b241-46e1-946b-26a2f54d0ee7" xlink:to="loc_us-gaap_EarningsPerShareBasic_749dbc3d-0dd6-45bf-9083-d9a949c999a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2051d81-0caf-44e5-806a-f00461ca0645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2051d81-0caf-44e5-806a-f00461ca0645" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fd0335e9-3029-458e-94f2-41fdf015c17b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_fa5f0947-79c4-4cb1-b19f-6a3144c76a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_fa5f0947-79c4-4cb1-b19f-6a3144c76a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_11a7f850-cff3-4e8d-b6ec-5fffe6df8523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_11a7f850-cff3-4e8d-b6ec-5fffe6df8523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_8dbdc77e-ef11-415d-9ac2-6cd5cd1f9cce" xlink:href="krys-20221231.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8aac2ad5-11ca-4f09-9ab4-994aabf9bda7" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_8dbdc77e-ef11-415d-9ac2-6cd5cd1f9cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_efee13ee-5893-47ef-a1a8-822f1eb73a26" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_383f8171-b8fc-4e8f-84ab-d10e3aea56e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:to="loc_us-gaap_CommercialPaperMember_383f8171-b8fc-4e8f-84ab-d10e3aea56e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2f4ef529-7a1d-419c-9c85-2ed00dcd2434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2f4ef529-7a1d-419c-9c85-2ed00dcd2434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_01d3a6ba-d37c-4119-bc39-b06542a9619d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_224f8f2c-c72b-47d3-829f-714fa3f8dff6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_01d3a6ba-d37c-4119-bc39-b06542a9619d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f692de08-0352-445d-ab8b-cb26edfbca90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_90067a72-c89b-4212-8490-6066d417b318" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f692de08-0352-445d-ab8b-cb26edfbca90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_87845c69-7f6b-465c-9bc0-383cfbc3138a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f692de08-0352-445d-ab8b-cb26edfbca90" xlink:to="loc_us-gaap_CashMember_87845c69-7f6b-465c-9bc0-383cfbc3138a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2e0d2fbc-dad4-49c5-aa71-d68a90a8aad2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a5776f29-4831-4da3-91f9-8cf55e5420f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a5776f29-4831-4da3-91f9-8cf55e5420f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5787642-693a-4cca-9546-05dceff87b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5564cd6b-ef7c-4046-9511-921a5b264f65" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5787642-693a-4cca-9546-05dceff87b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9a0f6084-1e9f-439f-982f-52d3a49cb484" xlink:to="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a705eff-e75e-421d-b85f-3112a0b1b5c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:to="loc_srt_MinimumMember_6a705eff-e75e-421d-b85f-3112a0b1b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5bef1cc-6a04-4ced-b978-3f1839535f42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3e971de-1c41-446e-9e1c-73dcfe7ea5e5" xlink:to="loc_srt_MaximumMember_e5bef1cc-6a04-4ced-b978-3f1839535f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f6c8e853-a9aa-4715-b783-5f1f4835a957" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c19b18cf-d290-4594-b9da-958bee65fdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c19b18cf-d290-4594-b9da-958bee65fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca2ad02d-3ba4-4348-8b57-c4b21aa0ae0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca2ad02d-3ba4-4348-8b57-c4b21aa0ae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07c47395-88ee-4fd2-aa95-8d554a182706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_07c47395-88ee-4fd2-aa95-8d554a182706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1e50a3bd-772d-49de-8826-4e3183e4f112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1e50a3bd-772d-49de-8826-4e3183e4f112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2edb46-19ac-4aa0-a53d-c68fba92bca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be2edb46-19ac-4aa0-a53d-c68fba92bca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56fcf371-1826-46dd-98ff-46e7f12c5d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56fcf371-1826-46dd-98ff-46e7f12c5d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_71d31169-3b2b-4685-a0bf-f02738d6da01" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_71d31169-3b2b-4685-a0bf-f02738d6da01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_9f2687f4-3237-4e41-9f55-f29692102b31" xlink:href="krys-20221231.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_9f2687f4-3237-4e41-9f55-f29692102b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_4081cc3e-bf16-41b8-b8b3-3a15dc152e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4ba3638-d5ba-4e09-b4d2-7e6449ffd083" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_4081cc3e-bf16-41b8-b8b3-3a15dc152e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20221231.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsAbstract_57c29415-cbc9-430d-bf67-dad452a95ee2" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_57c29415-cbc9-430d-bf67-dad452a95ee2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc66df8a-a8fb-42e0-85a8-ac9c9b8931f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_16bc56c2-a25d-4c59-ad89-1c033e4cca59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_ConstructionInProgressMember_16bc56c2-a25d-4c59-ad89-1c033e4cca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_30b7160f-2750-45d2-8e28-0d8fd515398b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_30b7160f-2750-45d2-8e28-0d8fd515398b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d90a82e0-e87e-48a8-8626-fa5055e7f563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d90a82e0-e87e-48a8-8626-fa5055e7f563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d7b1ee43-a3ec-4834-b4ad-9f0492758500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_us-gaap_ComputerEquipmentMember_d7b1ee43-a3ec-4834-b4ad-9f0492758500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_2155d58f-5e86-4cc7-9160-19df0e33e4fe" xlink:href="krys-20221231.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebcd22ee-e145-4376-b279-202513d3f1df" xlink:to="loc_krys_LabEquipmentMember_2155d58f-5e86-4cc7-9160-19df0e33e4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b760c76e-99f2-4f20-96b8-0b00f9c9ab0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_71e2d9ca-c4b6-424b-9656-3155ef5db5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_71e2d9ca-c4b6-424b-9656-3155ef5db5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27134ada-c406-4340-b161-06e18a6ba9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27134ada-c406-4340-b161-06e18a6ba9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_176daf33-bcae-445b-8402-03e51367f6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bc65df8f-2dd9-4a98-a113-9b9321d3d1e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_176daf33-bcae-445b-8402-03e51367f6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsAbstract_35546515-b623-41ef-b1ae-80d06885a2c4" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bfb12508-8e5a-4a59-8419-b7da22bd086f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_35546515-b623-41ef-b1ae-80d06885a2c4" xlink:to="loc_us-gaap_Depreciation_bfb12508-8e5a-4a59-8419-b7da22bd086f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:href="krys-20221231.xsd#krys_BalanceSheetComponentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_06d6f1cf-8b14-445f-bc08-5b2f30819466" xlink:href="krys-20221231.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_06d6f1cf-8b14-445f-bc08-5b2f30819466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6520bf26-d654-48d0-9e61-5a1def072597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6520bf26-d654-48d0-9e61-5a1def072597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_fb6ee48b-0048-47e7-8e08-ec31c5bb2a68" xlink:href="krys-20221231.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_krys_AccruedPayrollAndBenefits_fb6ee48b-0048-47e7-8e08-ec31c5bb2a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressAndLaboratoryEquipment_f56e0573-247e-41a9-8084-8c23044b4964" xlink:href="krys-20221231.xsd#krys_AccruedConstructionInProgressAndLaboratoryEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_krys_AccruedConstructionInProgressAndLaboratoryEquipment_f56e0573-247e-41a9-8084-8c23044b4964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_76107ea6-c135-424d-89be-4040bce9aeaa" xlink:href="krys-20221231.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_krys_AccruedFinancingFeesCurrent_76107ea6-c135-424d-89be-4040bce9aeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_38d4f0fa-8a6a-4a65-bb02-45e7e1e525d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_us-gaap_AccruedIncomeTaxes_38d4f0fa-8a6a-4a65-bb02-45e7e1e525d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fac79630-2625-4125-bed9-85db7576dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fac79630-2625-4125-bed9-85db7576dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_36ebb4b6-09c0-48ca-bb9e-867422ab991b" xlink:href="krys-20221231.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_BalanceSheetComponentsAbstract_e9615c63-1101-44c1-906c-62a0e33580ce" xlink:to="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_36ebb4b6-09c0-48ca-bb9e-867422ab991b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3dc6005-d97b-458f-b853-1f7c12380814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3dc6005-d97b-458f-b853-1f7c12380814" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_4d38a83a-4994-436b-b8c5-9bec3be8b445" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_891fb0ed-71d1-46ec-924c-0b522b4a8142" xlink:href="krys-20221231.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:to="loc_krys_ClinicalSupplyAgreementMember_891fb0ed-71d1-46ec-924c-0b522b4a8142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_91d4b4b8-e31a-4ecc-93e7-346d7ebfa67a" xlink:href="krys-20221231.xsd#krys_OtherContractualObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:to="loc_krys_OtherContractualObligationsMember_91d4b4b8-e31a-4ecc-93e7-346d7ebfa67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_7ce4002a-87a6-456a-886c-684ff5725f2b" xlink:href="krys-20221231.xsd#krys_ASTRAFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_de256010-b73a-4653-b25d-eb512dd02d44" xlink:to="loc_krys_ASTRAFacilityMember_7ce4002a-87a6-456a-886c-684ff5725f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_60a00640-b85d-4135-aff4-95a7e8c7f6ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b0886faa-4df0-471e-b303-1d86f47ae844" xlink:to="loc_srt_LitigationCaseTypeDomain_60a00640-b85d-4135-aff4-95a7e8c7f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_3518048b-587a-4764-8444-c5db30714163" xlink:href="krys-20221231.xsd#krys_PeriphaGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_60a00640-b85d-4135-aff4-95a7e8c7f6ed" xlink:to="loc_krys_PeriphaGenMember_3518048b-587a-4764-8444-c5db30714163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:href="krys-20221231.xsd#krys_MilestonesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:href="krys-20221231.xsd#krys_MilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesAxis_a0028a2f-3e06-40d0-a92c-4edd70c5536d" xlink:to="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_db4d80e6-7962-4a1b-a18c-a608a20ed3af" xlink:href="krys-20221231.xsd#krys_MilestoneThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:to="loc_krys_MilestoneThreeMember_db4d80e6-7962-4a1b-a18c-a608a20ed3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_a6dd0bcb-f24c-4041-992f-c6aafcf52784" xlink:href="krys-20221231.xsd#krys_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:to="loc_krys_MilestoneTwoMember_a6dd0bcb-f24c-4041-992f-c6aafcf52784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_a59db918-4e8d-42a9-9905-42cc5f4b6710" xlink:href="krys-20221231.xsd#krys_MilestoneOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_0fbb407f-de8d-4b8a-88a8-e31395fb2025" xlink:to="loc_krys_MilestoneOneMember_a59db918-4e8d-42a9-9905-42cc5f4b6710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_af8152a7-770f-4601-8162-968f367f94aa" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_e00c6502-3a88-4c19-ab82-0ba8226c29ae" xlink:href="krys-20221231.xsd#krys_RemainingCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_RemainingCommitmentAmount_e00c6502-3a88-4c19-ab82-0ba8226c29ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_781ecdd1-d776-4cc1-9411-f3dbb13f2d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_781ecdd1-d776-4cc1-9411-f3dbb13f2d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_453d4c11-d36b-403d-8b8d-6157b0200145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ProfessionalFees_453d4c11-d36b-403d-8b8d-6157b0200145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_353a8e27-ddee-4307-aeef-0e8c26dd193e" xlink:href="krys-20221231.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_353a8e27-ddee-4307-aeef-0e8c26dd193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_30977e73-9a47-4745-b118-a77c0d90b4de" xlink:href="krys-20221231.xsd#krys_CostOfWorkPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_CostOfWorkPercentage_30977e73-9a47-4745-b118-a77c0d90b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_8bd05859-12d8-4855-8283-8b314e54f000" xlink:href="krys-20221231.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_8bd05859-12d8-4855-8283-8b314e54f000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_587640be-db19-4156-9591-bdb9f9469a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_LitigationSettlementExpense_587640be-db19-4156-9591-bdb9f9469a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_68e910a4-fb32-4962-a8cf-a3a309185924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_68e910a4-fb32-4962-a8cf-a3a309185924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_a9e95661-889c-4cd5-a2ed-23bd89c06305" xlink:href="krys-20221231.xsd#krys_NumberOfMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_NumberOfMilestones_a9e95661-889c-4cd5-a2ed-23bd89c06305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_963988ee-d98a-4168-9739-1575f8e6c378" xlink:href="krys-20221231.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_963988ee-d98a-4168-9739-1575f8e6c378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_cd3d6368-5f73-4cf1-bd3b-d0dca60a5d4a" xlink:href="krys-20221231.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_krys_LitigationSettlementTotalConsideration_cd3d6368-5f73-4cf1-bd3b-d0dca60a5d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_2a72fca5-4243-44ba-ac9e-60e2aac315c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_2a72fca5-4243-44ba-ac9e-60e2aac315c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_5eb150b4-d1be-4cd0-ba73-3cb51ccf4086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_27b94916-7423-4a95-895f-2bc656e488d7" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_5eb150b4-d1be-4cd0-ba73-3cb51ccf4086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6bf38d2c-ce2d-4ca1-baf4-1b77f4beebcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6bf38d2c-ce2d-4ca1-baf4-1b77f4beebcf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_27dc3834-332d-423e-8977-8f2505771c5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_db74a133-7a85-4d39-9cb1-30a5837b8965" xlink:href="krys-20221231.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_db74a133-7a85-4d39-9cb1-30a5837b8965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShortTermAmendmentMember_68b33e5b-40fc-4129-bb49-ca9449e9eaaf" xlink:href="krys-20221231.xsd#krys_ShortTermAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_ShortTermAmendmentMember_68b33e5b-40fc-4129-bb49-ca9449e9eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember_7f49ba10-24ea-4e70-b551-d8cf6fe5ad26" xlink:href="krys-20221231.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_BostonMassachusettsLeaseMember_7f49ba10-24ea-4e70-b551-d8cf6fe5ad26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember_3cc757be-a864-4a13-af19-4e58b94a985c" xlink:href="krys-20221231.xsd#krys_SwitzerlandLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f74056c3-45d2-4bc1-9bf9-26d3a9124f90" xlink:to="loc_krys_SwitzerlandLeaseMember_3cc757be-a864-4a13-af19-4e58b94a985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a8cb75ed-629a-4ae3-bca2-cb46476360eb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_553223f2-05d8-457f-8818-4e915fda6cc8" xlink:href="krys-20221231.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_553223f2-05d8-457f-8818-4e915fda6cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_c3070f05-0303-4f59-ad32-ee66717a924f" xlink:href="krys-20221231.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_c3070f05-0303-4f59-ad32-ee66717a924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_40d7edc4-0d14-4593-94be-fc98fb2dfde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_ConstructionInProgressGross_40d7edc4-0d14-4593-94be-fc98fb2dfde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_19d74851-20af-4aca-96b4-3f3f8e8b7292" xlink:href="krys-20221231.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_19d74851-20af-4aca-96b4-3f3f8e8b7292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_c65eb526-359c-4e6b-90e5-d43b841b622b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_EscrowDeposit_c65eb526-359c-4e6b-90e5-d43b841b622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbb37179-d4fe-4a3a-84ea-1c85bdd904a1" xlink:href="krys-20221231.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbb37179-d4fe-4a3a-84ea-1c85bdd904a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_65b31db6-b5ad-4b11-b440-425f63218eac" xlink:href="krys-20221231.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_CumulativeEscalationClausePercent_65b31db6-b5ad-4b11-b440-425f63218eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_ed90fb7c-ff57-4171-9aa2-278866e7f5c0" xlink:href="krys-20221231.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_krys_CumulativeEscalationClauseTerm_ed90fb7c-ff57-4171-9aa2-278866e7f5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c7f64376-0034-4e40-bf04-190d6bbd576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8bad7322-8270-45ea-9854-d56cf29cf859" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c7f64376-0034-4e40-bf04-190d6bbd576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesMinimumcommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1610929f-0fe3-4d19-98cb-e13c6bccc899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1610929f-0fe3-4d19-98cb-e13c6bccc899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cfe4b31a-1411-4e5f-be63-580050e34e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cfe4b31a-1411-4e5f-be63-580050e34e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9e55212b-2fad-48e8-b8ed-619b452ba672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9e55212b-2fad-48e8-b8ed-619b452ba672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a786f4b9-3122-4ba3-9b9f-c281f2afad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a786f4b9-3122-4ba3-9b9f-c281f2afad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_11bbce0a-1153-445b-8f1d-f103f32b8e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_11bbce0a-1153-445b-8f1d-f103f32b8e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_53a8b50d-7572-44a4-9cc0-42b0cc1f5554" xlink:href="krys-20221231.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_53a8b50d-7572-44a4-9cc0-42b0cc1f5554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a50c431-5f3e-42f0-b889-89b6e62d8235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9a50c431-5f3e-42f0-b889-89b6e62d8235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d5b17d3e-5867-4be6-a194-0a4f405117e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d5b17d3e-5867-4be6-a194-0a4f405117e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c2a37d7c-74fa-45bf-9691-fe12600b8dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f7e9a1e-9549-4a9e-b3d1-65e590e76694" xlink:to="loc_us-gaap_OperatingLeaseLiability_c2a37d7c-74fa-45bf-9691-fe12600b8dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesMinimumcommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_07f75d87-d76a-450f-8bb4-b1e5dabbe8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_07f75d87-d76a-450f-8bb4-b1e5dabbe8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7fb5fcda-86e3-4d4b-8c61-555a47a95840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7fb5fcda-86e3-4d4b-8c61-555a47a95840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a7980d4c-1991-4543-8eb9-de1697a9f8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a7980d4c-1991-4543-8eb9-de1697a9f8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1c3c9d9c-7dde-4cb8-9782-7e47be9f815b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:to="loc_us-gaap_OperatingLeaseLiability_1c3c9d9c-7dde-4cb8-9782-7e47be9f815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_352174c8-d8b1-43d2-bb7b-2f4ba1a64078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_352174c8-d8b1-43d2-bb7b-2f4ba1a64078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3441b8b7-b177-42de-bf60-89f60109d062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39f13a9f-a49a-4dbc-853d-1752279342c8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3441b8b7-b177-42de-bf60-89f60109d062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#LeasesLeaseexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2daae8cb-0d4d-42b9-a3c7-b9d7f843a7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4c8a0678-c0a6-4c64-8cd1-0639b03036cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2daae8cb-0d4d-42b9-a3c7-b9d7f843a7cb" xlink:to="loc_us-gaap_OperatingLeaseCost_4c8a0678-c0a6-4c64-8cd1-0639b03036cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_81a381f4-c50b-4ba2-a3da-482813399f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2daae8cb-0d4d-42b9-a3c7-b9d7f843a7cb" xlink:to="loc_us-gaap_VariableLeaseCost_81a381f4-c50b-4ba2-a3da-482813399f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_481a2bad-b524-4f26-bb60-ae60bc310c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2daae8cb-0d4d-42b9-a3c7-b9d7f843a7cb" xlink:to="loc_us-gaap_LeaseCost_481a2bad-b524-4f26-bb60-ae60bc310c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8350ee99-0a28-4a35-ade0-c0bc570b725f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8350ee99-0a28-4a35-ade0-c0bc570b725f" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4df35edc-374c-4f29-a729-03918e066885" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_552853b6-6c09-4235-835c-16e9561cd008" xlink:href="krys-20221231.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_krys_PublicOfferingMember_552853b6-6c09-4235-835c-16e9561cd008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3d9dd383-cf31-47c1-8a0f-271132a300e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3d9dd383-cf31-47c1-8a0f-271132a300e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_2c2d8bc9-06bc-40a5-8171-19766ebf7953" xlink:href="krys-20221231.xsd#krys_PlacementSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_krys_PlacementSharesMember_2c2d8bc9-06bc-40a5-8171-19766ebf7953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_fdbfd09b-c7d3-4025-adfb-2b608ea4ecde" xlink:href="krys-20221231.xsd#krys_ATMProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eb20d402-0d31-4354-9a2e-7659f8e10b4b" xlink:to="loc_krys_ATMProgramMember_fdbfd09b-c7d3-4025-adfb-2b608ea4ecde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_324b23d2-7e01-4af7-a3a2-c2876d2e39e0" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f4c9e69c-4167-4345-ad73-1611632df36c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f4c9e69c-4167-4345-ad73-1611632df36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cf36536c-d25a-40ba-b9e7-1ef1e818d832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cf36536c-d25a-40ba-b9e7-1ef1e818d832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0881f865-2663-4587-b805-2a564d80c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0881f865-2663-4587-b805-2a564d80c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_8327ea72-8c31-4948-9ab6-962276f4f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_8327ea72-8c31-4948-9ab6-962276f4f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ecf57ecf-a667-4033-bab9-68b72b409f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ecf57ecf-a667-4033-bab9-68b72b409f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_277a6e76-4f9c-4ad0-85f1-089b28c2e648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_277a6e76-4f9c-4ad0-85f1-089b28c2e648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0bab58a0-2726-4680-bfcc-edfae4ad5a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0bab58a0-2726-4680-bfcc-edfae4ad5a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_99fd6158-794b-407c-8820-a2396662c0a2" xlink:href="krys-20221231.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_99fd6158-794b-407c-8820-a2396662c0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_22d6928e-b101-4e82-8357-f7e1cdd177d1" xlink:href="krys-20221231.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_ba9948ff-27df-4290-8274-3a3c6752c3fe" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_22d6928e-b101-4e82-8357-f7e1cdd177d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c239ec6-b7fa-44d0-82e9-2b1c3ddb17ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c239ec6-b7fa-44d0-82e9-2b1c3ddb17ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_138841c8-1607-4cf7-8a70-09f804e4b7b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_075c63d8-d2ce-478f-a566-1fd5001b5b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_us-gaap_EmployeeStockOptionMember_075c63d8-d2ce-478f-a566-1fd5001b5b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_7c8a9049-f7f8-40d8-a2f4-31119a9e39f9" xlink:href="krys-20221231.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_krys_NonEmployeeStockOptionMember_7c8a9049-f7f8-40d8-a2f4-31119a9e39f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_97f046cc-e9db-4ac8-94a9-54e35d99c3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_us-gaap_RestrictedStockMember_97f046cc-e9db-4ac8-94a9-54e35d99c3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_8175d388-0d69-4414-b5df-f38e37244c63" xlink:href="krys-20221231.xsd#krys_IncentiveStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcc2714f-76ed-4dff-a3db-daaef8dd4852" xlink:to="loc_krys_IncentiveStockOptionsMember_8175d388-0d69-4414-b5df-f38e37244c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_979a71a6-68bf-45d2-a7b6-eeebc9c1fa16" xlink:to="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fe32c56e-ce15-4bb8-a3ad-39d77f1b3ed6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:to="loc_srt_MinimumMember_fe32c56e-ce15-4bb8-a3ad-39d77f1b3ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aeaca4a8-a385-45ee-96b8-2f4a11b81977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4443253e-4b89-4a1b-8a63-f5ba1b29ad92" xlink:to="loc_srt_MaximumMember_aeaca4a8-a385-45ee-96b8-2f4a11b81977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96023f8f-ad1a-4376-9d79-7f2d656032f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_cfb89424-f30f-42b6-801a-3cdb51a7705c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96023f8f-ad1a-4376-9d79-7f2d656032f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_074092a0-b775-41b2-8358-015912c7a168" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96023f8f-ad1a-4376-9d79-7f2d656032f3" xlink:to="loc_srt_DirectorMember_074092a0-b775-41b2-8358-015912c7a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e39c630b-fc93-433c-adb3-713093d4c248" xlink:to="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_6e3eef14-80e1-42f1-9683-5191d99f564f" xlink:href="krys-20221231.xsd#krys_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:to="loc_krys_StockIncentivePlanMember_6e3eef14-80e1-42f1-9683-5191d99f564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_A2017IPOStockPlanMember_311cc259-5705-4f14-b3ec-1f82f89b0120" xlink:href="krys-20221231.xsd#krys_A2017IPOStockPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d750d451-d8e3-475d-b822-d35af1007303" xlink:to="loc_krys_A2017IPOStockPlanMember_311cc259-5705-4f14-b3ec-1f82f89b0120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8e2ca25-eb13-49b4-8462-e9e584817f5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94901cb0-682f-427f-97ff-1c4976a9e029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94901cb0-682f-427f-97ff-1c4976a9e029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_0a47b4a9-d9bf-499b-ac35-69d0ddfce4a2" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized_0a47b4a9-d9bf-499b-ac35-69d0ddfce4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7b6a0bb-0390-4d98-af6f-8980d2665afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d7b6a0bb-0390-4d98-af6f-8980d2665afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8328d81a-3c7a-420e-8c06-d3726eaea5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8328d81a-3c7a-420e-8c06-d3726eaea5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4b33960d-79a3-4456-afb7-b90316f637a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4b33960d-79a3-4456-afb7-b90316f637a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b2381774-4778-4392-8ca2-00bec4f61059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b2381774-4778-4392-8ca2-00bec4f61059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d88ae257-d586-4900-bd28-2feac77ee086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d88ae257-d586-4900-bd28-2feac77ee086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63263538-546c-4398-bc3d-f9293a5f8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_63263538-546c-4398-bc3d-f9293a5f8f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99707a6e-5333-4c7f-990d-09478c956719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_99707a6e-5333-4c7f-990d-09478c956719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b8598999-1eab-496f-b3a9-c486d8b0f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_b8598999-1eab-496f-b3a9-c486d8b0f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de5196b6-fe3d-4751-aae8-c7853d561af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_de5196b6-fe3d-4751-aae8-c7853d561af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_668b3ba0-81ef-418d-b9bf-b2f550a2cce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13b05f19-6019-4791-af69-dac7c021a7b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_668b3ba0-81ef-418d-b9bf-b2f550a2cce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16585cc8-c5d1-4f5d-b3bf-a8f33dc34da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16585cc8-c5d1-4f5d-b3bf-a8f33dc34da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_411e7d5e-5b3b-44fb-8bab-e0e0b395264a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_411e7d5e-5b3b-44fb-8bab-e0e0b395264a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f6abf6e-9769-4542-8e07-74656455de83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f6abf6e-9769-4542-8e07-74656455de83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40ef1680-9537-4199-b098-5c8a018624c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40ef1680-9537-4199-b098-5c8a018624c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b793ab16-8fdb-4ed3-8959-209b72e01a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b793ab16-8fdb-4ed3-8959-209b72e01a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99b4bc09-7117-4e28-a4c0-977dfc6df208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6bcd81e-8323-4f3a-bf36-d44ddafa6428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99b4bc09-7117-4e28-a4c0-977dfc6df208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78f58d2a-8174-4fa4-b150-ba38a772d10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78f58d2a-8174-4fa4-b150-ba38a772d10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9251310d-7724-4538-844b-95a768f36738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9251310d-7724-4538-844b-95a768f36738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85b9c240-8775-4da6-96ae-5da4b1b8f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_85b9c240-8775-4da6-96ae-5da4b1b8f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42811705-3f89-49f1-a801-637a8fca4f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42811705-3f89-49f1-a801-637a8fca4f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_493193d3-fcb2-40e3-afc9-6903f0ec795e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_493193d3-fcb2-40e3-afc9-6903f0ec795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8028179c-7b5b-4449-9bc5-acff73db0299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8028179c-7b5b-4449-9bc5-acff73db0299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e287ecda-8716-4621-bdc4-ebd806632cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5616a8cd-0518-4fb6-bdac-361dd3d1da69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e287ecda-8716-4621-bdc4-ebd806632cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5bd369d8-1e2b-4266-8ba9-8e6f9effda82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5bd369d8-1e2b-4266-8ba9-8e6f9effda82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22730e39-118a-40f8-ac2f-6dbceaf961bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22730e39-118a-40f8-ac2f-6dbceaf961bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_61e3cc4d-26c9-4612-8d11-5ef57ac41f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22730e39-118a-40f8-ac2f-6dbceaf961bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_61e3cc4d-26c9-4612-8d11-5ef57ac41f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9b4ae23b-e4db-4602-a47a-a487d946ab62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9b4ae23b-e4db-4602-a47a-a487d946ab62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d6532a9c-db26-4fa7-bab1-b891fa754c24" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d6532a9c-db26-4fa7-bab1-b891fa754c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_893dc553-a134-4aac-85ee-9b2541c3f572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_d6532a9c-db26-4fa7-bab1-b891fa754c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_893dc553-a134-4aac-85ee-9b2541c3f572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f57da7fb-06e0-4cbc-a473-3f9e31a6dbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6771e618-86ea-4c50-b660-b85a063f58eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f57da7fb-06e0-4cbc-a473-3f9e31a6dbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2b67741-5ebf-4d25-bd5e-6c008fde503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e2b67741-5ebf-4d25-bd5e-6c008fde503d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4c50937-af0a-40cf-94f8-0a9b4aeccbc2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923825d6-52f3-4fea-96dd-84adcf454207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_923825d6-52f3-4fea-96dd-84adcf454207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_070042fc-a6bc-46cf-89f0-7d6b786de03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9355aac-14ae-4763-a406-3f61bf623d45" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_070042fc-a6bc-46cf-89f0-7d6b786de03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:to="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_353bd532-5efc-46d9-9b17-d0475f04cfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b72b08b3-c539-436a-9f02-4edcf7ba6780" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_353bd532-5efc-46d9-9b17-d0475f04cfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f68273db-70cd-480e-821b-18ee85c230e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_353bd532-5efc-46d9-9b17-d0475f04cfd9" xlink:to="loc_us-gaap_RestrictedStockMember_f68273db-70cd-480e-821b-18ee85c230e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6214e61-3b04-4e5e-96a1-724fcfdda99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79b8fe88-11e7-47eb-b3f8-9fa542435136" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6214e61-3b04-4e5e-96a1-724fcfdda99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_af0f3d8e-e097-4861-805d-81a2f6279fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6214e61-3b04-4e5e-96a1-724fcfdda99f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_af0f3d8e-e097-4861-805d-81a2f6279fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_794dfbba-7595-4699-a21e-adfbf1c8304b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_794dfbba-7595-4699-a21e-adfbf1c8304b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:to="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8563e98-be97-4be8-b2b8-b52b2f3cf40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e71f2a0d-de45-49cb-acfc-83bb8cc8984b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8563e98-be97-4be8-b2b8-b52b2f3cf40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0a3defd3-06bc-4f2e-bcda-8fdfe62b94ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c8563e98-be97-4be8-b2b8-b52b2f3cf40c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0a3defd3-06bc-4f2e-bcda-8fdfe62b94ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef81d15-2d84-411e-9240-38d2b8c43e3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82ec5ccd-a397-4f00-b375-8af69be431b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82ec5ccd-a397-4f00-b375-8af69be431b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f0690d-dc7d-405b-a0c2-2be12f11ed14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_24f0690d-dc7d-405b-a0c2-2be12f11ed14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8fa27e38-f5a7-4e9d-aacb-58bcbcd1c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8fa27e38-f5a7-4e9d-aacb-58bcbcd1c4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_ae1872d5-a406-4d44-88e0-9ef649c2908f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_ae1872d5-a406-4d44-88e0-9ef649c2908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_62b042ec-435a-4af5-94b3-1cc1468af18d" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_62b042ec-435a-4af5-94b3-1cc1468af18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef6e9d5-8c53-4ae9-93d3-9841f488e153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db944783-0850-45d1-8c40-64809d67bfc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4ef6e9d5-8c53-4ae9-93d3-9841f488e153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40b91f4a-37dc-4c82-ba32-537232e9f6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40b91f4a-37dc-4c82-ba32-537232e9f6a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:to="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ff876b1-bb01-4c8d-8bd2-6a2239d4fee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_851a35b8-2d2a-4812-bb5f-34e4986c472b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ff876b1-bb01-4c8d-8bd2-6a2239d4fee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_294d9ddf-0662-4e41-92b6-c7b2d49829e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ff876b1-bb01-4c8d-8bd2-6a2239d4fee7" xlink:to="loc_us-gaap_RestrictedStockMember_294d9ddf-0662-4e41-92b6-c7b2d49829e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4681f11b-7a69-4569-900b-09dd28c335f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c4cb791-b888-4b5b-8362-e24188d4a903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c4cb791-b888-4b5b-8362-e24188d4a903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ea564d34-b452-44d7-8f90-d421b4c4d52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ea564d34-b452-44d7-8f90-d421b4c4d52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_282d1fcc-ae33-466c-8a94-532fcd33162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_282d1fcc-ae33-466c-8a94-532fcd33162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_4e13b33f-6784-4bb6-bc30-8ece564d2de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_4e13b33f-6784-4bb6-bc30-8ece564d2de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1355cbaa-d03d-476f-9fb9-72291bd3f62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1aff7fac-121c-4ad5-86cf-2ca3440a0e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1355cbaa-d03d-476f-9fb9-72291bd3f62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef326ad4-c548-49fb-b959-99251a4a8e1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da18c1e7-f34d-4455-84a6-f61d68d62d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_da18c1e7-f34d-4455-84a6-f61d68d62d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995f94d2-a91d-4de0-b18b-11399588a9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995f94d2-a91d-4de0-b18b-11399588a9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_153a1249-f502-4b7c-bb6e-d8f53ce02ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_153a1249-f502-4b7c-bb6e-d8f53ce02ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_43acb950-bf39-40d7-851e-40f38e116c28" xlink:href="krys-20221231.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_43acb950-bf39-40d7-851e-40f38e116c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4765623-1a0d-44a5-94e9-5b3779bb006b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_00596329-2b37-48ff-8bc2-6ba08b8dcac7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c4765623-1a0d-44a5-94e9-5b3779bb006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cffc2225-de1c-453a-8fc8-1391d2a3fa97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:href="krys-20221231.xsd#krys_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cffc2225-de1c-453a-8fc8-1391d2a3fa97" xlink:to="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2ebbd3bb-bf46-4c6c-8f79-852b0e1e1962" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_798d6526-3f9a-4bcf-b67d-7e4470e516ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:to="loc_us-gaap_DomesticCountryMember_798d6526-3f9a-4bcf-b67d-7e4470e516ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_3b8893ac-a692-4386-828f-d1630ecf0a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_849fbebb-dc01-4e45-b55d-10ae14337230" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_3b8893ac-a692-4386-828f-d1630ecf0a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_59d64385-5a3b-40c2-8251-bb812239d131" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8497c4d1-d7f8-4f18-a6e0-25bcac8d54e8" xlink:to="loc_srt_RangeMember_59d64385-5a3b-40c2-8251-bb812239d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3fb538c0-0ad8-48b6-aa0f-f88dd70ccc33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_59d64385-5a3b-40c2-8251-bb812239d131" xlink:to="loc_srt_MinimumMember_3fb538c0-0ad8-48b6-aa0f-f88dd70ccc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3bae0d58-a34e-4037-b948-3ccb6f31a83a" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_f82825d1-cccf-4629-9692-1bbba30119b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:to="loc_us-gaap_ResearchMember_f82825d1-cccf-4629-9692-1bbba30119b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OrphanDrugTaxCreditCarryforwardMember_60f31ae4-fc16-43ec-8502-858bd76ef061" xlink:href="krys-20221231.xsd#krys_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77eb103a-e047-4f5a-b608-b261ba5878ad" xlink:to="loc_krys_OrphanDrugTaxCreditCarryforwardMember_60f31ae4-fc16-43ec-8502-858bd76ef061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:href="krys-20221231.xsd#krys_IncomeTaxesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesTable_5738dbfc-db16-496c-9690-bad7a6aed906" xlink:to="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a5298a2-eb6b-4004-92ca-e16d7e660d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a5298a2-eb6b-4004-92ca-e16d7e660d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_296fe2c2-1171-44b8-8c37-1b603d418fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_296fe2c2-1171-44b8-8c37-1b603d418fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a30e9f35-6c5c-469b-9fe1-1d629d9a4c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a30e9f35-6c5c-469b-9fe1-1d629d9a4c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c76a553-28d6-4465-a11f-edce1660b74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0c76a553-28d6-4465-a11f-edce1660b74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_062b7e2b-795f-4eb4-9fb9-f168b34d7a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_062b7e2b-795f-4eb4-9fb9-f168b34d7a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9636ba10-73f3-445a-b5bc-9f0bec6e784e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9636ba10-73f3-445a-b5bc-9f0bec6e784e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OwnershipInterestRateChangeOverPeriod_e750dca4-2597-458e-884d-d4da4365fd90" xlink:href="krys-20221231.xsd#krys_OwnershipInterestRateChangeOverPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_krys_OwnershipInterestRateChangeOverPeriod_e750dca4-2597-458e-884d-d4da4365fd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeChangesInOwnershipInterestOfShareholders_eef93d55-f517-4b70-9db3-c128014f88c9" xlink:href="krys-20221231.xsd#krys_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_IncomeTaxesLineItems_4e447dd8-6af5-48d6-9596-c73bcc651acf" xlink:to="loc_krys_CumulativeChangesInOwnershipInterestOfShareholders_eef93d55-f517-4b70-9db3-c128014f88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_406f1b12-0342-44cb-9663-88ac1765e3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_406f1b12-0342-44cb-9663-88ac1765e3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9eaa02a1-e478-4ad1-95d5-4e93d4ae7109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9eaa02a1-e478-4ad1-95d5-4e93d4ae7109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_43ec9503-4b7e-4430-a27f-774c81c05eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_43ec9503-4b7e-4430-a27f-774c81c05eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_144d4e7f-877d-4e25-9416-97d78f841637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_144d4e7f-877d-4e25-9416-97d78f841637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_d06bb26d-bdc2-41ae-853e-0d1163b4f959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_d06bb26d-bdc2-41ae-853e-0d1163b4f959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_9fd61480-28bf-4a7d-839e-9feaf9b29de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_9fd61480-28bf-4a7d-839e-9feaf9b29de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_65ecb111-5dae-497c-8af8-3c7e7877ecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8e63c-e14d-4608-a745-3d2b53894aba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_65ecb111-5dae-497c-8af8-3c7e7877ecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="krys-20221231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2762814c-c64d-407f-a343-543642816e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2762814c-c64d-407f-a343-543642816e9e" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_dce5a235-dee3-403f-91d9-afcb888dde71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_dce5a235-dee3-403f-91d9-afcb888dde71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_766a938c-3d61-4d0c-890a-ed2fb8c212dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_766a938c-3d61-4d0c-890a-ed2fb8c212dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_DeferredTaxAssetsLeaseLiability_f9351e11-9784-4f57-b678-6e6da49a33e1" xlink:href="krys-20221231.xsd#krys_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_krys_DeferredTaxAssetsLeaseLiability_f9351e11-9784-4f57-b678-6e6da49a33e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_27eca7fe-2e23-4ab3-8187-15232ac72c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_27eca7fe-2e23-4ab3-8187-15232ac72c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2802b0c7-8f5f-44f0-a107-5ced87d66e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2802b0c7-8f5f-44f0-a107-5ced87d66e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_487db9e0-8c94-4990-b09c-e0bbbb863758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_487db9e0-8c94-4990-b09c-e0bbbb863758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_bd1f1b0d-0f6c-452f-8dea-c3ea9b869ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_bd1f1b0d-0f6c-452f-8dea-c3ea9b869ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_1f6966f0-7f1e-4dfb-b037-f5fa843df53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_1f6966f0-7f1e-4dfb-b037-f5fa843df53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_64988ba7-bfba-49f2-b73e-00232c85285b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_64988ba7-bfba-49f2-b73e-00232c85285b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98404155-dff2-4bd7-8243-3e55e9c0216c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98404155-dff2-4bd7-8243-3e55e9c0216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_350d3c58-221a-47ed-ad9b-4d015cde84ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_350d3c58-221a-47ed-ad9b-4d015cde84ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fb33ef5-9dd4-49a6-b649-6ec411567262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cc2ca9e8-56c5-4058-9f88-cf1e993c473c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fb33ef5-9dd4-49a6-b649-6ec411567262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_665f8441-e8c3-4d37-acd3-368fe0cd11cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fb33ef5-9dd4-49a6-b649-6ec411567262" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_665f8441-e8c3-4d37-acd3-368fe0cd11cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_DeferredTaxLiabilitiesRightOfUseAsset_e23ee748-677c-4af8-b470-363a15fc48ba" xlink:href="krys-20221231.xsd#krys_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fb33ef5-9dd4-49a6-b649-6ec411567262" xlink:to="loc_krys_DeferredTaxLiabilitiesRightOfUseAsset_e23ee748-677c-4af8-b470-363a15fc48ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2747acec-bccc-480e-aa5b-81f133ed4afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fb33ef5-9dd4-49a6-b649-6ec411567262" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2747acec-bccc-480e-aa5b-81f133ed4afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_32297118-0a3f-41b2-a932-b8a308fddd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fb33ef5-9dd4-49a6-b649-6ec411567262" xlink:to="loc_us-gaap_DeferredTaxLiabilities_32297118-0a3f-41b2-a932-b8a308fddd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7f32afab-da26-4447-b2da-31c45ee576c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2762814c-c64d-407f-a343-543642816e9e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7f32afab-da26-4447-b2da-31c45ee576c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>krys-20221231_g1.jpg
<TEXT>
begin 644 krys-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :&!2T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!KCP3\>+SQ)I=G:ZWX0\2^'%675O#OC"Q_L^_M(F&1*\99ALQ@DAOEW+N
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MB'E7![=P002"">ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX3C2?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\
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MTG^_=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !%
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M5@_\)QI/]^[_ / "X_\ B*/^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&D_W[O_P
MN/\ XBC_ (3C2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*/^$XTG^_
M=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !% &]16
M#_PG&D_W[O\ \ +C_P"(H_X3C2?[]W_X 7'_ ,10!O45@_\ "<:3_?N__ "X
M_P#B*KWWQ&T'3+5[F[N;BWMTQNDDL9P!D@#^#U(H Z:BL'_A.-)_OW?_ ( 7
M'_Q%'_"<:3_?N_\ P N/_B* -ZBL'_A.-)_OW?\ X 7'_P 11_PG&D_W[O\
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MX3C2?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\
M$4 ;U%8/_"<:3_?N_P#P N/_ (BC_A.-)_OW?_@!<?\ Q% &]16#_P )QI/]
M^[_\ +C_ .(H_P"$XTG^_=_^ %Q_\10!O45S,OQ&T&"[@M9+FX2XG#&*,V,^
MY]HR<?)V%6/^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&D_W[O_P N/\ XBC_ (3C
M2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*/^$XTG^_=_\ @!<?_$4
M;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !% &]16#_PG&D_W[O\
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MI/\ ?N__   N/_B* -ZBL'_A.-)_OW?_ ( 7'_Q%'_"<:3_?N_\ P N/_B*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\?O$/P9\%_%*Q\&+\.]%L?[=\82>&K>\NM;U"6)2S"VD/E0QL23A#\I7JP(
M\[F_;[^*<?[-NHZ<XTE/C)#X]_X5Y%K,< -F9CD_:_**[0PPRXP5R VW'R4
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MG_X3/Q#;QE;S7?[/CL?M;%B0WD1DI'A2%P#_  Y[UTE !1110 4444 %%%%
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MO(-/M)[JZGCMK6!&EEFF<(D:*,LS,>   22:_/+P+^TWXF^#/[+?[,D/PW\
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MJG[57["'[1!UNVT4ZGX;A2T.I>'%N8]/OXI&5DDBCN0)DY1N' .,<#D5]V_
M7_DAOPZ_[%S3O_26.@#=U7PO_:?BS0M:^U>7_9:SKY'EY\SS%"_>SQC'H<UO
M5R7B#7;ZQ^(7A33(9]EE?)=FXBV*=Y2,%>2,C!]"*ZV@#A?&'QW^&GP[UC^R
M?%7Q#\*>&=5\M9?L.L:W;6D^QL[6V2.&P<'!Q@XJ/Q_\>O /PQ\!VGC7Q#XE
MMH/"MW/%;6^J6:27L4KRDB,+Y"N2"0?F QZFO@[]H+6?"^A_\%)-<F\6?"76
M/C)IS^ H(X]!T7P[%K4T,IG7%P89" BJ R^8.09 /XJ\M^(GPA\8_!__ ()\
M>))?$?A^3PM'K_Q&MM:T;PA-<;Y-,M7;$<+L?N,=N,$ @ %@"2  ?L K!E!'
M(/(I:^1_AO\ M)?&#0_VG- ^%7Q=\,^$=/M_%6D3ZKHEQX6N;B:2U\K<Q@N7
ME.)'"H06157.",@X'@_BC_@J%XP\$?%*#3;V^^%?B+1FUI=/FT'PU)JMQJL,
M#2E"_P!L:,6;LH&3M8Y)&!UP ?IA17Q)\<OVUOB'X"_::O?AQHVF^!=!TO3X
M;:Y@D\=7EU93>(UD5"ZV%P +:-E9C'^]8@L/9E'-_M7?\%(M4^$OQIU?X>>%
M+KP3H$V@VL4NH:EXV@U2Z2ZGD02"WMX[")BK*K+EY"%)8CC;D@'W_6!-\0/"
M]OXP@\)2^)-(C\53PFYBT-[Z(7TD0!)D6#=O*X4_,!C@^E>?_LF_'T?M,_ G
MP[\0&TDZ)<ZAYT5Q9;RZ)+%(T;%&(&4)7(],X[9KYIU#X7^%_A?_ ,%0?A=!
MX9TF/31J7AC5=0OIO,>::ZN'-QNDEED9G=N@^8G   P!B@#[5^('CK2?ACX'
MU[Q9KLS0:/HME+?74B+N;RXU+$*.['& .Y(KD?#O[1G@;5/A5X8^(&N:Q:^
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M%?#7P?\ \*\^'?A?PM]K_M#^Q-,MM-^U^5Y?G>3$L>_9D[<[<XR<9ZFNDHH
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MAN/_  &@_P#B*-VN?]##<?\ @-!_\10!W=%<)NUS_H8;C_P&@_\ B*-VN?\
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MHW:Y_P!##<?^ T'_ ,10!W=%<)NUS_H8;C_P&@_^(HW:Y_T,-Q_X#0?_ !%
M'=T5PF[7/^AAN/\ P&@_^(HW:Y_T,-Q_X#0?_$4 =W5#2-=L=>6Z:QG\];6X
M>UF^1EVRIC<O(&<9'(XKD]VN?]##<?\ @-!_\17/>#-)\0:/#JZR:G-8FXU*
M:X4+% _F!B,2?=."<=.,8Z4 >N45PF[7/^AAN/\ P&@_^(HW:Y_T,-Q_X#0?
M_$4 =W17";M<_P"AAN/_  &@_P#B*-VN?]##<?\ @-!_\10!W=%<)NUS_H8;
MC_P&@_\ B*-VN?\ 0PW'_@-!_P#$4 =W17";M<_Z&&X_\!H/_B*-VN?]##<?
M^ T'_P 10!W=%<)NUS_H8;C_ ,!H/_B*-VN?]##<?^ T'_Q% '=T5PF[7/\
MH8;C_P !H/\ XBC=KG_0PW'_ (#0?_$4 =9=:[8V.K6.F33[+V^$AMXMC'>$
M&6Y P,#U(J_7D>L:3X@N_&'A^_74YIH[1;@-=&* &'>@  7;\V[IT./:NAW:
MY_T,-Q_X#0?_ !% '=T5PF[7/^AAN/\ P&@_^(HW:Y_T,-Q_X#0?_$4 =W17
M";M<_P"AAN/_  &@_P#B*-VN?]##<?\ @-!_\10!W=%<)NUS_H8;C_P&@_\
MB*-VN?\ 0PW'_@-!_P#$4 =W17";M<_Z&&X_\!H/_B*-VN?]##<?^ T'_P 1
M0!W=%<)NUS_H8;C_ ,!H/_B*-VN?]##<?^ T'_Q% '=U5U/4K;1]/N+Z\D\F
MUMT,DLFTMM4#). "3^%<=NUS_H8;C_P&@_\ B*RO%5CKVJ>&]2M$UB:[>:!T
M$#0P()"1]W.T8S]10!Z59W<5_:07,#;X)D62-L$94C(.#[&IJ\XT6WUVST>P
MMVUR>!HH(T,0@@8(0H&W.TYQ]:N;M<_Z&&X_\!H/_B* .[HKA-VN?]##<?\
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M ,10!W=%<)NUS_H8;C_P&@_^(HW:Y_T,-Q_X#0?_ !% '=T5PF[7/^AAN/\
MP&@_^(HW:Y_T,-Q_X#0?_$4 =W17";M<_P"AAN/_  &@_P#B*-VN?]##<?\
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M_P >:?\ 70?R-8-06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG;\>7L4'ICG.?45L5CZAX?\ M_B/2-5^T>7_ &>LR^3LSYF]0.N>,8]#6Q0
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MCV[XTF9"00 O'RC'7G-7/^%A:')Y'D3W5X9E+JMG87%P0H8IN81H2JDJV"V
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MX(_Z G_DW/\ _%T?7J?9_P!?,/JL^Z/DVBOK+_A1O@C_ * G_DW/_P#%T?\
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MPHWP1_T!/_)N?_XNC_A1O@C_ * G_DW/_P#%T?7J?9_U\P^JS[H^3:*^LO\
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M1K!K V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'[';_\ /"/_ +X%'V.W_P">$?\
MWP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ* (?L=O\ \\(_^^!1]CM_^>$?
M_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'[';_\ /"/_ +X%'V.W
M_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ* (?L=O\ \\(_^^!1
M]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'[';_\ /"/_
M +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ* (?L=O\
M\\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_? J:B@"'['
M;_\ /"/_ +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'_P!\"IJ*
M (?L=O\ \\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_ .>$?_?
MJ:B@"'[';_\ /"/_ +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4?8[?_GA'
M_P!\"IJ* (?L=O\ \\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\ [X%'V.W_
M .>$?_? J:B@"'[';_\ /"/_ +X%'V.W_P">$?\ WP*FHH A^QV__/"/_O@4
M?8[?_GA'_P!\"IJ* (?L=O\ \\(_^^!1]CM_^>$?_? J:B@"'[';_P#/"/\
M[X%'V.W_ .>$?_? J:B@"'[';_\ /"/_ +X%4=:\,Z7XATV;3[^S2:TFV[XU
M)0G#!ARI!'('0UJ5P?QT_P"26:W_ -L/_1\= ';?8[?_ )X1_P#? H^QV_\
MSPC_ .^!4U% $/V.W_YX1_\ ? H^QV__ #PC_P"^!4U% $/V.W_YX1_]\"C[
M';_\\(_^^!4U% $/V.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#?
M H^QV_\ SPC_ .^!4U% $/V.W_YX1_\ ? H^QV__ #PC_P"^!4U% $/V.W_Y
MX1_]\"J.E^&=+T5;E;.S2(7,[W,N26W2-C<?F)QTZ#BM2N#^$?\ QZ^*/^Q@
MO/YK0!VWV.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#? H^QV_\
MSPC_ .^!4U% $/V.W_YX1_\ ? H^QV__ #PC_P"^!4U% $/V.W_YX1_]\"C[
M';_\\(_^^!4U% $/V.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#?
M H^QV_\ SPC_ .^!4U% &7=>&=+O-4LM1FLT:\LPX@DR0%WC#?*#@Y'J#CM5
M[[';_P#/"/\ [X%<3XJ_Y*QX&_ZYWW_HH5WE $/V.W_YX1_]\"C[';_\\(_^
M^!4U% $/V.W_ .>$?_? H^QV_P#SPC_[X%344 0_8[?_ )X1_P#? H^QV_\
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M=EF]QNV[L^5B3'4==F,]LYYZ545=I";LKE__ (65X0_Z&K1/_!C#_P#%4?\
M"RO"'_0U:)_X,8?_ (JO@6BO6^HQ_F/.^M2['WU_PLKPA_T-6B?^#&'_ .*H
M_P"%E>$/^AJT3_P8P_\ Q5? M%'U&/\ ,'UJ78^^O^%E>$/^AJT3_P &,/\
M\51_PLKPA_T-6B?^#&'_ .*KX%HH^HQ_F#ZU+L??7_"RO"'_ $-6B?\ @QA_
M^*H_X65X0_Z&K1/_  8P_P#Q5? M%'U&/\P?6I=C[Z_X65X0_P"AJT3_ ,&,
M/_Q5'_"RO"'_ $-6B?\ @QA_^*KX%HH^HQ_F#ZU+L??7_"RO"'_0U:)_X,8?
M_BJ/^%E>$/\ H:M$_P#!C#_\57P+11]1C_,'UJ78^^O^%E>$/^AJT3_P8P__
M !59/AWXR>&M:COVNM8TK3#;WDEM&LVHQ?OD7&)1DCAL\=1QU-?#=%'U&/\
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M,Z8DV;-N/QSG\*WJP7\+[O'$?B+[5C9IYL?LWE]<R;]^[/X8Q^-;U !1110
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MBCJ7BSP'X;N4N=.\-G3(K4 IG8LLRLS2* 2N"!P2!MS7U+11[20<J/(OB/\
M"7Q_XA\076H^#?B]J7@JWO$1;C3I=)M]2@4JNW,/F;6AR.3@\G)J[\!?V?\
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MCO7950UW0K'Q+I4^FZE!]ILIMOF1;V7.&##E2#U [T 97_"M?"'_ $*NB?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW)'/3O0!FS>-H[,6UK:V]UXGO/L:W<DFE+%M\H\+)EY%7#$'"J6)P>,4L/Q
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M MLY ]3FN_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*V*YN35[M?B)%I@E_P!!;3#<&+:/]9YNW.<9Z=LXKI* "BBB@ HHHH ****
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M%% !6]H/_'F__70_R%8-;V@_\>;_ /70_P A0!I4444 %%%% !1110 4444
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MBM4'EA3%&A8D;L\Y9B>W0#M5]-)L8UM52RMU6T):W"Q*!"2"I*<?+P2..Q-
M'D^GZC?:MJ?PWU6^US[;+J5Q/=?8&CB58,VLQQ'M4-M7=M.XMDXY'0W-&\0:
M_<>&O"5Q=Z_*+CQ%,D$ES]G@5+4".1QY0V8WOL"Y<L,DD*.!7H=KX7T6QO)+
MNVTBPM[N23SGGBMD61I,,-Y8#);#N,]?F/J:EFT'3+C2?[+ETZTDTS:%^QO
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M!B_^)H^O1_E#ZK+N?%]%?:'_  @/AC_H7-)_\ 8O_B:/^$!\,?\ 0N:3_P"
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M **** "M[0?^/-_^NA_D*P:WM!_X\W_ZZ'^0H TJ*** "BBB@ HHHH ****
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M;]F[<ZKUP<?>ST[5L5C^+O#_ /PE7AV[TO[1]E\_9^]V;]NUU;ID9^[CKWH
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MWK(W?G[_ $?;MVX_'.:V*QV\/[O%R:W]HQMLC:>1L]7W;MV?PQBMB@ HHHH
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M!#14WV.X_P">$G_?!H^QW'_/"3_O@T 0T5-]CN/^>$G_ 'P:/L=Q_P \)/\
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M4*UE"\D61$6^>W99" Q3JF>"HP6! SG0:7)X7T7QGJBZ0N@:1-9?Z/HH,?\
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M*F^QW'_/"3_O@T?8[C_GA)_WP: (:*F^QW'_ #PD_P"^#1]CN/\ GA)_WP:
M(:*F^QW'_/"3_O@T?8[C_GA)_P!\&@"&BIOL=Q_SPD_[X-'V.X_YX2?]\&@"
M&BIOL=Q_SPD_[X-'V.X_YX2?]\&@"&M[0?\ CS?_ *Z'^0K'^QW'_/"3_O@U
MM:+&\5JX=&0[R<,,=A0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,^+/^0]X+_["\G_ *07==-7,^+/^0]X+_["\G_I
M!=UO1^)^C_)F-;X5ZK\T=-1116!L%%%% !1110 4444 %%%% !1110 4444
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M]ESOT\WWVGS.F)-FS;C\<Y_"MZ@ HHHH **** "BBB@ HHHH **** "BBB@
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MQGNOAWI-UH/@'PYIM]%Y-[9Z=;P31[@VUUC4,,@D'D'I70T4 %%%% !1110
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MDOAWKM]KUOKS7T_GM:ZQ<VL/R*NV-"NU> ,XR>3S4E'6T444 %%%% !1110
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MK"T@MH$V00HL<:Y)PH& ,GV%35D>$?\ D4]%_P"O*#_T6M:] !1110 4444
M%%%% !1110 4444 %%%% %!M"L6UQ=8,'_$Q6W^RB;>W^JW;MNW..O.<9J_7
M!S?\ERM_^Q?;_P!**[R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KF?%G_(>\%_]A>3_P!(+NNFKF?%G_(>
M\%_]A>3_ -(+NMZ/Q/T?Y,QK?"O5?FCIJ***P-@HHHH **** "BBB@ HHHH
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M_CI_PH_M>T_YZ_\ CI_PKFZ* .D_M>T_YZ_^.G_"C^U[3_GK_P".G_"N;HH
MZ3^U[3_GK_XZ?\*/[7M/^>O_ (Z?\*YNB@#I/[7M/^>O_CI_PH_M>T_YZ_\
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M^.G_  KFZ* .D_M>T_YZ_P#CI_PH_M>T_P">O_CI_P *YNB@#I/[7M/^>O\
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M_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\
MA7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_
M:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I
M_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\
MA7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_
M:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I
M_P ]?_'3_A1_:]I_SU_\=/\ A7-T4 =)_:]I_P ]?_'3_A4]O<1W2%HFW*#C
M."*Y2M[0?^/-_P#KH?Y"@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(M-'6X6TB\H7$S7$GS%MTC?>/)XZ=!Q0!<HHHH **** "BBB@ HHHH ****
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MQ R2'.Z4%4!7(S@ @ HH[U<\)_$C6?B;\9KR#P]J07P+HUNHN98H8W6\F8'
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M9;%I(H^?E&XA2^!C)PN?05Q.H^!]8\1:E<ZC?6^DZ=??V9<:>)K&:1S=F10
M928UVHI&0OSD%NO'(!IZEXXCM_#]TUI>VIU2SMX)KAKJ*5H(BY7AS&O#$$D*
M.>0<8YJ]J?Q!T'1]0GLKJ\=+BW*"?9;2NL&_&UI&52J*<CYF('7G@XYC_A6N
MJ:?X7U7P[87%J^EW<:2P_:)',D-QO#2@MM)=&(+!B=P)(Y&,:OB#P7?:MI?C
M6VAEMU?6X@EN79@$(A"?/A>.1VSQ0!VE+38U*1JIZ@ 4Z@ HHHH **** "BB
MB@ KC_BY_P D]U;_ +9?^CDKL*IZOJ]IH.GRWU]+Y%K%C?)M+8R0HX )ZD4
M7**\NUCXW?V3JU]8_P!B^;]FG>'S/M6-VUB,XV<9Q53_ (7[_P!0+_R<_P#M
M=>FLMQ4E=0_%?YG(\713LY?F>N45Y'_POW_J!?\ DY_]KH_X7[_U O\ R<_^
MUT_[,Q?\GXK_ #%]<H?S?@SURBO(_P#A?O\ U O_ "<_^UT?\+]_Z@7_ ).?
M_:Z/[,Q?\GXK_,/KE#^;\&>N45Y'_P +]_Z@7_DY_P#:Z/\ A?O_ % O_)S_
M .UT?V9B_P"3\5_F'URA_-^#/7**\C_X7[_U O\ R<_^UT?\+]_Z@7_DY_\
M:Z/[,Q?\GXK_ ##ZY0_F_!GKE%>1_P#"_?\ J!?^3G_VNC_A?O\ U O_ "<_
M^UT?V9B_Y/Q7^8?7*'\WX,]<KC_AK_Q[^(/^PS<_S6N3_P"%^_\ 4"_\G/\
M[71_POW_ *@7_DY_]KH_LS%_R?BO\P^N4/YOP9ZY17D?_"_?^H%_Y.?_ &NC
M_A?O_4"_\G/_ +71_9F+_D_%?YA]<H?S?@SURBO(_P#A?O\ U O_ "<_^UT?
M\+]_Z@7_ ).?_:Z/[,Q?\GXK_,/KE#^;\&>N45Y'_P +]_Z@7_DY_P#:Z/\
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M^5?&VD^#O!VE^#-6^&>H0CQN]S"C6VEW[73R;H_G#IO;;\V%V\ [B,'M[/\
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M^61XOW\H\MD9SL! Y7 W=3F@#VFBO'6UR6:XD<:Q>+XV36O)71UNW"_9Q/M
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MG%>*45%:>O\ F><\#3;O=_U\CYU_X5/XK_Z!7_DQ%_\ %T?\*G\5_P#0*_\
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M9U>[M?&GAVPBEV6EVER9H]H.[:@*\XR,'TKI* "BBB@ HHHH **** "BBB@
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M'%;W]@W']^/\S_A7%?"_29KBV\1E60;=<ND.2>H*^U '1T5I?V#<?WX_S/\
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M% &;16E_8-Q_?C_,_P"%']@W']^/\S_A0!FT5I?V#<?WX_S/^%']@W']^/\
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M@ HHHH **** "BBB@ KF?%G_ "'O!?\ V%Y/_2"[KIJYGQ9_R'O!?_87D_\
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MCX%_!SP/\9X?B?XGUW6[V:TGUC1-6N_-TN2.X0R>7'!M C X7CGDE=F!7!?
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MZ8#='SD ?.%ZG'KQ51M=7$]M#Q/_ (;"_P"I2_\ *E_]IH_X;"_ZE+_RI?\
MVFO./^&=OB%_T+__ ).V_P#\<H_X9V^(7_0O_P#D[;__ !RO9]EA>Z^__@GF
M>TQ'G]QZ/_PV%_U*7_E2_P#M-'_#87_4I?\ E2_^TUYQ_P ,[?$+_H7_ /R=
MM_\ XY1_PSM\0O\ H7__ "=M_P#XY1[+"]U]_P#P0]IB//[CT?\ X;"_ZE+_
M ,J7_P!IH_X;"_ZE+_RI?_::\X_X9V^(7_0O_P#D[;__ !RC_AG;XA?]"_\
M^3MO_P#'*/987NOO_P""'M,1Y_<>C_\ #87_ %*7_E2_^TT?\-A?]2E_Y4O_
M +37G'_#.WQ"_P"A?_\ )VW_ /CE'_#.WQ"_Z%__ ,G;?_XY1[+"]U]__!#V
MF(\_N/1_^&PO^I2_\J7_ -IH_P"&PO\ J4O_ "I?_::\X_X9V^(7_0O_ /D[
M;_\ QRC_ (9V^(7_ $+_ /Y.V_\ \<H]EA>Z^_\ X(>TQ'G]QZ/_ ,-A?]2E
M_P"5+_[31_PV%_U*7_E2_P#M-><?\,[?$+_H7_\ R=M__CE'_#.WQ"_Z%_\
M\G;?_P".4>RPO=??_P $/:8CS^X]'_X;"_ZE+_RI?_::H:1^UM?6:W0OM"_M
M%I+AY(6^V+%Y49QMCXB^;;S\QY.:X?\ X9V^(7_0O_\ D[;_ /QRC_AG;XA?
M]"__ .3MO_\ '*/987NOO_X(>TQ'G]QZ/_PV%_U*7_E2_P#M-'_#87_4I?\
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M $'AR[EO_#VEW,[;YYK6*21L 98H"3@>YK1J&SM8K"T@MH$V00HL<:Y)PH&
M,GV%34 %%%% !1110 4444 %%%% !1110 4444 <E)KM\OQ5AT<3_P#$N;1V
MNC#L7_6>=MW;L9Z<8SBNMJ@VA6+:XNL&#_B8K;_91-O;_5;MVW;G'7G.,U?H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10!L?\)!_P!._P#X_P#_ %J/^$@_Z=__ !__ .M6/10!L?\ "0?]._\ X_\
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MFKU &Q_PD'_3O_X__P#6H_X2#_IW_P#'_P#ZU8]% &Q_PD'_ $[_ /C_ /\
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M_P )!_T[_P#C_P#]:L>B@#8_X2#_ *=__'__ *U'_"0?].__ (__ /6K'HH
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M[_\ C_\ ]:L>B@#8_P"$@_Z=_P#Q_P#^M5^PO/MT)DV;,-MQG/85S%;V@_\
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M-=?; 9=QE$0=(MG*;F7.6!'. < FUHOCB;6O%%YI0M["U%M))&\,VH%;_:O
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MC^SM"K1,!;;F,;-TCC)VN.2>G-6%\%ZOXRGUB^UFZOO#_P!NMTL18VYM90T
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M *Z#^1K!K>U[_CS3_KH/Y&L&N [PHHHH **** "BBB@ HHHH **** "BBB@
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M_A7.=!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!@T5O?V#;_P!^3\Q_A1_8-O\
MWY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^% &#16]_8-O_ 'Y/S'^%']@V
M_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_,?X4 8-%;W]@V_\ ?D_,?X4?
MV#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!@T5O?V#;_P!^3\Q_
MA1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^% &#16]_8-O_ 'Y/
MS'^%']@V_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_,?X4 8-%;W]@V_\
M?D_,?X4?V#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!@T5O?V#;
M_P!^3\Q_A1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^% &#16]_
M8-O_ 'Y/S'^%']@V_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_,?X4 8-%
M;W]@V_\ ?D_,?X4?V#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]^3\Q_A0!
M@T5O?V#;_P!^3\Q_A1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#;_WY/S'^
M% &#16]_8-O_ 'Y/S'^%']@V_P#?D_,?X4 8-%;W]@V_]^3\Q_A1_8-O_?D_
M,?X4 8-%;W]@V_\ ?D_,?X4?V#;_ -^3\Q_A0!@T5O?V#;_WY/S'^%']@V_]
M^3\Q_A0!@T5O?V#;_P!^3\Q_A1_8-O\ WY/S'^% &#16]_8-O_?D_,?X4?V#
M;_WY/S'^% &#16]_8-O_ 'Y/S'^%']@V_P#?D_,?X4 8-<A\6D:3X?ZJJ*68
M^5@*,G_6I7IO]@V_]^3\Q_A6=X@.E>%]'N-3U">:*S@V[W4;B-S!1P!GJ10!
M2HK>_L&W_OR?F/\ "C^P;?\ OR?F/\* ,&BM[^P;?^_)^8_PH_L&W_OR?F/\
M* ,&BM[^P;?^_)^8_P */[!M_P"_)^8_PH P:*WO[!M_[\GYC_"C^P;?^_)^
M8_PH P:*WO[!M_[\GYC_  H_L&W_ +\GYC_"@#!HK>_L&W_OR?F/\*/[!M_[
M\GYC_"@#!KD/APC);Z_N4KG6+DC(QD97FO3?[!M_[\GYC_"L[13I7B!+MK*>
M:06MR]I+N&W$B8W#D<]>M %*BM[^P;?^_)^8_P */[!M_P"_)^8_PH P:*WO
M[!M_[\GYC_"C^P;?^_)^8_PH P:*WO[!M_[\GYC_  H_L&W_ +\GYC_"@#!H
MK>_L&W_OR?F/\*/[!M_[\GYC_"@#!HK>_L&W_OR?F/\ "C^P;?\ OR?F/\*
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M9C6^%>J_-'34445@;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,_45H53T>_.J:/8WI3RS<P1S% <[=R@XS^-7* "BBB@ HHHH **** "BBB@
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M%I5_B  !Z]* /8**\LD^(WB.;1K*9;2"T,5W=V.I:A!IMQJ44<L#E 5@B=9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "LG6M'DU/4M!N4D5%TZ]:Z=6SE@;::+
M]\R@_0&M:BJC)Q=T3**DK,****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *Y'QEX$@\9:]X<GO[2QU#3-/>=[BUOHA*'WQ[4(4J5)!
MYYQBNNHH Y>Y\(LOB[PU?V*6UKIFDV=U:_9HQLVB3R@@10,!0(SZ8XQ7,K\/
M->_L^7PVSZ=_PCKZL=1_M 32?:]AN?M/E>3LV9\SY=_F8V\[<\5Z=10!\\>%
M]:CL_%T$<MVNI1-X@N)(M!&IQ+>6TTDTBF8V:P%PJ!F8[IRH7+X!P!Z0/!6O
M6?@W7=.T_4(;74KW4[F]BECE= 8I+@R&,N%W1LR$J64$J3D9P*[^B@#R"#X3
MZY);^(3+):P2:E-ILD4,FJ75^8A;S[W#33+O;(&1@  G&!C<=WQ1\/=1UJW\
M?I!-:H?$%C%;6OF.PV,L3H2^%.!EATS7H5% 'GNK>#M;NO%D6H:;!::-^^@,
MVIV^K3[[B-,;A+9B(12,5W(&9B5!!!^4"O0J** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SO$&O
MV7A?1[C4]0D:*S@V[W52Q&Y@HX'/4BM&N4^*>@7OBCP'J>F:?&LMY/Y6Q&8*
M#ME1CR>.@- '5T444 %%%% !1110!F>*+&;5/#6K6=NH:>XM)H8U)P"S(0.?
MJ:\5\!?LK6&G^7=>*;K^T9^OV*V)6$>S-PS?AC\:]]HK6-6<$XQ=KF<J<9-.
M2*NF:79Z+9QVEA:PV=K&,)# @11^ JU1161H%%%% !6=HNOV7B!+MK*1I!:W
M+VDNY2N)$QN'/7KUK1KE/A[H%[X?M]=6]C6,W6KW%W%M8-F-RNT\=.G2@#JZ
M*** "BBB@ HHHH **** "BBB@ HHHH SKS7[*QUC3]+FD9;R_$C0(%)#!!EN
M>@X/>M&N4U[0+V^\?^%M4AC5K.P2Z6=RP!4O& N!U/([5U= !1110 4444 %
M%%% !1110 4444 %5-6U2WT73;F_NW*6UO&99&"DD*!DG ZU;K$\;:7<:UX1
MUBPM$#W-Q:R11J2 "Q& ,GI0!J65Y%J%G!=0'=#/&LJ,1C*L,@X^AJ>L_P .
MV<NG^'],M9UVS06L43J#G#*@!&?J*T* "BBB@ HHHH **** "BBB@ HHHH *
M*** ,YM?LE\0+HID;^T&MC=B/:<>6&VYSTZ]JT:Y230+UOBE#K0C7^SUT@VA
MDW#/F&;=C'7IWKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXB^T,'2P-C]GV<8,F_=G/X8Q6Y0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 4M4TB#5XT2>2ZC"'(^R
MW<MN?Q,;*3^-9W_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\
M_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#C
MM'_"%:?_ ,_&K?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&
MK?\ @YO/_CM;U% &#_PA6G_\_&K?^#F\_P#CM'_"%:?_ ,_&K?\ @YO/_CM;
MU% &#_PA6G_\_&K?^#F\_P#CM-D\$6#J0+O6$/\ >76;O(_.6N@HH P?^$*T
M_P#Y^-6_\'-Y_P#':/\ A"M/_P"?C5O_  <WG_QVMZB@#!_X0K3_ /GXU;_P
M<WG_ ,=H_P"$*T__ )^-6_\ !S>?_':WJ* ,'_A"M/\ ^?C5O_!S>?\ QVC_
M (0K3_\ GXU;_P '-Y_\=K>HH P?^$*T_P#Y^-6_\'-Y_P#':/\ A"M/_P"?
MC5O_  <WG_QVMZB@#!_X0K3_ /GXU;_P<WG_ ,=H_P"$*T__ )^-6_\ !S>?
M_':WJ* ,'_A"M/\ ^?C5O_!S>?\ QVC_ (0K3_\ GXU;_P '-Y_\=K>HH P?
M^$*T_P#Y^-6_\'-Y_P#'::G@BP7.;O6'R<_-K-WQ[<2UT%% &#_PA6G_ //Q
MJW_@YO/_ ([1_P (5I__ #\:M_X.;S_X[6]10!@_\(5I_P#S\:M_X.;S_P".
MT?\ "%:?_P _&K?^#F\_^.UO44 8/_"%:?\ \_&K?^#F\_\ CM'_  A6G_\
M/QJW_@YO/_CM;U% &#_PA6G_ //QJW_@YO/_ ([1_P (5I__ #\:M_X.;S_X
M[6]10!@_\(5I_P#S\:M_X.;S_P".T?\ "%:?_P _&K?^#F\_^.UO44 8/_"%
M:?\ \_&K?^#F\_\ CM'_  A6G_\ /QJW_@YO/_CM;U% '/MX(L"ZG[7K  ZJ
M-9N\'_R+3O\ A"M/_P"?C5O_  <WG_QVMZB@#!_X0K3_ /GXU;_P<WG_ ,=H
M_P"$*T__ )^-6_\ !S>?_':WJ* ,'_A"M/\ ^?C5O_!S>?\ QVC_ (0K3_\
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MI_\ S\:M_P"#F\_^.T?\(5I__/QJW_@YO/\ X[6]10!@_P#"%:?_ ,_&K?\
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MQ&4 LQ; DP">..*SK?X3:1;V4%JMS>F.&ULK1273.RUF,T9/R=2QPWJ.F.M
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MPB$A;YL\.!QTQD4 ;_B+5O[!T6ZO]L!\E=V;JX6WB7D#<\C<(HSDG!. < G
M/$Z?\7GU?1XYM/T^QU&_;5O[(VV6J"6T,AB\Q76<1_,F"N?DR/FX)&#V?B;P
M[!XHTHV,\T]MB6*>.>V91)')&ZNC#<"IPR@X8$'N*Q].^&]E8R":34-0OKDZ
MDNJO<7+QEI)A"(N0J !=H^ZH&#TP.* ,#4_C5:Z3XD?2KA-+C-M<6]G=1OJR
MK=^;*$R8+<QYEC7S%RQ*$X;"G'.UXX\92>$M0C<1RW$<>DW]^UNLB(DA@$1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB$I*Q")MRA&'5@2<\ #=0!W=%<?XRFU*X\2>'-+L=8NM&BO#<M-+9QP/(VQ
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M%J&@SQW-G:0ZA%;:=+]KDGAE+JHQM7$@,;949'3#-0!VE%(#D ]*6@ HHHH
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M*C(Y92/TJ9<L4Y-#CS2=DS"_X3CQ'_T']4_\#9/_ (JC_A./$?\ T']4_P#
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MF1QGGFNYHH \XTGX2S:%H=Y:V&HV%E=S:K%JL1MM+$5I"Z)&IC$"R#Y#L/\
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M R2/.Z/+/][AB5<X[%\]L&Y=?$&?3/&ND>'K_3(XOMMLDDMY#<F2.&=M^V(
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M ,53/^%\>#?^@A-_X#2?X4?\+X\&_P#00F_\!I/\*/8XS^67XASX?NOP'_\
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MN45(W>W,:HC+@_.K%B  >.G>T4 <KH'A>XDTK1#K8>VU+38EB":7JMR+=]H
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MRG%7:??;IW]"E0DW96^\\BHKTJQ\ ^&['P-8^(->O=2@>2YDMI+>S5&+,&8
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M445\X>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[27_ "(U
MC_V$8_\ T5+7J]<!\:/"6I^,O"UK9:5"L]Q'>K,RLX0;0D@)R3ZL*[<%*,,1
M"4G97.?$)RI22/E:BO0?^%#^,O\ H'P_^!,?^-'_  H?QE_T#X?_  )C_P :
M^X^N8?\ Y^+[T?/>PJ_RO[C6N/C!8+X^T76[:WN_L5M8"RNHI$4.XRV=HW$$
M9*GDCI19_%ZP7XB:KKMQ!=_V?-8FRM8(T0O&ORXR-P &0QX)ZUD_\*'\9?\
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M$[Z/_A']2U/SM)T_9=2C=:V^T>4S;<L=QR2?6N5NO#?Q'^#/_!/WX?\ QO\
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MJ[]G\?M/?!'6?AZ==/AO^T9;>7^T1:?:O+\J99,>7O3.=N/O#&:[KX:^#_\
MA7GP[\+^%OM?]H?V)IEMIOVORO+\[R8ECW[,G;G;G&3C/4T ?(T?C;Q/I_\
MP5)TCP.GB;5SX1A\$"3^Q/ML@LFE5&_>F -L+\?>QGWKR3]E[PK\4OVJIOC;
MIFJ?'3QSX9T;P[XGO8=+71=3=+H7#LP027#[G^S1K&N((V0$NQR*^OI_V61-
M^V);_'<>)BIBT(Z*= -AG=PP\WS_ #./O?=\OMUKX;_8U^ WCKXH:Q^T%>>!
M_BYK7PKOF\77>F7HM].BO[6ZA+RL?W3E#',I;B5'#*"1WS0!!HG[?7Q1T/\
MX)^:EJLFKMJ'Q"M?%O\ PA]KX@DC2>8PF#SO.Z;7E"AD#'.<JQW')K;^%OCK
MXP>#/CE\,Y?"&G_M(^(- U+4(K'Q?;_%K1I9-/6&5T0W%NR[_LX3<[\XQL7+
M%=P/U%;?\$ZOAK'^RS_PI.:?4)[)KO\ M5]?!1;TZCT^T\#;PO[L*0?W?RY)
M^:M3X5_LS_%CPCKWA]_%_P"T;KWC+PUH;H]KHEMH=MIK3[%*HEU<HSR7"8(R
MK'YB,DT >!? FZFL?V[_ -L"YMY&AN(=)62.1#AD81J00?4$5Y+9_&WXB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\
MP*_^M1_PB?\ U&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_
M ,"O_K5O44 >?>"?#NJW4.LG5M3UJ%H]5NH[;S+@C=;A_P!VPR.A'<<5T?\
MPB?_ %&=6_\  K_ZU5? 7B2[\20ZZ]V(P;+6+NQB\M2/W<;[5SSUQU-=16U9
M-5&FK&=/6*L8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]16)H8/_")
M_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ P*_^M1_P
MB?\ U&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O
M44 8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\
MP*_^M7./X=U7_A8D5N-3UK^PSI3R--]H.S[1YR@+G&,[-QQUKT&N7D\27:_$
MZ'0 (_L+Z/)?$[3O\P3H@YSTPQXQ6U)-WLKZ,SGTOW+7_")_]1G5O_ K_P"M
M1_PB?_49U;_P*_\ K5O45B:&#_PB?_49U;_P*_\ K4?\(G_U&=6_\"O_ *U;
MU% &#_PB?_49U;_P*_\ K4?\(G_U&=6_\"O_ *U;U% &#_PB?_49U;_P*_\
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M_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ P*_^M1_PB?\ U&=6_P#
MK_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O44 8/_")_P#4
M9U;_ ,"O_K5SGP[\.ZK>>"]*FUS4]:M]5>,FXCDN"K*VX]01GIBO0:Y?X8^)
M+OQ=X#T?6+X1B[NHB\@A4JN0S#@9/I6R3]E)VTNOU,W;G2\G^A:_X1/_ *C.
MK?\ @5_]:C_A$_\ J,ZM_P"!7_UJWJ*Q-#!_X1/_ *C.K?\ @5_]:C_A$_\
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MHH P?^$3_P"HSJW_ (%?_6H_X1/_ *C.K?\ @5_]:MZB@#!_X1/_ *C.K?\
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M;P6GBA_+\/:QXKT3[%I^L$XV?9IA(VX-N3:2 #O4=2!6)^T-^WMX*\*M\3/
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MI]C;Q+N2#4)GG?R[SJ"BC&2!Q0!]C4444 %%%% !1110 4444 %%%?#'Q/\
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MKY>_9Z^)'Q=O/VK_ (C> _B5XDTG5;?3M L-5M],T*P6&RL)9FPT<4KKY\P
M'WI&Y))"J,  'UA6!X#\5?\ ";>$=-UO[+]B^V1E_(\SS-F&(QNP,]/2M^L#
MP'J.DZMX1TV[T*U^QZ3+&3;P>6(]B[B"-H.!SFM4E[-NVMUK]_Y_H0[\R5^_
MZ&_117Q'\5O&GQJ\??MO:O\ "?P'\7%^&N@V/A"+7P[>'++5 TGG+&RGSE#
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MG1K2*'P]&@X<SVS.0 QP/-?)VX*Y930!^@=%%% '.ZOXN_LKQIX=T#[)YO\
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MTWIVKZYJ6J:?I'B>VM].M+V[DFBLHS%(2D*,2(U) X4 <4 ?4]%%% !1110
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M44 ?E]J'PD^(?AG]E_\ 9'\4P?#_ ,1ZQ>_#O6VOM<\,V>GO_:T<+71;*VS
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M+P#K6IW7AGXOW/BF]\*7-F\-UJ>GJ>L4,B_O0V> %.X$X!Z5[#^T1\3OB?\
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ML+37]/DCT/P_I\EPWEAV,DC(@9FZY9VR3G+&M'XF?#C7+?\ ;_\ @GXA\/\
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MV>%0N.W[L1''O6_6#X<\+?\ "/ZOXEOOM7G_ -LWZWOE^7M\G%O##MSD[O\
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MP@_9[\3_  (E\,ZK]K\1^(]6T&+0;>6U#*7@5(FV7.\*ZYY)W@'Y22/TPHH
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MDEXT_9\\4>%/B_\ &32?'.@_M ZOHOC#7+F^L)OA/<Q2Z3JEM,S%4OU9"JL
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M;?\ 0,U3_P !?_KT =/17,?\)];?] S5/_ 7_P"O1_PGUM_T#-4_\!?_ *]
M'3T5S'_"?6W_ $#-4_\  7_Z]'_"?6W_ $#-4_\  7_Z] '3T5S'_"?6W_0,
MU3_P%_\ KT?\)];?] S5/_ 7_P"O0!T]%<Q_PGUM_P! S5/_  %_^O1_PGUM
M_P! S5/_  %_^O0!T]%<Q_PGUM_T#-4_\!?_ *]'_"?6W_0,U3_P%_\ KT =
M/17,?\)];?\ 0,U3_P !?_KT?\)];?\ 0,U3_P !?_KT =/17,?\)];?] S5
M/_ 7_P"O1_PGUM_T#-4_\!?_ *] '3T5S'_"?6W_ $#-4_\  7_Z]'_"?6W_
M $#-4_\  7_Z] '3T5S'_"?6W_0,U3_P%_\ KT?\)];?] S5/_ 7_P"O0!T]
M%<Q_PGUM_P! S5/_  %_^O1_PGUM_P! S5/_  %_^O0!T]%<Q_PGUM_T#-4_
M\!?_ *]'_"?6W_0,U3_P%_\ KT =/17,?\)];?\ 0,U3_P !?_KT?\)];?\
M0,U3_P !?_KT =/17,?\)];?] S5/_ 7_P"O1_PGUM_T#-4_\!?_ *] '3T5
MS'_"?6W_ $#-4_\  7_Z]'_"?6W_ $#-4_\  7_Z] '3T5S'_"?6W_0,U3_P
M%_\ KT?\)];?] S5/_ 7_P"O0!T]%<Q_PGUM_P! S5/_  %_^O1_PGUM_P!
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MK;_H&:I_X"__ %ZQ-#IZ*YC_ (3ZV_Z!FJ?^ O\ ]>C_ (3ZV_Z!FJ?^ O\
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M,?\ "?6W_0,U3_P%_P#KT?\ "?6W_0,U3_P%_P#KT =/17,?\)];?] S5/\
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M\!?_ *]'_"?6W_0,U3_P%_\ KT =/17,?\)];?\ 0,U3_P !?_KT?\)];?\
M0,U3_P !?_KT =/17,?\)];?] S5/_ 7_P"O1_PGUM_T#-4_\!?_ *] '3T5
MS'_"?6W_ $#-4_\  7_Z]'_"?6W_ $#-4_\  7_Z] '3T5S'_"?6W_0,U3_P
M%_\ KT?\)];?] S5/_ 7_P"O0!%KWA>\U+XB>$];A,0L]+@OHYPS$.3,L03:
M,<_<.>?2NLKS+6O&-_-XZ\-7-I9ZNFC0PW@OX1 0KLRQ^22,X."'Z],UTW_"
M?6W_ $#-4_\  7_Z];U&W&%WT_5[F<4KRTZ_HCIZ*YC_ (3ZV_Z!FJ?^ O\
M]>C_ (3ZV_Z!FJ?^ O\ ]>L#0Z>BN8_X3ZV_Z!FJ?^ O_P!>C_A/K;_H&:I_
MX"__ %Z .GHKF/\ A/K;_H&:I_X"_P#UZ/\ A/K;_H&:I_X"_P#UZ .GHKF/
M^$^MO^@9JG_@+_\ 7H_X3ZV_Z!FJ?^ O_P!>@#IZ*YC_ (3ZV_Z!FJ?^ O\
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MFO/^/R?_ *Z-_.H: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH YKP/KUWKT.M-=E2;35KJSBVK
MC]W&^%SZG'>NEK$\+>)/^$ECU-_LWV;[%J$]CC?NW^6VW?T&,^G;UK;K:MI4
M>EO(SI_"M;A1116)H%%%% !1110 4444 %%%% !7-/KUVOQ(AT4%?L+:2]X1
MM^;S!,B#GTP3Q72UB-XDV^-(_#_V;[^GM??:-_3$BILVX_VLYSVZ5M3UOI?1
M_P##F<^FMM3;HHHK$T"BBB@ HHHH **** "BBB@ HHHH Y?6?$%Y8_$+PSH\
M3(+*_M+Z:<%<L6B\C9@]O]8WZ5U%86I>*/[/\8:'H7V;S/[3M[J?[1YF/+\G
MRN-N.=WF^HQM[YXW:WJ?##W;:??J]?T^1G'>6M]?NT7_  X4445@:!1110 4
M444 %%%% !7-?#?7KOQ-X(TG5+XJUU<QEI"B[1G<1P/PKI:Q/!?B3_A+_"^G
MZQ]F^R?:T+^3OW[<,1C=@9Z>E;+^%)VZK7[]/G^AF_C6O1_I_7S-NBBBL30*
M*** "BBB@ HHHH **** "N:\*Z]=ZMKGBRUN"IBTW44MK?:N"$-M!(<^IW2-
M72UB:!XD_MS5/$%G]G\C^R;U;/?OW>;F"*7=C V_ZW&.?NY[XK:G\,]+Z?=J
MO^&^9G+>.O\ 5C;HHHK$T"BBB@ HHHH **** "BBB@ HHHH Y?7/$%Y8>/O"
M^DQ%!9ZA#>O."N6)B6(I@]OOFNHK"U3Q1_9OBW0M$^S>9_:D5S)Y_F8\KR0A
MQMQSG?ZC&.];M;U/AA[MM/OU>OZ?(SCO+6^OW:+_ (<****P- HHHH ****
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MB5=>$+Y_^)!K4GVG3;I_X9#QL8^O 4^X4\;JY]=#\'ZY\;/'$?C"6TBMD*&
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M * L7_@0?_B:/^&A+C_H"Q?^!!_^)KFO^%,^*O\ GQC_ / A/\:/^%,^*O\
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M^!!_^)H_X:$N/^@+%_X$'_XFN:_X4SXJ_P"?&/\ \"$_QH_X4SXJ_P"?&/\
M\"$_QH^JY#WC_P"!/_,/:8WS^[_@'2_\-"7'_0%B_P# @_\ Q-'_  T)<?\
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M ,P]IC?/[O\ @'2_\-"7'_0%B_\  @__ !-'_#0EQ_T!8O\ P(/_ ,37-?\
M"F?%7_/C'_X$)_C1_P *9\5?\^,?_@0G^-'U7(>\?_ G_F'M,;Y_=_P#D=5O
MCJFJ7EZ4\LW$SS% <[=S$XS^-1VMW/8W"3VTTD$R'*R1L58?0BB\M)=/O)[6
M9=LT,C1NH.<,IP1GZBH:^LC&/(DMOT/,;=[O<]2\*_'.^L-D&M0_;X!Q]HC
M64?4=&_3ZUZ'\*YM*M_!^GZ9INJ1ZE]CC*LVSRWY8GE"21UQ7B_A7X8ZWXJV
M2QP?9+-N?M-P"JD?[(ZM^''O7JGPM^$MGX)TFREOHUN-:C4[Y=Y9$))^X,#M
MCDC-?G^=4<LIPDJ4K3NM(ZJ^N_;Y=]CVL)+$2DG)77=_(]%HHHKX4]H****
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M;>$?^A6T7_P70_\ Q-=$!@8 P*6BJJ5JE6WM)-V[NX1C&/PJP4445B4%%%%
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MA*R"-G.,YQYF,D'&<<5[S10%SQCQEKFW4O%\=]KM]I?B.T9/^$>T^WO)(?M
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M+TI=:\XZH(SY_P!H.9-VX]3],5T=<U\-]>N_$W@C2=4OBK75S&6D*+M&=Q'
M_"O)C?V4G;2Z_)_U]QT.W.O1_H=+1116!H%%%% !1110 4444 %%%% !7.>%
MTU1=:\5&_P#.^RMJ*&P\TY7R?LT.=GH/,\S\<UT=<UX5UZ[U;7/%EK<%3%IN
MHI;6^U<$(;:"0Y]3ND:MZ=^2=ET_5;&<K<T;_P!:,Z6BBBL#0**** "BBB@
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M110 4444 %%%% !1110 4444 %%%% !72:1_R#XOQ_F:YNNDTC_D'Q?C_,T
M7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKRKPY_R=-\0_^Q,\,_\ I=KU>JUY5X<_Y.F^(?\ V)GAG_TNUZ@#NKC19Y;B
M1P\8#,6&2>Y^E,_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\ "MZB
M@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_  K>
MHH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^_'^9_P *
MWJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\
M"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_
M  K>HH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^_'^9
M_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_
MF?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!N/[\
M?YG_  K>HH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^P;C^
M_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X
M_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#!_L&X_OQ_F?\*/[!
MN/[\?YG_  K>HH P?[!N/[\?YG_"C^P;C^_'^9_PK>HH P?[!N/[\?YG_"C^
MP;C^_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\*WJ* ,'^P;C^_'^9_PH
M_L&X_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?YG_"MZB@#A?"GAJP@CU0:
M1<Q3JVHW#W7SLVVX+?O%Z<8/:MS^P;C^_'^9_P *3PCX6_X16+5D^U?:OM^I
M7&H9\O9L\UMVSJ<X]>,^@K?K6JTYMIW(A=15U8P?[!N/[\?YG_"C^P;C^_'^
M9_PK>HK(LP?[!N/[\?YG_"C^P;C^_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_O
MQ_F?\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/
M[\?YG_"MZB@#!_L&X_OQ_F?\*PV\-6'_  F\<QN8O[=_LYD6'>W_ ![^:I+8
MQ_?VC/O7=5@-X6W>/(O$GVK&S37T_P"R^7UW2K)OW9_V<8QWZUK3:5[NVC(E
M?2R%_L&X_OQ_F?\ "C^P;C^_'^9_PK>HK(LP?[!N/[\?YG_"C^P;C^_'^9_P
MK>HH P?[!N/[\?YG_"C^P;C^_'^9_P *WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?
M\*WJ* ,'^P;C^_'^9_PH_L&X_OQ_F?\ "MZB@#!_L&X_OQ_F?\*/[!N/[\?Y
MG_"MZB@#@M4\,Z<_C+0IKJZB36X[>[%C#YC#?&?*\XXQSC$7TS6__8-Q_?C_
M #/^%1ZKX1_M/QOX?\0_:_+_ +)MKRW^S>7GS?/\GG=GY=OD],'.[MCGHJVF
MTXPL[Z?=J]/U^9$;WE=?U9&#_8-Q_?C_ #/^%']@W']^/\S_ (5O45B68/\
M8-Q_?C_,_P"%']@W']^/\S_A6]10!@_V#<?WX_S/^%']@W']^/\ ,_X5O44
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M/\S_ (4?V#<?WX_S/^%;U% &#_8-Q_?C_,_X5K6-NUK:I$Y!9<YV].I-6**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\J\.?\G3?$/_ +$SPS_Z7:]7JM>5>'/^3IOB'_V)GAG_ -+M>H ]5HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#E_ 7AN[\-PZZEV8R;W6+N^B\MB?W<C[ESQP<=1745R_
M@*/5XX==_M?SRQUB[-KY[9_T;?\ N]O^SCI745O6;=1W=S.G;E5@HHHK T"B
MBB@ HHHH **** "BBB@ KEY/#=VWQ.AU\&/["FCR6)&X[_,,Z..,=,*><UU%
M<O)'J_\ PLZ%QY_]@_V/(&^;]U]I\],<?WMF[\,UO2;]ZSMHS.=M+]SJ****
MP- HHHH **** "BBB@ HHHH **** .3USPO>:A\2/"NNQ&+[%IEG?P3AF(?=
M-Y&S:,<C]TV>?2NLKD]<CUEOB1X5>U-Q_8:V=^+[8W[KS#]G\G>.Y_UN/QKK
M*WJ-\L+OI^KW_K8RA:\K+K^B"BBBL#4**** "BBB@ HHHH *Y?X8^&[OPCX#
MT?1[XQF[M(BDAA8LN2S'@X'K745R_P ,8]7C\!Z.NO>>=7$1^T?:6S)NW-C<
M?IBMTW[*2OI=?D_Z^XS=N=>C_0ZBBBBL#0**** "BBB@ HHHH **** "N7\(
M^&[O0]>\87EP8S#JVII=V^QB2$%K!$=W'!W1-^&*ZBN7\(QZNNO>,#J1G^QM
MJ:'3O.;*^1]E@SL]%\SS?QS6]-OEG9]/U1G*UX_UT.HHHHK T"BBB@ HHHH
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M5_:0M/(T_F(R[_);^\!C&[WK2'#F-5[J+T[_ / (ECZ+MJSZBKPSXI_$K7/
M_P 1"NGW(>T-M&SVDXW1,><G'4'W!%<S_P -$^*O^>>G_P#?AO\ XJN*\7>+
M;[QIJW]HZ@(A<>6L?[E2JX&<<$GUKT\KR*M0KN6*BG%IKN88C&1G"U-M,^A/
M!OQVT+Q'L@OS_8UZW&V=LQ,?9^W_  +'XUZ2K!U#*0RL,@CD&OABNK\(?$[7
M_!;*EE=F6T!YL[C+Q?@.J_@15X[AF,KSPDK>3V^3_P Q4<P:TJKYGU[17FO@
MWX[:%XCV07Y_L:];C;.V8F/L_;_@6/QKTE6#*"#D'D$5\-B,+6PD^2M%Q?\
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 8\G'05N> -!N/"O@;P_HMV\<EUI]A!:RO"24+)&%)4D XR.X%;]% @HHHH
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M_P#(G_Q-'_#-6N?]!33_ /R)_P#$U]%44?ZQ8_\ F7W(/J-#L?.O_#-6N?\
M04T__P B?_$UCM\";Y?%T>BG4++^TVL6O!)M?;Y0D5",XZ[F'&*^HJP&M-'_
M .$\BNC-_P 3\::\:P[S_P >WFJ6;;_OA1FM8<0XYWO+IV1$L#1TLOQ/%/\
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M ,?_ /K4?\)!_P!._P#X_P#_ %J -BBL?_A(/^G?_P ?_P#K4?\ "0?]._\
MX_\ _6H V**Q_P#A(/\ IW_\?_\ K4?\)!_T[_\ C_\ ]:@#8HK'_P"$@_Z=
M_P#Q_P#^M1_PD'_3O_X__P#6H V**Q_^$@_Z=_\ Q_\ ^M1_PD'_ $[_ /C_
M /\ 6H V**Q_^$@_Z=__ !__ .M1_P )!_T[_P#C_P#]:@#8HK'_ .$@_P"G
M?_Q__P"M1_PD'_3O_P"/_P#UJ -BBL?_ (2#_IW_ /'_ /ZU'_"0?].__C__
M -:@#8HK'_X2#_IW_P#'_P#ZU'_"0?\ 3O\ ^/\ _P!:@#8HK'_X2#_IW_\
M'_\ ZU'_  D'_3O_ ./_ /UJ -BBL?\ X2#_ *=__'__ *U'_"0?].__ (__
M /6H V**Q_\ A(/^G?\ \?\ _K4?\)!_T[_^/_\ UJ -BBL?_A(/^G?_ ,?_
M /K4?\)!_P!._P#X_P#_ %J -BBL?_A(/^G?_P ?_P#K4?\ "0?]._\ X_\
M_6H V**Q_P#A(/\ IW_\?_\ K4?\)!_T[_\ C_\ ]:@#8HK'_P"$@_Z=_P#Q
M_P#^M1_PD'_3O_X__P#6H V**Q_^$@_Z=_\ Q_\ ^M1_PD'_ $[_ /C_ /\
M6H V**Q_^$@_Z=__ !__ .M1_P )!_T[_P#C_P#]:@#8HK'_ .$@_P"G?_Q_
M_P"M1_PD'_3O_P"/_P#UJ -BBL?_ (2#_IW_ /'_ /ZU'_"0?].__C__ -:@
M#8HK'_X2#_IW_P#'_P#ZU'_"0?\ 3O\ ^/\ _P!:@#8HK'_X2#_IW_\ '_\
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M_P#C_P#]:@#8KEY(]7_X6="X\_\ L'^QY WS?NOM/GICC^]LW?AFM#_A(/\
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M -:@#8KE_",>KKKWC ZD9_L;:FAT[SFROD?98,[/1?,\W\<UH?\ "0?]._\
MX_\ _6KF?"?CV\U;7?%UK<Q(T.G:DEM;!3@K&;6"0@G')W2-S[BMZ=^2=ET_
M5;&<K<T;_P!:,[ZBL?\ X2#_ *=__'__ *U'_"0?].__ (__ /6K T-BBL?_
M (2#_IW_ /'_ /ZU'_"0?].__C__ -:@#8HK'_X2#_IW_P#'_P#ZU'_"0?\
M3O\ ^/\ _P!:@#8HK'_X2#_IW_\ '_\ ZU'_  D'_3O_ ./_ /UJ -BBL?\
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MRH#*S'SW.%W$5N^'/^3IOB'_ -B9X9_]+M>H ZN\_P"/R?\ ZZ-_.H:FO/\
MC\G_ .NC?SJ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK-'>12-+<L421RKJX$8"N ,H^2#TH"QV-0R7D$5Q%;O-&EQ,&:.)G 9PN-Q
MZG&1G'3(KE_B5X8O?%&D64=G!:7XM;Q+J;3-0<K;WT:A@8G(5NY##*D;E7([
MCSR^\>Z=H'_",ZC8Z)<:<EF-0LFTN3Y4LY@\2L'==RQPJ3G>/E5,8'1: L>X
MT5YGJ6KW>B^)+F]N(=/N=9M_"TMT]Y LJQLR29"*ID(V9Y_O'U'2M/PWXHUZ
M3Q-8:9K0TZ1=2TQ]1A^P12(;<H\:M&S,Y\SB5<, GW3\O- '<T444""BBB@
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M6[6TVG&%G?3[M7I^OS(C>\KKK^B"BBBL2PHHHH **** "BBB@ HHHH ****
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M)8^&_L?B[5=<^T;_ +=:V]MY&S&SRFE.[=GG/F],#&WOFMNF2%%%% !1110
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MNRV[+_,B67U5;5?C_D>%45]*?\*@\(_] G_R9F_^+H_X5!X1_P"@3_Y,S?\
MQ=9_ZSX/^27W+_Y(O^SJO=?C_D?-=%?2G_"H/"/_ $"?_)F;_P"+H_X5!X1_
MZ!/_ ),S?_%T?ZSX/^27W+_Y(/[.J]U^/^1\UT5]*?\ "H/"/_0)_P#)F;_X
MNC_A4'A'_H$_^3,W_P 71_K/@_Y)?<O_ )(/[.J]U^/^1\UT5]*?\*@\(_\
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M!1116!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"/'_&C^R+3_GE_X\?\:N44 4_[(M/^>7_CQ_QH_LBT_P">7_CQ_P :N44
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MX\?\:N44 4_[(M/^>7_CQ_QH_LBT_P">7_CQ_P :N44 4_[(M/\ GE_X\?\
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MX\?\:/[(M/\ GE_X\?\ &KE% %/^R+3_ )Y?^/'_ !H_LBT_YY?^/'_&KE%
M%/\ LBT_YY?^/'_&C^R+3_GE_P"/'_&KE% %/^R+3_GE_P"/'_&C^R+3_GE_
MX\?\:N44 4_[(M/^>7_CQ_QH_LBT_P">7_CQ_P :N44 4_[(M/\ GE_X\?\
M&C^R+3_GE_X\?\:N44 4_P"R+3_GE_X\?\:/[(M/^>7_ (\?\:N44 4_[(M/
M^>7_ (\?\:/[(M/^>7_CQ_QJY10!3_LBT_YY?^/'_&C^R+3_ )Y?^/'_ !JY
M10!3_LBT_P">7_CQ_P :/[(M/^>7_CQ_QJY10!3_ +(M/^>7_CQ_QJS#"EO&
M(XQM0=!FGT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,IX>HVE+MOL<V(J.C2E..Z/6/$WQ!\/^#]1TNPU;4%M;W4Y!%:0+$\CRL2%
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MC1="3ES)W?2\9.+MY76FYMAJTZSESJUOU5]0HHHKY\[0HHHH **** "BBB@
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M\26)LM7TVTU6S+!S;WL"S1[AT.U@1D4MKH>FV*V:VVGVMNME&8;58H540(0
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M]^X__B:/]5\7_/'\?\@_M&EV9];45\D_\+B\9?\ 0<F_[]Q__$T?\+B\9?\
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M'S;O.ZY&-O?/'15SNJZEH]OXW\/V5U:^9K5S;7CV-QY8/E1IY/G#=G*[MT?
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MQYOV@KPS]?+Y [=: ,OX>^+;^#X<Z-<26&K>)=1N)+D;;8H\FU9Y!EY9G1
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MHB %9MQ"!0#ECQ5SQ9X3EUZZTS4M/U#^RM:TUW:VNFA$T95P!)%)'E2R, .
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MI,$=E+"\%S;:2R:G&B$-Y2W?GG"L=P8"/!5V&.<UW] !1110(**** "BBB@
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M ,!1_P#%5[;16?\ ;F8_\_?P7^1?U.A_+^9XE_PS+:_]!^;_ ,!1_P#%4?\
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MBL2PHHHH **** "BBB@ K \!VFCV/A'38- F^T:.D9%M+O+;EW'/)Z\YK?K
M\!^%O^$)\(Z;HGVK[;]CC*>?Y?E[\L3G;DXZ^M:IKV;5];K3[_R_4AWYD[=_
MT-^BBBLBPHHHH **** "BBB@ HHHH *P/#EIH]OJ_B6339O-O)[]9-17<3Y<
M_P!GA4+CM^[$1Q[UOU@^'/"W_"/ZOXEOOM7G_P!LWZWOE^7M\G%O##MSD[O]
M5NSQ][&.,G6#7+*[MI]^J_X<B5[K0WJ***R+"BBB@ HHHH **** "BBB@ HH
MHH YW5[/19O&GAZXO)]FMPQ78T^+>1O1A'YQQWP GTS715SNK^$O[5\:>'=?
M^U^5_9$5W%]G\O/F^<(QG=GY=OE^ASGMBNBK:;3C"SOI]VKT_7YD1O>5UU_1
M!1116)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW;FQN/TQ6Z;]E)7TNOR?]?<9NW.O1_H=11116!H%%%% !1110 4444 %%%%
M!7+^$?#=WH>O>,+RX,9AU;4TN[?8Q)""U@B.[C@[HF_#%=17+^$8]777O&!U
M(S_8VU-#IWG-E?(^RP9V>B^9YOXYK>FWRSL^GZHSE:\?ZZ'44445@:!1110
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M[9<?\]Y/^^S0!U5%<K]LN/\ GO)_WV:/MEQ_SWD_[[- '545ROVRX_Y[R?\
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M[- '545ROVRX_P">\G_?9H^V7'_/>3_OLT =517*_;+C_GO)_P!]FC[9<?\
M/>3_ +[- '545ROVRX_Y[R?]]FC[9<?\]Y/^^S0!U5%<K]LN/^>\G_?9H^V7
M'_/>3_OLT =517*_;+C_ )[R?]]FM_2W:2QB9V+,<Y+')ZF@"W1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5>'/\ DZ;X
MA_\ 8F>&?_2[7J]5KRKPY_R=-\0_^Q,\,_\ I=KU '5WG_'Y/_UT;^=0U->?
M\?D__71OYU#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% &)X6OM,OX]3.EV_V=8M0GAN!L"[YU
M;$C\=<GOWK;K$\+VNE6L>IC2I?.634)Y+GYBVVX+?O%]L'M6W6M6W.[?B1"_
M*KA1116184444 %%%% !1110 4444 %8C7VF#QI'9&W_ .)R=/:9;C8.(!(H
M*;NOWB#CVK;K$:UTK_A-([DR_P#$\&GM&L.X_P#'OYBDMC_>VC-:T[:W[,B5
M]+&W1116184444 %%%% !1110 4444 %%%% &%J6H:5#XPT.SN;;S-7N+>Z>
MSN/+!\N-/*\T;NHW;H^G7;[5NU@ZE:Z1)XPT.XNIMFLQ6]TME%N(WQMY7G''
M?&(_IFMZMIVY86OM^KV\OUN1&]Y?UT04445B6%%%% !1110 4444 %8G@N^T
MS4_"^GW6C6_V33)$)@AV!-J[B,8'3G-;=8G@NUTJR\+Z?!HDOGZ4B$6\FXMN
M7<>_?G-:JWLWWNO3K_2^9#OS+Y_H;=%%%9%A1110 4444 %%%% !1110 5B:
M#?Z9>:IX@BL+?R;JVO5BOGV!?-F,$3!LC[W[MHQD_P!W':MNL30+72K?5/$#
MZ?-YEW->J]^NXG9-Y$0 QV_=B,X]ZUA;EE>^WZK?^MR)7NC;HHHK(L**** "
MBBB@ HHHH **** "BBB@#"U34-*M_%NA6EU;>9JUQ%<M93^6#Y:J$\T;NHR"
MG3KBMVL+5+72)?%NA3W<VS6(8KD6,6XC>K!/-..^ $_.MVMIVY86OM^KV\OU
MN1&]Y>OZ(****Q+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KI-(_Y!\7X_S-<W72:1_P @^+\?YF@"Y1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>5>'/^3IOB'_ -B9X9_]
M+M>KU6O*O#G_ "=-\0_^Q,\,_P#I=KU '5WG_'Y/_P!=&_G4-37G_'Y/_P!=
M&_G7)>//B#IWP]L[&YU&&ZF2\N!;1BU16(8@G)W,..*VHT:F(J*E25Y/9$2E
M&$>:3LCIZ*Y/Q-\2=+\+^(M)T*2&[OM4U)L16]E&KLBYQO?+#"]>>>%)[5BZ
MM\<-,TOQ'J6BPZ%K^K7>GD?:&TVS69%! .?O@@<]2!792RW%UDG"FW=7^5[7
M]+Z&<L12AI*7D>C45R>B_%#P_KWA*X\1VEU(VGV_RS Q,98VX^4H 23R.F>M
M8UC\<=%FUZRTF^TO6M"GO6V6TFJV7DQRDG P=Q/)(&<8YHCEN,DYI4G>-[Z;
M6W^X'B*2M[RU/1:*Y#QA\3]*\'ZE;Z8]MJ&K:M.GF)I^E6_GS;.?F(R !P>^
M>*CT?XLZ#KGA+5-?M3<>1IB.UW:21A;B(J"2I4G&2!QSCKSP<0LOQ3IQK*F^
M5VL_71?>]$Q^VI\SCS:H[.BO.M!^-5MXCFL1:>$_%1MKQU2.];31]G 8XWEP
MY&T=S[5Z+6>(PM;"2Y:\;,=.I"HKP=PHHHKD-0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***@FOK>WN(+>6>*.>XW"&)W :3:,MM'4X')Q0!/14%G?
M6^HVZW%I/%=0-D++"X=3@D'!''!!'X5/0 4444 %%%% !1110!2UC6+30-+N
M=0OY?(M+==\D@1G('LJ@DGV )-2:;J5MK&G6M_9RB>TNHEFAE7.'1@"IY]0:
MXSX@W-]J6O>']"TNUM[ZX64ZK<0W=PT$7E0D! SJCD$RLA VG/EGI7!WVN:Y
MX?T"3P_/]GT_^S]947GE:E)!#%83*\L6;I8@\<>_]WO"#&W&1UH'8]XJ":^M
M[>X@MY9XHY[C<(8G<!I-HRVT=3@<G%>-KJ<LG@V5Y/&>APZ>NJJ8%7Q3*Z2Q
M^6"]L]_M656W$R @,< *<K4-U=:-JEU\/=7OI[_2=.\^\M3<3ZY<F,L%?85N
M#("ZNP.UR077 QCY: L>P:+KD&NQ74ENDB"WN9;1_, &7C8JQ&">,CBM&O%C
M;S:3;SZY;:CJ$=U_PEPM1"MTZV_E27@C=#""$;(=CN8%@<8(  %.'7M7G\7W
M"7.M:=IFM1ZT8XK?4?$<UNS6WFA5C6P\ORW#Q'Y6!)+-NW9& !8]@U+Q3I.D
MZ9>:A<WT0L[.3R;B2/,GE/D#:P7)!RR\8XS6K7@VZT\.:#\24L-5O+;78-1=
MO(;4YFE2%GA*R"-G.,YQYF,D'&<<5U-QJUD_C[5[?7]?O-*OH;JV71[&"]>$
M30E5.Y(5.)RTGF*VY7P%QQ2"QWVO>(K#PS9I<ZA,T:22+#&D43S22R'HJ1H"
MS'@G"@\ GH#56U\8:??7FEV]OYTAU!)GB9HC'L\HJ'5U?#*P+8VD9!!SBLSX
MD0Z/)IU@^K:T_AR2"Z$]GJJLJ+!,%8#<S@QX*EEVOPV<#G%><:AXD\6:U;^'
M;ZS6"[U1%U*)+RTC*&ZM5:(?:+>-L@R,@R@)V$X.2N 6%CV?^W++^W/['\[_
M (F/V?[7Y.QO]5NV[MV,=>,9S5^O(+CQ LBW#:+K%]<Z8/"%Q<02RW4CR&59
M,>8Q8Y\T'()/(((XQBM;PO'<Z+XXT6S74]1OH=2T.6[NA?W;SAIDDA =0QVQ
MY$K9"!5Z<<4 >DT444""BBB@ HHHH Q/"WA^/P_'J:Q7/VD7FH3WK' &QI&R
M4Z]JVZYSP3X?NO#\.LK=&,F[U6ZO8_+;/[N1\KGCKBNCK:L[S>M_,BG\*TL%
M%%%8EA1110 4444 %%%% !1110 5B-X?C;QI'KGVG$RZ>UE]FP.5,BOOSGU7
M'3O6W7./X?NF^(D.M@Q_8ETI[(C=\_F&97'&.F%/>MJ;M?6VC_X8B?32YT=%
M%>1^(_BUJ'A/QUJ5C+"E[IL;)MC^ZZ9C4G#=^23S^8KIP>"K8Z4H45=I7_+_
M #(JUHT4G/8]<HKG?"_C[1?%B@65T%N<9-K-\L@_#O\ AFNBKEJT:E"3A5BT
M_,TC*,U>+N@HHHK(H**** "BBB@ HHHH PM2\.17WC#0]::Z\N73K>ZA2WVC
M]Z)?*R<YXV^6.W\5;M<QK'AV[OO'_AO68S']DT^UO89@S$/NE\C9@8Y'[ML_
MA73UM4?NPUOI]VKT_7YF<=Y:6U^_1?\ #!1116)H%%%% !1110 4444 %8G@
MOP_'X5\+Z?I4-S]LCM4*+/@#?EB<X!/K6W7.?#OP_=>%O!>E:5>F,W5M&4<Q
M-E<[B>#CWK9/]U)7ZK3[]?E^IF_C6G1_H='1116)H%%%% !1110 4444 %%%
M% !6)H/A^/1M4\07:7/GMJEZMT\>T#RB((HMO7GB,-V^]6W7.>%_#]UH^M>*
MKN<QF+4]12Z@V,20@MH8CNXX.Z-OPQ6T'[L];:??JO\ A_D1+>.G]6.CHHHK
M$L**** "BBB@ HHHH **** "BBB@#"U3PY%J'BW0M8:Z\J738KF-+?:#YOFA
M 3G/&-@[=ZW:YC6O#MWJ'COPQK$1C^R:=#>1S!F(;,JQA<#'/W#FNGK:H_=A
MK?3[M7I^OS,X[RTMK]^B_P"&"BBBL30**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "NDTC_D'Q?C_ #-<W72:1_R#XOQ_F: +E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5X<
M_P"3IOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"EVO4 =7>?\?D__71O
MYUXA^U!G_A'?#FT9/]K1XS_N-7M]Y_Q^3_\ 71OYUPOQ0^'/_"R-/TVU_M#^
MSOL=VMUN\CS=^ 1MQN7'7K7LY/B*6%Q]*M6=HIZ_<^QRXJ$JE&4([LX#X'RQ
MW7Q"\7R^(E(\<+,599#\JV_ Q$/087G^[LQWK+TD>*6^-WCT>%CI(N2$\TZK
MYFW;A<;-G?/KQ7I7C#X6?\)!XRTCQ1IFJ'1=6L?ED=;?S5N$'\+#<O8L,\\'
MV%95W\(=<M_&FL^(M"\8_P!BRZH5\R+^S([C  '&7?U&> *^EAF.#J3J5G44
M74IJ/+)2<8R3CIHG[ME=6VV9Y[H58J,+-\LKW35VFGKJ]^YC_LY7"6>C^)=#
M$#0>(K&\=KPS.&C>0Y52-H&%!0@CGUSS@<U\2I/$6E^+O">K?$.&PN-$MKG$
M7]@NRJDN0V7$@W'[@. 0,#J#U]1\/_"2W\.Z'JUM;ZSJ"ZOJDJSW6LHX6=I
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M4EXG_P">5M_W_%'_  I+Q/\ \\K;_O\ BON_89#WC_X%_P $\;GQOG]QL?\
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MCK?^&@=1_P"@5:_]_&KS[Q/KTGB?7+K4Y8EADN"I,:$D#"A?Z5U/_"DO$_\
MSRMO^_XKD-<T6Y\/:I/I]X%6YA(#A&R.0".?H17;@*>6PJ-X.W-;H[Z??Z&5
M:6(<?WM[%)':-E9&*LIR&4X(->@>%?C1K&A[(;__ (FMH./WC8E4>S]_QS]:
M\]KI?"_P]UKQ8RM:6ICM2>;J?Y8_P/?\,UVXZEA*E)_6TN7S_1_Y&5&56,OW
M6Y[_ .%_'VB^+% LKH+<XR;6;Y9!^'?\,UT5<#X2^#ND>'6CN;O.IWR$,'D&
M(T/LO^.?PKOJ_(<;'"QJM823<?/]/^"D?4474<?WJU"BBBN V"BBB@ HHHH
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MGK>I?EA==/U>_P#6UC*%KRMW_1!1116!J%%%% !1110 4444 %%%% !1110
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M)8?D#(5*E%P0X;[Q]L=;10!Q]E\,=.LXV#7VH74KZI%K$DUQ*K/)<(BKS\N
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M;@; N^=6Q(_'7)[]ZVZUJI*;25B(?"KNX4445D6%%%% !1110 4444 %%%%
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M!<,1UP/2MVL3P7?:9J?A?3[K1K?[)IDB$P0[ FU=Q&,#ISFM4E[-NW5:_?\
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M(_Y!\7X_S-<W72:1_P @^+\?YF@"Y1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>5>'/^3IOB'_ -B9X9_]+M>KU6L.S\'Z
M?9>-M5\51"3^U=3T^STRX)?*>3;27,D6%['=>39/?Y?2@"C>?\?D_P#UT;^=
M0T7UY MY< S1@^8W\8]:A^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\
MSWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!-14/VRW_Y[Q_]]BC[
M9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?
M8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!-14/VRW_Y
M[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#SWC_[[% $U%0_;+?_
M )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!-
M14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#SWC_[[% $
MU%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^V6__ #WC
M_P"^Q0!-14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8H^V6_P#S
MWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[Q_\ ?8H^
MV6__ #WC_P"^Q0!-14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_ .>\?_?8
MH^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-14/VRW_Y[
MQ_\ ?8H^V6__ #WC_P"^Q0!-14/VRW_Y[Q_]]BC[9;_\]X_^^Q0!-14/VRW_
M .>\?_?8H^V6_P#SWC_[[% $U%0_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q0!-1
M4/VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q0!E>%[72K6/4QI4OG+)J$\ES\Q;;<%O
MWB^V#VK;KGO"^EV?AV/4UCU".Y^V:A/>L<@;#(V2G7M6W]LM_P#GO'_WV*UJ
MM.;:=R(7Y5=6)J*A^V6__/>/_OL4?;+?_GO'_P!]BLBR:BH?MEO_ ,]X_P#O
ML4?;+?\ Y[Q_]]B@":BH?MEO_P ]X_\ OL4?;+?_ )[Q_P#?8H FHJ'[9;_\
M]X_^^Q1]LM_^>\?_ 'V* )J*A^V6_P#SWC_[[%'VRW_Y[Q_]]B@":L1K72O^
M$TCN3+_Q/!I[1K#N/_'OYBDMC_>VC-:OVRW_ .>\?_?8K$;2[-O&D>N_VA'Y
MJZ>UE]GR.09%??G/^SCIWK6FTKW=M&1*^ED=#14/VRW_ .>\?_?8H^V6_P#S
MWC_[[%9%DU%0_;+?_GO'_P!]BC[9;_\ />/_ +[% $U%0_;+?_GO'_WV*/ME
MO_SWC_[[% $U%0_;+?\ Y[Q_]]BC[9;_ //>/_OL4 345#]LM_\ GO'_ -]B
MC[9;_P#/>/\ [[% $U%0_;+?_GO'_P!]BC[9;_\ />/_ +[% &/J5KI$GC#0
M[BZFV:S%;W2V46XC?&WE><<=\8C^F:WJYS4M'L[_ ,8:)K3:C''+IUO=0+;Y
M4^8)O*R<YXV^6.W\5;OVRW_Y[Q_]]BM9M.,+.^GW:O\ X?YD1O>6G]61-14/
MVRW_ .>\?_?8H^V6_P#SWC_[[%9%DU%0_;+?_GO'_P!]BC[9;_\ />/_ +[%
M $U%0_;+?_GO'_WV*/MEO_SWC_[[% $U%0_;+?\ Y[Q_]]BC[9;_ //>/_OL
M4 35B>"[72K+POI\&B2^?I2(1;R;BVY=Q[]^<UJ_;+?_ )[Q_P#?8K$\%Z79
M^%/"^GZ3%J$=W':H4$V0N[+$YQD^M:IKV;5];K3[_P OU(=^9.W?]#H:*A^V
M6_\ SWC_ .^Q1]LM_P#GO'_WV*R+)J*A^V6__/>/_OL4?;+?_GO'_P!]B@":
MBH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8
MH FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )JQ- M=*M]4\0/I\WF7<UZKW
MZ[B=DWD1 #';]V(SCWK5^V6__/>/_OL5BZ#I=GHNJ>(+M-0CG;5+U;ITR!Y1
M$$46WKSQ&#_P*M8-<LKNVGWZHB5[K0Z"BH?MEO\ \]X_^^Q1]LM_^>\?_?8K
M(LFHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'
M_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_
M .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* ,C5+72)?%NA3W<VS
M6(8KD6,6XC>K!/-..^ $_.MVN<U31[/4/%FA:RVH1QR:;%<QI!E3YOFA 3G/
M&-@[=ZW?MEO_ ,]X_P#OL5K-IQA9WT^[5_\ #_,B-[RT_JR)J*A^V6__ #WC
M_P"^Q1]LM_\ GO'_ -]BLBR:BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;
M_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV*
M)J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H
M FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">
M\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_
M^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FKI-(_Y!\7X_S-<K]L
MM_\ GO'_ -]BNHT5EDTV%E(93G!!R.IH O4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!DMX3T-V+-HVGLS'))M8R3^
ME)_PB.A?] 73O_ 2/_"M>B@#(_X1'0O^@+IW_@)'_A1_PB.A?] 73O\ P$C_
M ,*UZ* ,C_A$="_Z NG?^ D?^%'_  B.A?\ 0%T[_P !(_\ "M>B@#(_X1'0
MO^@+IW_@)'_A1_PB.A?] 73O_ 2/_"M>B@#(_P"$1T+_ * NG?\ @)'_ (4?
M\(CH7_0%T[_P$C_PK7HH R/^$1T+_H"Z=_X"1_X4?\(CH7_0%T[_ ,!(_P#"
MM>B@#(_X1'0O^@+IW_@)'_A1_P (CH7_ $!=._\  2/_  K7HH R/^$1T+_H
M"Z=_X"1_X4?\(CH7_0%T[_P$C_PK7HH R/\ A$="_P"@+IW_ ("1_P"%'_"(
MZ%_T!=._\!(_\*UZ* ,C_A$="_Z NG?^ D?^%'_"(Z%_T!=._P# 2/\ PK7H
MH R/^$1T+_H"Z=_X"1_X4?\ "(Z%_P! 73O_  $C_P *UZ* ,C_A$="_Z NG
M?^ D?^%'_"(Z%_T!=._\!(_\*UZ* ,C_ (1'0O\ H"Z=_P" D?\ A1_PB.A?
M] 73O_ 2/_"M>B@#(_X1'0O^@+IW_@)'_A1_PB.A?] 73O\ P$C_ ,*UZ* ,
MC_A$="_Z NG?^ D?^%'_  B.A?\ 0%T[_P !(_\ "M>B@#(_X1'0O^@+IW_@
M)'_A1_PB.A?] 73O_ 2/_"M>B@#(_P"$1T+_ * NG?\ @)'_ (4?\(CH7_0%
MT[_P$C_PK7HH R/^$1T+_H"Z=_X"1_X4?\(CH7_0%T[_ ,!(_P#"M>B@#(_X
M1'0O^@+IW_@)'_A1_P (CH7_ $!=._\  2/_  K7HH R/^$1T+_H"Z=_X"1_
MX4?\(CH7_0%T[_P$C_PK7HH R/\ A$="_P"@+IW_ ("1_P"%'_"(Z%_T!=._
M\!(_\*UZ* ,C_A$="_Z NG?^ D?^%'_"(Z%_T!=._P# 2/\ PK7HH R/^$1T
M+_H"Z=_X"1_X4?\ "(Z%_P! 73O_  $C_P *UZ* ,C_A$="_Z NG?^ D?^%'
M_"(Z%_T!=._\!(_\*UZ* ,C_ (1'0O\ H"Z=_P" D?\ A1_PB.A?] 73O_ 2
M/_"M>B@#(_X1'0O^@+IW_@)'_A1_PB.A?] 73O\ P$C_ ,*UZ* ,C_A$="_Z
M NG?^ D?^%'_  B.A?\ 0%T[_P !(_\ "M>B@#&3P;X?CSLT+35W'<=MI&,D
M]^E._P"$1T+_ * NG?\ @)'_ (5KT4 9'_"(Z%_T!=._\!(_\*/^$1T+_H"Z
M=_X"1_X5KT4 9'_"(Z%_T!=._P# 2/\ PH_X1'0O^@+IW_@)'_A6O10!D?\
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M7HH R/\ A$="_P"@+IW_ ("1_P"%'_"(Z%_T!=._\!(_\*UZ* ,C_A$="_Z
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M;][G=Y'7C&[H<<@%JS^(EG>:Q%9K87R6<UU)90:JZQBVFG0-NC7Y_,ZHX#%
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MXXYJ:?\ !T6?C*UUY[ZREDM[VXO%F&F*M[,)5D7RY;G>2ZKY@"@*H 0 @\$
M&SX5\7.OPKT[Q)K,S3.NFK>74JHH+83<Q & /T%0W?CS5(]6\.V\?A;44BU)
MI1*LDEH7C"KD'*W!7_:.,\=.>*U=#\,S^'_ ]GH-M=P33VMHMJES=6Q>)B%Q
MEH@X)!_N[A]:PM%^&MYH-GHZV6J6<%Q87L]T4CT]EM?+ER&ABA$N8@ 1CYV
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MVMD]\5=M? 6J6NM:UJT.L6-A?Z@L<8DT_2_*7"2%BTJM*XED*G9O^7 SQTP
M=L[K&C.Q"JHR6/  KRZ'XF:GJ7A3QC='[/:75MICZMI,MNN=UJZ2>2[!B0S9
MB)/&.5X]>_\ %&CR>(O#NHZ7%=M8->0- ;A%W,BL,,0,CG!.#V/-<9J'P5L
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M75FV0^:=C@HI#%F&<Y4@X !L_#C6+K7_  %H&I7TOGWEU9132R% FYBH).
M!] *Z.N:\'>%;WPGI^F:>=6^V6%CI\=F(#;*F^13S-NR2,C V]!C-=+0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>krys-20221231_g2.jpg
<TEXT>
begin 644 krys-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" &G WT# 2(  A$! Q$!_\0
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M?_GYE_)?\*/)?_GYE_)?\*EHH B\E_\ GYE_)?\ "CR7_P"?F7\E_P *EHH
MB\E_^?F7\E_PH\E_^?F7\E_PJ6B@"+R7_P"?F7\E_P */)?_ )^9?R7_  J6
MB@"+R7_Y^9?R7_"CR7_Y^9?R7_"I:* (O)?_ )^9?R7_  H\E_\ GYE_)?\
M"I:* (O)?_GYE_)?\*/)?_GYE_)?\*EHH B\E_\ GYE_)?\ "CR7_P"?F7\E
M_P *EHH B\E_^?F7\E_PH\E_^?F7\E_PJ6B@"+R7_P"?F7\E_P */)?_ )^9
M?R7_  J6B@"+R7_Y^9?R7_"CR7_Y^9?R7_"I:* (O)?_ )^9?R7_  H\E_\
MGYE_)?\ "I:* (O)?_GYE_)?\*/)?_GYE_)?\*EHH B\E_\ GYE_)?\ "CR7
M_P"?F7\E_P *EHH B\E_^?F7\E_PH\E_^?F7\E_PJ6B@"+R7_P"?F7\E_P *
M/)?_ )^9?R7_  J6B@"+R7_Y^9?R7_"CR7_Y^9?R7_"I:* (O)?_ )^9?R7_
M  H\E_\ GYE_)?\ "I:* (O)?_GYE_)?\*/)?_GYE_)?\*EHH B\E_\ GYE_
M)?\ "CR7_P"?F7\E_P *EHH B\E_^?F7\E_PH\E_^?F7\E_PJ6B@"+R7_P"?
MF7\E_P */)?_ )^9?R7_  J6B@"+R7_Y^9?R7_"CR7_Y^9?R7_"I:* (O)?_
M )^9?R7_  H\E_\ GYE_)?\ "I:* (O)?_GYE_)?\*/)?_GYE_)?\*EHH B\
ME_\ GYE_)?\ "CR7_P"?F7\E_P *EHH B\E_^?F7\E_PH\E_^?F7\E_PJ6B@
M"+R7_P"?F7\E_P */)?_ )^9?R7_  J6B@"+R7_Y^9?R7_"CR7_Y^9?R7_"I
M:* (O)?_ )^9?R7_  H\E_\ GYE_)?\ "I:* (O)?_GYE_)?\*/)?_GYE_)?
M\*EHH B\E_\ GYE_)?\ "CR7_P"?F7\E_P *EHH B\E_^?F7\E_PH\E_^?F7
M\E_PJ6B@"+R7_P"?F7\E_P */)?_ )^9?R7_  J6B@"+R7_Y^9?R7_"CR7_Y
M^9?R7_"I:* (O)?_ )^9?R7_  H\E_\ GYE_)?\ "I:* (O)?_GYE_)?\*/)
M?_GYE_)?\*EHH B\E_\ GYE_)?\ "CR7_P"?F7\E_P *EHH B\E_^?F7\E_P
MH\E_^?F7\E_PJ6B@"+R7_P"?F7\E_P */)?_ )^9?R7_  J6B@"+R7_Y^9?R
M7_"CR7_Y^9?R7_"I:* (O)?_ )^9?R7_  H\E_\ GYE_)?\ "I:* (O)?_GY
ME_)?\*/)?_GYE_)?\*EHH B\E_\ GYE_)?\ "CR7_P"?F7\E_P *EHH B\E_
M^?F7\E_PH@+;I5=R^U\ D#.-H/;ZU+44/^MN/^N@_P#05H (?];<?]=!_P"@
MK4M10_ZVX_ZZ#_T%:EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH K:CJ5GI&FW&H:G<QVMI;(9)9I6PJ*.YKS-?V
MA?"LCM);Z5XBGTY6(.IQ::3;@#J<[MV/^ YK(_:FOKFV^&-E;0%EAN]21)R.
MC!4=@I_%0?\ @->D^"=&L-/\$:7;6MO&(OLL>!M'(VB@#?MYX[JWCG@;?%(H
M9&]0>E25X1X@U?Q%XZ^-U[X%T?7+WP]H^D6ZL[Z=)Y4TS$(2=XY R^,=,#IS
M4'AGQ/XG\*?$3Q1X!UO6[K6+>WTV2YL;VY?=-&?+#CY^IX;OW48QF@#WZBOD
M_P ,3^.?$OP>U;Q-)X[UJ%M"$CP1I=,#+MP[>8V=SYS@ G Q5O4]7\>7/P?M
MOB1+XVU**[AEC1+2W81P,N_R_F0##,2-Q+9')&* /J6BOG#QWXZ\4ZAXA^'4
MOA_6KC2Y=;L$,B1.?)+RX&XQ_=8C=D9!P0*O0:GXG^&GQTT3P_?>)M2U[2]<
MA#21ZA.96C9BPRI/W<,H/&!@D>AH ^@:*^9/B!XAM]-GU>8?&35I-=MWD:UL
M;!I$M]P;B(K&I0$?=R6^M/\ ''Q'\33? /P?X@M]5N;/4Y;_ &7$]K(8O/V*
MX^8+@$':"1T)[4 >Y^/?%5YX.\+/JVFZ#<Z].LJ1BTMF(;!/+$A6.![ ]OK6
MSI-\VIZ/:7TEN]J]Q"LC02?>C)&2I]QTKYX\7VGC_P &?!W5-4UGQC?WEUJ%
MU;.DD=PZ-;Y)W*A#<*>.!@<=*;\0?&/B2UM?!"ZAK.L:3X;O-)ADO=2TLE9G
MN"#G+CGH$..^YNO8 ^E:*\"\3?$'4O"7P3M;CPQXJ;Q'/J5_]DM-6G&984(+
M$-GG>,8^89YSV%9OC.W\;?"?0-)\7VWC75]7,ETD5Y9:A<&6%]REOE4_='RD
M<<C(P>* /H^BOG;Q+X@\3Z[^T#::'H'B34-)L=3TR)FCCE)6-2F]BJ'*JYVX
MW8R,UL_#'6?$&@_&WQ%X UG7;W7+*UMEN8)[Z4RRH2(VQN//27!'3*\8H ]P
MHKR[X[>-]7\'^%+"#PY(+?4-6O!:I<D ^2N,DC/<\#/89[XK@O&:^,O@[8Z)
MXIA\9:OK5O<7:P7MGJ5P9HWRI;"@_=R%;ITXYH ])^('Q8/@WQ1IOAK2= FU
MW6=0B,Z6ZW(@54RP!WD'GY&XQVZUW%CJ+7.AQ:A=6TEHS0"66!SEHCC)7W(Z
M5\Q^,?#<NH?M-:99)K^L1MJD)NH[I;HB:T#K*WEQ-CY4&,!>P)%?3@LY1H9L
MGG::7R#%YLAY8[<9- 'F%E^T5H6I6_VC3O"?B^[AR1YD&FHZY';(EQ7JMC>)
M?V$%W$DB),@<)(NUER,X([&OG#2E^)/P*\$R2W.BZ'J6BP3[[@AY#,N]@/O<
M #) ^Z>M>I+\;_!%IH.D:AK>I-IC:I:BYB@:VEE*C.",HA'# C\* -/4?B=H
MFD_$BT\%ZC!>V]_>1B2WN7C7[/)D' #;MV<J5^[UXHU?XG:'H_Q!L/!LD5Y<
MZI>H'S;QJT< .<>82P(X&> >,>HK@_C;I=GXV^&EAX\\)W(DN-&(O+:Y52A>
M'(+<, 000&Y'\)]:\_\ #NKZI:>%_%7QCU"*.35;IQ!IX<;DBRZQYY[+T _V
M!ZT ?5M%?'K?$R^T?1M/\0Z9\2]4U3Q"94>]T>Z68VQ4\LH#($&.!P?4C%>L
M?$G7=/EN]/NM:^)E]X6LKBRCE33=-+).&).78QJSD'@8( ^4^] 'M5%?,_@?
MXA:]J'P]^(]B?$-WJ<>D6KOIFJ.[+<%") &W'##(16&>02:V/@A:>/?$ATOQ
M;JWBV[NM+C62W^P2RNPD5=R;FYPS;AG)!/OVH ]TU;5K#0M)N-3U>ZCM+*V3
M?+-(<*H_QSP!U).*\V3]H7PK*QFCTKQ$VFAB#J8TTFWP.^=V['_ <US_ .U7
M?7,'@'2;2%F6"YU#,V.C;48J#^)S^'M7K7AG1M/T[PO8VEI;QB!8%"@*.F*
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MR3G->XT4 ?/VB_ G74\"^+?#^I7EM#+JERD]K-"69/D<, V0#SC''3WK/O\
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M<;164,;C#*@!%344 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)?S6D"AB(X7? )(&=H/H?RH LT53_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
MB: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <
MO_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+_P#$T?VI!_SSNO\ P#E_
M^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\ B: +E%4_[4@_YYW7_@'+
M_P#$T?VI!_SSNO\ P#E_^)H N453_M2#_GG=?^ <O_Q-']J0?\\[K_P#E_\
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M#N.>>:T=+TN+2K5XHI)9FEE::6:8@O([')8X  ^@   X%7:* "J<7_(;N?\
MKWA_]"DJY5.+_D-W/_7O#_Z%)0!<HHHH **** "BBB@ HHHH **** "BBB@
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M?_GVE_-?\:/.?_GVE_-?\:EHH B\Y_\ GVE_-?\ &CSG_P"?:7\U_P :EHH
MB\Y_^?:7\U_QH\Y_^?:7\U_QJ6B@"+SG_P"?:7\U_P :/.?_ )]I?S7_ !J6
MB@"+SG_Y]I?S7_&CSG_Y]I?S7_&I:* (O.?_ )]I?S7_ !H\Y_\ GVE_-?\
M&I:* (O.?_GVE_-?\:/.?_GVE_-?\:EHH B\Y_\ GVE_-?\ &CSG_P"?:7\U
M_P :EHH B\Y_^?:7\U_QH\Y_^?:7\U_QJ6B@"+SG_P"?:7\U_P :/.?_ )]I
M?S7_ !J6B@"+SG_Y]I?S7_&CSG_Y]I?S7_&I:* (O.?_ )]I?S7_ !H\Y_\
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M_FO^-'G/_P ^TOYK_C4M% $7G/\ \^TOYK_C1YS_ //M+^:_XU+10!%YS_\
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M:)>1^2#^='_"#:U<?\?_ (MO&'=$# ?^A?TH]M-_#3?X+]0^J48_'6C\KO\
M0[9F5%W.P4#N3BJ4VN:5;9^T:G9Q^S3J/ZURZ_"_3';=>ZA?W#>[J/Z&KL'P
MY\-Q8WV<DQ_Z:3-_0BCGQ#VBE\_^ 'L\%'>HWZ1_S9;F\;^'(/OZK$?^N:L_
M\@:SYOB;X>B^X]S-_P!<X<?^A$5JP^$?#]OCR](M3C^_'O\ YYK0ATZRMO\
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M\:/LR?WI?^_K?XT 2T5%]F3^]+_W];_&C[,G]Z7_ +^M_C0!+147V9/[TO\
MW];_ !H^S)_>E_[^M_C0!+147V9/[TO_ '];_&C[,G]Z7_OZW^- $M%1?9D_
MO2_]_6_QH^S)_>E_[^M_C0!+147V9/[TO_?UO\:/LR?WI?\ OZW^- $M%1?9
MD_O2_P#?UO\ &C[,G]Z7_OZW^- $M%1?9D_O2_\ ?UO\:/LR?WI?^_K?XT 2
MT5%]F3^]+_W];_&C[,G]Z7_OZW^- $M%1?9D_O2_]_6_QH^S)_>E_P"_K?XT
M 2T5%]F3^]+_ -_6_P :/LR?WI?^_K?XT 2T5%]F3^]+_P!_6_QH^S)_>E_[
M^M_C0!+147V9/[TO_?UO\:/LR?WI?^_K?XT 2T5%]F3^]+_W];_&C[,G]Z7_
M +^M_C0!+147V9/[TO\ W];_ !H^S)_>E_[^M_C0!+147V9/[TO_ '];_&C[
M,G]Z7_OZW^- $M%1?9D_O2_]_6_QH^S)_>E_[^M_C0!+147V9/[TO_?UO\:Y
M7Q-XGCT^X&E:*LM[JTIVK&LK$1$^O/7V_.LZE2-./-(VHT*E>?)!?UW9H^)O
M%=IX=MPN/M%](,0VR]6/8GT'\^U<U;>!=2U\OJGB._>WO)RI$4: [$_ND=CC
MIZ=\]*U_#G@M;&7^T];E:\U60[FD+G$1]CW/O^5=/]F3^]+_ -_6_P :QA"=
M22J3TMLNWKYG94JTJ$'1HVE?>35[^23Z?F5]/TBPTNVCALK6.-4& 0HW'W)Z
MD^]7:B^S)_>E_P"_K?XT?9D_O2_]_6_QKI225D>?*3D[R9+147V9/[TO_?UO
M\:/LR?WI?^_K?XTR26BHOLR?WI?^_K?XT?9D_O2_]_6_QH EHJ+[,G]Z7_OZ
MW^-'V9/[TO\ W];_ !H EHJ+[,G]Z7_OZW^-'V9/[TO_ '];_&@"6BHOLR?W
MI?\ OZW^-'V9/[TO_?UO\: ):*B^S)_>E_[^M_C1]F3^]+_W];_&@"6BHOLR
M?WI?^_K?XT?9D_O2_P#?UO\ &@"6BHOLR?WI?^_K?XT?9D_O2_\ ?UO\: ):
M*B^S)_>E_P"_K?XT?9D_O2_]_6_QH EHJ+[,G]Z7_OZW^-'V9/[TO_?UO\:
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MOLR?WI?^_K?XT?9D_O2_]_6_QH EHJ+[,G]Z7_OZW^-'V9/[TO\ W];_ !H
MEHJ+[,G]Z7_OZW^-'V9/[TO_ '];_&@"6J>E_P#'H_\ U\3_ /HUJG^S)_>E
M_P"_K?XU!I0VV3 9XN)QR<_\M6H N5%#_K;C_KH/_05J6HH?];<?]=!_Z"M
M!#_K;C_KH/\ T%:EJ*'_ %MQ_P!=!_Z"M2T %%%% !1110 53B_Y#=S_ ->\
M/_H4E7*IQ?\ (;N?^O>'_P!"DH N4444 %%%% !1110 4444 %%%% !1110
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M!J=U<VMQ-:ZCIS%IKX#:Y\U0"23E?FRX],9K%AG$,FMV\SW3&\GL#J,\EK-
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MMUQ_SRB_[^G_ .)HW7'_ #RB_P"_I_\ B: ):*BW7'_/*+_OZ?\ XFC=<?\
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M_P#B:-UQ_P \HO\ OZ?_ (F@"6BHMUQ_SRB_[^G_ .)HW7'_ #RB_P"_I_\
MB: ):*BW7'_/*+_OZ?\ XFC=<?\ /*+_ +^G_P")H EJGI?_ !Z/_P!?$_\
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M?T_.NWZ=***UITHTU9?\.<^(Q$Z\KRV6R6R] HHHK4YPHHHH **** "BBB@
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M"6I$2!4*;/+WY(*L^?GSELC&,5JZ-I1TJWG$L_VBXNKA[B>0)L4NWHN3@
M9)/'4UHT4 %41%'+K=QYD:OBWAQN7./FDJ]5.+_D-W/_ %[P_P#H4E $_P!D
MM_\ GA%_WP*/LEO_ ,\(O^^!4M% $7V2W_YX1?\ ? H^R6__ #PB_P"^!4M%
M $7V2W_YX1?]\"C[);_\\(O^^!4M% $7V2W_ .>$7_? H^R6_P#SPB_[X%2T
M4 1?9+?_ )X1?]\"C[);_P#/"+_O@5+10!%]DM_^>$7_ 'P*/LEO_P \(O\
MO@5+10!%]DM_^>$7_? H^R6__/"+_O@5+10!%]DM_P#GA%_WP*/LEO\ \\(O
M^^!4M% $7V2W_P">$7_? H^R6_\ SPB_[X%2T4 1?9+?_GA%_P!\"C[);_\
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MI)*R/,E)R?-)W9%]DM_^>$7_ 'P*/LEO_P \(O\ O@5+13)(OLEO_P \(O\
MO@4?9+?_ )X1?]\"I:* (OLEO_SPB_[X%'V2W_YX1?\ ? J6B@"+[);_ //"
M+_O@4?9+?_GA%_WP*EHH B^R6_\ SPB_[X%'V2W_ .>$7_? J6B@"+[);_\
M/"+_ +X%'V2W_P">$7_? J6B@"+[);_\\(O^^!1]DM_^>$7_ 'P*EHH B^R6
M_P#SPB_[X%'V2W_YX1?]\"I:* (OLEO_ ,\(O^^!1]DM_P#GA%_WP*EHH B^
MR6__ #PB_P"^!1]DM_\ GA%_WP*EHH B^R6__/"+_O@4?9+?_GA%_P!\"I:*
M (OLEO\ \\(O^^!1]DM_^>$7_? J6B@"+[);_P#/"+_O@4?9+?\ YX1?]\"I
M:* (OLEO_P \(O\ O@4?9+?_ )X1?]\"I:* (OLEO_SPB_[X%'V2W_YX1?\
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MB_[X%'V2W_YX1?\ ? J6B@"+[);_ //"+_O@4?9+?_GA%_WP*EHH B^R6_\
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M?_'H_P#U\3_^C6H N5%#_K;C_KH/_05J6HH?];<?]=!_Z"M !#_K;C_KH/\
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M]MQ_SUB_[]G_ .*HVW'_ #UB_P"_9_\ BJEHH BVW'_/6+_OV?\ XJC;<?\
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M6+_OV?\ XJC;<?\ /6+_ +]G_P"*J6B@"+;<?\]8O^_9_P#BJ-MQ_P ]8O\
MOV?_ (JI:* (MMQ_SUB_[]G_ .*HVW'_ #UB_P"_9_\ BJEHH BVW'_/6+_O
MV?\ XJC;<?\ /6+_ +]G_P"*J6B@"+;<?\]8O^_9_P#BJ-MQ_P ]8O\ OV?_
M (JI:* (MMQ_SUB_[]G_ .*HVW'_ #UB_P"_9_\ BJEHH BVW'_/6+_OV?\
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MXK4M_!.A6N/)T;2LCH6L@Q_,DUT-%92Q%:7Q3?WLVCAZ,?A@E\D4K?3DM/\
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M?_"'>/\ 2O\ D#>,1=JO1;U2<CT^8/1_;WQ-TG_D(>'K34HA_';-\Q_!6_\
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MH1;]#:HKB'^(QO',?A_1+R_?IN*X _+/]*3'C[6.IM-'B;TP6Q_X\<_E7/\
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M%:0H4H:QB8U<9B*JM.;MVV7W+0****V.0**** "BBB@ HHHH **** "BBB@
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M3[_D:O\ PE/A_P#Z#NF_^!D?^-'_  E/A_\ Z#NF_P#@9'_C65_PK/PE_P!
MG_R9E_\ BJ/^%9^$?^@3_P"3,O\ \51>MV7X_P"0>_Y&K_PE/A__ *#NF_\
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M7_0)_P#)F7_XJC_A6?A+_H$_^3,O_P 51>MV7X_Y![_D:O\ PE&@?]!S3?\
MP+C_ ,:AG\7:1'-;I;WMO=)*^UY(9E98AZDC/M^I[50_X5GX2_Z!/_DS+_\
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M_P#/>+_OL4?:K?\ Y[Q?]]BI:* (OM5O_P ]XO\ OL4?:K?_ )[Q?]]BI:*
M(OM5O_SWB_[[%'VJW_Y[Q?\ ?8J6B@"+[5;_ //>+_OL4?:K?_GO%_WV*EHH
M B^U6_\ SWB_[[%'VJW_ .>\7_?8J6B@"+[5;_\ />+_ +[%'VJW_P">\7_?
M8J6B@"+[5;_\]XO^^Q1]JM_^>\7_ 'V*EHH B^U6_P#SWB_[[%'VJW_Y[Q?]
M]BI:* (OM5O_ ,]XO^^Q1]JM_P#GO%_WV*EHH B^U6__ #WB_P"^Q1]JM_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\
MS\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_DO\ A1Y+
M_P#/S+^2_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%
M'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_
M (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_
MDO\ A1Y+_P#/S+^2_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/
MS+^2_P"%'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_
M ,_,OY+_ (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>
M2_\ S\R_DO\ A1Y+_P#/S+^2_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T
M5%Y+_P#/S+^2_P"%'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0
M!+147DO_ ,_,OY+_ (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO
M^% $M%1>2_\ S\R_DO\ A1Y+_P#/S+^2_P"% $M%1>2__/S+^2_X4>2__/S+
M^2_X4 2T5%Y+_P#/S+^2_P"%'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY+_A1Y+_\
M_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'D
MO_S\R_DO^% $M%1>2_\ S\R_DO\ A1Y+_P#/S+^2_P"% $M%1>2__/S+^2_X
M4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%'DO_ ,_,OY+_ (4 2T5%Y+_\_,OY
M+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\ S\R_DO\ A0!+147DO_S\
MR_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_DO\ A1Y+_P#/S+^2_P"% $M%1>2_
M_/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%'DO_ ,_,OY+_ (4 2T5%
MY+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\ S\R_DO\ A0!+
M147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_DO\ A1Y+_P#/S+^2_P"%
M $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%'DO_ ,_,OY+_
M (4 2T5%Y+_\_,OY+_A1Y+_\_,OY+_A0!+147DO_ ,_,OY+_ (4>2_\ S\R_
MDO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M%1>2_\ S\R_DO\ A1Y+_P#/
MS+^2_P"% $M%1>2__/S+^2_X4>2__/S+^2_X4 2T5%Y+_P#/S+^2_P"%'DO_
M ,_,OY+_ (4 2U3TO_CT?_KXG_\ 1K5/Y+_\_,OY+_A1;P+;0^6A9@69R6ZD
MLQ8_J30!+44/^MN/^N@_]!6I:BA_UMQ_UT'_ *"M !#_ *VX_P"N@_\ 05J6
MHH?];<?]=!_Z"M2T %%%% !1110 4444 %%%% !117(^,=4UO2]7T%K"Y@AT
M^ZU*WM9E\O=+(79MPR1A5VJ.G.2>F.0#KJ*R]?>2'37N?[6.EV\"-)-,D2,W
M XP7RH&>V"3P 1WH>%M8OI/ %MJ_B4>7.L#S3ML"DHI)#%> ,J ?\* .CHKC
M_"-I=P^"KC4YI6@O]5>2_ED$!E9 W("H.6(0# YY/0]"_P &ZQ?W^K:W:7UY
M)<0VLR"U^U1+#<[2N27C"J0O0@E1G)H ZVBN/\-ZMKEQXYUO3-;N('2UAADC
MBMX\)'N&<!B-S<8R3WS@#I3]:!UKXA:/I2G-OIB'4KD \;_NQ#Z@Y/TH ZVB
MN/U[5M<L/'F@VD=Q!'I=],\9B2/=))A 278CCGH%_$]A>\:7DNDZ#<ZK'JMY
M9^1%B.&!(6$LA.%!WQL>20.#TH Z*BL[0%U%?#]E_;4WG7YB#3OL"_,><8
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MCA,N%Y'W!,J?<;D9  .,<4 =517+>!-3U34K/6%UJZ2YN+/59K172,(H5 O
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MC$15WQ@.RLA4D<XXP,G K<HH YSQ#X=O=8T.VTG[>T\+74;WLMR5622$-N*
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M/U?E=N1Q@;<<=.N=6B@##T7PU_PCYOGLM0N[EKR62XDCNO+V-,^,OE(P1T'
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M+>S"(*W4*@?:H_W0*NVNFVEE<SSVD"Q/<!!)M)"G8NU?EZ# P.!T ]!5JB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*'_ %MQ_P!=
M!_Z"M2U%#_K;C_KH/_05H :%F260HD;*[;AER#T ]#Z4[=<?\\HO^_I_^)HH
MH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_
M^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO
M^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?
M\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XF
MC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^
MG_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SR
MB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -U
MQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HH
MH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_
M^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO
M^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?
M\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XF
MC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^
MG_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SR
MB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -U
MQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HH
MH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_
M^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO
M^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?
M\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XF
MC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^
MG_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SR
MB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -U
MQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HH
MH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_
M^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO
M^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?
M\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XF
MC=<?\\HO^_I_^)HHH -UQ_SRB_[^G_XFC=<?\\HO^_I_^)HHH -UQ_SRB_[^
7G_XFB%'4R-(%!=LX4YQP!Z>U%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489968464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 20, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Krystal Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1080209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Wharton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pittsburgh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-5830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRYS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,763,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s definitive proxy statement relating to its 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Report where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369490093136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG, LLP<span></span>
</td>
<td class="text">Mayer Hoffman McCann P.C.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Pittsburgh, PA<span></span>
</td>
<td class="text">San Diego, CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489561552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 161,900<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">217,271<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,608<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">383,779<span></span>
</td>
<td class="nump">442,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">161,684<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,042<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">558,450<span></span>
</td>
<td class="nump">626,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,981<span></span>
</td>
<td class="nump">8,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">23,305<span></span>
</td>
<td class="nump">16,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,847<span></span>
</td>
<td class="nump">25,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,372<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,219<span></span>
</td>
<td class="nump">32,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.00001 par value; 80,000,000 shares authorized at December&#160;31, 2022 and 2021; 25,763,743 and 25,207,985 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">803,718<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(728)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(280,759)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">522,231<span></span>
</td>
<td class="nump">593,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 558,450<span></span>
</td>
<td class="nump">$ 626,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489616528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">25,763,743<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">25,763,743<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489702624">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 42,461<span></span>
</td>
<td class="nump">$ 27,884<span></span>
</td>
<td class="nump">$ 17,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,735<span></span>
</td>
<td class="nump">40,391<span></span>
</td>
<td class="nump">15,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145,196<span></span>
</td>
<td class="nump">68,275<span></span>
</td>
<td class="nump">32,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(145,196)<span></span>
</td>
<td class="num">(68,275)<span></span>
</td>
<td class="num">(32,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,221<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,492)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(139,975)<span></span>
</td>
<td class="num">(69,570)<span></span>
</td>
<td class="num">(32,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(565)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (140,540)<span></span>
</td>
<td class="num">$ (69,739)<span></span>
</td>
<td class="num">$ (32,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5.49)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5.49)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,491,721<span></span>
</td>
<td class="nump">22,196,846<span></span>
</td>
<td class="nump">18,787,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,491,721<span></span>
</td>
<td class="nump">22,196,846<span></span>
</td>
<td class="nump">18,787,161<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes foreign currency translation loss of $78 thousand, gain of $7 thousand, and loss of $1 thousand for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income (expense) and other nonoperating, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_InterestIncomeExpenseAndOtherNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369488657664">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,354,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 202,914<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 241,951<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (39,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,359,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">363,292<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(71,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax', window );">Foreign currency translation gain/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,493,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">355,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(69,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,570)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax', window );">Foreign currency translation gain/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(139,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139,975)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,763,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">522,231<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 803,718<span></span>
</td>
<td class="num">$ (728)<span></span>
</td>
<td class="num">$ (280,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax', window );">Foreign currency translation gain/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes foreign currency translation loss of $78 thousand, gain of $7 thousand, and loss of $1 thousand for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative translation gain (loss), before tax, from translating foreign currency financial statements into the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369488530384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (139,975)<span></span>
</td>
<td class="num">$ (69,570)<span></span>
</td>
<td class="num">$ (32,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">33,230<span></span>
</td>
<td class="nump">15,319<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(762)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(311)<span></span>
</td>
<td class="num">(691)<span></span>
</td>
<td class="num">(1,922)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(647)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,254)<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,173<span></span>
</td>
<td class="nump">2,705<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(100,569)<span></span>
</td>
<td class="num">(47,938)<span></span>
</td>
<td class="num">(26,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(52,979)<span></span>
</td>
<td class="num">(68,336)<span></span>
</td>
<td class="num">(14,843)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(318,781)<span></span>
</td>
<td class="num">(190,462)<span></span>
</td>
<td class="num">(3,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">257,677<span></span>
</td>
<td class="nump">32,028<span></span>
</td>
<td class="nump">6,867<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(114,083)<span></span>
</td>
<td class="num">(226,770)<span></span>
</td>
<td class="num">(11,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">35,996<span></span>
</td>
<td class="nump">355,645<span></span>
</td>
<td class="nump">118,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to settlement of restricted stock awards</a></td>
<td class="num">(649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PaymentsForSuitLiability', window );">Repayment of ASTRA build to suit liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,960)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">35,347<span></span>
</td>
<td class="nump">347,685<span></span>
</td>
<td class="nump">118,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(179,346)<span></span>
</td>
<td class="nump">72,977<span></span>
</td>
<td class="nump">80,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">341,246<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
<td class="nump">187,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">14,927<span></span>
</td>
<td class="nump">15,363<span></span>
</td>
<td class="nump">9,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of right-of-use assets</a></td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentsForSuitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Suit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentsForSuitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369494028544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics, Inc (&#8220;Jeune Aesthetics&#8221;), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, and December 2022, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's product pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practice ("CGMP") manufacturing capabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had an accumulated deficit of $280.8 million. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability, and unless and until it does the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, the sale of equity, and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all. </span></div>The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to expand it's commercialization capabilities in advance of the potential global regulatory approvals of it's lead product, B-VEC. The Company believes that its cash, cash equivalents and short-term investments of approximately $379.2 million as of December&#160;31, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Annual Report on Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489952288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash,&#160;Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, or general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in inactive markets, or other inputs that are observable, or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining life of lease</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress (&#8220;CIP&#8221;) is not depreciated until the asset is placed in service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company not experienced any triggering events or recognized any impairment losses for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain &#8220;sale-leaseback&#8221; criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the  consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the &#8220;sale-leaseback&#8221; criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organization and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;)  Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained in 2021, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, income taxes were recorded in accordance with FASB ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, we record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December&#160;31, 2022 and 2021.&#160;We intend to maintain a valuation allowance until sufficient evidence exists to support its reversal.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December&#160;31, 2022 and 2021, the Company did not have any significant uncertain tax positions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the consolidated statements of operations related to realized gains on sales of available-for-sale securities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the years ended December&#160;31, 2022, 2021, and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369492681344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,582,181, 2,043,179, and 853,614 common share equivalents outstanding in the form of stock options and 66,600, 98,800, and zero unvested restricted stock awards as of December&#160;31, 2022, 2021 and 2020, respectively, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,167)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common<br/>&#160;&#160; shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,491,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,787,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369582917760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Instruments</a></td>
<td class="text">Fair Value InstrumentsThe following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369494793616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_BalanceSheetComponentsDisclosureTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,331&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,872&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,477&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,793)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,684&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $2.6 million, $1.8 million and $1.5 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_BalanceSheetComponentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_BalanceSheetComponentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369492763376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations (&#8220;CROs&#8221;), Contract Manufacturing Organizations (&#8220;CMOs&#8221;) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of December&#160;31, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred research and development expenses under these agreements of $6.0 million, $5.0 million and $4.6 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones or as services are rendered. The estimated remaining commitment as of December&#160;31, 2022 is $8.4 million. The Company has incurred expenses under these activities of $14.2 million, $6.1 million and $1.9 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to complete the interior build-out of our second CGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of December&#160;31, 2022 is $16.3&#160;million. The Company has included costs incurred to-date associated with ASTRA within construction-in-progress as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company, which has been amended from time to time for change orders additional work is awarded to Whiting-Turner, is currently $85.5&#160;million. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement may not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement with Whiting-Turner constitutes only a portion of the total estimated cost of building and equipping ASTRA as there are various other third parties engaged in the project for which contracts are not individually material. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. (&#8220;PeriphaGen&#8221;), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint in June 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions. On March </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12, 2022, the Company entered into a binding term sheet to settle the dispute. In April 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $25.0&#160;million within litigation settlement expense on the consolidated statements of operations for the year ended December 31, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of December 31, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $1.1&#160;million and $1.6&#160;million of insurance proceeds during fiscal years ending December&#160;31, 2022 and 2021, respectively. Additionally, the Company had outstanding receivables of zero and $560&#160;thousand as of December&#160;31, 2022 and 2021, respectively, recorded within prepaid expenses and other current assets on the consolidated balance sheets, as management determined that the amounts were probable of collection. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the consolidated statements of operations and within operating activities on the consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369492681344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company signed an operating lease for laboratory and office space in Pittsburgh, Pennsylvania that commenced in June 2016 and was scheduled to expire in October 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 54,000 square feet and includes the commercial scale CGMP-compliant manufacturing facility, (&#8220;ANCORIS&#8221;). As a result of the lease amendments, the 2016 Lease expiration date was extended to October 2031. In September 2022, the Company amended the 2016 Lease (&#8220;Short-Term Amendment&#8221;) to add a short-term lease for additional office space that commenced in October 2022 and expires on September 2023. The Short-Term Amendment increased the area leased by approximately 7,000 square feet through September 2023. Due to the short-term nature of this amendment and the Company's lease accounting policy, the Company did not record a right-of-use asset or corresponding lease liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a lease agreement for a second commercial gene therapy facility, (&#8220;ASTRA&#8221;), in the Pittsburgh, Pennsylvania area (&#8220;ASTRA lease&#8221;) with Northfield I, LLC (the &#8220;Landlord&#8221;, &#8220;Northfield&#8221;, or &#8220;Lessor&#8221;) with an initial lease term that expired on October 2035. The ASTRA lease contained an option (&#8220;Purchase Option&#8221;) to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the &#8220;Ground Lease&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA. The Company recorded a $10&#160;million CIP asset and a corresponding build-to-suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contributions of $2.4&#160;million.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Purchase and Sale Agreement (&#8220;PSA&#8221;) for ASTRA with Northfield related to the purchase option exercised by the Company in October 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. In February 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement. As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale. As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. In March 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. The building continues to be held under construction-in-progress as of December&#160;31, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2023. For more information about the expected construction costs associated with ASTRA, see &#8220;ASTRA Contractual Obligations&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability in October 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office that commenced in September 2022 and expires December 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating&#160;Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369495069472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share. Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company completed a public offering of 2,275,000 shares of its common stock to the public at $55.00 per share. Net proceeds to the Company from the offering were $117.2&#160;million after deducting underwriting discounts and commissions of approximately $7.5&#160;million, and other offering expenses payable by the Company of approximately $463&#160;thousand.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC (&#8220;Cowen&#8221;) with respect to an at-the-market equity offering program (&#8220;ATM&#8221;) finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million (&#8220;Placement Shares&#8221;). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective &#8220;shelf&#8221; registration statement on Form S-3. During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting selling commissions of approximately $524&#160;thousand. During the year ended December&#160;31, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting selling commissions of approximately $900&#160;thousand, resulting in a remaining $102.5&#160;million available for issuance under the ATM Program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369494984992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company adopted the 2017 IPO Stock Plan (the &#8220;Plan&#8221;), which governs the issuance of stock options to employees, certain non-employee consultants, and directors. Initially, the Company reserved 900 thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of 900&#160;thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over a four-year period and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE5NQ_581f1165-b5dd-4145-a11c-77520dcce020">one</span>-year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxODQxNQ_e82f6b9b-070f-474c-9202-f9ee87935c71">three</span>-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 2,130,500 and 1,422,450 stock options to employees, non-employees, and directors during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:41.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130,500&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.14&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438,892)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,886&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.20&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December&#160;31, 2022 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $2.9&#160;million and $1.3&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the years ended December&#160;31, 2022 and 2021 was $44.50 and $43.05, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $104.4&#160;million of unrecognized stock-based compensation expense related to employees&#8217;, non-employees&#8217;, and directors&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.9 years as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the&#160;consolidated&#160;statements&#160;of operations for the years ended December&#160;31, 2022, 2021, and 2020&#160;as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:55.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,669&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of manufacturing facilities. There was $551&#160;thousand, $284&#160;thousand, and $34&#160;thousand of stock-based compensation that was capitalized in the years ended December&#160;31, 2022, 2021, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of options granted was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the years ended December&#160;31, 2022, 2021, and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture Rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards (&#8220;RSAs&#8221;) granted to employees vest ratably over a four-year period. The Company granted zero and 98,800 RSAs to employees of the Company during the year ended December&#160;31, 2022 and 2021 respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSA activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $3.8&#160;million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.2 years as of December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following stock-based compensation expense related to RSAs within general and administrative expenses in the accompanying consolidated statements of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:56.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company's stock incentive plan were 469,616, with a remaining sublimit for incentive stock options of 5,581, at December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369492677824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record a current or deferred income tax expense or benefit for the years ended December&#160;31, 2022 and 2021 due to the valuation allowance position. A reconciliation of income tax (benefit) expense computed at the statutory federal and state income tax rate for the year to income tax (benefit) expense as reflected in our financial statements for years ended December&#160;31, 2022, 2021 and 2020 are as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax (benefit) at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,395)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,578)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,752)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had federal research and development credit carryforwards of approximately $2.0 million and $2.4 million, respectively. The federal tax credit carryforwards will begin to expire in 2039 if not utilized. As of December&#160;31, 2022 and 2021, the Company also had orphan drug tax credit carryforwards of approximately $4.4 million and $910 thousand, respectively. The orphan drug tax credit carryforwards will begin to expire in 2038 if not utilized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had state research and development credit carryforwards of approximately $457 thousand and $321 thousand, respectively. The state tax credit carryforwards will begin to expire in 2032 if not utilized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cumulative U.S. federal NOL carryforwards of approximately $177.7 million. Of this amount, $5.0 million is available to offset future income tax liabilities and will expire in 2037, the remaining $172.7 million is available indefinitely to offset future income tax liabilities with no expiration period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had cumulative U.S. state NOL carryforwards of approximately $186.0 million. The state NOLs are available to offset future state income tax liabilities and will begin to expire in 2037.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Internal Revenue Code Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No deferred tax assets have been recognized on our consolidated balance sheets related to these NOLs, as they are fully offset by a valuation allowance. If we have previously had, or have in the future, one or more Section 382 &#8220;ownership changes,&#8221; including in connection with our initial public offering or another offering, or if we do not generate sufficient taxable income, we may not be able to utilize a material portion of our NOLs, even if we achieve profitability.</span></div>The Company files income tax returns in the United States at the federal and state level and in foreign jurisdictions in which the Company conducts business activities. The federal and state income tax returns are subject to tax examinations for the tax year ended December 31, 2019, 2020 and 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. Additionally, the Company is subject to tax examinations by taxing authorities in foreign jurisdictions where it has business operations. At this time, the Company is not undergoing examination by the Internal Revenue Service or any foreign taxing authorities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369582917760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489783872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be </span></div>representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash,&#160;Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, or general and administrative expenses in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in inactive markets, or other inputs that are observable, or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining life of lease</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense for the year ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress (&#8220;CIP&#8221;) is not depreciated until the asset is placed in service.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company not experienced any triggering events or recognized any impairment losses for the years ended December&#160;31, 2022, 2021, and 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.</span></div>For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain &#8220;sale-leaseback&#8221; criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the  consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the &#8220;sale-leaseback&#8221; criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organization and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;)  Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained in 2021, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div>The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, income taxes were recorded in accordance with FASB ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 740&#8221;), which provides for deferred taxes using an asset and liability approach. Under this method, we record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December&#160;31, 2022 and 2021.&#160;We intend to maintain a valuation allowance until sufficient evidence exists to support its reversal.</span></div>The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December&#160;31, 2022 and 2021, the Company did not have any significant uncertain tax positions.The Company may recognize interest and penalties related to uncertain tax positions in income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the consolidated statements of operations related to realized gains on sales of available-for-sale securities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the years ended December&#160;31, 2022, 2021, and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369494988512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Summary of Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining life of lease</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369494186912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,167)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common<br/>&#160;&#160; shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,491,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,787,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369491871408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively (in thousands):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s long-term marketable securities mature between one year and two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369494835600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,331&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,872&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,477&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,793)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,684&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369493152448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating&#160;Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Expense</a></td>
<td class="text"><div style="margin-top:2pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489932592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:41.082%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130,500&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.14&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438,892)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,751)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,886&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.20&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December&#160;31, 2022 and the exercise price of outstanding in-the-money options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the&#160;consolidated&#160;statements&#160;of operations for the years ended December&#160;31, 2022, 2021, and 2020&#160;as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:55.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,235&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,669&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the following stock-based compensation expense related to RSAs within general and administrative expenses in the accompanying consolidated statements of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:56.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options, Valuation Assumptions</a></td>
<td class="text">The fair value of options granted was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the years ended December&#160;31, 2022, 2021, and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture Rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSA activity:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:70.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.619%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369491870976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate</a></td>
<td class="text">A reconciliation of income tax (benefit) expense computed at the statutory federal and state income tax rate for the year to income tax (benefit) expense as reflected in our financial statements for years ended December&#160;31, 2022, 2021 and 2020 are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax (benefit) at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,395)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,578)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,752)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,724)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369493177424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (280,759)<span></span>
</td>
<td class="num">$ (140,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 379,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369488508240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Recognized impairment losses for long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489792464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369490682832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common stockholders</a></td>
<td class="nump">3,582,181<span></span>
</td>
<td class="nump">2,043,179<span></span>
</td>
<td class="nump">853,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common stockholders</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369488498048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss per common share</a></td>
<td class="num">$ (139,975)<span></span>
</td>
<td class="num">$ (69,570)<span></span>
</td>
<td class="num">$ (32,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,491,721<span></span>
</td>
<td class="nump">22,196,846<span></span>
</td>
<td class="nump">18,787,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,491,721<span></span>
</td>
<td class="nump">22,196,846<span></span>
</td>
<td class="nump">18,787,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (5.49)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in usd per share)</a></td>
<td class="num">$ (5.49)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487694816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 161,900<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized cost, total</a></td>
<td class="nump">384,448<span></span>
</td>
<td class="nump">502,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">383,792<span></span>
</td>
<td class="nump">502,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">222,548<span></span>
</td>
<td class="nump">161,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">221,892<span></span>
</td>
<td class="nump">161,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">63,624<span></span>
</td>
<td class="nump">40,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">63,606<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">82,241<span></span>
</td>
<td class="nump">83,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">81,835<span></span>
</td>
<td class="nump">83,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">76,683<span></span>
</td>
<td class="nump">37,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(393)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">76,451<span></span>
</td>
<td class="nump">37,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, aggregate fair value</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Cash and cash equivalents | Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, aggregate fair value</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">217,271<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 217,271<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 63,606<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">77,214<span></span>
</td>
<td class="nump">35,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">76,451<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Level 2:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 4,621<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Level 2: | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Level 2: | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">47,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489721168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 168,477<span></span>
</td>
<td class="nump">$ 116,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="num">(4,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">161,684<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">131,331<span></span>
</td>
<td class="nump">104,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">24,217<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 11,872<span></span>
</td>
<td class="nump">$ 5,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489533648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369490682800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedPreclinicalAndClinicalExpenses', window );">Accrued preclinical and clinical expenses</a></td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,397<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedPayrollAndBenefits', window );">Accrued payroll and benefits</a></td>
<td class="nump">6,781<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedConstructionInProgressAndLaboratoryEquipment', window );">Accrued construction in progress</a></td>
<td class="nump">11,452<span></span>
</td>
<td class="nump">9,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedFinancingFeesCurrent', window );">Accrued financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued taxes</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 23,305<span></span>
</td>
<td class="nump">$ 16,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedConstructionInProgressAndLaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress and laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedConstructionInProgressAndLaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedFinancingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Financing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedFinancingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPreclinicalAndClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPreclinicalAndClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet components.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487200688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 13, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,461,000<span></span>
</td>
<td class="nump">$ 27,884,000<span></span>
</td>
<td class="nump">$ 17,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PurchasePriceOfPotentialBuildingPurchase', window );">Purchase price of potential building purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid', window );">Loss contingency, guaranteed maximum price to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from insurance settlement, operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_NumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementTotalConsideration', window );">Litigation settlement, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember', window );">Other Contractual Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember', window );">A S T R A Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CostOfWorkPercentage', window );">Cost of work, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CostOfWorkPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of Work, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CostOfWorkPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payments, Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementMilestonePaymentsSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Total Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Guaranteed Maximum Price to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LossContingencyGuaranteedMaximumPriceToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PurchasePriceOfPotentialBuildingPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Potential Building Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PurchasePriceOfPotentialBuildingPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RemainingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RemainingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=krys_PeriphaGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=krys_PeriphaGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487110080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Mar. 16, 2022</div></th>
<th class="th"><div>Dec. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PurchasePriceOfPotentialBuildingPurchase', window );">Purchase price of potential building purchase</a></td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress, gross</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_PaymentToEscrowForReducingLeaseRentals', window );">Cash contribution</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments', window );">Annual lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CumulativeEscalationClausePercent', window );">Cumulative escalation clause, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CumulativeEscalationClauseTerm', window );">Cumulative escalation clause, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember', window );">2016 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ShortTermAmendmentMember', window );">Short-Term Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember', window );">Boston, Massachusetts Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember', window );">Switzerland Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AdditionalAreaOfRealEstatePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional area of real estate property leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AdditionalAreaOfRealEstatePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClausePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClausePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClauseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClauseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Liability, Annual Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LessorOperatingLeaseLiabilityAnnualLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentToEscrowForReducingLeaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to escrow for reducing lease rentals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentToEscrowForReducingLeaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PurchasePriceOfPotentialBuildingPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Potential Building Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PurchasePriceOfPotentialBuildingPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ShortTermAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ShortTermAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369490261808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">10,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="nump">17,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">8,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 8,933<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489784640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 8,042<span></span>
</td>
<td class="nump">$ 7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,372<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 8,933<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, in years</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369490683008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,532<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 1,758<span></span>
</td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">$ 824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487509552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">2,866,667<span></span>
</td>
<td class="nump">2,211,538<span></span>
</td>
<td class="nump">2,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in usd per share)</a></td>
<td class="nump">$ 75.00<span></span>
</td>
<td class="nump">$ 65.00<span></span>
</td>
<td class="nump">$ 55.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="nump">$ 201,900<span></span>
</td>
<td class="nump">$ 134,900<span></span>
</td>
<td class="nump">$ 117,200<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to additional paid in capital, stock issued, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,782<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="nump">$ 66.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">288,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember', window );">Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SaleOfStockAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SaleOfStockRemainingAvailableIssuanceAmount', window );">Remaining available issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockRemainingAvailableIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Available Issuance Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockRemainingAvailableIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487296448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,130,500<span></span>
</td>
<td class="nump">1,422,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based payment arrangement, amount capitalized | $</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options available for grant (in shares)</a></td>
<td class="nump">469,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_A2017IPOStockPlanMember', window );">2017 IPO Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized', window );">Annual increase in number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,130,500<span></span>
</td>
<td class="nump">1,422,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in usd per share) | $ / shares</a></td>
<td class="nump">$ 44.50<span></span>
</td>
<td class="nump">$ 43.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 104,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options available for grant (in shares)</a></td>
<td class="nump">5,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_A2017IPOStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_A2017IPOStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489744576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,043,179<span></span>
</td>
<td class="nump">853,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,130,500<span></span>
</td>
<td class="nump">1,422,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(138,855)<span></span>
</td>
<td class="num">(54,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(438,892)<span></span>
</td>
<td class="num">(175,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(13,751)<span></span>
</td>
<td class="num">(2,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,582,181<span></span>
</td>
<td class="nump">2,043,179<span></span>
</td>
<td class="nump">853,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">666,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="nump">$ 40.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">64.14<span></span>
</td>
<td class="nump">66.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">50.47<span></span>
</td>
<td class="nump">38.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in usd per share)</a></td>
<td class="nump">59.22<span></span>
</td>
<td class="nump">61.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="nump">78.80<span></span>
</td>
<td class="nump">75.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">61.50<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="nump">$ 40.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share)</a></td>
<td class="nump">$ 49.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual Life (years), exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 64,880<span></span>
</td>
<td class="nump">$ 31,331<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 20,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369488667120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 31,448<span></span>
</td>
<td class="nump">$ 13,669<span></span>
</td>
<td class="nump">$ 3,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">7,897<span></span>
</td>
<td class="nump">3,434<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">23,551<span></span>
</td>
<td class="nump">10,235<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,782<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369489720528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 64.14<span></span>
</td>
<td class="nump">$ 66.88<span></span>
</td>
<td class="nump">$ 47.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Forfeiture Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.74%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369488505744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(14,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Surrendered or forfeited (in shares)</a></td>
<td class="num">(17,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Surrendered or forfeited (in dollars per share)</a></td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="nump">$ 78.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487119168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Cumulative NOL carry forwards</a></td>
<td class="nump">$ 52,569,000<span></span>
</td>
<td class="nump">33,170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_OwnershipInterestRateChangeOverPeriod', window );">Cumulative changes in ownership interest rate period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CumulativeChangesInOwnershipInterestOfShareholders', window );">Cumulative changes in ownership interest of shareholders</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Cumulative NOL carry forwards</a></td>
<td class="nump">$ 177,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Cumulative NOL carry forwards with expiration</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Cumulative NOL carry forwards with no expiration</a></td>
<td class="nump">172,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal | Orphan Drug Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Cumulative NOL carry forwards</a></td>
<td class="nump">186,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 457,000<span></span>
</td>
<td class="nump">$ 321,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeChangesInOwnershipInterestOfShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative changes in ownership interest of shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeChangesInOwnershipInterestOfShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_OwnershipInterestRateChangeOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership interest rate change over period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_OwnershipInterestRateChangeOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=krys_OrphanDrugTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=krys_OrphanDrugTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369490617504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax (benefit) at statutory rate</a></td>
<td class="num">$ (29,395)<span></span>
</td>
<td class="num">$ (14,578)<span></span>
</td>
<td class="num">$ (6,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">39,781<span></span>
</td>
<td class="nump">20,689<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense net of federal benefit</a></td>
<td class="num">(10,438)<span></span>
</td>
<td class="num">(5,436)<span></span>
</td>
<td class="num">(2,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Credits</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="num">(1,295)<span></span>
</td>
<td class="num">(887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other non-deductible expenses</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140369487146736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 52,569<span></span>
</td>
<td class="nump">$ 33,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">7,445<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized costs</a></td>
<td class="nump">14,124<span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credits</a></td>
<td class="nump">6,708<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">85,816<span></span>
</td>
<td class="nump">45,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(82,513)<span></span>
</td>
<td class="num">(42,732)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">2,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="num">(2,312)<span></span>
</td>
<td class="num">(2,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(854)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,303)<span></span>
</td>
<td class="num">(2,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>krys-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krys="http://www.krystalbio.com/20221231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krys-20221231.xsd" xlink:type="simple"/>
    <context id="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52e1c55a604642dc8a755cffeb2fc42b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9cdc37180ee546aab3866b3edea133cc_I20230220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2023-02-20</instant>
        </period>
    </context>
    <context id="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49c0637d46d649d4bacab028175efbaa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5d56c1a54244984a5f923ac922fdede_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36267cfc53644c10b377545a419cdc2b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1791ab32bfb844bdb1549f6e0fa6ebf2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i496ec5ae5f474b68a6e6e266a5883626_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i804bccd139d04bf3b19b95e33e6df55e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c619239c03440b5b8db4727db939247_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id62eddb7037c4f82b6f2687e0a52e6ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1fd0edbd57ff47fb919fb61349c64819_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i208aa8cb27e54c60b096966b6240e133_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91001397acca4edbb0a19b9c79aa5b7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f9c855a0e3a4e13a53433cc5c0364b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia24f42b2bb4c47b89466941d0f5831db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i922596331dd24a1dbd0e0b79d3ef475b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf8e1134b7c94d26a0c3d22afc73d215_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb2f2c779195497fb1144f46db638bfb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie413a0f15f0d4717be8217ec39b221df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica5904f7fef443a68940ec9e9da0ce98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2465df77d804826b661dda93a47a9e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id8ca4dafce8c49c38953d0c3cc1e563b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a31534ac7ce4d699f4394d4b19576c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66ebe6bcc927412c83fb26d401bcacaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i996e18257f394eff9914fcba8ed4e078_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc4b03d778584b14ad55239cd91fef14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie289a738c54a427ea3a8922f170941dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57d5acffc6e34806bcad27370483078d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i915fb9f46db84704ab0d72c2ada7e20e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58f61bb3407246f1923b173d13ac2592_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3eafaed6c8534eb88f2e16210025076a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb62cd25fa1545ddb2adf0d82820735f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee87fb1c670d4a8fabfd071c375435ee_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61e616f277cb401d95b1e1572f6cf8c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73935a9788274be9a2a5a77ba030b6f2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2bd6fcadcdd473ea0f07dc041889bed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71e119a9d7434b2583f9e8b3f823f74b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8cdf55bd7cb34dc7b7afcf71ada77513_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd3eeb0d882a48b0b15625e5774f3daf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib15d39f02c324677aeac9f5d4a570fa7_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6afd13b46734de18b78209e7932208b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69af799c800a4519a24465b3e66df634_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85ab137db9d24527ad70578422157edc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb022f76121f4e10b847528fc749dceb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e196aef98d946ef9ba6a9d94c73d645_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic96d3206ab1847cd9a05a879d0efe67c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a6fa4bf942a419fbec493f4bf7f4b31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d46f0e247a640828b2290ff03d295cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e649be5847e4c318f3b5b62ca8bd797_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4613ad1330074364a3d902cd8b6f8599_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc145339ddd143598976c49d98e634a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75f7cf345d4447f6a47ad9669b43afd0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib381b024b3f44b17b2017dc67c13aab4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie820ccd74fbb44e0b053b5527111f83d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i474abeb633a744ebbe6c051fccc138d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2e9a31bc727469d97f0ab1f1c104519_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id15667ce7b0c40e5b2f6147b95913a03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c142c1f1d9844f38df3bcfa1684428a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36361a0fa8ca486fbe97852c6f806b2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8132445eec974341992bfe7b7684bafc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i457106579689420ea580675819005893_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ae3f849bf20446db2cc1146dcd478d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1e3d585465c4e46b41b696bc03baddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb5bf368359a4d94adb4f27bedbb43b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic622f20a96d14ab59d16de8af2ade381_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40c9585ccfdd4de685f78c97d566a741_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if32b08f8717549848438881335ea2b84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i719c13df2acf4bbc80d5a66f47c2c5f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56384752fd2647389a6264b9b7752b99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69f790be83c94488822a264523f7aa15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3da056f4632343f5ade54138b94c15a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i995af0deed0b466cb43a86929a821007_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b7449a1b73c48eba712df83a6750173_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id297898530e345fdb9c39bf76182c6cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbf57f87b5d64c0285b86a7324814667_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2664a396fda544d5b299ff5ebffde6f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3eedc946a09f4463a2514f7732506d68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb31ec5446de4fe8ac13a013fc88446a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a01a2413bfa418289c898f2b33b80ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieba9efc2fefc4fef9a71d9e9ad291bf5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib64f00a32bc643ec9155226e65fdce96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id09a4d167ef143e0bd15f47ab94c5ad3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38459e6001414efe8cfeb8e4f948bc27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36fe90f1305345ceb8f4eec74b095c49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i629b96ba6adf4d8aa35b23c9ad34341a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic01e245d2c6b4ecbb264de581059c082_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53a1d6851402493eb7158bcdc4c40c4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd317320604f464d92352b55af94077e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib85a7c903384425b9eb947f6782aa70b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i256fac5f703848e2b8ab04acc69e5f3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea876abef962460799265e18643c6fb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fc859be73b64ed295ad31b068c1c6b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic202baf205634534bffe9efeed3c7c9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8bb7ba5bc104672859794003515136c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie84cd465b49e427c810883f086042263_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02fbe5b2532b456baed4ef03a2689550_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6be49196b1a40cebb048dcca6eb9e34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e748ec3ff764d03a108335cdb1f671c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia61ac7a1eeb045dcacea633ccb659966_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i832fb48c719242fba8c5af845c762e6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc3bab3e2c074cf09d136a1988e3d2e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i495e2c1097804e028fc462ff30675a6f_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="i3fb54fd3a1a9429dbd4579a4ca4375c3_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4284a105f3d94405949b41403e9a7675_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie93b6151f6f9401a9cf2ece6f8285911_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66aa90c0684b46ac8099d45d53db5a8d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc45f2a4236a42068da733f353b95494_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="id2f6d31d7c164477b1d0048e8a3d3c31_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i945482856edd461ca395d4030b16ab54_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="ie8a82f78a44f492d8069e2d68d1056a8_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i6729dd8891e24732929f1da30607e91a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id3550b062fe645a5b0ed51ef12d694db_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ShortTermAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i4370047cb1b348508f41d2e789bc71c0_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="if35ae989164e43cdb1a778a5e6515540_I20211215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonMassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="ia171e05bea12459f9ba3be58aa9b540f_I20220316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-16</instant>
        </period>
    </context>
    <context id="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i30156baee55b420397418386f0108370_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i20353f3c4a5844c1812426b1fb75b765_I20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="id22d7707724741a49fc8f50872fbdfdb_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="ieb9b5e8d6ec94209880102cc2bc8b200_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i30752247a0714b92a9d3f37982cfdcaa_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i9957e8c329c246278995d54d846e0a2b_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-31</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ic18c855dfb0d4abf9b71ece6213ab70d_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i95615b0260094824b79b22c82e8d1a1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb780c5cb8b14431832716c15e1dac80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f7ad365543f4254838ab4c58a691a10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cef0fcaddce44cfa4ae5cd35b69a9db_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i94d7eb26698e4662a210b4e03cb7f40e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0436d21be92494794b2f1a66dba88ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd3104f8c0ce402b88a79fb05859ba61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:A2017IPOStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i73cbc13ff387448bbd68fa1f41555112_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id569cee70e244c0a91e103af3fdc3981_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic9274bc3d5034d649742d7cf95cad4c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44284afec0974ca383f35189fcf5836c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib074476f73164a7380886e3036b586df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae2d691354374a8292be807107fe9093_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idae3c74e3eaa49338980a2180ec9032f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2c0073addc8943b48ff41400a0b94650_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34ce9bbd561d4f208adfe62e207934e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i80f3a841eea6448987a04b6c2d676f22_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0747f5930bf4422fab3034a04de464a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec828eaae79146849fd3782a3949449d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idcdeed31d4564d29a353803d0d00dc6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34e51c635ee14313b6fb1c0daa7415bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic416c201f5284d9f943605c62536d8be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64502038e5f64b25854ef8736435d9a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d98e41008f24785ad933f9a46c178e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic06852b1b5d247e4803f084678fb20d7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc8ab265e2b84543a478bdf30eed184f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib231c197185e448c8293b564b7342929_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1eb9664479bc48ffb663071fe28743f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6cc6d3fd9adf476d8c19b91e06ad9df9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id57562bb09e14b62821f7c7ee59bc9d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i880d88ff54e545f6b66cbd9fa91d7c0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1e042df24d94919831c05275e22f61c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">krys:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c4cd79ab6b4405a9b60c9b5803d3e47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">krys:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba614e370fda465e9bd79ec170d9f9b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i299015c71eda4062b0883fb132997c3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i326eceb3ac84481fb3a1888cdd980f89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf96a3872b434ff2ba6fae61cdb19b56_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>krys:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>krys:milestone</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV80LTEtMS0xLTQ2NTM4_14a34afb-07eb-4984-a68a-7990978e720f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV82LTEtMS0xLTQ2NTM4_72239979-87d1-40dc-89df-7aa566d88a58">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV83LTEtMS0xLTQ2NTM4_babdd637-ddda-4c89-97b1-f4c9257181ec">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N180L2ZyYWc6MzM2YjllODM1N2ZiNDg4NDk2YzM4MDEzMTM0ZDUzZjUvdGFibGU6MzBlNGRjYTIyNGNkNDVmMDk0MWNiOTFjZjg1Nzk1YmUvdGFibGVyYW5nZTozMGU0ZGNhMjI0Y2Q0NWYwOTQxY2I5MWNmODU3OTViZV85LTEtMS0xLTQ2NTM4_6c999033-0f44-4d42-b54a-a7040e6d22ab">0001711279</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i73cbc13ff387448bbd68fa1f41555112_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE5NQ_581f1165-b5dd-4145-a11c-77520dcce020">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id569cee70e244c0a91e103af3fdc3981_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxODQxNQ_e82f6b9b-070f-474c-9202-f9ee87935c71">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized
      contextRef="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xNjM1L2ZyYWc6MDMzZDY3NzhiYTc0NGY5NGIyMDkwYzhjZGNiNGM0YzYvdGV4dHJlZ2lvbjowMzNkNjc3OGJhNzQ0Zjk0YjIwOTBjOGNkY2I0YzRjNl8yMTk5MDIzMjU1NTkx_1a15ccd3-d20c-49a0-97c3-e0da84de53c2"
      unitRef="number">0.04</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized>
    <dei:DocumentType
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTgy_f6e15c5d-25b8-4b5d-8edb-2e812ee233bf">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6MTRlMzI2ZTVhMmU3NDZkZThjYzlhYTRlNjg2YjBiMjgvdGFibGVyYW5nZToxNGUzMjZlNWEyZTc0NmRlOGNjOWFhNGU2ODZiMGIyOF8wLTAtMS0xLTQ2NTM4_041abf61-17c9-4046-898f-bfa9548dbd26">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N18yODg_7aceddbb-faac-4719-8839-a6d2268d45cf">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N18yODg_1abaf1bf-12fd-4268-92ae-ca67055762dd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6YzlhYWE5NDM2OTdjNGUxODkyY2IzOWM0ZDkxYzMxM2IvdGFibGVyYW5nZTpjOWFhYTk0MzY5N2M0ZTE4OTJjYjM5YzRkOTFjMzEzYl8wLTAtMS0xLTQ2NTM4_a8a4959a-2032-46bb-a773-1dae36db1997">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTg3_89d95551-07e3-428d-9fec-1410aa37e4d9">001-38210</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTkw_7689f0a4-805d-4d3c-a4fc-29f83915dee4">Krystal Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18wLTAtMS0xLTQ2NTM4_7199c703-5892-4650-9105-c4adef9c4ea8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18wLTEtMS0xLTQ2NTM4_ea82e976-8158-43fc-b865-cbd2302c3fe6">82-1080209</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18yLTAtMS0xLTQ2NTM4_5366df9a-a7f5-42f3-9843-010d384e0d01">2100 Wharton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY18zLTAtMS0xLTQ2NTM4_a845e90e-1ef1-4a45-8167-4f722af1a0c3">Suite 701</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY180LTAtMS0xLTQ2NTM4_3cfeaf3b-8345-47c5-a7c9-abb4d39796d8">Pittsburgh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY181LTAtMS0xLTQ2NTM4_58de99db-d14d-478b-a896-dc98a3bbc9df">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ODQ0N2Y2NmQ4ODdkNDMyYWIxNjJjNDc1NzUyZGUyYWMvdGFibGVyYW5nZTo4NDQ3ZjY2ZDg4N2Q0MzJhYjE2MmM0NzU3NTJkZTJhY181LTEtMS0xLTQ2NTM4_978aacdb-e2d3-4cca-9dbe-63427e6c800d">15203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTkx_58372ffe-0e91-438e-91cb-c21e1fb53f65">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTkz_a0dc090c-f422-4a05-936e-34342beb4c28">586-5830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZjYzNTRiMjEyNDUzNDhmZDk5MmZmNjFlOTRjZDVhYWYvdGFibGVyYW5nZTpmNjM1NGIyMTI0NTM0OGZkOTkyZmY2MWU5NGNkNWFhZl8xLTAtMS0xLTQ2NTM4_b62bdbe4-5caf-4de1-b9e6-3efa3c0d3419">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZjYzNTRiMjEyNDUzNDhmZDk5MmZmNjFlOTRjZDVhYWYvdGFibGVyYW5nZTpmNjM1NGIyMTI0NTM0OGZkOTkyZmY2MWU5NGNkNWFhZl8xLTEtMS0xLTQ2NTM4_9a766c79-2c8f-43a1-b1a2-54e68863f2a7">KRYS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZjYzNTRiMjEyNDUzNDhmZDk5MmZmNjFlOTRjZDVhYWYvdGFibGVyYW5nZTpmNjM1NGIyMTI0NTM0OGZkOTkyZmY2MWU5NGNkNWFhZl8xLTItMS0xLTQ2NTM4L3RleHRyZWdpb246YmI3ODUzYmNjM2ExNDgyOWE4NTNlODQ5NGMyOTUwZjdfNA_fc42c02e-b3c4-414e-ac99-e323d9a1cd42">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N181NDk3NTU4MjQ4MDU_c961f6e1-924f-4c30-83a2-3f73870c8742">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTk0_b90ffd06-0438-4f18-814c-7234cde8e514">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTk1_098b0b6a-a629-4eb7-947f-4e5f44da2098">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTky_894a4965-b348-42c1-b02a-e2eb8e9f20b6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZWY5MjZmYWEyYjhmNDMwN2JmMjUwNGVlMmEzODI5YjEvdGFibGVyYW5nZTplZjkyNmZhYTJiOGY0MzA3YmYyNTA0ZWUyYTM4MjliMV8wLTAtMS0xLTQ2NTM4_cbd69242-a0ff-4232-aab6-9abfc3b4d8a3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZWY5MjZmYWEyYjhmNDMwN2JmMjUwNGVlMmEzODI5YjEvdGFibGVyYW5nZTplZjkyNmZhYTJiOGY0MzA3YmYyNTA0ZWUyYTM4MjliMV8yLTMtMS0xLTQ2NTM4_d75177c5-7892-41a2-b53b-1b65f9f4bb67">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGFibGU6ZWY5MjZmYWEyYjhmNDMwN2JmMjUwNGVlMmEzODI5YjEvdGFibGVyYW5nZTplZjkyNmZhYTJiOGY0MzA3YmYyNTA0ZWUyYTM4MjliMV80LTEtMS0xLTQ2NTM4_06749d7b-cbd6-477c-bbec-7092e43b6634">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTg5_efdba7d5-e719-4275-9348-c60061770890">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTg1_5b19236c-6619-44f2-a083-9521b39989df">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i52e1c55a604642dc8a755cffeb2fc42b_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N18zMDk2_8ab134bc-6eab-4232-b07a-ad4ec28ec497"
      unitRef="usd">1400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9cdc37180ee546aab3866b3edea133cc_I20230220"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N181NDk3NTU4MjMyMjg_cee48360-bbb3-4c86-acc3-36488b0df707"
      unitRef="shares">25763743</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xL2ZyYWc6MGYyMDBjYWQ2N2RhNGZiMGI4M2U4YWQ4NjFiMjA1OTcvdGV4dHJlZ2lvbjowZjIwMGNhZDY3ZGE0ZmIwYjgzZThhZDg2MWIyMDU5N180NTk3_f9c267a2-96e8-4995-922b-91e6676abece">Portions of the Registrant&#x2019;s definitive proxy statement relating to its 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this Report where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDAwOQ_1c1af066-dc02-42bd-9de0-6c3b3a5dd534">KPMG, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDAyNg_b3e958a8-2eee-4af0-9a4c-b9f070a3bebb">Pittsburgh, PA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5Xzc0_8dfe7932-6316-4e01-aa37-568ef863f25d">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDIwNg_27bbf98a-a079-4881-94b5-30075d9096de">Mayer Hoffman McCann P.C.</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDIzMg_2a6dacf8-e7a0-402c-842f-222ef167c2cf">San Diego, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185MS9mcmFnOmZiMjk3N2FjZDIyMzQ5Mzg4Njg3YTNhZDc1YmY2NWNlL3RhYmxlOmI3YjE2YTUyOTZjYjQ1MzRiYmFjYWE5MmZiNTZhMzg0L3RhYmxlcmFuZ2U6YjdiMTZhNTI5NmNiNDUzNGJiYWNhYTkyZmI1NmEzODRfMC0wLTEtMS00NjUzOC90ZXh0cmVnaW9uOmQ3MmU2NjE4ZGY3ZDQ0ZDRhZjZhMzk1ODI2N2NhZTI5XzU0OTc1NTgxNDI0OA_5c1df667-0732-4131-a2d4-09be128d7c91">199</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNC0xLTEtMS00NjUzOA_2d08cab8-2a6e-48b7-937a-6a7d35c79166"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNC0zLTEtMS00NjUzOA_6eb08f49-1700-4f9a-9112-bc749d10dccf"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNS0xLTEtMS00NjUzOA_af62614f-b676-4faa-8fcd-acd29168e3ee"
      unitRef="usd">217271000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNS0zLTEtMS00NjUzOA_d13b2494-81f9-4b84-8052-d9bd1a0642b3"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNi0xLTEtMS00NjUzOA_d56552ca-385a-40d2-bd81-afeda0ed4d28"
      unitRef="usd">4608000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNi0zLTEtMS00NjUzOA_e326135a-4767-458e-90e7-8fc6448cbecb"
      unitRef="usd">4171000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNy0xLTEtMS00NjUzOA_06305982-d0fc-4594-ab74-a1fb39db52c6"
      unitRef="usd">383779000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfNy0zLTEtMS00NjUzOA_268b92e9-fa50-460c-ba9a-c692dc93738f"
      unitRef="usd">442267000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOC0xLTEtMS00NjUzOA_477781af-bf78-4c65-a296-84525a4d940a"
      unitRef="usd">161684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOC0zLTEtMS00NjUzOA_256cfad3-3f8d-4b7f-a862-6ad207c3dc3d"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOS0xLTEtMS00NjUzOA_e69e91ab-99f1-4299-b394-0513dbf1c9ab"
      unitRef="usd">4621000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfOS0zLTEtMS00NjUzOA_f4777800-18a2-40e2-be0b-81146280bc59"
      unitRef="usd">64371000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTAtMS0xLTEtNDY1Mzg_b33ff9ac-f566-4f59-b09b-94c69ba2a924"
      unitRef="usd">8042000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTAtMy0xLTEtNDY1Mzg_ae1ce9fb-5c83-4976-9677-2ead579064a8"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTEtMS0xLTEtNDY1Mzg_8baaaf84-24ec-4ed8-8973-ccc4f0befea1"
      unitRef="usd">324000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTEtMy0xLTEtNDY1Mzg_b7c063f4-adcb-4758-8b21-de01b9d8e07f"
      unitRef="usd">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTItMS0xLTEtNDY1Mzg_672a8a04-9343-4c74-a3da-053f060bf219"
      unitRef="usd">558450000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTItMy0xLTEtNDY1Mzg_8a89570f-6e56-42c2-940d-5eb77e0d45be"
      unitRef="usd">626295000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTUtMS0xLTEtNDY1Mzg_9c8dafa9-7c66-4e30-9db8-b227647bab19"
      unitRef="usd">3981000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTUtMy0xLTEtNDY1Mzg_d8bfc24a-2c61-4bdb-a014-d5682bbb9ca8"
      unitRef="usd">8398000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTYtMS0xLTEtNDY1Mzg_1197d4a9-029c-4bce-b057-51ecbb1cdbce"
      unitRef="usd">1561000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTYtMy0xLTEtNDY1Mzg_2afb0798-569e-41e0-8bce-dc0cddd1cb09"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTctMS0xLTEtNDY1Mzg_720c4262-1a23-42f5-8bdf-9914e4a83f66"
      unitRef="usd">23305000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTctMy0xLTEtNDY1Mzg_edb0a61b-0754-4362-8b61-03ec4247eecf"
      unitRef="usd">16297000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTktMS0xLTEtNDY1Mzg_13daea04-e8ab-47fb-9e8c-6bbab178529a"
      unitRef="usd">28847000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMTktMy0xLTEtNDY1Mzg_cf1c9eea-af4c-405c-b801-229d8ec82e24"
      unitRef="usd">25736000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjAtMS0xLTEtNDY1Mzg_b363fad2-ce4f-4b66-ac2c-ab9d7260ac35"
      unitRef="usd">7372000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjAtMy0xLTEtNDY1Mzg_2d82cd5e-9d20-44fd-a6fc-0c913a49d91d"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjItMS0xLTEtNDY1Mzg_ad8c85d6-481e-4781-92f7-a67b18ec5fe1"
      unitRef="usd">36219000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjItMy0xLTEtNDY1Mzg_35abde2b-d0bd-42c8-8d41-714f4000c7f8"
      unitRef="usd">32719000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjMtMS0xLTEtNDY1Mzg_9e4aaecd-b43b-4c9e-9749-6690b4750301"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjMtMy0xLTEtNDY1Mzg_8713ea94-724c-4efb-984a-19cada738931"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18xOA_98fd48de-b9a9-4cf3-b516-6ebc52b39108"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18xOA_a8864ab6-e3ca-4bcc-b42d-766d0b71cccb"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18zMg_298e9849-afa5-40f1-a30a-9ae50b85c407"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M18zMg_2ae8cd86-1bd4-40ca-8666-54343040ebdf"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M184Nw_2844dae5-0a3e-4177-930f-704b670cc11c"
      unitRef="shares">25763743</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M184Nw_4d141888-b5da-4657-94e8-e01d65df223a"
      unitRef="shares">25763743</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M185NA_54821823-0350-441d-ae14-92c9d91153eb"
      unitRef="shares">25207985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMC0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOWY1M2FiOTcxZTQ0YzY2YmJlZTU3MTc5YzEzNTE0M185NA_78b7dad3-82d9-4620-841d-5c6d115c3edc"
      unitRef="shares">25207985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMS0xLTEtNDY1Mzg_ce639684-238d-4a21-9e41-4fc551b226fc"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjYtMy0xLTEtNDY1Mzg_6c90d342-ea3b-4e13-b098-0b1f6f12f137"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjctMS0xLTEtNDY1Mzg_354f4b69-e0b1-4447-9d96-da92b150a35c"
      unitRef="usd">803718000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjctMy0xLTEtNDY1Mzg_74b582c8-dca9-4ab7-8073-bce93855b116"
      unitRef="usd">734523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjgtMS0xLTEtNDY1Mzg_f43aa299-c274-426c-a31c-f0c0befd1d4b"
      unitRef="usd">-728000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjgtMy0xLTEtNDY1Mzg_6ea69b30-4868-4dd4-8905-685665e31051"
      unitRef="usd">-163000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjktMS0xLTEtNDY1Mzg_b1fdbcfd-32f8-423a-a5da-b09a1b18066c"
      unitRef="usd">-280759000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMjktMy0xLTEtNDY1Mzg_e2064146-146f-4757-b604-ac4d30c9b6f2"
      unitRef="usd">-140784000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzAtMS0xLTEtNDY1Mzg_1365d6cb-a583-4182-a8d6-1c6a52e8e980"
      unitRef="usd">522231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzAtMy0xLTEtNDY1Mzg_2563565b-e7ed-4016-8382-93ca32309ccd"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzEtMS0xLTEtNDY1Mzg_d3cae2b6-a240-4dfd-8aa6-6b9934484758"
      unitRef="usd">558450000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N185Ny9mcmFnOjlkZGUwZWIzMDE2YjQxYmQ5M2I5ZTc0ZjFkOGE3YjU0L3RhYmxlOjdiMjQ4OTA4NGZmYTQ5OThhNmFlMWM1Mjg1NThjZTY4L3RhYmxlcmFuZ2U6N2IyNDg5MDg0ZmZhNDk5OGE2YWUxYzUyODU1OGNlNjhfMzEtMy0xLTEtNDY1Mzg_6bd808d4-47cc-4ca5-9531-0ab1e77ab30e"
      unitRef="usd">626295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzMtMS0xLTEtNDY1Mzg_f1d02abf-004a-4eed-b8aa-29b26c25afa6"
      unitRef="usd">42461000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzMtMy0xLTEtNDY1Mzg_cd3efb01-e26b-4d6f-840c-c5d6e0e3657f"
      unitRef="usd">27884000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzMtNS0xLTEtNDY4NDk_da371a8f-2622-461a-a528-5355a83abb5a"
      unitRef="usd">17936000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzQtMS0xLTEtNDY1Mzg_4c7adc16-8e7c-4c81-824b-9dc9e1dd9db5"
      unitRef="usd">77735000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzQtMy0xLTEtNDY1Mzg_09410bb4-927d-4f7a-ada8-559d77478064"
      unitRef="usd">40391000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzQtNS0xLTEtNDY4NDk_8cc561e9-1586-4009-beb0-680c4ac172fb"
      unitRef="usd">15063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMS0xLTEtNTIzNDc_d052ed8a-9285-4cd0-aedb-676b996016ea"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMy0xLTEtNTIzNDc_ec2ddac4-7c95-4acc-84a3-24063ad7bda0"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtNS0xLTEtNTIzNDc_6349336b-6bd1-4267-9b1b-f9c2a30a4003"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMS0xLTEtNDY1Mzg_8287d040-fb5d-418b-bcab-63714f8616d2"
      unitRef="usd">145196000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtMy0xLTEtNDY1Mzg_c32a4b7c-2f46-475d-8dcf-897e515d8295"
      unitRef="usd">68275000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzUtNS0xLTEtNDY4NDk_f37e74ff-c920-411b-a584-f2119f5c6774"
      unitRef="usd">32999000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzYtMS0xLTEtNDY1Mzg_a40f604f-a7a6-4f58-8a1a-b739b900314a"
      unitRef="usd">-145196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzYtMy0xLTEtNDY1Mzg_7abf5e67-f246-4e08-a36b-2d92d93eb513"
      unitRef="usd">-68275000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzYtNS0xLTEtNDY4NDk_500f7da0-5105-4968-ab80-b6a61532e795"
      unitRef="usd">-32999000</us-gaap:OperatingIncomeLoss>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzgtMS0xLTEtNDY1Mzg_c8328507-71f0-430b-bc99-dd9c4d400356"
      unitRef="usd">5221000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzgtMy0xLTEtNDY1Mzg_d68df78b-bdab-4bbe-ad33-18c805320b0b"
      unitRef="usd">197000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzgtNS0xLTEtNDY4NDk_c5de0b61-b61b-495d-8bf4-51cc6c6b2b94"
      unitRef="usd">832000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzktMS0xLTEtNDY1Mzg_51d05587-afba-4b74-837b-444cd5b53def"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzktMy0xLTEtNDY1Mzg_05ba315f-5a36-4123-a5a9-a87faa4a3c92"
      unitRef="usd">1492000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzktNS0xLTEtNDY4NDk_28e6b829-4740-40d5-8b80-22cdaaee3432"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i36267cfc53644c10b377545a419cdc2b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEwLTEtMS0xLTQ2NTM4_56fffb5c-ce93-4b86-b892-d0ffe887e8e1"
      unitRef="usd">-139975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEwLTMtMS0xLTQ2NTM4_a3b2089f-8f8d-4c98-a7bc-8f5f96b56735"
      unitRef="usd">-69570000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEwLTUtMS0xLTQ2ODQ5_932e4373-cc26-438d-aab2-49d803a7d8f5"
      unitRef="usd">-32167000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1791ab32bfb844bdb1549f6e0fa6ebf2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzExLTEtMS0xLTQ2NTM4_d121801a-8f56-4716-ab01-d038c3c5a0e4"
      unitRef="usd">-565000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzExLTMtMS0xLTQ2NTM4_a78c2f25-a53b-4cd7-9ec5-5677e4de9277"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzExLTUtMS0xLTQ2ODQ5_6c76bc7c-60c8-4583-bb1d-8b2a59c610f1"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEyLTEtMS0xLTQ2NTM4_6179d27c-af49-4cc1-823b-a9c8fabe9215"
      unitRef="usd">-140540000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEyLTMtMS0xLTQ2NTM4_e65cbdda-7956-4083-b6ae-44890cc18215"
      unitRef="usd">-69739000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzEyLTUtMS0xLTQ2ODQ5_2ccc9aec-4589-42b1-935a-13314bb187e3"
      unitRef="usd">-32171000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTEtMS0xLTQ2NTM4_33418728-4a61-48a4-a002-5e08d1a25ba5"
      unitRef="usdPerShare">-5.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTEtMS0xLTQ2NTM4_b3c541fd-54d3-49c0-9585-a834d1781a40"
      unitRef="usdPerShare">-5.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTMtMS0xLTQ2NTM4_24cbc321-144d-41db-88e4-53dc885e41b1"
      unitRef="usdPerShare">-3.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTMtMS0xLTQ2NTM4_500cfc1f-cc9b-436a-9645-06b5c8e4904e"
      unitRef="usdPerShare">-3.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTUtMS0xLTQ2ODQ5_86e082ae-c63a-48c7-9199-7d349e1ab0da"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE0LTUtMS0xLTQ2ODQ5_8f75da8d-049c-4b0b-9b48-1fccc094db9d"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTEtMS0xLTQ2NTM4_37048d14-5cae-44ed-bd7c-2fb4d715415d"
      unitRef="shares">25491721</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTEtMS0xLTQ2NTM4_7c03543e-f185-4d4f-8f43-e8db58c1950e"
      unitRef="shares">25491721</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTMtMS0xLTQ2NTM4_2b117dfd-5759-4364-b33b-841a2dd49372"
      unitRef="shares">22196846</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTMtMS0xLTQ2NTM4_6a124b09-2940-42c0-9d17-176f4fe3872e"
      unitRef="shares">22196846</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTUtMS0xLTQ2ODQ5_2c99d4d3-d049-4419-be65-0fc034016bd1"
      unitRef="shares">18787161</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDAvZnJhZzo4ZmE4OGEzY2FjNjc0YjQyYTdmZjE1MTAxNjQxMDE5My90YWJsZTpjNzc0ODk3MjE2ODA0NjkyYWI2ZmY0MDVhMmMxYWQyNS90YWJsZXJhbmdlOmM3NzQ4OTcyMTY4MDQ2OTJhYjZmZjQwNWEyYzFhZDI1XzE2LTUtMS0xLTQ2ODQ5_ec49537b-a2ee-4235-a107-2d3d5778d035"
      unitRef="shares">18787161</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItMS0xLTEtNDY1Mzg_3c4d3a3a-8f1c-429e-87ec-f7066c9b4042"
      unitRef="shares">17354310</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItMy0xLTEtNDY1Mzg_7be714c5-61b7-4f6f-aaa5-42f3d2795211"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i496ec5ae5f474b68a6e6e266a5883626_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItNS0xLTEtNDY1Mzg_ab18504b-04f2-4b93-bcc3-a1d508eb852d"
      unitRef="usd">241951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i804bccd139d04bf3b19b95e33e6df55e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItNy0xLTEtNDY1Mzg_3883b3f0-17a7-4526-8077-9ed1dd3df2f1"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c619239c03440b5b8db4727db939247_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItOS0xLTEtNDY1Mzg_24875321-3768-4c43-8f1d-0a1e76f653d7"
      unitRef="usd">-39047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id62eddb7037c4f82b6f2687e0a52e6ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzItMTEtMS0xLTQ2NTM4_024b0ccd-8c60-4bf8-9cff-8add17e61b25"
      unitRef="usd">202914000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1fd0edbd57ff47fb919fb61349c64819_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzMtMS0xLTEtNDY1Mzg_ec2e66c8-b84b-4868-ae91-d2f57ec8859e"
      unitRef="shares">2359910</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i208aa8cb27e54c60b096966b6240e133_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzMtNS0xLTEtNDY1Mzg_4ae552b7-d2ab-4c76-96d7-f6de33fb77e2"
      unitRef="usd">118035000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzMtMTEtMS0xLTQ2NTM4_6de85fde-56b6-43de-84cd-ab01d036510a"
      unitRef="usd">118035000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i208aa8cb27e54c60b096966b6240e133_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzQtNS0xLTEtNDY1Mzg_fb90f839-c5b9-463b-9c0a-707c3bb93f5d"
      unitRef="usd">3306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzQtMTEtMS0xLTQ2NTM4_5a910ab8-24cc-469b-a634-015db13a04d4"
      unitRef="usd">3306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i91001397acca4edbb0a19b9c79aa5b7d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtNy0xLTEtNDY1Mzg_a9cf32ce-a28e-49ee-980b-703d4bd72274"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtMTEtMS0xLTQ2NTM4_92072b1d-a959-4fb6-8610-776ba755c68f"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9f9c855a0e3a4e13a53433cc5c0364b4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzYtOS0xLTEtNDY1Mzg_8e0f90c5-a32a-4cbf-a7f8-e55a674937c7"
      unitRef="usd">-32167000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzYtMTEtMS0xLTQ2NTM4_96e57d43-71cd-4cc4-a985-871b140a813d"
      unitRef="usd">-32167000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia24f42b2bb4c47b89466941d0f5831db_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMS0xLTEtNDY5NTQ_45567069-fe4a-4ac6-b8e0-d377e372a06b"
      unitRef="shares">19714220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia24f42b2bb4c47b89466941d0f5831db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMy0xLTEtNDY5NTQ_b93636d0-cb8e-414f-8616-6f358fbae7b6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i922596331dd24a1dbd0e0b79d3ef475b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNS0xLTEtNDY5NTQ_0f53c029-c115-4323-b857-3c4eb6658012"
      unitRef="usd">363292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf8e1134b7c94d26a0c3d22afc73d215_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY5NTQ_aba97445-2766-4803-8cd1-9cdde296ada3"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb2f2c779195497fb1144f46db638bfb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctOS0xLTEtNDY5NTQ_efa93697-4d74-42f8-afba-c96749db66f1"
      unitRef="usd">-71214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2OTU0_3d077d4f-6440-4108-9ce9-d7c08c6cd235"
      unitRef="usd">292084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ica5904f7fef443a68940ec9e9da0ce98_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtMS0xLTEtNDY5NTQ_aa176841-daff-486f-aa1e-3f2e0a145396"
      unitRef="shares">5493765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if2465df77d804826b661dda93a47a9e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtNS0xLTEtNDY5NTQ_99d60330-d162-4319-aefd-3cb76c1c377c"
      unitRef="usd">355628000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtMTEtMS0xLTQ2OTU0_8b9dbc43-b47f-4768-9316-2021abf789d6"
      unitRef="usd">355628000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2465df77d804826b661dda93a47a9e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktNS0xLTEtNDY5NTQ_2efc6226-7cdb-447f-8586-89c0ed7405e1"
      unitRef="usd">15603000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMTEtMS0xLTQ2OTU0_33c670de-9320-4003-aafb-7d640a09a2fb"
      unitRef="usd">15603000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id8ca4dafce8c49c38953d0c3cc1e563b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTctMS0xLTQ2OTU0_eb74d109-be99-4c24-bab6-7e03aa46ecd8"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTExLTEtMS00Njk1NA_73410a37-24a9-4291-95c4-de61f9230b56"
      unitRef="usd">-169000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8a31534ac7ce4d699f4394d4b19576c9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzExLTktMS0xLTQ2OTU0_d2fc2560-7340-42a2-852f-127ef28218fc"
      unitRef="usd">-69570000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzExLTExLTEtMS00Njk1NA_a2151339-4899-4aae-b12c-6d33823a90d8"
      unitRef="usd">-69570000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i66ebe6bcc927412c83fb26d401bcacaa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTEtMS0xLTQ2OTcy_e26f0162-b071-4466-948c-891a28de0ba0"
      unitRef="shares">25207985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i66ebe6bcc927412c83fb26d401bcacaa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTMtMS0xLTQ2OTcy_64b0539a-b582-4f6d-b18d-6423b506ebdc"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i996e18257f394eff9914fcba8ed4e078_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTUtMS0xLTQ2OTcy_8a9f8375-1b5d-452d-aca3-128af779c268"
      unitRef="usd">734523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc4b03d778584b14ad55239cd91fef14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTctMS0xLTQ2OTcy_1da81279-95b4-4090-b820-45a83338bbc7"
      unitRef="usd">-163000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie289a738c54a427ea3a8922f170941dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTktMS0xLTQ2OTcy_01752a30-1250-408d-8dbc-5252f321535b"
      unitRef="usd">-140784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEyLTExLTEtMS00Njk3Mg_1a43d60f-fff9-4624-812a-ac8ba5527aa9"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i57d5acffc6e34806bcad27370483078d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEzLTEtMS0xLTQ2OTcy_9678ff83-532f-4130-968b-58aec047f4aa"
      unitRef="shares">573637</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEzLTUtMS0xLTQ2OTcy_6324b3b8-6901-47ec-b086-83a62b54c0f4"
      unitRef="usd">36063000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEzLTExLTEtMS00Njk3Mg_df7ddb6a-bae9-46dc-9e1b-bdd25014000e"
      unitRef="usd">36063000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i57d5acffc6e34806bcad27370483078d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTEtMS0xLTUwNzE2_cfa685c4-b24b-43f3-a195-327ab06c7744"
      unitRef="shares">17879</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTUtMS0xLTUwNzE2_d8294376-3c7f-4cc9-8acd-6d632a1c9dc2"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTExLTEtMS01MDcyNA_bd07d8a6-bbbc-465f-bede-ed67a5ed79c7"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e328077b437492ba4668d661dab9bb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTUtMS0xLTQ2OTcy_92c60fde-2cbe-4c1b-8dfc-621d8d7246d9"
      unitRef="usd">33781000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzE0LTExLTEtMS00Njk3Mg_342603d6-a3c4-4937-9719-751bbdea64f7"
      unitRef="usd">33781000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1791ab32bfb844bdb1549f6e0fa6ebf2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY1Mzg_66d153e5-c44b-4b13-957b-71394af8d915"
      unitRef="usd">-565000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2NTM4_d176a3eb-bacc-4ff4-ab00-5834e3bec456"
      unitRef="usd">-565000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i36267cfc53644c10b377545a419cdc2b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtOS0xLTEtNDY1Mzg_6fbbd09c-5af5-4c63-bb0b-b3329f8761e2"
      unitRef="usd">-139975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzgtMTEtMS0xLTQ2NTM4_99695553-d89e-4b2e-85bb-8b186e2bc227"
      unitRef="usd">-139975000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i915fb9f46db84704ab0d72c2ada7e20e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMS0xLTEtNDY1Mzg_119e90d5-d1ca-47ae-95c7-8aa09612bb56"
      unitRef="shares">25763743</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i915fb9f46db84704ab0d72c2ada7e20e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMy0xLTEtNDY1Mzg_067fd721-bbb5-4e6b-bfd6-ce1df9a1a1fb"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58f61bb3407246f1923b173d13ac2592_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktNS0xLTEtNDY1Mzg_64b49fdc-107f-430c-a316-6f36ab193471"
      unitRef="usd">803718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3eafaed6c8534eb88f2e16210025076a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktNy0xLTEtNDY1Mzg_58b1e7cc-b060-4d84-91c9-7ab739ce27c4"
      unitRef="usd">-728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb62cd25fa1545ddb2adf0d82820735f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktOS0xLTEtNDY1Mzg_4f60c08a-7f0f-4eb3-aa9a-4e03f528ea8c"
      unitRef="usd">-280759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzktMTEtMS0xLTQ2NTM4_7af04ada-bf09-4b04-8258-6bc44fbe3644"
      unitRef="usd">522231000</us-gaap:StockholdersEquity>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzEwOTk1MTE2MjgwNzM_d4730874-95f2-435c-9170-cc0a316b3c06"
      unitRef="usd">-78000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzEwOTk1MTE2MjgwODA_5206472d-0e69-4267-a88e-2d5e5176ce95"
      unitRef="usd">7000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzEwOTk1MTE2MjgxMzc_682bec3e-11ca-4962-9fd2-e1ec2dc0dfea"
      unitRef="usd">-1000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMtMS0xLTEtNDY1Mzg_e900da02-bd79-4d40-b6e2-8702dfdab390"
      unitRef="usd">-139975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMtMy0xLTEtNDY1Mzg_072d0e7a-dab7-4341-abd1-3159e83882ea"
      unitRef="usd">-69570000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMtNS0xLTEtNDcxMjQ_b3a1c958-bdb6-45e3-a914-243ad892852a"
      unitRef="usd">-32167000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzUtMS0xLTEtNDY1Mzg_3673f9b0-22c2-4998-bbb9-122694d3ecb2"
      unitRef="usd">4055000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzUtMy0xLTEtNDY1Mzg_3326ff16-06d5-4843-ad28-1e8608614b4e"
      unitRef="usd">2769000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzUtNS0xLTEtNDcxMjQ_000e2953-70f2-4f37-bede-90d6386e3d62"
      unitRef="usd">1851000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzYtMS0xLTEtNDY1Mzg_834be741-e2ad-4b6d-a74d-bedcc88b8114"
      unitRef="usd">33230000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzYtMy0xLTEtNDY1Mzg_5b53ad0a-4603-451d-a26a-9a2db1feb3aa"
      unitRef="usd">15319000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzYtNS0xLTEtNDcxMjQ_d5ba786c-a5b6-4601-98b1-51e2e69f606c"
      unitRef="usd">3272000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzctMS0xLTEtNDY1Mzg_8aa29233-ac78-4706-8bf9-743cf30adbdf"
      unitRef="usd">-72000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzctMy0xLTEtNDY1Mzg_00a0c022-b731-4049-90c5-40a3145a5fda"
      unitRef="usd">0</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzctNS0xLTEtNDcxMjQ_e3a54c2b-83a2-4029-bff2-c04c9110c467"
      unitRef="usd">-33000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:OtherNoncashExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzgtMS0xLTEtNDY1Mzg_0b500b1c-0a80-4fca-9d7f-3ab75a8eb045"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzgtMy0xLTEtNDY1Mzg_5366dc33-bad5-42ef-b957-519baa5140c6"
      unitRef="usd">1492000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzgtNS0xLTEtNDcxOTM_06c4d517-16da-400a-bcb1-5658e35a3664"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzktMS0xLTEtNTUzMTM_22c3affe-44b9-49cd-82d1-2451e0065fee"
      unitRef="usd">-762000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzktMy0xLTEtNTUzMTM_ef49cfe3-bea7-4672-86db-8242a33fed50"
      unitRef="usd">-454000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzktNS0xLTEtNTU5MzE_35b4c2a1-7e54-45a1-9034-b95a7a6406b5"
      unitRef="usd">11000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEwLTEtMS0xLTQ2NTM4_11b5cb03-2ca2-4e68-8503-8923d66d300d"
      unitRef="usd">311000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEwLTMtMS0xLTQ2NTM4_6511ae3c-ea22-44f4-ba5f-a1f9f9ad33e4"
      unitRef="usd">691000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEwLTUtMS0xLTQ3MTI0_f26a2a3f-5cff-4953-aeb9-f844a1f228cb"
      unitRef="usd">1922000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzExLTEtMS0xLTQ2NTM4_85a18622-76e8-4a3f-bec9-bd892d73b06d"
      unitRef="usd">150000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzExLTMtMS0xLTQ2NTM4_423a1978-b55f-4018-b7de-7632f289d47d"
      unitRef="usd">-65000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzExLTUtMS0xLTQ3MTI0_e3114a30-20aa-4559-8950-3b328451c8d8"
      unitRef="usd">934000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEyLTEtMS0xLTQ2NTM4_2157e8a2-c5d3-4eb9-8b57-735fa4bfe7b9"
      unitRef="usd">-647000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEyLTMtMS0xLTQ2NTM4_046966a8-2bb1-4e01-a7a7-4b8f4cb74e62"
      unitRef="usd">-285000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEyLTUtMS0xLTQ3MTI0_823ecf25-ac93-4280-8554-3d18badd2a78"
      unitRef="usd">685000</krys:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEzLTEtMS0xLTQ2NTM4_e089c88e-48e0-48cc-80e4-8b93c22d1f56"
      unitRef="usd">-1254000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEzLTMtMS0xLTQ2NTM4_5c3ca248-799f-43d9-a792-f4bc2b8cb9fa"
      unitRef="usd">712000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzEzLTUtMS0xLTQ3MTI0_e2d434b8-f345-424e-a097-88f4e421be8b"
      unitRef="usd">783000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE0LTEtMS0xLTQ2NTM4_a2ac8f03-ad75-49be-b660-7a11e9692a78"
      unitRef="usd">5173000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE0LTMtMS0xLTQ2NTM4_24c1dc25-9fa2-4902-a4a7-8f72484f01b0"
      unitRef="usd">2705000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE0LTUtMS0xLTQ3MTI0_6b772161-54b7-4b93-8b72-f5f704cc9515"
      unitRef="usd">2305000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE1LTEtMS0xLTQ2NTM4_2821392e-eb50-481d-9f56-f2f4fae7693e"
      unitRef="usd">-100569000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE1LTMtMS0xLTQ2NTM4_cdf4c121-cdaa-492d-976e-08dfbabfe850"
      unitRef="usd">-47938000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE1LTUtMS0xLTUwMjQ5_fb700f41-ab8a-4d79-861a-817972feb4c9"
      unitRef="usd">-26083000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE4LTEtMS0xLTQ2NTM4_7db38885-2849-48f2-bce9-03cebef5f3cf"
      unitRef="usd">52979000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE4LTMtMS0xLTQ2NTM4_a0341836-20d8-4605-a0d2-5b5412ad9966"
      unitRef="usd">68336000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE4LTUtMS0xLTQ3MTM5_e6d18d86-c64c-48a0-9527-91fa1b3fa42f"
      unitRef="usd">14843000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE5LTEtMS0xLTQ2NTM4_23da337d-1637-4a39-bffd-b0eb9a02f33d"
      unitRef="usd">318781000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE5LTMtMS0xLTQ2NTM4_7a224b6d-b6ba-4eea-96f5-dba235e30599"
      unitRef="usd">190462000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzE5LTUtMS0xLTQ3MTM5_709a1a8c-0589-4341-93a6-af8dd67cb13a"
      unitRef="usd">3205000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIwLTEtMS0xLTQ2NTM4_9c5b4ebb-e8da-4c39-ae49-603195a5e001"
      unitRef="usd">257677000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIwLTMtMS0xLTQ2NTM4_c185f400-2e35-4b6b-81a7-a9cd5b0c426b"
      unitRef="usd">32028000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIwLTUtMS0xLTQ3MTM5_9da1f554-d22d-458e-9ebe-76884a928814"
      unitRef="usd">6867000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIxLTEtMS0xLTQ2NTM4_3ad6ae9b-5ddb-4d4f-8618-3f3144438a6c"
      unitRef="usd">-114083000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIxLTMtMS0xLTQ2NTM4_c87b8494-a291-4400-b25f-7142076e95e7"
      unitRef="usd">-226770000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzIxLTUtMS0xLTUwMjU1_62d569c9-38a1-4f5a-8fb6-54b33fdc6379"
      unitRef="usd">-11181000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI0LTEtMS0xLTQ2NTM4_d4bff4f3-4eb4-4719-b55b-d9f7570da69a"
      unitRef="usd">35996000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI0LTMtMS0xLTQ2NTM4_158e2160-d337-4315-9361-23e25c7a121b"
      unitRef="usd">355645000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI0LTUtMS0xLTQ3MTUw_09440d53-73fb-4a93-8dd9-4441fa5e5fb7"
      unitRef="usd">118019000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTEtMS0xLTU1NDU3_25f415fd-2bca-47d6-92b8-1fa190392a06"
      unitRef="usd">649000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTMtMS0xLTU1NDY1_72914d36-8b41-4ca7-92a5-79a994f844ba"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTUtMS0xLTU1NDY1_f38ba818-eb02-4798-b7c0-8246b104d18f"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <krys:PaymentsForSuitLiability
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI1LTEtMS0xLTQ2NTM4_01070b4e-ed34-4338-994d-455f02ef60bf"
      unitRef="usd">0</krys:PaymentsForSuitLiability>
    <krys:PaymentsForSuitLiability
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI1LTMtMS0xLTQ2NTM4_ef8360b4-596b-4a87-aa00-36485724a076"
      unitRef="usd">7960000</krys:PaymentsForSuitLiability>
    <krys:PaymentsForSuitLiability
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI1LTUtMS0xLTQ3MTUw_d78cdc01-85c8-46f0-9b84-bc432973da08"
      unitRef="usd">0</krys:PaymentsForSuitLiability>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTEtMS0xLTQ2NTM4_855d9065-d4af-44be-b27d-76509003382b"
      unitRef="usd">35347000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTMtMS0xLTQ2NTM4_b1447741-9bfd-4333-954b-41863659fbbb"
      unitRef="usd">347685000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI2LTUtMS0xLTUwMjYx_b1ceabd1-5e51-40c6-91c6-3cc4d9ea50c2"
      unitRef="usd">118019000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTEtMS0xLTU4MTkw_da788347-6fa1-4bed-8526-1e8c22d533bd"
      unitRef="usd">-41000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTMtMS0xLTU4MTkw_c8c1c2ca-f111-4f9a-ba33-8014eec0986d"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTUtMS0xLTU4MTkw_04cef379-aa03-4e63-934c-a3790523ff81"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI3LTEtMS0xLTQ2NTM4_6f522234-d0e5-45ab-bbe5-ae9dfcfe849d"
      unitRef="usd">-179346000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI3LTMtMS0xLTQ2NTM4_7bbb5277-b3d0-42bf-ba65-3adbec93699a"
      unitRef="usd">72977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI3LTUtMS0xLTUyMzY4_acece8c8-5501-4755-be9f-72a2c16cf546"
      unitRef="usd">80755000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI5LTEtMS0xLTQ2NTM4_81a323dc-d55c-4436-9375-908fc98c7eff"
      unitRef="usd">341246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI5LTMtMS0xLTQ2NTM4_62b49187-aff2-44b0-9215-3e32375c7327"
      unitRef="usd">268269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id62eddb7037c4f82b6f2687e0a52e6ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzI5LTUtMS0xLTQ3MTYx_c2d2bdce-6134-42c2-9e78-6385796ea011"
      unitRef="usd">187514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTEtMS0xLTQ2NTM4_4e09f7e9-bdcc-4123-9770-edceac6a9edf"
      unitRef="usd">161900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTMtMS0xLTQ2NTM4_c58b0e7d-a987-47e2-9172-606d8b1ad661"
      unitRef="usd">341246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMwLTUtMS0xLTUyMzY4_1297b274-1bf8-4d82-b35e-7527d34c4c97"
      unitRef="usd">268269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMzLTEtMS0xLTQ2NTM4_ebf85e3f-8581-42f2-80e7-ceddf522ef90"
      unitRef="usd">14927000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMzLTMtMS0xLTQ2NTM4_0edff0b7-d938-496c-a139-21fd647c72f0"
      unitRef="usd">15363000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzMzLTUtMS0xLTQ3MjIx_a1c7835d-2016-4e27-ba99-0e2e9ca4ca02"
      unitRef="usd">9697000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzM0LTEtMS0xLTQ2NTM4_2c1bb753-a37f-4df3-b358-148cde1ec7e4"
      unitRef="usd">1556000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzM0LTMtMS0xLTQ2NTM4_204b7f9f-8e55-4cf8-8951-c0c8819eb75e"
      unitRef="usd">4396000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDYvZnJhZzowYjI3YmUwMmVmNGE0MzE2OGIwYTdjNGVjOGJiZjUzMy90YWJsZTpjZmFkN2EwOWE0M2M0OGI0YmM5NGM3OGY0OTU3MWQ5NS90YWJsZXJhbmdlOmNmYWQ3YTA5YTQzYzQ4YjRiYzk0Yzc4ZjQ5NTcxZDk1XzM0LTUtMS0xLTQ3MjIx_dafa6caa-0e6c-4952-bb7a-37c82f444e48"
      unitRef="usd">911000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTIvZnJhZzphZWIyNWI5MjRlOGE0ZWRiYWMwNmJiYmIwNTg1MjdjYy90ZXh0cmVnaW9uOmFlYjI1YjkyNGU4YTRlZGJhYzA2YmJiYjA1ODUyN2NjXzMyNTY_3a427e27-1378-4e53-8c00-a1c1c2c2a691">Organization&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Krystal Biotech, Inc. (the&#160;&#x201c;Company,&#x201d;&#160;or&#160;&#x201c;we&#x201d;&#160;or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics, Inc (&#x201c;Jeune Aesthetics&#x201d;), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, and December 2022, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's product pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#x2019;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#x2019;s office or potentially in the patient&#x2019;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practice ("CGMP") manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had an accumulated deficit of $280.8 million. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability, and unless and until it does the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, the sale of equity, and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all. &lt;/span&gt;&lt;/div&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to expand it's commercialization capabilities in advance of the potential global regulatory approvals of it's lead product, B-VEC. The Company believes that its cash, cash equivalents and short-term investments of approximately $379.2 million as of December&#160;31, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Annual Report on Form 10-K.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTIvZnJhZzphZWIyNWI5MjRlOGE0ZWRiYWMwNmJiYmIwNTg1MjdjYy90ZXh0cmVnaW9uOmFlYjI1YjkyNGU4YTRlZGJhYzA2YmJiYjA1ODUyN2NjXzE2NTk_23f0c114-30ec-4226-b089-ef02c9d95180"
      unitRef="usd">-280800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTIvZnJhZzphZWIyNWI5MjRlOGE0ZWRiYWMwNmJiYmIwNTg1MjdjYy90ZXh0cmVnaW9uOmFlYjI1YjkyNGU4YTRlZGJhYzA2YmJiYjA1ODUyN2NjXzE5MDE_e4da97ae-7120-4099-bfb6-b77818fca03c"
      unitRef="usd">379200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE5_87af4898-e356-495b-a268-51ed068958f6">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash,&#160;Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, or general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in inactive markets, or other inputs that are observable, or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress (&#x201c;CIP&#x201d;) is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company not experienced any triggering events or recognized any impairment losses for the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain &#x201c;sale-leaseback&#x201d; criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the  consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the &#x201c;sale-leaseback&#x201d; criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organization and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;)  Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained in 2021, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021, and 2020, income taxes were recorded in accordance with FASB ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. Under this method, we record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December&#160;31, 2022 and 2021.&#160;We intend to maintain a valuation allowance until sufficient evidence exists to support its reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December&#160;31, 2022 and 2021, the Company did not have any significant uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the consolidated statements of operations related to realized gains on sales of available-for-sale securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIw_8f660e02-1fc9-424d-b6dd-e3c7a41e335d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE2_ce91fb3d-2bca-4c87-a4d9-a66e0320e9d0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be &lt;/span&gt;&lt;/div&gt;representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTA4_820bd631-c5c6-49f7-9e0e-552cd82807ed">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzM4MDU_b382bbb1-c6ad-443f-a019-8a581519b52f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE3_903f81d6-5fc0-4288-a037-980cab9ea828">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIx_ead2daf1-28a9-4e9a-bfa6-f782a82da39e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash,&#160;Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, or general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE4_e12ec33d-f79a-4334-bf2e-b8ddc87f3478">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in inactive markets, or other inputs that are observable, or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzIxOTkwMjMyODAzMjE_9c8cc0c3-814a-4787-a7f7-2c2d8cad8e2d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A review performed by the Company in the current year indicated that certain pieces of lab equipment would be functional for a longer term than previously estimated and as a result, the Company increased the useful lives of these assets from 7 to 15 years. This change was effective and accounted for prospectively beginning in Q3 2022. The effect of this change in useful life estimate did not result in a material change to depreciation expense for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress (&#x201c;CIP&#x201d;) is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krys:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEy_f2d9154c-51ff-45d4-b941-8bbb55742fe9">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</krys:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iee87fb1c670d4a8fabfd071c375435ee_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzAtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpmMDhiM2ExYzJhZDc0YWRhYTY5ZDkzMTRmMDkxOTZjMl80_5d593198-a05d-4d82-afcf-9a10781d9f45">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i61e616f277cb401d95b1e1572f6cf8c4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzAtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpmMDhiM2ExYzJhZDc0YWRhYTY5ZDkzMTRmMDkxOTZjMl85_a1b3ce0e-0744-4f5f-bae5-9fb4becc3c4d">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i73935a9788274be9a2a5a77ba030b6f2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzEtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjplOTc3OThhYjEyNWU0OThhODY4MTNiMjk4YzczYTA0NF80_702a240d-b332-4c79-ac47-18f70c1600f5">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia2bd6fcadcdd473ea0f07dc041889bed_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzEtMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjplOTc3OThhYjEyNWU0OThhODY4MTNiMjk4YzczYTA0NF85_f098520c-ab2e-4cd0-a91b-bd0f861cba66">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i71e119a9d7434b2583f9e8b3f823f74b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzItMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOTZjZDc3ZjEzNTk0Y2E1OGU5ZGRkZDlhMzUxZGNiMl80_047c920e-38a0-49b0-9c88-66129d7c361b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8cdf55bd7cb34dc7b7afcf71ada77513_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90YWJsZTpjZDcyMWM1NjBlOGM0NDViYjk0MTI3NGNmMTM0ZDY0Zi90YWJsZXJhbmdlOmNkNzIxYzU2MGU4YzQ0NWJiOTQxMjc0Y2YxMzRkNjRmXzItMS0xLTEtNDY1MzgvdGV4dHJlZ2lvbjpjOTZjZDc3ZjEzNTk0Y2E1OGU5ZGRkZDlhMzUxZGNiMl85_a50aa6ef-980b-4a44-814f-71e2bc709b1c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icd3eeb0d882a48b0b15625e5774f3daf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzQzOTgwNDY1MzU4NTk_b2fdf40a-3aaf-4402-a4d7-04c313f993e2">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib15d39f02c324677aeac9f5d4a570fa7_D20220701-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzQzOTgwNDY1MzU4NjI_7aacf46a-1cbd-44a7-909e-cc363a972c9d">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEz_6a1bac82-f325-4bfb-a278-6f70f005f4f6">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition. In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company not experienced any triggering events or recognized any impairment losses for the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzEwMTgy_13e0f2c4-1d7c-457d-8b75-1387f226ca8c"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzEwMTgy_90438cd4-afe7-492c-b7bb-4237ca9265d5"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzEwMTgy_eacfade9-17b2-4724-8aaf-01315e7a5144"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIy_1b1ed3d7-36fb-40a8-9a04-cc6c4c8af4fc">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain &#x201c;sale-leaseback&#x201d; criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the  consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the &#x201c;sale-leaseback&#x201d; criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTIz_8fca8e1b-9c69-411d-9aa6-34734e13bdc4">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organization and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTE0_d99d4800-aa33-4c78-9a4d-4da53b556a1e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;)  Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;), to account for stock-based compensation. Compensation costs related to stock options granted are based on the estimated fair value of the awards on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained in 2021, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEw_70629728-b945-4ef4-bf4b-e81bbd243ef1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021, and 2020, income taxes were recorded in accordance with FASB ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 740&#x201d;), which provides for deferred taxes using an asset and liability approach. Under this method, we record deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect when the differences are expected to reverse. Valuation allowances are provided when necessary to reduce net deferred tax assets to the amount that is more likely than not to be realized. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December&#160;31, 2022 and 2021.&#160;We intend to maintain a valuation allowance until sufficient evidence exists to support its reversal.&lt;/span&gt;&lt;/div&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December&#160;31, 2022 and 2021, the Company did not have any significant uncertain tax positions.The Company may recognize interest and penalties related to uncertain tax positions in income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3NjI3_5fd3be95-cf71-4040-b288-04f2c9177e69"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3NjI3_9f9ab752-a3a6-4a42-b677-2e8188d5c685"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3Njk5_2a2ea254-f233-4244-a978-a25e39253d9c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE3Njk5_6dd14899-e778-488e-8faf-634d9e989490"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTI0_047774a6-c514-4f82-8a79-080a1bca51b6">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the consolidated statements of operations related to realized gains on sales of available-for-sale securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the years ended December&#160;31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTUvZnJhZzoxZjBkZWZmMTNlMTI0NTA5OGQwYjgxMDIwNWI2YjkxMi90ZXh0cmVnaW9uOjFmMGRlZmYxM2UxMjQ1MDk4ZDBiODEwMjA1YjZiOTEyXzE5NTEx_71a88df6-7df3-4885-a384-43caa005f663">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzkyNw_57090242-7d75-4949-a2b1-e7cc7568e217">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,582,181, 2,043,179, and 853,614 common share equivalents outstanding in the form of stock options and 66,600, 98,800, and zero unvested restricted stock awards as of December&#160;31, 2022, 2021 and 2020, respectively, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and diluted common&lt;br/&gt;&#160;&#160; shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,491,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,196,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,787,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU3OA_71211a2d-8478-4feb-bcd8-fb9e4d2c3298"
      unitRef="shares">3582181</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU4NQ_4d053cdd-ba5e-48d8-8ef6-618e78794c8c"
      unitRef="shares">2043179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU0OTc1NTgxNTEwNA_dcd033a9-153c-476e-baaa-2fa88c456ec5"
      unitRef="shares">853614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzU0OTc1NTgxNTA1Ng_2c4d146b-55b8-460f-a63b-81b39c587670"
      unitRef="shares">66600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzY2NQ_d7737f0c-cf3f-45a7-9cc7-85baf4d96395"
      unitRef="shares">98800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i85ab137db9d24527ad70578422157edc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzEwOTk1MTE2MjkwNTE_8bda7aba-4046-497d-a13e-1da6720a1976"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90ZXh0cmVnaW9uOmE4MDllOTYxN2U3OTRmZTRiZDRiOWUyZjJiZmY0MDIyXzkyOA_4af47766-cda4-4a08-999c-0e7092d827e1">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and diluted common&lt;br/&gt;&#160;&#160; shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,491,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,196,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,787,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzMtMS0xLTEtNDY1Mzg_51845e2f-e78f-46f9-baac-0ca9c7a1eaf3"
      unitRef="usd">-139975000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzMtMy0xLTEtNDY1Mzg_36350f34-73f3-4e25-bc78-c7c7ecb8b472"
      unitRef="usd">-69570000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzMtNS0xLTEtNDc0MzM_034dc218-5aec-42bb-807a-a749cf140f07"
      unitRef="usd">-32167000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMS0xLTEtNDY1Mzg_08439eeb-7567-4a5e-8cc0-80028632a664"
      unitRef="shares">25491721</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMS0xLTEtNDY1Mzg_3d918934-fcf5-4c93-ae43-8499962bf52e"
      unitRef="shares">25491721</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMy0xLTEtNDY1Mzg_5d8334b7-55e6-4f66-ab75-b24efc5544d8"
      unitRef="shares">22196846</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtMy0xLTEtNDY1Mzg_8536af16-2e75-43db-ba5a-671366cb5f43"
      unitRef="shares">22196846</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtNS0xLTEtNDc0MzM_a91e1d4a-6419-44c3-8a12-544b30a1d25f"
      unitRef="shares">18787161</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzUtNS0xLTEtNDc0MzM_d5992968-338a-4aa1-9f01-5a6a3ab5930c"
      unitRef="shares">18787161</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMS0xLTEtNDY1Mzg_ba77e3d1-1e41-4fdc-8064-56745f1c7a00"
      unitRef="usdPerShare">-5.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMS0xLTEtNDY1Mzg_bf5a109a-ae89-4d7b-b00d-4261c85dcebc"
      unitRef="usdPerShare">-5.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMy0xLTEtNDY1Mzg_4333b454-17d6-444e-9342-4260095ee060"
      unitRef="usdPerShare">-3.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtMy0xLTEtNDY1Mzg_583338df-04ee-4512-8481-67a6d2d2d1d1"
      unitRef="usdPerShare">-3.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtNS0xLTEtNDc0NDU_884ac310-c93b-4271-9ee8-2944f97733f0"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMTgvZnJhZzphODA5ZTk2MTdlNzk0ZmU0YmQ0YjllMmYyYmZmNDAyMi90YWJsZTo4OWRhZThkYjMyMTE0OGMwOGU4ZTFlYzYzNThmYjVhYS90YWJsZXJhbmdlOjg5ZGFlOGRiMzIxMTQ4YzA4ZThlMWVjNjM1OGZiNWFhXzYtNS0xLTEtNDc0NDU_aafda770-bd85-400b-8fc1-f584857b26c7"
      unitRef="usdPerShare">-1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzQ4Mw_5bb52e55-7381-42ee-8bc5-4904291bc53c">Fair Value InstrumentsThe following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;The Company&#x2019;s long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 to these consolidated financial statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzQ4NA_2adede45-2ea9-43a8-b090-d7ddbddc3384">The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of December&#160;31, 2022 and 2021, respectively (in thousands):&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;The Company&#x2019;s long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb022f76121f4e10b847528fc749dceb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzMtMS0xLTEtNDY1Mzg_43a501a6-0545-409f-9878-ef80e336fd30"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb022f76121f4e10b847528fc749dceb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzMtNy0xLTEtNDY1Mzg_4a192392-f502-4d0c-9ef5-f7331af2b589"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e196aef98d946ef9ba6a9d94c73d645_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzMtOS0xLTEtNDY1Mzg_0c9cbd7b-a503-4c30-9f1b-4bf3c5895e90"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic96d3206ab1847cd9a05a879d0efe67c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzQtMS0xLTEtNDY1Mzg_14ce845c-7a4b-425e-abd4-adba57126e0d"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic96d3206ab1847cd9a05a879d0efe67c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzQtNy0xLTEtNDY1Mzg_0df70bfe-8f94-4532-8bbc-2eac6a0f774d"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3a6fa4bf942a419fbec493f4bf7f4b31_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzQtOS0xLTEtNDY1Mzg_ab969990-d257-48c3-8f65-32c3e0c59970"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMS0xLTEtNDY1Mzg_a2a6eeeb-a832-4adf-a0b4-87f1830c6082"
      unitRef="usd">63624000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMy0xLTEtNDY1Mzg_7e3c8ca6-e751-45c4-8e59-199cee8f9ad4"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtNS0xLTEtNDY1Mzg_7e2277fb-0a21-42d8-b622-fa2dc912305f"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d46f0e247a640828b2290ff03d295cc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtNy0xLTEtNDY1Mzg_ed5ef5b0-c27d-4198-b414-9802f89da314"
      unitRef="usd">63606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e649be5847e4c318f3b5b62ca8bd797_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMTEtMS0xLTQ2NTM4_a5deff8b-3bee-4a39-8b20-2b5794a16d89"
      unitRef="usd">63606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4613ad1330074364a3d902cd8b6f8599_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzYtMTMtMS0xLTQ2NTM4_ffce909c-802a-4588-9455-bc00aca49061"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc145339ddd143598976c49d98e634a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMS0xLTEtNDY1Mzg_0b1600ee-262f-44b6-ad34-fd77fe6c2090"
      unitRef="usd">82241000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc145339ddd143598976c49d98e634a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMy0xLTEtNDY1Mzg_98b61186-351a-43f6-a66b-dcc13e6db2bc"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc145339ddd143598976c49d98e634a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctNS0xLTEtNDY1Mzg_71e642f9-9544-4fba-98cf-39d3aa4a965f"
      unitRef="usd">419000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc145339ddd143598976c49d98e634a4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctNy0xLTEtNDY1Mzg_f2abe9e1-d6b2-41cb-8ecb-df755d11d6d8"
      unitRef="usd">81835000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75f7cf345d4447f6a47ad9669b43afd0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMTEtMS0xLTQ2NTM4_516f2918-0bc2-47c3-8547-67ee6f094c84"
      unitRef="usd">77214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib381b024b3f44b17b2017dc67c13aab4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzctMTMtMS0xLTQ2NTM4_dd6c7b96-4686-49a8-ba60-aa8a1a9128e7"
      unitRef="usd">4621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMS0xLTEtNDY1Mzg_2d159ec2-3358-41a4-a676-1f626a2f488b"
      unitRef="usd">76683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMy0xLTEtNDY1Mzg_550e6e5e-1724-4913-ab26-f315f60c3249"
      unitRef="usd">161000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtNS0xLTEtNDY1Mzg_71c2019a-f948-4824-96e8-302608f07354"
      unitRef="usd">393000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86e826a843ea4aa58ebb96cd9cc7616d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtNy0xLTEtNDY1Mzg_8adfbf69-b49e-410a-97de-96049d245b13"
      unitRef="usd">76451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie820ccd74fbb44e0b053b5527111f83d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMTEtMS0xLTQ2NTM4_5cdd1747-8e0c-4a75-9398-16d59519833c"
      unitRef="usd">76451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i474abeb633a744ebbe6c051fccc138d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzgtMTMtMS0xLTQ2NTM4_12b70a35-a940-4d4f-9915-3d3b46cd8cc0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMS0xLTEtNDY1Mzg_441ec2b4-e25f-496f-bf12-19edf06a5599"
      unitRef="usd">222548000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMy0xLTEtNDY1Mzg_0fd3d9bc-a8ea-47f0-92fe-b2c65d260bb0"
      unitRef="usd">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktNS0xLTEtNDY1Mzg_5e5a977a-fa63-4441-bcc6-cd679746ee23"
      unitRef="usd">835000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2e9a31bc727469d97f0ab1f1c104519_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktNy0xLTEtNDY1Mzg_1b2b3d91-69ec-4bc4-9e1b-f53a1cabbd17"
      unitRef="usd">221892000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id15667ce7b0c40e5b2f6147b95913a03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMTEtMS0xLTQ2NTM4_bc96df5b-180e-4968-98b1-53f61994f98e"
      unitRef="usd">217271000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c142c1f1d9844f38df3bcfa1684428a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzktMTMtMS0xLTQ2NTM4_3638f834-cff8-4758-b6b9-50603394a4c0"
      unitRef="usd">4621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTEtMS0xLTQ2NTM4_ef3647e9-5f23-47e2-9acd-7a6b4b291d60"
      unitRef="usd">384448000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTMtMS0xLTQ2NTM4_96bcddac-e336-4daf-9bb4-242342403473"
      unitRef="usd">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTUtMS0xLTQ2NTM4_96efc850-d363-4727-bafb-a88b65d0e7b9"
      unitRef="usd">835000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTctMS0xLTQ2NTM4_08d1a9d2-2644-4e66-8412-87eb5f8325ba"
      unitRef="usd">383792000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i36361a0fa8ca486fbe97852c6f806b2e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTktMS0xLTQ2NTM4_d77fadfa-6184-4eac-be76-02922b63006b"
      unitRef="usd">161900000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i8132445eec974341992bfe7b7684bafc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTExLTEtMS00NjUzOA_d5f9f482-7f28-4223-9bdb-785d61816972"
      unitRef="usd">217271000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i457106579689420ea580675819005893_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpmMmVhMTc5ODhmODM0YzFkODE2YmNlZTUxNmJkZWY3Zi90YWJsZXJhbmdlOmYyZWExNzk4OGY4MzRjMWQ4MTZiY2VlNTE2YmRlZjdmXzEwLTEzLTEtMS00NjUzOA_0348de0e-bdb8-444b-8ba7-ec694cf6e708"
      unitRef="usd">4621000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4ae3f849bf20446db2cc1146dcd478d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzMtMS0xLTEtNDY1Mzg_1086bca8-556d-432d-8d19-a46daeb68dcd"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4ae3f849bf20446db2cc1146dcd478d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzMtNy0xLTEtNDY1Mzg_0dbdcd5e-82f5-4ee1-8da0-5f85a79a8508"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic1e3d585465c4e46b41b696bc03baddf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzMtOS0xLTEtNDY1Mzg_0115666b-5427-4bb6-ab92-80960ce3fadb"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb5bf368359a4d94adb4f27bedbb43b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzQtMS0xLTEtNDY1Mzg_db330f53-954d-44a4-bba4-451c1439ee35"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb5bf368359a4d94adb4f27bedbb43b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzQtNy0xLTEtNDY1Mzg_a3c4973e-4ba4-490d-99cc-b9d3a9910681"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic622f20a96d14ab59d16de8af2ade381_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzQtOS0xLTEtNDY1Mzg_54a9d73a-19a9-45cf-8c54-147b10125c96"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMS0xLTEtNDc2MjQ_535d5c13-ff05-471d-93f2-bb6b9d93dfa2"
      unitRef="usd">40469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMy0xLTEtNDc2MjQ_45f62dfc-d30d-446d-991a-4b3c5c0480b1"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNS0xLTEtNDc2MjQ_2632afd8-17be-4609-b423-20e1b92bc8ae"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40c9585ccfdd4de685f78c97d566a741_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNy0xLTEtNDc2MjQ_912bbd1a-fd7e-44fb-a789-0d0384089b7d"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if32b08f8717549848438881335ea2b84_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTEtMS0xLTQ3NjI0_70bc190b-ecc3-4bd0-a8c3-6adcd69b60e8"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i719c13df2acf4bbc80d5a66f47c2c5f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTMtMS0xLTQ3NjI0_679691ae-ad8f-4ec9-a013-4b7337ea2a62"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i56384752fd2647389a6264b9b7752b99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMS0xLTEtNDc2MjQ_b890d6eb-0ed1-4741-a804-070f10a614e0"
      unitRef="usd">83300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56384752fd2647389a6264b9b7752b99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMy0xLTEtNDc2MjQ_f449381b-bd72-4eda-ab91-af94da092599"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56384752fd2647389a6264b9b7752b99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNS0xLTEtNDc2MjQ_60fdbaa4-d57f-423b-8185-3040e61e1312"
      unitRef="usd">114000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56384752fd2647389a6264b9b7752b99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNy0xLTEtNDc2MjQ_ea9e9b9a-e6dc-48f5-8371-6993fd5e09a0"
      unitRef="usd">83196000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69f790be83c94488822a264523f7aa15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTEtMS0xLTQ3NjI0_f738d021-be3f-4afc-99ca-717087cb4c3b"
      unitRef="usd">35768000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3da056f4632343f5ade54138b94c15a3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTMtMS0xLTQ3NjI0_fb1a7e5f-fdac-4ca5-9336-af0fbd042614"
      unitRef="usd">47428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i995af0deed0b466cb43a86929a821007_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMS0xLTEtNDY1Mzg_a5a4a350-74a5-4f88-922e-0f44496180d1"
      unitRef="usd">37621000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i995af0deed0b466cb43a86929a821007_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMy0xLTEtNDY1Mzg_c1b0a6e8-dbc0-4095-accb-5c7b94aa619d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i995af0deed0b466cb43a86929a821007_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNS0xLTEtNDY1Mzg_5b564e39-f0e0-4dcc-8f6b-8f9d5fadb188"
      unitRef="usd">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i995af0deed0b466cb43a86929a821007_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtNy0xLTEtNDY1Mzg_53a01047-b223-4937-8211-de104e32e158"
      unitRef="usd">37559000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b7449a1b73c48eba712df83a6750173_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTEtMS0xLTQ2NTM4_7eb0af04-4091-4d3d-ad90-1028f7a431d2"
      unitRef="usd">20616000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id297898530e345fdb9c39bf76182c6cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzYtMTMtMS0xLTQ2NTM4_2cd3135b-abbb-47a6-becf-d3ab3bc4b873"
      unitRef="usd">16943000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMS0xLTEtNDY1Mzg_14a1f9c8-b4c4-4569-bd57-f6caf5921d34"
      unitRef="usd">161390000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMy0xLTEtNDY1Mzg_af1a4807-39f3-447d-bd15-67bc64b9b3c3"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNS0xLTEtNDY1Mzg_a400b5ab-5d32-49cd-a7c5-089d02cf1783"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbf57f87b5d64c0285b86a7324814667_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctNy0xLTEtNDY1Mzg_47fddb83-3047-46bb-8fe1-d11e4e1209b7"
      unitRef="usd">161221000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2664a396fda544d5b299ff5ebffde6f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTEtMS0xLTQ2NTM4_8a6ce455-e357-4f2f-8d19-3408e7c963c7"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3eedc946a09f4463a2514f7732506d68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzctMTMtMS0xLTQ2NTM4_d53e0aa1-e136-453b-8f90-2b3326a16038"
      unitRef="usd">64371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMS0xLTEtNDY1Mzg_41af07f0-65af-4af8-8259-5fbbfa5f136a"
      unitRef="usd">502636000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMy0xLTEtNDY1Mzg_4c832540-a168-4f4a-bfc0-1f0c3e0974c6"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtNS0xLTEtNDY1Mzg_ab82059d-d87e-470d-a57b-4b011470a8bc"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtNy0xLTEtNDY1Mzg_eda886cb-ca59-42f8-89c8-a91b41a18ed9"
      unitRef="usd">502467000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ifb31ec5446de4fe8ac13a013fc88446a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtOS0xLTEtNDY1Mzg_bdeb1d9d-8eef-4a1a-bb3c-39a11c42ea48"
      unitRef="usd">341246000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i8a01a2413bfa418289c898f2b33b80ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMTEtMS0xLTQ2NTM4_db26da48-afc3-4119-afbf-31fc10e96bbf"
      unitRef="usd">96850000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ieba9efc2fefc4fef9a71d9e9ad291bf5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90YWJsZTpjMmI4MzEyMWI3OGE0M2FlYjI0NzQ4M2ViM2E3OTFkMS90YWJsZXJhbmdlOmMyYjgzMTIxYjc4YTQzYWViMjQ3NDgzZWIzYTc5MWQxXzgtMTMtMS0xLTQ2NTM4_fba23ab7-904e-470d-8405-3ceb5d1a6764"
      unitRef="usd">64371000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="id15667ce7b0c40e5b2f6147b95913a03_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzI3Mg_2eaecf9c-7b8a-4542-b13d-a6220d89274d">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ib64f00a32bc643ec9155226e65fdce96_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzM0NQ_08f521ca-ae33-4da3-9ccb-cfc10befe978">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="id09a4d167ef143e0bd15f47ab94c5ad3_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjEvZnJhZzpjMDc3NWZiZjExYjI0ZWIwODA4MmM4YzdmMDZmZjc2NC90ZXh0cmVnaW9uOmMwNzc1ZmJmMTFiMjRlYjA4MDgyYzhjN2YwNmZmNzY0XzM1Mg_b436baf6-5e05-4c72-8952-43da7ad80343">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <krys:BalanceSheetComponentsDisclosureTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzQxMQ_d3217920-87e2-47de-b662-7c8069d25fe6">Balance Sheet Components&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $2.6 million, $1.8 million and $1.5 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</krys:BalanceSheetComponentsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzQxMg_c12aafa7-b33d-466e-a0eb-6c36263fdf5a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i38459e6001414efe8cfeb8e4f948bc27_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzEtMS0xLTEtNDY1Mzg_77822047-44a4-4cc7-b7bf-37d3638a4752"
      unitRef="usd">131331000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i36fe90f1305345ceb8f4eec74b095c49_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzEtMy0xLTEtNDY1Mzg_34531b36-13d1-4d0c-94c9-b1fa3231cfae"
      unitRef="usd">104340000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i629b96ba6adf4d8aa35b23c9ad34341a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzItMS0xLTEtNDY1Mzg_d7ee31c4-9e92-44e9-9f49-8265f1a54a93"
      unitRef="usd">24217000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic01e245d2c6b4ecbb264de581059c082_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzItMy0xLTEtNDY1Mzg_81ec8b69-6d12-460e-911f-569a775d41f0"
      unitRef="usd">5723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53a1d6851402493eb7158bcdc4c40c4b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzMtMS0xLTEtNDY1Mzg_4b801d83-67d2-42a9-a329-6e45a646e197"
      unitRef="usd">957000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibd317320604f464d92352b55af94077e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzMtMy0xLTEtNDY1Mzg_a89c1774-a76b-410b-8fcf-19e1f21e35d1"
      unitRef="usd">891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib85a7c903384425b9eb947f6782aa70b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzQtMS0xLTEtNDY1Mzg_ec385178-d4c0-498e-a364-ae0bc40d2bc9"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i256fac5f703848e2b8ab04acc69e5f3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzQtMy0xLTEtNDY1Mzg_fefac8ff-1a12-4054-a4c9-0655f147caae"
      unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iea876abef962460799265e18643c6fb9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzUtMS0xLTEtNDY1Mzg_2d6862ec-a038-47c4-a635-09fb3ec7707c"
      unitRef="usd">11872000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fc859be73b64ed295ad31b068c1c6b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzUtMy0xLTEtNDY1Mzg_6b9527df-a664-407c-b514-29a18d3d7586"
      unitRef="usd">5530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzYtMS0xLTEtNDY1Mzg_31af1a41-2dbb-46b3-ad85-afa3e86dfc73"
      unitRef="usd">168477000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzYtMy0xLTEtNDY1Mzg_e8e5e347-e473-4bc6-b2ab-a56e078f8fc7"
      unitRef="usd">116569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzctMS0xLTEtNDY1Mzg_4ea43a10-5fb6-4884-9c38-998b22075def"
      unitRef="usd">6793000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzctMy0xLTEtNDY1Mzg_27df393e-3a81-4765-8072-7c26174a8ce9"
      unitRef="usd">4214000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzgtMS0xLTEtNDY1Mzg_9b883451-c54f-46cc-956e-753071f9977d"
      unitRef="usd">161684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZTo4NmJhNDliYTFhMzU0N2Q1OGQzYzAzZDgyNDRkY2EyNS90YWJsZXJhbmdlOjg2YmE0OWJhMWEzNTQ3ZDU4ZDNjMDNkODI0NGRjYTI1XzgtMy0xLTEtNDY1Mzg_dcc1ff90-4900-4821-b3d0-abda65116579"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzU0OTc1NTgxNDQ2Mw_7fb25e26-6078-4432-aed4-cb3bd59bc3c0"
      unitRef="usd">2600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzU0OTc1NTgxNDMyMA_eb831d9b-1ad6-41bf-8e08-70fe1eeecbff"
      unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzU0OTc1NTgxNDMzMA_4ccf555a-fd56-4f6e-a2d5-d680038b4edf"
      unitRef="usd">1500000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90ZXh0cmVnaW9uOjc2ZWI5ZDY4Yjc3MTRkYzFhOWE2NzNjODM0MmZhYjIxXzQxMw_7893b61f-c86f-4919-ba29-91a5efc2acb8">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following as of December&#160;31, 2022 and 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzEtMS0xLTEtNDY1Mzg_ed0356a3-7ba3-4175-80d5-48f0548a13f3"
      unitRef="usd">1365000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzEtMy0xLTEtNDY1Mzg_083d6945-1c74-4caf-9cdb-0e7a0dd9acbb"
      unitRef="usd">1602000</krys:AccruedPreclinicalAndClinicalExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzItMS0xLTEtNDY1Mzg_0efa9838-2772-4fdd-baff-128f6899ebca"
      unitRef="usd">3397000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzItMy0xLTEtNDY1Mzg_0f7a41b8-9177-4db7-90a8-586416f817d0"
      unitRef="usd">2011000</us-gaap:AccruedProfessionalFeesCurrent>
    <krys:AccruedPayrollAndBenefits
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzMtMS0xLTEtNDY1Mzg_5829c54c-f682-4574-8f22-6c26eeb1f758"
      unitRef="usd">6781000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPayrollAndBenefits
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzMtMy0xLTEtNDY1Mzg_fd2fbe3c-3b67-4c48-a071-0b2fd5ac7211"
      unitRef="usd">2882000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedConstructionInProgressAndLaboratoryEquipment
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzUtMS0xLTEtNDY1Mzg_674c7828-8ef0-4f45-be76-83f855ee229a"
      unitRef="usd">11452000</krys:AccruedConstructionInProgressAndLaboratoryEquipment>
    <krys:AccruedConstructionInProgressAndLaboratoryEquipment
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzUtMy0xLTEtNDY1Mzg_e83f7fd8-f476-44e7-88ad-ff13e74d87a4"
      unitRef="usd">9606000</krys:AccruedConstructionInProgressAndLaboratoryEquipment>
    <krys:AccruedFinancingFeesCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzYtMS0xLTEtNDY1Mzg_594f366d-9984-4a00-a957-0d22fc46b7d8"
      unitRef="usd">0</krys:AccruedFinancingFeesCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzYtMy0xLTEtNDY1Mzg_984b2d5c-814b-4b9c-829a-f66bfa253c98"
      unitRef="usd">26000</krys:AccruedFinancingFeesCurrent>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMS0xLTEtNTkzMTQ_8d9a8705-99a1-46d3-98c7-4db36f0e7a64"
      unitRef="usd">43000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMy0xLTEtNTkzMTQ_e4e634f7-10a1-4c45-aeec-eb6657bf0e63"
      unitRef="usd">83000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMS0xLTEtNDY1Mzg_0a5c1679-2533-4c88-838c-9de1ba2ac274"
      unitRef="usd">267000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzctMy0xLTEtNDY1Mzg_1cb45a5a-e054-475a-868c-860e687973dc"
      unitRef="usd">87000</us-gaap:OtherLiabilitiesCurrent>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzgtMS0xLTEtNDY1Mzg_e44a89f1-e66b-4500-ba65-912d4acb1723"
      unitRef="usd">23305000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjQvZnJhZzo3NmViOWQ2OGI3NzE0ZGMxYTlhNjczYzgzNDJmYWIyMS90YWJsZToxZGVhOWU3YmNiYWY0ODNkOWI4MmM4MGRhNGI1YTRhMy90YWJsZXJhbmdlOjFkZWE5ZTdiY2JhZjQ4M2Q5YjgyYzgwZGE0YjVhNGEzXzgtMy0xLTEtNDY1Mzg_ed8413d5-b6b9-4931-8919-84f01f8cccd1"
      unitRef="usd">16297000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzIxOTkwMjMyNzY4ODk_db7358d9-07e4-4542-afcf-68dfb5076da6">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Contracts and Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreements with Contract Manufacturing Organizations and Contract Research Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various agreements in the normal course of business with Contract Research Organizations (&#x201c;CROs&#x201d;), Contract Manufacturing Organizations (&#x201c;CMOs&#x201d;) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of December&#160;31, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred research and development expenses under these agreements of $6.0 million, $5.0 million and $4.6 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Preparedness Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate, B-VEC. These contracts typically call for the payment of fees for services upon the achievement of certain milestones or as services are rendered. The estimated remaining commitment as of December&#160;31, 2022 is $8.4 million. The Company has incurred expenses under these activities of $14.2 million, $6.1 million and $1.9 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASTRA Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to complete the interior build-out of our second CGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of December&#160;31, 2022 is $16.3&#160;million. The Company has included costs incurred to-date associated with ASTRA within construction-in-progress as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#x201c;Agreement&#x201d;) with The Whiting-Turner Contracting Company (&#x201c;Whiting-Turner&#x201d;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company, which has been amended from time to time for change orders additional work is awarded to Whiting-Turner, is currently $85.5&#160;million. Whiting-Turner&#x2019;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#x2019;s work under the Agreement may not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement with Whiting-Turner constitutes only a portion of the total estimated cost of building and equipping ASTRA as there are various other third parties engaged in the project for which contracts are not individually material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. (&#x201c;PeriphaGen&#x201d;), which also named our Chief Executive Officer and President, R&amp;amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserts were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint in June 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#x2019;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions. On March &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12, 2022, the Company entered into a binding term sheet to settle the dispute. In April 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the $25.0&#160;million within litigation settlement expense on the consolidated statements of operations for the year ended December 31, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of December 31, 2022, and therefore no additional accrual has been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received $1.1&#160;million and $1.6&#160;million of insurance proceeds during fiscal years ending December&#160;31, 2022 and 2021, respectively. Additionally, the Company had outstanding receivables of zero and $560&#160;thousand as of December&#160;31, 2022 and 2021, respectively, recorded within prepaid expenses and other current assets on the consolidated balance sheets, as management determined that the amounts were probable of collection. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the consolidated statements of operations and within operating activities on the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <krys:RemainingCommitmentAmount
      contextRef="ic202baf205634534bffe9efeed3c7c9c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzYxMDk_491f0f1a-26a2-4d12-bdd5-8b479fc44021"
      unitRef="usd">2100000</krys:RemainingCommitmentAmount>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie8bb7ba5bc104672859794003515136c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzg4Nw_04c50fd8-9bb7-442e-a10e-fa7a5d5252fd"
      unitRef="usd">6000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie84cd465b49e427c810883f086042263_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzg2Nw_97725f86-ea11-42b4-9f4b-80e71452c6f9"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i02fbe5b2532b456baed4ef03a2689550_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzg3MQ_76201d00-cd8e-48c7-8410-142f08bdd8d4"
      unitRef="usd">4600000</us-gaap:ResearchAndDevelopmentExpense>
    <krys:RemainingCommitmentAmount
      contextRef="ie6be49196b1a40cebb048dcca6eb9e34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzY2MjE_8a2c730c-d92e-42e8-8cf7-df7910ce7b7f"
      unitRef="usd">8400000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i9e748ec3ff764d03a108335cdb1f671c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzkwOQ_e31685b6-390b-4367-ba04-109f81715be2"
      unitRef="usd">14200000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ia61ac7a1eeb045dcacea633ccb659966_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzkwMg_aa2c54af-31c3-4f11-b401-100627faac15"
      unitRef="usd">6100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i832fb48c719242fba8c5af845c762e6d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgyNzkwNg_d33b0dfa-3c07-4e90-93fc-43b82f30bdfe"
      unitRef="usd">1900000</us-gaap:ProfessionalFees>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTg0MTAxOA_8212a5fe-bcaa-4a47-ab74-fde8a96b6087"
      unitRef="usd">16300000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <krys:CostOfWorkPercentage
      contextRef="ifc3bab3e2c074cf09d136a1988e3d2e6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1Xzc3NzY_4dc9c43b-724a-4aae-955b-d62fd2588ceb"
      unitRef="number">0.0175</krys:CostOfWorkPercentage>
    <krys:LossContingencyGuaranteedMaximumPriceToBePaid
      contextRef="i495e2c1097804e028fc462ff30675a6f_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzgyNjg_08e3c042-ffeb-45d5-b86a-fa05c4a72d87"
      unitRef="usd">85500000</krys:LossContingencyGuaranteedMaximumPriceToBePaid>
    <us-gaap:LitigationSettlementExpense
      contextRef="i3fb54fd3a1a9429dbd4579a4ca4375c3_D20220428-20220428"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMDU_9d5aa0cf-3e21-4662-87b0-bd84e54ca575"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMjA_0b73274f-a4a5-4dda-9324-36dc13dda4ee"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:NumberOfMilestones
      contextRef="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzI0MzE_95f2189a-4f4d-4a7b-8e32-716a3275618e"
      unitRef="milestone">3</krys:NumberOfMilestones>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i4284a105f3d94405949b41403e9a7675_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMzc_2b557880-5350-4387-a8dc-7e360a80ba1c"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ie93b6151f6f9401a9cf2ece6f8285911_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMzc_69fba005-6c2c-46ad-beea-6f5e838e8567"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i66aa90c0684b46ac8099d45d53db5a8d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzMzc_e106258d-3443-448f-b08e-4213da552ff3"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="idc45f2a4236a42068da733f353b95494_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzNTI_7c916303-d9f5-4f5c-b409-008ef7bf38ad"
      unitRef="usd">100000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="id2f6d31d7c164477b1d0048e8a3d3c31_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzNjg_4450af0a-2245-4b5c-bce5-f7629d495b92"
      unitRef="usd">200000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i945482856edd461ca395d4030b16ab54_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzIzODQ_cd45f4c7-3873-4007-973a-ca893ae0a4b0"
      unitRef="usd">300000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementTotalConsideration
      contextRef="ie8a82f78a44f492d8069e2d68d1056a8_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzI0MDA_928f6cbb-0982-4aae-bee8-e8407de8d760"
      unitRef="usd">75000000</krys:LitigationSettlementTotalConsideration>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic3087b8a6d9a46e38f8c58cc89c69658_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzQzOTgwNDY1MzI0MTU_1b2dffed-8ee6-46d0-84af-6113587bfadc"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTg0MDYxOQ_6df20bc4-3caf-4f82-874f-aefe69264bfc"
      unitRef="usd">1100000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgzMzgzMg_b7eb3991-eaa4-4b4e-a84e-a75bfc90e87d"
      unitRef="usd">1600000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTg0MDQ2OQ_85a4e7d0-98a0-4d7a-bcfb-74be6304c7d1"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMjcvZnJhZzo4YjkwODU3N2IyY2Q0NTJkOWZlODExNjlmZTNmZTY4NS90ZXh0cmVnaW9uOjhiOTA4NTc3YjJjZDQ1MmQ5ZmU4MTE2OWZlM2ZlNjg1XzU0OTc1NTgzNDk3Mg_2a89fda1-67c5-45e3-8202-c7a98ef15304"
      unitRef="usd">560000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDM_8ea97014-3fc0-4c0f-b584-9c74fee9ee24">Leases&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, the Company signed an operating lease for laboratory and office space in Pittsburgh, Pennsylvania that commenced in June 2016 and was scheduled to expire in October 2017 (the &#x201c;2016 Lease&#x201d;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 54,000 square feet and includes the commercial scale CGMP-compliant manufacturing facility, (&#x201c;ANCORIS&#x201d;). As a result of the lease amendments, the 2016 Lease expiration date was extended to October 2031. In September 2022, the Company amended the 2016 Lease (&#x201c;Short-Term Amendment&#x201d;) to add a short-term lease for additional office space that commenced in October 2022 and expires on September 2023. The Short-Term Amendment increased the area leased by approximately 7,000 square feet through September 2023. Due to the short-term nature of this amendment and the Company's lease accounting policy, the Company did not record a right-of-use asset or corresponding lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company entered into a lease agreement for a second commercial gene therapy facility, (&#x201c;ASTRA&#x201d;), in the Pittsburgh, Pennsylvania area (&#x201c;ASTRA lease&#x201d;) with Northfield I, LLC (the &#x201c;Landlord&#x201d;, &#x201c;Northfield&#x201d;, or &#x201c;Lessor&#x201d;) with an initial lease term that expired on October 2035. The ASTRA lease contained an option (&#x201c;Purchase Option&#x201d;) to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the &#x201c;Ground Lease&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA. The Company recorded a $10&#160;million CIP asset and a corresponding build-to-suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contributions of $2.4&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Purchase and Sale Agreement (&#x201c;PSA&#x201d;) for ASTRA with Northfield related to the purchase option exercised by the Company in October 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. In February 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement. As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale. As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. In March 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. The building continues to be held under construction-in-progress as of December&#160;31, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2023. For more information about the expected construction costs associated with ASTRA, see &#x201c;ASTRA Contractual Obligations&#x201d; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability in October 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office that commenced in September 2022 and expires December 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&#160;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="i6729dd8891e24732929f1da30607e91a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzEwOTk1MTE2NDc1NjI_6c561065-9e8a-44ee-85b2-52e0e9c7f211"
      unitRef="sqft">54000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="id3550b062fe645a5b0ed51ef12d694db_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzg0Mw_2a9dcaac-2220-4a06-8ce6-b8fcfac8fbbc"
      unitRef="sqft">7000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzE5Nzk3_1f76f470-6258-4680-8df2-8f4f96103383"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:ConstructionInProgressGross
      contextRef="i4370047cb1b348508f41d2e789bc71c0_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzE5ODA1_3cbe941c-66c7-4e04-bb05-93ad007a5ba2"
      unitRef="usd">10000000</us-gaap:ConstructionInProgressGross>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i4370047cb1b348508f41d2e789bc71c0_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzE5ODAx_4aed6625-b1d0-4657-bddf-3d4f75174ebd"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzI1ODM_ed6904f4-b1e4-4c0c-8233-4fca4200625a"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:EscrowDeposit
      contextRef="i4370047cb1b348508f41d2e789bc71c0_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzI2MTg_7b770694-f06a-4835-aaae-38055ee975ce"
      unitRef="usd">1500000</us-gaap:EscrowDeposit>
    <krys:LessorOperatingLeaseLiabilityAnnualLeasePayments
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ0NzQ_c9e6ae07-333f-470f-a3c1-04803f45de75"
      unitRef="usd">82000</krys:LessorOperatingLeaseLiabilityAnnualLeasePayments>
    <krys:CumulativeEscalationClausePercent
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ1MTA_3ab9e177-6992-47da-842b-cfc9bd335c46"
      unitRef="number">0.10</krys:CumulativeEscalationClausePercent>
    <krys:CumulativeEscalationClauseTerm
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ1Mzc_27835c95-9d63-4b68-864c-0e585b37403a">P5Y</krys:CumulativeEscalationClauseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if35ae989164e43cdb1a778a5e6515540_I20211215"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ2MDM_df5df25f-f9e0-4de6-a215-3e220ba7db22">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia171e05bea12459f9ba3be58aa9b540f_I20220316"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzQ3Njg_ad6a24c8-e8a9-4b4d-89dc-5d7c6c90bb74">P16M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDI_d827ab14-8155-443a-bf87-a620eb01923c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&#160;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzEtMS0xLTEtNTM3NTI_033101e3-dbb0-4da5-a316-ab18cf165d50"
      unitRef="usd">1648000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzItMS0xLTEtNTM3NTI_c73b5cd5-cfa5-4add-a773-a3d4dc284aac"
      unitRef="usd">1539000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzMtMS0xLTEtNTM3NTI_4b12abf9-dd69-4825-b441-1ec1a4d91475"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzQtMS0xLTEtNTM3NTI_8e7243b7-156e-4949-aae9-9eab0e444e06"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzUtMS0xLTEtNTM3NTI_d70faba6-9719-4ab5-b3ab-7e9bc5a7af2b"
      unitRef="usd">1300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzYtMS0xLTEtNTM3NTI_654db54f-0a03-4e4f-889f-4703d7b2354d"
      unitRef="usd">10762000</krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzctMS0xLTEtNTM3NTI_0e64958e-3e07-404f-b540-b0de4faa4cf6"
      unitRef="usd">17803000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzgtMS0xLTEtNTM3NTI_51e0cc31-4940-4118-b667-476baae40158"
      unitRef="usd">8870000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo1NWU4NDI1NTZiN2M0NjFiYmY5YzdmNDAxNmZlYmIxZS90YWJsZXJhbmdlOjU1ZTg0MjU1NmI3YzQ2MWJiZjljN2Y0MDE2ZmViYjFlXzktMS0xLTEtNTM3NTI_56ab659e-7102-4a18-92de-41b0e387e164"
      unitRef="usd">8933000</us-gaap:OperatingLeaseLiability>
    <krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDQ_4088322f-65a8-450f-a1fe-783035615919">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzItMS0xLTEtNTM3NTI_1a11eb55-6812-4629-abf9-bdb8c4386f00"
      unitRef="usd">8042000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzItMy0xLTEtNTM3NTI_0ca5e246-26db-4ee9-8229-d5d608ce8e28"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzMtMS0xLTEtNTM3NTI_6e80a332-db54-4273-a83a-0e838d1c7c03"
      unitRef="usd">1561000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzMtMy0xLTEtNTM3NTI_49e799f7-90ba-4f98-a03f-fdd5364c79b9"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzQtMS0xLTEtNTM3NTI_e17b5c4f-1644-4099-a093-370b9ddff856"
      unitRef="usd">7372000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzQtMy0xLTEtNTM3NTI_3c56e76a-1dc9-426b-b476-9793cef36af3"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzUtMS0xLTEtNTM3NTI_88c2dd1c-7cda-488c-93a6-0050c7f5896b"
      unitRef="usd">8933000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzUtMy0xLTEtNTY3MTQ_5f6a8d0b-8c60-4968-ae5b-bd815998cc65"
      unitRef="usd">8024000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzYtMS0xLTEtNTM3NTI_82e44fa8-4571-4dff-b8e2-29e3748fbaf3">P12Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzYtMy0xLTEtNTM3NTI_6dea0813-034a-4312-97c9-56050d3ab13c">P14Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzctMS0xLTEtNTM3NTI_c70b770b-e212-4263-bb06-c8fed549cc68"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo0MzVhMjE3NzMxN2Y0OTM0YmJhYmI5NmMxOTJmMWM0MS90YWJsZXJhbmdlOjQzNWEyMTc3MzE3ZjQ5MzRiYmFiYjk2YzE5MmYxYzQxXzctMy0xLTEtNTM3NTI_9f51ac12-075a-4d3a-85cb-56bab7f48711"
      unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90ZXh0cmVnaW9uOjNhNDZiMmI0ZjAxNjQzMmZiNDFmMzQyODExNWE1NzBiXzIxOTkwMjMyNzU5NDU_ffcc67c1-ecdd-4ad2-aa50-6da484648a70">&lt;div style="margin-top:2pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzQtMS0xLTEtNTM3NTI_a0cf0206-9cbe-46a8-93f8-0172bb073a7b"
      unitRef="usd">1532000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzQtMy0xLTEtNTM3NTI_6fd5b2a2-47f0-4aea-b2ee-3d588e3c2c22"
      unitRef="usd">1275000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzQtNS0xLTEtNTM3NTI_c055a392-b026-474b-bc9f-2f76f410deab"
      unitRef="usd">767000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzUtMS0xLTEtNTM3NTI_24e2bf7c-f4fe-4443-a668-2062a80e4968"
      unitRef="usd">226000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzUtMy0xLTEtNTM3NTI_c66ca83d-e931-466d-aad4-9f29639d0643"
      unitRef="usd">160000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzUtNS0xLTEtNTM3NTI_a8ba57da-d3f8-4013-9122-db36e9e7bef0"
      unitRef="usd">57000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzYtMS0xLTEtNTY3MTc_9a42ef36-dcbb-40b8-84ef-5416670d845c"
      unitRef="usd">1758000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzYtMy0xLTEtNTY3MTc_9bbad3a6-e933-48e6-b130-0efcf00c218d"
      unitRef="usd">1435000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N181NDk3NTU4MTU0NjIvZnJhZzozYTQ2YjJiNGYwMTY0MzJmYjQxZjM0MjgxMTVhNTcwYi90YWJsZTo4OGUzMWUwZWFjZjk0MGViYThhMmFhNWU2YmFiM2I0Zi90YWJsZXJhbmdlOjg4ZTMxZTBlYWNmOTQwZWJhOGEyYWE1ZTZiYWIzYjRmXzYtNS0xLTEtNTY3MTc_58d66aff-a904-4fc2-bf30-dc7f9dd7994b"
      unitRef="usd">824000</us-gaap:LeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzE5OTE_bc60303e-afef-41db-b6af-953dc318151d">Capitalization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share. Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company completed a public offering of 2,275,000 shares of its common stock to the public at $55.00 per share. Net proceeds to the Company from the offering were $117.2&#160;million after deducting underwriting discounts and commissions of approximately $7.5&#160;million, and other offering expenses payable by the Company of approximately $463&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) with respect to an at-the-market equity offering program (&#x201c;ATM&#x201d;) finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million (&#x201c;Placement Shares&#x201d;). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective &#x201c;shelf&#x201d; registration statement on Form S-3. During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting selling commissions of approximately $524&#160;thousand. During the year ended December&#160;31, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting selling commissions of approximately $900&#160;thousand, resulting in a remaining $102.5&#160;million available for issuance under the ATM Program.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzEwOA_695aa5e3-16e9-40ed-935a-f49fb60ec28e"
      unitRef="shares">2866667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i30156baee55b420397418386f0108370_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzE0OQ_d742af12-8d70-4e36-86ed-a0984ec2d60d"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i20353f3c4a5844c1812426b1fb75b765_I20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzE5Mw_128dc125-cd9e-4ca1-87fa-9b2df5fabef3"
      unitRef="usdPerShare">75.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzI1OQ_d024c7a5-0e7e-4813-b304-217c03d0b132"
      unitRef="usd">201900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i4add09931eef4d8d8a0a0d516506c802_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzMzNA_72b42431-7fbd-41be-980a-9ed427dc07e8"
      unitRef="usd">12900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id22d7707724741a49fc8f50872fbdfdb_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzM5Mg_56229491-6eca-4c56-9ce6-0fad6a7d53d1"
      unitRef="usd">227000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzQ2MA_8e641da4-a43d-4f5a-8303-afbaf8a0278b"
      unitRef="shares">2211538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ieb9b5e8d6ec94209880102cc2bc8b200_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzUwMQ_b0aa6df1-5366-4603-9e4e-437ac32c91bd"
      unitRef="shares">288461</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i30752247a0714b92a9d3f37982cfdcaa_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0NQ_00ee61ea-6a1b-4612-9395-336f94c0e864"
      unitRef="usdPerShare">65.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzYxMQ_0d316add-9fb3-4a47-b718-ce38a83f1382"
      unitRef="usd">134900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i5c02a09bd56f485cbfd6e34c0316a052_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzY4Ng_380dd778-8c87-477c-bd5a-fad3d3836403"
      unitRef="usd">8600000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9957e8c329c246278995d54d846e0a2b_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2Xzc0NA_30bb8bea-654e-44d9-b723-bd1ae6c5e51f"
      unitRef="usd">198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDIyMg_c8128a5b-b157-4941-b661-85683c751292"
      unitRef="shares">2275000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ic18c855dfb0d4abf9b71ece6213ab70d_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDI3MA_92cb4457-1c7e-4d36-b422-304b3b640fef"
      unitRef="usdPerShare">55.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDMzNg_825fb016-122f-45c0-9913-d2ec526dc745"
      unitRef="usd">117200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDQxMg_a382ed6e-1ec2-4183-8839-f35a6eb28bf0"
      unitRef="usd">7500000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0c088d1acbb0431a9732bbd2a1b08cf9_D20200531-20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTg0MDQ4NQ_fc9792ab-99b8-4bd4-ae27-027d035309de"
      unitRef="usd">463000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <krys:SaleOfStockAggregateOfferingPrice
      contextRef="i95615b0260094824b79b22c82e8d1a1a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODIyOA_3e03970b-b166-48d3-87ea-5f5a54e8213b"
      unitRef="usd">150000000</krys:SaleOfStockAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icb780c5cb8b14431832716c15e1dac80_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODQ3Mg_7b56cac6-7858-40c1-b8c5-7d39a80f9171"
      unitRef="shares">262500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7f7ad365543f4254838ab4c58a691a10_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODUzMA_b234b436-4dad-480c-98bb-568c5eb2f40b"
      unitRef="usdPerShare">66.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i7cef0fcaddce44cfa4ae5cd35b69a9db_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODU2NA_b72ffd95-c449-4ff0-8a82-e1fe92f468e5"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i7cef0fcaddce44cfa4ae5cd35b69a9db_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODYyMQ_d7a0b98a-baa2-442a-bc41-a8c86dda6044"
      unitRef="usd">524000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i94d7eb26698e4662a210b4e03cb7f40e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODcwMw_4e341ea5-418c-4f8b-8f8f-2ce04e453a8d"
      unitRef="shares">434782</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id0436d21be92494794b2f1a66dba88ec_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODc2MQ_e5d6621d-ffbd-4788-999a-b6621892ed49"
      unitRef="usdPerShare">69.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i94d7eb26698e4662a210b4e03cb7f40e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODc5NQ_96740def-5e0b-4679-b148-a86f2c5c296e"
      unitRef="usd">29100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="idd3104f8c0ce402b88a79fb05859ba61_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODg1Mg_2ae9303f-6e41-4bfc-9bed-d10fc5636042"
      unitRef="usd">900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <krys:SaleOfStockRemainingAvailableIssuanceAmount
      contextRef="idd3104f8c0ce402b88a79fb05859ba61_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzAvZnJhZzowYjk3ZmVkZGQ1NDM0ZTcwYWViZGMxYWRhNmU5Mzk0Ni90ZXh0cmVnaW9uOjBiOTdmZWRkZDU0MzRlNzBhZWJkYzFhZGE2ZTkzOTQ2XzU0OTc1NTgzODg4Mg_84ea66ee-e337-413c-b3ea-84b7101efe8a"
      unitRef="usd">102500000</krys:SaleOfStockRemainingAvailableIssuanceAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NTk_ce2937b1-987d-4f88-924f-4d1127121c39">Stock-Based Compensation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company adopted the 2017 IPO Stock Plan (the &#x201c;Plan&#x201d;), which governs the issuance of stock options to employees, certain non-employee consultants, and directors. Initially, the Company reserved 900 thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of 900&#160;thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees and non-employees vest ratably over a four-year period and stock options granted to directors of the company vest ratably over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE5NQ_581f1165-b5dd-4145-a11c-77520dcce020"&gt;one&lt;/span&gt;-year to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxODQxNQ_e82f6b9b-070f-474c-9202-f9ee87935c71"&gt;three&lt;/span&gt;-year periods. Stock options have a life of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 2,130,500 and 1,422,450 stock options to employees, non-employees, and directors during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,130,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,582,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December&#160;31, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the years ended December&#160;31, 2022 and 2021 was $2.9&#160;million and $1.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the years ended December&#160;31, 2022 and 2021 was $44.50 and $43.05, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $104.4&#160;million of unrecognized stock-based compensation expense related to employees&#x2019;, non-employees&#x2019;, and directors&#x2019;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.9 years as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the&#160;consolidated&#160;statements&#160;of operations for the years ended December&#160;31, 2022, 2021, and 2020&#160;as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the portion of stock-based compensation that relates to work performed on the construction of manufacturing facilities. There was $551&#160;thousand, $284&#160;thousand, and $34&#160;thousand of stock-based compensation that was capitalized in the years ended December&#160;31, 2022, 2021, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value of options granted was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the years ended December&#160;31, 2022, 2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards (&#x201c;RSAs&#x201d;) granted to employees vest ratably over a four-year period. The Company granted zero and 98,800 RSAs to employees of the Company during the year ended December&#160;31, 2022 and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSA activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $3.8&#160;million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.2 years as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following stock-based compensation expense related to RSAs within general and administrative expenses in the accompanying consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares remaining available for grant under the Company's stock incentive plan were 469,616, with a remaining sublimit for incentive stock options of 5,581, at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzEwOTk1MTE2MzE2NTQ_35ec1637-2945-40d1-ae35-239c62a51312"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i927bd69a74cf45ff9656d9b5b2f2b3f3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzEwOTk1MTE2MzE3NTc_d65e7afa-da93-493f-8b75-2169d3786e2a"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjI_f6e358da-4a03-474e-85ad-3f79045b19d9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI0Nw_a6ef1e8d-c60e-474e-8706-81c90c01e169">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic9274bc3d5034d649742d7cf95cad4c7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxNjk2MQ_85815005-846b-40a1-b78d-836d4e78bc61"
      unitRef="shares">2130500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i44284afec0974ca383f35189fcf5836c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3OQ_f92f63c1-ceb9-4319-8022-872ea87663ca"
      unitRef="shares">1422450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjA_3dc716b1-6a6d-4886-9257-95f0bc0e7a33">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,130,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,582,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December&#160;31, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtMS0xLTEtNDY1Mzg_7256a6da-ae9f-4fee-bc26-1b9caaa71237"
      unitRef="shares">853614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtMy0xLTEtNDY1Mzg_87b8f2a6-6217-49f7-b947-b97d26a6a632"
      unitRef="usdPerShare">40.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtNS0xLTEtNDY1Mzg_6e4760de-6207-43aa-809e-6cfe02d21aa9">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie413a0f15f0d4717be8217ec39b221df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzYtNy0xLTEtNDY1Mzg_fe536cb6-006f-4261-85cc-89f9848b5ba4"
      unitRef="usd">16804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzctMS0xLTEtNDY1Mzg_f3391b90-6f75-4e34-9fa1-be1f1ba2c5a1"
      unitRef="shares">1422450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzctMy0xLTEtNDY1Mzg_ba541387-8afe-46fd-a421-dbfaf0fa3577"
      unitRef="usdPerShare">66.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzgtMS0xLTEtNDY1Mzg_4dadccba-2f80-42ea-a757-263a15a3ba84"
      unitRef="shares">54260</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzgtMy0xLTEtNDY1Mzg_73b41705-2282-4758-ac5a-b27dadf7c5ef"
      unitRef="usdPerShare">38.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzktMS0xLTEtNDY1Mzg_7a27b0b9-a9b7-41c2-8af1-bbb965264fbd"
      unitRef="shares">175750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzktMy0xLTEtNDY1Mzg_a7607f59-96b2-4611-ac01-26c28d973a17"
      unitRef="usdPerShare">61.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEwLTEtMS0xLTQ2NTM4_9e7101a5-15bb-4521-a4c5-1b712e11eea4"
      unitRef="shares">2875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEwLTMtMS0xLTQ2NTM4_a8348acc-e932-484d-97a6-39407eab76e3"
      unitRef="usdPerShare">75.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTEtMS0xLTQ2NTM4_ee42d460-1ab6-4bec-854f-0eba8f6baffd"
      unitRef="shares">2043179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTMtMS0xLTQ2NTM4_bd041708-e3d2-49d7-a307-66fae780e0ea"
      unitRef="usdPerShare">57.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTUtMS0xLTQ2NTM4_1d1e7104-f742-439d-b849-527fe9598283">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTctMS0xLTQ2NTM4_2b7b8964-79b0-46bd-8ff8-29c81b8be5f0"
      unitRef="usd">31331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTEtMS0xLTQ4NTkw_c20c3544-e6da-4ae6-8929-e2b7b2a9ed92"
      unitRef="shares">2130500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTMtMS0xLTQ4NTkw_fab4bc7b-aa3f-4dbd-aafc-2fc8b527e170"
      unitRef="usdPerShare">64.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEzLTEtMS0xLTQ4NTkw_86c17198-59ba-4439-b14d-72628225f5db"
      unitRef="shares">138855</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEzLTMtMS0xLTQ4NTkw_ba773311-fe45-42cf-bad5-01975d249905"
      unitRef="usdPerShare">50.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE0LTEtMS0xLTQ4NTkw_aa9bc26e-8036-41d7-ac08-289c3b440e91"
      unitRef="shares">438892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE0LTMtMS0xLTQ4NTkw_7595db2c-b665-43fd-8f15-ac4e9e87270c"
      unitRef="usdPerShare">59.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE1LTEtMS0xLTQ4NTkw_34a7704f-728e-4b1c-97ce-49932aa9bfda"
      unitRef="shares">13751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE1LTMtMS0xLTQ4NTkw_fbc72762-aede-4bd1-bcd0-af1a0dbed4a6"
      unitRef="usdPerShare">78.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE2LTEtMS0xLTQ4NTkw_13b836f7-bcd4-4fc9-9ece-37d816a93085"
      unitRef="shares">3582181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzE2LTMtMS0xLTQ4NTkw_a525d2a8-3322-4b5a-91fd-b9287224f34b"
      unitRef="usdPerShare">61.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTUtMS0xLTUyNTg3_b77a0e5e-ddd5-43be-a0ca-09995f9a0039">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzExLTctMS0xLTUyNTg3_7b203544-c53d-4205-89b0-2e73efefb395"
      unitRef="usd">64880000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTEtMS0xLTQ2NTM4_127ccc56-e383-45c0-aeab-cec903da1900"
      unitRef="shares">666886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTMtMS0xLTQ2NTM4_97af4dc3-82fc-40db-aad0-5bbe9465d927"
      unitRef="usdPerShare">49.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTUtMS0xLTQ2NTM4_a625ac6f-e641-4048-aab3-05927b23a984">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpiNDc1MjZjMGQxMWE0N2Y3YmJkNjQ5ZTJkNzZiOTY1Zi90YWJsZXJhbmdlOmI0NzUyNmMwZDExYTQ3ZjdiYmQ2NDllMmQ3NmI5NjVmXzEyLTctMS0xLTQ2NTM4_8bf0b906-d977-4fe4-9606-70748382c4f7"
      unitRef="usd">20055000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic9274bc3d5034d649742d7cf95cad4c7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzc4OA_7d797b5e-8897-46c0-9b9f-5dc2e31216c1"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i44284afec0974ca383f35189fcf5836c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzc5NQ_d2015589-22fb-49cf-93d9-cdc9d07ff402"
      unitRef="usd">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzk1Ng_6a6d20dc-30ae-41b8-a3f5-d22b290d375c"
      unitRef="usdPerShare">44.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzk2Mw_75cb81fb-c83c-4235-a5f7-b3f41b6a4294"
      unitRef="usdPerShare">43.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ib074476f73164a7380886e3036b586df_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzk5MQ_bcbfc5c1-4063-4240-9e3b-04805c73ab4c"
      unitRef="usd">104400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iae2d691354374a8292be807107fe9093_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxNzE4Mw_393821d1-a9fd-4983-8441-a4905c0451b4">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjE_f0b34634-a2f9-4e2a-bcab-a50caf87bec0">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the&#160;consolidated&#160;statements&#160;of operations for the years ended December&#160;31, 2022, 2021, and 2020&#160;as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the following stock-based compensation expense related to RSAs within general and administrative expenses in the accompanying consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idae3c74e3eaa49338980a2180ec9032f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzItMS0xLTEtNDY1Mzg_72cc15d4-499f-4574-83d8-19d783f45462"
      unitRef="usd">7897000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2c0073addc8943b48ff41400a0b94650_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzItMy0xLTEtNDY1Mzg_ba481c43-ed06-48a8-8a5d-e050146f84a3"
      unitRef="usd">3434000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34ce9bbd561d4f208adfe62e207934e6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzItNS0xLTEtNDg3MDA_11a54d3f-dc6d-43c8-8094-c859f93335cf"
      unitRef="usd">994000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80f3a841eea6448987a04b6c2d676f22_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzMtMS0xLTEtNDY1Mzg_9f1d2fc2-0f9d-48ee-8d62-a7408a691f3a"
      unitRef="usd">23551000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0747f5930bf4422fab3034a04de464a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzMtMy0xLTEtNDY1Mzg_1de7b2d5-5148-41c0-ad2f-6a8f6a7f6024"
      unitRef="usd">10235000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec828eaae79146849fd3782a3949449d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzMtNS0xLTEtNDg3MDA_e8ac3ebc-5f52-49ad-869c-03ddf6aaf729"
      unitRef="usd">2278000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzQtMS0xLTEtNDY1Mzg_05ece547-5a53-4074-9cca-010f9765a353"
      unitRef="usd">31448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzQtMy0xLTEtNDY1Mzg_4f252415-f9f9-4d93-a0b5-6310af75a7f8"
      unitRef="usd">13669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTo1OTAzNzhmZDk2OGU0YTdiODA1OTA2MjdmMzIwZGE4Ni90YWJsZXJhbmdlOjU5MDM3OGZkOTY4ZTRhN2I4MDU5MDYyN2YzMjBkYTg2XzQtNS0xLTEtNDg3MDA_2979da9b-b921-4f84-9009-137e8a336ffb"
      unitRef="usd">3272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE1Mjg_2dce690e-01f7-4716-8c63-354909ece340"
      unitRef="usd">551000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzE1MzU_3fcd19ce-c625-4432-88f0-23d504a64760"
      unitRef="usd">284000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzU0OTc1NTgxNzAzMQ_7d23414f-f99d-4c59-bb9f-79986f2296b9"
      unitRef="usd">34000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjQ_210aec09-5f87-42f1-b194-219855530513">The fair value of options granted was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the years ended December&#160;31, 2022, 2021, and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzItMS0xLTEtNDY1Mzg_8997c2c5-0b08-453e-b271-86097dd8b2cc"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzItMy0xLTEtNDY1Mzg_6aef4eef-1cc2-4645-a223-dbf8cd45e7d5"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzItNS0xLTEtNDg3OTM_1ac516e6-d8ec-4b82-9a4f-f43997aa365e"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzMtMS0xLTEtNDY1Mzg_378c63ef-d918-4991-a581-8a653c32673a">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzMtMy0xLTEtNDY1Mzg_adc11827-48d1-402f-8b3a-881bafdafadc">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzMtNS0xLTEtNDg3OTM_732e4adf-d294-4000-b329-170f1b6247ff">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzQtMS0xLTEtNDY1Mzg_0ac0c0a4-456c-4b12-8351-6121be8b8cb6"
      unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzQtMy0xLTEtNDY1Mzg_a10ee80e-44a9-4a39-97b6-2d8873f872e9"
      unitRef="number">0.0110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzQtNS0xLTEtNDg3OTM_72822ef1-c1c7-4bf4-af27-3512ed650c03"
      unitRef="number">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="idcdeed31d4564d29a353803d0d00dc6b_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzUtMS0xLTEtNDY1Mzg_5ee25126-493c-4073-9d5b-9d61a75309d6"
      unitRef="usdPerShare">64.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i34e51c635ee14313b6fb1c0daa7415bb_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzUtMy0xLTEtNDY1Mzg_5fc63db0-c9b9-48a6-87e5-48766dc6ab2a"
      unitRef="usdPerShare">66.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ic416c201f5284d9f943605c62536d8be_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzUtNS0xLTEtNDg3OTM_4076991c-b089-474b-b108-f6c49a8d1e79"
      unitRef="usdPerShare">47.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzYtMS0xLTEtNDY1Mzg_8782fb94-5e69-45b9-8dd6-05f99be6fe99"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzYtMy0xLTEtNDY1Mzg_45ac8675-085b-441c-bc59-035528d45d60"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzYtNS0xLTEtNDg3OTM_711b7cc6-c890-4c8f-992d-2bde28eb30ea"
      unitRef="number">0.1474</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib6afd13b46734de18b78209e7932208b_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzctMS0xLTEtNTk0MzA_886b7398-eb37-480f-9434-8316587c1528"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0ef58c03f35f49538f292e54ffd0d402_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzctMy0xLTEtNTk0MzA_7dac2f9b-fbe1-44aa-8f21-b5b94c5a1c48"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i69af799c800a4519a24465b3e66df634_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkZTRlNmMyMjgzNDc0MjU1YjIzNGZmZWNkOGM2ZGMzNS90YWJsZXJhbmdlOmRlNGU2YzIyODM0NzQyNTViMjM0ZmZlY2Q4YzZkYzM1XzctNS0xLTEtNTk0MzA_a30bb3db-8647-4623-84d1-84a4adefd7b5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjU_e70dfd47-6a24-4e14-9c5d-5166a9c44b3d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIwNDk_789c9425-76fe-413f-9011-b60b2f551755"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIwNTY_8f84b127-adf7-4839-8f40-055f7e3cf133"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NjY_036012df-cc7d-4a79-8d37-8570001ad25b">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSA activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i64502038e5f64b25854ef8736435d9a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzEtMS0xLTEtNDY1Mzg_c68a1aba-1db8-4ac1-bc24-1b93fa43ea0d"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i64502038e5f64b25854ef8736435d9a6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzEtMy0xLTEtNDY1Mzg_5a429553-3e92-4066-908b-b75f20d37cdb"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzItMS0xLTEtNDY1Mzg_dd34d431-c26b-4187-ac88-eaaed7cfb7e4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzItMy0xLTEtNDY1Mzg_26805550-5505-4bf4-8b60-870ce0d0534e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzMtMS0xLTEtNDY1Mzg_7450f91a-2d5e-4b06-a14a-93c7b054c04b"
      unitRef="shares">14321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzMtMy0xLTEtNDY1Mzg_e82933ff-93b0-4a23-a993-73493905b826"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzQtMS0xLTEtNDY1Mzg_ef594c44-4c80-478a-af89-7c5cc91ce6be"
      unitRef="shares">17879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzQtMy0xLTEtNDY1Mzg_9713ac0f-05bc-4864-9146-943ba6987b46"
      unitRef="usdPerShare">78.89</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0d98e41008f24785ad933f9a46c178e8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzUtMS0xLTEtNDY1Mzg_eae25a7c-1295-41c9-a8d2-9aed74f36c54"
      unitRef="shares">66600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0d98e41008f24785ad933f9a46c178e8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpkY2EyYzQ5ODUwZTE0ZDI0YjlkYWY4NzdmYzkxZWZiNy90YWJsZXJhbmdlOmRjYTJjNDk4NTBlMTRkMjRiOWRhZjg3N2ZjOTFlZmI3XzUtMy0xLTEtNDY1Mzg_44cc30e2-d6fa-4e2c-b4f3-b5dd92435916"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0d98e41008f24785ad933f9a46c178e8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIyMDg_ab0fbb0f-5737-4af2-9c67-fe92ae927316"
      unitRef="usd">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzIzNTc_0e371199-6e5e-4c37-92a3-378a9adb648d">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic06852b1b5d247e4803f084678fb20d7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzItMS0xLTEtNDY1Mzg_6b410142-73af-4e7d-97c2-60c27d01b217"
      unitRef="usd">1782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc8ab265e2b84543a478bdf30eed184f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzItMy0xLTEtNDg5MzI_c23d2ab1-7146-4dc2-a1a5-0e87f138c29e"
      unitRef="usd">1650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib231c197185e448c8293b564b7342929_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzItNS0xLTEtNDg5MzI_3ccd2fe6-4188-40ae-a510-3abfa9c194f3"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzMtMS0xLTEtNDY1Mzg_ec0399b5-ef0e-428f-8f3f-eea44b672268"
      unitRef="usd">1782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia821fff3f49443948ae96fbcf013b0d4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzMtMy0xLTEtNTI1OTQ_0d6ce3e9-5cee-4249-af5c-23dc443f7d54"
      unitRef="usd">1650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85ab137db9d24527ad70578422157edc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90YWJsZTpjNDgyZDA3M2YxMWQ0NzU5YmMxNDJlNGQ5YTAzZDVjNy90YWJsZXJhbmdlOmM0ODJkMDczZjExZDQ3NTliYzE0MmU0ZDlhMDNkNWM3XzMtNS0xLTEtNTI1OTE_1408fde6-9c45-4e95-8994-0913789ed8bf"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1eb9664479bc48ffb663071fe28743f9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI2OTk_951ab5bf-83e8-45c6-bd9c-b7135498c101"
      unitRef="shares">469616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6cc6d3fd9adf476d8c19b91e06ad9df9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzMvZnJhZzpiYmM4NGFmZjUyODA0N2YyYTczMDE2ZjA0YTI0ZDlhMi90ZXh0cmVnaW9uOmJiYzg0YWZmNTI4MDQ3ZjJhNzMwMTZmMDRhMjRkOWEyXzI3NTA_97d623c7-a888-453c-9c05-490c672e2941"
      unitRef="shares">5581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODI_c0d8d3e5-eee7-414e-910a-1f04466f2900">Income Taxes&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record a current or deferred income tax expense or benefit for the years ended December&#160;31, 2022 and 2021 due to the valuation allowance position. A reconciliation of income tax (benefit) expense computed at the statutory federal and state income tax rate for the year to income tax (benefit) expense as reflected in our financial statements for years ended December&#160;31, 2022, 2021 and 2020 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized loss on marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#x2019;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company had federal research and development credit carryforwards of approximately $2.0 million and $2.4 million, respectively. The federal tax credit carryforwards will begin to expire in 2039 if not utilized. As of December&#160;31, 2022 and 2021, the Company also had orphan drug tax credit carryforwards of approximately $4.4 million and $910 thousand, respectively. The orphan drug tax credit carryforwards will begin to expire in 2038 if not utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company had state research and development credit carryforwards of approximately $457 thousand and $321 thousand, respectively. The state tax credit carryforwards will begin to expire in 2032 if not utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had cumulative U.S. federal NOL carryforwards of approximately $177.7 million. Of this amount, $5.0 million is available to offset future income tax liabilities and will expire in 2037, the remaining $172.7 million is available indefinitely to offset future income tax liabilities with no expiration period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had cumulative U.S. state NOL carryforwards of approximately $186.0 million. The state NOLs are available to offset future state income tax liabilities and will begin to expire in 2037.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of the Internal Revenue Code, the NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Internal Revenue Code Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No deferred tax assets have been recognized on our consolidated balance sheets related to these NOLs, as they are fully offset by a valuation allowance. If we have previously had, or have in the future, one or more Section 382 &#x201c;ownership changes,&#x201d; including in connection with our initial public offering or another offering, or if we do not generate sufficient taxable income, we may not be able to utilize a material portion of our NOLs, even if we achieve profitability.&lt;/span&gt;&lt;/div&gt;The Company files income tax returns in the United States at the federal and state level and in foreign jurisdictions in which the Company conducts business activities. The federal and state income tax returns are subject to tax examinations for the tax year ended December 31, 2019, 2020 and 2021. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. Additionally, the Company is subject to tax examinations by taxing authorities in foreign jurisdictions where it has business operations. At this time, the Company is not undergoing examination by the Internal Revenue Service or any foreign taxing authorities.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_186e7fbe-cd00-4f8b-a314-a89ed46d2e2f"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_27063663-157a-475e-91f4-58a3ebae7577"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_9ca9824a-74e2-4141-bcfa-f493d96737c7"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI4_b9c106af-11ef-417d-854d-ba3efda01a52"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODM_fed6dd5c-038a-4625-ad7a-bf643a3b25a3">A reconciliation of income tax (benefit) expense computed at the statutory federal and state income tax rate for the year to income tax (benefit) expense as reflected in our financial statements for years ended December&#160;31, 2022, 2021 and 2020 are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzItMS0xLTEtNDY1Mzg_542e5ad6-26c1-40ee-afe2-ba409394e0d8"
      unitRef="usd">-29395000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzItMy0xLTEtNDY1Mzg_062fe08f-2fb1-45f1-abfa-1b6776287511"
      unitRef="usd">-14578000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzMtNS0xLTEtNDkxMzY_621292a9-5a55-4727-9bb9-f1765d1fb9a2"
      unitRef="usd">-6752000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzMtMS0xLTEtNDY1Mzg_57cd0311-b0da-4bda-b948-dc8c71229265"
      unitRef="usd">39781000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzMtMy0xLTEtNDY1Mzg_b089aba8-2351-4df7-a853-5922e7aa12e9"
      unitRef="usd">20689000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzQtNS0xLTEtNDkxMzY_9aea6f77-9f60-4b69-9575-a831b376c024"
      unitRef="usd">11112000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzQtMS0xLTEtNDY1Mzg_3afbfc64-bd52-484e-89b4-9cb49e6b698a"
      unitRef="usd">-10438000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzQtMy0xLTEtNDY1Mzg_1c1e2bc0-234a-4b36-867c-da2b773096b0"
      unitRef="usd">-5436000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzUtNS0xLTEtNDkxMzY_158dfe2b-8d35-45a4-9dca-1dc984c4e560"
      unitRef="usd">-2632000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzUtMS0xLTEtNDY1Mzg_4900087d-4c02-4f17-997b-751187e73294"
      unitRef="usd">1736000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzUtMy0xLTEtNDY1Mzg_a9c93050-aac4-491c-af8d-81f18c11bf77"
      unitRef="usd">1295000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzYtNS0xLTEtNDkxMzY_15cf2a64-8cfd-4b09-9b6c-fbe9d93f8877"
      unitRef="usd">887000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzYtMS0xLTEtNDY1Mzg_fa52d01a-3d03-445e-9879-8950b565f15b"
      unitRef="usd">2182000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzYtMy0xLTEtNDY1Mzg_59f2a855-6dc0-4772-a9cc-4d1f79c23700"
      unitRef="usd">675000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzctNS0xLTEtNDkxMzY_ac931041-836b-4882-aeb5-14dc0cd76395"
      unitRef="usd">-216000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzctMS0xLTEtNDY1Mzg_ba74a07c-f517-4050-86b3-c71d771310bf"
      unitRef="usd">-394000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzctMy0xLTEtNDY1Mzg_f7df4f1e-ee77-49a8-a397-6dc4e24c7413"
      unitRef="usd">-55000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzgtNS0xLTEtNDkxMzY_132aa770-b92c-4a8f-aece-cab9050043b7"
      unitRef="usd">-625000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzgtMS0xLTEtNDY1Mzg_7abaab61-e36a-43b1-ac89-98d88c692af5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9c13f7e9c7e4dcf9144135ad4952e09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzgtMy0xLTEtNDY1Mzg_c2acf143-309a-48da-8033-4ffca8494a09"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iad46c4fdaa7e431f9d50faef585d3c41_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTpjY2ZjYjI0YWQ4ODM0MTIwYTdlZDUyNjgzZGNhOGJmNC90YWJsZXJhbmdlOmNjZmNiMjRhZDg4MzQxMjBhN2VkNTI2ODNkY2E4YmY0XzktNS0xLTEtNDkxMzY_94babbe6-0033-494d-854a-63d2e81b3a2a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODQ_db262569-509e-499a-8194-fd2c2905924e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized loss on marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzMtMS0xLTEtNDY1Mzg_ed986e65-a30e-4362-ae8d-ca162fc10e21"
      unitRef="usd">52569000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzMtMy0xLTEtNDY1Mzg_23791cc4-342c-47f3-9039-86dc86bbd028"
      unitRef="usd">33170000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzQtMS0xLTEtNDY1Mzg_c94f9c79-da3b-4015-863b-dfee177f36b5"
      unitRef="usd">7445000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzQtMy0xLTEtNDY1Mzg_bc214c57-82b9-45a8-8472-9212499a7fce"
      unitRef="usd">3906000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <krys:DeferredTaxAssetsLeaseLiability
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzYtMS0xLTEtNDY1Mzg_cc038048-3258-46de-bed8-bad919ee4236"
      unitRef="usd">2572000</krys:DeferredTaxAssetsLeaseLiability>
    <krys:DeferredTaxAssetsLeaseLiability
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzYtMy0xLTEtNDY1Mzg_0a74ea3c-64cb-4adf-93fc-48191b2b0325"
      unitRef="usd">2344000</krys:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzctMS0xLTEtNDY1Mzg_28cecf0c-9ec9-4608-8b05-a214a36fb3c1"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzctMy0xLTEtNDY1Mzg_78ec0bac-76fb-4a11-894e-e5db67211c50"
      unitRef="usd">679000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzgtMS0xLTEtNDY1Mzg_87704a9d-ce5b-4dfc-bc73-f434a351768e"
      unitRef="usd">2206000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzgtMy0xLTEtNDY1Mzg_c078ec1b-8e6c-4dc3-b310-5a3d6e4eb439"
      unitRef="usd">817000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzktMS0xLTEtNDY1Mzg_9c8b9dfe-2e7d-4b62-ad4a-4108af886e8e"
      unitRef="usd">14124000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzktMy0xLTEtNDY1Mzg_38f1d301-718c-4cc7-8a7c-92018f6e6f4f"
      unitRef="usd">884000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEwLTEtMS0xLTQ2NTM4_38ab9950-2ebb-46d4-be28-875ce2442db0"
      unitRef="usd">6708000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEwLTMtMS0xLTQ2NTM4_f1901f88-3e28-47c2-97e0-3d503d9b086d"
      unitRef="usd">3607000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTEtMS0xLTY0NTU2_cb38ddf2-5058-49ba-9402-385c7b49d9f5"
      unitRef="usd">192000</us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTMtMS0xLTY0NTU2_87f48cbb-4d60-4116-acff-92761fd9793c"
      unitRef="usd">49000</us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTEtMS0xLTQ2NTM4_2a230c9c-b5b5-4845-9fc7-d7a6c00dc60d"
      unitRef="usd">85816000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzExLTMtMS0xLTQ2NTM4_5206ea5f-5f86-4807-b3c5-ec9fe9b489ab"
      unitRef="usd">45456000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEyLTEtMS0xLTQ2NTM4_7de31dd7-aa99-41f5-9b3a-2da02aad6f8d"
      unitRef="usd">82513000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEyLTMtMS0xLTQ2NTM4_99c1ecd3-0ab1-45c2-a4a2-81a8a5d7016a"
      unitRef="usd">42732000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEzLTEtMS0xLTQ2NTM4_6f41b305-ceb3-4aed-8c74-5fcdc6c2614b"
      unitRef="usd">3303000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzEzLTMtMS0xLTQ2NTM4_936f935e-526f-4a1d-8646-548c2fd23fb3"
      unitRef="usd">2724000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE1LTEtMS0xLTQ2NTM4_506469f8-1c4e-4f65-9071-c64b43f449fe"
      unitRef="usd">137000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE1LTMtMS0xLTQ2NTM4_ad63eaf7-28c4-4cf5-aca6-944d919c5130"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <krys:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE2LTEtMS0xLTQ2NTM4_b7592759-93fb-4c67-b4cf-719f7cb64115"
      unitRef="usd">2312000</krys:DeferredTaxLiabilitiesRightOfUseAsset>
    <krys:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE2LTMtMS0xLTQ2NTM4_3a5a83de-7cf1-4c0a-9aee-7f3836aea54e"
      unitRef="usd">2111000</krys:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE3LTEtMS0xLTQ2NTM4_ee9efafd-7ef0-4810-b330-31d0c4ea0f9c"
      unitRef="usd">854000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE3LTMtMS0xLTQ2NTM4_b0be5418-2089-4b99-941a-c52ada6dd6cd"
      unitRef="usd">613000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE5LTEtMS0xLTQ2NTM4_53ac5cff-ea0c-4da8-b16c-f075dfc8dd3d"
      unitRef="usd">3303000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzE5LTMtMS0xLTQ2NTM4_861b1ac3-eb50-4543-91d1-edfcb9a23f71"
      unitRef="usd">2724000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i49c0637d46d649d4bacab028175efbaa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzIwLTEtMS0xLTQ2NTM4_3a98241c-da86-4629-aa80-032bc417aa13"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ic5d56c1a54244984a5f923ac922fdede_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90YWJsZTo3MzE3OWFjYTVjNDI0MGFmOWEyZTk2ZjQ0MDgxNWM3Yy90YWJsZXJhbmdlOjczMTc5YWNhNWM0MjQwYWY5YTJlOTZmNDQwODE1YzdjXzIwLTMtMS0xLTQ2NTM4_ae7ba598-054b-4ad7-94bd-6bc7a21cc226"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id57562bb09e14b62821f7c7ee59bc9d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTMyNA_3410859e-278f-4ebc-b7d0-733d6525f74c"
      unitRef="usd">2000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i880d88ff54e545f6b66cbd9fa91d7c0f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTMzMw_f94d5c83-ae50-4e96-b4a3-0ccdae85bb89"
      unitRef="usd">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic1e042df24d94919831c05275e22f61c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM0MA_984598a4-136a-44de-9b42-6d3189580b95"
      unitRef="usd">4400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i4c4cd79ab6b4405a9b60c9b5803d3e47_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM0OQ_edce8db2-bf7e-4af2-89d5-fd5a1f208f3d"
      unitRef="usd">910000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="iba614e370fda465e9bd79ec170d9f9b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM1Ng_b3b10aa2-ed72-4b64-b79f-bb28e5c3b55b"
      unitRef="usd">457000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i299015c71eda4062b0883fb132997c3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzU0OTc1NTgxOTM2NQ_32a0472c-75fa-419f-98a1-7b0b29e78a10"
      unitRef="usd">321000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzE4NjU_69d38031-b9eb-41f2-9cd3-250acf0ecf20"
      unitRef="usd">177700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzE4ODU_eed992d8-bb1e-4b1c-b632-3fd20bd73bb8"
      unitRef="usd">5000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i1a14c340844e4e62a771c87b9aa3f4c9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzE5Nzg_4d73d86f-a25d-4e5f-b9b4-3f9759c00cd6"
      unitRef="usd">172700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i326eceb3ac84481fb3a1888cdd980f89_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzIxNTc_df857c58-1a66-4bca-84fc-9f3f67d6f357"
      unitRef="usd">186000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <krys:OwnershipInterestRateChangeOverPeriod
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzM4ODU_6a472a34-5228-4993-a3f5-b3774f84cc8b">P3Y</krys:OwnershipInterestRateChangeOverPeriod>
    <krys:CumulativeChangesInOwnershipInterestOfShareholders
      contextRef="idf96a3872b434ff2ba6fae61cdb19b56_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMzYvZnJhZzo1MmM2NTJkYWViNTM0YWRmODc4YWFiZjAwZmIyNjk5ZC90ZXh0cmVnaW9uOjUyYzY1MmRhZWI1MzRhZGY4NzhhYWJmMDBmYjI2OTlkXzI2Mzk_b6afba04-2dbf-4ba6-8677-d57d673218ec"
      unitRef="number">0.50</krys:CumulativeChangesInOwnershipInterestOfShareholders>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xNDIvZnJhZzoxMjVjZGRiMmEwN2M0MjI0YjVjMWM4NzdjNjc5OTgxMy90ZXh0cmVnaW9uOjEyNWNkZGIyYTA3YzQyMjRiNWMxYzg3N2M2Nzk5ODEzXzQxNw_b0b3932f-e369-4c23-aa8c-f7a8cb77d8c8">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the consolidated financial statements.</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTExLTEtMS00Njk1NA_73410a37-24a9-4291-95c4-de61f9230b56"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTExLTEtMS00Njk1NA_73410a37-24a9-4291-95c4-de61f9230b56"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtMTEtMS0xLTQ2NTM4_92072b1d-a959-4fb6-8610-776ba755c68f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtMTEtMS0xLTQ2NTM4_92072b1d-a959-4fb6-8610-776ba755c68f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtNy0xLTEtNDY1Mzg_a9cf32ce-a28e-49ee-980b-703d4bd72274"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtNy0xLTEtNDY1Mzg_a9cf32ce-a28e-49ee-980b-703d4bd72274"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTctMS0xLTQ2OTU0_eb74d109-be99-4c24-bab6-7e03aa46ecd8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTctMS0xLTQ2OTU0_eb74d109-be99-4c24-bab6-7e03aa46ecd8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY1Mzg_66d153e5-c44b-4b13-957b-71394af8d915"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY1Mzg_66d153e5-c44b-4b13-957b-71394af8d915"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2NTM4_d176a3eb-bacc-4ff4-ab00-5834e3bec456"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2NTM4_d176a3eb-bacc-4ff4-ab00-5834e3bec456"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes foreign currency translation loss of $78 thousand, gain of $7 thousand, and loss of $1 thousand for the years ended December&#160;31, 2022, 2021, and 2020, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTExLTEtMS00Njk1NA_73410a37-24a9-4291-95c4-de61f9230b56"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtMTEtMS0xLTQ2NTM4_92072b1d-a959-4fb6-8610-776ba755c68f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzUtNy0xLTEtNDY1Mzg_a9cf32ce-a28e-49ee-980b-703d4bd72274"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzEwLTctMS0xLTQ2OTU0_eb74d109-be99-4c24-bab6-7e03aa46ecd8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctNy0xLTEtNDY1Mzg_66d153e5-c44b-4b13-957b-71394af8d915"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90YWJsZTo3Y2E4YzE4ZjcwMGM0ODlmYjdjNWM0MTc3OTkyYTljMS90YWJsZXJhbmdlOjdjYThjMThmNzAwYzQ4OWZiN2M1YzQxNzc5OTJhOWMxXzctMTEtMS0xLTQ2NTM4_d176a3eb-bacc-4ff4-ab00-5834e3bec456"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmY1MGZkZjFhNDY5YTQxMDRiYmU2ZjRjMjE2Y2ZmMjc3L3NlYzpmNTBmZGYxYTQ2OWE0MTA0YmJlNmY0YzIxNmNmZjI3N18xMDMvZnJhZzo4MzI1Mjc1ZWJiZjc0ZjAwOWY0ODgyZWY2MWY4MWNhMi90ZXh0cmVnaW9uOjgzMjUyNzVlYmJmNzRmMDA5ZjQ4ODJlZjYxZjgxY2EyXzIxOTkwMjMyNTYyNTg_c02b12cf-5e2b-42e9-8230-d31c9bce77c4"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^3Q*\W_1ICBWUVLA/TLECW?%< 4Q2XJ_Y'4'XJA@X)PHP+L"_*; /?4-WJ[
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M4Z':CMY.C*R:IKB4!EML,RSP$@1E _#]2DJSF]@^VU^KZ1]02P,$%     @
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MAA,_9^)\3F?+9W)V$3_JGDH"=W ZO"T4H%]ETHTPX4Q-.*]( =9U6CL\'\J
ML78"M:AH'+4FA44T\9A]2M"S*H<^#:E>J%8(^J,\LK!(< 7$K,TPY.F2@)T(
MV"#!'[AIR'"=6GO.+-WRXKB]XA8V81@'43M?VG0>HV'40W$J8^C@-W_VI<#=
M3);^B\6FAB%ZJW#@:<;O,[C&;<^UY!G@1V&U+_$; ?(T!2W<;W[0V%_T;VNT
MO"Y<$'9"95'1,&X'RJ+R>X)TJESH<.ER66GW#GJWTL"YZ 9^9]):A&$<>1T6
MBPX'/:(]/*?BA0Y7+\>I2_#C0C"/Y/J[O^4E3/4>+UV1E[AYV,O$O#<OK.FZ
M;B6^&+>Q'[=Q+3)O3+TVK45&Q[VPI]*&#M<V [!)FNWU-NN)N.'3<"TR&ZY%
M-H![JH/H<"'TU>S$(;GF!ZP<-G"!C.M[KZ3"-8PU4CW85M1N5<,"/Z91]Q-B
M43(L0"9^V :VE%V3:!+1L(_Y5"W1X7+I_S#78VZE[M8_?=0690]U5_D#:EU6
M76ZP3W4"&ZX3,+]BF97M$X3&W(U1*0@F[A**U2/!_4DALZK(KU+]FKR()D35
MAP179,-Q'9BG9P]UOF_DM'FA_>,-D$?<U$D"^I" X"8;\GLHJ]+GN->OMNR5
M)[W[OB(X*#LP!U+9X]A6(3EGYR<YE!MS<"5Q6/>%JG:<S=/F<.R-.1)J/9_3
MZ9):GK^F\72!H;:\8>YT49VS.:>FJU.Z][S<I(4D&:RQ&^XXPI155@=?U8T2
M.W.R<R^4$KFYW )/H-0"?+\60AUO= /-\>/L/U!+ P04    " #).5M6@JJ"
M=/$'  !K/   &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+U;VW+;-A#]
M%8R::9N9*"( 7L34]DQBBVP>VF;BI'W(](&A((D37A22LN-^?<%+2 &$(#+>
MY,46*>Q9< ]QV:/%Q7V6?RIVC)7H2Q*GQ>5L5Y;[%XM%$>Y8$A3/LSU+^3>;
M+$^"DE_FVT6QSUFPKHV2>$$,PUXD093.KB[J>V_RJXOL4,91RM[DJ#@D29 _
MO&)Q=G\YP[.O-]Y&VUU9W5A<7>R#+;MEY?O]FYQ?+3J4=92PM(BR%.5L<SE[
MB5_XU*H,ZA9_1^R^./J,JD?YF&6?JHO7Z\N94?6(Q2PL*XB _[MCURR.*R3>
MC\\MZ*SS61D>?_Z*[M4/SQ_F8U"PZRS^)UJ7N\O9<H;6;!,<XO)M=O\[:Q^H
M[F"8Q47]%]VW;8T9"@]%F26M,>]!$J7-_^!+&X@C TQ/&)#6@(PUH*T!'6M@
MM@:F9$"<$P96:V!)!J9]PL!N#6S9PZDH.:V!4Y/51+>FYB8H@ZN+/+M'>=6:
MHU4?:GYK:\Y(E%:OXFV9\V\C;E=>76=ID<71.BC9&MV6_!]_S\H"91M^E86?
M=EF\9GGQ"UI]/D3E YJC][<WZ-<G3]$3%*7HW2X[%$&Z+BX6)>]-A;D(6\_7
MC6=RPO.[K QBA=F-WNPZ2Y(L_?DG;!N_U3U40*ST$"_7ZZ@:!T&,W@31>LZ?
MXSK81^KN>&>PPO"0'.(Z?'^5.Y8CWD$^*>RJT7K'T.LTS!*&?HVSHGBJ@/?'
MP]^P311&I0BRX'QWI)..=%*CFB=07[%ME*91NN6C. [2D/>/QZ#8!3DKGJ*@
MY*["YXCB9X@8V%51J\6OIL\7Q3X(V>6,AZ)@^1V;7364J0AOP.P:K)HZ[ZZP
M0RV38N-B<7=,*Z17#Q+,!P(3V*0=FW0BFV,8;#"=HZ 3@[C8%$-^,VPFDZ(
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M$YDQ'BH/<VR[,K.@8@<HFC?J"7PHGR*QO>"!];J$+DG&B@3?=BW'D$D E2A
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MPPZB FQ@;P-7KL)L#PR2AGTD*#+(%<:SK@URPHU0!,!'%1S^$XBS --\_NP
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MP'MTV24TKH+_O00MX6QF(2!!\C4?'/AXM(RX#XF5MI@63(QTX&@/3:A]Q?0
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MHQTC>*C6X)1U#%^C[^ F]W0F@?H8LDY7@Q<9[(\9@*\ PAR&!30[.)E*[?=
MP&>:__O0;/@Y;VY(:"RT N^^A2]M&A:1165QBDLH[-0ALB#!OL .=3LT0.K;
M2G_:XR% 7@T>%L@+9DFT &6]5=V&WO+D^>&R239HT9UML:;E/[VW0(GV8:DA
MY'/J1*)DY,S H<WNMYH!!V( '!BW4'7=-9Z)FJ"$U*U8DI+VW;'@KX=^P#IY
M1=0Q'$"T#Y3"PAYZ3C0Y& U1494CW&B#/20*!HS%!K&4!^JK-F>X\*^"H/$7
M\42$59#+(!"["1,EUL&C(/(B)6L<XIE.S$E\DZ"8.WF9:?54P-:V11!'Y%3T
M:L%9T+'^>$X!4E.1ZH![0@TB9N?U@E3*#7@:OL#KO*<RKKI3[2"$3=)J.GCA
M@<55%N(LQ\CBX<HZ)X X)@XL50N =-4:M2(9,9'1]";M+K H@I^L>X!\1 V!
MG';B@8C 5:\^59"*>FB#R;W5H@ZTZ3^TW3BUW[+<O.TD-*;]?Q9!!EQ>E@L-
ML3F$G32826,[?@)TP2I-O@>N L"K%=@+T33U%N^S*N-=XX%W3Q"/YT =U9TR
M+;..L-<CCJN#F+FMT<EH Z!&UX8C:3*C;D'&/7YUCJ]HR<;98;\0Q:D-L;7:
M(D*!$A#=:H(&>F '%[TC5D+M(.KLB;5C $%=T8C@=1(;IE[H80BK.PKIY]X;
M'5&F!94!19-1 6 @<K9W8,<B4-=XWCFM!RLR6T&[@D\(&T@2S9^,W58!MUH/
M/3,=*MX,-5G2&PN$NSY"A)UN($:FKWXQ_B-O]?-Z??Y:@HKJEA,M?O1F3M1%
M07/KX(?5[]&E18I2M""'.-J)_0GTGYRN\ML%_UN1$X54)(]FNCLH>;#_[^>B
M @KP#DP;&U8S53]O3Z+Y#D0_@"'N(Y!<#["->,\Z^&&2G94-7T3*5GNU)U'<
MV#OM.M$N1'N P6N$/ZS%8OJ5HW E.)N5ZCZ"71RFQ% PH,2?H4[*\;LAE%(;
MIX-K=[H5@0B/IC3($<K(6IHETP^)V5MD?9$9<+ =:4TI_J G+)[U(<K+^!9,
M#P2OZT4$.9F,&GSBT "Y_M0SP4)P@VC0.K)G=B;*"2%MQ6FBF"1#ACEX*=I_
M(-M'4>U$.A!1>HI_V&H[ ^Z0'</W 9'6D@&@[?P Q8KL8+8U5LN[*\3+P!+2
M-*$&;90''3EU!!&*8(;D9$N@YKV%A 062E>@'39=,\106Q9J^K?Z82+4;S,9
MX 5L#Z;BGTG'L=CS*[F<AA-+!2H]@]\B7#V'].X6+%70_=9@>:EE@IPS&T/!
M$MQ!U!/ \9\75:,.OF)O2*&56 V2 8XY8+A!.+TL,.0-RWWX91@B,:('K1S#
MFJ<;.;@%?)\C?FQ>1Y-U9 ^.3 :]\9"1>!0C&  *TQ]%JK7=YM^#4X'!9R!P
M'8(C3D7)\I*7SZTK-FF]_2PF8#< /3B*+0SK>GQ444J$*,Y8VC#F(;17$4T@
MYN/D+*2@H\.%_TPD.U!44,"HLJCD'/N<>TAZB>5#CX4?RCE&KL\BPX7P=.C
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MLJD@ ]*PBK6:8>7-=NIW'!-Y%0H1NB=13MRIU=[TDD@MJP](>"CVWULH]B(
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M.:\Z225[4O2";,+![!A*)9O?!\]+1XTSS!".[;CD&YBZK&Y"O)=]*<8AJ&\
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M7'UBRX[DRW7Y^- D]J2V,L=IJLM,TP.#1P5-\@&=L9^F^H -ESX@9'&H+J]
MSI*T).0R&RZ2)]'1AHPHL(DCMC(=DIAMEA&_0DP8S(>VC..%$J3BK]%,C?*2
MM#8 '/([SE(G]8.<Y-S4)+KOE/ UG^V5@90TP0])AQVDC%' #34,$@;D3>21
M68?(*-[KEHKU,GT>^^')8SS6R26S+&!DHV7TH$.0DKB9S7'1IK9DC[1#*]+!
M-EN^K-Z,.SJ>Q M=:^D(]4P,KI5F!:CD:W-)I:3&V588FUQN+ VSP6%,8W@E
M$SND)$/1^\V2=BZ.WG?B#<:@*K-5Q88B$25#)3GWD@>.2WD>.H1VLJFD7HZR
M;\MC,UD]*!.K1YOO4(RNUL? &1FV:T'%121/S-9\EE-P_!HH7>2/PJ0=2T5,
M(T)02C50$825JC^&^+2JG>'0."6(Y;+T/$Q^C-QE+[W3D^PAYKM4.AIY(46F
M=E(#SO4P&OS3) NC[3KZ_^ %*FT8>6IT)F&F&,!(?4O6)9M7TC0(S&8PC8P
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M7<LONXW+Y??Q?E)N0\K2ZC5>O5@^_^I,IDSB'[W=\^^\K6S?VQU_I)Z+=K0
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MVUUKKIK3_&EX<R?ZR,U&X)J4L$9HW!OC+<(T]XSFP^G*G^TK[?"FX)L%7LW
MT #\O];:[3\H0'?96WP#4$L#!!0    ( ,DY6U9U8-[-I00  ,T+   9
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MY$O6UO:#VO[*^WHF#J]0M?&_L.U\XR2 HC56-7TP9M (V?VS;WT?C@+RZ)D
MV@=0GW>WD<_R-;-L=J/5%K3S1C2W\*7Z:$Q.2'<H<ZO1*C#.SMXPH>$SJUL.
M;Z6QNL6&6W,SMHCM/,9%CW/?X=!G< B%=TK:E8&?9<G+QP!C3&K(C.XSNZ=G
M$5_SX@IB$@*-*#V#%P^5QAXO_G&EKX4I:F5:S0W\>;? LI$<?YTJNH-,3D.Z
M"W-MUJS@MP'>",/UA@>S%S^1-'IU)N%D2#@YA_XOCN:_X'Q<<5BJ&B^ED!58
MMJBQ&6:%*5JT/*AFS>3NQ4\Y)=DK P4SJ]#_ O_:B@VK'08P60+;,%&[\)?X
MB7AIT *&%ZT65B#B8@=&5%(L1<&D!2$WW%B7 ()97BF] V9 +0&/FS<+KH<C
M]^"X0!%[N^;^^M8[N!024U2M0;L979\(O&N4MN)O7F(9QL(O6AG3_]Y5E>85
M[@R^*P^N(+>/7\Q7&/?2<MW .Z:_<-\4F!^*N20C^$W)ZJP/11^.F0*Y/N!_
MU[D+("D)IU&$*]]E^NK1ZF ]YS=O%U995@].>\/^?Z]_SMYE2J_=@3=<%P*Q
MUFR-W4SC,*4)3+"@>.2E*!W"GH@/2J^5=EU=*#P4R&E($P(DALN$3$>0DS"/
M)X-[EH64))#@!@0^7<VA4ANNI6<%/@2RV!TS*$O#-(]=!7 93S$75"03<D![
M+ XMH92&DR0'DDWA$K<?H0;SF-+!%:D=THSTB7ST41<0YTF88-R%C[SH8YT^
M#C.,/CZ1/<)%C_&4B^1_PL4X(7ABZ3-</%C/^0V-WSL]Y=I>_YS]>2XF49BD
M4T ")*-..$0_$;^C8AS&CO\1-HQ@-,ID>G"/)V&6YI!D84+S'W,QSOPQ[Z,O
M4VPPZB:3Z8%449B2%#D23I/X\06-IY@(%D'R:.05] AKFH;Y)((T">/L0,9)
M1,,T=@TGCF5=:*=.TNS1B?0 %WL(1Y"/)S[EYL"LYL":HR)QU,&7$3_5H"2'
M'6<:E 9\'LR59]0IT'I@XEG,!;=;SH^ '1_M5GD!X>><P^\*#X^"5>XA,AP*
M)8VJ18EG6L)22"8],XQ%A7_)\!E#H+(4;LQ#2XFO>VOZJ;%BNO0/W(FDE^[:
M;?S#V'#FQ@&/=W7J[1X?C5A(SLH/DO@NJE;:;MH:M,.L>M>-: ?W;M#%NUH)
MB3WC2PR-KK)) +H;'CO!JK4?V!;*XOCGERN<M[EV#FA?*FQ1+[@-A@E^]@]0
M2P,$%     @ R3E;5A,WS[P !   7@D  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&ULO59M;]LV$/XK!S4H$D"U)4J6Y=0QD*0I-B#=@F8O'X9]H.63
M350B59**D_WZ'2E9=C#'0+_LB\WC/??P7DG-MTI_,QM$"\]U)<U5L+&VN1R/
M3;'!FIN1:E"2IE2ZYI9$O1Z;1B-?>:.Z&K,HRL8U%S)8S/W>@U[,56LK(?%!
M@VGKFNN7&ZS4]BJ(@]W&5['>6+<Q7LP;OL9'M+\W#YJD\<"R$C5*(Y0$C>55
M<!U?WJ0.[P%_"-R:@S6X2)9*?7/"SZNK('(.886%=0R<_I[P%JO*$9$;WWO.
M8#C2&1ZN=^R??>P4RY(;O%75GV)E-U=!'L *2]Y6]JO:_H1]/!/'5ZC*^%_8
M=M@D"Z!HC55U;TP>U$)V__RYS\.!01Z]8<!Z ^;][@[R7G[BEB_F6FU!.S2Q
MN84/U5N3<T*ZHCQ:35I!=G9QPRLN"X1'WP&WJFZ41&G-?&R)W6'&1<]TTS&Q
M-YAB!E^4M!L#=W*%J]<$8W)K\(WM?+MA)QD_83&") Z!18R=X$N&6!//E_Q@
MK/#7]=)830WR][&P.]+T.*D;FDO3\ *O IH*@_H)@\7[=W$6?3SA<CJXG)YB
M_Z'RG&0Z[N>;&7G0-/;:O@"7*[C[WHJ&!M&&\ O!7NEPKY.D*Q2-J[&@2K ;
MA%)5-/5"KH$;MT<5Q7J)>JBJYZ %B>14@WY&JQ<X%Y((5&M(;RXN7QN^$F[I
M1*M;/^,?A/S0:+4F*@-G$),^26*WBM(P22.X1QK@C:I6(&H"/F'MHV5IR.(I
M3,(I2^!SJZ6PK4;O6RF>W=K ;#*%?!;[)+66#A\B]SBC2KOE9!1'$>03N.=+
MI;E5NDM3S65;4H.UVB5C;QK'83YE=/(DB> W97D%S='T0ISE83J=DD463K(9
M7!=%6[<5M[BB6XA*6@C>W7-DQFNEK?BGVSC/PNDLN8!S%V5Z<;)^E*HL#K,\
M=:N8A<ED0ND^8,=G>@X,PI8*>L9&&=U)546*$,[B4;Z3/#5M3(8->CY\1[P@
MUP;0W1#_[8:P;X6^*:+733%R,>N6#.\Z)XP'_DJT&FY;K5V:[@5?BDI80=H=
M' _ARL.+'EX=P/O>)8/_KWMW+KH,T\2*@AK D0["X#O5(TRRB?_/(G9@J4IJ
M=\HQH4LD9!(FLRFP,(KC/8J_:(K&<R]18BFH[:DO\IB >;ZG*P[&"2B,89RH
M4],)@QD=G@WH4DBZ/UR&_,GOW^4L9A^![1&6/Y,B32!/^DH=2SW+:+BF_0"<
M :,0(A]J%C**Y=A%.CYX\VK4:_^RNR*VTG;/W[ [?#Q<=V_F'MY]>7SA>BVD
M@0I+,HU&TTD NGO-.\&JQK^@2V7I/?;+#7T H78 TI=*V9W@#A@^J1;_ E!+
M P04    " #).5M6Q=]&.]T,  !D(P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6RM6EMSVS86_BL8U=M-9F194FPGS<4SCIWMMMU,/';2/NSL T1"
M$M8DP0*@9??7[W<.0)"4);?9]L7F!3@XE^]<J;<;8V_=6BDO[LNB<N]&:^_K
MUT='+ENK4KJ)J56%-TMC2^EQ:U='KK9*YKRI+([FT^GI42EU-3I[R\^N[-E;
MT_A"5^K*"M>4I;0/[U5A-N]&LU'[X%JOUIX>')V]K>5*W2C_I;ZRN#M*5')=
MJLII4PFKEN]&Y[/7[X]I/2_X6:N-ZUT+DF1AS"W=_)"_&TV)(56HS!,%B7]W
MZD(5!1$"&[]&FJ-T)&WL7[?4_\&R0Y:%=.K"%+_HW*_?C5Z-1*Z6LBG\M=G\
M4T5Y3HA>9@K'?\4FK#V9CT36.&_*N!D<E+H*_^5]U$-OPZOIG@WSN&'.?(>#
MF,M+Z>796VLVPM)J4*,+%I5W@SE=D5%NO,5;C7W^[,*4I?;0LG="5KFX,)77
MU4I5F5;N[9''$;3P*(ODW@=R\SWD9G/Q$1363GRH<I4/"1R!M\3@O&7P_?Q)
MBI<JFX@7L[&83^?S)^B]2 *_8'HO_A^!Q:5V66%<8Y7X]_G">0O4_&>7&L(A
MQ[L/(4]Z[6J9J7<CN(I3]DZ-SK[]9G8Z??.$",=)A..GJ'^]S?X$.7&C5Y5>
MZDQ6GM^01L*Z\Y55*FSK76ZT7Z>%XJ.LFB4N&@N*XI-=R4K_)LD?N[-XX36T
M)&VVWEKS>:VPIJQE]2! 7EDG=.6-N)-6FP8TNH-U)3Q65^2KA<A,8YT29BD6
MC8/ ;INS/0<^^_:;5_/Y],W%]2?'E[,WS\=_3)ZT]6.WE84TX,N".6US44OK
M2:T(IP+0R& ,Z+80MF7'^2;'@K%(K[S5L@CJ\LJ1:?BZ'+!"&-.9<A-6F=RV
M!UC"$87T2D![I*?A=NC)0;NZ4&*E<.1:>J$= LZ]R@,)71VNH7$%KDW>9'A\
MA\!J8!#I6"JB0827N@+3N6U6<:D7LJX+C1TP4::L1ZJ@Q;#0MI#,O1OP7\H'
M@3<&F[.BR56G*5)"KNZ05VI:&@*\]JP\Q$V+G#(&9]FM7$'$L2CD0A5\A9U'
MT'^KS<A+WQQ$N[TY=!ZD6F&BAEM00DEF4>@5-)N3:DMY"]U"C^"@PB;Y$,1H
M$ YM7WJ_)6@@2QR53,LJ2JG$7I;\DU2-K0B)JER 7!L6(_5MDL0<5&_-/=,L
M'L3!?#(C[@H =BA'4O."-5P#T'H!-!!.R:I1$#I>BI)"/,A%T(FE4A'0YK\
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ML+0 [Y?&^/:&#D@_K#G['U!+ P04    " #).5M6:V=[HJ0*  "9&P  &0
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MJ")IW'NT>3?:O?FZDB1S9V#>@N5%X:>X'9Q1=M7H0 VB'3&*%94%(E2P#86
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MRZ7@\ \1X/M<2M,^T ;=_R-<_0]02P,$%     @ R3E;5I-DPNU="   )Q8
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M2U6JE?8"!4!XB#PH:9U0%&^!:*GM4MECQ(0L<WJ(15Y!DN$5M[*H9,C! D5
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MXX;/9D'_JN_WS.+=H$53#N7OH"L#V*ON&V:AMX<&R5-*"X)D;PY,>QQ?PPI
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M0B3L&.@X./I[T28, )P[;2BW0#C"N4#5=A$X4RW-DN+*EFR[Z;LRGR:'!!6
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M_/*2_-&Y#?_:T=QUG5OS1RK"&D\#\'SA7)?^H 7R[U^]_C]02P,$%     @
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M [A(/@"D&T :='>!@LHKX<5T;$T+EKV)C1<AU8 F<5)S49;>DE42SD^773'
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M"[)HT+JG:<!9##%MP.#;Q1@*M4)=>U70CZ+.-X<*2I,@R2*7 72C(7&AB7C
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M2WV9'\ZI$4;M'&A]II3=&6Z#MK4>_0=02P,$%     @ R3E;5E?8=37J P
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MO@"72[C_WHF6NL2&\ O:4[3/ I^F_2H"'B)(.JY244<:ZXC8-4*E:FIL(5?
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MWYXTU\PM>7-9?\?EG.8W*'%&1STWH:E#-A?@YD6+I;UT3H6F*ZQ=+I"3NH:
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M9\,V&T638'QZGOK;?2D#<6$2C"=)'_<LRZ3/,GDURSG5Y3')S9? 0\.VE(-
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MGPFB;$G+B>*Y;0/G7.FFT@Z7NHT'81;HYPGG:C,Q&]1_#(S^ %!+ P04
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M9H(M1[5S;+LPLG:3W4H:G!/=;8FC/RAK@,_74IK7A7U!_V=B_B]02P,$%
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M=VP,PK)#&\V5FAX$12S>N(X\/*?<XTI-#Y[B'N^%UR0N4&CI#-9X6,\Z++W
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M.+FF=P?-2D.A=1_PV[#D]B:0B[U;PW6?6L>A>^1>0YGO>\=IUCYX?Z-?GGU
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M=V]R:W-H965T<R]S:&5E=#,U+GAM;*V6;6_3,!#'OXH5$ ()EJ<V34<;:>M
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M&[QI@;(&N%Y*:>XG]BSO[V[9'U!+ P04    " #).5M68ZT6'-<(   -70
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M'24AY;J NK]A3#Z?Z KJ_9SS_P!02P,$%     @ R3E;5D:L>^W] @  #0L
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M0!U2^B"1E0;#@F0;E*AO+,KQBSY5VL*-#L/Y@>7NA>N<OF<XV_IW4%J=\6Z
M\S&ZSN3^ !>M!Y]U$",(_/V_6/<T?6,TSGN[,\9"F68";7%2 *+K:G<2@I<D
M(>*E-9A]<#X$(W=_>]I&Z<_VM@EL-FH552C>8K8A&9<8:RFSSGWYT6-E[54V
M!,UU^;*D0A9#^C:6]2HP-4#VKRD5KPU5$=45</@74$L#!!0    ( ,DY6U:
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MFMQ ?;YB3#Z_R1NH'X59_ M02P,$%     @ R3E;5G<,6%:R!P  )D$  !D
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M0)^_S4)E'C4Y0W<)S=K,8:5T=;^0L  21H!@AA2CC12C(X^A(T@1(6$!)(P
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M%%"_/^6Y7'\I+K#YTPB3_P%02P,$%     @ R3E;5KAQ1,F/!0  H!P  !D
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M<FMS:&5E=',O<VAE970T-"YX;6S-6-]OVS80_E<(K1A:H(E^6K8SVT <=5N
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M1+HD96^^?8>4(M^T:F1?;/&8/^?'8S@<KH5\40L 37X4.5<C;Z'U\M;W5;J
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M4-^HQ!"C2 XSE RN>Y@9R.I-4A6T6-JT_EEH?"38SP6^XT":#M@^$T*_%<P
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M.HK\[">_D7R='9_<<REYG%V&0)6'T0W4^R7G\OE&)RA/X&;_ U!+ P04
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MC+N+<7 ;;1PVOUT0C_7_A%$ME[R ,U4T%4C;Q5&#\(#2K'EM$B)9!=-DINY
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MW_TWAJ8B11#>@[,0$[-0'ME"3YC^O2X; :V/FKH6[8IBB(E9*(]LH2?,=H/
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M]';4VY^I=\JG74RWGNL:CVZ>274^OQMOG[\LKS<1Y^$%YP!'K>^_4$L#!!0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( ,DY6U9"*WFW[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " #).5M62M._(G$%  #K%0  &
M    @('J$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MR3E;5J:L"4Z; @  8@<  !@              ("!D1@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,DY6U:E * T8P4  (H4   8
M          " @6(;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " #).5M6@JJ"=/$'  !K/   &               @('[(   >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ R3E;5KV9/42!!P  KB(
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,DY6U83-\^\  0  %X)   9
M      " @>!:  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ R3E;5L7?1CO=#   9",  !D              ("!%U\  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #).5M6:V=[HJ0*  "9&P
M&0              @($K;   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( ,DY6U9_41"T+@4  ,T.   9              " @09W  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ R3E;5NXI>N^P
M"   4Q@  !D              ("!:WP  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " #).5M6DV3"[5T(   G%@  &0
M@(%2A0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,DY
M6U8'1/Z8E (  .P%   9              " @>:-  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ R3E;5BAUR6)T%P  "TL  !D
M         ("!L9   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " #).5M6:F$'P-("   G!@  &0              @(%<J   >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,DY6U95,[,!OP(  !(&
M   9              " @66K  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ R3E;5F.^4*IW!   9@L  !D              ("!6ZX
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #).5M65]AU
M->H#  !,"0  &0              @($)LP  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( ,DY6U:+>2(@ 00  ,$)   9
M  " @2JW  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MR3E;5N7[8_17!@  D1   !D              ("!8KL  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " #).5M6^=7T== $  !]"P  &0
M            @('PP0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( ,DY6U:1S'G=;P(  /T%   9              " @??&  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ R3E;5H K"=L=!
MDA4  !D              ("!G<D  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " #).5M6CB. 8U@#   D$   &0              @('Q
MS0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,DY6U8^
MJVCC3@,  %@,   9              " @8#1  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ R3E;5H&ORU=B P  N H  !D
M     ("!!=4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,DY6U9CK18<UP@   U=   9              "
M@5/L  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ R3E;
M5E]+J&V !0  VRD  !D              ("!8?4  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " #).5M61JQ[[?T"   -"P  &0
M        @($8^P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( ,DY6U: ,A[:'@,  .D(   9              " @4S^  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ R3E;5MKZU2>J @  !@@
M !D              ("!H0$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " #).5M6M09QD(@&   6,P  &0              @(&"! $
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,DY6U9W#%A6
ML@<  "9!   9              " @4$+ 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ R3E;5KAQ1,F/!0  H!P  !D
M ("!*A,! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #)
M.5M63- 2<0T$  #4%0  &0              @('P& $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,DY6U9%BUS@D ,  'X+   9
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M970T.2YX;6Q02P$"% ,4    " #).5M61&?FGT@#  #4%   #0
M    @ $(,@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,DY6U:7BKL<P
M !,"   +              "  7LU 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M ,DY6U;596B\"00  +\@   /              "  60V 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #).5M6CF$X^KT!  !Z'0  &@
M@ &:.@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #)
M.5M6G"O3#[T!  !W'0  $P              @ &// $ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     .0 Y (8/  !]/@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>175</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstruments</Role>
      <ShortName>Fair Value Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsTables</Role>
      <ShortName>Fair Value Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/FairValueInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Leases - Minimum commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails</Role>
      <ShortName>Leases - Minimum commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Leases - Lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesLeaseexpenseDetails</Role>
      <ShortName>Leases - Lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Capitalization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail</Role>
      <ShortName>Capitalization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Income Taxes - Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="krys-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  krys-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="krys-20221231.htm">krys-20221231.htm</File>
    <File>krys-20221231.xsd</File>
    <File>krys-20221231_cal.xml</File>
    <File>krys-20221231_def.xml</File>
    <File>krys-20221231_lab.xml</File>
    <File>krys-20221231_pre.xml</File>
    <File>krys-20221231ex1023xformof.htm</File>
    <File>krys-20221231ex211xlistofs.htm</File>
    <File>krys-20221231ex231xkpmgcon.htm</File>
    <File>krys-20221231ex232xmhmcons.htm</File>
    <File>krys-20221231ex311.htm</File>
    <File>krys-20221231ex312.htm</File>
    <File>krys-20221231ex321.htm</File>
    <File>krys-20221231ex43xdescript.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>krys-20221231_g1.jpg</File>
    <File>krys-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="619">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krys-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 619,
    "http://xbrl.sec.gov/dei/2022": 41
   },
   "contextCount": 175,
   "dts": {
    "calculationLink": {
     "local": [
      "krys-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krys-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krys-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krys-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krys-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krys-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 427,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://www.krystalbio.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 7
   },
   "keyCustom": 35,
   "keyStandard": 251,
   "memberCustom": 21,
   "memberStandard": 28,
   "nsprefix": "krys",
   "nsuri": "http://www.krystalbio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.krystalbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Instruments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.krystalbio.com/role/FairValueInstruments",
     "shortName": "Fair Value Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:BalanceSheetComponentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:BalanceSheetComponentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.krystalbio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Capitalization",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.krystalbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.krystalbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.krystalbio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.krystalbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.krystalbio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value Instruments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables",
     "shortName": "Fair Value Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.krystalbio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.krystalbio.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Organization - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "iee87fb1c670d4a8fabfd071c375435ee_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "iee87fb1c670d4a8fabfd071c375435ee_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ib6afd13b46734de18b78209e7932208b_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ib6afd13b46734de18b78209e7932208b_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedPreclinicalAndClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedPreclinicalAndClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i495e2c1097804e028fc462ff30675a6f_I20210913",
      "decimals": "-5",
      "lang": "en-US",
      "name": "krys:LossContingencyGuaranteedMaximumPriceToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i694bb0a0a44a457fa226ada68ec0d789_D20201031-20201031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PurchasePriceOfPotentialBuildingPurchase",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Leases - Additional information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i4370047cb1b348508f41d2e789bc71c0_I20201031",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ConstructionInProgressGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Leases - Minimum commitments (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails",
     "shortName": "Leases - Minimum commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Leases - Lease expense (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails",
     "shortName": "Leases - Lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "id22d7707724741a49fc8f50872fbdfdb_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Capitalization - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
     "shortName": "Capitalization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "id22d7707724741a49fc8f50872fbdfdb_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ic5d56c1a54244984a5f923ac922fdede_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ib6afd13b46734de18b78209e7932208b_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ib6afd13b46734de18b78209e7932208b_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i64502038e5f64b25854ef8736435d9a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i84eb26ae6c8d4c569a65871adaa581cc_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Income Taxes - Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail",
     "shortName": "Income Taxes - Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i49c0637d46d649d4bacab028175efbaa_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "ib3f5b6fe2f5e4f5d8bf1bc40fe2c3214_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.krystalbio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20221231.htm",
      "contextRef": "i7757ac4e2ca049e39c188fe061516d4f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "krys_A2017IPOStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 IPO Stock Plan",
        "label": "2017 IPO Stock Plan [Member]",
        "terseLabel": "2017 IPO Stock Plan"
       }
      }
     },
     "localname": "A2017IPOStockPlanMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ASTRAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A S T R A Facility",
        "label": "A S T R A Facility [Member]",
        "terseLabel": "A S T R A Facility"
       }
      }
     },
     "localname": "ASTRAFacilityMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_AccruedConstructionInProgressAndLaboratoryEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued construction in progress and laboratory equipment.",
        "label": "Accrued Construction In Progress And Laboratory Equipment",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressAndLaboratoryEquipment",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current Liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedFinancingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Financing Fees, Current",
        "label": "Accrued Financing Fees, Current",
        "terseLabel": "Accrued financing fees"
       }
      }
     },
     "localname": "AccruedFinancingFeesCurrent",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPayrollAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll and benefits.",
        "label": "Accrued Payroll And Benefits",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedPayrollAndBenefits",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPreclinicalAndClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical expenses.",
        "label": "Accrued Preclinical And Clinical Expenses",
        "terseLabel": "Accrued preclinical and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpenses",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AdditionalAreaOfRealEstatePropertyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of real estate property leased.",
        "label": "Additional Area Of Real Estate Property Leased",
        "terseLabel": "Additional area of real estate property leased"
       }
      }
     },
     "localname": "AdditionalAreaOfRealEstatePropertyLeased",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "krys_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.krystalbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "krys_BalanceSheetComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet components.",
        "label": "Balance Sheet Components [Abstract]",
        "terseLabel": "Balance Sheet Components [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetComponentsAbstract",
     "nsuri": "http://www.krystalbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "krys_BalanceSheetComponentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance sheet components disclosure.",
        "label": "Balance Sheet Components Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "BalanceSheetComponentsDisclosureTextBlock",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_BostonMassachusettsLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston, Massachusetts Lease",
        "label": "Boston, Massachusetts Lease [Member]",
        "terseLabel": "Boston, Massachusetts Lease"
       }
      }
     },
     "localname": "BostonMassachusettsLeaseMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale",
        "totalLabel": "Aggregate fair value, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Amortized cost, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreements"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CostOfWorkPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Work, Percentage",
        "label": "Cost Of Work, Percentage",
        "terseLabel": "Cost of work, percentage"
       }
      }
     },
     "localname": "CostOfWorkPercentage",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeChangesInOwnershipInterestOfShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative changes in ownership interest of shareholders.",
        "label": "Cumulative Changes In Ownership Interest Of Shareholders",
        "terseLabel": "Cumulative changes in ownership interest of shareholders"
       }
      }
     },
     "localname": "CumulativeChangesInOwnershipInterestOfShareholders",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_CumulativeEscalationClausePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Percent",
        "label": "Cumulative Escalation Clause, Percent",
        "terseLabel": "Cumulative escalation clause, percent"
       }
      }
     },
     "localname": "CumulativeEscalationClausePercent",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClauseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Term",
        "label": "Cumulative Escalation Clause, Term",
        "terseLabel": "Cumulative escalation clause, term"
       }
      }
     },
     "localname": "CumulativeEscalationClauseTerm",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "krys_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right-of-use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful lives of assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Liability",
        "label": "Increase (Decrease) In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_InterestIncomeExpenseAndOtherNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (expense) and other nonoperating, net.",
        "label": "Interest Income Expense And Other Nonoperating Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseAndOtherNonoperatingNet",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment",
        "verboseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LessorOperatingLeaseLiabilityAnnualLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "label": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "terseLabel": "Annual lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeaseLiabilityAnnualLeasePayments",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementMilestonePaymentsSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "label": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "terseLabel": "Litigation settlement, milestone payments, sales threshold"
       }
      }
     },
     "localname": "LitigationSettlementMilestonePaymentsSalesThreshold",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementTotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Total Consideration",
        "label": "Litigation Settlement, Total Consideration",
        "terseLabel": "Litigation settlement, total consideration"
       }
      }
     },
     "localname": "LitigationSettlementTotalConsideration",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LossContingencyGuaranteedMaximumPriceToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "label": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "terseLabel": "Loss contingency, guaranteed maximum price to be paid"
       }
      }
     },
     "localname": "LossContingencyGuaranteedMaximumPriceToBePaid",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones",
        "label": "Milestones [Axis]",
        "terseLabel": "Milestones [Axis]"
       }
      }
     },
     "localname": "MilestonesAxis",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_MilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones [Domain]",
        "label": "Milestones [Domain]",
        "terseLabel": "Milestones [Domain]"
       }
      }
     },
     "localname": "MilestonesDomain",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Milestones",
        "label": "Number of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "NumberOfMilestones",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "krys_OrphanDrugTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug Tax Credit Carryforward",
        "label": "Orphan Drug Tax Credit Carryforward [Member]",
        "terseLabel": "Orphan Drug Tax Credit Carryforward"
       }
      }
     },
     "localname": "OrphanDrugTaxCreditCarryforwardMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_OtherContractualObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Contractual Obligations",
        "label": "Other Contractual Obligations [Member]",
        "terseLabel": "Other Contractual Obligations"
       }
      }
     },
     "localname": "OtherContractualObligationsMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_OwnershipInterestRateChangeOverPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest rate change over period.",
        "label": "Ownership Interest Rate Change Over Period",
        "terseLabel": "Cumulative changes in ownership interest rate period"
       }
      }
     },
     "localname": "OwnershipInterestRateChangeOverPeriod",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "krys_PaymentToEscrowForReducingLeaseRentals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to escrow for reducing lease rentals.",
        "label": "Payment To Escrow For Reducing Lease Rentals",
        "terseLabel": "Cash contribution"
       }
      }
     },
     "localname": "PaymentToEscrowForReducingLeaseRentals",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PaymentsForSuitLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Suit Liability",
        "label": "Payments For Suit Liability",
        "negatedTerseLabel": "Repayment of ASTRA build to suit liability"
       }
      }
     },
     "localname": "PaymentsForSuitLiability",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PeriphaGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PeriphaGen",
        "label": "PeriphaGen [Member]",
        "terseLabel": "PeriphaGen"
       }
      }
     },
     "localname": "PeriphaGenMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares",
        "label": "Placement Shares [Member]",
        "terseLabel": "Placement Shares"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PurchasePriceOfPotentialBuildingPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Potential Building Purchase",
        "label": "Purchase Price Of Potential Building Purchase",
        "terseLabel": "Purchase price of potential building purchase"
       }
      }
     },
     "localname": "PurchasePriceOfPotentialBuildingPurchase",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RemainingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining commitment amount.",
        "label": "Remaining Commitment Amount",
        "terseLabel": "Estimated remaining commitment"
       }
      }
     },
     "localname": "RemainingCommitmentAmount",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPrice",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockRemainingAvailableIssuanceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Available Issuance Amount",
        "label": "Sale Of Stock, Remaining Available Issuance Amount",
        "terseLabel": "Remaining available issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingAvailableIssuanceAmount",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases",
        "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Number of Shares Authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Number of Shares Authorized",
        "terseLabel": "Annual increase in number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorized",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "verboseLabel": "Forfeiture Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Surrendered or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_ShortTermAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Amendment",
        "label": "Short-Term Amendment [Member]",
        "terseLabel": "Short-Term Amendment"
       }
      }
     },
     "localname": "ShortTermAmendmentMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_SwitzerlandLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Switzerland Lease",
        "label": "Switzerland Lease [Member]",
        "terseLabel": "Switzerland Lease"
       }
      }
     },
     "localname": "SwitzerlandLeaseMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_TwoThousandSixteenLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen lease agreement.",
        "label": "Two Thousand Sixteen Lease Agreement [Member]",
        "terseLabel": "2016 Lease Agreement"
       }
      }
     },
     "localname": "TwoThousandSixteenLeaseAgreementMember",
     "nsuri": "http://www.krystalbio.com/20221231",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r258",
      "r396",
      "r406",
      "r420",
      "r421",
      "r431",
      "r435",
      "r441",
      "r475",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r258",
      "r396",
      "r406",
      "r420",
      "r421",
      "r431",
      "r435",
      "r441",
      "r475",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r251",
      "r258",
      "r288",
      "r289",
      "r290",
      "r372",
      "r396",
      "r406",
      "r420",
      "r421",
      "r431",
      "r435",
      "r441",
      "r470",
      "r475",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r251",
      "r258",
      "r288",
      "r289",
      "r290",
      "r372",
      "r396",
      "r406",
      "r420",
      "r421",
      "r431",
      "r435",
      "r441",
      "r470",
      "r475",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r465",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r440"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r1",
      "r2",
      "r82",
      "r102",
      "r112"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r129"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r132",
      "r402",
      "r411",
      "r412"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r88",
      "r363",
      "r407",
      "r408",
      "r454",
      "r455",
      "r456",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r440"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r460",
      "r461",
      "r462",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r76",
      "r77",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Adjustments to additional paid in capital, stock issued, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common stockholders"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r111",
      "r131",
      "r153",
      "r190",
      "r198",
      "r200",
      "r207",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r329",
      "r331",
      "r342",
      "r440",
      "r473",
      "r474",
      "r514"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r124",
      "r133",
      "r153",
      "r207",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r329",
      "r331",
      "r342",
      "r440",
      "r473",
      "r474",
      "r514"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r204",
      "r214"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r49",
      "r203",
      "r214",
      "r398"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r48",
      "r214"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r40",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r126",
      "r422"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, aggregate fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r35",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r34",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r29",
      "r98"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r106",
      "r117"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r220",
      "r221",
      "r416",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r460",
      "r461",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r440"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized at December\u00a031, 2022 and 2021; 25,763,743 and 25,207,985 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r137",
      "r139",
      "r145",
      "r399",
      "r403"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress, gross"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r315",
      "r323",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Debt securities, available-for-sale, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r32",
      "r87",
      "r316",
      "r322",
      "r323",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Capitalized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r86",
      "r505"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "verboseLabel": "Cumulative NOL carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Cumulative NOL carry forwards with no expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Cumulative NOL carry forwards with expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r84",
      "r86",
      "r505"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r86",
      "r505"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r86",
      "r505"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross": {
     "auth_ref": [
      "r505"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Deferred Tax Asset, Debt Securities, Available-for-Sale, Unrealized Loss",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r79",
      "r504"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r86",
      "r505"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r32",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r32",
      "r188"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r262",
      "r294",
      "r295",
      "r297",
      "r302",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r146",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r169",
      "r171",
      "r173",
      "r174",
      "r175",
      "r179",
      "r336",
      "r337",
      "r400",
      "r404",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share: basic (in usd per share)",
        "verboseLabel": "Basic net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r146",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r171",
      "r173",
      "r174",
      "r175",
      "r179",
      "r336",
      "r337",
      "r400",
      "r404",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share: diluted (in usd per share)",
        "verboseLabel": "Diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based payment arrangement, amount capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r64",
      "r122",
      "r141",
      "r142",
      "r143",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r181",
      "r208",
      "r250",
      "r298",
      "r299",
      "r300",
      "r318",
      "r319",
      "r335",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r363",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r105",
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r338",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r235",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r339",
      "r369",
      "r370",
      "r371",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r235",
      "r252",
      "r257",
      "r339",
      "r369",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r235",
      "r252",
      "r257",
      "r339",
      "r370",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r235",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r369",
      "r370",
      "r371",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r236",
      "r248",
      "r333",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r428",
      "r466",
      "r467",
      "r468",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Gain related to litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.",
        "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainsLossesOnSalesOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r32",
      "r55",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Recognized impairment losses for long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r307",
      "r309",
      "r314",
      "r320",
      "r324",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r155",
      "r167",
      "r168",
      "r189",
      "r305",
      "r321",
      "r325",
      "r405"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r303",
      "r304",
      "r309",
      "r310",
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income tax (benefit) at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax expense net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesSummaryofReconciliationofIncomeTaxExpenseBenefitComputedatStatutoryFederalandStateIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r99",
      "r109",
      "r144",
      "r187",
      "r350"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Capital Share Transactions [Abstract]",
        "terseLabel": "Investment Company, Capital Share Transactions [Abstract]"
       }
      }
     },
     "localname": "InvestmentCompanyCapitalShareTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r360",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lessee, Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r153",
      "r207",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r330",
      "r331",
      "r332",
      "r342",
      "r426",
      "r473",
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r104",
      "r115",
      "r440",
      "r458",
      "r469",
      "r508"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r125",
      "r153",
      "r207",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r330",
      "r331",
      "r332",
      "r342",
      "r440",
      "r473",
      "r514",
      "r515"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r33",
      "r107",
      "r118",
      "r123",
      "r136",
      "r138",
      "r143",
      "r153",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r172",
      "r190",
      "r197",
      "r199",
      "r201",
      "r207",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r337",
      "r342",
      "r427",
      "r473"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r190",
      "r197",
      "r199",
      "r201",
      "r427"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r355",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r359",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r358",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities and other",
        "verboseLabel": "Unrealized loss on investments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r440"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to settlement of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r26",
      "r47",
      "r147"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r149",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from insurance settlement, operating activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial offering of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Project management service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r57",
      "r128"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r59",
      "r116",
      "r401",
      "r440"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/LeasesAdditionalinformationDetails",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r78",
      "r121",
      "r522"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r65",
      "r114",
      "r410",
      "r412",
      "r440"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r122",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r208",
      "r298",
      "r299",
      "r300",
      "r318",
      "r319",
      "r335",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r357",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal and State Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r259",
      "r261",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r67",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedTerseLabel": "Surrendered or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Stock options available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in usd per share)",
        "periodStartLabel": "Beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of the award (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual Life (years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r64",
      "r122",
      "r141",
      "r142",
      "r143",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r168",
      "r181",
      "r208",
      "r250",
      "r298",
      "r299",
      "r300",
      "r318",
      "r319",
      "r335",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r363",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r181",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r65",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r46",
      "r440",
      "r458",
      "r469",
      "r508"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r152",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r3",
      "r103",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement [Domain]"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r3",
      "r103",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment [Axis]"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r236",
      "r248",
      "r333",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r466",
      "r467",
      "r468",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax": {
     "auth_ref": [
      "r18",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative translation gain (loss), before tax, from translating foreign currency financial statements into the reporting currency.",
        "label": "Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax",
        "terseLabel": "Foreign currency translation gain/(loss)"
       }
      }
     },
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r424",
      "r432",
      "r434",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties amounts recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r356",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r170",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r169",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r447": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r448": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r449": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r451": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r452": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001711279-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001711279-23-000008-xbrl.zip
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M-?[;WW_K; H-.A",8F1MPKB4BF:<*VJ-E9A2K<-L4C^ABS6;U(?9R(_.9A7
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ML92D1@DJ"$N?#<D>WU1Y%/H83JPQ*D4T!9,\(Z"@",]2BR0X[]RYIZ//O&8
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MDHA?0E:@N614FW&_R0HSEP<S@7+OR^+4S[%=@>3RB-L*))>.:C,>.%V!Y/*
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M[]]**IFC@)0OF?R[B!3Z/ITE6 R!DVQ11]I<QMHE*JZPZ6J48B5WW$Q!!A2
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M!NZU$7*90'A*<.&,;S0E20_(W;Q&[<;!)7-N?B6]V^W6@P;2Z(,G'OUFA,2
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M/AM=UQ-1XH++K&9 9&^YV'M6!9G8%DVL,]0P3&Y-%BY?&0U$-D6XS94,S[>
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M>KVC(CZ":/7HR;M^0.Q<>"O,;#VFXU$1Y$0?_8/[\0J2R49@F<!J<F"\Y].
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M)G:'?-F4^8:X,IA.TY7QI;#SM2%3N[3D#0B3+[SDF53'&*("RK*US%683-"
MY02'X:>/FSWPM?4H,:;O_LJ4O_M?D=G?$)83??:N8>?W;B YOTBT.,[*)LP7
M8[M++W293OC(,N<!<_38_&,]WQ/;B$MI:)$D%\4@E22V9IP&*'L36P>'U:>K
M; KLQO0R+29>43&]B%"=-3P[;1*VWA28Q$^8U<+X>E%67@F&H0D?$>VJMV*7
M@2Q**-J.:V0NQ-&8<S,0T#P%5L.)T)J^-]&F >Y)P/@(G38GY Q1DP FD6A
M7_?:CW#[+D].MVN='E;B)P]H]%T*47QG*$<->C<KU8,P:ML,^OP:>I=A$CK+
M^GY2K;PBL7+5LA2N^A?DY)=U>O<=ON.D:!G7JC4^DC8]F9&+QZ,Z(Z\,UO75
M"TY?2 :M*,,,\-#YCH^]?/5",M[ CM#".UQ'_0,T T)/*@Q7);C^N4^G<?,2
M^N+NN8"WL/X[9(>&Z[\G0L7(OKP"@*)W<!.R:IA)IK+C )+'F*C0CI+CL2L+
MH<@[2>L&&.,*8=Q9QP+YSJR>D*=M R,!5G22VWF5SAHC'/,&)VR$[VC!9U[B
M,-CB& EK*TSC@MN>3= 8,Z6NAU4)6C$D+\B*G2U*5V2?DPN9A7'N,,CLZWN(
M_O@3< P+<R_E_HS[C%CN+TR5W3*YCV3>>O*.E]6ZZ4OZOWL4AAJX!,^<DF?F
MMR?F@_-G@:O&TM-U/QV!8](3=8F<_[FS07DGY#C2>45RZW2R:!9K#).^^\[!
M5KGS8O>>7,<*;9,\E0#B=I8VZ;PLLG13UMZ^/5'V"\GN0L8VN);$NS@^/SGU
M6%<28*]>VR+HUF(=K4BOQT(J5JM_76#H<5FE*<O7]U,^WSM8JP8<'^MB6E&L
M<L\$D?-&7<%;I/47!&IS5[Y"I&SXX-<)U^8M[KNHG:PQCR!YC0&@B(KNF:"A
MILKTM'EG) JG%E$6CN:B@'J_:">YRR9[X$W?$Q>/1R*DRWJ8M._D=029ND!)
M%.1K+[)R1*;EI)QV1W>/DH^K#*%ZT4BH_NAE\J[,'6=).I_<S1SK0GD>WG<H
MS^U*:I[&O<5GVEM\-_3?EYM9I<8+!D!73 6GQ]7,0CB; PG),LT*!B_T<HB-
M@O!JT/&W,C%Q6]DSC-CR*=61\A*65WN+\FHD" Q!NJ*@#OZ^K)@A>><'=T7W
MK_ X7*/A/*#!HDJ>V<5:B7]MY.[^.GV"%+E.*+Q36%!6M-0\*SD[B+G<&(8L
M_X@YIV.NE,$F]$3F5:%46Z$>,%XK&R&L\MH7C;"-FC^2+LK^1L6(IUHC;FX-
M;5>>RA[ I"D %O3 SDU+GF76,C\$6M;MHJ:\>^PM14D_Q@6INHM'C9^:MPI0
M@*S0"3V<GG;;F_&C'167@[E:2&3F"\V(Y]I@6J!E?'.C1PE@M#5C>VPHARQ
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MP<.#PRWKWO48['(&NYS!+F>PRQGL<@:[G,'=V;)=SN /SAD\>?KCZ-'#I[O
M99<SV.4,OI S^$H4RF K0UDPFH3'Y4W*>NGBL>[;B(R,FT'Z%;(E(U;H8D"6
MA.GIH^1?;0K&6VYZ^ %HSM7*I15HIG?XDZ_/2!S]N,M([#(2OV]&XM'!DUU&
M8I>1V&4D=AF)74;BQK=EEY'8921V&8E;ZAM:1H+LZ>CQT;-=X+++2-PTGZ-%
M_K>9U[&_;"$ZX,AC>/C@1&8WSFQV8QC+I?TK&$\D5^$IACKI-F]Y5'7=5.WD
MW^D'_1;/)[^;HQ\.GOQP=/#H8)=8N#.)A3\W!B<]OG\@W2"_-0A_N/_HX='O
M'GX^>[3_\,>GOT?X^1M%C(3TNS\BM_-X_^GCKS"F ]U-.#9[#_</!UXD1@M*
MGN?_?+4R_#;VXTV5%O!)=+R>S?-F#P_F1MIUDP??O3K[[GN>NULORJMB/SG6
M^7P\ HYCM6APYI:K@,R?S=>$@U[,,"PQ;FW.>7F;98>IG9R'KY*YKHX_#V[2
MBI:X3->8R)=>IEF.<SR4.-_).F1])^S=#6''>YJX$$KS$-=D6B9%V23IA.5,
M6#:*M<DU"=Z2OD/_KKF$4[<K'3LHPQ1-Z$&!E<V 1W4\&6/EIEE*4CX)7ZYE
M-NI72_"_UP=Z:Z<.OP'?B0R</'=S<)I@WZ @SA2T>XPYII=][^"NSC!E'1C'
M?"/^U>N7QU!ZS.E2)^.,QWI.PB#<T/O.M,S2UKX.?^>RA5S)37GT^>NRG(Z2
MEU4[%S:U$RM;'M.>/D!H='3P_/7+DV/^Y^'S[V4A9^TXIP_][-*\620?7769
M35SG.V<_?XR^@TM7_L5)/#)OLRE/R>T,XZ2K4TR6IU?U/D^2P;U'":XFTXRY
M6CHI*PI95J6H^_C"<Q84NN&RA"%@F]$LZ%.Z@[1ON,VH.YV3CF8Z<RBN.@QK
M32?T+SI?./QS< 5,/J5S^5A35NF<3FF%6M T^>3<BO\P!8=.-FZE5ELYS/?E
M/]##T3]3^7TZ90U3"ZV^A63T>I:E6<2*"0IX&.EEF7,E>.,][R>G[U]V,>Q*
MN0\!@:FMW+_:K"+I&;N95*,+?!-76[3TZ&&ZO6X(@L:!^P1;G6-STLDB^F:5
MJ1HKZ62([AN4NS#U.LDPF/@R<U=8VMJ6/-)1LTF>+5GFLX(<_6(BM [)^U0W
MYY1^G35&7:3"9P+W_O3G6$;%(\"4H'-Z5<MQ5I!#D+Q\?TS/= D^AS5H"NEV
MC1.E>WY\8A+'@GOXY#G):4LQ=Y7]JOH&0VJ7I"R@@V4 ;]ABTB^?W#5;>2'3
MNGG .,;%CHVL2<47*TI5B;%WDW/RT=4F]V0^QC6]5RA!(!'RC$\/3]V-IC@G
M,SG:$%8V*'EIDVNQ3M)W_ ?>Q?ZQ5+$1VL7/[$[1 6&R"]P<8WSQSAO2=G)!
M["H/\Z7C6+;51*]YY=A2P33"6B'.PC#FL1^HZ^5S\.'ILSJ*?=:2X'7F,8<!
MPJ11M\Q6OP^#K/^106V%$\)CTCGZYI/V0@6L3E[1EK7!'I[;"&([%R<O7IW;
MP8B,QZ"!V$_TMOC22-\4CBLDH/,-D1SA%@OFQT<!'Z!&66XN(FJ5,_N@K>W#
MQ9E?FDDY5-@BK1/22R0X6;V0@6#T\'E.:Z]&R456UZT(X!NL26Z!F&#S:(=M
MN'AS<7SB[R9#VC,R-7A4C 2'JI"'I6W@7UZ5U:>:]%U98VHXGS-61Z<_^\62
MTA@E5XN,]GN9?G(UVP42T&+:U<OX#MVCLX7\%')>7#$GJ\*[ER8KL:UD429M
M72MLJN;V(SB)D:VB5V5'NRXG&!N>VU7MW<A\<?)ZZ=]L<8IY.>0?L [W)E?>
M@'#GN,A26ZY1#Z1E&X>=#?RV$L,1_!*R$%5YQ5:MG/+<;'_Q:3EI99 X/?+)
MNY-@:<@4PDK-(^=!+">9NK3>6$&T.K(L>8X/R#N":8R'?.M0;FA-&34^)250
MK;WZ_YKGW*YLODE6E1Z5Q_UC5;GE=N.5*(41:P15#KF;,Y213EF%\S,NVZ8C
MS"/^"2K:W$%VT/5W?JH]!;DYU'[=Y@WKJI#)Z7H1\(7%VQ0*KD4VSLR[-R?(
MU>8FM+7;]P$)*S,^D1@M0TJ-''=:N90H^%83T^UUQZF9^Q"Q)NUUR0X,OL3N
MI ZFHC7/VHI5ARU8_&N*Q!<%+.IZ/WE7L@.MSW#I.L]&SS/)TVRI\7CD?]2L
M7=H"VID?FW0NJ;M%^FM:377K:$&7T"5MG<S(Z>\X,S9J*]AB2$1X*O.9Y DU
M$= UDFFC]YF2AEG+WLL-!]PL=D('W2<-$R/E1P%'P]8=8-@Z4W^.+CZE+2+=
MZGA+2<RR6E1;,EFD!2S:54;Z%PLM**YQTU&\F119E3GZ:GE;O1V0KT[9*><W
M1_=I=/LI9C"QX%=!#T";$7_C"KO RGQ)<5LCKBMD5Q9$MFB&;1[I#MX15_'K
MT8I'GOW87,3@=KV,S-F9G,*[\?C7/JRY+!R86< F!KT3DZ4#\2@<FO"A;"#Q
MT@W<0ESM@U>+_]*-H"^ZCQY7N950V&_<*3A,&OMK^#LK\YQ=II^^YF5MF+_'
M3X/UV_[^]OZ0%WCT52^0G?(?G]\0_!_T9)T->WBX_Q1[P3&VL[X%4D+>'\W)
M@E:B36$O:TM?7&:7%+DVY.FJ+S]!DBA$Z4TONS!IJPIG\4U93I.WX:)GF@3R
MP<N;MV<AM]'/HVD>"$JY8R+,6>>$C^,. WJ.:.UID2TUUZ#N='PE?Y/MR(C;
M*G9?IS=NF]@=8<.^^^^Z'2\SB?NBI![T5]%/^UGHF4)!U!N9/>3G. (=DV$N
MR*KG4&%\M?$_'0S"E43[#P^2*;G?=^]%WVG]XATQLB5#F54*_9Q7%9;Z%!?X
M7)(R+TJXEJ8D3L]?=)(IW:^0-R!Y@X'<R.F+DZ!>U)Q!\'H+4B-&OVN0:)SN
MY.5/E9>5JT#HS^:$F?M)V7.<Q G7/-_# ("*G 7R*(95@=@CCL/*#6/$1NC$
MOK%I@D[.^EG$8($H;.G$@@-6*"IWTN)E?3ZP))TG"BF4>!:2W<\*?F;1=K1J
M'_#HF!^6:$ZA:>'&B)E]UNL:KXP;[IHZI(3(1MX]H;[3UH[<JE5:A?3U==8O
MLGP]Q]VK4HZ!)=M(ZXYK%@ZI3#TZED!=M56FXK,BZ2Q(>C@LEPP')Q:+LM@H
ME7$9HGNT=E+SITI-*$KH4>>#C>1 (250JP-,0HD/<;_W;W?OZ\_U:>G0UJBV
MZSN)XBI]8UE1KX)YD-@]*M!;IIZ36OIO!%E78/WGCU^CYCVUFR3]4^0>ZXT2
MZLF;=V==T\7&B#_?\DTTL11N/_)]W%*99/,K>4!OG25/1GMY^:5U>DL,1=5P
MJ[<IJKJA.''>+*(N<%-8K+Q8C^UD^L^U7'@!;%I8XU#0WYCHQD9CTUBP8Z_Y
M8TGY-%KB)"E(D3< 3JRL_.4BN_<<U]N]YS_U/:=KJ_^1>TC:QPH/ L9B0\1S
M*(,W$H-&]N](AOG:5_-"8T+O *V3@JY\G<XMQ,>O>\7?:^%!HXXYC[*GR.QR
M46)>=A)QNJ!]"E>ZOS0HG(OS7<XC)6K)Z.E]%FX)]-8: <;G;&(NH4U/$^16
MX.[H)_J"2>'5>[40!2>(I2[9>LVV/*+:FA#>I$FEL"=?=O<X"BZ8(2VML*YP
MV?XN\,ZQI5, @X*#-D*XCN$+;^S-V[.O0]/\>*OE]X04LN9:>1=ZWON(MR@M
M\#;;NN44?-@Y1Z^G+I<D2B7I!L;T#LC@2,I,::UI52\>]&XHQI$7CLH88P!K
MEW!A3CT'"H*SHJ3#$:1/JAD G'GT4XBPHZA8J[F<KC%!%J=@L:Z%PF:1(IBG
MG4-/F''.^,,K&#X6(X-T,;0J]44/B;5B;VS+]YFPQBJ:<%7@QFS)A6^X6R+1
MW?O8"@QS-TE7G)U&AQM)+CT0?3,W38)OJ'^4C-.&MN.ZA^V<O>V T; @^@.O
MP]Z'^7Y\.E4S<N$QN&]]MRWRUFQEO-_Q^FR!??!E#/'SB%2_,[7+'0JLHDAH
M-2B':BU]+)ZS":3?3%$>^& #*:,-X#F0D:M[[;9-2[H8('ZFF=N"7K);25_5
MU$'BE"\E016;4RWUPN6S),]F7U=YO=UJY6(S1PI0<EVJI' RHU$8G4\I#&IJ
MO(.YE-'Y>'3/02<+EI) K(6="@[C2-)OUA$0%L3>).-(&_B8B&'8%H74F/^H
M <!&'1PQA4VI>*%2>MA//D(-#B@_3@TC_LF*5C1;PK@>OA:*%EFMFT'B)B##
M+0@TCM/]"J2N81<1+-O$06+'JO/.CT](U";9U#QJ($8-0K>1)A"D,BWF*JVD
M02C@ZAFI (4$H(C*?S=4A?SNP%XQV*L_Q_O>@;V&]<]-]870&5"19E%775,K
MW$?K,E$*Q4M\2R<SUR/9E6D[0WI=-;@!!RJ0=UQ]R8 F?_(793YEI.:UN(>T
M8>W$@'$M+&&&HFBU?GEBVG*Z1/UF#U>C+U! O1?R-?O):= 1LB[RH[I+&]E%
M#8=NP%SU/^ S2=S> ?A+^8%VIB"O0KMER.$+C0 =Z >9:*NHP$)?P4$I%/0>
M<D912CM4<>$T 'TU:UDQ#X"P5!\9UJZC$SN[%\4A7.@=R43+M*%_X''IERW]
M4H'!?%GN6:N ?M85UL#Z\_?H:3.>$<WNK%[[CL2POQ$E]3,7H7S)ZT($YA=^
MZ_*:[KZ+<M([8XHLDKQ29_9WWU4>.,TD85*66R=T%3368@@Y8(9T!8YF0H-9
MW:[0%69BSP[P+&/HDX&YH;JN%F6$>T+F5.(6.NCB7#HZ]>5:CAW=*=Q TZVV
M[([[M9_TGSNM(H=7KW)5P1\I6,@C%P2N*SE3'--MBPH$0)%=A@BCJ\Q&Y!W7
M/H(A?8=DL58YU5<W?>,^4[#-VS2IX*EEJ>\N0&5L"3]:#S<"?TX3T*HRVKYP
M1<T3A\"])M%<<7=1FYMKI(GLM.^S&D:3OX,W-...U)01OIU@M5XPO+2<4#2]
MG[P":,';&%\(1O>#Y!'4F?0?\<&*N8);W$UU^$B]BK(<0W?34[C93';=$"MJ
MTDBWNVS5=#K*%.WBT0SPZ&"%?!MEFC$+2F1EV/53!+/OGAAREV7;.);+4^M2
MDU^61=\.A7?B[\6KV58"]XC9SW+7!H$5^APH$(1_KX5QTMZ?T A8:-Z!CFFM
M"31LF<4A<5<-;S\:M:  \*K("*(^VEW<=OP'*0*Q,#V[-VC@E@) #N;WRX8L
M );,5-^#&+&OB#:B;\GVR($69.B78(-Q[BZB)'YSTDVHQ*(7]=QQ,EOT@3@8
M/?G3KA^-.9E"H:@9 _Y:H//#?:#V7+Z]4Z&)=#51WI"+\Q>"3'IQ L\0"HP[
MA[%"OF86($OX@*#;!B31SHC?1%$5=/F,T>#5G.[)>V>P$]V#*Y?/4@V$F4A'
M]+=TLJ9H_L](1AI?T*MI)TC[DEY>UC[!9WAWWE0<0X@L25I&^];B'?LKQ:CB
M#3 .>D;I5TMV*GFWN._ '_2L$#VD6 @DT_B:W'):N%EF.3/>5OCINMT&&ZZ6
MOBZI!0QI<NJ^5Y$%KYKI",G[&H2DB9"HAPF8CK26(,'I<#$.=4?61Q?+@"RJ
M:VI'(=-I%FW@94OP8JG8Z:9M#YW25:_5M].P&S<>0QA?8(J\=L=F':R<1PW(
MWL1/4[(]1/-]2EY*M[KGSQ)_BRZ&/&J]N:C&8"K^GOH><2RXDF"[)9&0OCA_
M>48;3Z4=D&M1ZZCJ ('D3(FD0-1:Z,ZZXC*K2FXGN0>J]>=AO.MZA1_5FPQJ
MEH]AY9 JY1YJ/O*+M'81M0;>;IZNL%VL7?#:W/3NX>[O=,'U#"\E.90S<6V)
M$?D.;I=@")]!/.B?<-OJ)>Q;P83!##G4R$7\KB[BD//E').;)TWN>SI'Q),[
MYM@G53$F?VHE*5ARRM-QF6?ULLO\8 Y]Y>PGSF=:TQ2G5^?L5Q>D7RO+,7@G
M3).,WL\M.!>C?"!P\!B])DG8C80!+Y\<=<FQ(,6^!X$'%0VN;<1_9+X!M9&=
MNT*R8TO15="^30G;!I@-5UJX0LJ52NDSQ#'3,!(6<2A '*G9X;>EVV]YXPSV
M%S%8YYQ:.+F?J"QL'/)N,RYK0?BL_N@/7@X55;';M(+-=7ZU1MP=\]_OF!]]
M^9C75KA7[]BSA.A[I>.U:H.?I)9Q[4]="&+Y6,F15]/*[MM(05JX;I%6]/C^
MCF(U-Z'% T!B/E0S' ZXGUB?I]K4XCZ7Q.@6;D"[E*194#76O^ ;FD&H)PLW
M;3>HGG;B^6>(YT-300\'_7<XBIPJKMS,597A"Q/%S*^RR[))<\7-6S+5NG:"
MMJ)W4$*#^TPN_!'UJ ,PS(.AK5V+));DM-?=:]VQ'"*AYZLC>!:Z<$Z]X=6*
M>SZ0QF?#8T_OU_YEK&6P![H?!7(9*0/L-X_L*$[_(0[)FXP<??IM.2?5;D8&
M-)PXQ%O =)RJNJ8?8B#'8- [<@5F-MU7]KGD!G1&2Y@QF6443'EXC\(NN^YY
M/#W8\.BLW.KAV"_FH>AV-< +Y=B<E-,/&NH)&NAZ_)!%[FFT&0A3Q#6P[QBO
MU4Z?_+GZI*QIQZQ/80. !*>NX37T5(D<P$>;WU#_+,HC<2YTLRGB.B&TA+(X
MI0%@!/*G*N-J&7=$2((S(ICV/I5F-X(T1S@UY$2L4U%R(B#PH1,%>0QH*CU'
MTN>\UZ[N06CZ4BJ<.,4:8P*RY)$9,4'-D/(V'BZE?R3UK/D1:S]AN+'UM>>1
M/"G24&@S.DB0 2!RIQ2#%%K1"AB$V3:4Q2ZJAPPA6?I2=5V.?T>5TT%//+GO
MZ(D[5Q&.J(DCFE%HJXAH;-TO&=]]=74:E+\=U[C(H%1DL#'C\E*J3$BB<S$Q
M9%@B^\$9C;2:6N5QM>+<P8:V"*E;W%,I"F)D6)>1C#$,T^22@K2RK8>HPVC9
M:=5G0(V<[K)M\/CQ6J4OJ>X"P2SW#Y^4,^'6BX$-P./-1:?'#&&!$X\>=:AV
M_)/O3&76SP"CDZSO ,T8K?PY?PE\:#'J5W ;4H[EGFQ&NTN O,$3\#R^[]0A
MQ\_/PQ!QE),I3(U1*.;D=EM1]+H@'WQ[O-&48A>IA>E1&IX8F 2QZ47@692
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M[>EQH&&I.NDE9)9X;WO-'+K)G+A29,,*"3N6CAAN^HM?V=G+7UX?*Q(#<O*
M]A,'"4SN.-Z>*,'38[\,R^)T-:I(ELBKO_=Q&\ GT@LEA7)&!+"*9]Y":8",
M\,%3J($ZK"EJDN0*F!DG3D3)]^1S7)OWZ%W_.2^U3M+J?HFJR+UAM)09OPCE
MRN9OP6,/'>(>,A?Z>#BU.JDR+N:%&X"#TB57:7:IJ$:2$AF#I2W=OL4B*SQ
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MK;IL8EAWG*I/,E56PJ).7MHRA=>OJ7OJK7F . QX1]E7)OE=AD(YQT5PKXM
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M'5@[K=IZK!_?Y2'XMV3S-/G/1OKY3__]\ON3L^]FQ'(<* M.Z0OI+)2RAK8
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M!>LU4GXT&B9VQ+HM2:%KT3>0:Q?-WVHI".HG8NL=$9QJ78,KM*06C_B]IP_
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MQUE,A+[CKQ /T-H6R:3,V&[3L$@I ^<7<CIKQO3%JQ2[)K%D6EY3IB\.'?9
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M<'F9K$3BEN(T3M=5FAXCCZ+/QP%,@B3'QHBCC""#<_GLO"98B;7XINSHG*4
MDD5#ZVV\KPD<X9YCA# C-#!CBEI9]J*7)T*5@E/NH]'0 TCK_<)&L[PI6<X%
M<@X*W:@K27E5TEV9BB;T]42KX&UJ"B@)Y4QK20 TF^A!5/P!072MFHSE$9>-
MY(*^?_&,LT<Y^8(@,!2P:F;9K3^'D%(0437.M0L7VJ7>XBMHQ<>639'R<9GR
MAR7A5"%C1=6)=K+&4ABP)&L0X@J8IYAM+^. <U:?WC;0537A3#6,*M/2N:@:
MVZQ,B[2AF"#N^SA-<P!T%SLBMQ7]I50C1]T:6RR52=E#I+ZK4&\%O+5N0*(
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MU55$_.9[3+6[XCKE&(_S=._SU!<(S]*F7%5QH&F0)5EK&B&WCE-VOSZ,D_\
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M5Q$3+9*>"9+MR2DS#\2[\'%N0ILUQ:$ZQ!5.KW+-;7%-NTAQ/5WV=B_%/[B
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M<5^"C+I2'^%7@KIW[*R9DHCC^-69HJO%%;XCR2I*PZ$?&1<IO9O7ZX;4?9$
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ME+@U5>\9%I=+TM01H/ E\G,!W8:D :21QDZ#HGZ\KKJ*"5K-,#=!(EHH X6
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M]\P[B^ZV?E.6U0V)L0:H>93S*LT$PX&=/[D\@WQ1/%60+A$_14/D@' U/KT
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MG@'^0 $LBR+'JA@M<*6Q(&TC2-X44K66D$G+DG= 0=)J,=0'JS9M<^!U33+
M\L5 LQ5X3N+-UT&< @I-10=[D0DD2*/0- 0THL:8=1*^!XZ!D>V-GQA"C)N$
M* [Z,K@-08BQ;$DN("^ D1$#4)%'7SJA./@[4V?@;%O@+)>/B9,!,PQ2UCXL
MY9ATGJT: &J7T3M1KU<M1-'*#%-9G7$&[!NXH 2S&P[Y\692R'"0I#F3$C)R
M[33N88)HMUT50%$4">#1J<3QV%*Q@7213-F'4K2N4(F&@DK6[K4=%';2C8/O
MI1O3A-H[@L=9/6"L7BJK@N^D^]=MSW002CA[X2,)Z\_YP1<\Z&AH/_^3#.UM
MAA NV,DQ+-@W_[G%22*Y$ *99EBXB=,,KWR-^^%=#MA@"H!(-IX4?U-AVS..
M7(-Q15AK*,+BAAK.F*&3 >;0O"U9A*)GWN^%SX0V!Z/EXXPPFA";_';]]0CG
M@/\\X?_&L,0D:6;,6/(QYU!%G0&7GN(N1./%'LTAW4"X;3=T6W"_R$%O7!.8
M-,JA[IB:'@)Y@QJ'>$-RG^,-?GK8R'?8T>S +QK:/Y_#4=X$QE8M%@1;"CB/
M-%FP*0K,%C(0:,XPH,,T,OZ2\->"!/'GT)I"^)S-,T"*3+EI@((CKBP;9U</
M;9/($@3-W4!39KI.6#Q5.E?.[,\:7Q$A77%@ANZI(+-%EEXS1899S,K' V1T
M<-OE%19^Y\OO]MKK(;77O2]Y^J+37]D2I)$L2;XP0STWK.8L_G2#JH.SD#&5
M%M8QM W7VXPS^1!L7AX>M62G@ T14+():'W&V)_T0>^1<RI284+S!U4$!E=;
M(([%'S/.XL@/:"1$M(DTYUY52?]R3[E4KCEV= P8*I78'3 Q%-FR'P!I^0JK
ML:0$8:/.\>3Q\"+,<T(TA</3WHY2:C0;'G6WRD&1C+/"4IDQ-R9RIU FUHUI
M?X"_F/EA"15^0"]!M"ZAPILALK4BEYH$Q.MH&XHD:B:S;,Y<9^)T!+P*@A,R
MS<WGR4?JJP*2BY8QW8J4&*03;)[@G&%WI39[F7E0F?G;FW>7FQ@YWI@XQ0=/
M- SR\=JY-M6<B:5?"543_PX</,&G_>W-A]>O_B8 -89:0HG(FF0=E\#Z(:%.
M4T@A"BV..ZKF9>Z<JJAN(57_<Y5B;F$IH$:<!W[Q'3ES<73%\94X>MW-P;Q$
M=.]>_AY4_GZIEKIGT?L6^##I>B.A4<_Z1Z=? #9MY?$7*$%L6(\)0O:[B$#T
M\ZXPL*1CB^AF1K'O$'C,%.2B'[6ZP !3K.[BN#;)E<;M-%W+G)X$V11#!VAC
MB'.2&C<.1 ,E1(.&BWL^W*="PDK?&*^\K60"%XA5PH,@[@T_G8M" J2+<Z_
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MKH+6[%0*AC%@)'%$L(KB7L988]&]YNP)T!BMEYINSV!K1?;(>Y^V*EZ[,QQ
MM3MCVHF;!COAAGFHW?H=0Q5[TQ:@SYEBA&(0Y*KJ2)RWT2+%7%M*/4(F[<CB
MJ 2>4=HV)*X&+S6K:_>M!H#<2<T0U0+KO-M2:C[0IP;N_QIC%%,R_QMIIW6;
M^80=N-Y./6+OWD3R\BHOW(Z:'Q##P(CKK.K)'TT1RO%S!M! QS6,VMQFY'M@
M)(VN!<R?X<:P/*+*Z>(^\N7]A'E(B#5DHQK0OL'I<:+$HEA#XJXBGZQP>^LN
M2#?/.K-08BHAH?I<@S0;X#B5AX71(EBFQ,M!D7&+*!&V3FBINP*^UR'Y@;VH
MDP(?T6T-VRL+$7KE,SK$N0]>*67K.-R-<6HW4.>F4@T -@CFY"](BEW^OC3(
MGMN=X^5 A<BG 3(*N'.P)%197$B!$1.^V)H=0^%(H< I5?Y0B''-QIC0(,4%
M-.P9\SK,%QF4_MQDVMC.A!+=#<H,RL3JQ1QJ1M10H@W/33*D8 T[CCX;MW++
MD.!COP-?K<99?:!BX%8:MR:PKG"7>_<6\V)U%.(Z^V7L)8_M-7N>4:Q\W%8P
M05@*#P%G[/_,/,:"1WKZM]QO2O\64WZP:2CUQZD KIU;QHQ<I;NA*J5/67"0
MZ"A.2=GUBJ04($A)_*%@^&'T:_\R$Z.[=P=7%+\$NC9X<5?;$8(MFRZYT1LF
M-#;I@>#@HQ)SLQ49L 6,Z ]DD&EHF)K-(SONN)DT=!?*/'D7JF/11[C-=/4#
M6#*EUDJX(R;: 2HI<=&#-3=ECX:T_@W:--G2WTI^3YU?LH08MQOF]QD4K83-
M"'6XGO,6NU F$PV7J.7*80U..,=]@PGSFP<@%"MECC$-8#B6'1I" X9KPLUV
M;P"$4J!UTSA1O44K2C2"6P7LBH6798&,ODYB8KGIYTQ2!:"363L'ZP-,)=I<
M#A Q3R&:)8WR_:M&Z4)]16MD:T5,_"XFN!KL039X1! #V;DS/6X-'NFFZZ\^
MHN_!^U,F$UB,]D!HNG;3H.5TBP$T!M)6O('MGK(:IJ(J03J0_MP$,_Z.ZJ,8
M(5(B2O1&6WQ694<[?P?O=;]P/^'E[JAH*D.TF?0J@$X;,-E.W*5O[87'(1"I
M@Q9?0*RV%94B:[Y*\E1(\D(-AX6U$NY>8KV3A^S W?=+UT>2F I&BXI-9SO
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M3DM$G,'7;,_'Q)FX=9FME-9@FC'_HCV!,!<TO $Q)ZW!Q3M.#.+N3K,#6JF
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M\-)3^B I5LV24=9"B^26#KM-L%LN0R"@J5Q'QG22"\ONWF#FB@B%/*N8,T@
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M"-#GQ\=Q]/<:$ 57A_0?94*(W:MVGD0_^S\2 <']]_P3M]GN<BP,WPQ)X.A
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MOKS<OAFH'J@3[/CBMV/:ED8#BW:MNUJ5&$M 74OU-A!2 .RB]T2YB^69ONV
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M<-,@0PX8S$LDN #;=Q]A?%B$!+0<IJK\=CFK:O>X-"I;;"#-!]3O+&59Z+Z
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M0'CG.K8=7,6W)!(J#2\T4H!_DW$8'*@$!%_)6F?@IMDGL+_<;9,%O*3P;T.
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MY*W3T_2*D]$]FVH\37%"\Y9ERIM/OQY>'?;DY&7EK@#G+/Z<-$TRF3FI6'+
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MC*Y;@:;#@+02]L.(93A4!O'*8*< 8RP0[HL+ 2.&BZZME8>MJ&ZA"SJ4:2V
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M>E1?NW'#O;.5:;45V<C%X?%#X.F&Y1HZ79-9,;<-N]T=/FG1#R:#W]GQ6%W
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MX:8PDZCM$#Y7/.C+ZC[G817L"1IU;Y6(7@E Z98UDSH?DX!@ _H4>7%%7O"
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MN/["Z^)4>K_Q-JA@O*!0X.!5VP_\M/.6@]ITV+:T,U+";)%\O?!C5V'"*:B
M])0K$(^'>GH4BHX\_3('4IKXCH]#CN(U@^J+_*16403PU;L1IA> 'O;(Q( T
M%@5- &@.ZJLJC'G:$\J$S'GE1;%$GV/.*WJW<4-'B%3J::^"2,E*Q)#B*O]
MVI:X@&D]"XV-!RC!QRZB]V*%AS$2;H]\K+'U&7]-8<."+0N^4E3ZL#PC;-AO
M_.ZMCD\ICR.'8:]CKJS7ZG_I%Q&Z];THN"E$J.0BZB*!:I$ >IY% D^TW"E
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M9,Z/&(**_FJ4M?+HQ]=<Q&>Z-ZU8=9<DJE6;2U3[,I)DOFEWO]U-;Y]>2:.
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MO5D<)-(2RS3T=.^ \8?$41N6):J5_I$N7]5*ORE*/QU!"6EQAAG0C)A(L"F
M\I:!$#I%(? *"[%W@/A#[F?42K_!2K_&ZU:UTF^*TD]%3=P*;JRP@$,K 662
M &-0K#7#FBG+$<S0WL%LQ[6M5?GGQDDQH75SSXC6FQK:N 6Y<V.ZY>>_.Z9@
M?00<<ZS &,WK!-G*H/YZ)JCC(9)W.$"]SJ@*_IV-'9V"IZ>5E9DVP;]#+#)Q
MP":CZTR1;U*&K(:_&OX>-?RMX>_1X&\JO/6<6>.<!D+%G!:,GB[7'E J%0Q@
M*!/\<=449)T,!#7ZU>BWX>BWOCQ C7Z/AGY3<3ZVUBKM;0SQ@_.'#0(J&#2
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M5?(0,F'M@>5$ATC*"J"04D X$N(?I UT^EY&ZM$$H392JQ*%3#"GI0,A\K6
M&FB ,E0"E%EKH:+.*+=W@/;G)-YWQTC5R?;G.,HZV?X0/^%#^H=W0(=1Z7,_
MD7#O-[K#07^@.VDZ]\B^W^-V<+X:-XGB%E7&+[2]^?*N-H$)IZUMN;>'^=8>
M#R^-[YUDA=%-!KA_,M[@Y4[':Q.]E(G&LWEO :ETB )F4T50T#GC4D=70YU
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M@K!L);A9>Z6K ]7I@V":<6BAU$!D,'BEWA"@M=+A)T@RAJ77TNX=8 F;@JV
MU*@&UAI8GRVPW@%7J;*0$^$H=YPJ1\.J:0.Q1(+YS.@;_-$:3A\U<3I]'"]T
M!JEV&I@,*D -I$!B)@$WEM+,^%@TM7? ,&Z&O7M^4?[BL_Q?!SH,.?SM6E\/
M_B/\43[K4O?.6YU\_#CH6?$($ 'O!>$E"K8ZSG?^'WMOVMPVCBT,_Q65ZU;=
MF2K!38( "70_;ZK<V6[ZMNWNQ.F,\\6%U98M2[Y:XCB__CT'("EJ\99XD1W.
M5">.)8+ P=G7R:\$?W/7Y"VO(V\:]*99$?F#OWT>*I1O<AK  /CEA\/)8#AQ
M3Y.@/__G*#&G_PS4)SG=/3[\MGW\\6+GVS]]> \0Z/O3[5=;_/,Q$.FK/_J?
MC_>_?CX^_ K$?_$?>#\0^?GV\?;%SMX^_'=X8!*J4VH\X8YJPJB30)M90FP&
M9J0VKD #LE/!Z_T0;^]H,CG[]9=?SL_/-[_J47]S.#K\A29)]LL(/OZE^N[&
MBW<#TY]:N$W@KG M@XX),Q[,16<R@DOMQWZ"L0N![_S76J1I[<UV-FMD\F8Z
M,+&+R=[PO3L; NT/#E^6AX%3CIP:NU<N_OUVA)50L<[I.8N5[\?"U^> A2F(
M";I]?'B^\VW[P+(B2T3!B.2>$I9Q0V1:),28!/W!.@/)O_&B6/9B="9'PREP
M"-OM'*K>X+9XY !Q,E_ 7X5CUGB9,I9F7%DF.75)["^75GAT@['.+?H\-/KL
MOMHZX#3)64$M25P."@;-"Z*$<(1:[GA:Y,9)#NAS%?9@WY/OX42 *KEAWBH%
M&)2E7EJ>>.4\%]QFAJ4!@Y(*@Y*6$ZTO*GW=_F8.<D&U,YDC:<B;DCDETEM*
M7.H,M2:QWJF-%\M::HU*<7C1D>M<.#4:=W"DD:U3%:,N6^4KAC_3B'N('-W.
MR(W/'"SXQ?4O-L,[*FGZHE: K] %Y;SY:P!AW*A4_%[\/SWZY8=7N3,%+DUN
MI#_N 2"5P?[#:G !J-Y!6(P[:@2_QL9%$W<X4OW.F1I-D'(![F.'!!HT>NP$
MWO&]@1J8'GQI/(%?A"Y'FY>"H7PYHYL%1[UZ. Z-QWX=85]QN);?SGMV<E39
MKHT'2T,CF3VB-&QB.KG\D76!\1N2S\.C^2?N-S %#WS-^E2Q7"J6)DQKEWMF
M:)H;[VE1'*0HHLNGCD;5(<[4H2,:V-$)41[.^*OJGZN+\<8O\]@'J+< ^LN@
MUD#4?-'R27FQR1>,GX;MLXH$EC#@X6]E*=,YW,K_CBX 8?N=WWN \>:HVP'N
M?CG>KLNN7S9)[T--<$B;+]7XJ/.F/SP?WX0)\7!KP?Z=D5@PVN$H?74V=K]6
M/_QF>^.SOKKXM3<(&PH/_5:N5=(E8L6"S1Y %C^>(=MF$A&NS*(OWUQ^O!D^
M6O! Q,\XWP2%]=*/D\WTTL^N6C:EFR""OFO9JS_CV>4O;3?[8YOE-WKRFF*-
MM6A;<+T *>M95WGHZD.EXB:GBFSK<5S3JVM-]H,"]WI.@<-:D[F#/H5KO-EQ
M__5N4"NQX\M;/S8<FC=UHJ[W-5]9.72;TUY:5?D<09:V(+LMR)*[!]F3KOB[
M7J4,D-L]<R.%;H[.%EK&H;G432!Y361H&<2W1<SO;EG6;O()-()Z()R_72>H
M'R[.7SO=\>8I$:N.^$BI#3<\6]MXX+L=P?N5(_A\'WX'ZYYOG_YSNO,6GOOV
MFNZ^?7>^OV>/=][^<[S[%AW$'[]M7U29#F?'GT_?G.S0U^?A/70[@>_#N[;Y
MSMOM;/?M?K*[]S';_O0WWUG,=( ]['_Z.]O?V\(S?<-,A_UC.->W$]BC89^/
MX9D]\_7SJY/T/]^VEXING4P2JQ)*M"TD898E1.>.$E$DU'JK=":39]AWH&5,
MSY@QW4&(M&5,#\Z8%FM7"VH35R@"/*@@+&,I4=JF)$NY="(3@F)4*Y==7B0M
M7VKYTA/@2_<7>&_YTKWQI5G]I_FZ??SW@<Y4:B07H##IG##N,J) P!#*,F6%
MI()3X$L9[:;Y<O;&D^5+3WK*T U)N3$%K#,9=D8.B-?T^JXS*$U;_"W^;# L
M.,4IPYB^5?MZU)WX>M;%4_+LU[@CITR4P'23\C5WT+QR9X#2O9C!BOD[ZA1S
ML;Z%7SR7_MTWA,5C#AMLW@/\W'<A76Y@MQK7T8KPNQ/A'Y=\'EE>9%[JA%!J
M*&%2"FR0(TE*:2Z9S9S1=.,%ZR9\V>/1=D!^-I1]YYG4+64_.&4O. VRC.;>
MISE)<LL)$PR4<TL%29W($Y&G3#,0O[1;Y,M%L"UE/QO*O@-#NZ7LQZ7L1;,;
M<,M1R3-2)%ANX[.":&<=D8G-,Y&[S.;8Z;PK>#O@]_(I2$_!3@FUSB1,VNZ8
MQJCMCON*/[OG,N'W"9@JH0'R[XLSSUM&=W>,;G_).!$9TZY@*7%46<)T;HDJ
MF$5N9XP06J0I"Z/,:;8<]VAG)#X;8KYSZZ0EY@<@YL5>9YIGRB:*L#S)".,I
M$#/-%9&*6IUZIS.%I7F\FZ4_;)"TQ+R^Q'SG!DE+S/=/S(LFB.5:%2(W1'&,
M_.5P65+HE/#449=+GR>Y <G<I05]9K3\LX5*_@Q5]8,.5ND-QZJ/M8"A+7U'
MC<=N\FRFG:ZE"7))B@,.;![CQ3B<V0R,;+SKM\)MM(SM5HS-+)L<2E%)LXPH
M4PC"BB0G0GM)"I89GR7*:NNQ(^LS<ZRTA'N?YL95]+KVXSZ>"!TOIDPF*C'
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M81_AB+4,1VKD?E=C9X$SXGP8A9MLN=_MN!^=&2P?TYU7'[,#RCU+N;>$:J/
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M977YPOE31TUP.NC#&<L?)Z!]][!4S,T#]AP 7D,7MP1:@\6_1ZJ'J4@VB@
MB8GI@2C@AB&>47E>@2D'<Z4TN4#P&M17@*VKPP@)U!9 0<5E/2C<\ <>J:EL
M3D#F3 ^/ G@!T$=UFZ!5_8(B*QFC($$]%CZHCFR=GLRV%<^.L *:!V [=[+J
M0-6[U6B$5MCI3 ,+"H [!%F(_F?06L:=F6E9G1/N!<X"N-#1#K0,S-Z:!AT\
M*EB-%^+9H]P%F,.7U1<%UBF6[B%:NM'I&!FB.PLN_*#JS"X*C!P?]) ^J 8+
M'LX%)\/3E!VK7277NSZ:9!$T$'V,XV01@WOCDW&@XL@8HI9>&E$(VGDE'D"
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MC]F'(<060@Z-)!D<*PO\&*->,RE4^NTQN0A_40<-IQ,0EJZ*[<U+EK'KHSC
MS((@AZ/H\@JSEI!Y!_$"OZEWL>K-FS-=:4GJ^2&Z6T-6%SXZ)VZ N9L3$E.P
M0B &+*4 #>3P \R# 3D/FJ2M?E&&@;SJC3I?5'\: 5L306^ T=_36<2SAX-X
MR\Z4>C@:Q8V, G# -D&/KJNS3WN5],$G<?4RE0GW'^(B<>>SHUD'^D2T.1'
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MA=/*E()YO(:S@G8&+SWM34_A9+W@4$.SIF2&X<VGZ$'_-JMF =H"_7",U1D
MV\ _0P; X"(X#4,<Y;*U3/ IVI@Q$4CX C81WU &'&)^ WRMKC4)VRMUU/(%
M\1YJ5;HWF%%6B-D'@,; 1+<S<)/@=RPSX>(K&A7;7UP=85D)M$;VQ?KD<;T!
MQ/L'\6[7U_;INYE:_1-KG:_9@4NI,UEF0<T$A9-E&0.MDSJBA;5&%#YCA5B,
MV#JO>>%<D3O'&4_@/I)"BUQ0P[#3SE)3GR>JI2+>=/ZIHH<SUT8#=YZ^?'DS
M"Y&&@MY:EXR92+VJV/(\9$GIP$D<\(' F,:NWP\A86S%&?HSX*"ZT$D"MH1)
M5*K1LP=9.:9Z @,&Q;21[PK+3LY="&<'_3>X.DP/H#&IE<]3I]">#U(/>4U5
M'1H8_N1HY!R)!<%'/6 ZP$<O2K<3IL;VD"N/RTCOV7323"U"G:$W"*6V,U!$
M;T4/LU)G^R\K#LM8;FB_H,9EW'K\ZTU002YVW>-BUG3O<O0@CX@?(7TYKSMW
M/C1EKMK4/ @SBB#<>/$GWG[4E=)[WNVU $OI;_]4T;Y&ZYC_FPY#;QFDJEA(
M&;H(E6@?Z\=Z>..QP#7,J@A&6.]V?3E:-'L0-*-/&,VJ]FTED@7-NYG>,K_&
M/&)>^WA4,N??VIW569<LN,Y]'6J P1<T(\*7RGI_@VDXNNS:!?QX]JU*3( 8
M4"T]K \]9&M*#XOXIH?8@*+AG)_U'JCD?U/;B%T^9NCW#)P*>W/AE@B81B9;
ML]W9Z="Z?I!"BV ,SK$&5:*CH0&FRCZ,Q%JU98C:5IW;W@#YK%I@"(M7:>O!
M'P0J(^ =-MN+BV#H"Y^N<]O=5_2;C2.CF&_]=YF&!V>,OC"P@P-[:\19,(_F
M$+3&;V5B.JS21'/8T\H 31UPBXIHG14YAUDS];0)Y=!,;'B.FZG;VL3] \SK
M'G0WQMG-A7;K3Q=1@XX_JV0;#.>C:K'(H +&#(-/W>1H:$'-QTJ#;\MX86/'
MLV#CA*JW<57VYFQE6<R]M3)HQK6M$C"BDW;+'\HVE/$?6;1U+E8LWA8AW+((
M0;9%"&T1PJV+$*XM*EAL+U!P[;7C>:(4<P67-D&_5I$)5S#ITLL2_*]UA3U9
MOAM<]Z%LKDK'N"R%OHKWA":J_JKF8HWH0C>6N?5F*?L-=W05J8CF17>6?'&F
M+J*=L)COO^+A>8-D/B-_N2/<-<6$W=*+OKJ:HAG: ),)KKF'=833JM48?!H"
M5(U@W#/0(K%QZ7* J-N,Q<6(SHI08A6ON7WX\^/FA\UKLJM&KAD+B\5_I91>
MC<$Q!V>^6F3Y@=+8#6[2J%,&-V!L\GR923NO!C?L6]A<<*.6;05"7EQL]C>Z
MH>U;)B:-@Y4>U-N&93Z#1S>X;$,;8M"3S30$E1K-!LHT.(_-CDIM/X3G8ET1
MK/*EJG?1 .DCW,!"Q+E11WHEF -H H KN(7BW%%O7.: ]7LGCIST!O:RYS&9
M/&XQ@!H#FT"3%JGM$AA%3W8/,^P T5:H7_/JUOU&HO["IM^CR<5??6P,-+"8
M]Q*:U/WLU3;OON[NG<#OMB]V7VU]@_T?2".,24Q&1,H4806V'2A\0:BA5AAE
MA://I?"FPHJ WC5*A&#LTQ<2<X=S<X?K!IMV$H<GQ&:$W3+A:*YY,79Y[)7M
M2+95Z'@:(O.X8M AJH[K=AB2,JL.W5AT@QX..]^K.S85J%KXUR[,41W:#B*C
M6<(RCJT309@$L=5W9>-$S-M2Q]CTK>1_9=*6FZ!XJ#E>V0T5[=#-SD=LE&M[
M8S#%5+];;B:>-+2E+8/Z*X^/\ (#?_BE&I(Q*3OAU(FI:'/&O@:A6@A[PPQC
M/U]\=E$+6MURI7-/3/ $3)E?J_I/^W'L_+3_)U[*K@^C_,9[R+Q_7AX8 O(7
M!YY:F7)F"$^])XQ;1K1D*1%::\X+1KV32]8+M1G37%/%&;/2B4+EN@"C!*XF
M3W6QR"A?+2%5F1T2I7+H 0PJ0IB<CB1=^E,ZPW*&0:W]AC H]GJ^FKHJ;2],
M>&B&3*_JO'8),V>7,?/5G=JN@\R+_Q=[ M>N$@Q/XTS OCH;NU^K'WY#DNVK
MBU][@\#CPD._E?LJ_2OH3U@811@V&C^>N1HVD^ANP*&"LR&(Y<>;X:.% 8GQ
MLTQNYD)>^G&RF5[ZV57+<K&9II<_VEPVS$$LM[UBJ.+"N,;KYK/"=3[2 %,T
M_Z:8!ED+I-A,=N@G..EF<4SE71VU=F8\]'FOXN@.:,+KU.1%8ID27FEODR(U
M6<%9QIW[$;6V8O+>+5=4VND(<T^?*)NO1[&^,A?;G[;3G>/?^[MOMY.=5__T
MX#OP3EC_[0ZLM9U\?K6??.XMC6(]V8&]['_[2+>Q#^ZWOY.=3W^ *(#S'9MD
MGX+(^/;^9.?X_>E_OFV58UA?3P &Z?:WPR_V[3_,_L\?_<^T_T4?GYUNOSKJ
M;=/7L!Z<Y14\_^G]T?[>/O_\ZN3;]MY[^/P$5.S/Q]M]D1QPRV662BS%XY8P
M*RA1WG@B59H4(K72,[[Q(EMDSQURI6J0I\!1<VP*:S1+8!6N4Y?R@OK<>&%8
MBTC/#)'X@4IU9K =0E(P1ICG6)7D.)%>,^V,R0RS&R^*)43"^UK(G7M6\N5/
M%9PWH0%ZK']OC-FI9<Y/)6:*3&9<R4((6@!N2 4:F2H*K9(LT< U6N[P^-SA
M]77<H;^[9[+=O:.C_>/7%SN?/B;X\^ZK?09GZ6T?G\#ZYML^P&'G#8B9(J&*
MLL02G664,%-( J9C05+AB\2D>9+X[Q SBFJ;>Z.LL985F5.)3PIK$@:&J-3.
MMHCTS!")'_A$"DX30Y2F#A#))D3)5!-M$R_RU&B5YQLO:/+3R9DWT]&@%WIW
MJ> S_XH_CW\NN0(Z9BJ5M 4#0Y]RD7FP\G7F!<T\2)J6'3P^.WAW'3LX1HT2
M]I)]/G[];6?O!)Y_G>Z^_<@_OWU_\OE5_VC[V\>OG]\":T#S)6&%D12TSDRH
MA#"I$R*-$"3/4PIX8+(\U;>7*\)8S[F&YW7&K"ET@391D2H+:@I/LQ:1GADB
M@?G"$Z5RY[$;C29,@0TC4N8)\!2J39%(G9J?TGS!=H=8*5F%4N9KG>Y8K#S&
M"3'*Y$:Q3>6IBLFAM2?;N]B/OOH@_L;'+I!S4 @7_DOP!:\*)C_=J%VS)0EV
M\'?GXVO\_N7TQA6Q/LQO557 (HQ^"Y%XS!NH>N*5,8?FFDO#X<M6V]CN#C-*
MJKA=&-T4[PK[)IC8?AIS'4+_:EBJ6W>)QA7G9DLW)E^&RK8^;*B>P%V]<59R
MC//?0E #CP=?&)Z"$"E[9L-Y?-7 &I"K;+EM>Z:<N%R6L35WK<L&J&%L5,R:
M09P<A?.Y>IY#*-5OS%%0@U@<-\%PY!S8?#V2;9:JHBRB%GYU%A?LA0L)N;.A
M9TYYJ9N=EV4^;>.7,819!AG+S88+A<NNHSSA1C%191:M+*^T2L:JD\E"^L=X
M89]57"D4W'T)B=PKZ/++L\B:VBH)JNK&N#)IO0FZT*&A0B4;4<E4@S]ZSI2M
M*I1ND%Q=K3DCB1+-2MP*^5B+F#6C[MBG'IL*!Z3I+NP/QYV'./D"T<[:U9<7
M&Z+45VE=QF8X=M(*0143.M$ISREWO"B8SZQ:C"<G>9:T6M</!)G__K:[=W@>
MM:>/#(<*:^JM9XDBF5*>,)90G.]1D(29+ 5C2F:.KE*"@&=>=;%PD3:3.)@X
MHRPO"N64D9Y;IGB1>%64%UNTZO2]7.SQNX-"*>-9KDAJ-/;I5 61B73$@(&4
M*5G@R.B-%RE?K=YB2B3V%(E2XAR802U0Z\$:,XG0$ 9]G. )K'A02IJ_LS!C
ML6QD'H=*5*,/9S*H*<,J-M2Q/1L2>B(3BF*KFM-1/0MH.)<B4^;PA%TA>PK<
M$X>UVDN&/SX#D8)9]F&:-78*AAW#;1R.,(^JFD/U\ET]A@IU H1I#317S;"N
MY3%^Y:RO3$P4PJS*GEFL>GO8#A[O3C'+"TE_=_2JS)W:]7^"*,,$(AO3AW[V
M',J0/_3M(%>I5D90XC/*"=,>ARL6@N0>^&Z2<,]PN.*S2)R<H45(V,8\\X /
MG8@03Y^PYP8Y1UO)E;VY^N&@E9J%++B>PMR;@04LGT'LQ1E*.,U,OS>]D9F>
M8G?/6"0>U<NH>,[IZ@NJ.DZ<B)TO0]88*.ZA)K;SR55Z;<P *S^*G3/*)0;
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MV+/:,%S./T8OX3RJS'J;_MY7@&P?S-&PC^K?6<G18Q/UT%^\@F:-HY-J=&1
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M'S]T]D9A<-;<"(F8<U$/WHXR.&:XP%?Q'Z7E>QFUSGAV(-SYD@2,.\0BES
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ME44T9<X;SAFS8DW1I54M'@-A!,]RY=.<4(<5GIG56.VA2%ZD69X;S3W+0%:
M,2;SKF!Y*RM^+EGQ@QZ7EOC7B?@7/3%*IBZU#*B=I9(P9D!'5"DE("9TEJC4
M4N[7%&%:Y>+AT<5R*:G,!<DRH< ,52F1'NZ1JUQE2G.9)6;C12JZA2BZ:?[L
M[8J?(1OG]R4GW:5%!=_IF2U3NC.X2#N<8H)XR']J^&T7/_IY@CL_")OU5D2N
M#/Q4I1=WZ[6BE\9_%DL^2H6DE1FWDAG[2[XHK8K"938EJ6,I&*36$)'DC/"\
M8-RGIE!)<G4KW<?&A%*Q:/'@Q_# <Y4F4A'E!*B:M@ [,TDL831/#:B&QFG0
M'?@F6VXC<&<QP!_CID\C':*5IJTTO3$/_4'/7BM-[YV++GCK6)9EFG%&TL+F
M8+ S1V3&*'+1))'<@?C[/FGZ8)C02M.[P ,N !&$]21ASA'&4TH$$RG)"Y5;
M"O]/L9U=MIEFK31MI6DK31]$FOZ@Y[/EH??+0YO>S)U7'P^$8,ID:4*,S#1(
MT"(ETCE!J&3,RZ+(,O]]LO3!\*#5JNX&$Y2"RRJ*A&@K. &&H(GP)B5P8TSP
M0M/<%!LOTLWB!A[MGT^:!B_X+Z%+QXH.U77?ZDMG_5[21O>R]C W[&Y-T_7M
M;LT>J[OU&]4;X8!NX!QCTQ^.IR,W7IL^-OB>R#R.MU^9;.?3Y][GX]=?]X_?
M)9\_O3L'AL*V3[>!L.WI]JO/\)RA.R\7^]ALG^]\,^GGTS].M_?>]+:/W_?W
MC^&Y5X<7^]^.CG?H_OD.,IYO^\E_OOW-ML\/N-9@X'!.B@ST9T9!G1;:8*_K
MA%&9PH^96>QP;87C2@H*M^L9HTP88R2@7JYY:FRRU/<&P1X&H[O.N\$8?E>.
M![BJ@_53[$2]NNWV]=":ARZ8L,X4.=.%]4RX3'#FA&.%1YM7F_S>^T#55+(5
MAK5O#>R?/:5[_=!V;=LI)!N[.WB/K=BPES5\86>(X]CB/U$[&Z]7BZA'(*V=
MK0.J<%8FXX0Z)0G+E" ZD0FQA;7:6@,6+%N\?),QE24N%]0#5Z=:.5M(R0!-
M,M#5BJ71(7NA$RC.J@_=NQ'JX\[X:'B^>L":&A]UPY]SW44QNGGUE"4]/Q&X
M%WJ]A5$Y1DW<X7!T<65[M\80VF9CM\Z_>HU>.__^]0;S'2[C$0NCWJL!E;^&
MJ4GPLDN'OY=Z1S)[1.GQ$/7*-9H7?\ET$I+2A?D8C3^/1K-N/(>.Z)%3)T1Y
MV.ZOJG^N+L8;O\QS66"Q"U!<'P"LUB/^=W0QGJA^Y_?>$&=K=T&ZF,L;\ZW+
MKG=@L^,XU:$Q]^M-/?WDPVP"6"!<^AM^,_*(I<-=KBM>,0CB9A)F^;EKF=-E
M8CLV/7SP[G<\3[^G^QW-P-+YOF9J5RTK-L5WMJF[FQ9MM]LKJ M/9*\%W'/V
M1/8J-Y/O[/[W&#CP=/!5;LKTZ># ?>U5/$*KQH=IR[;:27U=YS[Y_0T)'[/;
M7+/K8N>&W?J^)S]S38'R?7=]?4>Y%3[#=3GR:CS8.AW"7G#.Z\OA>')71_^1
M%H3?!<+'[$+X=H0#F5$YGLT8#O]\BY-S6Y#>)4C_#&./6YA^#Z4?'H[<(9A]
M'?2]!6@&!UP+S.\ YDMT;Z'#"7\(L'P]\W4] 8A>F2#QD/Z,FX'[PQ%(*8)3
ML1_/\W*SG6ZKT8D+_H1UW^ELRDD]L?U.=R%OU@D]_?>"2ZDEFCNZX#^'@\.6
M9IXCS=";T\P=U=1YGWBSIC5UEV"_^^+ZG?37FPCCR\Y[EXSB40L,;V[87G?U
M-V&O+3A;<+;@;,'9@K,%9PO.)PG.!^J5^JB@JWTXB[E*/](JX\;E*(]Z])N7
MHZPZXK7YSX]ZMMLT]M<)I;[(4YIZYM)$"U9P*KPIF,1BZ8-WE\TOF4]F1$S:
M&EC\J^$&W)J\5*/1!8 M^%F?2+_K[TQCC.4%9Z?;I_\<;>\9OOOJZ'3WU3:L
M_^9D]Q7LZ72G_WGO([SKCY//G_:SS[V%\H+3_8O/GUY_W?EVPG;?[K/M;W"6
M3W^S[;W/O7WZ3W]G#]=XW_]\;$]7C3-AF>))JG*2<(;E!=(3*0I!G!>)R[+<
MVRS9>)'F:5>NF$'\D"UR:N*XRW9J]\*BGDC%W'>QJ$<]6YER][0;,[58UV+=
M\\&Z5AUKU;%6'?MN=6QGL8>&2B7-)"6>)Y0PFQ@BG>?$%UF6*D\U%[)5QUH6
MM19GNP6+REPJ<^6\%%:R'/[6*E<2?C9%9G/&?XQ%K2@=;=G47;*IW<69'T8:
MC6W2P'C,"#-90J1/-6':9P98%'>RM1I;_7T]SM;J[RW6M5CW75CWO!)>5E_4
MAZF>#">J_UT3W.YDW.>3UNR,S&U&DUSI%,Q.8Z5*N!*%M(GS+B],:WRNJ5;W
M]U(L(&7&"<8-*13#IE/<$:4M(\IJQ8N4YBZQ=Z;5W=\$S.]3^:[IR??(W. )
MBK*G-.*TO>#V@EMYWLKSIRW/%YW)B?5%HKTCPDM&&,\H$5H;;'ED<I7XHF"M
M/&^YP95^6Y5[4 8!?ZABJ?3:&28S#[\IX(\L;?VV:\T1%OVV2LM<2FQS1GE!
MF,"9:C[G)*,F<XGA4A9WY[=M.4*K +8*8'O!#W/!SROS^JK://I]M7G71!?:
M-=HUVC4><(V?84#GR^'IJ1N%SIEGZLR-?B3&\@2E[BT,+699[A-'6:%RE@@J
M-*4R\3[)+)7<W-CMLE6U"GXS''T 6^F5TY-9]7W=M0J;5H5>T*V]=7?VUO)@
M0455[IS31(F,$J:L)RK1C(C"IR)+3 XWO?$BS[HY97=D;JV+/M92]\-3MS'3
MTVD?6Q:'1F"S'F#84>UW!Y3N]M37EJIO2]4+?M7"9488E1-7\)0P;H"@'9<D
ME1*067BI+-MXP5N"?F($?>5<K36C:&SHUU+T]U+TSH=%BJ:T*+PFB:(X:,4*
MHG-* <VH-1)N,>%^XP5='EAXZXE*/Q4U/Y4HQWT1\XR0Y\FZ5;KOE)@7Q+.S
MW'FN$V)H80E+)1 S2QF1(J%>2*NRE$6E.\D?548_>ACC"5+U#SFR?ZIK>BJV
M4>IR)K7C@A6.F2P5/M,<I*]10MM"%BWS76?FNPV,-WH]_J8[>]OL0'$+."LT
MR31.?U:9)"!.$T(U+R13:6ZQ@G$-N.\3U:F>"EFS/,V43;,L20J6Y8 (5B;4
M6*%S+[B4]TO6_O]G[\U[VLBV]>&O8J%[W]\YDC>]YR%]A90.22M]&\A .H?\
M@_8(3HS-]1 "G_Y=NZH\,YG10+74CK%=57M:SYK7:OV* 9W%7K>FZ*4I>FN6
MHE/RT6#C$<A/%G&A-3)<".0\QM9;;K D8\;\S$CZ>7F5+W+2](Z[O5S@WG4[
MX>(J[)=!VG53T)XTI"5/N&#,A! (9\)HHZ3G)A@=)>.6USZ:U<<WO^"CP0X
M"H.L0B5-B',GD0V,HQ242E%ZBG,NLZ9-RA=;;#_M]+Z:NA^>NFL?S?U0]9P1
MR("<28B6B D"0@M+0-52.A2\)RS*X*CS:QMDT:);4_1J4_0R3IK')NG:27,;
MDEYPTF1+$4T&&<$YXLE99+1/"/:76<NMD=E)PXFYA9?F)9+S4_'2W!<UUX;"
M!Z'F.0:=J'711(*"=!1QXAW2$5Y"4D($0H(,&L1NTM3LUI$4MZ+J>ZD@],RI
M^A&*GSS1;7HJVI$22?G$N B<<Y6DY<H&(Z5QG-D4< V^JPR^"UX:062BAFB$
MG0?T53D14'"%I(I1)FRXUWQM0ZDF);<.3'V),M53(6O'-'&8<L<2YXXH1S%1
MP4L%6K*UKI:I5IRLYUPU(4BOG)&(2PTOQFKDK,3(6FV)-83JJ$!%:DKZW$R9
M+R&;YLOZY\9!%T;4.8J=0<,>Q(X_;?3'Q%5GUUP$<UI&3:75G$7+K14Z.J 2
M'XSW2A(9:L_-ZL/=P8+GA@8B3 3YA3&A086T'%FI)"))PF;3Q+5V(,3(IM2W
MMO.NF%^ZINZ'I^[:<W,_5#UG&!("1QE%1$11#C(,8<@Z*E%B1"2)/:.\+(%?
MD_03(^EE7#>/3=.UZ^8V-+WHNO&@6!J+DN' J340MH$-1@Q3B77"B@F^ML%,
MG6#SA(R\*T#-M9GA0:AYCD-K&Y)+TB#'302Y&UMD5(A TIB;0+EPA!5R-Q>/
MRZ2?:.;&$W3=O,1M>BKJ$4 O]CXHGISC/&*'!7-"4$4(29K5X+O2X+OHNO$A
M$,45TA%[Q*T2R#"C$;!1800QFC&_$NC[1&6JIT+67''KHI.,605D[5R4'@N2
M?(YPU('5"38K2]%S7AM"G<*6"60-QX@'GI Q1" 6F.,@)6OO<9U@\W03;&[5
M8:::[X4U.)^BC+F,@YI&8QEQ7E'%I0E&)6P=2<03# SNQFF$M>?FX2#OQV+7
M>4ZBIXZC2$5"W,B$7"(4$1-#PM(*8<S:!J6T*;B^(T_U]2CH"06<U9!PKY!0
MNWON!PKFFU2DP()Q'ED=+>*PE\C0%)&C7HI )78NEZ17BU']-0P\/QA8QD7T
MV#A0NXAN@P/S+B(1A35*63A7DB$.$@)RWDOD@U0&]C=&RM8VSDL&6#J[Y^5
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MBSZAP*QCSG.G%5O;(+)I.'MF9/T24E-NU4BFFN]SJ^2Y!-@YEX1*6CD1)/?
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M:URM#06UH6!5#06U;>!.\75.=HW!:BV]0]X*@SC-MH$<3&T-<9Q8HF,PI6V
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M*:&LYY%ZB[F)S'BB=8I8$D%DX&E_,_-13#!!\PRUL++\8=NPNO'S88R#C%G
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MR4"  "6.R!"2D)#&*B4")PFO;8BFHDNVRGM@^GOV=JUWPQY08@X+S#Z5!+0
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M(B$Q%,1!9[47-FDN/$B-48:E1?9Z\V^R^=L'^X$QAT.RB'D,:GLT&!F6/""
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M2#DQUWL^SG^5BU?"':Q6=O2,]-WS A5CYP 8_!C*1O$_&5!*])FHI_E6>8F
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M0."7?2#PUMG;?2,2)=K8W*TP(&Z50SHRBA21%DZ*D$3#@1@< MM>#/NZ(5@
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M/XL*9(6U?KI*S=(]06YX,.< NXPWVNV^[?M>]^1=M_<IAJ$?V;(_Y:JG[?J
M7O> _MKG-@8)4(UR>@3 M5"YEV5"+/"D!%$\NI![65X!U^N-NFK-E55K9%VU
MIJY:LW35FBL]-W.>GA18\E*QW/.#Q^",,99ARBB+B25EEZQRLT)ZU%\6%J9W
M>G6MX@_3LE_.JIDJY3E6CC^/S0:%2C*I7C^M_L\QS['@5\F"(_GPO%R+6:VO
M-&^,KR]+C2[)06O=9U69Z7NRL[FU#YP42"Z!B$<BSPYCCS1EN?62S]FK.1O7
M7D/UF>O$D(_AS?7EVTI=(W6@E+<V8\%XZR-QC2-!MW8/]I53"@/=HH2E15PS
M@6S.=V$:"Q&C4<(7;9BNJ-"2[8"A7/L%B)K4*Q[;V.9MJX72D&L2%5Z55G]\
MKQQ!U/" G*W!3"W9.9S*CIXV7- Y*/Q0[Z+K30'QU%@J*U7EO"G]1-FC/"GV
MW#Z=5) NFSR$./WCG[95MO0I -/GNHL+Q=4'A[D54:]U<%!: D:6T-(5M:#A
MS[(*H(XJ+*JRL;6*VJ6=?D5+(UM^[N0 [*],;H/SC(JGY**MT]X %[T=%O:!
M2:G4TA\1RW3!<<$I6]RE&-C(,C"ZHGA\RIM8<IG25IQ7?7%FS5'YJ_& Q]R_
MJD=?C2Y7FR];AUYH=RAUR53*,CD-;]S2JMCFLACEA-F.#T4^"S$L6 3GH]UZ
MN:YKOS^I83KNIG#!>/+X*^93Y37FZ>=<V%F#=+::YG6;KDA;=0D8&S+G#9VC
M:TZ+'K VE!L[-E3F\P#[N-[($>JS(YRRGHY4Z)(61L\8K<OL.<OFFX,."#BA
M'%3L3Y)UBEX%N719>?336)J<[$"C+.-7A1>6/H%\)$>%@"MU?"H+LRR?FPW*
M.9QQW%"JV*P\U-$P2_8R7IC1\>E7Q^=P@BDWZ^%3W/["?9CI5[#XF-)5WR]6
MR@_&9WH$&>6A^VE'<CB<GM+/]RYWT^KV9@JP-JS++<A*9*QN-[>SV11R;ANC
M9J[,VYCQ$UW0_*T2(F&4[>[),_!7O.X7IM9Q#?L)TLP%'.0:WQG^CJJ8G0DH
MCLLTY\^GW3K-4398:20=%SX>64FKI<][/),,6=73*P)EQ\%0Y_A8;>$ZO,3)
M.B^7YV8)L7(9?GY=%5;OP+Z<C?*=1],==+L_SG-Y%5#]__IST\R)SCY/H*#>
MXE@5SYAUR#6+GC)%>%,YSG$V7?9KNR+HH2")(F%[_.626L-M$[YF0R#*"<]&
MD/X]6M[7Q4B+ST8U#9Y$5/PCBXH?\?;9QWUOHK01*\082X@KG)!EGB#,-6:)
MBQ!S74V]V*=W-BJ^))]\@*8<*':Z+,%RO:GN+J>F;%(U'L?;O/<%AKYI9QFJ
M:EJU,AVK'OM0$!C;/K/.1*(4DL90.!3!(LVI0SYYXT)NJ<WEN?Z#_RX"C<OU
MS;53,TC&PH%\3R'F5^QNCO):K.,8AKV<4_;2-SJ7YU.@&WHCD F2(>ZD1EIR
MCW 46CBF.&9V;4/,1XI7*7FC\">*%7D&,LAL(-$5QK[+SG-BPD:C#9$\<I;;
MSUNEM!51"B($+ZT?A%"R6 +AG$R)?(9WTD@.K$_SN:>9;FUN[8<D0J(BH61B
MSO:+$EE8Y%PRFF)G57"4KFVP<T_SN9%A>?__Z.;" $W02_L@D1X.<Q6$_B@F
M]9S ]HFU>#8:=?8[\3SHI>H4='D%]\M(Q1)%8O8N6$)YKI3O+', /M8:!Y22
MJ@!91A8B!6Y(*D?PY>'+IA66BY_9("WE/I>_L28G< >D3?!(!.6E-]@YQ7,#
MWP5B*1;P0FKY-CQH-CZ#ZG$6>^VI')%%0ID-*Y\AE6D49NL+:4D/G*DVUC.V
M<OPN_+N;5<(Z?>V\]+7W^T%391WA2 .K0YPSBUS*57\EQ=%A8BCS\^EHRS5_
M6Q7X>WV).:K92,,BV#OGO.8F?Y,NZ?TITWD%F.-N5G,Y5Z-V/_VJ4GJ_\:\B
MTKA4N?K_?G4='B)F%W'LUAX4AHUQA$-N981R,K ][L=7HS>_YYIJ;7OZJM4I
M%J"XZ/?J[E581'X B/B#W(.@>DCQO/+K*D# F'6%58X1&/3@_S!Z<!4^L%Z$
M#_PV"(O?:;XNV,5?XW5RX7>7W387H&7R1K>]_#O!^+6N_*U8B'(Q8+GS1A86
MB7% 1LBFI%?T^%>#G+>%\VM>+O?#TT(1^5&E$8^.8S7WU9V6OBH*HYC5F ^4
MTQMES5Y[DCA/\9K[G5T\!X4U#U6S\S[&E'Z_9,7:,2V0WE$KA'9\I&.0^?7\
M^EPUOPIZ"L _'C2*:)=&'NK,S''CFO-_5#+XKWN:_/2D"P/T2LUZJ?;/'DNF
M I=!<A,X+(QUF&JB1$S.VO-;SB^61KE43AL9@3>'<1N>O'L2VS_C5A9;7Y!=
M>._K7_UONUVR_?4+![F,;.^"#$>WX'[O8)PPYK-PM+T)\MW1M_;>T?M?WSY7
MU_SGKT-W%-H[W[^0;[F0#OR[??2>[64=^^M?K6_?V]^W*3Q[\RW,\)_6WO=W
M[?^<O1UL?<:__MY].]C>W6*Y,#=F# 3MR%!P+NOB5B +6AP"V5#[1*0( H-^
MT91<7V!:OA]:RE\M25.7(/V5J'T[%I"*_YX:"^ 7LDBZW%S/!?T:_Y; O[UH
M>[LGW1KV[@?VWB_ GE?,"1\$\BDWQX+#C*Q2#+ O\.!STR*;:R<V!3.WA;WS
MP>%>P6WND2]1OA4W K=SYEJ#VYV 6^XJ5L/;_<#;U@*\<4>H=<F@$*1!7.<,
M'LX)(M$3RX,A/$<+D"95ZHZDNEIV>U!XD[7LMDKP]JX[[-7H=C_H]G$!W714
ME#.G$!$R(FZX0=9&@TR$C8Z<\XCE':%;+;P]!KJI6GA;*71K_:QEMWM"MR\+
MZ!843M99B8PB(+M9![(;LPZI:)P75ME$748W=D[5JUIV6W5TV\V=28K4[5J"
MNR^,&X>B7PAPN]T_X@?;"J_S1M0"W/U"W-X"Q$G!@Q,\(6PQ0SS".ZU-$=;.
M@G*4P?<Y;KFIY$4![2]<@BO&3T59VV&57:WO9N-KYJL5C])6:F]T[8U>&9FW
M9@3WPPC\HO<YPH8*'1'+J4T<\UQ$GV/D< "F8"WW*6ORJJDQJ]W/-V!Q3X%%
M9+)\U7A?I4'78O&CPN"73FCUJQ(!;W_E @NOBY8T-2;>#R8>+&"B(!%[ST@V
M;&+$"='(20GHJ"1L<N28"+VVH9M:W5K_KV7C1Z7]#X!W.2GCIVT/BR(,<_GH
M-V1M5;PW@Y4(W6&.'B_86RTRWW9I:DXRQTDNX"$UK[@?7O%CD5=(ZZ0P$2F"
M<Z]TX!6&A@A<P^'(M(I$\LPK#+MC\?E6A/3HPO5O17[,=#'2Z?9:]Y@!_[EJ
MGK23/@^/C\O.D+;]IIN3I/HQ3%>1_*,L[O,YMPY\/RE;,VDR679GJW/<+LIQ
M^[C/L=:,TH2DL!IQD6MFD 3$HAEF O;,$/,\<MRF3]-LU\F9DD=3]2JKQ+56
M?RIM[5IY:E7'MX=-2P,.MXY++K=L7IK*J5[J/O+2F+A9NMM5>6GWDD3'S7TD
MT0&+N<LDNAFD7NG$M*OK Q>G=9PAS4BSJ.N;N<)-,].>ZX*0%4_5 ]1[))%^
M9R[/^-4U5FIYP^>T>':- [><O/4D!GF7%E=U+;O#XYVI3PN%\:[O?+NNF?4)
MVPO.FV*M]U^J]Q<G:B=]Z<?7^3B]..T??O//(8R';9]M_<I:^\[N5G[N(6C\
M8OMH"_22OXZVOL+U"]K_QS/07TZW=CW;.GO+OGW_*+;.\AS?@<;_@^Z=O15;
M1S"?LX^_SDMB(I:0Z(1 4A/0_B4UJ CZ=\%ISYF6">.L_6/^W*(H:I!ZOB#E
M11#2$RLXY=QH;D4RE%EO0),/,<115;8:I%83I$[G7/S>BDBY1%0&AWB,!FD*
M2!5$D%C[J"/5N8DKI;=.,%\QD+I+=]:J2Y5ORJK=C>-N;U3,_0IGUC(A_;=P
M73UI*+QG/TVU:346W@\6+J9ERJBQ98RB'/V*.,T)YYI9A*-F.A"O/&9%UKDD
M+R;:J8:"1Y2*:BAX,"B8$XNXB<J8I)#!SB*>C$86LX12"())[I5Q)D,!YB\'
M"A[ ##?MKT-\_1SGTR.'0MY>9JIC(6\O&6UW.[Y&Q/M$Q,6L[DB4$YXG1"0'
MX0@; XAH&&(*.Q-"2EK(K"@R]0RM635E/Y"@4U/V U#VG*S#O)!128M(\ ;4
M'NF0XRHG.!OF8V+2)E![9-/H6T>IK1AEWZ4)B-!UNNH1S;O='(!T-V',+SI0
MN0Y%KD.15QGD%\M6:.UI",0CY4/N9:L],LQ*A+' 7B6AC73W$HJ\P@IM#78U
MV#V@;%N#W;V!W5BBA97:_;@ODK0Z8(>TEQAQ(S6R48!8&S01QFCOI2@B+^A%
MW=R?']@]4/6>Q_-Q?BW^R%V&84CV(#9Z\:CJ4UM*O+G!=='=M6B[=Z-8S6I-
MIG9[/L7FDN5:66P\-Y=F&<GO,O@;;<OK<E<^C39EW&F,/.=>? ^+A(NE?#2-
MG*<BO481Q$-*R.E($361*:YA([-NG[OX+.19W8(^;A4)O!R-J9'Z_91I;1G!
MHZ:UE:&U.3N:#-%B31C"C(.*Q0A%1GF#A 0=*S#K",M%Z_DZOW=:>_:I%PO,
M?E06HP'D$.OZI)?T!+^92><*)6<.>3:KW?@$F_$L6X,_+-8L5F;R"CL%_Z-(
M<VPYE0PYAR7R.L4@8(N]U&L;9OVN])M;:C&/017_?9MLK+N(A7KV2'(S>TF-
M)(^+)'-2BTF"6 \@@I4 J07D%*2%=R"U..M4XEH1DI%$U$CRH&4N\M^9VEJ=
M85$=X**$__,K'U0KM5$D\5Y8-Z":):=E--9QM]_*CWI5%")H_8R3]/[_GBV]
M4!4'P)-+K.MWV\/!Q9><USSW,6HQO$-$S2[(].MA;Y+2?!"1ZT7[ Q7UH%_9
M]HD][:_]-KL1L MSJ[@Z"["0XUTLP/_V3OO9#?Q'JSN(_K#9>-_QZQ<>D549
M]38,MI\K8TP786F\:W5LQ[=@-I\'\$'9&+KH TU_S[_,U!/#PN0N)HYQ=_1I
MTBN93 HL>:D8CP;S&)PQQC),&64QL:3LY2K^G715!_;XIML?U%5E+JPJ\V4_
M)9!]E2<H^A!RZSB*K!48R6"YYI)KJ_ UJ\JL=E&9W<.8^Z$?=SO%J>^FZ5[H
M_Z]?&;WCK^-<NZAA9SJ@7[N4S/FLY<E4EQ%RG6+S= JV/+'J,M=KT;XB@[WV
M,3A'NAL=94#W>$T;VWF7U+^\@X6]RD8YDT.0\7FE=(GSE:;Q-(E>M<I!^EJ%
M@W*3CG[C+:QZ:,P4$;I:<[K%$;B.?^FZCOD5K\QTS<I45T_W9:W9=8I7U6LV
MNV;XH=;L!I3_]#U790Z9!S7N?LJ%K7ZML.<UPH<^[T^XMME<O;R1;EK7-WLA
MI8-N9 .[?J!M-HV]N!A;OO/GE[.MKU].OGU]]_W;]Q]XZ\]_6GN[AX=;1S#V
MKU]H]@-MT??X6VO>;W3 O^UN_?JV^T=[[^OVT<[N1[C'7X<[?[X]W?OZEGS;
M_=;:^_K^;._[IZ/S\D$M]@ED!8F,=Q%Q:34R+&F$B:+.8<6L*OI@"O8,\T%K
MB'JF$!4!DUA2\(^*//AD".>$"1NX$31B4T 4&4'4TKD -43=*T3-!^2E(!RU
M%'&5,.(V6N1HC(@%H75DGGI*RT;DMW9NUQ!50]0#011@D?0\!6L!HAA))@B<
M;$Q"B\ \)P5$X1%$X9M!5(U"-T:A[?E0/2R$988BAZD$*.(..6\2HDG)Q D.
MT8*@I*1:>0Q:#=/.DU!U_[&]5N$DO533?:G1A ^@&HXVH,:TVV/:8C8YA9UR
M27F4> +ECW.&K)0:]D92JW',*9=K&Y3*U0@:K". GX2N5-/LG=+LG#;DI?16
MLX"BR=U+I0S(PEXADZB1S 0L>4X%E+=N6UK3[.K2[)TK#S7-WB7-SNL.5CLK
M5+ H9-,JQX0A0V@N4,QD-%&YF/#:AKBUZG#O)+M"7C*R^IV'I^MTW=!)5C<;
MOM^E>38<X<XUK]K0?<]L8KK*0ZYWX_>-Y307:D3!.P=LPFFD>4Q(<"*EPD%S
MD3//FTK<51./I]!G^)8&\AI!:P1]'#VX1M#[1]#3.01USH9<#Q&48X:XCA(Y
MPC#",?F$L:=$AXR@G-V5J[!&T!I!:P2])ZM$;8VX"Y#<GA,SA0Y2VI20-9@C
MGCQ%+@%(!J]@RX(RAN<:LK<OJKBR$'D79HR;I/V7"<A %"$1RR7(^P1SYZ),
M'%B3]"E1I?:!8:U=G=+Y2 G<>KT\!(NO]YPV_7G0]3\.NVTX+/VW_S<LF@P,
MBKHB[6Y_V%N51.I?6V>O1ZAPLO?]!_MV],^/;W]^!.38PM\R GS]I_7MSZU?
M>U\_'6X??1%;9S_P]D+R]!^MG=UP].WKIQ_?-K\ FGQJ;Y_]<0A4_F/O[-WA
MMS_?TF^[/\Z \NE_SMZ*G=VW^\Y+S#"+R"90&3D)#CF@<F0$"YX!= E2X761
M3/\Z2Z.$.AZB8RY8QI5-SAG-1+#!*:J%7DBP?F./6P,@L[/B3%]8_NSBY/LK
M'_@X)[ZXXZMB:OX:-/ 96%%.U'[3/3J"F14G\SJ9V'*E$]'?=R8I?UG!:4XG
MHA<IZNU8E&K+,@!0X4FO-1C$3N,8L!SHO9L2/+=SD!?F0IFA?VA[L3]?R0S0
M&!O#2(R)!QVTQ18'  :!I=>8EHH7#)*AT9MIL>']]KMSL>)]OP_G?'.8!_4!
MAM8-GXNGPW(57_6OIY;AEX<G)SNO]Z41UHK($)'1((YC0 :4X?^?O7=O2BO;
M^D:_"N5YWG-Z5SG=\WY)=EEEMTG*_6ZPDYCN;?ZQYE51!!_ &/WT9\P%& 14
M4%# U54=N:VUYF6,W[C,<4&)F^0DCIYJ  2ZJ:7<E!."GBJ]K<[44.]V,OED
M5NGDC<G%>WWC,DO@&2F%89+K&<4HA.- !D9QHHL.W 1KIG!)*2],*7C_\U%0
MG-I$*-)!8<0CDTA+(!>+C>9 )T'BD!,2\2;@U[UT<G'9]B>@[8>*NRZ YQ9C
M0-[G;SN7MMG-E6/@RWJ[TKHHZ 7>#ZZL9*4N?V@;_9MN5FRW\C\/&3"PV\56
MC] 9T(U@"4P6*S3GH*L0FOOID.24<$J*046TQ\FK&$>/OOX$&1E_/?#M$HVH
M7AT1JH,G5" ?3$3<6X*T2A891T,2R;J8"QHKL36)9"Y 0A4[O 6RKUNY:+=\
MC*'3)XY;D97:K?/B@UO1=!7;\6&"F*]H0F*4(/[LC_4CC"V3A6WZN ?/K]O&
MGX4<W>^/=3K(D6^.>O9(AAQ,N5=6(!P54$\NUNL8V+*4Y-Z^ 3O":(8<LF7N
ML6%!?VKDO2]J@L&.A4M?9#3>HDY^,RA&VP&=)Q0BK-[IP%6%5+,70'<_83>Z
ML7']ND3UH7>V_"67>XOAH 5&4;===Y=Y(/OMK[']H^YA/CO-\&UH>A_CM(+M
M[5%9]::V<Z3 6*&<$:22"V!1N8B,QH!1,7"J@L<JZJ+H^B-$MEF03PN0J/T+
MBOKQ "#:['418=P7>P/P @J;A:8"I4$IK!3EH!-94-*\3@)K16'L*;C':&K,
M];83LGE25&([:.W<2M8_;3WL-?MVX)#R-,"R[*R;DJI>V97W&E0EJL='0E)J
MN"%(1F]!\HF<>ADEPLD&:54 <YWDF-O[@H&Z)ZU+,//"_;7^5LGB_!A=^]*V
MKU_6XA0>4U!/71 R\5PF-049&0?90:3%HH_ V46-!B]*.V*!C/&95G>.=)2<
M!,N1Y0S@-H&QJ1G@E<W=+4!&4J5=MC@!O38%&X^ 6(C%&9UQ(FH@#V_ XC1:
M@ZE)O:?.:P<V34DI+TLIWZZJGX\<ME:&1)!@4B(N@4A,Y* (,F4]H]X0ERU.
MK3>Y'._KOI06)\-*4)#=%BO"G:'6!#! E='4I^#[U?RG(J_2XAPG&ES[?(1Q
MC))$BZ0E#H@FM_5@1B#&9#( _5%+OK$M'[4X%VUR/E,VE2;GW,GG\"=@#@YY
M_4- )CF&N.4*.44T\I%IJUDB3.<D=,:7TN2<.U&5)N?<J8S7CH^8Q@'L.(VT
MUPIQI3R"/;.@?@<6F&:2@]VVK;?N2\A[08O3& 'V+XA;XRF7H)S!!T'PH+F,
MV%+W&$F5%N<+$)7'M9TCAIW3+DL^D94D'@Q %V5 6<1&Z444) %TF?N"BM?+
MXJS:PMC$]QJ;SS<OL<=:P^)ZYS!GQ!K%J'.!@N*!M4^F'P<E6"\.*K\HC8:%
MZG_[!Y[4#HYQ=7?ONGI\Y#6AVN9.LD0 S!I.D).2("VD9EX)0@TM3$TE'CRT
MFF!J#C3"/A$]T1SP! 2 $"$Y'+AUR8"N$7V4E##K% Z%.3 5X93FP,/DP*H[
M1X9ZQSE0 O'Y."$PB1RG%#','7,@<U,$@!2O?1CU3%@I+8.%4E+U!O0W306P
M+)&(4)H0![4;&4,8"C1Z067PB@L0M41MW5=-[S6MA+D36&DE+)+B8"['1Q;L
MS@C&' +Y0%$.AT%:,X,2$U9&1[7+J<7JWKY?S[087H_82OOAI<F-USX?)6^4
MH=8!K#F-N L<V4@5PE2%'#2#38@;VURR>=@22Q7TN7-0K8# /&[;\]6W@PZ&
MN+@3&XW.D$9[1YOMJ2WPZ$*?R7^''>-9^;UHQQ]UV%1@__@S^LML0W6 74 V
M';=CT<NK\EM&C8VOQ:<[@T\W_E&YJG=/8!Q7L5G 3W]$FY7__.>/RF^Y_Q?%
M[XNOB]?D??\*&.A%],4(8.EL%\'M$:S]&>A?L0@-_X5A%[TMN[T=;./MS5*]
MF8.98<"MYIUV%WT#L9"YE:N3NK\=I<\RMS/2HLD>YTG"#/[9:L,#ZTU?O["-
M8DKG8&W6,]X4[_)2CR_I9B44-EUQ5Y#ZYX,F4",+MGG?)IW8'_GRO!;'\.-C
M ./A!0"MOW)YD9\VDW]'2")RK3N,#=>4.V4<I1ZD349MTCN1&,_AN=4!SMK7
MG7=Y!ONI0-V=P= &2F5ACI1R_A'@O=D'DW5_YXC%'.Z*L\F:S[QT #FOHD4B
M"2MXU& 9YCK- F_=5_AGH%D...'/AO4]]NP9B0.VV*ID=*CWQ6./;OL![YDH
M1R\;50IZ3#.!?(O>9><VQ-&SM2%.BD ;/K>LK/0'V3F)C=0?&?#]<58@>_D$
MG4&GP,R\'X&(*E\1VZKTW",3P@D*+@R]Z;0:84:7CG=*8R^\TXYP4%<THXI(
M3T0DP7J-'TD.GF29_V*-6M&5%]X,&>M[S8,V 'QO<*5CYW$N^<Q &U9.2&^]
M1$J+7&C'$^2T%T@%9JS&R1"5@VLDW10/NW7NX*L%VJU<C;:J[P'K8U[S>QP\
M*BD;F!2"L\2IX)IIZ[@7VDH#Z(HG]UQ^F(Q*_\XX57R[J>X<.<JXXPQ@,]@
MV(D],MKEWLA &V C)8X!.Z7<$@_Y=S(/5IK#+IX93TR4CPDG;T/PD7.?++=1
M^,"$D\::08S>_04&2O_-0BF%UH!2%$TI&($\YP;QE##25E,428H&Z$3JF/TW
M<N9#WJSYY;]S\]4\EYC&S.=%^VK>L/$,U'5X7<V9,A8[HRUR-E>SYQ1>>4Z0
MU5[+$*S$G&]LBWL3KV^-YX&6D_6;ZVC;E7BG8U_OUWT[ALY3#3(\* !,*8V.
M7$IJ@<0<!]74YQ[S.#Y29:I4@Q9.:/ZJ>G7$(^,D6I']@1Y@3#NDDTZ(^HAY
MY(+97 :%,[ZI]+@C^@75H(!!+ =*'* K-UP9#M*86"F#LUI'7ZA!8V1$2R5H
M-IJ@ #Y1!&!8$E JLAF4UBBW/L\'GY1H0V/@!I0@\_ AU[.5H&<B2*D$+992
M1.WSD9&*XY#KSD6<(R6506#T:A!3,E&P@:F1.?77;(W'UKZP$A0"(QC@S6-0
M@C!U6EMEDL-""^.L)#,7/2R5H$52US$!$YW::!AF"<D(J@]W"8PQ%P,*!-19
M(1DH071CVTQ H;M*T&9V U\V"L*J ZW!VW-;;^:W+TE"]_H[OPR&L_/#UAOY
M^&R 3COG^>RVA*,I"(8#P6@>02&($47&%&@TS"/'HD6:.P7;$E/4%FPR3!\[
MXP25I;\3A12[]7#^\E@.G?&,'% ]KYX/6]YZ/N:UZOG\JMRSG[)Q KA;K&P?
M>XMCV4*)^SWG:/QIKWLGNTM3Y:?:YXL+N&>5USY]A.^^7>_O[N :/;P^// W
MU5V@ZU.XQ\$>_K[;.*F.\L7YO^N'-\?X\._O\.P]7MW]S+Z?_OND=E.]JA[
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MGW<E(XC%D55<G@68?*CU?]O7G>R$^+W>ZD9_LEG9:_K[,\Z69=2YGT7!2W\
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MQZ2:<:BZ]6X5WJ/U3JYY<7@:46A2%$QZ)Q'&$LP^6C2%\!YIDXSFV@EG>2X
MMJGQF[+Z9G:?I>*_B>,G=(N*)7>E?>I%UC[);S9AZNOI&C.>L*3@#RATP2=#
M.("G #W/"!JQ*<- UPPN_9B7+#%FB#,8R:0$RF7'D$DY CF21)RE7ECR4!SI
MC(CY *@L"A1''GFOF??& .$!#]#S4&%V5U!G)E HW4'SA(,1[<E9 7NM%=(V
M1<1E"LAR2E!PR28P]IE0JBBTJ^_K-;<.4%#>8V['K2NC+PYPY&D:XX3)KXB
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M13 6"!=+9W;/K\??C$D^JZ9K/PTHRV3EE<''$<W:"BH"M1HQ1BEHUL(B0U)
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M5UH]7-JZ)>Z" D;%]!!%G-OV<;Y#=@S3NZ+Q]++3K:?K.R2R" IY7#P4)'(
M*]%M=6UC;#]^RXMDSX%%NA5W7;DZJ?N38N&2K;<K,,.SV.W_-/[T,88X:5W_
MD1>VOR6]5;S]0:B$HO)+<576+.&K9K[+ QN7Z\U6KFRG\C^SE+$%!8L[SX+
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M'D88G&\=-V'V8;AX9*GZW,,-HOKYR'F7O/#9%RT9< ,')3HRAS#76'C%K..
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M :_O(J"S7!//&8H!2\2UU4A;$5#$ A,ND^:6Y2IMG#V_H^6,G+-P!.R-IT3
M$@&G1$#&?33.!2%)X(EB;4.*DD:*E6$\R@(!\0 !\?P0L 2YF4"N=JOF';/J
M[LX1(5;PP!(*7@;$F0>0PX8CKX5)H,LSX=/&MC%O"N*>[F1<+IO^4VS&MFT4
M)KT-Y_5FO=/-)U _XA151]:I_.XX7FF<F-6<Q&@EYV"Q*HNYDYX&J62BM+19
MEQ[,JF,VJTDDT.0IPLD F.D8D0ZY0+OB()"D(;#G&]N4;8H)[1D>Q+/%(=,,
M'1?6FR.QXBH)P[!+G%.:K&.8<>#*$+GDEI0VU"IPY(@-14)4C@:!!.$:<9*+
M]0"+(FEUDE8EB2G/@7R;E,V8MEERY,(Y,GI-=;0V*@/VKN8F!:8TM<QPP[D)
M"]/I2XZ<'T>.*OQ16\^B\T@D01$W-B MC4>8A0 L:9.B!F3D)E5ZJ1ER[0_D
MBL#:>X/6GNA<[\=G3<AG?[L^F[DOT-H(@&?VN"H%P.L+@,]C1A(6T4?!%1)6
M,,1![4;&YV+9!*PF)85E(KNUR2:8Q?,]V9L#;ZW&T=_DB;YAB)WOZJP-OD8
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M"R-[D)]8B&^U-W'(ES6MM;;D6=UWS@&>,]VWM6:D7+.9UPRO)&0L72?&U\U
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MNXY2+DPG%T;--&6=M4X2%)FT"*0 0=9K@XP.6GMIJ$UB;EUPY\Y(+^2TFL^
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MT!8F'!]^[/+]\DVY%/\3 35NHP*NWU@9D!?4\L[:UYUQA"^6?Q#7<UV"]?S
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M% AJD%" (V%P60@3WQ6A0ZKSGLM@O2)@1,@IMHG.@BVK5+ K09:H)&"3]&P
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M9"X*%T^+&'YZH#\C9@F&RH)<.5HC:J6C(BE)MM")5D.$ !O1EPUCH2^J_E(
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M'FT]2X[,OUW7G,!_^L%P\(__!U!+ P04    " #).5M6',(\H<\/  "$HP
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M839DVS5!^A$'F;Q+[L\@\+G02^8%YGP%>9MRK^5#JDC<B'$^>H2+.5W" D'
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MVG5?;-]2U^A-LD'5"T52/5OL+'B,&01Y=-DQ[C ?\'3*O9_AZ(,AMU>^;B.
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M+_#2]=?*1,MT;1SJ:G&9BA!L\<!RRNBC2ZYY=\[;$0UFQZ1?VO0@GC9;U^>
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MO8!>G^>7_^%U:O2/RS_25V?#O\X6__VODQ3F"_4\RL*KE=^HO\'%UZ!^!%R
MY'_Y-LL__,>_O7JUE%R8INEDA!^PO#K_\1\?WMZE=#B>_YB')S^>?^?',!H1
MQ8LGS,^^X-]^F U/OHSPXK/C*9:5U%^P7(G2E9S_7I_VX]8T'1,ATW0:$>A3
M'%> -Z3QOJ=O3_/ELX 0'DY'\X84WWUV4WHG)V'84L!W'MV VL6#X 1/(DY;
MDGKCN=?HO"#R-H7UD7],SVA7&,7AY"]I<O+C@L"?)^/99#3,=6/].*=_ZTX[
MFY2/\TGZXW@RRK1/__+_3H?SL\>IK\\G$H7@8KG*__L:3[_& X%E.![6_>=7
M^O7\%97:WKC!;W,<9\P_O!KFO_TPI(-!9JXL<YB4S2%&JQV/)K'L=<0T6.,]
ME:T+QD:3=..UH[K-3BYQ,0H11XM/!Z<S^!S"E\'EPTD2^)9^G VX-Q9-C)!%
M5*"LY!"RBQ <)P*%8E:GNZB:7:"TA%E<X.K\%3]6A?V(H_GLXI.%"A?J6TW%
M4EV;\_5VG.@PG^%K7/[_V_%=T7V8C$9O)M,_PS0/7#(<"\N@E/:@HDP0DQ!T
MA,>HI11<AM*8Z35)O"F1*P@?32]D<[XG;+AI5$NG*3;FD]VI9 D+XN^'5Y,I
M/>YO/[!M$?3Q.$QQ]NYT7@V=:CL.,#E9"F,0F9&@##?@,]EH2:DLO$THHVJ]
M,&X3L7L4]*JV24N9WP4!WQH$=U@=,)>T2+8 [=@.%&W9X(D22#PB-R698G/S
M[?'^T^S9PF [J=_%@6B"@[>SV2GFUZ=3 N9[G XG>8G7W_'/Q9]F ^5I7RPN
M \^52J<YQ)PR!*_(^4N&<=1]8.-1REX 7MIJYRZ&9$\8^F<8G>(5D3[(X"0F
MX N@AV @HA%UUW/&E)P\MC9$.A'V(A&TA6[N DBUL4C>AV$FEC^%;_\:SH^K
M-(A<^F#QUY](3OGGR<D7\C,7 9:!X:&HZ IMEU* RIRDPK, SK2*M!PXJGM\
MQ 9&RWIT/G-X]:VYNVC3VZ+M*/_GZ6R^\#L_X*@ZHI\F74E/*1=30@!6T(#R
MA8/SB, EH@[*65%$8]!M0>[SQMZN]'@7@J8A!#]-CG)>:"6,ZCIZ._XY?!G.
MPVA!>;Q-^0<D&<Z&<_R(TZ_#A,OM_ .FR>>E;A<[^T#QD%,P'M X#DH*1TNL
M,!"<>X_.81&N/YSVPM.+ ?/^$7$7\79;Q+^;'^.TDCW%XQHJ_DK23),3_,>8
M1#L:_A?F_[5<LW\GS?PZF<W>C3]B(HME/L39T908''^^;L#\CO-WA5;[0%3G
M*5@'(O-"ATF1$"221TV.E4W"!9MY8Z3WQ<OS1OA!(. NLMVVR"8ZEHQ4F@<R
M)RQ*,%":UV7F' 2;ZD\>O911HV_M*-\@X'EC:'-9WU6\;Q]'+2*)'),%(PH2
M&8F0:$2$&#DO/"=6>.M3]Y$X:I/ 8.2>HW 1?%*:C*64P"7&@;S&C%%D,J1:
M&[V/!0;7Y^O3-(QGH\6)>776OCD=I^5!^VGR ;],IG.2X,^GTRF.T]EM8/]]
M6C>EQ9;#I0C.AP0832")*%45K<$53IR@S4G;QA)I2?^3OW'9FS)[B<2?B^93
MB",<V*!IJ>4(UE?/)$<+T1H%&ADGH92BM.GKDG)!04-P7,LTZ1T26XCQ/J6^
M6N8-_#6-)F1O_^V'^?04KSZ<C.?X;?[+:/'"O_TPP\_UAV9(6.YXU5::C*M'
M</1M.!M8[X4/RM?3I,)4(+B Q%8*/#+&.,;F\:Z'"&J(DP>R?Q[ S0:*7H69
MK07>P[YPBZ;7BXVV$U&#6_E(C=!P+T$MCY)5^50/8&![Q4WZDOK.(%&"(92;
M#$E((FYAJ-4(/EHMO/2*S$[V=*%P(U5M_TA81]@]((#(.9DL':S?%B;7("I)
MWFY.0-L?$62$AWH;"*GD&(TWN;C6VK]#Q.[MR0;*F;24; ]I.BN"@.?$L91=
M"LP"<O(W%08'GH<(PC,9,HO9V=9FXH,$/0<(M)-X#RO_**73D]/%-<>J2-HY
MH4Y&0=:RABR-KV$1PJV-CMP;Y3POPB@66T.C*W'/ B:]:**'W)X/."=>,?\2
MIF-RA6>70"Y1(?E6TD6BRL5ZV:\2D+$<3"K6*=TZ1'D_)<\!# UDO#(CY]]_
MO"48\I3_V#QA_>/IR4F8GDW*Q^'G\; ,4QC/"<N3TW$-E+R?C(:I1MHO-\&W
MXS*9GBR"+*\KEQVJ1N[FL6__TB;I[8UYOY7U;EQ.QF1K><R*\7H2H,A&6ZW0
ML&(&V[]^NYW@_71"'O;\[/VHOGB<ZSKX<C/V$FW)SBL)KEA!>U6L21E)0*%-
M*G#)B\?6]VB/4[7M#KCR#?^883D=_3HL. B99RYC!!.05C^60JM?.Z"%[YG-
M(2/*73%^1=;N]\;&&+F]4;9611^)\>D8\^D(WY65Q"YC3C'G8J(OP(VU]9[1
MT+E>:LZN%3[)R&7["Y&.M.TJ>MLS6GI1Q:'$>5>R]-/9)WK$(G+AB@A)N@*:
M9>*K< F!"04B6>%0296Q=:U2![+V%O/M!0Y==Z@-U=*#$[B:>WK N37;A<2>
M(L0=R-M/O+BY:KM"9TN][ E")J<H5%# 8B'O14<%+F4#S#%E6/ AZ=9737N#
MSB/QY4- SCKJZ.G684'2N6\;LA51*0M&1V+79R)') Y:ZDQ'.OD]V#KT>(N$
M S*.-U73/9<-F\IXI26\E_C!Y;=^F<V')S5(=F'@?\79I!S-9CB?]1U/6(>(
M'<87-I;-K7@#)A=0(#H3BK(R1!&8"C:J$G-@Q76,-ZQ#3N_Q!X9*(R.(EUK]
MJ 2+$%5 "%G9XJ+TPNW,#=]I_ &-*=(%#B%E!RJ3R>JR-6 #BUD($7AL':Y_
MJO&'=3"R2?QA'57L,_Z@4Z$C!16$R$@.T3$R.%@!RXRSQ5OF>/-&%D\O_K -
M6GI1Q5.*/P0AI>-90_)*$%^B@ M6@-2>#!F>9#"MC;SG$']8"PX;Q!_64<N>
MG,<N)'Z//VRIV@V\R$WTLB<(\5PR2\P#N<ZU0%@*"(Y^#<:17YU*4NQ[_&%W
MR%E''?WDO'TYG>/TMH_,!5>9.0FYYO6I7"(X:2*4+.EC935CK3V&%:0<D+&\
MJ=KN9L-M+?.&%G)UN0>_AGB;G&0]ENP+H'>UH"Q%\"8H(-RK0K:>4NK6I?7=
MB,**9S\?G;807@_+^LWIE"1Z.D5B]<WP6_WI(GLF<*VC-AJ(HP@J,(2((1-Y
M6<I0F]Q@Z_*JU=0\'R TEGS#C+79=#[X$,:?E^>9BL'::"6YX474Y*D(0<0
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M*KDD@S9:"*RFNS/KP0EE0!3K)&.HK0BMRP!6$;.'AH9[U_7M"H(FBNK!G?F
ML_ETF!;SWJZ:Z]0)H3X8 5R2/:2<(2X5+V!D2%X:%81JW;;H7D*^(Z>!@G85
M-GT3AM-%-_.W8R)Y,=KVJHCAYS [KO^K=Z=?PZC^+8SST=<P'%4+N$RF'^G3
M*P-Z\_AI'V0T":3V+I];$=4D.:_].DOU(1+C@3N6"R:-(90<V* /@K;,.KF@
M:%G=0BOIUV&(P]'B#;]AF)U.,;\;?ZAOK;W&Z0N_3\;3BU]I30YGUSQ]%8,T
MY%5E'6O# E878!9@T2CE2ZFI4JT355HRL'5J'JF/7G!+BT?SG\-T>D9O6XX>
M2-Q'[E*!3$;4N>_I<P"O722O5)?<?+Q@)\)VO_?O#WUW$OR::ZX'T^%^(B^%
M^'HXJW$IDMD@!1$R$QED# J45 Y<U!:2BH*'P *RUK,+.Q/W'6:M-=A'>[V+
M8^?-\MAYC7%^;?S$2>TF_E_59)O-%^(9,)N4E5Z#<TCV42&!A%!_S5HK.@B%
M9<T;,*Y)XTL&7J_Z[*%7WR/T7K4<7#2NOYJ94H>E_%1M)5RTLD?-@HP9K*65
MI'Q&8D<8J*WHG$3R#7CS\60M"/^.U%UJ?F7#P=W#M^9;7#$142!9% 9X'<>@
M:->'H&6&9%R)P8N80NN\[R:$?X?O+C5_%[Y;#R"]S<1UI_,Z.P-M2BK2<N"+
MQ65R!N]*H9_0%BZ2)A.F9X2NHNT["!OK[R[.-AX]NBC!N2?>01*YM5YN,7+#
M4!E8GB7GQI.-+"+1[#0$%@L4)JQTV>3 NI4[;4W*2P3;'I1X%X(;CQ[=F/J!
M+Z*6F2B00M;&YXJ#+UK7M@K&"\Y$E/VA[CO0^E+576QM/>3S8>H^X?1DH&JM
M4I((L7#:@'ET$%V4( /7.7$MT+6> O\X52\19#WI["ZJMAZPV4)6RR2H8I)#
MIR4$'TA.EFN(UDG0A1?EI"9_OWE=:2OB=Y4%>3C(W(_>#R4+\J<P"N.$'X^Q
M5B6DY25QS5 AF4FID>P')FJ;08?@5:U+XR47QG7BS7/Z5]&RK]S(/2%CTH.&
M>@AEWT?7Q:2+#I3UE.>XFJK]9"NVT5X'2&PA^MV"PX601,@:.$^T%@KMU3[$
MV@]"A1"+C[EY]&W7H'@D%7#7F%A'XGTTUKGW<NX\_Z<$3?0H"]8G!2I%#I'[
M B9(KE2R)JC6/08?HF?W)GHKO76Z$=U Z'U4'AU/IO-J\K\=?\7E4.4+RC@/
MMCC-()4BR9!S&:+!1 =E*5A'X6G1.M-E-37/!@R-!-YP;U@V"YJ,/U>J?@O3
M/W!1_WKE(5Z,-LLQ)VL1L'!.^Z#.Q'42M21>I\R+3^G1/+J.[WKRVNY#ICU<
M0;\9CHGK82UGODC66QQ^6!"Y1 3M/"'18H' @P,G1.$8K0RB=:;#"E)>MK_1
M0C\]P.;3-(QGI=;#C_-'G'X=)F+Y7;F'VEG-79[=_Z?SY=6%EYX<E)9\[,>E
M:0*0R8%IMP>[MRE/0JCBBDB0;+W.L5D2.V2R6:Y*D,7E4EKOCH>/U$?\K(,'
MZCI*[:?CZ0F=3L,ZB)B.J7/S0#IZ,[?D$KB2JD58P*D0(7.&,F#0!EL7\M]+
MR.[ML?WI]IXAX=LIIH\LZ<GTRV0:YOC3I(KGEE$IBL*BA0<;>":CTB?PR6D0
MF!G+*0LEFR??/T30BT9/*T7UL.?\X^.GZ<*2/;M#&>-9!A,#9&E3[:#E(29)
M_S"CE0C><-\ZN7XU-2\8/XU4U(,/L**:I)[IGC%C:S?RY#PQ3-X_;8Z>@6'&
M9,5ME-SMIOCGQ3N0C;340_KP50GJ_30^&#3M0GM//N,V=._'1VR%@94UQ#M2
M8 \GX%8\%.-%1N: 22U *9TA1!<A16$PEYB"[Z^>_5# ]XC;=XC86T=O/5W!
M741_K5,Z&;+_BJEYH9KLOY@8D'>1B [)I6O=3^/J[;NWJG:GM7M.P0U$WH/C
M=FD5_'1V^>/_&N*47G)\]BM^Q=%B;0AD61 YD$-6H'S2$ )YF]DX8C.X$'+K
MFH-NE+UL:ZH'[?50V7))VKE<3F[4WU[2>^&==""V)U-J+4+W%%_O0>.K0-6;
MNOJ8Y+(6T5H;E3+MMUBJJ\J4 :\Y!R]XT+1_JV):AS$/ %N/1<0/#5KK:*E/
M2+T=?SF=SQ82X!>=B;2UIM0\+"=KKZ,@P=?61RX5K5$KP8KO"T!WR=EC[4![
M1:Z"S)9:Z--VND::."<M:NNL40*,EW2JIU0;EA#?3.>$I3@;;6M?[ %R7AI
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M$_PXIT5<'_?K.9\+5X^<.4T^G05:OW4T?2K@%?'#@H\J8$HQM<Y.?("<_4?
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M93[6K$:3'*KN^&0A@O3/OXI$=@N+17L'=SQ-.3E9Y+'GOMK309YEKC]6MJI
M29!@V>151Q(Z%U\&-QO6-?#QP2-G)<V\YSLUT$B=J1W=G1L_'C"!LX2SIQ]#
MP6.LH2'6IF<NA3<?]$#O::RG*F,3O%&:/7E?)N253CZ8=Y'3])J;]]&'(KXA
M.!D3L[78.#2$,8C=@X+/K4+V6> RIIYF6YMK&81NJ(K8?[YU3#!;?J$PR?JE
ML.1EE\N7C?36NS&UWF'-TJ!JFU3SIYR >HAP0)F9AQ-GHK$J7C+JC*MF2/-Y
MG5\WS\ZE= )/IL7P&'8F@$SDI 4TDH^DN2'+0(..9AGKM.ND];@3F*IUXJ%;
M24I=MA%?;R9++_QH"/[Q"8>",P$N<= 3O[Z/3X^O?49[3%>=GBOW<N9,%6DM
M,==8ISZO9*#A,:T__PAL;NML#N1M<<57BTBLW%9%"!,@66(G+Q.LAG3-\$^(
MYSR3>R^0RM..Y#YYX'RC]X5A6W#, ]L)?9X8:@DE@)[?*$V]'"!GL2] &UD=
M,;-0NOZ(?I%-8/KY"MNI+\'O>3AE2DZ>77VF#VQ+*>&PH))JA^I^%!PTF#,F
M9<?X5O#^6)$[&C.$7S=H3N[WCVH]]=U)35"-K?M2R$\':*<9%HKNP%2[M<KJ
MM,^*H]S(?.U9NB,1&6_=8=HC744'$-I[>KL6SEF ()=?L+]QS\V+@SP_67;O
M;K5??\J TBN9@+NC1?M2UP-P\4N/BJY1?8J]9JHE)\HV_-#Y'VS4?IX#0L?>
M,X'6:S Q!"@%W>^1M1\,*?,X%3]9FN[UM$HE@K],2GKBPLPU5\HOR_*.MY+
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M5A"[YC",W4K5!J9'4:KT(GP?GQW5)HV>6E61M+#T=5-4=69 HCNWS]OF,%[
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MP5OT)$\8&YAFG>'TC? >><S7WIVKM+-Q\=7A"\H'C(R.&YGQ5^C*V&!9QCD
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MX&E@<?[KM\_EL;+O/K]+BM,4@DO7XZR-QT4M>?J;U>A)<)SR,(S-#M-F2[$
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M1#RTVFZY0ODV[7T'F9G\M3)-OA>JIJE;<V WR,80".QNA7+0SI-4(HOM:!?
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M!QK*EFD6WQB7NNK:FFP6X\V?,'2'&?60>21W7<TZN&FQNPQ/*I5J^7ZT7(5
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M]A\6=3$"%RVYB(8SK''B_!D)?2;B^)W*!W^S_8IU2F!UZ130;J\6Z EE_#5
MD6?'$TCZ$QK/7XPLU3K+TC2^!L0(70-* L_NMQ0C_@R%OHH !2]9OD#<)I^B
M9D%?+GG')<$%J@7&$2K&??(&'RM7+[X1S%W]X'.85O_^MBGG*O[2;+D4"SU
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MQ>WGH-A-AC&B;C@+*9<":DXFJ<.KE#E)*G9U+3X,2G:(:5.U58A@?GF=]G$
MM/6XX?YX0=J"1/YWD3FC&67;LVN FYQVEY1C.*!>SL,XYT 6W:4_;JJB_,S:
M]IA]]_/W&=8+\$A93(*]1.!1FG>YM+%7[.("*NO%*.)8;X_'N[:R:AZR8,#
M#B:9<CY\#QD V P;.Z] *6T2"58UP>[K4=*<HI57,PQ</:=#3"D7&W ?DRY]
MUA#(24V-/6VLK>!C@SYF[>5HLKZ'!8K^UP#;:/&M)S0_M872>$8U=1Z;5XUW
MC)1G7<%ZK;.B/F)B=8>J$^,!^:FP25MR1:-<0H]?CT:U-WD-G+C&[XY\)&Q
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M2HN:_VI<"K]P=GXL/71^%C)N.<_ .FRB]U>C*MAJQI>FWR%PF(#II'!O@#R
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M27EM>J[S-VHZ_];4)BN;$0,4IZI'WNF5[<,>R>[@[D['6%BS'CU/4[HRLK/
MW1:MU2ZR=]"$T8;1TK+BQVM=#9V> >?D7@,$N\,>+OZQ2A4L*V-.R2-SZY14
MY.Q-3=3\5QS=?.:#?9V_7;+]IF'1-0#K.WJ*K[)H;*/R8BO&3^WFT]NHBL/_
M;J;"/YQ8]C^*D7ZL1;$8/N:,KC6#64XAK@&;[Z"GWPKRBXA"?;OLKP&23->
MIEL,%C77@+0;ZVP1,S?3[\$%7?,E,@:-(O.)7D1#%*X!WK=AX8"0W1O+[*@5
M>+&D?B(!/5MFN$)RV+!C,I3-7@.&;NS ?7^%O_B#SWC_A_[_H?\OHJ\^T2"8
M@PI1259MKE J9IUM$F;!;\.A+<!VPGVJG]!RZ7(-B-,KO@;,DEPQT '<%O_,
M3LR?J6NJ/[ES]2>&I/],_08"/_TC1^Q_Y)U<F R#Y$_\9/V)]U=C:MC _SQ]
MCNBDY51>.8.$B@K%H/Y]9QXE\(B(*,/'%)<?8L7/?ZEM0%?SKV?@OS9 :G=C
MZI%]865N>9 0J(]O!5_@B=$JT6%@8.PVL836_I]_:Z@:WKQ6!*%!URU"?V08
MK?_W2?AWZ'^9B0XQ*]0=LG0%T2:.9D0_P[)[=4Q-Q80L/.Z_?'&C/SXK#.>'
M2=< &2&,&E#V]-1,FSU1I34A>UDF8I",$".^9W4BYT^D4W^YL?T_-R._2_]-
M3;!+]422MHCUR7'@;JMABH=7C86=V_%^Y/A?SM.+Q4/#FY6S:V)_Q5YR^+]P
M;_B?HH]:54S""P\L(3-/_]MI[[][8: ?58%^ND!P#?C:D'XNXVXD["S-=0UX
M?QIP,PV\;.CW1A,_?=E^7 -8+0R6C0N/%%3DR+1Q6GX'B?UU(X\HN;&@%JAK
MHXDLC$>%"K*-MNB.UQPJ>!S?4P?+>WW'&2=/ST0%*A^P9,!'7#FE-*9U,V"]
M+I^P".^)/F*2C);:D?T#:.2@Z>NNO!#?*V'H"\";T:/!7G[U.H78\[9=N@].
M@078PQ8-KFH'":D&B'("9%K6'!3T 65_X, 8+#NQL+TP8?#1O*YV?JWUQ@)'
M4(,+QY:<'$?\N/YT)T&K1)A36;G0P'HO(WAEZY-IL!)F0X?\!AY^WQT,-KH@
MO7\<#^6#X(B8X,J"8^[GT J]IS7]218B BT*M_&W%6R:#9,ZP+<OVILPQH7F
M14@J%P;6/1SMM099Y"7+L#Y+_< J_CTL_N6^?+U%*?>H[M!F<7';S,"A "*!
MO\X#2ZQ[S5%G)P[EGF%B)7)^N"BS)CQ1YNQ*,E@,%^6LJF6C;EDZ>D('_ATC
MEXRG:I:&3K_K!<PGJ:;UJ3U%IT0K80VCJ:EG[ W1 YP@'Y\#@E98"I]]>9ER
MF2//,0U!)R;RY4O5S\)_K%A)/H"*7Z$(6KHR4/TZP:O=JKS^-EA/_N&9(K:@
MBW%6"6ZC,"7;:]:1\506LNZWT2O,B6QZYHYU1G@/_/=(/'T>!/V1&ZVQ8TXP
M@VIM4T-\3U7-4^9R,'?5DQXQ0#Q*ZTOKP6"R<Q%$0J^L(F807EL5)Y8U1^E\
MUT] $>O@,Y&71&TI@K'.OZ9%@"NV&J\W]KV#3Y2*W@)M56);VXQ1Y58Y!&P>
M+7=C/OO=C=WCE/_=I$-VD7IS^,J/#2CJ8U7SS#L)FBMM1'V-!1VDT_E&&G_W
M#:/O__%:^"\VPZ$(X)K44O,%0<\U()O2=51'<&7HC 3"BVX]A&[=FK=76/&-
M.7PKW$2^W2STVVLBIK8>EFV+,Q*MT+NXT6O5R@C6R98D#?WM)/U,!=JGEI_J
MOA=6JWG8.GVC3]'AQD4D+VVA";>AI(,A*[K>@I:^<.^W(#%M4#47I3?'VS9&
M-NQ$VD+"U^9-MP^(3JI )!UB.<KI*!W-2QFM@Q<PCVN TN&S(ZJQUZ:/'IQ)
MVM^-*9VX!E2W&S.$G#P*DF3G[@I.J-S?W2]/Z5JS-_HHA>HR]O$HR7OY*&>N
M+76ZJ<M]&3JKW#*S&%ZI@JN+W(^X)'$N(3?B@9)M,;P../CHERE*/-WSYJQI
MOU]\ PZ,-JEB\X-:_LB,:8>_J[E?V<L<H3"J_K;>A8VF-U%+;J>O?!.7FHG\
MD+=3J8D18@<,\.5#-;[Y;,- 4@FJMZ]H6Z9^HS0.$X+,0*5>KE9S);S J@K6
M89S\?F-!2@=F]5P(HS9-(E3*'Q=-)#JD*H%'$21X]:%?J/EK2W3?"T:KL.$=
M*?1[#_:?^+"M2$<47 J7'XR-BB0M7T3Q"[LEHFY9,5JU?W+(]I-->\*6]JF4
M8;C9SAY@ QN,M7?-@>3)#E>%#50GKQB9*/%9N\>D9KVN#VN1ZO4#1E@->&QV
M<?9% %&L$Q$G3@K)GZUB%9\ '9*])W00SI9O2';)E[3\[S#S_T#8?S,DM9-A
M=!PD\'W[P8RR6<?4R8?$#95Q\>H'D #-)+/DABR-:-!:P2_243. $FX5N'EG
M]DOOPXICO\8'?<-V-E((]!6065F\M8B*WFR5YD6V:R?AS&V=;X0(&/>TWMG"
M?JCPFN6@%BNJ. T'U"%I@319Z=CLM"?QUD%R=P4Q-X2TW;$>F8$D*J?#9&F;
ML!4%3X/QWVR*DT^A^X"5K 4'1W('VC=#I* C:$?3U5_@9) G)_I_W#?,5>)X
MRA0@,(_1,X3?X33OW:NRT+][*7BPTZ:?Y_\3> ^DV1P$/N:+J-<)\ )!UJT:
M!@(\,J.H'=\S+^M&/F(+1WB+KOCP=M[7W_847K&Y[UR?[:X68)X$(F>AH7+M
M%GO3F^*@XC$^Z=?P='D1VUMH1 BDK +20,Y]IVZ:=@$C=!6LN;CZ+XR^]074
M6YC3V#VA9@H[@.Z.%ER:HM2S45ZZX\Q(XRRS$N-M#3ESBKWQRYX-QW6_;C=_
MQJF!J@^6[/C+3BW'7TMYNKY CE;&0_Q<$;C*=:.N!IUC>X2JW(E)'@YEO/%<
M?@7AE'H,_*:=Q$M4U2(%)>NTBN%MC'S=<WC V"UCO0/2;VC^L:I2C%0LC=&%
M/H6&>THB>::G@O*M$Y#^0S%X1#^N9TF'T6RRF^(MT-BH@QSQ4VEQ#C[\\U?/
M)[2YC?=6\S/# _X43Z@MC;P&'+XX'CJ]00?#!4;%,EX6X +]QJKY!AWM0P=D
MO_]PW1 CTN,SL<#YA783*D,ZB:)")#5[QMKM=)^HX:Y@WP.8%F-]EMGMS]@8
M:3C4'D."RT,,VS5I?,@%7F'.1C9C2E:1QH!>&NN[3#SE!MFV=F0..*QLP9NX
MY#N<%K8UI1#N%4HP55@))@G?9^8@[DE G.,>2%05:1)2F;S96/[=I4^BRYG)
MT&"Z,T[P_;<RT[I!ZKIK@-7Y=]PTE$F[,;,.4NKX!'X>#@E0*MZH\-*U".:2
M80[]H?5T[VJ"6#>P=HD7(.QMMD)RV_I\>K+DF 2E:#:R5PHNMHL;KIR&\11C
MR68:??Z \=:T76S;22$OBD1%M_CA?9_\Z._Q=FFR*[0%FE\MUGLKB"7N24R0
M+[89$4OA:H_^5)$>:M.TH=C K1\!:^#CXF)_N*U(O96VF0-P])2;:"ZP3F.J
MK1^OZIM_("1X"+IOJ,V&>!']^G;3,[N6)X9W$\Y"^]Q&D:5A;*,(+O";!F4O
M BB^@0E[O$V0 Y7$'M-G#.=X_ZYB(R2T]:.W:)&A2;\09,1 O@+$3:E(07'$
MR<>2^Y0YS8+0[*4\%A#7G4YK,\C%Z.DN@\WP+@^T FE[N?,*6F%!=7@HK0IO
MY/_NJ8:; 'D(5C YR NJ2I[W/+#C\68C0K0[=MC=DS46V%9(>%_T<K4R@$06
ME]RRK?F.,&B("F)/"4M8B"^)B*<Q;GE#5!D:FZ3'?6/:W1;#(B5M<PX,_SDM
MR9G9?^[<%&N*R/7CTBM^GVQH0:_#P"9SZOC]E38] ?(DP?NT6I_XDR5D[S4H
MPDML1-Z)BH*+DGDY.?TDIAC@81\L7$H)HD!C)T(I!IN1L08O[=ZYB;3U3/F/
M9_32BM^6X6U\N2);"K!"V;?#@\OR(=3["S2%S57;$T[SPI6^K]-DXOB6$&<$
MMK>J36E7\\BW$L_I4VVJ03CIH-O3F-698EK/ )%W/C+P*-"J$X?DS@H1$:>#
M2)\<*MU5?$4U(_LBLI:6@GDMND[\,PD_LBO,6XX PJ0^YKHY]F R&T80(5(5
M+)9)@!V7E:&U6.NA*VY.O!ID#(AI2Y,>+_4V6_Y:<R.?A%*">-)%&4ORHO _
MR@<'T-Z.G%M::7PI1:D:9CO.Q1UK&P;2TGV%AZ^1G<?PJ(UOM8RI4;T<J1KB
M,MO#@Q BXIG85N Y:K.\+\%/2$!!$*?XEOH/"I[>MG(-N(/2Z--[_'/F _I!
MR MX8TTY3$)[=)/?:>!&<=6R'AWV/S6[>*\XAO(J@)3OOZJ*0W/K[\C#RX]>
MUX\#*\8U[#_DO><V+),GG!-C!ILDEWA>D;2<DP0S)_ST(549,3:ED"^KC+ZW
MY()K17UI#5<(N)1:OMCB=6G$?3%JSZP1XVAI2:LA$(=_*T&&\3W)\A/:F*@&
M8%[+ ? ;O'<6JV (RE(_)R@HFECMSOQP;5F'.8Z26C(%]C.\9?P2:SG]CG'R
M@&8;[&6.V[='M0UEX7IX=#@;&@Z<KJ_D,U[=TJ("$ +8,:Q^<R>6"J#JEN:Q
MU.'(8\1"2.Z\L2'(S4'%43C;GCDV3D;>7$ 'BTKRE>@,?;S7ZK2WA'0,X3E]
M?%8Q(B9D.5RHNC9A_;V$Q[,B6QT;__H@ =*6FRG5S&Q@ZY@Q#ELIQ>[(L)X1
M'@HN'@HKWBWA,LS$8^' YR_2$& _2_CZ#M-)L8=Y\_+) 7;S74D 5XGBA7R$
M^2FLW69JUH.F$N\=\8)Y_VK-WMAWW.]C.C!(WU-%-!L$5QM47_<F[M# I<8#
MZG@[0B+@.2/ SB*RK.?L"38Q9\:!:#LG+\D4R"E"1184Q3-BD*L]NL?D?\*S
MR[4!Y-J,CO0Z5\.5GYSH\:)+-GQ6XR0_DE/GN"'P".,CKP;&&^R3[N."G4YA
M;B]#Y% 4=U7S'3J@FI?J[<6%+]:QDH!8E@HAJ$23!Q8QB?A%%NW6#[38 6MM
MC8C&PXW5EW$K$JO+LSN*8!9#7\3E!B:X)7I"6[7629P,XP?\96,NZ*#__&V6
M=7ZV %4.2&E"G2;Z2X=2RXFP;X-]2]/;I+Q+#LKAZ07E$_Q(TC;",J&[/K$&
M5O0@'(M("J:T%I!;E\&DM^J21*.]F@J'$:GZ2&Z=BK38NE*&MJRZL3HK<R]R
M2K=;"O\SB4)F Q1-(9)E89]I=?Z,?XKJ)Z?!AEF6\7;HBW"MAUK^-?)99F?S
M8>)4N-@3%9#)CL?S[?S6B=6/.5,II#2LJB*LLQ,?4:=0/<>)7.4\C<;KFA=?
MPAK)+WV$7 P3O@:00TZ?- >JU52,N)(0=^0W);,TQ)D*YB[A?>!!0WP:B$72
MJBH.[+6K#>AXG]8IAV6,EP08R5F#N/N#)X!I]O.=11T&!-2,CALGGXE/PI$@
MA :1R;)Q<LY0GJ&-A=(D0JCK*[SF<+TVC-6$7<AYMP4"DV; BH<E<N:.2/*N
M>KA892.KLFQ$$E5R.D+71]J$K"4S-/D[]1@@5CV&9A4I?AA['W1("B^!R/W@
M2XDBHRU]J9)4-[AK.UCJBX<].W_*6;;SH^Y!$S;)XXWJAEO7@(>\(=!=&O U
M(#/13[00J\N7@QX?F7-2"6Z:X'8CQ8_OFZ\;ESXAYJ^7DM"^<DRG%FI&Q 0U
ML08.'+KI-78BZBO6S5^XTKE92%6D>6K)&66S[I:87 ."$I9)SN]7JEY2M5T#
M.M2O 02<K0P_A:W24?PAUX#P4G^K4H-M?K3%X/E8/8,/M+47&7)%I,^&)C2[
M!JSD_]I?YUNE^C'5-8#/Q\8HIJEY^0WD*3JXF/0:@,-W#3AX]4OWPB5]]O-(
MZ$?I*IZN11-D><.#:\!3[;!K0" 5%/4%^$MO+20WF8\\L)]!/\EBOQ2E9WSG
M&I!1^.P:T!()O-1B^+4[BB)<.HMA@Z18N>QT\I*K% _Z?3P3NM3)@.:(^;6S
M-X$<@WK,$>Y$SM3%#II"YQWPA\TP$&E!<J-$>M)TJ)[E8AN)$_B$4#'?[((2
M^/Y ?L?%FJ&Y>IR8[<&8X]ADF\O_UT:M\-=]FVYEQN1WG07N:.SZ'/^J(UF_
M]#7!'%88L[AL.2YPDUX;DQ: V RU/]9.IRC+,9Q9X,H%C8^93X/+9-3F8H_H
M<10O009_I__Y/Z*A63<*:OJW]+-PLW0FN=U3-?1F ZA.^**W#2+3Q"=*;7U.
MRL*?FKTJ!DR :)$7<W%9*RD)/OX8HB%93.<>(,T!B5^^S+K@N&KJ2ZGZ< V0
M)+H&8"".#1D\SWF_F51.AEPJK<^"E*\"?>?L8VL,ZDZ@R]< ?P<I%>\H.9 F
MR>WZXA?+^BXG0/EEF$1HG&[JF[#.=1?&8-Q:J:WC@ZX6\2:FB X3_# 3E<6+
M8:_T,A+#S8SCZ2.=*0J@]04MT/8N0?'-FL5_5-\T=Q13#*G*OZ $S1T_&CL)
M/RF3(E,WW&C12V.=:%ZF0Z*SOG@ K2Z8B403ZNVNLL0&B8$<HT5#I%8W, D"
M51^YW*^X*L$)&9BM?[L<N<H$3 7HC@B3((Q8>T_[#IM&,576-__OJ+[=%VL*
MAFE]E82D3QM7,.R0_C_6MYC_78>>:7.X&VH%2'R5)/'SR.<D73"7>;K"#DB[
MB2S>;H$2[!VT^SZ\T!:QWNC:73 Q[&GVW453=:T:C/T__RSW7WLL7,9_\3P:
M#*/2LRX_1=D'>98.T F3J>O2T),B)T\T1R4I+0]>MNF.)[7#3&)X7\-KJT!
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M[ DAK"%!:+)9E/;Y^%*@;.+,6$V"H-67&E3+;+(_*P&AGX$EHV?*&#TNTJZ
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M9=0R9[74:7M4NX)O4,_/;>D6-%\ :,PH'4]F*\?XQ@ECRUH"E_7::MY'^-.
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MW@*SZN(U?X/]Y0#D%<Z,<WUD5>^#L7([#8ZX*)D:JW<1YJ^Y]RF&B*IBK"\
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M/=\.\JW*9FF-7!2?F\14&9:^383OFMZ=)S9S_R.U=DE$/A+[G5$S48T_75@
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MD6S8:,!X1$?1'P/W$)]V?MI?.H0K&_7=(>0L^\79K#>;IZ3K$CG6P@Z:^\6
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M7S';H%WP[YJ6/N.>.?&&+:Y<0LJ4OXC!<[)$LGQ&L_%!(^("T'1^ <BDPBC
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M!BFH0HHB%%5?[>[;M_?>YV1_?7I\YW;?>_O'&H-1:S+G._UYYGS7\WK25#R
M\4[1F^#KE2VOU36US5+9C<(&N<B?/7(4C5W^>8TTNU":U<DA#ZGX..C%=/G-
MO7VXP>IBVH699SN(ZWB!=K1#;LM1S$WB"ZGUUQ:WVD&+AKB^2L\V457;02-&
M^R6!A9Y+N4M^=YJ1]K%MNSV7=A$+R!'?&S]K-R/E\H2>8;,XD<4+PNM&M\!
M'BDE<'_2C:!(,@#@^JQ5Q8,)M\]\Z'LBU7N5R/<^$46)=-WZB> 9]X0ZV[N^
M-:\ ^?"$9NN[Y*K>?G^+ T90\I/\9T>X>U2B@E[G&A<^K$O4XG&ZQTJ,..7Q
M?ZE3,HVSL<*&-%TW>M*CGS=-YY!R8TYCD-X+3E3D_*CSW:E(!@9 D-4+.B7
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M<O+SXDRPM0]1-@,;V 3&.^)PPDJT@C<R1'=T8>[5II;,&6Y.MFQ.B@W\VZP
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M2HP.SE^P>7AX(L!WL!%MN>2\X/C0V4OZQ$"D#]0U49DZ)I\TK#(C0A^E9_%
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MZPHXKE*ZZ5T]Y8_N9WK/E<S=% M0C4&QZ/.%-20\G7+#FV9+TKMS_NCZYS>
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M9Y;S.R'6-4,*>/M)KKFRO)^\Z_#'%H>HOI:;R-@$+6*P8WG"'BL.;;"XJ9V
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M H?!)G_:%PJZ(!/H3@FW</,4FI[HX ;EYWT?M:W@3:A"Y*B/MV!*G&_&%MN
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MVYTEM:?V25FKC>5URE@1OIY.<N)F=9L4X&]L ^C.2?&7+8'2A;/H=6NFMM#
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MAIC3CNKJ5IFN7_0M)^[;<LJKKZNR?9*29,I/I4^G2YA;I?Q>ZW6<2X+?G2C
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M--1=9@MD*:5$6OQS0)?)#YP=J<[!K2I6)V9.\?P*9N0[K&X),CH[6V( U7@
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MOH163C33;#CS@.XGJ6!#VO7<6L3]^D+8XO"SQ87YW:M(:,CK>D@&2OY!7:I
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M,S2&* T]C]/C!-SB(.^E2=9[8RLQ;"*BT:7R1?:B-2;R;H6_'K=\KAZ5N9#
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M?<YB-D5[_ W9M:KV:5V6K-5TGD=Y^\26H.,P8S];CL&6$T04"5P;PU!<PK&
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MLOGPJA&^>@!%OGPYY>Q^3.L_8<*&- Z_X(;)9&0XI=Q/?)**ZN(95J67'!'
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M#=%4!:4!5K8&[+FY=3Z%4)97[JE#1%@ )+(GBG*^F",D6(X9^'K"5!!E>H%
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M= #Y-*4A\-93#DE8_7'%49G5IZ5A: FI?!>CF=#LMWKB<SJ3U8!>'=?" 1K
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MQ2\X(':L[F4[:>+H-R,$\D5@@+DV!-6<+HJU;583Y;:&/B+E9T*F6[PKE[S
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M[EETHL5T=S\C%//S_GA+%3K&P$NB$R VO.Y=^'07FMH<VG>5(8H4O-NH+"H
M=^9XF5+5S#&VT4H#'#Z+[RT@HKA("),?3WZ YBJ.Y\P\C*RTVCBVDJ$W=6A/
M3WR[^<^W3R]X^6OP@4]!_+"; 2D3"M:QFK*S8!VNO0YA_.& R]:\'C6HEZ@*
MJ#-F$KX&,R7>-'4/0'[O2UTXVN[C.#<^MR^T4"F=690[&".SD3=9,+BS]UIP
MRM0:?I/NIS\Q,VVWK9 /HGCA1XDY>.8UYAD:@,661-8;],R' K%LS#J(GB&3
MR10=\_<(E5<ADI-"<X#%MJ15--U3+T'8G";LKF61+U+NX4=#Z1;%]\8R5G_E
MP='V>QVYDRX#9YL[%6L:S:.*OY$<'IW\+/3"M:?N6H/LP<<*1* F^P]-1E(M
M)@K":E$ZK&CMTVIQ>XGH!^5KNJ%E/TO=,XL# "@1WJ_C45ETBV(!&:[)3HI8
M0E59C<*8AS7'L>?=!F_&@\X97GX0T_+\GB5W<K+/&W$''6P]P=AT!A51J'F<
MVCJ2"&,<EMUA8VCU5K88XG3FEJEY_KC&5^[AN2='\-9( ?4,UVV+* !E"[_0
M-,TEK$Q<2=EHW,\;AVK+HIWB#;([YUW<W[D=8WWRX++<YLMGWR9,&RY\HO 3
M>,.;D#]3!OH:4W(:/KRGNXHK%L%L8MI)=X\K&Y[M>ME]K8&U#">9T .+IIO=
M\3;_!UQ62W*<T<S#3*-Q1!<@/M05B(^!V&'(: .O_!;BXO;WBKC[KPV\7T?4
MS3T!/.*7/'*-T72*3J8FOS)2 ='SH PF#T&9DK2P&Y%3(J2@QW;L"1\AIG>L
M=;]QW2SM!+E_#4\0%+(O;>>Z>S)@7*F!G81P)>M3'A/DP]19W#],34'/EU?\
MP%27BX[U+TL+/7T6_R286>'S>-4ZI2ZP8M>:Y] >,[X/L]LFSP-]0CI4N (3
M(,W!/SK!SE2!N29(6"9JV^"LQ--R$N]EH9,QZV]>91WEF.(EEJPFS$S"6^"B
M-(!SO:[ICQU9><-ABB'(/<]Z"JUWW+0T(OL(QAMPZ_WKKGB5DOS%_X0[H>?G
M"3UU)_2X!KV4I-KT+)^%A,2IY,*; T TP+6>!S3 (?C^]J'!?JL.BN3(]/;Q
M82">GP8HT?U-[9JP!F_WW_WG?T'\+XC_!?$O@0!D',9/3H=A1N^OMANLE_H$
M\">V4M=U)[[B0N(R:Z*VP$=(7<1>X4<N(WYU:^?R/62+2:R@*OEW0_9XP)HU
M_V^ZLS0!#8%JDP<'SHOG97Y%D R+4(L"G^ S\C2 S6]KI5=4_:3?T77U_C@U
M*"6/>I@&V%G\NRK#/X 1^)\"8FX6/SD.O1MNRP3\G(LX&RD81P-<[(V[VG'G
M_,(5%!YI"?]Q^2$-T&A+K?<HP4E/D\R,K%DU;,E'G<$G;LP*HYRVWH2-ISD^
M>IR"3G A>O<G]UGZ921H>XC^YJ^_K3UQ\MPV5:!K])VJ P9%0\H1&F"E_[?5
M'\R&_S$,P'\)"$:+A= -18Y($=[1)PH!T7?*4,'/NV^LIWX;*[=[3<[MTWP[
M8IKL0E5 I78T"'VM*!L>U X;V0%_X.0L$??5U!._>G5<TB99LV+PMURW4Z\S
M\=AG<,<_N4WZ^UU4YC^<R16&&_\UW$ ]27+;:-9DZ-_VQPG4ED=DA_')?)7I
M" E:T?\M:4;5\+OMII4BQP?6=L8U;' F<9?DSL8?7NVIQDFD92A8GCMX\W:_
M9*BG)$#-$_YAZ<H_H/3(N?#_%A/.;&B%>@E5]OFP,G6QKEKAG1?(0&Z-J"!Q
MNB)8O#:.?3$5WR;_FS5OM1&F_M075 3)-=#I,TT<"-"R'QQ^+R,>LOHC_Q[+
MC&_TF<8=R7J0085 ]C[L8Z]EQ_ZBG\$_$$H[D1_^6\C&?PB"RW6*OVZH00QB
M:/FR56:[6CXK[3+G;'<I(UJA;T)E8:"F:TO6M5UY"[+28JJ4Z%?C]*,%(H_A
MY"SN+MV3B)F9"5\95/R?LC3^?PRBRG-2RTM?:OV^RF/SRR^3E:J;Q%^3[AWY
M))49>.R?+L4/# BCQ/ V0TZ2\JHE\(LGZ+(IV3$9J;SF,=TVM]HAJ-F2-KO0
MW<XT=8UOBPJ4I &*8RG+IU+^S?<_?!#I/ZO,UW&46*_\6#'P?IAJ8+'<*UN
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MMOJEI8QDI'BB772%<=8Z9[S'F;M$KTJ&-&K$^N-5!(2B"!Y=%](M[C\<4OG
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MB]:R@?^\D2VYP]<9!#O@IUS\PPS OWL&42\;_DU3OF,O97XE>P X*\J/H_0
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M"Q42I0?<V:<FP! Q5.$-&=EIN_FY0FIS2 ".@&J=GSKE HIF2? ^&'\ZU*T
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MS:= :DI8ZWG&I8;\&A^UZ(>=-JGK,^W.4+XGXCS"':?LW75H&C).P7?GLR@
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MN, ?HDG_LYX_AE5N&?^!XW2H<_N,'H*2-/M59VQ!S-T4P)W-3%C#+0K@/@5
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M?^OQJ<\$U4#XLRTM(>5^JU=E6AJ=3E*]PLRE8J^0*GJ\51T7_:B<3=9H'U
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M,^3NB=O[:+J-(^!G/XVM-()CF@R0J=F1]5FY#_PDD4T<*K71,;S75?88<!^
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M/D"XG5VO&37UO5%XT&[\Y0@P<Z1*Q&$K\&RRC](L]A:-+$WYXM.)ZR1>3FT
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MYES(/S#-_FMO[(N]04N,#2WG #2H;C=WV*0VDO/PS?))YB61?O)O8AX0Q+)
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M6;(_!X#;:%ON;=-A\+#7719\L NF_QD])()D9Z2.R3"W5MI/SMH[,/R$V><
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MQ3])L=-*')?D'V?:$E1ZU@E"2+-@W?FI'#F<PO$+>W?BWW5 $X]ALY8IQO/
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M( 8R AI>M&A0!?!7WX1B+.E2_3.'+5[R!%(4#+U9K3&DB,:JO/?/=;/\>OK
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MTHS<,OD%J3KTCWT/^Q?_XI\$RR_*?P!02P,$%     @ R3E;5GIBQS <:@
M4*@  !0   !K<GES+3(P,C(Q,C,Q7V<R+FIP9^R\!U14S[(WNA$022((2!X4
M$"2J)(D#*DDD2I(H")*S('D0!"1+%B1)D R2@\"0@^2,9&;(<<@###/?>-X[
M_W#?.=^]Y]S[WGGW?FY6K]7087=5=U7]JJLVF$G, G#MB:R"+("#@P.\P/X
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MNO_V"N7#J,^ES80L_.H(*A.G(2)J5H%%MKV?I/V%LO\887[_%&6_$?8[75,
M"2X.=O-PR0$P<,9!R)ID-"^*_P)0A<X2U)SDN/-A /!]M"*:\A&Z"HZN([O
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MLHF?TL>GYFGV%SIF"[X99'B9:P@KSK1(<\1N!Q-YV:CXG2+)1,?%@MQ5(TD
MMACF;R^R0&(>H:RBN\HC>0TE_Q5AE[U@[:WWU(#HC3N%B^QUQ8['MC^N?<6#
ML^?V/RC)P$Z65@GQFV.#(M46[<E:V3XV#/,QZ84/"XUKL>^DU!_MANPT\KE=
MU]P;:'T@H,18-+S/]?'++5?.+,ZO6.)]K X]L.C=AP7%/R&NB8"WZ@I]/.YQ
MR9Z186TQ-R,IH'U6#1S$S%-M4CM6:*EVP$ER<:@$*0$UF7^L:*AB@*(:#%#L
MCP&D=>,S@BYL.R]>@\Z(!G'(SJ8CS]; AU1Y5AQ_N-"4PJ=J61>N=IU(.+EQ
M4J:WZ:S[?5]GOJ5T.@;$8?(!(.)X .9G8$@FU^015\O_Y'Y+\71.[UU%H!#4
MCS7ZSI>8E_(A(;BR.%TF5[@O$]*FD\EDU"0*>FN!*(0#M=7CYO0^5AF)JYWF
MD0<JT+S@>/@C%-A>F\L4_+98,%V0ZT+LN1[>%B\\K$<8$F!)B6_&38F3?)<
MN"JJ>KF/4M.R9,$/PH8:_\!APA(P#T1?=O5?@W "Y3+/T*/^:/=9R (#%*4$
MFOH &1 K0>$F8*4IG3A6$[PM#UY-F4#C]&" MJ&+/ +401T&:!*!(). VE]C
M?XW]-?;7V%]C_SN,U:FNB=@@YV:-98U,?/)!NIE&/$(ZG9"3XV_&XRR WXS=
MZ#L[]:ONC!&<#_YHZ!C:#,F$+05\F$=Y73C&V*HK*43]&7@_*[!I*HK@TK*B
M<_B[%XFMLS]N:)],C(ASD3CW#A4T457[?2*7W6Y6E@>_=NV2P*?$\9NCJ/H@
M7C9O*'&NG' )];$MM^N;+*#D:\OZTNXJ/-6]B)%/,?1)I5M&]/.DY[J6KS[Z
M[8LQQ#\ R-(!X &5:PC F6RT3U^+ 4K<((=W.)>?A:(?O0$?[9*A ]@ _8P0
M#N"_7S$ME\-[I; D/^AB_@) *>$TMJX5<^DB@_'C<QCH]!4\26S141QV5PX?
M#:;YI#1TZAE#[/,F9=S-V!/Q>N+L!R-SQ=65,0"X<[!6NM/GTZG',3<6S'01
M<63X_J7D9&. SDP,,-&& <X$\Y>?#6, ^! &V(1!+NA&<9Q^ASG_T<!M,>3I
M'F-_MJ,CMZCFR/HV>72'BP;(8LIAUFBY7]I@VHG_D5LC#>NWB/.GT I/>75M
M[?WDTC<_Z,AX94\3:P"8KR@1%QZR[ >U_')I0\0I+\6,3MPCKF_%R\U7G]$_
M8MAIFG+N:K=8URT4K2R,;F7X6J]>P?_H+@[,Y0&G@_RA")[?E15?WK$'T"5A
M9PQ@B,  :^J:WW-NH )W()MSH NB)UA)^,=NEOXUY>9-C7AFG-'4L1A/6 .Q
MRL!4I:)#:WZFO3&25^EI-DU!]^0PY:K:%"'TD6$(; 69^&*?IB)%\D0UX>OC
M*;(#<+;<12D\Y1E:7,#B-7)@;P;TT<<4LB88-)ZWS>A-U=^>H*T[6J%]DF2$
M4(;E&UK5^:02-C945Q]'2^7L%RNBR<DH-KPV?6Y'45ZL%4D#YXX5/G%V XM5
M;VW>Z+.>1(XF9C-?/]17/X[+1K3,E:"*F5J)R6":T%CMC2W1$YA<T+:"SJND
M[3.3*Y%&!29YD!8S&*-B.%GK_6VPJU[TP[0EL.[&5H6WL#+NEI 0@AREUH&#
M.AN;DDBQ]'I6G8$![IU[L4H2:6. ZQ=4$:!SODZ/')3/1M69C7F^E*0Q\BT&
M*'\&0UJ:<_L9F#]K&&7=>7[L?[J$KIP:4MFHF&]_L]%^\=G 4GGH4,%'#,W.
MXH*8EXVW=K9<T7T<=#*427T0-)KLOR.FK8E'KCN=1;U7J";[68WR!4<>1Q&<
MBI&\4[0\KS % Q@98H"[&2&<82TA'.F7?I:\=<C>&@8XV@.CPZUJ-0ZAR$/(
M&3(- \A6 OI_O-:LY)'YS2E(O_3[M2;#MI@4.\,E1[76/X@,7%R$9-AZ4S(Q
MQ\"2VB'QY:AM5HWVVR]B\N3,)I<)6;\21DU&.YP*,#Z!/ZYMC 8$W2MICLC*
MZT-/3#[0+,Y<E82]388[,\5-JDDQ/*Z3+>(+ABS>5A*2<2LVF7ZQW[E2_Y ]
M_-/-JLN]66^_?6@(;K=WL^M8&:<_W37>9VULB%YZJ,,OF\69RVIJ3D38S)+Z
MI<HB_5+N._/Q':&N[E WGS4&U+"'OW;^'U4KQZ6?:1ZK*T;=D);(WVK9&;ZW
M]HW0/F:H!!3'7RN<NAR7^'YU_M7Y5^=_KS/QMI'RB*S];M'V1=:'2S[^><4W
MGB,C[XP.6H@Q#5^^@,M#-R^D!C@ESE:G"_,,]:/&C@6.G52/HX<EYN8GCDK7
M)!4QP$ O-!H#!##]7G540Y:WB_9:G8&"XCF2O<KU):69TE/2T16[6V1T5FG[
MUR>&O_.CJ#.C3E^>)JV>M20T4Z.U4/WSN340.L?(_MT=;='I8)/R2.^YS"7V
MDVQ3M;.0YH:]_K=F41<E;*UDBWYW,4#QC$^E[OQB:BSK@0M7P;=3E6>LGZ11
MM1?6'CVMNKPID666\5VMF;$D\XG=&<A@FVC4HP1\%?<GAL%LR%DT 0\&(!S/
MS'5<O*!7K2/(BN8, .G? 15)W$0&Y$7.J5A_D9V5I:P" _/#WXICU;;8^2+L
ME],;JY5!+5D)1<NGZTB&!\@W/'ND)9LGU3EY,@]PT6?LIT0CY8C+;TVE%5]R
M>0P$\R/)(X?K=#DS [-O^!A-'-QR0ST=2YXRB$^+TJ6GK J3LUMA9:06D %]
MT(WY/;VMV#^\:O;'#2P7#P[XEJ"+<K_5U(>DWO^K$^O^7G?_)S1E+Q3 Z]?W
M/=%'_Q6([@OWD/@ A7PXZXL;4DUQ!%_D;!9&UOX"3_,=(5UVJ^B&1>P,605Q
MRGRGI#-8+%D//J.,Q7'ZJ]7\EY8"SWP=RYXZ]#XQUC0KL1*I+.HO[[:E$/VH
MTJTX*7M]B:8+[T(/],7ZSG@.6?#D6G9 B1[2P6;3HAB$IH!0;\Q8S#&>"]@.
MZY5Y>!Q40$3!BS?V7A7T5\+XRC-=0@:94I-M0?UE9YW"S=08 !^9 E9;0@O*
M=ZZ^.>%*L=TIREDO^'0^R?-7>78Z@6D%V<T9I$WQ98GCD+C]Y=66-HWT%D)]
MC<OF#3%Y_%T.*D..9RMU8A*\K<H&5=0.>I%GYC3J$#KP%-L4./0"]R(D[4 )
M RQP'9FS8 6'+[323@!"1BP_G95@>GBT:K\O &GA@A5II]BWO<*3,*G (_%P
MQ"Y\AR-S S7/\ EU8P%DN(0F80'%S<_M.+F"20_IU>E@(B6F&T_W&<S7:BZ<
MM8OKJ=)GE>Q6.AX\)A"[B4,MO;;@0M4@8TDGD%%$DTD(OT?%N"R$-N$,4,T'
M@!> J/J0C(U3 *6:%/Y_M/SI4(XY_0E7 ;5J?S,F+(7W=V+(E3=Q8@,!O[O2
MNU),$,H3)KISK[/D-WE%#7&]&0LS[N,3'??JK]6>$D6$5CH0,HSRY<Y-ZK8;
M.]GQ[+K0;#M[)&55X_9$FT7(3BUJW3ZMF;PK[" +%)<H(E("/[&&H<TF6SLO
MS<CO\]1S _MQ!N]QEU=INN#I>;<07\))DX\SQK)"W-[QK:JP%K* 7#03@U7)
MF.]@O6D+W,0DZX]>^E["C-L;ZP>S+1VR=5%9:DORVS2Q*0O\LCF[IJ9OFXN#
M6LIZ!S=<1Y2XN\US%?'X^!/L^8B:J,6KB,FC%6 Y&.#=2P6A:+W*^C#6.'-+
M7=BC>U$.5/7#T\W "Z_9!^O:-@+G!O<GMH[53AUWS$5,>GL[V1*#V8(E%%@'
M\9,R&&/T:J;I)6T7S[,<#Q0V9 S_)+#IA*A5K-:PA AB #KQWZL_E4P_Y/0X
MX<!H+_.OE;\HF5_=?W7_EW3_\%63[3W@<MN7Y2 -[9V-FD!9_+5B36RT]R7M
M\ZGC%S[SE[VJ-:<W:MFKO^Z>C2F6!.OB71$/JJF+\CV]]=Z/[/-LY(A@;'X+
MT;ZKJ.6BM:;K.SL,4'3NU9_Y_UA*,3^: DJY46_APV"A>AB_]N'*T:H%^C6D
M101.JH=^B&;6>S!=Z)J^1*8LA 'XGWN__+00"O%#*4?^ 35]ZGLUHF(PT8]5
M94D]=*L'5JL[C6QK#O?D\?M&4X"0>WX^61B DQM-M^8@G.AAA[4(I4E/+_F$
M1HXFK6U5A(.5]'6>2]OO,KRX?B2A!-JFV :UH]^BVU5.OV  !-59.1:,O,MI
M]RBA8P\BN>*A^%J^ZXAV"IPBZP6&,VI@@#;X\^@I_G$QI0:)!UP7U@T9D04'
M7D[V""-?;\\8I #\+_K?,=Z(3,#:=?Z-K;LWN_JK."GVM2R?VN*([RT#ROHZ
MEHKVNW3,['L#@I]EK(D$%A$=G8+ZFA[S;9],#9VQ +,"FH0!PIE^KRK*6#E'
MN0]@ ,EAM#5:X+>:( \ESHUD+'C:YEN!PN5^JV%A%/FO[O]T=U5+.:&G\BP7
MMWS([.<J]?,]C% >X LO%0R0J>O+^\\$+'^SSW^X.=7_L]$@_D=SO_[]HI\6
M4F]3QSC\0^=Q@K#5HR<,'TI+]!U1CU\?;F[+5I?-9)6XSD9O'(M^YPJW#SZC
M>)R=^>W@RFFF3J#&F>D'3C[D\UN04P(+T8"!G)XPM-2$6+N:<K^<C1-*(VY4
MX)2Q@:H-TO(<5I"&/$ D1YGGI/9=/!PZ+GFO;<!MP]V\IHB+ <KIT@K;47>@
M,:!C;YF][USCBH>UTT/Z<L?"D;Q0^*IAY5L5BX2H4^:?&H"T2!_2B0%"[6G>
M/"8A0 =<<!R/0$B%D7RCDGFR8$8+5#$&>%3U2L.@OUEJ1YDS=FHESC:MPLK5
M\5Q@ USDM(F /G6=]<PUFA'^EHL.+&Y&K+8ZOO1.C@&=6?)#'G*LMDED) R@
M 4]QRC>Y\UF0OOB5/6@0\_E9H1RZM@"\?[E\!?EI<:T1/M.' ?07.]'O9*Q:
M%T%DT_">81YE,)0)ZV,F#08IEU5A@$A/,;?2BZXXR(<<FT<;"=U!0I?%9%7&
MLL_XH[".81P#!MB_.GA$G*822X)^GHFFV*74QP"=:>]6(B5(EJ&YNMMKF3\T
M/4?/H\D*%Q-:9;RF(4N.(%MD@,O)ZTUB*0^*IK2+*U@5!B[S\G1!0_4KJI^A
M[N5VH6+.)NQE0-J-^_:K:.FCE48Z!Z/C;0P@EBR'NDFW/(""N%4A(M9I7H /
M;Z+RY%I))65)O?.,9D!OU%#-Q5,AD@5R^="^H.-XKJWO<\%\W0RWLQ'?)[HB
MSRD6TV/ODAT'<A<VUE_-/+JPSAVJ!^>LN09397&:XJZFQ-YPGHFYX%(.F;JK
M]H3+K&Q[S:F_8F4FZ\BSL63LB(@CH[#M'_VLZ']7.%.Q/A=3) 8PNHX!UL8+
MXE2P3G>D' 8H"<8 A]:J^-__D,\X^B=A!&[^[:O"O*NN*34$#!3\4@S%"3 E
MV?WQ\^="@]U9%ZD*MG&\.-'\3$YEI% NX72>:IJ<Y\B>;5&\I*B0EE>W:1:J
M2T?%CRW-;FH)?^=MC9;P3)T9_SI\Y)EBIZ2S?N83YVG/,*C *O-]_KNFZ[?P
M?*^OLG+<GN9A"?-NYAICN[R"8FFES^<RI(_E%Z.R'PXIK."RQ#[S\S$DP&5/
MC<4QJ]=V9IQ>CUXOA5A?9#QX6:V88>*P-@#MY;BBFGMZRA_7Z35>')I?56#O
M\,I_ZX2ZFLQ6W/@DUZ63<Y(6[YH<<##\-0LQ5\3[U>7@6&!T&"8<,?ETFSS\
MI<6/IY_XHUF=4Y(=1#;U1"\G2J;@3\]];!SQ=#U1YV:-?3B)(\U\/4"M_[**
ML11=Y1_=RSBGW/?C2G9P1^-0-Y_-./0="8Y+1U0W?L2<8SV+^7$L9I#L39M+
M0*.KD8-X%1I&KU1VL;L#T4-9G-^'>!B=G\W#I2B&U+P3P0U\%Q?V>YE;W1?K
MD-U-2#B@*"-S;(H^A)X<03LBR]E/LC$ M @M@,/S:_K_3Z>O-;KNEBHAN6"I
MR]GC6?#$M=":BYQ<LO[H&+4I&L>B+#XLE/DPVWU?&F+P(Q-F3S7EYCK#*SGD
MS=PFU#,6:>)-<+"M/U;]UH7'JS$/)G9279^<1R[KNZ6R$S4)S\GQ.BR"7'7C
ML3%#CXPO6_=I/:K-XG4D/Y88@"X;@/] 2<>U% 7.F.%IWKE&<[,G%;G20YF6
M1NZ"GJ>L9SYFWF#YK\/;F8'?QQ^,7<8A$@8Y><3L:EOQ_<Z7WV@LCHW6DDN[
M(R+6'?TW*;^O8)';^%>N#?W& U^VC(S?F";WAW4!\2&AOPT&_<[A2[J<?^OU
MZ82_IO\U_;\S_;^)!4-^>YG@Y5BA'W=I83#'[@%4Y3]Q0</S^X< ?U;B>>T8
MX.:WM+.3( SP,-J7]Q]-RON[12GZ<>#M:&V-Q[2O7OH2Y DV6]'U9\/UU@5*
M2.+]E1]5K2#]A,FDM[='SXDZBC25WMB;NA@CAHNG&S*J[<TN7+DW&[F_C;K@
M?D9*>VW&[/>Y2FX]:B0[0I59OVR5I*Q ;-=Z762<*;^J->Z6:#H$#33H#U;0
M\Y&MP\:;[Z6:1C4>!HVFK>MJ4JX+\UD^TT;RJ1P(%@6'!)6F%S&5%#9 'F-9
M\3KY7Q)8_E/0\C_M,LC+__3+2:(]5?'4YJ0%EXY+N^NL';[(-)\^,F<XW+*R
M6N"F%;_C<ETR\7*.B[.UHV!Q9LX]RQ+?J=4^54+691^;FL,.:VK:MOO6K@<2
M(_3=6U<SQ>/+I8C$/W[:S9W*$AHD0ZPRX/J2/<^HA\'&QT%T52$?9*@#>"Z@
M*58A>)*6U5%^5 S&B2:L+V/\Y^J,"/+;+Q?9 \36]OE*C'5\L^&7AS7E7C#4
M=-K%X@QI_IND@ P2?[V:_3&]"R:&'1L(96J'+Y^:FAV6^E0UR/S(SPR:.CC:
M708K'5CN7/]IL7XU_D]J'//</+>]WZ]8L!Y/\Q*K)LX\TZPRBS:'+.C<ZT;Q
MGHC>XGY7$31(6MD]9:E;$F'/,B8XB0KGN6J[51TW)Z$"*O&9I!I0K^9:"BQ#
M5XLY(,T>G.N6Q!.70-A63Z]TJB-#W1Z_4B0C:T.EAHN !D[)G W&TW)TU[7N
M3>D\_-I*LR@'<?),\]!Y&3U'&4ALP1)^>4S&Z5*DE-#(B3YD@ .ZNXX!8);#
MF5VGV85I:B;W>/-5_9;]?OB4?,,J]EFL8A7/P.KF' P0G.G2B=H/1:/3T+>K
M'W1;Y%;_/M[B3QU_6HI?C;\:?S7^IQNM_NS[Y_U!9JU(N< FMDVXQ\'[./\L
M6GIE*<DX?*A0;#92N!BHF$C\K= J"S<R]AI!3^>3FF.A:._,WLJ QN%/[+,T
MDE8+8<(G@80TDI42E#@*KPWN"(R/3#PMUV,72YK4*XGO9%XJOC>*B]0,M;;@
MWAZ>&Z99"+SW+H*5*%_"=T&C @L(8!C@P^S A6<K!OBLH,WYYSR?Y7\DJO>W
MBC$RH5THE:&2'JMWWV!]L^\^KR1S!C7!UY$-KVLO?\K*F1:T5!X-OKQ(*S$]
M/WV0BQ)<."ZO$VV$\DV[/)>T*?W>YMUP<79UK$>T++8AA>>L,11-N*;>VI),
M92,[>^,Y)/K@/"2)/6#7)5S:98#&9]_NZ_.H_38Q4XA*_S>?%(Z,RIPG F,)
M*)&!]VW*]24\\=TV#9=".(J4'?Z5:9U_@EW%FA)\: D0NI$= PP52=WX#R3A
M_C%PGYU^*02.DBBTHHO;/NHQFDQ,NCV;K=@HPFUP]=I=UB4&5%^E<S/M%QG8
MYFZYT:G3^E2B@FW1-N_66#Q!TJLIM4;7_MX"!J8@!CI@:ZU8!J60WUXHY#MO
M$J-N_3Z:*XJXT%!/=I^?YB0F:OEK!]J)C"'DQZ"@6+@L<==N/%_%#X.&PG"B
M. 6AA4 @6E8SB/:!R(JOH-7_.VFX<BX10NXTMSAZ^!D "0L<Z]")>CUG=Z_7
M8$*^*3Z=[>AEGRV61C)E"0\R9TT7'D_U/>_#)+F <JIH5+7P*C/Y#)D]%NUO
M5(#()I$>37J3.;WNT:]  D&C/Y-D:K]_6\[)\H#N8P#^T7!.-YD! T-OENE^
MH^636!3_(I<1V>-7SL<I#]42BXVB%38(TB^47E.J&=Q]9\RD4W25J-)<U\Z%
M<?KG'6/7?^4=X[_R7O(FK3H.2T1FI=SOT-\"-[YJL/)3SZ)[H5%+M=:]/GLS
M<>K/ST_R(T7V>PGA8E)J:4WX-8AW9^].M),B,FFA<;=T;E=6[D=3!Y]D4O&V
M1^S4&G?B,EKG9OB*)"!2>JO#\Q7R9 4C*^0$WA!:/9:G(K+9/UGR*SP]/8CO
MZKBG6R<4^[K O:W\(@.VL;C#_N%V.^]<:(PO )C&=#[3%< JK\=J/44S[E$%
ML#D&.WWX2G3)GU&^*AX&,*W&0D!RR/RER#(]##!P!;K[]F=TQ3MZ'NV&18->
M1)+=]ECE?@L#-.(KR@ RQXJ0T\4;%PB.<S8H"A&*1E+]#+K\X,$ J^^,3IHR
MM^(QP$$+W_E/[8EG]'_,[!J"*58]#[]:-SPT"![2<.KW!G:?J*MIFSVD2(XU
M*9X\[QBI.)>K;="Y&7@OWE7MK3X+VVX;_7"\&@8PMU 3HE/U%>\\NQ"]>BHH
M^"4Q%WFV)\AH(_$E(DCH.,3!] 0,/]7V_+^R<8<*U62%,IB;U/13CUF\;R*A
M2((<MQ>NXR6+H .('^>DQ93/)S/&HNPL!8JK]]-C=E2<M7S^R 27K.@R\6Z%
M[@.%V:B_PZ?[\HV__PKZC0L_L_+^RC?*WX?^C%7_QC>UOW+X+ZE]O[%-[C<6
M_PQB_YK]U^S_S6:GNAQ[Z<==5>#&=5^"_Z)8,E60&>P;<=_#'7P>QGKRQ)=U
MKUTB7)X%$]U3S;K3R9R\*L&I4Z^6I6CK(E+KIC5$M:+WGC5X3&\GI?ASA <)
M;DP3%DBL%4;!O-FWHI7M6-4H"W ?'^]SM\@"^:<R;Z*ENYJ6G(>+U\_"B_.L
MCT/OB'>=W&?X+*OUS*^P$$?]RIJ4 ,ZK/]\N%O\;TX#__:\?P?R'2[%Y.Q.O
MTLWXUJ>1VTF%\]P.S+-?4P-*4?F<&N$/#N2GPFDGTEBI?MBWI7*4(V;3+:&>
MSLP7?75IB0,E7T\*&>E;A>O0Z76K89=7-NU-9*GO3;.<^?C$.;?Z7(LG;BU$
M1JA4694Q-MW[WGJXG3;H>E1<50M7UDP35*KC.Q SUTVEYDUEG#,P.Y/K&<@%
M ( $9Q"[K+J!N_]UZ"$C=6=N\M4*C$.N,.+&Z="KX^N6=HHR+_7=H*WQM0='
MLQ+R:'*G=VBIE7)>20XWR7FQRG?.ZPSWA2#7:HHR'U8TTE3OO[K?IA;9+M!H
ML<E1 JY!#BVZ0<9XCCIS$@!:[/'[J E!ZGU914L;4HWQ'HPL=T!V/XR5-<&,
M)L\/4;V&8)+&^=F2)0\9JA4,@$AQF]I%BXN3"HBL'\?;;U!';H-")M*<Y4>X
M-0[98M,N2*%QX+P^+_60T\_>KF2+86D7=0/R[$#,<'T->I")B@ M+H@]KS8F
M&  >]V(MC;)$XR*S3=0[G_SDI73:,'C3\*$/N=L2 \18&(WW" .TCU-9<KI6
MQ!P*9VN.-L F\@Y7XO(>%5H<>\3EN@3N4";=8\;Q^XIG3KN:5&WX+-/2B+(>
M_/F'M#5OVAM*U5M%R=EO'E^*_)#,ZSBR"RHRP*+*M[ +OG#/YF=ED0T\GTTR
M]TG NC^,V=G<%,"IT/ PP_ODKLFZIY9(_<,D+M]R9/=B;5I/8\1QBW0KX><9
M@HM]A0NNS*][)8&5W,1*=GT?#[5C93L1-G3];KH(9'K?S9#/SQ:3SON^WR$?
M?TQ*?_G98%Z70&7_Z_]0'N9_-O\RBYU('F]O\$WNXI_\5H<SJKV*1OG#F_F*
M68](^MZ8N5C\*'? Y78L57U>)C])'/G4,6DD--QD"JYM+;:[328Z[LZ=U&]Q
MK/?H+H3CABJKS_/WM-T+YD#JV0.3($@<G5Q#:.,8KC-3UEF:AS?@P-_NPA<*
M762-^'Y4L5:\2$I;^4&^29KUE30Y?9=6+-FW5$(&9P.R@/2XFZ,[V8$ZZB>J
M\6[J&AS3=_,)GW7U#SM(B>]S_?Q*\#T%HQW\NYG1H5MYK0+ZCD3[O\V+/)Z!
M#.A =W]@W?G<:2QY$M@C!#7' "$_=6G5_^F-V:DP>IW>!'XYHJM%+/B@Q&(/
M#-")9OK:=6X_I0\AK4NX\/"I3-YX"+I>6LE)92WV+-3G_9K0WYNMF!]]W=M:
M ]XZQY D W:U#@M 8X66*0O=L==8@M7?C"8\0BP8@'L[J!>\FX;F+#W[_O,3
M!:,"4?1GCI_)=@7?SN/ZRS;V;%[.>WI;VZ7-Q=J""K3%('MD\N5L)O4W(B^F
M/5W%+Q1QE"J1EEF%J78YCBZY3WSVXI72T?KHRJ%)BZ17'PDFN7D66)#Q][X=
M;,KL_<RU"_BJ<>+T"0,T:6\,W-T3#G:Q-;YE'6H=+MDD9/+]/O:D1<]E?@7I
M;H@3+/XH+-1[5O^>YZB'@C7Y1HSQFD=XUL'NYIH8;=%BK50"N1QG( FU# D.
M@_^ H[I62/30][[B!DCVX'>W!$O9E%$S6[Z,:GM#Z%C&GQB3:=N).@I%7V!I
MSLZH>M#U_ZLS\#^IT:IH/,?X!;^WIZT->+TB/ZUW1*':]/:PMNDW._!JH=')
M%@;8T[#]&4@HA<R78^V$-OC-WHT6K><'+CWFG:B]7NC9%<$@E[VTUGM"TSJ[
M)32(1@UF7 S@?0WR9"V"HO[8_SS"T@2!0'YI/*C_>UM<?X"F=JWU[@A=2'GX
MPD/A]@(T WZ4>:X'2\W$2L/9[;0<60_Q0F*ROH'](LEL-2];/JTP=(,"BK!G
MB'_P[^JK$O&?&>0P6>P<-T'4>E-WT/0:2SY/H/V12 TG0PS0]:;=(QOM$08'
MGPQ929;(@ADU]Y4PP =ODXI&(I45K)7@#Y]H?."6H+AW.]O8UC*[7JC:J2D,
MT:6@Z92>#*YT;:1!%N48(0VGSMM$L\/C#@-0D[<"9:<#F1T(Q7W)X/I]$UO[
MK/6)V_4RRRW]3RW9OJQHLOO*.\;LOCTLGF[! ,2'C,2/_494RRO&>#.Y#5=T
M)-$Z4?O1CKY2**[4M+(5G^'C?5%.3T/-K6W(_:+.]EW21VF\%SO@S928, PP
M_UCS^E[\L'.X\!-H'?AHYS*$77!>;TU7YHMD3_8/Z8A4@SJ^?2HO(!V?!C>=
M:FC[;H&%\ 8&Z&9 #U">Y"9D0?I23259W,HVT=+H*]^,?RPI &#D#ECW@YL_
M+& 5Y>EFTC&KLO=T@?RT"QSGH43I;1*-M.1+F=\ :>6C.4N6S<Z8[(]50F^D
MV!]^ R _GD6B7'*Q#.?J3(#L7<!?!4GX]!:"XZ<.0SC.EB9::4JBR?*D4>HQ
M&* Z;<V]P(NMH1;+ZX2P2K'"HRX[B+# F@^1A5K5>O$N+QGDGN_ <LAAR!UO
M3W+4^.'(/EV3,30:70U);-=#W4$T-)(=OU8'/6?2NA"&5?*@KG_6A7</511&
M!!3Z@WIC#$BI8DNILO>4+K:F'GC<0[Y(Z*8L.ERJP "1.C98(U?L.@V)*J#_
M_7QK\E"%VN[81.N1__&@JV%A@ <61/L,8  J]2%Y4[V_(Q$_KQ/^-VWXQ'V\
MC-*N\],_#/B>*EDQ^'RI[<'B(S0=M-M6=(X W&[').Z#LW>F;29C331V!T5A
MO6(F*K#AY:BRY)Z#NK-<[G1V(UB05.0@JCH9,L^F)':."WN%92,S!B"?VE"+
M7*@U2H3N9H//J#R4J(:.I@;@%0WJYL*C%B5^>X>V3!9H7F1P-J1+N^7>+.>1
MM7@IR\3R*[3&5R^34@4\W?;PE10^A^-I7ZP5>WO!-9POLKU0%];I3.)\<Z.,
MP_B43J*!T.LU>F7B-.AK"<BO9 [[8I;$KTC_Q3XY)KGWW*JI(QU#D#53;6E[
MD;K(WLIO58G@!KH=T$>K=BC2<U%)3M(GV.;=B2]-)/J!C/,)Z'*%2TS?L""/
MG')"J<(CG#/<LZ&>=_'#CD?:*&B72*GC'*=AQ'S::0IZ.O)T\\;%.1BE^<>-
M6H4@@MPPP!/LR1$.DYDJD6E0=Y*0?'$(L?=2&H8LW5S<5'IR$^7:=P!JQOJ"
M9ID;^4;X\M 4Z%VLG[9WI]NKY%3_4*D:=##.=WX,0>;_P2X7#&C#4%HVU]LD
M&48/Q]=\#":Q@-TO:>HK\O,B/0I_3(L W.I(+Q?9%N932=$,NU6\@-9%RW32
M!\64)9VNGZ;(_NT%4Z7F&.<6;TL>SZU[K!!J8H"H LW>$>7>#27!US)_/&!_
M&/\RC1ZIP0"BL,3N\,06!*ZGJD+55^\\_23FT:T@!987WS?<\<A'/8=I9O\F
M)?E85YCG/]?B_V1@\I,KX?GC4^:7:-U_;7*U.@65@@G $.VI)8@!P@08A6_!
MU=_5H*]$?IR/7@6%/\VAX>J>'$[AC&/\3'U!FL_U'O*^8Z_7!S3$QS?_!5:#
MNS]PF-4961GQ940NN.&N'@BY-["LCP%T_9'7$S+$P.4;G;I%C\;02>55T8]#
M[N_795PM[ 2TJ#! A#@X9TDAMY,_<L'7/2T7?E3X'LW ,^-G=,U:.,G_J&.+
M;()]O]UNTDWNX8B#;467\-5(C@/Z QM8A,WC*@6/S5.R&'P5V*>$C++S^5,:
M AC^3L83I'/KB?:CBK(PCC,XRU'FEJ'$.!B^<3RM\/Y(_JN.SW,P\N@-UKG%
M!5Y?"I%XE[W7!U7"W8Q=1-$I>)P/[(T@'M1(TOWH9OZD.VHO2.N9X(WU1_C/
M)J2-%XOHGS:7C=C"C8>^V]F?KRV-9U-E<:@'E@:'Z[^ZE5^QLCUM=L+S,_83
M(?5W8PQ^#\-BWFY8Q9[U)]BF56QH?8"7)(J6' @,VQN+L-6ZAC2G=3+=J!Y(
M+-%A@#BY0):3!M)@:?[IFP5!DE'-+#[?'/7DR'3UI"]Z.W22R.>L=^4,9!RN
MH\P1%<_WT;/@"V=?LHLK(458LQ<Q##DE<//4K#T\!0:6D\9>./)M\=^(;.6K
M@O(/<]'!.YCH*FNBYS;;Z$SY'[>S1BAVC46];<:[WES\"$TM%UP,@7<VZ0:*
MB6<C(/LT:)>%NGKAL^I002UK6<7JVE3+=-!^[PY;D&0*%V>-1VS<ZFG.*=UP
MV[/"J:"EB17O-V;>UKE3;.-ISJ1C]8D_!"@(9)N;FQE<:/(VVR09UQLEH0C!
MZ#71RM2T+W8Q/7/I71"W'^A+'JLUQ7&-#,C O3?6J:+U=U!J[35\Z'<$Z[JR
M 9*:=T85=^WW^>-OY?"K?IF?25CQ8&N?K<RPJZL)P3^*:HD<+[5#O5FTYCX]
MVXYBR0U1N8MU0&N+I25O('E_H/J>Z29A!>#]@-M[LB6<"ZM#4?:6"_[/PUDL
M)8DNJSX!X60;#L@O\QF*!Z:>3_6KPK0+[/<?5T-H4.RV:;?U"J!G<#M9R&Y#
MI0J:NF%Y%^6+ N7-K69>D\)J=$UHBG4K#(ICJ7/.<$R-7#^V?H8!RHHH4!J(
M"HC3CB5DIMI^ _]1^XO,"OM-OOVOM8YDL/R$# P@U!N)E&^\;07>@R^&*K*"
MVQTPP%W4#(037"K)@?WK"8R>_LH XF&F PIK$%X5.'D9#>),DQ9_YG>=IHA<
M&9U'ZLH:(?<1X]G@G)[()5*5XS@VA"S7,J0?=DP.850 IT"YJ*"+6AL),YL^
M J/%;S>":W!.2T'9NA5(P46+JW:2TZZ>IR-89-9%F89(<XN&((\0,@C&I(=(
MK*K !R&B45)I:(EZ+CR?5&L,$$JD(E!XJ YAL^\F-;Y;#66[L,,*AM,(EJT!
MW*5+:UKAD:=;7XPN2)*FJ[Z6EQE4N7[0BY3/)$85O#_7;MN,/'48L84L/,&"
MQ\@D<'GC[1GO[9=*58Q-4I#CQ&)WDWP5V ID(G&(9B2HF=@K AVR %ZDW.O%
MZO<#V'+DQ/='%T FFFJE5ACEXS:MZCBK\0!TQG^FY3/LC=7@N,J6KF)G(7JY
MV+J!./85C0O:Q!B *&/*"'DQ47GGPL<!G&JETW@-Z02&LAU"=WNA0S(,8Y"$
M/>*!4BPNY1BQ,29E[!7FU;\30?OH+D'>@P%I%4F.09SF"8%!.54[.)Y/Y7=%
M!'PKX3[IM4>DWUY>V!0^CQ!-)=4?0=.ME> *5>?("(Z(W)8O9L,)JL$C05/9
M3^DIZI=X=&  %)LD"*N?=[">WMLH#! .0L0B(6C_.GOT93FT8!QVE0,MX$-"
M+&A,Q%H%\.)SI"+Z+?B4GP]KL-0\9A-@*M E*PS0\@S+Z+.KZU D+0@YA $(
M58(PP)K8%PRP8 J!/S="%*+8,(!4&BHQX2?N1U.EO8.L7<< ,?=_PB7#:C/L
MIG[P1,N6_&?6([/I:A1Y2O#/+@CZ3R_(Z%^\(#?L@I+LT?B=_]""U-(A@\Y8
M;Z<):\<[/J>U3SUVULMNV&X8?G)N*/]*2R<HCT5R/F];X\]3/+_O)9%*N&S
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M*_,ILZMPC!.;R)O']P+0S@  '/1 KLE'',YVGG06$2GPS]31?*>*NJ7IX']
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MV+[$X3/PBK^Z^?$E"^E<.B$L!Y&8O*+7R5JRZ_TC!VM.]NM,TZO<;JGF6I_
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MM2X;MAK$:,81LBJU3$VGB/%Q+%"8C5U$TEC63\+R%O8J(^ ]@<@^WBF=<R
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MRHGW[2OH&4^:T^^3)A(R<J,+AJ'BQ&)1OOSY+U&0(8-=#)!(GVCT20Z'T\"
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M/ZL)U"+_$*QR?:7> 9Q0?_N-_3-_+F:WGW__D*\><OKXNWQD,I]) 4F<AB'
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M27HDJ8VI0X^M[1@9;I\V>EU<ZFG7=+#* U6)?]5V=\P7PW*C/+5Y_LMLL34
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M1^::T\V]<P1RLU%_+:L_[Y:WG.=ZQ)8/\W8IRHC>W;Z_Y?)6,,41DR'(E)(
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M1=ZVKRGC,E=EI"RO(V7[5(RR0=^.:#QC.C#C-' VW?-V<<>5Q#=-_+$_DG$
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MQO$)Y8EK>M33N>4\WTBQC:)?BOOU5YF_VN2Y-AK?S2F;+\I.O#,&$\I8J(#
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M7>$XRG=W?D _%FNZZ;V635>]6U[U9M/;/\H6<A:%7)$TQB#%IH]&$A+ 4JP
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MQ,#=;2^0''@D\^D$P>/+>B8)TGPY7SX4317\7VDQYS,8DR2.B0",F33E-"*
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M6^E* :P8(8J(.(5.#>TLQYW:&M"(;0(V]P7?YO=\,<('I?2N7:4LY\+.F!P
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MCUR8ZXQZQ^6XSEUX;5BHE</F=E%.E?[;O=JY9#Z4=8B,S57L&F/&28H4C!'
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MLC!.B.8;84IU9@HP'D,@M(&B*&41)4ZEQ:U'GAKME(+?!$OIR#;V4%MZ6H<
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MW?!4**93F&' D*NAKC((&&0IH)F2+#<IMO_KWC;W:+:QF825>&!AP+,U8GC
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MF<-!8'8P@</&OZ&+BIV@\OS_?\_+<J7**D9ODV>JL@PAE@.*)0(HS2B@@@@
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MW5E1S*0FN=9!:4>A HR-PNSC6(1Q53#D?IS5)Y!]G^)4HKM\RZ-"REOY)Z[
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M@4^3_4$X/3 .N+=CNSN]6FE]6!SG7B\?/YO-YGV*)"$,8@YRI21 S%! :2Z
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MUG*DA0$,4PB$TFFNH6+"+SFUP]QC,WTJ\=WYX$X!_S[RH;BW<U3/:/;,4V>
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M_G9%C]_^*U=WV"SM98'63J:C$H,4\0)FQ@"#<P40SUPND:: T,)2 5)*&:\
M6I_)QL8$'[O4;/1"U6.O%!&KG@GA((V[EK6IJM&E2-LUZ *V3!$A'&C7]':_
M:@"OH3RJ'!IK_^0)3NL6ZMH8P^VB/+4YV$CYWM.Y&8K46JW>6T$_S%?/2^=H
MW9U\;8MNWLEU^:,NZZ!X+ED*-6#894AQ*5RK00U0RC3*\D()C )[HP2*,#8&
MWFB0N.5.RHT.!P?QBVWQ6+[5([A_2NA2^=ER_2Y S[1^B/U6_(-C^5WAWKOK
MV'?IN=(1OG@M6$(%&+HC2T> SC1HZ3I2>+^6NV=5VI7_Z!Z LFJ*C0EG5 !I
MBA0@I340)D7 ,*(S 2'2POBV:SD:>VR$UHB7;.3S;]-R#%H[ ]T(1=_'1[XH
M!'5GN:!OI^8LQV,-UIOE@A+[K5DN71+^(KZ;KZVA\[Z<Z>4;OM;?%\N7*:,%
MS06RV[P<V@V?%"E@+NX.8VO\09GF1GN_C&?&']L+68N85#(F&R']W\IS"%Y_
M,V_$I>>W,PR2H%>T1?%.K^FY\09[55N4V7]=VRZ+L+58K9[=M_JS>;-X?%S,
M*Y?05!FJ4YH70"+BRNQ+"BB%$B@.=0YUIHWLOI,X-^/87NNCC4,CLJNX+RNA
M:Y?D))FW%)KKB'V'K<&MB Z[$]@#LY:W]I'W9/>W8=.'F7]VOM>SZMO4;S7B
M6V_LQCM'\8F?GIW+^;.I@A[WF\JZO -+D8@XHC$ <LP!H@0!*C(*M&9IFFJ>
M*41#."AH]K'QT49XP)N YPT-5=+O-P#_<R*< F&L%+8R?@S5&]X]L]5);'DM
MN:.K6O;#+MR_MZ(=S%V=4(O$8V%S#\IIG6 YYK=N@W0,A9E5:ZW5^:COIJO$
M5&B5,UVDH$ D!X@@!CAB&< RS8B2G#.>!H7&>$T[-G:K2QY7)A4057Z(W!,Z
M,'#&#W@_#HL/9\_D=:7!QN1J.Y/P.)L@B&+%W?A-.FP<3A 0)W$Y87=W(Z5/
M5A.^>O@P_Z%7ZSK?\WTYMV:>_?G#6C^NMO4GA5&(H0P"*$0*$"RDW0"F"BBB
M[>^IR#GU.L4)GGELU/3M^>FI/L.V#/6V7,G98E5EIUESP(5$O[%:)5NUJIRU
MK6(^3HT;U\F/QGI!OV<F:V2^B&TE=R]U0X/1BD1J_O,.RFO!<!Q36_@ W=C-
M;53+=56;R4[Q9C%WDVD[C5Y-)<X)<UO(#%(#4,XP8)1+H 7*4RDSE>9!&6DM
M<XV-P?9$K5XAN2]L\MNGQ5HG16!Z=AO4?I04"<">2>@8NP,YXS&.!QB1.*9M
MID%9Q4/E8Q[QN27<A]54+GIY]U,^.#/YDWT<IBS#C!92 )Q* A#&KLN$)L (
MB#$K>"&@U]G3I0G&QA$;&9.-D(F3TM^-=1;$ZWZL6Z'I>S,5ADJ0)ZM-]4ZN
MK+,##N;+:E-GWYG5>MWK%)?9._AI+0K"$4DS;K=$/,NY:QT( 5,, LQ1D:5,
M8):SZ5.5B/]MS9=K/T-B(.E#WJIC'?I[P7[7W\OYW%GS@L\JG]!KUXWQ?1B0
M8#"C!0<<"0B0X@H(C@N C"*,J$)1+9J'X=U<_>*/PD:#/D,&U*_X%/B9NB-<
MUP%/(6^M"'3@;/EEZOX$KME(*OSX2OU+U?()7(K857M"I^]F!'W5J[4=QIT?
M.R]*4QY H)QDN%# N);'2!<98(50@ NB4"KRC.=!WJ6SLXQM+[,3\DI<20"0
M?D1_,SP]T_(Q,CWT16F%(!++G9]C4$YJ5?.80=HO[O:^_X67\]7'Q6JE5Y_G
MK@CSZK.IDY"F(D_=.R]!88C=ITAB7WHD$, %@[P@3&24;GKH^KWVER?S>K@/
M6^CV_/8[,1-K::AR];18\9GSTYCRIWWDZW2X,#9H@=F/$FZ$;AA><$(FOSDI
M_^2@>UM!5U8&FT6OR<@TB^7&^V)1_::7/^Q7:Y/ 8[]S\3CD.F:1B*1EHD'9
MY+K"QY3B<4>'7.ZO^M&.:PV5W4EK76!KRCA6F, 4V =( 91BY#(+4X!3E\.=
MY28GS#N+^^(T8[,DWJW6Y:/CK&2Y$;F*NZME#LA)O@QL.XO$@ZMWRV*#ST[(
MIN9>%)@"DK:CP#50NO;7,X]54Q@R5IKV53A:$[0OWSU<:O95#0Z2LJ]?W3EG
MPG[JUB]?[ *N7?G5__-</KG1/Y9S77FQIP3!C$*1 E5 "1#."B"TR0'+52JT
M()GQ<QKY3SDVPMQ(/$DJF;<-7BNIDS^<W'7<1F#/" _P_<RQN)#V3*H1T.R2
M.N$)4+S<B6L3#IT\X0G F>P)WSL[[OGTW!K;,SOTG7JT'.>"9JI6X75LX*8D
M).89SA4#+D0/("0T$)1I0+0C(8@9"6N3ZS7KV(BH$;IZ9?B!V('[/R_(/;>"
ML8'L>U>XA^&AQ)L@XA[.CX) BK4-])ISV!UA" PGF\.@F[O&VBV?%G98_?MB
MKDXZ2N=:""FH!I1A 1#$!:"I1" 3/"-YFAI3!*6/MLXV-N[9"IL(*VW@@5,[
MKGY$$PVMG@EF!Y03M-]^W5Z81(NQ:YMKX"@[#[5/X^Q\;NI:+>(?>C;[W_/%
MO^;?-%\MYEJY3%-76)VD!,J4 JXP ZA0&G!2"&"W5(;FI$"<9F%U(R[,-#:^
M:,HE.&G!/YVXR4;>I!8XM)K$)83;V2,J;CTS1W?(.E2;N +'#74G+HT\< 6*
M*PJ>UJ*X=D/'.#[YH-7S3'\VVVI154$]51]LUST?828EQE2!#&8Y0,9(0(M"
M R,RAC41UK((Z^7F,>G8"&,CLW/.[ JHU6)OO#6=6G-ZK8"?#1(;UYX))0:D
MX3%& 1C%"A#RF7+8Z)X $$Y"<T+N[;C/X:L'EVQ@_W+G.3_XS*4?-.8X@R0C
MG'+ "T@!TB('%%J312K!<D:QS+0*VN:T3#8V$JKR'JN4&/?#GKB!^YTV?#VW
M.Y%0ZWNW<PFP/G8['I#$VNRT337L7L=#Z9.MCL\]X3N=-XL?>KG-T97(I"@E
M$@A*72XU%?8G8ZSU@H3 E%)[O^_.YF#DT7&"$\XG)?<*8-<W*IUAZ/U(PQ.!
MH'W(66T[[3L.1QILGW%6@?U]Q?D+.K:JU/;KKRM#8/5E,2OER[W^N?Y]YFJK
MN6R-E& -2,K<%]ME\T":N98$L#",JC2LK$'+7&-[.6LA QM+MD#I]W&.!%#/
MKVTMY:0V^.T'N98T<:(FE:P1O\T>B,1J"-DRT[#M'Z^K?-+LT>.6KB>0?U_,
MGN=KOJQK:JZF"FJ3,R.!*I3]/E-&@"BX!L:5.2$Y0YG?F<+%&<9&!<WQV5;*
MNE2K)S=<QM'W?/$&=(8Y5_0&IL-IX@7E;SA%/!YQX-/#"PJ=GAI>NK#;5WY7
MBJ>J4+E-S/FJ9RYB\\UBM5Z=Y.6L=I\OHR#$-!,@YZQPU24E8"S#P" D4H93
MJ?W*5$>29VP4464JG,G@"[,?;ETD/QMC0.C[/H9LK]Z6_-&+11()OTA6RZW2
M#&K91(+NV/J)->S !17>\W+Y=SY[UG>KU?-CG?[XM5S]\_U2ZP]S2UMZM?YJ
M%9BB#)/<;;Z,R*S%Q6$*!,HD2 O&,TUPENLP+T[?$H^-GIV,P%@AD[*1,G$.
M^X&RY+W7V=-7-*;5&Y#A.V;&.ZV32NUD3^])XC1/G.K)1O?D:]LS,5Q.?.@Z
MO78VO+>\OT8>?"C\T3+@@R<.W]&_;1)U5JZS:1.VI'Y_^>I:\VD+Z\Z6Q!(A
MXSXR*$44()1C0#$4().44U5@+J"7LRYHUK%]-[:")_N2.\+9RNY_"N"/_?63
M@5X0[9G+/<",;+%W0JK3T8+_+(,=-P0KOG\$$7YSQS2QQA9O+/7[Q3W_^8]R
M_?"PF+D*(.\7R_-L.F4"YH0( Z2D!%AVHH C"0$IN(8J+Z0A?).U?Q^00]91
M'J_7[#"Q_WX _K+2ZU7RQ$N7DEMIE*P7>]T\7?S.<E?EHJHHGW#W+0IMZ=EU
M'?U,WEZ79:#LM%J%2=6U>4_VR7G;=6<M1$Q6NQ'%6"EL7<48-K'M1K!.TMUN
M':^C=[=IKUQJ5P2V.J9T,UKN<0$<ZY=I"K&6N4Q!CA@'R% (&%<%R&!:8,F$
M+ES^FVLXX>GBO3)AD(FWG;9'BJQZ:<QV4E=!1ZL]N?\CT97D@;[@:\![.H0C
MPMFW5_@(PW?MJ(5[@CVAB.4.OC;=L#YA3^5/',.^]]T:A'[2W=U.MS=Y%5RZ
MV^&HHN!$67N-%;( "$((*,L)2*&K,$^T%@)WBTL/DF-L^\UOY?=Y:4KITM?=
M1V QK_9+UDK;J%69#W<=2C-U72G/,\G^\>_[I'$OI/T,V!6C[3-<'=[>3\S+
MC6A&#WX/D^*5XN$[074Y1+[;<-U8U&VR'[6=Z:MV:MLI*M//_N*-E:!T1>I$
MD6N4%B!5W!73AAI0ZL[E)-)"*8:DR<.*U%V=L\.6MF=V; 0+X[WKV/HQ7!R\
M!HK+,4;+JO) +77%8^[D.#D4OMZ,UO)/KM6?"F8Q;\0B\=7U^09E)F_UCSG(
M_\:.H4#'S/:7Q4+]JYRY"@@?YFO[()66VYJRC0QC2G)- 2VH)1Z8(4 )S@!%
MDH@,XP(9'A3W$S#YV*RS-_RIM)O%\M]5P\55*!,%X>X9RM,3FGU[ D[MJTFR
M$;VRM';"7S-VP\-W.F 6*U8G9.IA W,Z@'(2A=-EC%@4MERL5M,49U"GT(",
M".S.LE+ <P.!UIG*!):Y,47(6=;Y:<9Y@J4V[]3:OE-=:O=>P+0K$84B]2J4
MXX3LDUGV0>B-0ZI)7IDM]A6]S@L'5W<HO!LUPL*5>7+>K_>+I='E^GFIJU@L
MA6@A<\)  9V#$<(4T%11D&:2IUFN!-'Y](=>BH57$=\!1 YYV_8%[^^EV\G7
M'EKU.BO<SFQC7+6^C\"<*LF58+O?FV"[Y$RPW858NV2C>3+N!R*@:O+('HR!
MZB_7"W_:<3[AA]&8J[WKGIH'I(HJ2(Q[0'Y4#PC?>T#TY@$QNP?$A9S$JNH\
MX'*UUH<>0H[A*DT/B.I!S>HAY^VV/WGW^#1;O&C=M'VX('#=PM[^]-FXHY[O
M<W>R\*5J(5>E+'S<5FLN:$XP3R% G.8 :2F 2%,-&!=2(P8SQ8.RKR++-[:#
MFCJB1GA&C8MS4>,'MSEM;RC''?MI\-N2O>(:#V&G7 Z8FFSJ[:JF?LSVU&YS
MQMU3,?">$(^T<8PMW: [SIZ@/=ZJ]C5-MZ_(]G/U8?[T;(?5/_0,;LJ6PX+C
M'.8 0N%B] L,N,P*D#&*<R**(D^#:FFUS#4V=J]D2^"?PTBX#4P_0HT$4<_D
MN-N"39):4%>GHT*LA\I9'IA$HJ^VF0:E(@^5CVG%YY8.5;.>ETO[N7M?KB2?
M_;?FRW=S]=;M8S.14<0) 01B Y"$KN(>D< (: R%4@J_-I9MDXR-%!HYDUK0
MQ$F:6%&3M]['#*V0MC-$+*!ZIH9.&(55WKH"0K<B7)<&':X>UQ6U#DIS7;NV
MFRWPM_ER:VK<\Y^_Z[DV99V>4\4*?-%S/FNB/#>Y@G=2+I^UFG*&4IT3!0SD
MF=U":@&HX7;W*+7,->.,RZ!@RQMD&1MM-&+MTL(7R^1I(_Y^SLRS?4B6:]?X
MT?G7-OT> UULMRRBGXTRT-+T3%3[6E0.NXT>D_V IJTNFXB!>@4;=>+9.!$P
MC60#W2+)H#92!,B.;:@80W9P-7Y<S+_?Z^7C7_GRGWKM@CY/NHS0HB IT1CD
MQG4-S[  /"T8T QA2Z]&YJE7B)3G?&.C4"<QL!,])CN9]YJ3!/AX/+#V\-G%
M1;!GIG/")O<7P;N^8^N$8H"C*RZ: _FI=H_DXP[5U5;N6%XE?VQ:G4(>PPSG
MT_'7Z< E$W#;+55J#^O6;\+Q7_XV5];<=B>[6KW[*>VE31]<I"43D*< ,E<X
M2<@"L(Q0P)@B2.12:A;48K23%*,C;"O9G[?V4I<*MZ'+X&>[]@YNWUS>5,4]
M:H@QV:8-O4R2?3626H_H<?<WX1BUEFZH#*]09;<C3.?K[W8=K(-=NA=4MY>5
M]+7\_K#^;/ZVJL-LIQF"7!>* $ZUW?EC20!#2H+"R,(Y";B6QB]MR']2KS=R
MT+RA2D"P,.!YI8-"8P.0]C!,XZ'W"B&S^ZF/E<C)9Y-8H>M8VNAP!EBHT6$=
MR$A]NQ^PO5]_8'GRN,8R6(.@:K59_48:SFP-TNS <@V[LV,X$%_.[5=A]477
M13[>EK-G2WO35&!E$,J 4IFPYFD. <U( 33"&!>:R!P')5==F&=L!N@GO4YF
M"VOYV,^EBR-\7,SKD,$_)ZJ6./FMG"?/*U5=4?W3GP)#;BX@SA'C/$\YR*6&
MSFTN 8.Y!I)JDJJ<45%0OZCNB)@/$XS=");,+Z'?&^A^YG\$('O^(&XD3*R(
M=>S8)&FDC!A$U Y#K&"@"[,,&]33KNI)<,Z5RSM6,.$NV[\JC/+)KOUG<[_D
M\Q67[N/_=O'(R_E465M9<J0 5Z( "/$,<)ZE &,H[/_E&-*@]MS7IQP;8SN)
M76&,2N; NB/7\?7CA[BH]4P5!X E?]3RQ:P0X@U&K&(@UR<<MNZ'-P G)3[\
M[QRX'GSUQ]_URIT@U.&$V511:.PF78 <4M<"CW%7*$D!+'->4/O?V)5G&Z#T
M^QGA1L=2U<NVJ.+ZDQ^UJ,Z8L;(.5.G]W IZLMLKK4O?/'A[_?8ZLZS1,/G2
MOIS#%6EOP?VUZ[&?$^W7*+W> FJT*NMM<W0C_#OU/\^K==U39'&G5!4:Q&=?
M>*D^S)OT@TH6<2SN5U=9<E6N-P'GM3Q-4+F[H(H:G2*89ZDJA-VPIJ[C&C&
M$EB -&>(FHPA^U?(1Z!O@4?Y80!G\A9UG2@2]G7H?;G]OAAC6L2>OR)W7SZ\
MN5HGN8H-6SK'B\LBK7.V]G2*]\D8"OA(GY'>Q1WTTS(4^,>?F\'FO;G,<Q.
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M)]FKA[_8N[*.@[3V\M*U*7RKZ[_M?\^>W7G'NY_RP9V .3NZMJZG.-?:"&X
M)S!SW9TEH!P+(/)"PAQID]+4)UWM=<0/^JP-D-[FRG#6,KIW7,9S_0SX1/B[
ME\:YS@.XL"8G&7639*=L4E_B%O[HEX=WU"@D&QB2WS9 _&F2;+%(-F#4)R(U
M''$]9\,O8T3OW(#"#^X!''YASGD97T&*&UL\'1X15>>Z[E-M7X;9]AJ]FA:4
MYI+E"!!COW\(00PHD@4H6$$Y(D)Q'G30'CC_V+9D]?EW61_!NMK<33',9&X_
M:@N3F.:L7-1'ZAU[17FNC=]'J$?$>_Z*^)YY3QJWA/N85.KL75]5*:O:6?30
MBBH,T=@=JCQG?YW&56'07.QG%3C,S?T([E8K;4EYN7C2R_7+%_LXKNU\NZUY
MFAI(782JX"D'2!(&A)0$9$P74!702..5Y!0^]=B8\*U^6FI9MCO^;X7;C^'Z
M ;%G<CMH4U"+/4DV@MN?G.@5HUT_=;JE88$G8/$[%UR;^+5:&'@"TM++P'>$
MCD<?B\='O;0OWNP+MQ,TX8Z&%X2[&/J4* 8099:7"*- ,YHAC7+.=%!G\[.S
MC(V"=D(F3T[*P!.#LT!Z;NQOA:?O_?<.F4K /L))VR"(M7<].\>P6\PV-4]V
M@JT7=TVX?F-)8^GL':5__F_],I6$J*+(","9,<[+3H" 3 &I,CN"H'EAO,+"
M+\XPMO>\21=NI$PJ,1,K9VAB]3&0[>]Z%'CZWB&%(M,A@?J"]C<D3A^/.'#"
M] 6%3A.E+UTXMI)!GQ95!76M_J'+[P_V[[L?>LF_Z[_8H==O[99IVR+EZV(V
M>[]8NE&G3$!.L:410J"K8@\)8"F3=F<C98:PT"Q#@Z17]Z/?V$AL(WO2")]4
MTB=._&375F@L98BZ/5)^QM/(I!X1G0]7U&B+U"3Q>S![J<@ZTB?AM1/5>]+N
MUTAS[W=IAZNZ=)N8'2+N.JO2"'SW_?NR2OWZ8*V><KXJ927=MK TIZ(PD.76
M2G -$U%* :=9 3@WDFHCB$+*.SJO9V'']O'?BIMLY0WYW@^RONT?[[&MVB!?
M8N'Y)1;GOL3;;^W%Q0\N^3[(<Q 0?3BBYV&@2,5!GHM(08T#K4YK &3?,@P7
M+#D0F@>!E4/-V>U 8]?!:_55SZJ<\85O>C7/E9 %UB#%D@.4B@PPS T@6*$L
M)S)G,NV0&W^#2%YD,^X4^;##@UN6SV^CW_=JC"1)?A.T-5AV? 1<(VUQ;Y%D
MT.UH!,B.MXXQAKPU<_[J!V)UZ0M1Y81.<8%SJ5 .3"HU0(4I7(4A" Q-$29"
M0I3K;FGT-THVM@W<?BJVCPVX:C4"FR3MP$9/\9;=\YSV-1:S;S(_6<?VT]95
MZW'KU76\(<,^$N;1T^UOE>N5<N\CP7DY$3_6!%VC@JJ"=,MJTJ_EZI]OK*58
MKMU/4\*%HCS% !%( %+$G=FA#&"2"4Y8!B7W2JOUF&MLM'T@ZLJ]]+6LB1.V
M,I\_&V/?[)DKD6S?\_^_NFOK;=S&PN_]%7K;*3 $1(J2J)<"Z5R* 8(F6+1/
M^V#PF@J;V@/+3CO[ZY?4Q98=.R8I4J.^S 2)11Y^-#\='AY^1\KN3ZZ91-?!
MM\TG"@)I]*RBD94M3N_'>+Y/'C?/-?^6_*?_/XH&B054P;*/KO<T<P[2S2&_
MSD2Z_8A[/M('4T!0[W4^;(1<H0*QM(3:6519JGW'*@.,EP0HR!3*>0E39I4_
M<-[PXCC$G*<:XQ)CG7W.T0E8MU.-?"&(O>;M1N^45W1IJ%[I1"<-S99%=,G\
M<?+0Q;][AMBZF]6/VXV23:.7,GW^+&7SH8T&[58%TK9#5@).% <85@K0BNO%
M2&F54ZH8EDXUP]_N;FD+<U -^#HR-U'2.0[V-L:6H:Y@R$5>SP-H8TL38ZI^
ME7?&!HQ368$2*A3U=F?S1INL!OXJH&3WE!^3_"+7YF+BW5K<B3_K==VTOL&+
M' 2F: JE@+0"2"AADHHS0$F6 RY%5I0YPXP[:4W?Z&]I7-*;VVX)Z(G!;F1R
M"V8[-@D(7F0Z&>-V:FMX/2]+5 +QR:W>9B44RZ&?,XKM8Y[.27O/Z9 WP#C.
M(4(4*"$5P!6O ,&T &51"H8(@D0XA1E.FU\:8736.7H:IX!9>A;>,,3V)%K#
MHN2%7AYS*$?AM/%Y'8.+ WOE"%S^E.=AD;DS;6*-#ZJM56'.IO3ZZ/(7#]]%
MS N19A@#E2.D=Q*, ZHW\B"7D@A)4\0KM\L -KTN;4T?C&Y/!T9F_VM(JW9-
MV'*;!,MCF=#0QCYR"8&J^T&*"TJA#DFL^ISW ,0%AE>'&TX/>]+3GC6UJ.GV
MFRG1WG=T]W?=K&B65B4M%,A+F@&<5@H0PCDH4Z,IK+A@V$WB_5I/BZ,AVI]/
M&@,=>>8JFI;<$@*CV'PRAD=SA[8N)&_<0B 45USM9UY^N#7<5YQP\X&@NE2'
M7_=;EKY4P=VN+TIPJ%)P(G^^8B3/4P(A8%6FN4,[,(#EJ@)E)M,L+1#$A9,<
M0E#KEL8W0WV'D:K5.S:4A*"[I#E4@M@Z%WL(.ZUV)/;=)BLR\5F7@-!S-LSI
ML8K'V3.SJ6)-@SVN9I:G;4M0U)H&JZ7>UL1._-X$O\J=T4A\W&Y>:B'%S]]^
M;Z3XLOY<KZFV;/UT9]9 O:OE,9*"E$0,$@)03C# 1&]<*Z(WLU4I424SPF'N
M%'IR-V%QG#Z8FAQM=6-NCVFPH^>XX$;F8*-=W(K4#N:;_,!W9@3Z]?EC<@GV
M*-M;?Q #,:J' ;/2IC] Y]PXH24_ M0]<2E%\UD/ZDO3[$UNVI>U[H$^/^[9
M<\T?M".PU3VO$*J*7*4*"((AP'I##"A'&2@51ADO*^WE.J5O6_>\-+H;#$_,
M%T&OQ-9DO4GLK#6[Q:YRI!L%VD^$'?-%@3<RX9TB.UB=]&8GG=W)8'@X@G/&
M*A"OV?<[*YTYPW'.8NX-A%0Y6K$R+R%$"%#"<H +S  IBQ+@M!2(240I<\I4
MFGYK;)X#A0W_;W\!A(]O&,@;9^,NT%I&]O[QU^Q^U2NE+0\0.J]@OG*R2R@8
MZU82-M35M?8ZLUYM!Q747FXSRQ 6:<D 32D"N"0E8$QP0'(H)2:$%-)*3_E*
M^TLCA/MC#2.3,?,G7>^5=ACWK9<B;PK]6D&:LXQE154!C)B&M"@AJ#*AM\7:
M'82,LD)@OGJ16[:9 =1Q/_]L6-^FV0!01>97;=Q12OJV'JP5)@Y2(=.PF4G=
MPV 4O+;8]9&_J9QQX;'YQ"ZNVWRB3_'&QV;6R.P%+UIQK>;+NJNJ<E-Y:U6*
MDG"""D!5K@F3<PQ8A;C)?^6(\S2G.(!;&LW^I;W>!H,![:4$GXS)0)@S"F6D
M!%]:V2,C2-WNQ\W&?-.-O/NH]OW>U>MDWXCCAWZ<21/3\RLTQ?U>Q!=C1K_>
M4]/RH)C4H6"JQG4XV(I7+D"Q<MH\?F]%2D_K%["[B3XUP10E)YKA&6ON#&A^
MV]QQ_2;?RNNU6!"FC!54@;2J2H 5)X!!B0&D J><$XZS<I!LL@PW6W=NQ6>G
MXDRQ(\ZZH3_T%+:7RK_V=K>[#\?]AL=,6$:;PZ([4[BY-SK9;9+>[/.B..]C
M5<5Q!RQ4S-F^XWF#SLZ O(HZN[?@QV/_EHW4#YE2BQ_EBWS>M(WVH<)^MTI@
MG@F198 A(C2!06*T:Q&HL* B$P7"R*EVET6?2W/0!Y/;)22.1KM1E0W8=AP5
M&,+(Y'2"WLC>(20=H<J. T"!R,BFQUE9R &"<_IQ>=2/=SXU>BQ_?91?-TV]
M6V5*\2+')2!*((")T#OA E:@XKGD N:*ILB%84Y:7QJ7=,9I%FFM<V.04]CL
MN,(;C,BLT./P\08.SDO_XG@#+?+3MF==SA>'=;YP+W]HDH;&N'!N6D&E78$4
M2)SKK0PFVA/(% 1EH?(,225$[G39_7472UNL@^Q#JQOKI8_A7GAX&BJ15^T
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M=!S/;,/4GI#QG+Y\N_RX^',^,2ZGQ"R95"QR4.1L0W E@<@2,VJE2S@NA/'
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MCR:' BR9VD6W;)*N..A<'+*0<_2M%<MVY7&ZW@\60-R+D1U8M:^G(4YGFW@
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MLD:X/5-)R];^]%/T!;CFSA*CWRXW:^:-9_L.EYONJQ/AF9.&!9",T=83'<"
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MG$42]/_!]=8MHGJKD'PBC76,:'K%VO*,Z#@_/=4R/K<&+CEZ[>\F*:'4S%M
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M0NI0D=\S(>98_H_=8HD^X3;YR7HLV1= [\A]5RF"-Z%FXP=55$"E%/^1-_#
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M66UU@!_#MPE'S8*,&:RE4ZL\>13."4.\EN0"H"KD CXMH'<C_.=_/'T2E ^
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M@SN-8]@+*F/WGV@ASP>A<2!SQ[Y.WN%R^N5S^"O.+^K--7>L)@]HTH'$#:.
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M5J_V^#KC5G2, )6]F=N!;;-ETTW%6??QMEQT19[47H=*6@.T/%G[6'LB%J:
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M&8[.23ST8TW3"<^N=IA,@,@A8*VJ(P^IMN\BORC(1/+WV1:G9+"I?8'V<)F
M.CUH0L8S,&,=)!;JH#JC*(#(')B1/M9;S*8Y33^NHJN8?Q\I/VU#]F9P!UO4
M'V$QK2T[;@AP/$C'BX*D6:PU+H+X01&G<L)Q*;TOMO5)U@^+Z"J</P8@Q[&W
M WS< C:M7,20(6JA0!5AR/>B[2^@83%)SI(:)"^Z,QY.%9$?@X?#V-FO-_%3
M^#*E]Z;_W@CCNOO*Z_O=H@_Q+G;_\4;>QH'4-/(^:D^NU;>;PTRI&:+WP()P
M]2:MAI"1T;X2D[8L6M&\%N_N"HXU'3?SO^_R=?.43:,H*504-8RSR"B@"\76
MB4RB%E1:DP5*CZT3R3LL:US_Y @<W#<WK470P8;T_BHNIWD:%M_JW)VWY?UJ
MGOY[W6U7Y2(UY@32JE0M*MEE2R],>NZ0&>-<ZZ*O1Q<S+H*:B_T^K)K(H <P
MW2S_3?A,?WY8A-DRK)OS;+LB8A2TSS-!N[VL*2>MP >!8(WVQ2%G4;4.F)Y?
MU<CP:B/^^Z!J*XNQ*Z!_OXJ7T_2VT),I/MRVQ-1:."VC 9.8KPW!-9!Y3\!-
M'4W'4V9LMS9_#_WZR*!H++YY2UYV8&K>?L7%Q>7E?+69L539\KU/:O8Y2R<A
ME<H6FSBXP H(R[D403*&K><0/;J8<0/O@3#45@2C&Y;+D-8%5>\_$5.76PI$
M$MG%1*;61+*\+) VU!X9W%MC,!;KM=S-LCST\^/&WX.:EJ.Y.38>+C[\<]U%
M,'S>+K[D6#+S$9+-DA8O:L!0(HAHF,.@,.5G0^\'?WG<L^TA47 4#SO87)YV
M^'^[[I\2@_?*E6K8<J$]T[/:246!##(9JT62!5L[L[LM;>2-9^B :0#Y] "[
MJHROE\LKS*^NJFOV.SEH\[PQI6_PS_5'RTE1R:.IS09YO70A554F*\E3X]Q(
M03&#:5URNMO*>H[2#P3%?>"UEU /N%LO?T/6ND<S4;5^;T+^F]&T6,A"![+;
M,4#T:(%CX>BXRTZV+J!X=#$]F[1&Z&HBAPX =6<D+I%3;R2\GDUKS^^[L>>$
M.<>+,QJ$,752AK,0':-_!FU4=BQQT=J6[;RXD;WT$P!N&#EU ,"?-\4MUX-Q
M7TV7J\4T7E4&OEV\Q\77:>WV?#'+_YJ1&/]<3&O5P2](MILTR6*P ERJ3B_Q
MEIS>:, ;(:PIJ@C;>O[CX:L=.80X 41/),D.,'N1_^MJN;F(]V%^<UA:NPR\
MGFT9?,O_^*ZO]?1[.<%4M*47"*9Z'$Q*B"%Z,+5+>53,%]7Z!NLQZQVWY/84
MN#V9-#M [NU4PE6-]^D?MUR9U[-;J86)L#88M 94J0YRR,1473@PYZ-P2:!I
M7O>RS_K&K<<]B9<YE+3Z0N)=!YH\YJA=8,0P0<085UO1I@282T B2X?FN_IC
M:QFW8\F)$7:X%,;. ]\BXOKJQ,77,+VLV:OOYGK;!L/[D@W7#JQ7=;ZG3>"<
M8!"$],88D=C]6W>/S3K<_:'C=AX9$D:#LK\C6%U\_+C C^36?H^RULHR$2(;
M+QQ"Y#4QBD[4@U@+Q2)/.7-K[S<C>1Y,#S]JW&8CIX10 U;W6S2ZIO ?8=T(
MXG.-EH8H'MW_(8V*2(^DKE$Q:;W =#E?7BTJ7&^M8QN7KMWV]1X7ZTJ_M^NZ
M*3I,9(HP&8BV=KU1U8T2Z$%$GF3.D=N0&[L?QZVXW0G:^AD_RF]!3N;']4GQ
M\A_?;KZS7<?%GV&1-^=$V:%(06C R"5%\5&!4T8 >M1..6Z+'NZ,[<C%CWL@
M<D+,/GY =TKQ=Q" ;%9.7U[7[W'IG.+) 3>,XOA4++A@&5  [YA"%6UL/0/@
MS@)Z.9 [*0CN)V(.ED@'<#J<<3=DSW*=4EYK/+9E'3$E8;DJ8 UF4)E<JR!S
MA'H/I[B<E=.#'.HUIF-<<!\!JX=._<:4<0<X_YE<T/DWQ+6S=Z>4D%F=C,P.
MLD@(RCHB1!L#O&3-&(\ZBM:C*QY=S,CF='2<W#^::2*TL0/R-Q1Q/DJ(32YX
MICQ%A,6!8D12$(5B3\ZY#QZE+_ZYR.G9IXQ<V- +K-I*HP.C]@[K464B5WM-
MRI8(;PM3IB8]/3%$!=HTO H>M$*IL_=)-N_0]>!"1JYNZ 5U[80UMB%[/:MM
M5:9?;RO.]P)L<I%U)A\%6#:>8CFN(.I<H$B'T@JER%SO9,>>>,C(M0B] *JI
M+$;$U'*QFKRKS%L[N-[Z8'DP]0BZ@-)90+#1 "+&Y!,O@>]TJ89^]9;%HG_=
M6*L[#^REV&^,R/5PSO< ERW*E5)2Z#J@(+K:.YQ'BHB,A*(C_2U\R'ZG;6X7
MP(SIG1\AK/OB/H!S(PM\VT+\^R4/E")I@Y"0:UI]=+6B/X/TV=K"H\3<PD;<
M>>C(0C]$9/,6_!M;\.&O6PL/&%)0H2[7Z3I&&,$;6CWYYH'SZ+BW.\7HSPG^
M]D/'V2":"?Y@_HTL^ _35=T67\_R].LT7X7+M=E+A<A70I$/P^H1+5D\QW@
MF7+4/%C+]$Y5W,\ X,&']U*E/9:G<+Q$>H/4_YVN/JW/J*K3_&GZY</\9_*E
M5]^V3KDW3,A24TJ9"%K/%R<#Z<$6D8TV3(HBAP#;T\L:;R-J ("GX-10&B,#
M[=5T@8D^ODY2*N9%8!"M):M+YKH6?U!8QK7G(EERU78J1'T&1W>?VA%,6@IV
MWH3+'>3LOB< UCJ$TE,LSB*4Y,DD2YF(&5&"Y9)YF542S4N5;S^_E\L=8Y[>
M'BR/CK"T5:AL-<M*<R!^T.JMSA"=$)"E#H4S9B7;:=\Z $T]')@>+LE'('$
M6\=.T6XN?'S/#59"ME;2H$0LG!2#(:\S'3E% $Z"YIYG[XLVZEYSPL=J/A]Y
M0A^R/T1D\];\&QL$%X)Q^_KWMYOZ^!L:).<I">U!DV\&JE)#(7\"7IPHSD?&
M!=L) X\\8-R4:BL(M.!>!WO#LWOJ8UOJ;]=UT5Q&I@OW8!B]*.LYA&(\Y)!L
M8H)\_-AZ/SE^U;U<_!O3ISFQ[,\9[7<OJ%U<K3[-%]-_8YYXY1E/D8$A]2:#
M;PMX6PKPI+PUP2,3K2LKFQ/1>3E18Q2V4H(FD!C;!SB8^HO9[*K>>4B+VOG\
M]>Q1;K"@;*RE"MG7DRCO(X0D-1B?6<XEH=KU2MK02^V\_&D8->@0!>>\3ZQ?
M_L#EZKHE$R<7,YK 8JS=<AFH[%T52P%71_0)8\C1;'YQI.'Z.Z_/ZG1W.!8(
MO2A!?)[V>)_VG__Z,EVLO[RAO#9 <=FMD_XVT([($%QBAH(L*PP&##JV;@K2
M;/&=5Y.= /XGAT OV#^$[]L2NU_IBZOEZRWUOR[FR^5$12F]81FL#Q2J*6U(
M$'7LG&>2FV*D;5YP.P 9(P?.'>C#B+!X 9KQ\U^X2-,E7G/APWQ57<C58CI;
M3M,?X?(*)U%(QZU5)![K0$E?>V<% 8Q%3*H8SG0W4?4>=(W<T^>\=:<Y<%Z
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M.5N64I([W2-]1N1W'CJRT \1V;P%_SIP&,C*_41/G:Y^"HO%M[+)3*ZU0,:
M+&O"OE0UF2\M1*\<R)2B*9(')UM7ISRZF'$.B=O'M6VXW2ML;G64L18C9S(
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M6=;&,'R55NA&92_I@@);)BEJBG1O@,.@/JUU."=WOXF%+RT=C[^UE-Q'EON
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M-.Y4837A?PTQ46*K1+>EY<#6C^VDQ+HUU&AI.%)&@0XFE1K!)"7#C84C3
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M#51GM$E4YSJE]4.XT*CG*JF;H*%^T-'QB(KL[5AW58,=M3_9;]ET$&#G<BN
MI]?%"7MM=FWHG,9[4_ZDT!%+Z,[4)5Y64I66J99RD<:<%D5N@[K,RA(+F9O3
MO8O]\WVWS#O9P;,11QL651Y26Q-?HB5-@(^-XR\K+P0O_+JGJY\[-]%U'Z\.
M%?$SS(P$7V%4(GK/'-<(B^JV+P%^AE:#6373HKT655;/QQ&(VB]+5;YTO)QS
M(MMP[>/O?>UO%0=5(P1/]Y\\0]"\D4)![FG 5;O+F][+2KQ.I#*1\UMNZ#-4
MP9PZ'W!)QECFB2(A$468W=1UY&7K%:F?^-Y2:2*2H(G": ]CW8&L+[HD#%+O
M2>U*-&H[Y9TY2.O&%5Y-L>1/6L_1+*HQ]CR00&*M]%9S/<0L_,KWR.YN]1TR
M.O@MWD&Q;DB>=Z&6SENY[^P4C0OIGAL9O4/UK[Z&0)E472^WBID;C-+(WBGA
M$"<#DI9G2>(: DF:;"UW;E):W6N)0]#$R99N!+V9PRU6=XE)*$BT1C@TU;3*
MI*$3O3T%U$2;#;7P ?19$#AX7F 3_ZQ 9HPX*$32JK0>1CHD900XD2$4=$VY
M!$DDE!,@+VDS)F6*-.D5L?2>;NR6'6JLED=Y"ZYV6$B3#=+L\.BD6)FDL2Q1
M7&\XS/)A#?H6MZ\>Z:_O5E&[7 ZK-I$36&RPJ4[6C[V''B>[Q0U<7QG)H(,3
ME@\2B T57[V8^J71BUN[HK9-'VA*K>(J6(NZ]:!9L\%@TRQ+^2K2[4&(^'=;
M"F=97[N^T8ZTQ!UKK'2 ,Z\A4@2[F$VQ-MA5$-\3PLR)VH8EV]($:R?>:-'A
M:/^YEAP\!?*.M0/)P/>L]E9LK]V?-2B&?2?0;LRR,Y>\:Z#$HR2L@,3 6<5B
M&&XUWDPAJ"8+/=8%$6Q@5W,11B=3@15J(9OA*A,?_ASFV1=@NRB4QT#-#0"B
MU:*TY1":":VDQ$N9^W6J3.%U*QH8#M4T3#!V;@7E72;DJ\AWZ#,._Y2'JIZ^
M-E&@2N#OW#(IS[A7XQ]'Z<^=YG&:@1-[-RW'%M=J/61Y*K3*&AH3#EI<=R6.
ME@AN:3MG^;2WQG+T0IJ,<HPEYF3&2L*B&.5'6<%&=[0/+1=^L,PB!HX_2^,Q
MHQ]Q8_=< " SNI)TLI1$E&%=B1;/T(*]S0!3"PH35E^Q:23%%]O"P290$U>"
M^UOJ(6-.4RN69--RI+?;,\I:_Q&/-;(@]77$U7<9H7SDO!'C=U@K"C<Z+Y$L
MJ\TF,U?5MON4E"DN75FQIYR21TVB71U&'D2]$@<;(FK<A\_QOX_OP^?NP^?N
M6A#=$KF_YL?82H%_HR5^N.Q'(O(?3]7H2PN.*9?V8V/.JSTCT>$WE);O6 ]H
MVSQB0A?1"L(41.)+$-B?@+A>%2@N%@&YW7<T3QVK*^2]1C#U'Z.$22-.-]E:
M4 _ N!2:_UMEO88L$FV47,>5URLTDB)A^C&XBH.^A.N<'O$Z<7G]U#M?,2XB
M5TZQKDQ7KV _14V<QRUS\DXKV%GLVGK=G'C#Z1=P B/$1"0M#3H-B90[_][E
MB5Q-#NG77(UXB*6B;XW'N@4$I&XR)V^7[EG;JLM8]?;OH!,4&5N?G&"K]<>:
MC<>%*DOMH&(<*IP&M3;1D)+:*%6GA:0ZS.%XAE09D%,+X7!)/1875K%;/U2G
M&'U-Y]4%31H:VHN9<I;EQ)U8<7 SI#1Z.PSFAJ-3JO4XC"6QSI@B0T"W6>VB
M4.TZG_5)3$1471<#L49N;EXH?EP/AK!A=5I%BA2O;[0P.HR$)1D"R02/E$S.
M *1S)G,QJ%XPPHQZT+#&?N.EF#3 AAX23G )!ER1=]-4\[_A!*$F8EA"8O,O
M[=,M2DXX+[/YGN'WG'1ZUXR^FTI9#_37H&<<0RJQ3E'=7>(D[>)-U[M8;MI=
MJSS6,[5.K,NQSJDHV]"S.(E'O0"(F;ET&QK'IL<6E+)>.(?<*L3! -?I#\]'
M8JHYX9O95>JD&U)#%UP2AR@[*X([%IHI66">F6A+:42"8V$3]SRJU^!T=GG3
MO>EEFZ!+H)6>"78]?]F&4,)G6W1Y^VI<%1CKF1F1?0/""?T<3S%#F8#WG7C7
M*TN9,9IB9:K";6_$P;OH8QTJX$QL=EU5?+->R9+DH>OK$)(P&>L%J9!$5JK/
M8'BJDTV<B:N B8]7%Y>:EBR<-%5=!$JRWO-:ZC26%U9<0B";>1,Y]8)EW^Y&
MM^#^/-^J^R,<!*!]JB9X<AMP?[P >]T#T.\.YO$.*2= 7BO\/.&=.&R0O%B(
M@N:K:DC%]6(J#8=7\Q)CPTMV0J \SPX7RGZ/G,9U?@E.)_-^J:J)*<GLE=HT
M!=#T2F@W4K;.38JI:3;HNZ-PDRQ?U2R,.L%L_OUP.O3V.Q_@1X>ZWK[YS UI
MCSO] 773'70">"APVAK0(QWJNGK.;5S; WJ^W>T%-VM_$+SI##YU.CVOWREV
M7,6_>^W?]-OOSTY/.GU=5OEFJ_VM_1F&#P;]=N_\;:??A\>HUS#VJ3T^/NN?
MM'O''>ZV>GYQ_-YMM]N&M7SXC'OBSK,P\EDO>-L][=CNK.>=XWYGT.Y_KG6P
MW0*2^&*+2.)I-OJR=S&W//(^<?E/E+B\&:?JL3E2A:3MX#+IUS[J1(72Z!)-
M%=*]E00L4"Y&:+1B(Z@U*]BN&&XX]"F.<V''6>[W8:JO&A>Q1 YB"$2+<OO0
M/6(_X>0,XE-S[=75<E_+,8ZBF0K>SF:PWCPNOOBUP+"3!.MWQ-&!;6OOARY%
MWRS].G7G-4Q,<5D)8_> (4%?A5?^R%0\@E<S=MIS<1PRUM'?%"NB$S3U*,S*
M210NW&W3]USMJ'84Z&*?E_Z';%FT$9]+9YK;TDF9]PA0@2_859#L6?BY?F<W
MB*I<VTL/GQ_L11P9'%,)6#<9CY5E% !U"AQ5<K/]CDGL<,L4F^@:,A/:YJM.
MO9GVB)X^?'%TY/8B:1GHX_GRV6'9::P'RVO#*=!:+9;S.K9*]U4R<R^N[4#,
MQ5>QS(YIF&G+0B_=N*6Y3-UIW^B\5A0EDP(UZ\!R<?,]@Z6>?:2IAH^'$;6$
MI01Y4C770+(5,JDRG:AY]%U#5I-G:[5!&[QVJCJ^M'-"@M649;G'2<M%-^<H
M'8RDM>A\BMJ&;.1/2\RDG*J*AZ-2,NJ:\M=.^>07V\ >MRHQLY<%;;RJ=-T_
M2>F^8VE["^!WD.2.&>C)$KZ1S1[5,5'0M"5D&;T;?!/K6:F'\-Y%=:YB"##D
MNT,6'HKFFL>YTUQD">^MO\XI5/L")*I5[A.7);#=!IT@0[A:6>J2://<"FFB
M#I+6*DN1690;4:4[2V&YE)#;US)7,^L<691IFNZ^E)C\^^0^%NH^%NJN6=3A
MP>:HYT?7]@4"@IL[G>+)Z!6\RP#1L94<IN9L@&KG-K5WNMA[IG>G_"F+<K2Q
MT)KF1:[#$-B&K'_R=HF8.,-V5[DT(9$R&L!B"A7IRL)Q+A.4[+3G=EQ.HKYC
M8?5*DZR2)&^\G);IAB#<8Y9%S//""*O&8J4%/QK"[9K.>IRP%V!F'.I";%UG
M>%&$\4J]V0M>+I2[0TS&8RLO'45>,1^NIT/@2!/"+SM+K*N@H-W5&'Q+4:!,
MKTU=_'C"80:V.0?7L<VD,R96_,JQ!C*)Y%=9E42.-;M6#H?$")D5AW&S] *G
M'O<MEJG+Z; :B_N-JM)I/2\HB/D 4UH<24MNY;*Z3]E#]*%RP\L8XJ#&J0EG
MAE>I-,_B<$L27V@;CC@BGC0,J(&O*.XM5]BYQ5%?">VG7#F5O[+#;H&B<+A!
M?6^OI<+'F55G-X#<CD*IZ%X52YUG&R@O-SZ%*5'[1Y64+$ I!@ZY:"3T2GJ,
MAG0-_,(C\JZ-#J V+(#J<RS.+@D#'9&-L=VAD\"91M+G1T@*U<SZ*O$9!9P%
M93U(43DV$/%E3"KT_6CZ)G\N/Z>'P/RQPH0;X374IL#,!CBPC<\HW7Q'@>HF
M50%7JZ7;<SCK#$8):CP+[;-RDE.WX;)M4+?1:R^;$[*I,^:Z'I+==5@R< .R
MI<D-0-4$I1J_]$_H[V+IIOALQ!&=EAF*:0+ Q<*<2Z2E$W:8>O%%S2G? PZC
M0EU1%^'$6(2F[33FH)NEC.-4;N4PYDC5C&V/*(=M1^#/X0;U![WV4GRDXG-4
M<#:D&OEP=/];Y8M@@-WK-H G:;F=!$Z6[#A%#;N'A%+W,,MU#AM92$&2(\RI
MN$]*[J4,WO9R#"E9Q;3R].OT<&>>$1KWJIRB)*PX2%D#+.AQ\U!Z) &%W!<V
ML00$UM%S&C:V:'_^MEI<@\$,SV$,-*CNB:[3^01DO 6I!"@[]\7<L;.R&KQ=
M_Q59ITSW3&P&SMH$)5ERG10A'E1@@SPZW )2NUFHAQTJ+]P/7,SQX4+L@UP"
M43>QX_1#YX!KY^N<B+?\'X.MSU9&8WQH]P?=SGG0/CT_"SI_QRB'\]//P:=V
M]V,GP ")?O?=^P'&''P.WK?AL[,^!3O0[X.SH!W\[T7_<S#H=]NG&)R KU"$
MP_E%%X,;C@?=LQZ^]*%_=MSIG'1[[^Z0TCQXC25PZ:Q3XA082+_.]GEX)!BI
MSUF:AN@^DW%Z&29QU*#+Q)391=(86WI'+&,M*?>VO>*2TN-JS+IBCN2I"B)[
M167)A<I7$*,*7>615TE%8[=+,]J@9FC7\J7-""!O4^%&TG],3%F6.R3/=H0U
M6#8!6IFZI7.L)F2U(*-N)PMY@4+C6,@! 4BG-$F9A4B119YNCLEVHHK/VC;!
M>92D1XRR24J=;]17K"B)GMHX(2(94TP[UYG%6^8.W<C>Z,WAPLFIHD]V8O_:
M:1M-TQB[TJ@89BFQZ@2Y+]'G"VN;AW'4PC107*:]ETYG4\S8H/O'SU!RUA0C
MT7DJ4@!1;21+5$NB:YV4+O<](@N&$7%*O=1ITD>UG.ZUO*1MN.D;U-7BVIM^
M&H*"#9AQU[DB?D(")G"9UF;+P=XV:,6TM]7U$P5C2*RDL 7^F")B0I!Y>+>N
MB;&33JAU-M5.%?N"?5&W!(,E /O"@&].Q>2[IM^5IUI-'W*T!P4<98DQ0E@;
M"E()R8<>UBO(;P.V;U":U/5\S51')]/772-]*E5_M'6A*:_0+5!2B]G9DE#I
MS8NM?/#:T(C8+]%WF2556H(*FRQJMA<M!]MR2BBK O?BBOLMJ;VL [.TM-NR
M46-%!?*S#CG0N:T-/A^;']](+?RZBBO\<M3[>@M08^/BBA@UV# . -7XP*ZX
M;#0*"RZ90?XEW72$^B2:+I(46%JQ6\@)K>02VL330(DG.H2FA(@%)XX0X]:+
M2:PJ<HS)UXI$6OVWDU5$'R@L[#['!43)P@1?AL76X,#&E=]^\)K"+4'7+1H#
M'6NGIQ-"=44OL0/5BJ\M!6)MQ^%$FW0X]H+6G>Q<8BN>FQ+5+H$WEWA;@*XV
M">B68=X<Z-;UJ$FCI8%4'-Y61S?1=O71I<9 7O-EDL:-<KA]4UH-U(,])$K7
MC(.J@>:Z:V:TZ@1>_FD\=U*^+6O>%E0:;PXJ/=T_.%QBL'BDVB6=9OF,V296
M&Z26W5@P0*6%\;9Q?1)CPY2*F$5C W6WKLDH3$:5>"$X<4*JFF!!:C9%L/YF
M2XZTJ.%%BC$T</02HZ[M-[H6BE1*P15@"L">_E[S!EQ\K'NHEU(5FD).53)&
MPXWA^VX[/1F<1<H4JPUR913Q9TBL#XB!.7?^]J $L&EY7A?)'[D*N88SB@9Z
M'X6)95];37@]LO]DT:Y/[Z-=[Z-=[YRN3S:'KFNYS"OB9-RA3N$@),IH<%M1
M/*B1]+2<0*5:-.0-Y) KIUB["=1@*R%7TT]=II]9^[S)#S2$E&4!*W3\#H*Y
M.5@TW3PL8A\W*5B785(9+&$K'KFL3?EI^!"M8VP &86IG#0<,OK8E7350_=)
M"*>_-:?RW6M-WKX-#6?RD,CAQ3F)Q1(DE%$2QC.2W? &)"SHP#VK2W!25%HD
M>F[HQHX?I]I;O3%:A/W&*GV]/;PPSPA6F!Q3\J\U=5IK27\HZW):GKE.8HX!
M;+""K"I,J\CEZA8-Y5AW:M[V*R"+18;")W=]] NMP=Z0EZ'_;"Q-IY)PB.FE
MX56QJ\7!QH.0WG+>-CWRZP248(>8L*BU]] 5ZFL;,+7!.=:##MD4^Z#3HUL%
M*A+U9EE7Y; V2HS"9Y5R[UP)SX'U$[Y01,!2F [:O6A*=K3 OUA/!&0D/9D;
M6.0W-+:^7Q<0>E#)_W+:;QIME3J*<N]1I;Y@4+:*%GZL3!/F;PNI^>=&DAHK
M1B!"?]/MW+G5U6IN#;%DMFVS =8FBUOK>\:-HW505+O)-JC3YL-U!GV;@(#1
M#7&ZZQ@MG#0!D]80L36C2=HR6>DT!669:+6/6\Y:X8B"<"+;R%K"+B3#$ZM)
M$E'@G6OP7>D2N0T3</X'0Y[#N4,GI5IBMS&R5J58%>)2Z2AN5P_FY]VFOF;J
M728[XW551'\<YC2%TW*LW=2)0'>MP5AL4Z>3<%3];8X/Z8^V??AM2[:%\'S9
M',+C2IZ:&VK+E &]-))L!2;C!V.E4VK[&$:7Q':PR6Q<+Y;\1;^-H4$S] 5*
MK4<_L/SF.HT8;);[V(#<PY84,92M%IWY[L"EW@)$238'432'JMU4W38-L$#"
MJ%!"PP:D*VW;J+.8:#,'K2@\R\.K HN)?BNJ2+GSTB*A1/0V1,ML0ZC)!A7U
MO#;4Y"0L0^R(>QF.[K8Y^.:?Z_</$/D]S16T!VS@QJ?QE5=?,5@+9'Y6GZHT
MG WC"4H3R4)7CS!%?=$,K"2_ +-B26R4PCHDNU ?@3Q+L7J'CAQ *U5KE?!B
MXU41UT*WL\:UV8-#T?AF&:EFA=-,JUD8UFZT6ONE%5JC]KT9T4?W+L-^D=B
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M+8JAB;]RQ.+:]LAP47"Y?SP?IBN<BTBESY&6)!1IM(V8NT'%B1W,'8=QKOM
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MS[N\:T&K,&8^]+S5:N6N0E>JF3>]]ZRKKE=*J='-3-8:Q?8+C<BRT9/XJ>/
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MYL4:*BR9S9:#77S;OK^;L(1R=&$.F_RB\1\FN#<V[U/]4HZ^ E!+ P04
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M+;=4EF"[W:J2VUW8<16C4I&SX&M,58@BX<V:B&<T"SA-D.L]_J(R_EZ6.)'
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M$*M0>L++,55LCB8 NJ"^B(69H09X;%A<9!9X%E-N?2Q579"N-IW<%@YEN<H
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M7J3GX9&CHA^_]NF(CY?K^_8/A91[V*UT/D5<K_=JS4ZFCSF%[P7+9C V07_
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M'4*F6!#F<G/(UK?&:\?\YP7ZAPY'_P)02P,$%     @ R3E;5HG84I@L$@
M8%8  !X   !K<GES+3(P,C(Q,C,Q97@T,WAD97-C<FEP="YH=&WM7&N3V[BQ
M_7Y_!>*]2;Q5TCP]MG?LN&I6XTU<\2LSL]G*IUL0"4F(28(+@"/K_OK;#X $
M)6H>6ZD=V==;M;8ED4 WT-TX?;K)EW\X_S"Y^M?'UV+ART)\_/G'MV\FXM%X
M?_^7X\G^_OG5N?C;U;NWXLG>P:&XLK)RVFM3R6)___7[1^+1POOZ=']_N5SN
M+8_WC)WO7UWLXU!/]@MCG-K+??[HU4O\!OY4,G_U7R__,!Z+<Y,UI:J\R*R2
M7N6B<;J:BU]RY3Z)\3A<-3'URNKYPHNC@Z-C\8NQG_2UY-^]]H5Z%<=YN<^?
M7^[3)"^G)E^]>IGK:Z'SOSS2S^3SV>SH\.1PFF5/Y,DSJ62FIL<GZD0=/%53
M]3^'(.0^7,[W.+\JU%\>E;H:+Q3.?_KLJ/8OECKWB]/#@X,_/NI=Y]5G/Y:%
MGE>G)"W\.C.@6_@Y,X6QI]\=T'\O\)?Q3):Z6)W^^4J7RHGW:BDN3"FK/X\<
MK/#8*:MG?*'3_ZM@1IB</BZ#-#!.H2L5I6.17G]>Z*GVL%?'+_?Q\JC2AF);
M!(9ELZ_ZMZ:K(>T<%F1JO#?EZ2$N2#).!IN@[ -I?O[Z<G+QYN/5FP_OQ8>?
MQ.3#NW?PK\NK#Y._WT.=WUWX'TY ]K^J2EE9[)*<3X;D_-!8(1N_,!;NR44F
M:^UE 4*8[)/(# 0&YYTP,_'\8 2"X/_"+:15]&5FRM)4?/5(_/?!'@I[*&II
MQ;4L&B5J9?GRD9!5#OX^,$AMU4Q9"[/?89P]@1*G\PKMA%5SD%/A&$V5P[67
M*L. )@Z/'D^_QTG\0N&7C85 !].^_IPM9#57XBSS^//A#\=/0$0G)(2='(9Y
MC#?\Z;OG1T<'+]*+Z:O#%]_OB5^46,AK)2HC#%P,\G7#WR!/%"8==$_LO)U<
M@<@S4Q1FB0$=XGEF=4TJN:8$(6$D1WJ5QGFAR]I8+T%*6(22=MFL;=N>^%%E
MLG%*0&R#+315L1(RC+8:X;>Y@3$KX]$.O=25D$5!<^AJ9FPI:7J_D%Z4<B6F
M*IW6B)5I]@2*G0H+$VF(:+3%N-O=?&B>\.NO#02^F8:?83X-I@\!4%OE8?R5
M($-55:9P?%0(MMS ?=%H< PP:D]'7Z:LAY$R^(#ZZRHS%L1CJ1_CW<&\)OT+
MWZ071G.CH?&>P:FFJT(N76_0'^FKSEI_,G O;D!=*-];DQ&N%#B7:8J<-8S:
MW208"<"3[.V2\0X&XPG;W27:W4X(2R.>8J35V>WBG^MKG<.VBPO\SNV$!K?%
MBH4I(.X->KZ ,$YN!<@N1UNS*E,:(FD>](2[&HK*LP8_%&H.C@_!X5KJ0DX+
M\',>=&JDS?&Z'#PT\\:Z4?3:7(-]*S;O7&$0 B$=3J:=:]*IT(XAIE0A 'D*
M,)Y6@T)"15_(TC25=QQMAN>F(-3.M2,A_7Z&]D_C,;I_(6;VMWN8F*F4N#8>
MSS K($M8,)H0"P5!S_#) @>*Q_%<,RVU]WRCY-M@#AHXF'5Z^GL , :M*:?!
M(7%I"@B1US0A+B=^BS:DB@ ">E8#!G9;K-T#C  ?<QBL@),J<2T)0O\;H!L<
M3P%6=+!J8TV6&I2$4Y)<"%0C>4CS<'4K%(.L&\/_ DY//'ZFA78+/(]$5DCG
M^.@<<DSV.'0HF-HOK%)\!PB[U![VP\OYG! 3_3A>*0!_A!Y &G1-W$*ZH[]^
M42O2!@7QO+^RJN H%Z52M E!Q7031SPQKAH#N"@/P@U=->G>654" $$DQ^NL
M+9Z^-6XH;/2&Q#OA._?S_?=&? 0MRIHT K4O-4P+&GTAT6 H+4#G3*- W2E(
M";)K81]>"7[_;_0(N! LX!HLA(X/,$FZ"1T7#$A7G\@PX&ABQ\>KOL@=IXU%
M;2_"^?M6_]KHG/W['/(7JZ<-?MC]S?^Y-AQ&BTX%##G.F:*)6P>9"X;0<5./
M^$P'9_=#\ *=/D_T;]%^$CS$DO#R5'57TKT0'N'O%0(&L!)_&Q+RC"@0;XQ2
M ZRM1F,#1=Q,MJ<&Q>K&0Z@D30!M3#U9<*'E5!>4>^Z&)=YD=V?@D>,K^4D9
M\#$(.M&'=DGPK;BV<WG<D',%"1#B"/AK=+><"2_BO E, 4V(8 3A@]E,,1N1
MP[ KV&#$KDB-T %&-@FW6#G'S[+B0ZL&VX*A9]:40F9@_70U'F'6%(G1U;):
M43[L4B7@#%QH/"U!AS:11[.&1']$B'9(O%0.'S=RJG-'$ZQH-%DX@VFFGE<J
M)UQ>2^M'!#PJOET%X0%R*451%0$7Z:!2#1H"[I6: Y["=9UIZSP?WL-0G. 9
MZ* 5R1Y _515:J:9S8)LW"KI%,5PW^$R'*^&+\!$ 3RP4ZWZL].\LA)--;,:
M4@B$)A8^0:C1F28(PBI8]%6R)YH>5DWFU[("G*/<QC)*%*0V#F9-%@$TGP:6
M) H0!/5Q(^F>:$N 29K"XV*#@+K$?5;$Q[>HY8O%)ZVKO97+G1#_ID@!YL<>
MU09TOQ$[(B5X=' <P7NK8V"/Q20)'J!WCY4\_^OD;>1W$*7,*>T@W^>;5.N;
MX!!O*C'G04>#,\-@*!^5&I 7JQM ]AG8-F5(K6!I-*.0HZHY&S#:G)ABO4<Y
M-,=RJBN^+CH,$F](646BEP]&.FTE1@)M<A8'<P,$TRYA',F#**A6(631BG+P
M0Q\IU0US-%4!4OWINY/G+VZS'6_JTV/8XUKFA!8*-?.GQT]C6023@,J?C@^?
M/Y1MT9X_;?7XW27HK\SAD[T37 D&+,'0\W#Z$96"U46&, R[!IB3<&GOJ*PI
M>.5":3KFZ,XAZPH)6C)-L ^.A:JE<%)[ (,Q)9^B6TP&;.6'[;:2E@\A %/Q
M]-0JSONW%A1#6#KH;I%3 JB;MVRMW*5_+FP<N88S93R%$^W36,Y G5-9+.7*
M/?I/UCVW"C/L0T^_^=!]?8A+&X,!S"PKYC8*0"U>/#_Y8W2:0#)Q/C'@2&F^
MD+";&TZ#>0F6-@"KJ<]9T>21_J@;&,P%R!+HS1B1^Y-W,XW 5STEU<2N)"+T
M[R"MIBNQ77.*V>*Q_KYEMN(]$3LN%X8.VRZ<(,PF^&EF@,3A,G)F^OJQ'A@)
MTOO"K%0($:(N8%4P:G <:7]%_ H(#X T$LR&U&O1L8W)=,L (X*=(<F,4!(.
MTN5"<9F09Z=S=1T@P,PMH455*LOQ2X9/&.U4+!R"=B%.P==W.=:^N>2]71+9
M?HO;Y-2OC:K\W4ZXH7-*N^Y,"Q9_QY,0K;FKT$O,^".[B;+5*M-]HK-/<N+]
M:*HPZ=(BKUU171^4&45!)/@)U5.O54MWM['FZ=.]I\_:<+/5ERG-"DS:'?QZ
M,P7Y;<TJ#V.L 9\C&[\%]$*""3$4BTBP,W:N[(CY)MHR6C!(V]0(/W(>G\9B
MO ;DXIB;_(!Y\)RC"*.;%GC/8-Z*["!DN=%0MZR^.-N*E;5C..X(29E1-R<#
M>;"5 A/A$&>=,QE]'.&V@\26>75"71V2[^/#$"/;;':+*%C>;JAVD./@XA"/
M/2M*8]E$Q5JE_/#9"[?50HD44)]KBK?(9WS&%@TLYI-I:]?E9R@G17;R-*_'
M+<D12!!:B5  (*72/=I2'FR[&4(8H(U#0B!3)!J=6#@;'C$^\!;;4C5D9IAA
MB20"# "^7=:Q2%G2@900 LA^E[HI!2E"K1K2?E)8OH)#LJUT##?W\'$%'MVK
M@NV$G]Z/1KCDCHVSI(WB(K91W,K=#=X5R+POB,>\M;BWQE.&6 8F5#7EE&M@
M"9=!YL;\$SFV6!CG=9'0#T1>(J>)_P SO*8644(Q!+2&V<I1F#B"S98,N#F/
M_W^.<+:ZPYTQSX\Q=IVWL>N?,L/C):DN/,#ZW5Z4[GJ2.L04.LNV!&6(W3/$
MV]>HH.]^6.C:I?97J24,$KN:'?S%G!JN7P?\.O?H9D"LY;5O&)QM[QPA*0'V
M(T:88B<<1.%8O)*YJ;G/*ZWX1Z2&@W*7VB 5OD[YA\I5=$/9)^.0TPOD>/0[
MW*(XSX#P;0/-7')BN.;- [> 'KCJ<8(.RUQ'.^,3ELAZ./<K)&N4(F4T+M<G
MC!N>@4"N,<O#4PX+MYP:,88N(\]RDR@-]6^4QB>%?VZG 'N%8Q7I\X%FGM^
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M^_SN57H+[*O_ U!+ 0(4 Q0    ( ,DY6U8CT*?XS3$# (Q;&P 1
M      "  0    !K<GES+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( ,DY6U8<
MPCRASP\  (2C   1              "  ?PQ P!K<GES+3(P,C(Q,C,Q+GAS
M9%!+ 0(4 Q0    ( ,DY6U:Z02E8&AL  +0( 0 5              "  ?I!
M P!K<GES+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #).5M6;=#B,- X
M  #H;@( %0              @ %'70, :W)Y<RTR,#(R,3(S,5]D968N>&UL
M4$L! A0#%     @ R3E;5D,Z^X$V7P( ID\# !0              ( !2I8#
M &MR>7,M,C R,C$R,S%?9S$N:G!G4$L! A0#%     @ R3E;5GIBQS <:@
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M,7AL:7-T;V9S+FAT;5!+ 0(4 Q0    ( ,DY6U8PES[*V@(  (0'   >
M          "  0C/!P!K<GES+3(P,C(Q,C,Q97@R,S%X:W!M9V-O;BYH=&U0
M2P$"% ,4    " #).5M6C=]C/84#   %$0  '@              @ $>T@<
M:W)Y<RTR,#(R,3(S,65X,C,R>&UH;6-O;G,N:'1M4$L! A0#%     @ R3E;
M5LEOX/2-"   !"P  !8              ( !W]4' &MR>7,M,C R,C$R,S%E
M>#,Q,2YH=&U02P$"% ,4    " #).5M63763]H<(  #N*P  %@
M    @ &@W@< :W)Y<RTR,#(R,3(S,65X,S$R+FAT;5!+ 0(4 Q0    ( ,DY
M6U:/[6AQ9@4  $,A   6              "  5OG!P!K<GES+3(P,C(Q,C,Q
M97@S,C$N:'1M4$L! A0#%     @ R3E;5HG84I@L$@  8%8  !X
M     ( !]>P' &MR>7,M,C R,C$R,S%E>#0S>&1E<V-R:7!T+FAT;5!+!08
1    $  0 %8$  !=_P<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
